<?xml version="1.0"?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Trials</journal-id>
      <journal-id journal-id-type="iso-abbrev">Trials</journal-id>
      <journal-title-group>
        <journal-title>Trials</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1745-6215</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32183886</article-id>
      <article-id pub-id-type="pmc">7079402</article-id>
      <article-id pub-id-type="publisher-id">4141</article-id>
      <article-id pub-id-type="doi">10.1186/s13063-020-4141-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Study Protocol</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6073-4354</contrib-id>
          <name>
            <surname>Pottecher</surname>
            <given-names>Julien</given-names>
          </name>
          <address>
            <email>julien.pottecher@chru-strasbourg.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Noll</surname>
            <given-names>Eric</given-names>
          </name>
          <address>
            <email>eric.noll@chru-strasbourg.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Borel</surname>
            <given-names>Marie</given-names>
          </name>
          <address>
            <email>marie.borel@psl.aphp.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Audibert</surname>
            <given-names>G&#xE9;rard</given-names>
          </name>
          <address>
            <email>g.audibert@chru-nancy.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gette</surname>
            <given-names>S&#xE9;bastien</given-names>
          </name>
          <address>
            <email>s.gette@chr-metz-thionville.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meyer</surname>
            <given-names>Christian</given-names>
          </name>
          <address>
            <email>meyerchristian@ghrmsa.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gaertner</surname>
            <given-names>Elisabeth</given-names>
          </name>
          <address>
            <email>elisabeth.gaertner@ch-colmar.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Legros</surname>
            <given-names>Vincent</given-names>
          </name>
          <address>
            <email>vlegros@chu-reims.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carapito</surname>
            <given-names>Rapha&#xEB;l</given-names>
          </name>
          <address>
            <email>carapito@unistra.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff10">10</xref>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Uring-Lambert</surname>
            <given-names>B&#xE9;atrice</given-names>
          </name>
          <address>
            <email>uringbeatrice@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff10">10</xref>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sauleau</surname>
            <given-names>Erik</given-names>
          </name>
          <address>
            <email>erik.sauleau@chru-strasbourg.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Land</surname>
            <given-names>Walter G.</given-names>
          </name>
          <address>
            <email>land.w.damps@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bahram</surname>
            <given-names>Seiamak</given-names>
          </name>
          <address>
            <email>seiamak.bahram@chru-strasbourg.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff10">10</xref>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meyer</surname>
            <given-names>Alain</given-names>
          </name>
          <address>
            <email>alain.meyer1@chru-strasbourg.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Geny</surname>
            <given-names>Bernard</given-names>
          </name>
          <address>
            <email>bernard.geny@chru-strasbourg.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Diemunsch</surname>
            <given-names>Pierre</given-names>
          </name>
          <address>
            <email>pierre.diemunsch@chru-strasbourg.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.412201.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0593 6932</institution-id><institution>H&#xF4;pitaux Universitaires de Strasbourg, </institution><institution>H&#xF4;pital de Hautepierre, Service d&#x2019;Anesth&#xE9;sie-R&#xE9;animation Chirurgicale, </institution></institution-wrap>1 Avenue Moli&#xE8;re, 67098 Strasbourg, France </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.11843.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 9291</institution-id><institution>Universit&#xE9; de Strasbourg, Facult&#xE9; de M&#xE9;decine, </institution><institution>F&#xE9;d&#xE9;ration de M&#xE9;decine Translationnelle de Strasbourg (FMTS), </institution></institution-wrap>EA3072, 4 Rue Kirschleger, 67085 Strasbourg, France </aff>
        <aff id="Aff3"><label>3</label>F&#xE9;d&#xE9;ration Hospitalo-Universitaire OMICARE, Centre de Recherche d&#x2019;Immunologie et d&#x2019;H&#xE9;matologie, 4 rue Kirschleger, 67085 Strasbourg Cedex, France </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.50550.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2175 4109</institution-id><institution>Sorbonne Universit&#xE9;s, UPMC Universit&#xE9; Paris 06, INSERM UMR_S 1158 Neurophysiologie Respiratoire Exp&#xE9;rimentale et Clinique, </institution><institution>AP-HP, Groupe Hospitalier Piti&#xE9;-Salp&#xEA;tri&#xE8;re Charles Foix, D&#xE9;partement d&#x2019;Anesth&#xE9;sie R&#xE9;animation, </institution></institution-wrap>47-83 Boulevard de l&#x2019;H&#xF4;pital, 75651 Paris Cedex 13, France </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.410527.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1765 1301</institution-id><institution>CHRU Nancy, H&#xF4;pital Central, </institution><institution>Service d&#x2019;Anesth&#xE9;sie-R&#xE9;animation, </institution></institution-wrap>29 Avenue de Lattre de Tassigny, 54000 Nancy, France </aff>
        <aff id="Aff6"><label>6</label>CHR Metz-Thionville&#x2014;Site de Mercy, Service de R&#xE9;animation Polyvalente, 1 All&#xE9;e du Ch&#xE2;teau, 57350 Ars-Laquenexy, France </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.490143.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 6003 7868</institution-id><institution>Groupe Hospitalier de la R&#xE9;gion de Mulhouse et Sud Alsace (GHRMSA), </institution><institution>P&#xF4;le d&#x2019;Anesth&#xE9;sie-R&#xE9;animation, </institution></institution-wrap>20 rue du Dr Laennec, 68051 Mulhouse Cedex 1, France </aff>
        <aff id="Aff8"><label>8</label>H&#xF4;pital Louis Pasteur, Service d&#x2019;Anesth&#xE9;sie-R&#xE9;animation P&#xF4;le 2, 39 Avenue de la Libert&#xE9;, 68024 Colmar Cedex, France </aff>
        <aff id="Aff9"><label>9</label>CHU de Reims, H&#xF4;pital Maison Blanche, R&#xE9;animation Chirurgicale et Traumatologique, SAMU 51, 45 rue Cognacq-Jay, 51092 Reims, France </aff>
        <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.413866.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 8928 6711</institution-id><institution>H&#xF4;pitaux Universitaires de Strasbourg, Nouvel H&#xF4;pital Civil, </institution><institution>Laboratoire Central d&#x2019;Immunologie, </institution></institution-wrap>1 Place de l&#x2019;H&#xF4;pital, 67091 Strasbourg Cedex, France </aff>
        <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.11843.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 9291</institution-id><institution>Universit&#xE9; de Strasbourg, Facult&#xE9; de M&#xE9;decine, F&#xE9;d&#xE9;ration de M&#xE9;decine Translationnelle de Strasbourg (FMTS), </institution><institution>Laboratoire d&#x2019;ImmunoRhumatologie Mol&#xE9;culaire, </institution></institution-wrap>INSERM UMR_S 1109, 4 rue Kirschleger, 67085 Strasbourg Cedex, France </aff>
        <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.413866.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 8928 6711</institution-id><institution>H&#xF4;pitaux Universitaires de Strasbourg, H&#xF4;pital Civil, </institution><institution>P&#xF4;le Sant&#xE9; Publique, Groupe M&#xE9;thode en Recherche Clinique (GMRC), </institution></institution-wrap>1 Place de l&#x2019;H&#xF4;pital, 67091 Strasbourg Cedex, France </aff>
        <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.413866.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 8928 6711</institution-id><institution>H&#xF4;pitaux Universitaires de Strasbourg, Nouvel H&#xF4;pital Civil, </institution><institution>Service de Physiologie et d&#x2019;Explorations Fonctionnelles, </institution></institution-wrap>1 Place de l&#x2019;H&#xF4;pital, 67091 Strasbourg Cedex, France </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>3</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>3</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>21</volume>
      <elocation-id>274</elocation-id>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>1</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>2</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s). 2020</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p id="Par1">Acute respiratory distress syndrome continues to drive significant morbidity and mortality after severe trauma. The incidence of trauma-induced, moderate-to-severe hypoxaemia, according to the Berlin definition, could be as high as 45%. Its pathophysiology includes the release of damage-associated molecular patterns (DAMPs), which propagate tissue injuries by triggering neutrophil extracellular traps (NETs). NETs include a DNA backbone coated with cytoplasmic proteins, which drive pulmonary cytotoxic effects. The structure of NETs and many DAMPs includes double-stranded DNA, which prevents their neutralization by plasma. Dornase alfa is a US Food and Drug Administration-approved recombinant DNase, which cleaves extracellular DNA and may therefore break up the backbone of NETs and DAMPs. Aerosolized dornase alfa was shown to reduce trauma-induced lung injury in experimental models and to improve arterial oxygenation in ventilated patients.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p id="Par2">TRAUMADORNASE will be an institution-led, multicentre, double-blinded, placebo-controlled randomized trial in ventilated trauma patients. The primary trial objective is to demonstrate a reduction in the incidence of moderate-to-severe hypoxaemia in severe trauma patients during the first 7 days from 45% to 30% by providing aerosolized dornase alfa as compared to placebo. The secondary objectives are to demonstrate an improvement in lung function and a reduction in morbidity and mortality. Randomization of 250 patients per treatment arm will be carried out through a secure, web-based system. Statistical analyses will include a descriptive step and an inferential step using fully Bayesian techniques. The study was approved by both the Agence Nationale de la S&#xE9;curit&#xE9; du M&#xE9;dicament et des Produits de Sant&#xE9; (ANSM, on 5 October 2018) and a National Institutional Review Board (CPP, on 6 November 2018). Participant recruitment began in March 2019. Results will be published in international peer-reviewed medical journals.</p>
        </sec>
        <sec>
          <title>Discussion</title>
          <p id="Par3">If early administration of inhaled dornase alfa actually reduces the incidence of moderate-to-severe hypoxaemia in patients with severe trauma, this new therapeutic strategy may be easily implemented in many clinical trauma care settings. This treatment may facilitate ventilator weaning, reduce the burden of trauma-induced lung inflammation and facilitate recovery and rehabilitation in severe trauma patients.</p>
        </sec>
        <sec>
          <title>Trial registration</title>
          <p id="Par4">ClinicalTrials.gov, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03368092">NCT03368092</ext-link>. Registered on 11 December 2017.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Acute respiratory distress syndrome</kwd>
        <kwd>Adult</kwd>
        <kwd>Hypoxaemia</kwd>
        <kwd>Multiple trauma</kwd>
        <kwd>Deoxyribonuclease I</kwd>
        <kwd>Neutrophil extracellular traps</kwd>
        <kwd>Randomized controlled trial</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004571</institution-id>
              <institution>Minist&#xE8;re des Affaires Sociales et de la Sant&#xE9;</institution>
            </institution-wrap>
          </funding-source>
          <award-id>PHRCI-2017-S09</award-id>
          <principal-award-recipient>
            <name>
              <surname>Pottecher</surname>
              <given-names>Julien</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>Aerogen</institution>
          </funding-source>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec100">
      <title>Administrative information</title>
      <p id="Par370">Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see <ext-link ext-link-type="uri" xlink:href="http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/">http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/</ext-link>).
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td>Title {1}</td><td>Protocol for TRAUMADORNASE: a prospective, randomised, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate to severe hypoxemia in ventilated trauma patients</td></tr><tr><td>Trial registration {2a and 2b}</td><td>ClinicalTrials.gov NCT03368092</td></tr><tr><td>Protocol version {3}</td><td>8.0, November 13, 2018</td></tr><tr><td>Funding {4}</td><td><p>Aerogen (Ireland) will provide nebulizers to study centres at an estimated value of 28k&#x20AC;.</p><p>After validation from its Scientific Committee, the TRAUMADORNASE study is supported by a 300k&#x20AC; grant from the French Ministry of Health (PHRCI-2017-S09).</p></td></tr><tr><td>Author details {5a}</td><td><p><sup>1</sup> H&#xF4;pitaux Universitaires de Strasbourg, H&#xF4;pital de Hautepierre, Service d&#x2019;Anesth&#xE9;sie-R&#xE9;animation Chirurgicale, 1 Avenue Moli&#xE8;re, 67098 Strasbourg, France.</p><p><sup>2</sup> Universit&#xE9; de Strasbourg, Facult&#xE9; de M&#xE9;decine, F&#xE9;d&#xE9;ration de M&#xE9;decine Translationnelle de Strasbourg (FMTS), EA3072, 4 Rue Kirschleger, 67085 Strasbourg, France.</p><p><sup>3</sup> F&#xE9;d&#xE9;ration Hospitalo-Universitaire OMICARE, Centre de Recherche d&#x2019;Immunologie et d&#x2019;H&#xE9;matologie, 4 rue Kirschleger, 67085 Strasbourg Cedex, France.</p><p><sup>4</sup> Sorbonne Universit&#xE9;s, UPMC Universit&#xE9; Paris 06, INSERM UMR_S 1158 Neurophysiologie Respiratoire Exp&#xE9;rimentale et Clinique, AP-HP, Groupe Hospitalier Piti&#xE9;-Salp&#xEA;tri&#xE8;re Charles Foix, D&#xE9;partement d'Anesth&#xE9;sie R&#xE9;animation, 47-83 Boulevard de l&#x2019;H&#xF4;pital 75651 Paris Cedex 13, France.</p><p><sup>5</sup> CHRU Nancy, H&#xF4;pital Central, Service d&#x2019;Anesth&#xE9;sie-R&#xE9;animation, 29 Avenue de Lattre de Tassigny, 54000 Nancy, France.</p><p><sup>6</sup> CHR Metz-Thionville &#x2013; Site de Mercy, Service de R&#xE9;animation Polyvalente, 1 All&#xE9;e du Ch&#xE2;teau, 57350 Ars Laqueney, France</p><p><sup>7</sup> Groupe Hospitalier de la R&#xE9;gion de Mulhouse et Sud Alsace (GHRMSA), P&#xF4;le d&#x2019;Anesth&#xE9;sie-R&#xE9;animation, 20 rue du Dr Laennec, 68051, Mulhouse Cedex 1, France.</p><p><sup>8</sup> H&#xF4;pital Louis Pasteur, Service d&#x2019;Anesth&#xE9;sie-R&#xE9;animation P&#xF4;le 2, 39 Avenue de la Libert&#xE9;, 68024 Colmar Cedex, France.</p><p><sup>9</sup> CHU de Reims, H&#xF4;pital Maison Blanche, R&#xE9;animation Chirurgicale et Traumatologique &#x2013; SAMU 51, 45 rue Cognacq-Jay 51092, Reims, France.</p><p><sup>10</sup> H&#xF4;pitaux Universitaires de Strasbourg, Nouvel H&#xF4;pital Civil, Laboratoire Central d&#x2019;Immunologie, 1 Place de l&#x2019;H&#xF4;pital 67091 Strasbourg Cedex, France.</p><p><sup>11</sup> Universit&#xE9; de Strasbourg, Facult&#xE9; de M&#xE9;decine, F&#xE9;d&#xE9;ration de M&#xE9;decine Translationnelle de Strasbourg (FMTS), Laboratoire d&#x2019;ImmunoRhumatologie Mol&#xE9;culaire, INSERM UMR_S 1109, 4 rue Kirschleger, 67085 Strasbourg Cedex, France.</p><p><sup>12</sup> H&#xF4;pitaux Universitaires de Strasbourg, H&#xF4;pital Civil, P&#xF4;le Sant&#xE9; Publique, Groupe M&#xE9;thode en Recherche Clinique (GMRC), 1 Place de l&#x2019;H&#xF4;pital, 67091 Strasbourg Cedex, France.</p><p><sup>13</sup> H&#xF4;pitaux Universitaires de Strasbourg, Nouvel H&#xF4;pital Civil, Service de Physiologie et d&#x2019;Explorations Fonctionnelles, 1 Place de l&#x2019;H&#xF4;pital 67091 Strasbourg Cedex, France.</p></td></tr><tr><td>Name and contact information for the trial sponsor {5b}</td><td>French Ministry of Health, GIRCI Est, Ms Nathalie PORTIER, CHU de Dijon, 14, rue Paul Gaffarel, BP 77908, 21079 Dijon Cedex, France</td></tr><tr><td>Role of sponsor {5c}</td><td>Funders will have no role in the study&#x2019;s design, collection, management, analysis, interpretation of data, writing of the report, and the decision to submit the report for publication.</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec1">
      <title>Introduction</title>
      <sec id="Sec2">
        <title>Background and rationale {6a}</title>
        <p id="Par37">Severe trauma remains a major socio-economic burden worldwide [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Indeed, it is the third cause of fatality overall, the first cause of fatality and invalidity in the 16&#x2013;45 age group and the first cause of disability-adjusted life years (DALYs). Aside from civilian and military trauma cases, terrorist attacks have added new threats [<xref ref-type="bibr" rid="CR3">3</xref>]. While the first peak of trauma-associated mortality happens within the very first hours from exsanguination and severe central nervous system injuries, secondary deaths are triggered by multi-organ failure (MOF) and acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU) [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
        <p id="Par38">The taxonomy of ARDS was recently refined by the last Berlin definition [<xref ref-type="bibr" rid="CR5">5</xref>], which also distinguished three levels of increasing hypoxaemia severity (mild/moderate/severe) based on the ratio of partial arterial oxygen tension (PaO<sub>2</sub>) over inspired oxygen fraction (FiO<sub>2</sub>). Patients who develop moderate-to-severe ARDS in the ICU have a worse prognosis compared to mild ARDS patients, including increased mortality rates (48% vs<italic>.</italic> 29%), impaired functional recovery, compromised quality of life and cognitive dysfunction [<xref ref-type="bibr" rid="CR6">6</xref>]. Severe trauma definitely remains a significant risk factor for hypoxaemia, implicating both direct and indirect lung injuries [<xref ref-type="bibr" rid="CR7">7</xref>]. Notwithstanding improvements in prehospital care, resuscitation and mechanical ventilation, the incidence of hypoxaemia in trauma patients has remained consistently high during the last 30&#x2009;years [<xref ref-type="bibr" rid="CR8">8</xref>&#x2013;<xref ref-type="bibr" rid="CR11">11</xref>]. In the most severely injured trauma patients (Injury Severity Score (ISS) [<xref ref-type="bibr" rid="CR12">12</xref>] above 15) requiring blood transfusion, the incidence of hypoxaemia may exceed 40%. Indeed, a recent analysis of the PROMMTT registry underlines that the incidence of moderate-to-severe hypoxaemia could be as high as 45% [<xref ref-type="bibr" rid="CR13">13</xref>]. In trauma patients, ARDS increases the duration of mechanical ventilation, ICU and hospital lengths of stay, incidence of ventilation-acquired pneumonias, healthcare-associated costs and mortality [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
      </sec>
      <sec id="Sec3">
        <title>Pathophysiology of trauma-associated hypoxaemia and acute respiratory distress syndrome</title>
        <p id="Par39">As previously stated [<xref ref-type="bibr" rid="CR7">7</xref>], severe trauma may contribute to hypoxaemia by both direct injuries (lung contusion, aspiration) and indirect injuries (non-thoracic trauma, musculoskeletal injuries, haemorrhagic shock, transfusion-associated acute lung injury [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]). Whatever the mechanism implicated, inflammation is a key player [<xref ref-type="bibr" rid="CR17">17</xref>&#x2013;<xref ref-type="bibr" rid="CR19">19</xref>]. Indeed, tissue injury triggers a massive and short-lived release of damage-associated molecular patterns (DAMPs) [<xref ref-type="bibr" rid="CR20">20</xref>], which bind both Toll-like receptors (TLRs) [<xref ref-type="bibr" rid="CR21">21</xref>] and receptors for advanced glycation end products (RAGE) [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], which recruit and activate neutrophils, resulting in a widespread systemic inflammatory response [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
        <p id="Par40">The molecular structure of DAMPs is diverse but the most potent are made of double-stranded DNA [<xref ref-type="bibr" rid="CR25">25</xref>], either fully (e.g. mitochondrial DNA [<xref ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref ref-type="bibr" rid="CR28">28</xref>]) or partly (e.g. nucleosomes [<xref ref-type="bibr" rid="CR29">29</xref>], high mobility group box-1 (HMGB1), heat shock proteins (HSP)).</p>
        <p id="Par41">Once bound to neutrophils, DAMPs induce profound conformational changes in these cells (NETosis), which trigger both non-self pathogen killing [<xref ref-type="bibr" rid="CR30">30</xref>] and self tissue injury [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Indeed, NETosis refers to the release of neutrophil extracellular traps (NETs), composed of a backbone (decondensed chromatin fibres) coated with antimicrobial granular and cytoplasmic proteins, such as myeloperoxidase, neutrophil elastase (NE) and &#x3B1;-defensins [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. The detrimental effects of excessive NET release are particularly important to ARDS, because NETs can expand more easily in the pulmonary alveoli, causing extensive lung injury [<xref ref-type="bibr" rid="CR33">33</xref>] and hypoxaemia. Moreover, while unbound NE is usually rapidly inactivated when released into plasma, DNA-bound NE is protected from neutralization by plasma [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
        <p id="Par42">Double-stranded DNA thus constitutes the backbone of both DAMPs and NETs, and prevents NETs from plasma neutralization. Extracellular DNA is physiologically broken up by endogenous deoxyribonucleases (DNases [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]), which may become overwhelmed by a massive influx of both DAMPs and NETs. This is exacerbated as the activity of endogenous DNases is reduced in severe trauma patients (0.059&#x2009;&#xB1;&#x2009;0.0033&#x2009;U/ml) compared to healthy controls (0.174&#x2009;&#xB1;&#x2009;0.031&#xA0;U/ml; <italic>p</italic>&#xA0;&lt;&#x2009;0.0001 [<xref ref-type="bibr" rid="CR36">36</xref>]).</p>
        <p id="Par43">However, an FDA-approved recombinant DNase has been commercially available since 1994 (dornase alfa, Pulmozyme; Roche, Basel, Switzerland and Genentech, San Francisco, CA, USA) and prescribed for the treatment of pulmonary exacerbations in cystic fibrosis patients. As dornase alfa is usually administered via the intratracheal route (aerosols), its biological actions and pharmacokinetic properties could be an excellent prerequisite for a clinical breakthrough in trauma-induced hypoxaemia. Indeed, dornase alfa was shown to reduce trauma-induced lung injury in mice [<xref ref-type="bibr" rid="CR37">37</xref>], to fight against sepsis-induced ARDS [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] and to reduce mechanical ventilation-induced lung injury [<xref ref-type="bibr" rid="CR40">40</xref>], which are traditional &#x201C;second hits&#x201D; for lung damage in ventilated trauma patients. In a small, randomized clinical trial, aerosolized dornase alfa was also shown to improve oxygenation in mechanically ventilated ICU patients with lobar atelectasis [<xref ref-type="bibr" rid="CR41">41</xref>].</p>
      </sec>
      <sec id="Sec4">
        <title>Objectives {7}</title>
        <sec id="Sec5">
          <title>Primary objective</title>
          <p id="Par44">The primary objective of the TRAUMADORNASE study is to demonstrate a reduction in the incidence of moderate-to-severe hypoxaemia from 45% to 30% in severe trauma patients during the first 7 ICU days by providing aerosolized dornase alfa once during the first 2 ICU days as compared to equivalent provision of placebo (NaCl 0.9%).</p>
        </sec>
        <sec id="Sec6">
          <title>Secondary objectives</title>
          <p id="Par45">The secondary objectives are to demonstrate, using aerosolized dornase alfa as compared to placebo, an improvement in static lung compliance, a reduction in mechanical ventilation duration or an increase in ventilation-free ICU days, a reduction in the length of ICU stay, a reduction in the hospital length of stay, a reduction in the incidence of multi-organ failure, a reduction in the incidence of ventilator-associated pneumonia (VAP) and a reduction in mortality at day 30.</p>
        </sec>
      </sec>
      <sec id="Sec7">
        <title>Trial design {8}</title>
        <p id="Par46">This will be an investigator-initiated, institution-led, multicentre, double-blinded, placebo-controlled, parallel-group, superiority, randomized trial in ventilated, trauma ICU patients.</p>
        <p id="Par47">Randomization will be carried out through a secure web-based randomization system, stratified by the centre and the presence of severe traumatic brain injury (Glasgow Coma Score&#x2009;&lt;&#x2009;9 on scene).</p>
      </sec>
    </sec>
    <sec id="Sec8">
      <title>Methods: participants, interventions and outcomes</title>
      <sec id="Sec9">
        <title>Study setting {9}</title>
        <p id="Par48">The study will be conducted in seven French participating hospitals, both university-affiliated and non-university-affiliated.</p>
      </sec>
      <sec id="Sec10">
        <title>Eligibility criteria {10}</title>
        <p id="Par49">Inclusion criteria will be checked before inclusion in the study.</p>
        <p id="Par50">The inclusion criteria are as follows:
<list list-type="bullet"><list-item><p id="Par51">Adult patient (&gt;&#x2009;18&#x2009;years old) of either sex affiliated to the National Health Service</p></list-item><list-item><p id="Par52">Severe trauma patient (either blunt or penetrating) with ISS [<xref ref-type="bibr" rid="CR12">12</xref>] &gt;&#x2009;15</p></list-item><list-item><p id="Par53">Under mechanical ventilation for an expected duration &gt;&#x2009;48&#x2009;h</p></list-item><list-item><p id="Par54">Admitted to the ICU</p></list-item><list-item><p id="Par55">Signed informed consent from the patient or the patient&#x2019;s relative or emergency consent procedure</p></list-item><list-item><p id="Par56">Patient equipped with an indwelling arterial catheter</p></list-item><list-item><p id="Par57">Negative pregnancy test in women of childbearing age</p></list-item></list></p>
        <p id="Par58">The exclusion criteria are as follows:
<list list-type="bullet"><list-item><p id="Par59">Pregnancy or breast-feeding</p></list-item><list-item><p id="Par60">Opposition from the patient or his/her relatives</p></list-item><list-item><p id="Par61">Protected major (Guardianship)</p></list-item><list-item><p id="Par62">Contraindication to the use of dornase alfa</p></list-item><list-item><p id="Par63">Known intolerance to dornase alfa</p></list-item><list-item><p id="Par64">Patient whose life expectancy is less than 24&#x2009;h, according to the treating physician</p></list-item><list-item><p id="Par65">&#x201C;Do not resuscitate&#x201D; order</p></list-item></list></p>
      </sec>
      <sec id="Sec11">
        <title>Who will take informed consent? {26a}</title>
        <p id="Par66">Inclusion will be feasible after patient approval, relative approval or emergency consent procedure (according to French law [<xref ref-type="bibr" rid="CR42">42</xref>]).</p>
        <p id="Par67">Subsequent confirmation of consent will be obtained from the relatives and from the patient as soon as possible. The consent forms are available from the corresponding author on request.</p>
        <p id="Par68">After primary haemostasis and emergent surgical interventions, patients will be randomized in the ICU within 6&#x2009;h. In the case of emergent surgical intervention before ICU admission, a maximum delay of 18&#x2009;h will be tolerated from hospital admission (trauma bay) to study drug administration. Day 0 will be considered the day of ICU admission.</p>
      </sec>
      <sec id="Sec12">
        <title>Additional consent provisions for collection and use of participant data and biological specimens {26b}</title>
        <p id="Par69">Additional consent will be required for the collection of biological specimens in ancillary studies, which will be stored for a maximum duration of 15&#x2009;years.</p>
      </sec>
      <sec id="Sec13">
        <title>Interventions</title>
        <sec id="Sec14">
          <title>Explanation for the choice of comparators {6b}</title>
          <p id="Par70">The comparator will be normal saline (NaCl 0.9%, 2.5&#x2009;ml, administered through the Aerogen solo device). NaCl is neutral regarding DAMPs, NETs and occurrence of either hypoxaemia or ARDS, and therefore is considered a placebo.</p>
        </sec>
        <sec id="Sec15">
          <title>Intervention description {11a}</title>
          <p id="Par71">Treatment with either dornase alfa or placebo will be administered using aerosol (Aerogen solo) in the ventilation circuit once per day (average treatment length: 7&#x2009;min) for the first 2 days. The Aerogen device was shown to optimize dornase alfa deposition in the distal lung airways [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Dornase alfa has an excellent safety profile and aerosolized NaCl 0.9% has a neutral effect on lung physiology.</p>
          <p id="Par72">The variables under study will be gathered every day and recorded on the electronic clinical research form (CleanWeb; Telemedicine Technologies S.A.S., Boulogne Billancourt, France).</p>
          <p id="Par73">For safety purposes, patient variables will be closely monitored before, during and within the first post-administration hour: lowest SpO<sub>2</sub>, maximal value and maximal increase in peak inspiratory airway pressure, maximal value and maximal increase in plateau airway pressure, extreme values of heart rate and mean arterial pressure, skin erythema, urticaria and variations in central temperature exceeding 1&#x2009;&#xB0;C.</p>
          <p id="Par74">During the first 7 days, at least one blood gas analysis and chest X-ray will be performed every day at 8:00&#x2009;a.m. to compute the primary endpoint: presence or absence of ARDS and severity of hypoxaemia according to the Berlin definition. Additional blood gas analysis will be allowed and the worst daily PaO<sub>2</sub>/FiO<sub>2</sub> ratio will be considered.</p>
        </sec>
        <sec id="Sec16">
          <title>Ancillary mechanistic study</title>
          <p id="Par75">On days 0, 3 and 5, additional blood samples (6&#x2009;ml on each day) will be drawn into EDTA tubes, centrifuged and stored (&#x2212;&#x2009;80&#x2009;&#xB0;C) for subsequent analysis of DAMPs (mitochondrial DNA by qPCR; HMGB1, HSP70 and sRAGE by ELISA) at the end of enrolment. Whole blood samples will be drawn (days 0, 3 and 5) for extemporaneous quantification of NETs on fresh blood using a flow cytometric assay [<xref ref-type="bibr" rid="CR45">45</xref>] in patients at the Strasbourg centre.</p>
        </sec>
      </sec>
      <sec id="Sec17">
        <title>Criteria for discontinuing or modifying allocated interventions {11b}</title>
        <p id="Par76">In the case of an adverse event following treatment administration (desaturation, bronchospasm, anaphylactic reaction), treatment will be immediately discontinued and the second treatment dose will not be given on day 1.</p>
      </sec>
      <sec id="Sec18">
        <title>Strategies to improve adherence to interventions {11c}</title>
        <p id="Par77">In each centre, boxes containing both full and empty treatment vials will be returned to the pharmacy responsible for clinical studies. For every included patient, a sheet will be completed (date, hour, nurse in charge) and signed for every study treatment preparation, administration and clinical surveillance.</p>
        <p id="Par78">For safety purposes, patient variables will be closely monitored before, during and within the first post-administration hour: lowest SpO<sub>2</sub>, maximal value and maximal increase in peak inspiratory airway pressure, maximal value and maximal increase in plateau airway pressure, extreme values of heart rate and mean arterial pressure, skin erythema, urticaria and variations in central temperature exceeding 1&#x2009;&#xB0;C.</p>
        <p id="Par79">At least one blood gas analysis and chest X-ray will be performed every day at 8:00&#x2009;a.m. to compute the primary endpoint: presence or absence of ARDS and severity of hypoxaemia according to the Berlin definition. Additional blood gas analysis will be allowed and the worst daily PaO<sub>2</sub>/FiO<sub>2</sub> ratio will be taken into account.</p>
      </sec>
      <sec id="Sec19">
        <title>Relevant concomitant care permitted or prohibited during the trial {11d}</title>
        <sec id="Sec20">
          <title>Standardization of respiratory care</title>
          <p id="Par80">Daily care for the included patients will be protocolized according to good clinical practices, especially concerning respiratory care (semi-recumbent position, protective mechanical ventilation (6&#x2013;8&#x2009;ml/kg predicted body weight), PEEP &gt;&#x2009;5 cmH<sub>2</sub>O, plateau pressure&#x2009;&lt;&#x2009;30 cmH<sub>2</sub>O, close tracheal cuff pressure monitoring, early enteral feeding (500&#x2009;ml on day 1), glucose control and protocolized sedation based on both CPOT and RASS scores [<xref ref-type="bibr" rid="CR46">46</xref>]). Adherence to guidelines will be checked in every centre for every patient.</p>
          <p id="Par81">Patients will be followed until day 30 for the record of study outcomes.</p>
          <p id="Par82">Every concomitant care will be allowed except aerosols during study drug administration.</p>
        </sec>
      </sec>
      <sec id="Sec21">
        <title>Provisions for post-trial care {30}</title>
        <p id="Par83">Post-trial care is not planned. Patients who suffer harm from trial participation will be cared for in the intensive care unit. Should prejudice linked to study participation occur, financial compensation will be provided by the insurance (Soci&#xE9;t&#xE9; Hospitali&#xE8;re d&#x2019;Assurances Mutuelles&#x2014;SHAM, 18 rue Edouard Rochet, 69,372 Lyon Cedex 08, France; contract number: 143.380) contracted by the promotor (H&#xF4;pitaux Universitaires de Strasbourg).</p>
        <p id="Par84">At 6&#x2009;months, the respiratory status will be assessed using the modified MRC dyspnoea questionnaire [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] and a chest X-ray.</p>
      </sec>
      <sec id="Sec22">
        <title>Outcomes {12}</title>
        <sec id="Sec23">
          <title>Primary endpoint</title>
          <p id="Par85">The primary endpoint will be the incidence of moderate-to-severe hypoxaemia (PaO<sub>2</sub>/FiO<sub>2</sub>&#xA0;&lt;&#x2009;200, according to the Berlin definition [<xref ref-type="bibr" rid="CR5">5</xref>]) in severe trauma patients (ISS&#x2009;&gt;&#x2009;15) during the first 7 ICU days. The PaO<sub>2</sub>/FiO<sub>2</sub> ratio will be computed at least once daily (8:00&#x2009;a.m.) together with the supine chest X-ray and the worst daily PaO<sub>2</sub>/FiO<sub>2</sub> value will be taken into account to define hypoxaemia severity. In ARDS patients, the severity of hypoxaemia allows for its classification according to the Berlin definition and is strongly associated with mortality, length of recovery and quality of life [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p>
        </sec>
        <sec id="Sec24">
          <title>Secondary endpoints</title>
          <p id="Par86">The following secondary endpoints will be recorded:
<list list-type="bullet"><list-item><p id="Par87">Static lung compliance (ml/cmH<sub>2</sub>O) (measured at least once daily at 8:00&#x2009;a.m. during the first 7 days)</p></list-item><list-item><p id="Par88">Duration of mechanical ventilation (h) from ICU admission to first extubation success (&gt;&#x2009;48&#x2009;h without reintubation)</p></list-item><list-item><p id="Par89">Length of ICU stay (h)</p></list-item><list-item><p id="Par90">Length of stay in the hospital (days)</p></list-item><list-item><p id="Par91">Incidence of multi-organ failure (a SOFA score of 3 or more in at least two organ systems [<xref ref-type="bibr" rid="CR49">49</xref>]), assessed daily during the first 7 days</p></list-item><list-item><p id="Par92">Incidence of VAP according to both the American Thoracic Society (ATS) [<xref ref-type="bibr" rid="CR50">50</xref>] and the Center for Disease Control and Prevention (CDC) [<xref ref-type="bibr" rid="CR51">51</xref>] definitions, assessed daily during the first 7 days</p></list-item><list-item><p id="Par93">Mortality on day 30</p></list-item></list></p>
          <p id="Par94">The effects of dornase alfa and normal saline will be assessed according to the plasma concentrations of DAMPs (mitochondrial DNA, HMGB-1, HSP70, sRAGE) and NETs (Strasbourg centre only) divided into quartiles at day 0, day 3 and day 5. It is anticipated that trauma patients with the highest blood concentrations of either DAMPs or NETs will develop the most severe complications (including hypoxaemia and ARDS). The time course of DAMP and NET blood concentrations will also be analysed according to treatment group to unveil a potential quicker decrease in patients randomized in the dornase alfa group.</p>
        </sec>
      </sec>
      <sec id="Sec25">
        <title>Participant timeline {13}</title>
        <p id="Par95">The total duration of participation in the study will be 30&#x2009;days. The forecast study duration is 36&#x2009;months from first to last patient recruitment (Table <xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Template of recommended content for the schedule of enrolment, interventions and assessments</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>Visit</th><th/><th/><th/><th/></tr><tr><th>Information</th><th>Enrolment</th><th>Allocation, visit 0</th><th>Post-allocation, visits 1&#x2013;7</th><th>Close-out</th></tr></thead><tbody><tr><td>Timepoint</td><td>Day 0</td><td>Day 0</td><td>Day 0</td><td>Days 1&#x2013;7</td><td>Day 30</td></tr><tr><td>Location</td><td>Hospital</td><td>Hospital</td><td>Hospital</td><td>Hospital</td><td>Hospital</td></tr><tr><td>Next of kin information</td><td>X*</td><td>X*</td><td>X</td><td/><td/></tr><tr><td>Signed informed consent</td><td/><td>X*</td><td/><td/><td/></tr><tr><td>Plasma <bold>&#x3B2;</bold>HCG assay</td><td/><td>X(*)</td><td/><td/><td/></tr><tr><td>Eligibility criteria check</td><td>X*</td><td>X*</td><td>X*</td><td/><td/></tr><tr><td>Randomization</td><td/><td/><td>X*</td><td/><td/></tr><tr><td>Study drug administration</td><td/><td/><td>X*<sup>d</sup></td><td>X*<sup>d</sup></td><td/></tr><tr><td>Clinical examination<sup>a</sup></td><td/><td>X</td><td>X</td><td>X</td><td/></tr><tr><td>Diagnostic tests<sup>b</sup></td><td/><td>X</td><td>X</td><td>X</td><td/></tr><tr><td>Blood assay<sup>c</sup></td><td/><td/><td>X*</td><td>X*</td><td/></tr><tr><td>Adverse effect recording</td><td/><td>X*</td><td>X*</td><td>X*</td><td>X*</td></tr><tr><td>Concomitant medications</td><td/><td>X</td><td>X</td><td>X</td><td>X</td></tr></tbody></table><table-wrap-foot><p><italic>&#x3B2;HCG</italic> beta human chorionic gonadotropin, <italic>X</italic> diagnostic test performed on a daily basis according to the standard of care in participating centres, <italic>X*</italic> diagnostic tests performed for the purpose of the TRAUMADORNASE study</p><p><sup>a</sup>Clinical examination includes physical examination (auscultation of the chest, central body temperature, positive end-expiratory pressure and inspired oxygen fraction levels) and recording of Utstein criteria [<xref ref-type="bibr" rid="CR49">49</xref>]</p><p><sup>b</sup>Diagnostic tests include arterial blood gases, chest X-ray, leukocyte and platelet counts, creatinine, blood urea nitrogen, bilirubin and quantitative lung bacteriologic samplings (bronchoalveolar lavage fluid or protected specimen brush) in the case of suspected lung infection</p><p><sup>c</sup>Blood withdrawal: 6&#x2009;ml of blood on day 0, day 3 and day 5</p><p><sup>d</sup>Study treatment will be given on day 0 and day 1</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec26">
        <title>Sample size {14}</title>
        <p id="Par96">The sample size was determined to be 250 subjects per arm (i.e. 500 subjects in total). Dornase alfa is expected to reduce the incidence of moderate-to-severe hypoxaemia from 0.45 to 0.30. Considering a reasonable standard deviation of 0.03, and using Bayesian techniques [<xref ref-type="bibr" rid="CR52">52</xref>], 200 subjects per arm were estimated to show a difference of more than 0.12 (instead of the expected 0.15). Assuming 25% loss to follow-up, this number was increased to 250 subjects per arm, although these subjects will not be replaced.</p>
      </sec>
      <sec id="Sec27">
        <title>Recruitment {15}</title>
        <p id="Par97">Patients will be recruited in seven French participating hospitals, both university-affiliated and non-university-affiliated and admitting severe trauma patients:
<list list-type="bullet"><list-item><p id="Par98">H&#xF4;pitaux Universitaires de Strasbourg, H&#xF4;pital de Hautepierre (150 severe trauma patients per year)</p></list-item><list-item><p id="Par99">H&#xF4;pitaux de Colmar, H&#xF4;pital Louis Pasteur (50 severe trauma patients per year)</p></list-item><list-item><p id="Par100">Centre Hospitalo-Universitaire de Reims, H&#xF4;pital Maison Blanche (150 severe trauma patients per year)</p></list-item><list-item><p id="Par101">Centre Hospitalier R&#xE9;gional Metz-Thionville, H&#xF4;pital de Mercy (50 severe trauma patients per year)</p></list-item><list-item><p id="Par102">Groupe Hospitalier de la R&#xE9;gion de Mulhouse et Sud-Alsace, H&#xF4;pital du Moenchsberg&#x2014;Emile Muller (50 severe trauma patients per year)</p></list-item><list-item><p id="Par103">Centre Hospitalier R&#xE9;gional Universitaire de Nancy, H&#xF4;pital Central (220 severe trauma patients per year)</p></list-item><list-item><p id="Par104">Assistance Publique&#x2014;H&#xF4;pitaux de Paris, H&#xF4;pital Universitaire Piti&#xE9; Salp&#xEA;tri&#xE8;re&#x2014;Charles Foix (500 severe trauma patients per year)</p></list-item></list></p>
        <p id="Par105">Taken as a whole, more than 3500 patients per year fulfil the inclusion criteria, allowing for an inclusion ratio of one patient included out of seven patients admitted to one of the participating centres.</p>
      </sec>
      <sec id="Sec28">
        <title>Assignment of interventions: allocation</title>
        <sec id="Sec29">
          <title>Sequence generation {16a}</title>
          <p id="Par106">Randomization will be conducted over a dedicated, password-protected, SSL-encrypted website (CleanWeb; Telemedicine Technologies S.A.S.) to allow immediate and concealed allocation. Allocation will also be stratified by centre and the presence of severe traumatic brain injury (Glasgow Coma Score&#x2009;&lt;&#x2009;9 on scene).</p>
        </sec>
        <sec id="Sec30">
          <title>Concealment mechanism {16b}</title>
          <p id="Par107">The experimental study drug and placebo will be provided in identical boxes, allowing double-blind administration. The logistics of the trial fluid distribution to each of the seven participating centres that are anticipated to be recruiting will be coordinated by the pharmacy of the coordinating centre (H&#xF4;pitaux Universitaires de Strasbourg).</p>
        </sec>
        <sec id="Sec31">
          <title>Implementation {16c}</title>
          <p id="Par108">The allocation sequence will be computer-generated (CleanWeb; Telemedicine Technologies S.A.S.). Patients will be enrolled by registered investigators, who will also assign patients to a treatment consisting of either dornase alfa or placebo.</p>
        </sec>
      </sec>
      <sec id="Sec32">
        <title>Assignment of interventions: blinding</title>
        <sec id="Sec33">
          <title>Who will be blinded {17a}</title>
          <p id="Par109">Trial participants, care providers, outcome assessors and data analysts will remain blinded after assignment to interventions, until the final analysis.</p>
        </sec>
        <sec id="Sec34">
          <title>Procedure for unblinding if needed {17b}</title>
          <p id="Par110">Unblinding is permissible whenever an adverse event occurs, via immediate request to the poison centre of the study coordinator hospital (H&#xF4;pitaux Universitaires de Strasbourg) 24&#x2009;h per day and 365&#x2009;days per year. The procedure for revealing a participant&#x2019;s allocated intervention during the trial includes an explicit mention in the patient record.</p>
        </sec>
      </sec>
      <sec id="Sec35">
        <title>Data collection and management</title>
        <sec id="Sec36">
          <title>Plans for assessment and collection of outcomes {18a}</title>
          <p id="Par111">Clinical research associates will ensure that patient inclusion, data collection, registry and rapport are in line with the protocol, and that the study is conducted in accordance with the Good Clinical Practice guidelines. Furthermore, clinical research associates will check the following variables: patient initials, date of birth, sex, signed consent form, eligibility criteria, date of randomization, treatment assignment, adverse events and study endpoints. The data monitoring committee is institution-based and independent from potential industrial sponsors.</p>
        </sec>
        <sec id="Sec37">
          <title>Plans to promote participant retention and complete follow-up {18b}</title>
          <p id="Par112">A dedicated card will be given to any included patient and participation in the TRAUMADORNASE trial will be explicitly mentioned during transfer to another ward or hospital during handovers.</p>
        </sec>
        <sec id="Sec38">
          <title>Data management {19}</title>
          <p id="Par113">Data will be collected in each centre by clinical data technicians on an electronic case report form (CleanWeb; Telemedicine Technologies S.A.S.) using double password-protected computers. Pre-specified lists, range of values and drop-down menus in the electronic case report form will facilitate data entry and prevent writing errors. Study documents will be de-identified, stored in each recruitment centre and kept for at least 15&#x2009;years in a locked, secure office, according to French law. All personnel involved in data analysis will be masked. Only the principal investigators and the statisticians will have access to the final data set.</p>
        </sec>
        <sec id="Sec39">
          <title>Confidentiality {27}</title>
          <p id="Par114">People with direct access to the data will take all necessary precautions to maintain confidentiality. All data collected during the study will be rendered anonymous. Only initials and inclusion number will be registered.</p>
        </sec>
        <sec id="Sec40">
          <title>Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}</title>
          <p id="Par115">On days 0, 3 and 5, additional blood samples (6&#x2009;ml on each day) will be drawn into EDTA tubes, centrifuged and stored (&#x2212;&#x2009;80&#x2009;&#xB0;C) for subsequent analysis of DAMPs (mitochondrial DNA by qPCR; HMGB1, HSP70 and sRAGE by ELISA) at the end of enrolment. In patients included in the Strasbourg centre, whole blood samples will be drawn (days 0, 3 and 5) for extemporaneous quantification of NETs on fresh blood using a flow cytometric assay [<xref ref-type="bibr" rid="CR45">45</xref>]. The remaining biological specimens will be stored in 0.5-ml aliquots at &#x201C;Biomax&#x201D; biobank, Laboratoire d&#x2019;ImmunoRhumatologie Mol&#xE9;culaire, INSERM UMR_S 1109, 4, rue Kirchleger, 67,085 Strasbourg, France (Pr Siamak Bahram) for a maximum duration of 15&#x2009;years (BB-0033-00084, CIM code: I00-I99 / A00-B99 / D50-D89 / M00-M99 / F00-F99 / G00-G99).</p>
        </sec>
      </sec>
      <sec id="Sec41">
        <title>Statistical methods</title>
        <sec id="Sec42">
          <title>Statistical methods for primary and secondary outcomes {20a}</title>
          <p id="Par116">Statistical analyses will include a descriptive step and an inferential step using fully Bayesian techniques. The estimates will use Markov chains to Monte Carlo integrations (McMC), choosing prior distributions to be nearly conjugated situations. Unless the diagnoses for convergence give clues to the contrary, we will use three Markov chains with separated starting points, a burn-in of 100,000 for each chain and 100,000 more iterations with a thinning of 25 for building a total sample of 12,000 iterations on which the Monte Carlo integrations are used to retrieve characteristics of posterior distributions. The analyses will be carried out using R software (with ad hoc packages) and OpenBUGS. Sensitivity analyses will be systematically conducted, considering three scenarios with different priors: a default non-informative prior (e.g. Jeffreys prior), then an optimist prior and, finally, a pessimist prior.</p>
          <p id="Par117">In the descriptive step, all of the variables collected will be summarized: number and frequency for qualitative variables (ordinal and categorical) and minimum, quantiles (2.5, 25, 50, 75 and 97.5), maximum, mean and standard deviation for quantitative variables (discrete and continuous). For variables gathered over time, these descriptions will be provided globally and at each time. This description will be enriched by inference to extrapolate the observed quantities on the sample. For quantitative variables, we will assume a normal likelihood combined with a normal prior on the mean (mean 0 and variance 100) and &#x3B3; on the precision (inverse of variance) with parameters 0.0005 and 0.005, and therefore mean 0.1 and variance 20. For binary variables (for which one proportion needs to be estimated), we will assume a binomial likelihood and a &#x3B2; prior on the proportion (Jeffreys prior with parameters 0.5 and 0.5, and thus mean 0.5 and variance 0.125). For categorical variables with more than two categories, we will assume a categorical likelihood together with a Dirichlet prior (Jeffreys prior with all parameters at 0.5).</p>
          <p id="Par118">The aim of this study is to show that the frequency of moderate-to-severe hypoxaemia is lower in the dornase alpha group than in the placebo group. The main variable is then dichotomous &#x201C;moderate-to-severe hypoxaemia yes/no&#x201D;, modelled in a logistic mixed regression. We will assume that this variable is Bernoulli distributed with parameter &#x3C0;. The logit of this parameter (linear predictor) is additively written as:
<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{logit}\left({\pi}_i\right)={\alpha}_0+{\alpha}_1I\left({g}_i=1\right)+{\beta}_i, $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mtext>logit</mml:mtext><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#x3C0;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x3B1;</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3B1;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>I</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3B2;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:math><graphic xlink:href="13063_2020_4141_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p>
          <p id="Par119">where:
<list list-type="bullet"><list-item><p id="Par120"><italic>&#x3B1;</italic><sub>0</sub> is a grand mean, with mean 0 normal prior (the variance in this normal is 6, corresponding to a low informative prior)</p></list-item><list-item><p id="Par121"><italic>I</italic>(<italic>g</italic><sub><italic>i</italic></sub>&#x2009;=&#x2009;1) is a dummy covariate coded for the group of subject <italic>i</italic> (1 for the dornase alpha group and 0 for the placebo group) &#x2014; the prior on the parameter of this covariate is the same normal as that for the grand mean</p></list-item><list-item><p id="Par122"><italic>&#x3B2;</italic><sub><italic>i</italic></sub> is a (random) subject effect, on which is assumed a normal prior with mean 0 and low variance (e.g.&#xA0;10)</p></list-item></list></p>
          <p id="Par123">Because the linear predictor is on the logit scale, the probability for moderate-to-severe hypoxaemia will be obtained by monitoring the back-transformation of the logit.</p>
          <p id="Par124">This regression model without covariates except group will be completed for taking into account potential confounding variables. In the model, the entire set of these variables will be added and, secondly, selected using stochastic search variable selection (SSVS) [<xref ref-type="bibr" rid="CR53">53</xref>]. In such a model, the prior distribution on each parameter is a mixture of two mean 0 normal distributions, one with low variance and the other with high variance: if the posterior weight on this second normal is strongly around 0, then the prior on the parameter is essentially driven by a normal distribution whose mean is centred on 0; this is the clue for a &#x201C;non-significant&#x201D; parameter.</p>
          <p id="Par125">The secondary analyses will be conducted as the main analysis with a regressive model, testing the difference of a parameter between the two groups. Only the likelihood model will be changed to take into account the type of variable studied: &#x3B3; distribution for continuous variables such as length of stay and duration of ventilation. Dichotomous variables such as 30-day mortality will be studied with logistic regression.</p>
          <p id="Par126">No statistical procedure for replacing missing values will be used. All variables and subjects will be considered in the descriptive analyses, but, for inference, 20% missing data or more will result in rejection of the variable or individual.</p>
        </sec>
        <sec id="Sec43">
          <title>Interim analyses {21b}</title>
          <p id="Par127">An interim analysis will be performed after inclusion of the first 250 patients. These preliminary data will be available to the data safety and monitoring board (see later for details), which will have the ability to stop the trial for either futility or harm.</p>
        </sec>
        <sec id="Sec44">
          <title>Methods for additional analyses (e.g. subgroup analyses) {20b}</title>
          <p id="Par128">Analyses will be performed in intention to treat. To verify the impact of possible deviations from the protocol, these analyses will be supplemented by an analysis per protocol. Subgroup analyses will be conducted according to the Glasgow Coma Scale on site (score either &#x2264;&#x2009;8 or&#x2009;&gt;&#x2009;9).</p>
        </sec>
        <sec id="Sec45">
          <title>Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}</title>
          <p id="Par129">No statistical procedure for replacing missing values will be used. All variables and subjects will be considered in the descriptive analyses, but, for inference, 20% missing data or more will result in rejection of the variable or individual.</p>
        </sec>
        <sec id="Sec46">
          <title>Plans to give access to the full protocol, participant-level data and statistical code {31c}</title>
          <p id="Par130">The protocol is available on the <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> website (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03368092?term=traumadornase&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT03368092?term=traumadornase&amp;draw=2&amp;rank=1</ext-link>). Study documents will be de-identified, stored in each recruitment centre and kept for at least 15&#x2009;years in a locked, secure office, according to French law. All personnel involved in data analysis will be masked. Only the principal investigators and the statisticians will have access to the final data set.</p>
        </sec>
      </sec>
      <sec id="Sec47">
        <title>Oversight and monitoring</title>
        <sec id="Sec48">
          <title>Composition of the coordinating centre and trial steering committee {5d}</title>
          <p id="Par131">Coordinating centre: Direction de la Recherche Clinique et de l&#x2019;Innovation (DRCI) des H&#xF4;pitaux Universitaires de Strasbourg, 1 Place de l&#x2019;H&#xF4;pital, 67,085 Strasbourg Cedex, France.</p>
          <p id="Par132">Steering committee: Julien Pottecher, MD, PhD (H&#xF4;pitaux Universitaires de Strasbourg), Eric Noll, MD, PhD (H&#xF4;pitaux Universitaires de Strasbourg), Mathieu Raux, MD, PhD (AP-HP, H&#xF4;pital Universitaire Piti&#xE9; Salp&#xEA;tri&#xE8;re), G&#xE9;rard Audibert, MD, PhD (CHRU Nancy), Alain Leon, MD, PhD (CHU de Reims) and Pierre Diemunsch, MD, PhD (H&#xF4;pitaux Universitaires de Strasbourg).</p>
          <p id="Par133">Endpoint adjudication committee: TraumaBase Group.</p>
          <p id="Par134">Data management team: Erik Sauleau, MD, PhD and Groupe M&#xE9;thode en Recherche Clinique (GMRC), H&#xF4;pitaux Universitaires de Strasbourg, Strasbourg, France.</p>
        </sec>
        <sec id="Sec49">
          <title>Composition of the data monitoring committee, its role and reporting structure {21a}</title>
          <p id="Par135">The data safety and monitoring board (DSMB) will include Dr Laure Peyro-Saint Paul (drug monitoring specialist), Prof. Bernard Asselain (methodologist and biostatistician), Prof. Catherine Paugam-Burtz (anaesthesiologist and intensive care physician), Prof. Samir Jaber (anaesthesiologist and intensive care physician) and Prof. Boris Jung (intensive care physician).</p>
          <p id="Par136">The DSMB, independent from the study sponsor and principal investigator, including three intensive care physicians, one methodologist and one drug safety specialist, will meet after inclusion of the first 20 patients to assess the safety of dornase alfa administration in ventilated trauma patients. The safety variables under study are detailed in the &#x201C;Interventions&#x201D; section. The DSMB will meet subsequently after further incremental inclusions of 100 patients. The DSMB charter was signed by all of its members.</p>
        </sec>
        <sec id="Sec50">
          <title>Adverse event reporting and harms {22}</title>
          <p id="Par137">Adverse events and unintended effects of the trial intervention or trial conduct will be declared to the promotor within 24&#x2009;h of occurrence. Moreover, the DSMB will meet after inclusion of the first 20 patients to assess the safety of dornase alfa administration in ventilated trauma patients. The safety variables under study are detailed in the following. For safety purposes, patient variables will be closely monitored before, during and within the first post-administration hour: lowest SpO<sub>2</sub>, maximal value and maximal increase in peak inspiratory airway pressure, maximal value and maximal increase in plateau airway pressure, extreme values of heart rate and mean arterial pressure, skin erythema, urticaria and variations in central temperature exceeding 1&#x2009;&#xB0;C. The DSMB will meet subsequently after further incremental inclusions of 100 patients.</p>
        </sec>
        <sec id="Sec51">
          <title>Frequency and plans for auditing trial conduct {23}</title>
          <p id="Par138">In every centre, an audit will be performed by the Direction de la Recherche Clinique des H&#xF4;pitaux Universitaires de Strasbourg after inclusion of the first patient, then yearly and after enrolment of the last patient.</p>
        </sec>
        <sec id="Sec52">
          <title>Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25}</title>
          <p id="Par139">Important protocol modifications will be communicated to investigators, IRB and trial registries via e-mail. Every protocol amendment will be first submitted to the IRB and, after validation, transmitted to investigating centres, which will acknowledge receipt.</p>
        </sec>
      </sec>
      <sec id="Sec53">
        <title>Dissemination plans {31a}</title>
        <p id="Par140">The results of the study will be released to the participating physicians, referring physicians and medical community no later than 1 year after the completion of the trial, through presentation at scientific conferences and publication in peer-reviewed journals. Eligible authors will meet all four requirements of the ICMJE guidelines:
<list list-type="bullet"><list-item><p id="Par141">Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work</p></list-item><list-item><p id="Par142">Drafting the work or revising it critically for important intellectual content</p></list-item><list-item><p id="Par143">Final approval of the version to be published</p></list-item><list-item><p id="Par144">Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved</p></list-item></list></p>
      </sec>
    </sec>
    <sec id="Sec54">
      <title>Discussion</title>
      <p id="Par145">To the best of our knowledge, TRAUMADORNASE is the first large-scale study to evaluate the usefulness of inhaled dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in a population of severe trauma patients, who will also benefit from other lung-protective measures. The benefits are expected to include a reduction in both duration of mechanical ventilation and stay in the ICU, lower costs of hospital stay, fewer days on mechanical ventilation and a reduction in the selective pressure on multidrug-resistant bacteria.</p>
      <p id="Par146">In order to keep management practices as standardized as possible, we decided to limit the number of investigating centres to seven university-affiliated and non university-affiliated hospitals, all of which are recognized in the field of trauma care and treat more than 50 severe trauma patients per year. These centres belong to the TraumaBase network (<ext-link ext-link-type="uri" xlink:href="http://www.traumabase.eu">www.traumabase.eu</ext-link>), which promotes multicentre clinical research on trauma and ensures consistent recording of clinical data according to the TraumaBase registry guidelines. These seven centres also share the same standards of care and, except for Piti&#xE9;-Salp&#xEA;tri&#xE8;re centre, belong to the same region of France (Grand Est).</p>
      <p id="Par147">From a translational point of view, the study will challenge the hypothesis that breaking up the double-stranded DNA backbone of both DAMPs and NETs with dornase alfa may reduce inflammation and NET-induced epithelial and endothelial cell injuries in the lungs of trauma patients.</p>
      <p id="Par148">Dornase alfa is a long-standingFDA-approved mucolytic agent used in cystic fibrosis patients. Its safety profile and limited side effects make it an appropriate candidate to curb DAMP-induced, NET-mediated inflammation. As we will use high-end vibrating mesh nebulizers, which provide excellent lung deposition and drug bioavailability, we expect that dornase alfa will be deposited within the depth of the lung parenchyma, where it may be the most useful.</p>
      <sec id="Sec55">
        <title>Study limitations</title>
        <p id="Par149">The incidence of moderate-to-severe hypoxaemia is the primary study endpoint. A 45% basal incidence of moderate-to-severe hypoxaemia may appear overstated to some experts, but it must be underlined that only severe trauma patients will be included and that a 45% incidence was reported in the last randomized PROMTT trial [<xref ref-type="bibr" rid="CR13">13</xref>], in the era of damage-control resuscitation [<xref ref-type="bibr" rid="CR54">54</xref>]. A 15% absolute reduction seems ambitious for a single intervention. However, previous studies using dornase alfa in animal lung injury models and in ventilated patients suffering atelectasis demonstrated striking results [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x2013;<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR55">55</xref>].</p>
        <p id="Par150">Because fluid loading regimens and transfusion strategies are based on local written protocols, they may act as potential confounding variables. However, this will be controlled by the stratification of the randomization at the centre level and adjustment of statistical analyses in cases of differences between groups.</p>
        <p id="Par151">In conclusion, this trial is the first multicentre, randomized controlled, double-blinded study adequately powered to test the hypothesis that aerosolized dornase alfa reduces the incidence of moderate-to-severe hypoxaemia in mechanically ventilated severe trauma patients.</p>
      </sec>
    </sec>
    <sec id="Sec56">
      <title>Trial status</title>
      <p id="Par152">Protocol version 8.0 was approved by the National Institutional Review Board on 6 November 2018. The study started on 10 March 2019 and is expected to last until September 2022 (36-month inclusion period plus 6-month participation period).</p>
      <p id="Par153">After validation from its Scientific Committee, the TRAUMADORNASE study was funded by the French Ministry of Health.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ARDS</term>
          <def>
            <p id="Par5">Acute respiratory distress syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>ATS</term>
          <def>
            <p id="Par6">American Thoracic Society</p>
          </def>
        </def-item>
        <def-item>
          <term>CDC</term>
          <def>
            <p id="Par7">Center for Disease Control and Prevention</p>
          </def>
        </def-item>
        <def-item>
          <term>CPOT</term>
          <def>
            <p id="Par8">Critical Care Pain Observation Tool</p>
          </def>
        </def-item>
        <def-item>
          <term>DALY</term>
          <def>
            <p id="Par9">Disability-adjusted life year</p>
          </def>
        </def-item>
        <def-item>
          <term>DAMP</term>
          <def>
            <p id="Par10">Damage-associated molecular pattern</p>
          </def>
        </def-item>
        <def-item>
          <term>DSMB</term>
          <def>
            <p id="Par11">Data safety and monitoring board</p>
          </def>
        </def-item>
        <def-item>
          <term>EDTA</term>
          <def>
            <p id="Par12">Ethylenediaminetetraacetic acid</p>
          </def>
        </def-item>
        <def-item>
          <term>ELISA</term>
          <def>
            <p id="Par13">Enzyme-linked immunosorbent assay</p>
          </def>
        </def-item>
        <def-item>
          <term>FDA</term>
          <def>
            <p id="Par14">US Food and Drug Administration</p>
          </def>
        </def-item>
        <def-item>
          <term>FiO<sub>2</sub></term>
          <def>
            <p id="Par15">Inspired oxygen fraction</p>
          </def>
        </def-item>
        <def-item>
          <term>HMGB1</term>
          <def>
            <p id="Par16">High mobility group box-1</p>
          </def>
        </def-item>
        <def-item>
          <term>HSP</term>
          <def>
            <p id="Par17">Heat shock proteins</p>
          </def>
        </def-item>
        <def-item>
          <term>ICMJE</term>
          <def>
            <p id="Par18">International Committee of Medical Journal Editors</p>
          </def>
        </def-item>
        <def-item>
          <term>ICU</term>
          <def>
            <p id="Par19">Intensive care unit</p>
          </def>
        </def-item>
        <def-item>
          <term>IRB </term>
          <def>
            <p id="Par20">Institutional review board</p>
          </def>
        </def-item>
        <def-item>
          <term>ISS</term>
          <def>
            <p id="Par21">Injury Severity Score</p>
          </def>
        </def-item>
        <def-item>
          <term>McMC</term>
          <def>
            <p id="Par22">Markov chain Monte Carlo</p>
          </def>
        </def-item>
        <def-item>
          <term>MOF</term>
          <def>
            <p id="Par23">Multi-organ failure</p>
          </def>
        </def-item>
        <def-item>
          <term>MRC</term>
          <def>
            <p id="Par24">Medical Research Council</p>
          </def>
        </def-item>
        <def-item>
          <term>NE </term>
          <def>
            <p id="Par25">Neutrophil elastase</p>
          </def>
        </def-item>
        <def-item>
          <term>NET</term>
          <def>
            <p id="Par26">Neutrophil extracellular trap</p>
          </def>
        </def-item>
        <def-item>
          <term>PaO<sub>2</sub></term>
          <def>
            <p id="Par27">Partial arterial oxygen tension</p>
          </def>
        </def-item>
        <def-item>
          <term>PEEP</term>
          <def>
            <p id="Par28">Positive end-expiratory pressure</p>
          </def>
        </def-item>
        <def-item>
          <term>qPCR</term>
          <def>
            <p id="Par29">Quantitative polymerase chain reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>RAGE</term>
          <def>
            <p id="Par30">Receptors for advanced glycation end products</p>
          </def>
        </def-item>
        <def-item>
          <term>RASS</term>
          <def>
            <p id="Par31">Richmond Agitation and Sedation Scale</p>
          </def>
        </def-item>
        <def-item>
          <term>SOFA</term>
          <def>
            <p id="Par32">Sequential Organ Failure Assessment</p>
          </def>
        </def-item>
        <def-item>
          <term>SSL</term>
          <def>
            <p id="Par33">Secure Sockets Layer</p>
          </def>
        </def-item>
        <def-item>
          <term>SSVS</term>
          <def>
            <p id="Par34">Stochastic search variable selection</p>
          </def>
        </def-item>
        <def-item>
          <term>TLR</term>
          <def>
            <p id="Par35">Toll-like receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>VAP</term>
          <def>
            <p id="Par36">Ventilator-associated pneumonia</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors are greatly indebted to Barbara Jung and Mathias Candusso, clinical research associates, for writing the study draft. The authors thank Jo-Ann Elicia West, MSc, an independent consultant in Cartigny L&#x2019;Epinay, France, for providing editorial support, which was funded by H&#xF4;pitaux Universitaires Strasbourg, Direction de la Recherche Clinique et des Innovations, Strasbourg, France in accordance with Good Publication Practice (GPP3) guidelines (<ext-link ext-link-type="uri" xlink:href="http://www.ismpp.org/gpp3">http://www.ismpp.org/gpp3</ext-link>).</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions {31b}</title>
      <p>JP conceived the study, coordinated its design, drafted and wrote the manuscript. JP, EN, MB, GA, SG, CM, EG, VL, RC, BU-L, ES, WGL, SB, AM, BG and PD read and were involved in critical appraisal and revision of the manuscript. ES provided statistical expertise. All authors approved the final manuscript prior to submission.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding {4}</title>
      <p>Aerogen (Ireland) will provide nebulizers to the study centres (estimated value: &#x20AC;28,000).</p>
      <p>After validation from its Scientific Committee, the TRAUMADORNASE study is supported by a &#x20AC;300,000 grant from the French Ministry of Health (PHRCI-2017-S09). Funders will have no role in the study&#x2019;s design, collection, management, analysis and interpretation of data, writing of the report and the decision to submit the report for publication conception or in the data analysis.</p>
      <p>Name and contact information for the trial sponsor: Ms Nathalie PORTIER, French Ministry of Health, GIRCI Est, CHU de Dijon, 14, rue Paul Gaffarel, BP 77908, 21079 Dijon Cedex, France.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials {29}</title>
      <p>Only the principal investigators, the DSMB and the statisticians will have access to the final data set.</p>
      <p>The data sets used and analysed during the current study will be available from the corresponding author on reasonable request, after publication of the main core article.</p>
    </notes>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate {24}</title>
      <p id="Par154">The clinical trial will adhere to the principles of the Declaration of Helsinki and to the Clinical Trials Directive 2001/20/EC of the European Parliament on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of Good Clinical Practices in the conduct of clinical trials on medicinal products for human use. Ethical aspects of this research project have been approved by the French Agence Nationale de la S&#xE9;curit&#xE9; du M&#xE9;dicament et des Produits de Sant&#xE9; (ANSM, on 5 October 2018) and a National Institutional Review Board (CPP, on 6 November 2018), which covers all participant sites. The trial will be monitored by the research monitoring officers of Strasbourg University Hospital. Significant changes to the protocol will be submitted for approbation by the National Institutional Review Board.</p>
      <p id="Par155">Prior consent of the subject will not be possible in most cases due to traumatic brain injury, haemorrhagic shock or prehospital sedation requirements. Therefore, consent of the subject&#x2019;s legally acceptable representative will be requested. A consent form specifically designed for the subject&#x2019;s legally acceptable representative will be provided with documented approval or favourable opinion of the institutional review board in order to protect the rights, safety and well-being of the subject and to ensure compliance with any applicable regulatory requirements. Consent to participation in the study by the patient&#x2019;s relatives will be solicited, according to the requirements of the ethics committee. In cases where neither patient consent nor relative&#x2019;s consent is available within the 6-h inclusion timeline, the subject will be included following the emergency consent procedure (according to French law [<xref ref-type="bibr" rid="CR42">42</xref>], Code de la Sant&#xE9; Publique, Article L1122&#x2013;1).</p>
      <p id="Par156">Subsequent confirmation of consent will be obtained from the relatives and the patient as soon as possible.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication {32}</title>
      <p id="Par157">Although it is not anticipated, owing to the trial design, publication of any personal information about a patient will require her/his consent.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests {28}</title>
      <p id="Par158">The authors declare that they have no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>CJL</given-names>
            </name>
            <name>
              <surname>Vos</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lozano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Naghavi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Flaxman</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Michaud</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990&#x2013;2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title>
          <source>Lancet</source>
          <year>2012</year>
          <volume>380</volume>
          <fpage>2197</fpage>
          <lpage>2223</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(12)61689-4</pub-id>
          <pub-id pub-id-type="pmid">23245608</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davis</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Fabian</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Cioffi</surname>
              <given-names>WG</given-names>
            </name>
          </person-group>
          <article-title>The toll of death and disability from traumatic injury in the United States&#x2014;the &#x201C;neglected disease&#x201D; of modern society, still neglected after 50 years</article-title>
          <source>JAMA Surg</source>
          <year>2017</year>
          <volume>152</volume>
          <fpage>221</fpage>
          <pub-id pub-id-type="doi">10.1001/jamasurg.2016.4625</pub-id>
          <pub-id pub-id-type="pmid">28030708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orban</surname>
              <given-names>J-C</given-names>
            </name>
            <name>
              <surname>Quintard</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ichai</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>ICU specialists facing terrorist attack: the Nice experience</article-title>
          <source>Intensive Care Med</source>
          <year>2017</year>
          <volume>43</volume>
          <fpage>683</fpage>
          <lpage>685</lpage>
          <pub-id pub-id-type="doi">10.1007/s00134-016-4570-6</pub-id>
          <pub-id pub-id-type="pmid">27695883</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riou</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Landais</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vivien</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Stell</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Labbene</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Carli</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Distribution of the probability of survival is a strategic issue for randomized trials in critically ill patients</article-title>
          <source>Anesthesiology</source>
          <year>2001</year>
          <volume>95</volume>
          <fpage>56</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="doi">10.1097/00000542-200107000-00014</pub-id>
          <pub-id pub-id-type="pmid">11465584</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>The ARDS Definition Task Force</collab>
            <name>
              <surname>Ranieri</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Rubenfeld</surname>
              <given-names>GD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute respiratory distress syndrome: the Berlin Definition</article-title>
          <source>JAMA</source>
          <year>2012</year>
          <volume>307</volume>
          <issue>23</issue>
          <fpage>2526</fpage>
          <lpage>2533</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.2012.5669</pub-id>
          <pub-id pub-id-type="pmid">22797452</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herridge</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Tansey</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Matt&#xE9;</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tomlinson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Diaz-Granados</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Functional disability 5 years after acute respiratory distress syndrome</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>364</volume>
          <fpage>1293</fpage>
          <lpage>1304</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1011802</pub-id>
          <pub-id pub-id-type="pmid">21470008</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>KD</given-names>
            </name>
          </person-group>
          <article-title>Acute respiratory distress syndrome</article-title>
          <source>N Engl J Med</source>
          <year>2017</year>
          <volume>377</volume>
          <fpage>562</fpage>
          <lpage>572</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra1608077</pub-id>
          <pub-id pub-id-type="pmid">28792873</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pfeifer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Heussen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Michalewicz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hilgers</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Pape</surname>
              <given-names>HC</given-names>
            </name>
          </person-group>
          <article-title>Incidence of adult respiratory distress syndrome in trauma patients: a systematic review and meta-analysis over a period of three decades</article-title>
          <source>J Trauma Acute Care Surg</source>
          <year>2017</year>
          <volume>83</volume>
          <fpage>496</fpage>
          <lpage>506</lpage>
          <pub-id pub-id-type="doi">10.1097/TA.0000000000001571</pub-id>
          <pub-id pub-id-type="pmid">28590348</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Leary</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Keeley</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Yule</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Suruki</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Plurad</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Moazzez</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical predictors of early acute respiratory distress syndrome in trauma patients</article-title>
          <source>Am J Surg</source>
          <year>2016</year>
          <volume>212</volume>
          <fpage>1096</fpage>
          <lpage>1100</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjsurg.2016.09.008</pub-id>
          <pub-id pub-id-type="pmid">27780558</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hendrickson</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Howard</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Kornblith</surname>
              <given-names>LZ</given-names>
            </name>
            <name>
              <surname>Conroy</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Zhuo</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The acute respiratory distress syndrome following isolated severe traumatic brain injury</article-title>
          <source>J Trauma Acute Care Surg</source>
          <year>2016</year>
          <volume>80</volume>
          <fpage>989</fpage>
          <lpage>997</lpage>
          <pub-id pub-id-type="doi">10.1097/TA.0000000000000982</pub-id>
          <pub-id pub-id-type="pmid">26881489</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reilly</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Bellamy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shashaty</surname>
              <given-names>MGS</given-names>
            </name>
            <name>
              <surname>Gallop</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Lanken</surname>
              <given-names>PN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Heterogeneous phenotypes of acute respiratory distress syndrome after major trauma</article-title>
          <source>Ann Am Thorac Soc</source>
          <year>2014</year>
          <volume>11</volume>
          <fpage>728</fpage>
          <lpage>736</lpage>
          <pub-id pub-id-type="doi">10.1513/AnnalsATS.201308-280OC</pub-id>
          <pub-id pub-id-type="pmid">24712298</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Copes</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Champion</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Sacco</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Lawnick</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Keast</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Bain</surname>
              <given-names>LW</given-names>
            </name>
          </person-group>
          <article-title>The Injury Severity Score revisited</article-title>
          <source>J Trauma</source>
          <year>1988</year>
          <volume>28</volume>
          <fpage>69</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="doi">10.1097/00005373-198801000-00010</pub-id>
          <pub-id pub-id-type="pmid">3123707</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>BRH</given-names>
            </name>
            <name>
              <surname>Cotton</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Pritts</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Branson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Holcomb</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Muskat</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Application of the Berlin definition in PROMMTT patients: the impact of resuscitation on the incidence of hypoxemia</article-title>
          <source>J Trauma Acute Care Surg</source>
          <year>2013</year>
          <volume>75</volume>
          <fpage>S61</fpage>
          <lpage>S67</lpage>
          <pub-id pub-id-type="doi">10.1097/TA.0b013e31828fa408</pub-id>
          <pub-id pub-id-type="pmid">23778513</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakowitz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bruns</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>McCunn</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Acute lung injury and the acute respiratory distress syndrome in the injured patient</article-title>
          <source>Scand J Trauma Resusc Emerg Med</source>
          <year>2012</year>
          <volume>20</volume>
          <fpage>54</fpage>
          <pub-id pub-id-type="doi">10.1186/1757-7241-20-54</pub-id>
          <pub-id pub-id-type="pmid">22883052</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simmons</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>Y-LL</given-names>
            </name>
            <name>
              <surname>Pastukh</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Capley</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Muscat</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Muscat</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Potential contribution of mitochondrial (mt) DNA damage associated molecular patterns (DAMPs) in transfusion products to the development of acute respiratory distress syndrome (ARDS) after multiple transfusions</article-title>
          <source>J Trauma Acute Care Surg</source>
          <year>2017</year>
          <volume>82</volume>
          <fpage>1023</fpage>
          <lpage>1029</lpage>
          <pub-id pub-id-type="doi">10.1097/TA.0000000000001421</pub-id>
          <pub-id pub-id-type="pmid">28301393</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Land</surname>
              <given-names>WG</given-names>
            </name>
          </person-group>
          <article-title>Transfusion-related acute lung injury: the work of DAMPs</article-title>
          <source>Transfus Med Hemother</source>
          <year>2013</year>
          <volume>40</volume>
          <fpage>3</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1159/000345688</pub-id>
          <pub-id pub-id-type="pmid">23637644</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mindrinos</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Seok</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cuschieri</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cuenca</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A genomic storm in critically injured humans</article-title>
          <source>J Exp Med</source>
          <year>2011</year>
          <volume>208</volume>
          <fpage>2581</fpage>
          <lpage>2590</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20111354</pub-id>
          <pub-id pub-id-type="pmid">22110166</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>GY</given-names>
            </name>
            <name>
              <surname>Nu&#xF1;ez</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Sterile inflammation: sensing and reacting to damage</article-title>
          <source>Nature Rev Immunol</source>
          <year>2010</year>
          <volume>10</volume>
          <fpage>826</fpage>
          <lpage>837</lpage>
          <pub-id pub-id-type="doi">10.1038/nri2873</pub-id>
          <pub-id pub-id-type="pmid">21088683</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raymond</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Holden</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Mira</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Stortz</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Loftus</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Mohr</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Microbial recognition and danger signals in sepsis and trauma</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1863</year>
          <volume>2017</volume>
          <fpage>2564</fpage>
          <lpage>2573</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bbadis.2017.01.013</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Timmermans</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kox</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vaneker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>van den Berg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>John</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>van Laarhoven</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasma levels of danger-associated molecular patterns are associated with immune suppression in trauma patients</article-title>
          <source>Intensive Care Med</source>
          <year>2016</year>
          <volume>42</volume>
          <fpage>551</fpage>
          <lpage>561</lpage>
          <pub-id pub-id-type="doi">10.1007/s00134-015-4205-3</pub-id>
          <pub-id pub-id-type="pmid">26912315</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goulopoulou</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McCarthy</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Toll-like receptors in the vascular system: sensing the dangers within</article-title>
          <source>Pharmacol Rev</source>
          <year>2016</year>
          <volume>68</volume>
          <fpage>142</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="doi">10.1124/pr.114.010090</pub-id>
          <pub-id pub-id-type="pmid">26721702</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huebener</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pradere</surname>
              <given-names>J-P</given-names>
            </name>
            <name>
              <surname>Hernandez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gwak</surname>
              <given-names>GY</given-names>
            </name>
            <name>
              <surname>Caviglia</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mu</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis</article-title>
          <source>J Clin Invest</source>
          <year>2015</year>
          <volume>125</volume>
          <fpage>539</fpage>
          <lpage>550</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI76887</pub-id>
          <pub-id pub-id-type="pmid">25562324</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Allette</surname>
              <given-names>YM</given-names>
            </name>
            <name>
              <surname>Wilkes</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>FA</given-names>
            </name>
          </person-group>
          <article-title>The HMGB1&#x2013;RAGE inflammatory pathway: implications for brain injury-induced pulmonary dysfunction</article-title>
          <source>Antioxid Redox Signal</source>
          <year>2015</year>
          <volume>23</volume>
          <fpage>1316</fpage>
          <lpage>1328</lpage>
          <pub-id pub-id-type="doi">10.1089/ars.2015.6299</pub-id>
          <pub-id pub-id-type="pmid">25751601</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balogh</surname>
              <given-names>ZJ</given-names>
            </name>
            <name>
              <surname>Reumann</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Gruen</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Mayer-Kuckuk</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schuetz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>IA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Trauma Surgery 3. Advances and future directions for management of trauma patients with musculoskeletal injuries</article-title>
          <source>Lancet</source>
          <year>2012</year>
          <volume>380</volume>
          <fpage>1109</fpage>
          <lpage>1119</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60991-X</pub-id>
          <pub-id pub-id-type="pmid">22998720</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Raoof</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sumi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sursal</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Junger</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Circulating mitochondrial DAMPs cause inflammatory responses to injury</article-title>
          <source>Nature</source>
          <year>2010</year>
          <volume>464</volume>
          <fpage>104</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="doi">10.1038/nature08780</pub-id>
          <pub-id pub-id-type="pmid">20203610</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calfee</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Matthay</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Clinical immunology: culprits with evolutionary ties</article-title>
          <source>Nature</source>
          <year>2010</year>
          <volume>464</volume>
          <fpage>41</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1038/464041a</pub-id>
          <pub-id pub-id-type="pmid">20203598</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simmons</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>Y-L</given-names>
            </name>
            <name>
              <surname>Mulekar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kuck</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Brevard</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>RP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects</article-title>
          <source>Ann Surg</source>
          <year>2013</year>
          <volume>258</volume>
          <fpage>591</fpage>
          <lpage>598</lpage>
          <pub-id pub-id-type="doi">10.1097/SLA.0b013e3182a4ea46</pub-id>
          <pub-id pub-id-type="pmid">23979273</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamanouchi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kudo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Miyagawa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Furukawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kushimoto</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Plasma mitochondrial DNA levels in patients with trauma and severe sepsis: time course and the association with clinical status</article-title>
          <source>J Crit Care</source>
          <year>2013</year>
          <volume>28</volume>
          <fpage>1027</fpage>
          <lpage>1031</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcrc.2013.05.006</pub-id>
          <pub-id pub-id-type="pmid">23787023</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abrams</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Manson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dart</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Baluwa</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Circulating histones are mediators of trauma-associated lung injury</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2013</year>
          <volume>187</volume>
          <fpage>160</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.201206-1037OC</pub-id>
          <pub-id pub-id-type="pmid">23220920</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kolaczkowska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kubes</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil recruitment and function in health and inflammation</article-title>
          <source>Nat Revi Immunol</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>159</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3399</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saffarzadeh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Juenemann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Queisser</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lochnit</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Barreto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Galuska</surname>
              <given-names>SP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones</article-title>
          <source>PLoS One</source>
          <year>2012</year>
          <volume>7</volume>
          <fpage>e32366</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0032366</pub-id>
          <pub-id pub-id-type="pmid">22389696</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>F-C</given-names>
            </name>
            <name>
              <surname>Chuang</surname>
              <given-names>Y-H</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>Y-F</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Role of neutrophil extracellular traps following injury</article-title>
          <source>Shock</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>491</fpage>
          <lpage>498</lpage>
          <pub-id pub-id-type="doi">10.1097/SHK.0000000000000146</pub-id>
          <pub-id pub-id-type="pmid">24837201</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Porto</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>RT</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps in pulmonary diseases: too much of a good thing?</article-title>
          <source>Front Immunol</source>
          <year>2016</year>
          <volume>7</volume>
          <fpage>311</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2016.00311</pub-id>
          <pub-id pub-id-type="pmid">27574522</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kolaczkowska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jenne</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Surewaard</surname>
              <given-names>BGJ</given-names>
            </name>
            <name>
              <surname>Thanabalasuriar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Sanz</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular mechanisms of NET formation and degradation revealed by intravital imaging in the liver vasculature</article-title>
          <source>Nat Commun</source>
          <year>2015</year>
          <volume>6</volume>
          <fpage>6673</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms7673</pub-id>
          <pub-id pub-id-type="pmid">25809117</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yuzhen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Xiaoxiang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Changquing</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>DNaseI protects against Paraquat-induced acute lung injury and pulmonary fibrosis mediated by mitochondrial DNA</article-title>
          <source>Biomed Res Int</source>
          <year>2015</year>
          <volume>2015</volume>
          <fpage>386952</fpage>
          <pub-id pub-id-type="doi">10.1155/2015/386952</pub-id>
          <pub-id pub-id-type="pmid">25759818</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McIlroy</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Minahan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Keely</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lott</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hansbro</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>DW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reduced deoxyribonuclease enzyme activity in response to high postinjury mitochondrial DNA concentration provides a therapeutic target for systemic inflammatory response syndrome</article-title>
          <source>J Trauma Acute Care Surg</source>
          <year>2018</year>
          <volume>85</volume>
          <fpage>354</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="doi">10.1097/TA.0000000000001919</pub-id>
          <pub-id pub-id-type="pmid">30080781</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sercundes</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Ortolan</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Debone</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Soeiro-Pereira</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Aitken</surname>
              <given-names>EH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Targeting neutrophils to prevent malaria-associated acute lung injury/acute respiratory distress syndrome in mice</article-title>
          <source>PLoS Pathog</source>
          <year>2016</year>
          <volume>12</volume>
          <fpage>e1006054</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.ppat.1006054</pub-id>
          <pub-id pub-id-type="pmid">27926944</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simmons</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Freno</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Muscat</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Obiako</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Pastukh</surname>
              <given-names>VM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mitochondrial DNA damage associated molecular patterns in ventilator-associated pneumonia: prevention and reversal by intratracheal DNase I</article-title>
          <source>J Trauma Acute Care Surg</source>
          <year>2017</year>
          <volume>82</volume>
          <fpage>120</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="doi">10.1097/TA.0000000000001269</pub-id>
          <pub-id pub-id-type="pmid">27787436</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuck</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Obiako</surname>
              <given-names>BO</given-names>
            </name>
            <name>
              <surname>Gorodnya</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Pastukh</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Kua</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Simmons</surname>
              <given-names>JD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mitochondrial DNA damage-associated molecular patterns mediate a feed-forward cycle of bacteria-induced vascular injury in perfused rat lungs</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2015</year>
          <volume>308</volume>
          <fpage>L1078</fpage>
          <lpage>L1085</lpage>
          <pub-id pub-id-type="doi">10.1152/ajplung.00015.2015</pub-id>
          <pub-id pub-id-type="pmid">25795724</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yildiz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Palaniyar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Otulakowski</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Post</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kuebler</surname>
              <given-names>WM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mechanical ventilation induces neutrophil extracellular trap formation</article-title>
          <source>Anesthesiology</source>
          <year>2015</year>
          <volume>122</volume>
          <fpage>864</fpage>
          <lpage>875</lpage>
          <pub-id pub-id-type="doi">10.1097/ALN.0000000000000605</pub-id>
          <pub-id pub-id-type="pmid">25665049</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zitter</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Maldjian</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Brimacombe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fennelly</surname>
              <given-names>KP</given-names>
            </name>
          </person-group>
          <article-title>Inhaled dornase alfa (Pulmozyme) as a noninvasive treatment of atelectasis in mechanically ventilated patients</article-title>
          <source>J Crit Care</source>
          <year>2013</year>
          <volume>28</volume>
          <fpage>218</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jcrc.2012.09.015</pub-id>
          <pub-id pub-id-type="pmid">23266402</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toulouse</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Masseguin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lafont</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>McGurk</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Harbonn</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>French legal approach to clinical research</article-title>
          <source>Anaesth Crit Care Pain Med</source>
          <year>2018</year>
          <volume>37</volume>
          <issue>6</issue>
          <fpage>607</fpage>
          <lpage>614</lpage>
          <pub-id pub-id-type="doi">10.1016/j.accpm.2018.10.013</pub-id>
          <pub-id pub-id-type="pmid">30580775</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Waldrep</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dhand</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Aerosol delivery of recombinant human DNase I: in vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer</article-title>
          <source>Respir Care</source>
          <year>2008</year>
          <volume>53</volume>
          <issue>12</issue>
          <fpage>1703</fpage>
          <lpage>1708</lpage>
          <pub-id pub-id-type="pmid">19025706</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scherer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Geller</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Owyang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tservistas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boden</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A technical feasibility study of dornase alfa delivery with eFlow</article-title>
          <source>J Pharm Sci</source>
          <year>2016</year>
          <volume>100</volume>
          <fpage>98</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="doi">10.1002/jps.22231</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gavillet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Martinod</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Renella</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>NI</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>DD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Flow cytometric assay for direct quantification of neutrophil extracellular traps in blood samples</article-title>
          <source>Am J Hematol</source>
          <year>2015</year>
          <volume>90</volume>
          <fpage>1155</fpage>
          <lpage>1158</lpage>
          <pub-id pub-id-type="doi">10.1002/ajh.24185</pub-id>
          <pub-id pub-id-type="pmid">26347989</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leone</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bouadma</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bouhemad</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Brissaud</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Dauger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gibot</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hospital-acquired pneumonia in ICU</article-title>
          <source>Anaesth Crit Care Pain Med</source>
          <year>2018</year>
          <volume>37</volume>
          <issue>1</issue>
          <fpage>83</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="doi">10.1016/j.accpm.2017.11.006</pub-id>
          <pub-id pub-id-type="pmid">29155054</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mahler</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>CK</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of clinical methods for rating dyspnea</article-title>
          <source>Chest</source>
          <year>1988</year>
          <volume>93</volume>
          <fpage>580</fpage>
          <lpage>586</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.93.3.580</pub-id>
          <pub-id pub-id-type="pmid">3342669</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Celli</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Cote</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Marin</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Montes de Oca</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mendez</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>1005</fpage>
          <lpage>1012</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa021322</pub-id>
          <pub-id pub-id-type="pmid">14999112</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Innerhofer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fries</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mittermayr</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Innerhofer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>von Langen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hell</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial</article-title>
          <source>Lancet Haematol</source>
          <year>2017</year>
          <volume>4</volume>
          <fpage>e258</fpage>
          <lpage>e271</lpage>
          <pub-id pub-id-type="doi">10.1016/S2352-3026(17)30077-7</pub-id>
          <pub-id pub-id-type="pmid">28457980</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>American Thoracic Society, Infectious Diseases Society of America</collab>
          </person-group>
          <article-title>Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia</article-title>
          <source>Am J Resp Crit Care Med</source>
          <year>2005</year>
          <volume>171</volume>
          <fpage>388</fpage>
          <lpage>416</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.200405-644ST</pub-id>
          <pub-id pub-id-type="pmid">15699079</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klompas</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Complications of mechanical ventilation&#x2014;the CDC's new surveillance paradigm</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>368</volume>
          <fpage>1472</fpage>
          <lpage>1475</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMp1300633</pub-id>
          <pub-id pub-id-type="pmid">23594002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joseph</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>du Berger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>B&#xE9;lisle</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Bayesian and mixed Bayesian/likelihood criteria for sample size determination</article-title>
          <source>Stat Med</source>
          <year>1997</year>
          <volume>16</volume>
          <fpage>769</fpage>
          <lpage>781</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19970415)16:7&lt;769::AID-SIM495&gt;3.0.CO;2-V</pub-id>
          <pub-id pub-id-type="pmid">9131764</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>George</surname>
              <given-names>EI</given-names>
            </name>
            <name>
              <surname>McCulloch</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Variable selection via Gibbs sampling</article-title>
          <source>J Am Stat Assoc</source>
          <year>1993</year>
          <volume>88</volume>
          <fpage>881</fpage>
          <lpage>889</lpage>
          <pub-id pub-id-type="doi">10.1007/BF01889985</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holcomb</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>del Junco</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Wade</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Schreiber</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks</article-title>
          <source>JAMA Surg</source>
          <year>2013</year>
          <volume>148</volume>
          <fpage>127</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="doi">10.1001/2013.jamasurg.387</pub-id>
          <pub-id pub-id-type="pmid">23560283</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cortjens</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bonsing</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>van Woensel</surname>
              <given-names>JBM</given-names>
            </name>
            <name>
              <surname>Antonis</surname>
              <given-names>AFG</given-names>
            </name>
            <name>
              <surname>Bem</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Local dornase alfa treatment reduces NETs-induced airway obstruction during severe RSV infection</article-title>
          <source>Thorax</source>
          <year>2018</year>
          <volume>73</volume>
          <fpage>578</fpage>
          <lpage>580</lpage>
          <pub-id pub-id-type="doi">10.1136/thoraxjnl-2017-210289</pub-id>
          <pub-id pub-id-type="pmid">28780505</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">New Microbes New Infect</journal-id>
      <journal-id journal-id-type="iso-abbrev">New Microbes New Infect</journal-id>
      <journal-title-group>
        <journal-title>New Microbes and New Infections</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2052-2975</issn>
      <publisher>
        <publisher-name>The Authors. Published by Elsevier Ltd.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32922804</article-id>
      <article-id pub-id-type="pmc">7476504</article-id>
      <article-id pub-id-type="pii">S2052-2975(20)30108-6</article-id>
      <article-id pub-id-type="doi">10.1016/j.nmni.2020.100756</article-id>
      <article-id pub-id-type="publisher-id">100756</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>First Clinical Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Preliminary report of <italic>in&#xA0;vitro</italic> and <italic>in&#xA0;vivo</italic> effectiveness of dornase alfa on SARS-CoV-2 infection</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="au1">
          <name>
            <surname>Okur</surname>
            <given-names>H.K.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author" id="au2">
          <name>
            <surname>Yalcin</surname>
            <given-names>K.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
          <xref rid="aff3" ref-type="aff">3</xref>
          <xref rid="cor1" ref-type="corresp">&#x2217;</xref>
        </contrib>
        <contrib contrib-type="author" id="au3">
          <name>
            <surname>Tastan</surname>
            <given-names>C.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" id="au4">
          <name>
            <surname>Demir</surname>
            <given-names>S.</given-names>
          </name>
          <xref rid="aff4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author" id="au5">
          <name>
            <surname>Yurtsever</surname>
            <given-names>B.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" id="au6">
          <name>
            <surname>Karakus</surname>
            <given-names>G.S.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" id="au7">
          <name>
            <surname>Kancagi</surname>
            <given-names>D.D.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" id="au8">
          <name>
            <surname>Abanuz</surname>
            <given-names>S.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" id="au9">
          <name>
            <surname>Seyis</surname>
            <given-names>U.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" id="au10">
          <name>
            <surname>Zengin</surname>
            <given-names>R.</given-names>
          </name>
          <xref rid="aff5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author" id="au11">
          <name>
            <surname>Hemsinlioglu</surname>
            <given-names>C.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" id="au12">
          <name>
            <surname>Kara</surname>
            <given-names>M.</given-names>
          </name>
          <xref rid="aff6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author" id="au13">
          <name>
            <surname>Yildiz</surname>
            <given-names>M.E.</given-names>
          </name>
          <xref rid="aff7" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author" id="au14">
          <name>
            <surname>Deliceo</surname>
            <given-names>E.</given-names>
          </name>
          <xref rid="aff8" ref-type="aff">8</xref>
        </contrib>
        <contrib contrib-type="author" id="au15">
          <name>
            <surname>Birgen</surname>
            <given-names>N.</given-names>
          </name>
          <xref rid="aff9" ref-type="aff">9</xref>
        </contrib>
        <contrib contrib-type="author" id="au16">
          <name>
            <surname>Pelit</surname>
            <given-names>N.B.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" id="au17">
          <name>
            <surname>Cuhadaroglu</surname>
            <given-names>C.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author" id="au18">
          <name>
            <surname>Kocagoz</surname>
            <given-names>A.S.</given-names>
          </name>
          <xref rid="aff5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author" id="au19">
          <name>
            <surname>Ovali</surname>
            <given-names>E.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <aff id="aff1"><label>1)</label>Acibadem Altunizade Hospital, Chest Disease Unit, Istanbul, Turkey</aff>
        <aff id="aff2"><label>2)</label>Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey</aff>
        <aff id="aff3"><label>3)</label>Medical Park Goztepe Hospital, Paediatric Bone Marrow Transplantation Unit, Istanbul, Turkey</aff>
        <aff id="aff4"><label>4)</label>Genetic and Bioengineering Department, Yeditepe University, Istanbul, Turkey</aff>
        <aff id="aff5"><label>5)</label>Acibadem Altunizade Hospital, Infectious Disease Unit, Istanbul, Turkey</aff>
        <aff id="aff6"><label>6)</label>Acibadem Altunizade Hospital, Internal Medicine Unit Department of Endocrinology, Istanbul, Turkey</aff>
        <aff id="aff7"><label>7)</label>Acibadem Altunizade Hospital, Radiology Unit, Istanbul, Turkey</aff>
        <aff id="aff8"><label>8)</label>Acibadem Mehmet Ali Aydinlar University, School of Medicine, Department of Pediatrics, Istanbul, Turkey</aff>
        <aff id="aff9"><label>9)</label>Acibadem Altunizade Hospital, Cellular Therapy Centre, Istanbul, Turkey</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>&#x2217;</label><bold>Corresponding author:</bold> K. Yalcin, Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey.</corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>7</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>7</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <volume>37</volume>
      <fpage>100756</fpage>
      <lpage>100756</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>5</month>
          <year>2020</year>
        </date>
        <date date-type="rev-recd">
          <day>2</day>
          <month>9</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>9</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2020 The Authors</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license>
          <license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
        </license>
      </permissions>
      <abstract id="abs0010">
        <p>Dornase alfa, the recombinant form of the human DNase I enzyme, breaks down neutrophil extracellular traps (NET) that include a vast amount of DNA fragments, histones, microbicidal proteins and oxidant enzymes released from necrotic neutrophils in the highly viscous mucus of cystic fibrosis patients. Dornase alfa has been used for decades in patients with cystic fibrosis to reduce the viscoelasticity of respiratory tract secretions, to decrease the severity of respiratory tract infections, and to improve lung function. Previous studies have linked abnormal NET formations to lung diseases, especially to acute respiratory distress syndrome (ARDS). It is well known that novel coronavirus disease 2019 (COVID-19) pneumonia progresses to ARDS and even multiple organ failure. High blood neutrophil levels are an early indicator of COVID-19 and predict severe respiratory diseases. Also it is reported that mucus structure in COVID-19 is very similar to that in cystic fibrosis due to the accumulation of excessive NET in the lungs. In this study, we showed the recovery of three individuals with COVID-19 after including dornase alfa in their treatment. We followed clinical improvement in the radiological analysis (two of three cases), oxygen saturation (Sp<sc>o</sc><sub>2</sub>), respiratory rate, disappearance of dyspnoea, coughing and a decrease in NET formation and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load after the treatment. Also here, we share our preliminary results suggesting that dornase alfa has an anti-viral effect against SARS-CoV-2 infection in a green monkey kidney cell line, Vero, and a bovine kidney cell line, MDBK, without determined cytotoxicity on healthy peripheral blood mononuclear cells.</p>
      </abstract>
      <kwd-group id="kwrds0010">
        <title>Keywords</title>
        <kwd>Coronavirus disease 2019</kwd>
        <kwd>dornase alfa</kwd>
        <kwd>NETosis</kwd>
        <kwd>neutrophil extracellular traps</kwd>
        <kwd>severe acute respiratory syndrome coronavirus 2</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>Introduction</title>
      <p id="p0010">The coronavirus disease 2019 (COVID-19) pandemic has affected more than 23 million people around the world, resulting in unprecedented health, social and economic crises. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is manifested by flu-like symptoms and in some patients by acute respiratory distress syndrome (ARDS) and even viral pneumonia that progresses to multiple organ failure [<xref rid="bib1" ref-type="bibr">1</xref>]. The exudative phase of ARDS is characterized by the productive and excessive immune response of pro-inflammatory cytokines and chemokines; increased neutrophil infiltration and accumulation in the alveoli; and alveolar epithelial capillary barrier disruption [<xref rid="bib2" ref-type="bibr">2</xref>]. High blood neutrophil levels are an early indicator of SARS-CoV-2 infection and cause serious respiratory diseases. A pathogenic role has been demonstrated [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib4" ref-type="bibr">4</xref>] for neutrophil-derived extracellular traps (neutrophil extracellular traps, NETs) in a variety of thrombo-inflammatory conditions, including sepsis [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>], thrombosis [<xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>] and respiratory failure [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>]. NETs are DNA fragments, histones, microbicidal proteins and oxidant enzymes that are released by neutrophils during infection. However, in over-response, NETs have the potential to initiate and spread inflammation and thrombosis [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>]. NETs have been reported in many lung and cardiovascular diseases in association with interleukin-1&#x3B2; secretion [<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>]. Although the exact determination of COVID-19 pathophysiology requires the development of model systems, the neutrophilic infiltration relationship has been established many times in the infection sites of influenza A (H1N1) virus, SARS-CoV and Middle East respiratory syndrome coronavirus and the development of ARDS in these patients [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib18" ref-type="bibr">18</xref>]. <italic>In&#xA0;vitro</italic> culturing of neutrophils from influenza-infected lungs with infected alveolar epithelial cells triggers NETosis and increased endothelial damage. Mice lacking neutrophil cells have a mild response to influenza virus [<xref rid="bib19" ref-type="bibr">19</xref>], and higher plasma NET levels have been reported for patients with transfusion-related ARDS [<xref rid="bib20" ref-type="bibr">20</xref>]. Similarly, recent studies confirmed the role of immune hyperactivation in the pathogenesis of COVID-19 [<xref rid="bib21" ref-type="bibr">21</xref>]. Immune cells, especially neutrophils, infiltrate pulmonary capillaries, which causes acute fibrin deposition and extravasation into the alveolar space. This excessive accumulation of neutrophils constitutes NETs, which makes the mucus thick and viscous. The highly viscous mucus lowers the patient's respiratory function and impairs ventilation [<xref rid="bib22" ref-type="bibr">22</xref>], suggesting that NETs may play a major role in the disease. As a mechanism, double-stranded DNA constitutes the backbone of NETs and dornase alfa promotes the clearance of NETs from plasma neutralization. Endogenous DNases, which physiologically break up this extracellular DNA, may become overwhelmed by a massive influx of NETs [<xref rid="bib23" ref-type="bibr">23</xref>,<xref rid="bib24" ref-type="bibr">24</xref>]. Clinically, recombinant human DNase I (rhDNase, dornase alfa) has the identical primary amino acid sequence with the native human enzyme and has been approved for the management of cystic fibrosis. Daily administration of dornase alfa is effective in the treatment of individuals with cystic fibrosis and improves pulmonary functions [<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib26" ref-type="bibr">26</xref>]. The similarity of mucus secretions in COVID-19 and cystic fibrosis patients with regard to NETs makes dornase alfa a therapeutic option in COVID-19 [<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib28" ref-type="bibr">28</xref>]. In this study, preliminary data are presented about <italic>in&#xA0;vitro</italic> and <italic>in&#xA0;vivo</italic> anti-viral and nuclease activities of dornase alfa for the clearance of SARS-CoV-2 viral load and NETs in the lungs of individuals with COVID-19.</p>
    </sec>
    <sec id="sec2">
      <title>Materials and methods</title>
      <sec id="sec2.1">
        <title><italic>In&#xA0;vitro</italic> anti-viral efficiency of dornase alfa</title>
        <p id="p0015">
<italic>In&#xA0;vitro</italic> isolation and propagation of SARS-CoV-2 from individuals diagnosed with COVID-19 are described in our previous study [<xref rid="bib29" ref-type="bibr">29</xref>]. The median tissue culture infectious dose (TCID<sub>50</sub>) of SARS-CoV-2 was determined (see Supplementary material, <xref rid="appsec1" ref-type="sec">Fig.&#xA0;S1</xref>) and was incubated with the Madin-Darby bovine kidney cell line (MDBK; ATCC CCL-22) and a 10&#xA0;&#xD7;&#xA0;TCID<sub>50</sub> dose of the virus was incubated with the Vero cell line (CCL81; ATCC) along with dornase alfa (Pulmozyme&#xAE;, Basel, Switzerland) in a dose-dependent manner (3, 30 and 100 U/mL) with 420 mg/L MgSO<sub>4</sub> (magnesium sulphate 15%; Onfarma, Samsun, Turkey) for 8 days. The cytopathic effect (CPE) test was performed as described previously [<xref rid="bib29" ref-type="bibr">29</xref>].</p>
        <sec id="sec2.1.1">
          <title>RT-PCR and gel electrophoresis</title>
          <p id="p0020">Total RNA isolation from SARS-CoV-2 was performed using Direct-zol RNA Miniprep Kits (Zymo Research, Irvine, CA, USA), and concentrations were determined using a Qubit fluorometer with the Qubit RNA HS Assay (Thermo Fisher Scientific, Waltham, MA, USA). Fifty nanograms of the SARS-CoV-2 RNA genome were incubated with none, 3 U or 10 U of dornase alfa along with 420 mg/L MgSO<sub>4</sub> at room temperature for 20 min. Next, samples were heated at 72&#xB0;C for 10 min to inactivate the dornase alfa before RT-PCR assay. SARS-CoV-2-specific RT-PCR was performed with a Bosphore Novel Coronavirus (2019-nCoV) Detection Kit (Anatolia Geneworks, Istanbul, Turkey) along with Orf1ab and E gene primers. The RT-PCR analysis was performed in a Roche Lightcycler 96.</p>
        </sec>
      </sec>
      <sec id="sec2.2">
        <title>Anti-viral effect of dornase alfa using real-time cell analysis, xCELLigence</title>
        <p id="p0025">Vero cells (25&#xA0;000&#xA0;cells/well) were incubated in gold microelectrode-embedded microtitre wells in xCELLigence&#xAE; Real-Time Cell Analysis (RTCA) instruments (ACEA, Roche) at 37&#xB0;C for 24 hours to normalize cell index with coated cells. Then, dornase alfa in a serial dilution was pre-incubated with 10&#xA0;&#xD7;&#xA0;TCID<sub>50</sub> of SARS-CoV-2 at room temperature for 60 min. The pre-incubated mixture was inoculated into the Vero-coated cells, which were analysed in real-time for 120 hours (in total 145 hours). Cell analysis was normalized to the value of the 24th hour of culturing before incubation with dornase alfa and SARS-CoV-2 mixtures. Normalized cell index shows the proliferation and viability of the adherent cells (a higher cell index indicates higher viability and proliferation). CPE was determined by assessing cell index value in untreated control Vero cells (normalized to 1% CPE) and treated wells.</p>
      </sec>
      <sec id="sec2.3">
        <title>Clearance of NET formation by dornase alfa</title>
        <p id="p0030">Following the isolation of peripheral blood mononuclear cells (PBMCs) by overlaying blood on Ficoll-paque plus (GE Healthcare, Chalfont St Giles, UK), the cells were frozen at &#x2013;140&#xB0;C with DMSO freezing solution (40% DMSO and 60% Dextran 40). Following 24 hours of freezing, the cells were thawed and washed twice with phosphate-buffered saline. Samples were then incubated at 37&#xB0;C for 2 hours in T-cell medium. (6% Human AB Serum and 1% penicillin/streptomycin, Texmacs medium) until cryopreservation and thawing-induced NET formation was detected. Next, clump-containing samples were separated into two T300 flasks with 50 mL T-cell medium and one T300 flask from each donor was treated with 100 U/mL dornase alfa (Pulmozyme&#xAE;) and 420 &#x3BC;g/mL MgSO<sub>4</sub> for 15 min. The supernatant from three donor samples was collected and a viable cell count was performed with Trypan blue and haemocytometer. Also, a peripheral smear was collected from the supernatant of both dornase alfa-treated and untreated control cultures stained with Wright stain as described previously [<xref rid="bib30" ref-type="bibr">30</xref>].</p>
      </sec>
      <sec id="sec2.4">
        <title>Cytotoxicity of dornase alfa on PBMCs</title>
        <p id="p0035">Three healthy adult blood samples were obtained from the Acibadem Labcell Cellular Therapy Laboratory. Following the isolation of PBMCs by overlaying blood on Ficoll-paque plus (GE Healthcare), the serially diluted (300, 100, 30, 10 and 3 U/mL) dornase alfa along with 420 &#x3BC;g/mL MgSO<sub>4</sub> was incubated with the PBMCs for 48 hours in T-cell medium (6% human AB Serum and 1% penicillin/streptomycin, Texmacs medium). Immune cell subtypes and their activation levels were determined by Miltenyi MACSQuant flow cytometry analysis using alfaCD3-phycoerythrin, alfaCD19-phycoerythrin.Cy7, alfaCD56-fluorescein isothiocyanate, alfaCD4-Viogreen, alfaCD8-Vioblue, alfaCD25-allophycocyanin and alfaCD107a-phycoerythrin.Cy5.5 (Miltenyi Biotec, Bergisch Gladbach, Germany). Viable cells were determined by assessing the proportion of 7-aminoactinomycin D (Miltenyi Biotec) negative cells through staining for flow cytometry.</p>
      </sec>
      <sec id="sec2.5">
        <title>Ethical approval and consent to participate</title>
        <p id="p0040">Individuals with COVID-19 were recruited to the clinical study within the scope of &#x2018;Dornase Alpha for the Treatment of COVID-19&#x2019; (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0010">ClinicalTrials.gov</ext-link> Identifier: NCT04432987) at Acibadem Altunizade Hospital, Istanbul. Each patient was informed and approved the patient information and consent form, which is named &#x2018;Determination of Dornase Alpha Activity in COVID-19 Treatment&#x2019;. Isolation of PBMCs, SARS-CoV-2 isolation and propagation, and anti-viral <italic>in&#xA0;vitro</italic> tests were performed in the Acibadem Labcell Cellular Therapy Laboratory GMP and BSL-3 units. Clinical Scientific Research Studies approval (2020-04-29 T15_24_57) was acquired from the Research and Development Health Services General Directorate of the T.C. Ministry of Health.</p>
      </sec>
      <sec id="sec2.6">
        <title>A preliminary clinical COVID-19 case study with dornase alfa</title>
        <p id="p0045">This study involves three patients diagnosed with COVID-19 from specific PCR test and clinical/radiological findings in the Acibadem Altunizade Hospital, Istanbul. All the patients were dyspnoeic and supported by oxygen without mechanical ventilation before dornase alfa treatment. Dornase alfa was always used as add-on therapy combined with other investigational drugs for COVID-19. All patients were followed with clinical findings (oxygen saturation, i.e. Sp<sc>o</sc>
<sub>2</sub>, respiratory rate, fever, coughing and dyspnoea) and radiography with CT of the thorax. Dornase alfa was used daily for 3 days at a dose of 2.5 mg with a jet nebulizer at least 1 hour before chest physiotherapy, as recommended [<xref rid="bib31" ref-type="bibr">31</xref>]. All necessary patient consents were obtained and the forms have been archived.</p>
      </sec>
      <sec id="sec2.7">
        <title>Quantitative RT-PCR to determine viral copy number</title>
        <p id="p0050">Nasopharyngeal and oropharyngeal specimens were collected from the three COVID-19 patients on the day before and 7 days after dornase alfa treatment. Total RNA isolations from 100 &#x3BC;L patient specimens in 100 &#x3BC;L DNA/RNA Shield solution (Zymo Research) was performed with Direct-zol RNA Miniprep Kits (Zymo Research) and isolated RNA samples were suspended in 25 &#x3BC;L RNAse-free water. Quantitative RT-PCR was performed with the FDA-approved QuantiVirus&#x2122; SARS-CoV-2 Test Kit (Diacarta, Richmond, CA, USA) according to the manufacturer's protocol. The quantitative RT-PCR was analysed in a Roche Lightcycler 96. Three SARS-CoV-2 genes&#x2014;Orf1ab, N and E genes&#x2014;were detected in the sample. SARS-CoV-2 viral copy number per mL of each patient sample was calculated based on the standard curve produced with Ct (threshold cycle) values and logarithmic viral gene copy number of the extraction control provided in the kit in a dose-dependent manner.</p>
      </sec>
      <sec id="sec2.8">
        <title>Statistics</title>
        <p id="p0055">In the bar graphs, independent two-tailed <italic>t</italic>-tests were performed using SPSS <sc>Statistics</sc> software (SPSS Inc., Armonk, NY, USA). No outliers were excluded in any of the statistical tests and each data point represents an independent measurement. Bar plots report the mean and standard deviation. The threshold of significance for all tests was set at p&#xA0;&lt;&#xA0;0.05.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>Results</title>
      <sec id="sec3.1">
        <title><italic>In&#xA0;vitro</italic> anti-viral efficiency of dornase alfa</title>
        <p id="p0060">Dornase alfa degrades extracellular DNA and helps the clearance of NET that is constituted primarily from DNA fragments [<xref rid="bib32" ref-type="bibr">32</xref>]. Although SARS-CoV-2 is a positive-strand RNA virus [<xref rid="bib33" ref-type="bibr">33</xref>], we wanted to determine an anti-viral effect of dornase alfa co-incubated with a 1&#xA0;&#xD7;&#xA0;TCID<sub>50</sub> dose of SARS-CoV-2 and the MDBK cell line. The results show that dornase alfa, even with a small dose (3 U/mL), efficiently inhibits the infectious capacity of SARS-CoV-2, as seen by the CPE that was lost in higher doses of dornase alfa (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>
a). We then investigated whether dornase alfa can degrade the SARS-CoV-2 positive-strand RNA genome. Isolated total SARS-CoV-2 RNA was pre-incubated with dornase alfa at different doses and dornase alfa was inactivated at 72&#xB0;C before RT-PCR. We detected amplifications of the E and Orf1ab genes at higher cycles than the control that included only RNA with MgSO<sub>4</sub> (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>b). We determined that high doses of dornase alfa increased cycle threshold (Ct) of the E gene from 10 in the controls (No dornase alfa) to 14 in the 10 U dornase alfa-treated condition; a 16-fold difference (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>c). In addition, the Ct of the Orf1ab gene significantly increased from 11 in the No dornase alfa control to 17 in the 10 U dornase alfa-treated condition; a 64-fold difference (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>c). This preliminary study suggested that dornase alfa may have an anti-viral effect; although the mechanism is yet to be elucidated.<fig id="fig1"><label>FIG. 1</label><caption><p>Anti-viral effect of dornase alfa against SARS-CoV-2. (a) Cytopathic effect (CPE) in MDBK cells infected with SARS-CoV-2 (10&#xA0;&#xD7;&#xA0;TCID<sub>50</sub>) along with dornase alfa in a dose-dependent manner for 8 days. (b) Detected cycle of real-time PCR fluorescence intensity of the SARS-CoV-2 RNA genome that were pre-incubated with dornase alfa at different doses. PC, positive control, synthetic E or Orf1ab genes. NC, negative control, dH<sub>2</sub>O. (c) The bar graphs showing cycle threshold (Ct) values of the dornase-alfa-treated SARS-CoV-2 samples, PC, and NC in (b). &#x2217;p&#xA0;&lt;&#xA0;0.05; NS, not significant.</p></caption><alt-text id="alttext0015">FIG. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p>
      </sec>
      <sec id="sec3.2">
        <title>Anti-viral effect of dornase alfa using real-time cell analysis</title>
        <p id="p0065">After we determined that dornase alfa may have nuclease activity against the SARS-CoV-2 genome. We asked whether dornase alfa can interfere with SARS-CoV-2 infection in a real-time cell culture system, namely xCELLigence real-time cell analysis (RTCA). A 10&#xA0;&#xD7;&#xA0;TCID<sub>50</sub> dose of SARS-CoV-2 pre-incubated with dornase alfa at different doses&#x2014;control (No dornase alfa), 3, 10, 30, 50 and 100 U along with MgSO<sub>4</sub> for 1 hour. The different cultures were inoculated on coated Vero cells in RTCA wells and cell proliferation and viability were screened with &#x2018;normalized cell index&#x2019; values analysed by the <sc>xCELLigence</sc> automated system. Increasing cell index meant the proliferation of viable cells. Only the SARS-CoV-2-incubated Vero cells had a significantly lowered cell index, the value recovered when SARS-CoV-2 virus was pre-incubated with dornase alfa (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>
a). Furthermore, we determined that cell index value for 100 U dornase alfa plus SARS-CoV-2 was significantly higher than that of the control Vero cell condition for 120 hours of incubation (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>a). Between 120 and 144 hours, inhibition of SARS-CoV-2 propagation on the Vero cells showing CPE was more evident, showing a possible dose-dependent effect upon dornase alfa pre-treatment (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>a). Also, after 144 hours, normalized cell index analysis showed that incubation of SARS-CoV-2 with increasing doses of dornase alfa significantly increased the cell index similar to the untreated control Vero cells in a dose-dependent manner (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>b). Next, we used the same values and transformed them to CPE% by normalizing the cell index value to the CPE value (control-only Vero cell condition was normalized to 0% CPE and other cell index values were normalized with respect to that value). A lower cell index gave a higher CPE value. The CPE rate was highest in the only SARS-CoV-2-incubated condition (i.e. control No dornase alfa; <xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>b) whereas the value was significantly the lowest in the 100 U dornase alfa-treated SARS-CoV-2 incubated wells (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>c). This RTCA data further showed that dornase alfa may have an anti-viral effect against SARS-CoV-2. Yet, plaque assay can be perfomed to determine change in TCID<sub>50</sub> value in dornase alfa treatment, which will be a more direct approach to show the anti-viral effect.<fig id="fig2"><label>FIG. 2</label><caption><p>Cytopathic effect of SARS-CoV-2&#x2013;dornase alfa incubated Vero cells in real-time cell analysis (RTCA). (a) Representative normalized cell index histogram showing proliferating viable cells that were control only Vero (green line), 100 U (blue line) or 10 U (purple line) dornase alfa-preincubated SARS-CoV-2 (blue line), and only 10&#xA0;&#xD7;&#xA0;TCID<sub>50</sub> dose of SARS-CoV-2 (red line). Cell index was normalized based on the values at the end of 24-hour pre-culture. (b) Bar graph showing quantification of the normalized cell index value of the conditions treated with the SARS-CoV-2 along with/without dornase alfa. (c) Bar graph showing normalized cytopathic effect (% CPE) using values of normalized cell index. &#x2217;p&#xA0;&lt;&#xA0;0.05; NS, not significant.</p></caption><alt-text id="alttext0020">FIG. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p>
      </sec>
      <sec id="sec3.3">
        <title><italic>In&#xA0;vitro</italic> clearance of NET formation by dornase alfa</title>
        <p id="p0070">Dornase alfa has been used in the treatment of patients with cystic fibrosis for decades for the clearance of NET formation [<xref rid="bib32" ref-type="bibr">32</xref>,<xref rid="bib34" ref-type="bibr">34</xref>]. Several studies have shown DNase activity of dornase alfa by degrading DNA fragment-trapped NETs [<xref rid="bib26" ref-type="bibr">26</xref>,<xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>, <xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>]. In this study, we wanted to show a new approach to evaluate <italic>in&#xA0;vitro</italic> clearance of NET by dornase alfa as a proof of concept. We mimicked <italic>in&#xA0;vitro</italic> NETosis with a clump formation comprising extracellular DNA fragments, erythrocytes, lymphocytes and neutrophils [<xref rid="bib38" ref-type="bibr">38</xref>,<xref rid="bib39" ref-type="bibr">39</xref>]. In the test, we thawed adult human mononuclear cells. Following NET formation, we treated the cells with dornase alfa along with MgSO<sub>4</sub> to induce nuclease activity (see <xref rid="appsec1" ref-type="sec">Supplementary material, Fig.&#xA0;S2A</xref>). Similar to previous reports, a large number of single-cell mononuclear cells were freely determined after dornase alfa treatment; however, the untreated control had clumps that could be seen without a microscope (see <xref rid="appsec1" ref-type="sec">Supplementary material, Fig.&#xA0;S2B</xref>). We then showed that the number and viability of the cells in the culture supernatant after dornase alfa treatment significantly increased with respect to the untreated control, which still had clumps trapping most of the cells (see <xref rid="appsec1" ref-type="sec">Supplementary material, Fig.&#xA0;S2C,D</xref>) Before dornase alfa treatment there were up to 1.8&#xA0;&#xD7;&#xA0;10<sup>6</sup> &#xB1; 1.15&#xA0;&#xD7;&#xA0;10<sup>6</sup> in three PBMCs. However, after the treatment, the count increased to 12.9&#xA0;&#xD7;&#xA0;10<sup>6</sup> &#xB1; 5.45&#xA0;&#xD7;&#xA0;10<sup>6</sup> viable cells. Also, we determined that viability was not affected by dornase alfa treatment using the dye exclusion test by staining the cells with Trypan blue (see <xref rid="appsec1" ref-type="sec">Supplementary material, Fig.&#xA0;S2E</xref>). This proof-of-concept study showed similar results to previous studies [<xref rid="bib26" ref-type="bibr">26</xref>,<xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib36" ref-type="bibr">36</xref>,<xref rid="bib37" ref-type="bibr">37</xref>,<xref rid="bib40" ref-type="bibr">40</xref>] that dornase alfa efficiently clears NETs that trapped large amount of mononuclear cells.</p>
      </sec>
      <sec id="sec3.4">
        <title>Cytotoxicity test of dornase alfa on PBMCs</title>
        <p id="p0075">PBMCs include most of the immune cell subtypes in the human blood such as lymphocytes, neutrophils, B cells, natural killer T cells and monocytes. Healthy PBMCs are widely used in toxicology analysis of drug studies because peripheral blood is the front-line of exposure to chemicals in the body. Therefore, toxicity analysis with PBMCs is very important [<xref rid="bib39" ref-type="bibr">39</xref>]. Although dornase alfa has been used in clinics for many years without serious adverse effect [<xref rid="bib36" ref-type="bibr">36</xref>], we wanted to determine the cytotoxicity on healthy adult PBMCs. We incubated PBMCs with dornase alfa in a dose-dependent manner for 48 hours and assessed changes in proportions of the immune cell subtypes and up-regulation of activation markers (CD25 and CD107a) in the cells using flow cytometry as shown in <xref rid="fig3" ref-type="fig">Fig.&#xA0;3</xref>
a. We did not determine a statistically significant increase in the frequency of CD3<sup>+</sup> T cells, especially CD3<sup>+</sup> CD4<sup>+</sup> T helper cells, except CD3<sup>+</sup> CD8<sup>+</sup> cytotoxic T cells (<xref rid="fig3" ref-type="fig">Fig.&#xA0;3</xref>b,c). Similarly, CD19<sup>+</sup> B-cell proportions did not change upon increasing the dornase alfa concentration (<xref rid="fig3" ref-type="fig">Fig.&#xA0;3</xref>c). However, the proportion of CD3<sup>+</sup> CD56<sup>+</sup> natural killer T cells significantly increased in a dose-dependent manner (<xref rid="fig3" ref-type="fig">Fig.&#xA0;3</xref>c). We did not determine a significant increase in CD25 and CD107a expression, suggesting that dornase alfa does not induce lymphocyte activation (<xref rid="fig3" ref-type="fig">Fig.&#xA0;3</xref>c). Furthermore, we labelled dead cells in PBMCs that were treated with dornase alfa in a dose-dependent manner with 7-aminoactinomycin D after 72 hour of incubation (<xref rid="fig3" ref-type="fig">Fig.&#xA0;3</xref>d) and determined that there was no significant cytotoxic effect of dornase alfa up to 100 U, although there was 10% cytotoxicity at the highest dose, 300 U (<xref rid="fig3" ref-type="fig">Fig.&#xA0;3</xref>d). These results suggest that dornase alfa does not show cytotoxicity in PBMCs up to 100 U and it may increase the proportion of natural killer T cells, although the mechanism for this requires further study.<fig id="fig3"><label>FIG. 3</label><caption><p>Drug toxicities of dornase alfa on peripheral blood mononuclear cells (PBMCs). Three healthy adult PBMC samples were inoculated with dornase alfa in a dose-dependent manner for 48 h before flow cytometric analysis. (a) Flow cytometry plots that show immune cell subtypes (CD19<sup>+</sup> B, CD3<sup>+</sup> CD4<sup>+</sup> T helper, CD3<sup>+</sup> CD8<sup>+</sup> cytotoxic T, and CD3<sup>+</sup> CD56<sup>+</sup> natural killer T (NKT) cells) and their activation (with alfaCD25 and alfaCD107a). (b) The bar graph that shows the change in average frequency of total CD3<sup>+</sup> T lymphocytes in the PBMCs after treatment. (c) The bar graphs that show average proportions of the immune cell subtypes and their activation. (d) The flow cytometry plots showing viability of the cells analysed with 7aminoactinomycin D staining in flow cytometry. The bar graph showing viable proportion of the PBMCs treated with dornase alfa. &#x2217;p&#xA0;&lt;&#xA0;0.05; NS, not significant.</p></caption><alt-text id="alttext0025">FIG. 3</alt-text><graphic xlink:href="gr3_lrg"/></fig></p>
      </sec>
      <sec id="sec3.5">
        <title>Preliminary case study of dornase alfa in COVID-19 patients</title>
        <sec id="sec3.5.1">
          <title>Case 1</title>
          <p id="p0080">The individual was a 64-year-old man, with type 2 diabetes mellitus using daily metformin (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>
). He had a fever and was dyspnoeic at admission. After 5 days on hydroxychloroquine therapy, he was coughing, still dyspnoeic with Sp<sc>o</sc>
<sub>2</sub> 97% in room air and a respiratory rate of 20 breaths/min. Favipiravir was added but after 3 days on favipiravir, he was coughing, still dyspnoeic with Sp<sc>o</sc>
<sub>2</sub> decreasing to 95% in room air and respiratory rate still 20 breaths/min (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>). There were extensive ground-glass opacities on thorax CT. Dornase alfa was added on day 8 of the hospitalization. Twenty-four hours after the first dornase alfa administration, cough increased, dyspnoea disappeared, the respiratory rate decreased to 18 breaths/min and Sp<sc>o</sc>
<sub>2</sub> increased to 97% in room air (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>). On the 3rd day of dornase alfa therapy, thorax CT image showed significant improvement (<xref rid="fig4" ref-type="fig">Fig.&#xA0;4</xref>
a). Also, fever, dyspnoea and coughing disappeared, Sp<sc>o</sc>
<sub>2</sub> was 97% without oxygen support (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>
a) with respiratory rate 18 breaths/min (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>b). Inflammatory biomarkers like C-reactive protein and procalcitonin levels decreased after 3 days of treatment (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>c, d) and (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>).<table-wrap position="float" id="tbl1"><label>Table&#xA0;1</label><caption><p>Clinical characteristics of patients and comparison of clinical and laboratory results before and after dornase alfa therapy</p></caption><alt-text id="alttext0050">Table&#xA0;1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>Case 1</th><th>Case 2</th><th>Case 3</th></tr></thead><tbody><tr><td>Gender</td><td>M</td><td>F</td><td>F</td></tr><tr><td>Age (years)</td><td>64</td><td>33</td><td>27</td></tr><tr><td>PCR</td><td>Positive</td><td>Positive</td><td>Positive</td></tr><tr><td>Comorbidity</td><td>Diabetes mellitus</td><td>Breast cancer</td><td>Critical</td></tr><tr><td colspan="4">Disease presentation and course</td></tr><tr><td>Interval between admission and dornase alfa (days)</td><td>8</td><td>2</td><td>11</td></tr><tr><td>Treatments</td><td>H, F</td><td>H, F</td><td>H, F</td></tr><tr><td colspan="4">Clinical characteristics</td></tr><tr><td colspan="4">Body temperature (&#xB0;C)</td></tr><tr><td>&#xA0;Before dornase alfa</td><td>36.3</td><td>38.3</td><td>37</td></tr><tr><td>&#xA0;Day 1 post dornase alfa</td><td>37.1</td><td>37.3</td><td>37.4</td></tr><tr><td>&#xA0;Day 2 post dornase alfa</td><td>36.7</td><td>37.2</td><td>36.6</td></tr><tr><td>&#xA0;Day 3 post dornase alfa</td><td>36.3</td><td>36</td><td>36.4</td></tr><tr><td colspan="4">Dyspnoea</td></tr><tr><td>&#xA0;Before dornase alfa</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>&#xA0;Day 1 post dornase alfa</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td>&#xA0;Day 2 post dornase alfa</td><td>No</td><td>No</td><td>No</td></tr><tr><td>&#xA0;Day 3 post dornase alfa</td><td>No</td><td>No</td><td>No</td></tr><tr><td colspan="4">Coughing</td></tr><tr><td>&#xA0;Before dornase alfa</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>&#xA0;Day 1 post dornase alfa</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>&#xA0;Day 2 post dornase alfa</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>&#xA0;Day 3 post dornase alfa</td><td>No</td><td>No</td><td>No</td></tr><tr><td colspan="4">Respiratory rate</td></tr><tr><td>&#xA0;Before dornase alfa</td><td>20</td><td>19</td><td>20</td></tr><tr><td>&#xA0;Day 1 post dornase alfa</td><td>18</td><td>19</td><td>20</td></tr><tr><td>&#xA0;Day 2 post dornase alfa</td><td>18</td><td>19</td><td>20</td></tr><tr><td>&#xA0;Day 3 post dornase alfa</td><td>18</td><td>18</td><td>18</td></tr><tr><td colspan="4">Sp<sc>o</sc><sub>2</sub></td></tr><tr><td>&#xA0;Before dornase alfa</td><td>95</td><td>96 (with oxygen)</td><td>91 (with oxygen)</td></tr><tr><td>&#xA0;Day 1 post dornase alfa</td><td>97</td><td>96</td><td>95 (with oxygen)</td></tr><tr><td>&#xA0;Day 2 post dornase alfa</td><td>97</td><td>96</td><td>97 (with oxygen)</td></tr><tr><td>&#xA0;Day 3 post dornase alfa</td><td>97</td><td>97</td><td>99 (with oxygen)</td></tr><tr><td colspan="4">C-reactive protein (mg/L)</td></tr><tr><td>&#xA0;Before dornase alfa</td><td>9.1</td><td>5.6</td><td>16.4</td></tr><tr><td>&#xA0;Day 1 post dornase alfa</td><td>9.1</td><td>2.9</td><td>12.4</td></tr><tr><td>&#xA0;Day 2 post dornase alfa</td><td>7.3</td><td>1.9</td><td>11.9</td></tr><tr><td>&#xA0;Day 3 post dornase alfa</td><td>5.9</td><td>1.3</td><td>6.1</td></tr><tr><td colspan="4">Procalcitonin (ng/mL)</td></tr><tr><td>&#xA0;Before dornase alfa</td><td>0.12</td><td>0.01</td><td>0.01</td></tr><tr><td>&#xA0;Day 1 post dornase alfa</td><td>0.12</td><td>0.01</td><td>0.03</td></tr><tr><td>&#xA0;Day 2 post dornase alfa</td><td>0.11</td><td>0.01</td><td>0.03</td></tr><tr><td>&#xA0;Day 3 post dornase alfa</td><td>0.06</td><td>0.01</td><td>0.01</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Sp<sc>o</sc><sub>2</sub>, peripheral capillary oxygen saturation; H, hydroxychloroquine; F, favipiravir.</p></fn></table-wrap-foot></table-wrap><fig id="fig4"><label>FIG. 4</label><caption><p>Comparison of thorax CT images before (left) and after (right) dornase alfa therapy for all three patients. In Case 1 (a) and Case 3 (c) significant improvement occurred, in Case 2 (b) persistent lesions were detected.</p></caption><alt-text id="alttext0030">FIG. 4</alt-text><graphic xlink:href="gr4_lrg"/></fig><fig id="fig5"><label>FIG. 5</label><caption><p>Improvement in clinical outcomes following dornase alfa treatment. Temporal changes of (a) Sp<sc>o</sc><sub>2</sub> per patient, (b) respiratory rate per patient, (c) C-reactive protein per patient and (d) procalcitonin per patient.</p></caption><alt-text id="alttext0035">FIG. 5</alt-text><graphic xlink:href="gr5_lrg"/></fig></p>
        </sec>
        <sec id="sec3.5.2">
          <title>Case 2</title>
          <p id="p0085">The individual was a 33-year-old woman with breast cancer still receiving tamoxifen therapy (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>). At admission, she had a fever, was coughing and dyspnoeic, with Sp<sc>o</sc>
<sub>2</sub> 99% with oxygen support, and respiratory rate 19 breaths/min. After 2 days on hydroxychloroquine and favipiravir treatment, she was still dyspnoeic and coughing, respiratory rate 19 breaths/min and Sp<sc>o</sc>
<sub>2</sub> decreasing to 96% with oxygen support (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>). She had extensive ground-glass opacities on thorax CT. Dornase alfa was added on the 2nd day of the hospitalization. After dornase alfa administration, a thorax CT image showed persistent lesions (<xref rid="fig4" ref-type="fig">Fig.&#xA0;4</xref>b). Coughing increased, dyspnoea disappeared, Sp<sc>o</sc>
<sub>2</sub> was 96% with oxygen support after 24 hours of the treatment (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>a), and respiratory rate was 19 breaths/min (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>b). On the 3rd day of dornase alfa therapy, fever, dyspnoea and coughing had disappeared, Sp<sc>o</sc>
<sub>2</sub> was 97% (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>a) without oxygen support and respiratory rate was 18 breaths/min (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>b). Also, the C-reactive protein level decreased (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>c) but the procalcitonin level was stable (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>d) after 3 days of treatment (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>).</p>
        </sec>
        <sec id="sec3.5.3">
          <title>Case 3</title>
          <p id="p0090">This individual was a 27-year-old woman, without comorbidities (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>). At first admission to another centre, she had a fever, was coughing and dyspnoeic. She had extensive ground glass opacities on thorax CT and hydroxychloroquine was started. After 5 days of hydroxychloroquine therapy, she deteriorated and favipiravir was started. At admission to our centre, she was on the 3rd day of favipiravir therapy with dyspnoea and coughing, her respiratory rate was 20 breaths/min and Spo<sub>2</sub> was 91% with oxygen support (4 L/min) (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>). After dornase alfa administration, a thorax CT image showed significant improvement (<xref rid="fig4" ref-type="fig">Fig.&#xA0;4</xref>c). Twenty-four hours after first dornase alfa administration, cough increased, dyspnoea persisted, Sp<sc>o</sc>
<sub>2</sub> was 95% with oxygen support (3 L/min) (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>a), and respiratory rate was 20 breaths/min (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>b). On the 3rd day of dornase alfa therapy, fever, dyspnoea and coughing had disappeared, Sp<sc>o</sc>
<sub>2</sub> was 99% with oxygen support (1 L/min) (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>a) and respiratory rate was 18 breaths/min (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>b). The C-reactive protein level decreased (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>c) but the procalcitonin level was stable (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>d) after 3 days of the treatment (<xref rid="tbl1" ref-type="table">Table&#xA0;1</xref>).</p>
        </sec>
      </sec>
      <sec id="sec3.6">
        <title>A decrease in the SARS-CoV-2 virus load in dornase-alfa-treated patient specimens</title>
        <p id="p0095">In addition to a clinical improvement in the dornase-alfa-treated patients, we also collected nasopharyngeal and oropharyngeal specimens from the patients on the day before the treatment and after 7 days of the dornase alfa treatment to assess their SARS-CoV-2 viral load using quantitative RT-PCR analysis. We determined a decrease in viral load in all three patients after dornase alfa treatment (<xref rid="fig6" ref-type="fig">Fig.&#xA0;6</xref>
). This study suggests that dornase alfa participates in the clearance of virus load and NETs in the infected lung (<xref rid="fig7" ref-type="fig">Fig.&#xA0;7</xref>
).<fig id="fig6"><label>FIG. 6</label><caption><p>SARS-CoV-2 viral load in three dornase alfa-treated COVID-19 patients. The bar graphs showing SARS-CoV-2 viral copy numbers the day before the treatment and 7 days after dornase alfa treatment.</p></caption><alt-text id="alttext0040">FIG. 6</alt-text><graphic xlink:href="gr6_lrg"/></fig><fig id="fig7"><label>FIG. 7</label><caption><p>Summary of the anti-viral and nuclease activities of dornase alfa. SARS-CoV-2-infected alveoli in infected lungs that induce formation of NETs (NETosis) trapping DNA and histone fragments along with macrophages (blue) and neutrophils (pink). Dornase alfa clears SARS-CoV-2 viral load and NETs in the alveoli.</p></caption><alt-text id="alttext0045">FIG. 7</alt-text><graphic xlink:href="gr7_lrg"/></fig></p>
      </sec>
    </sec>
    <sec id="sec4">
      <title>Discussion</title>
      <p id="p0100">Detection of SARS-CoV-2 RNA in COVID-19 patient samples from higher respiratory tract with low Ct values on the 4th and 7th days of the course of the disease suggests high viral loads and capability for transmission [<xref rid="bib41" ref-type="bibr">41</xref>]. Neutrophil levels are an early indicator of SARS-CoV-2 infection and have a pathogenic role [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib4" ref-type="bibr">4</xref>] in neutrophil-derived NETosis, which could be reversed using recombinant DNAse I. Dornase alfa has been used to resolve the highly viscous mucus of cystic fibrosis patients for decades [<xref rid="bib32" ref-type="bibr">32</xref>,<xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib42" ref-type="bibr">42</xref>]. A similar mucus structure was detected in COVID-19 patients due to the accumulation of excessive NETs in the lungs [<xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib22" ref-type="bibr">22</xref>]. Here, we show our preliminary results with dornase alfa, which may have an <italic>in&#xA0;vitro</italic> anti-viral effect against SARS-CoV-2 infection without cytotoxicity. In this preliminary study, we also showed the effect of dornase alfa in the clearance of NET formation and SARS-CoV-2 viral load in three individuals with COVID-19 who showed clinical improvement in the radiological analysis (two out of three cases), oxygen saturation (Sp<sc>o</sc>
<sub>2</sub>), respiratory rate, disappearance of dyspnoea and coughing.</p>
      <p id="p0105">Dornase alfa degrades extracellular DNA fragments and promotes clearance of NET formation. In our daily-process of patient blood apheresis, we frequently use dornase alfa to clear NET-like clumps that can easily form after the cryopreservation and thawing process. Dornase alfa has been used in patients with cystic fibrosis to clear NETs in the respiratory tract. As reported in the literature [<xref rid="bib26" ref-type="bibr">26</xref>,<xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib36" ref-type="bibr">36</xref>,<xref rid="bib37" ref-type="bibr">37</xref>,<xref rid="bib40" ref-type="bibr">40</xref>], we recapitulated that NETs were cleared by dornase alfa in the Supplementary material (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>). This result gave rise to the thought that dornase alfa could be used in people with COVID-19, who can have NET-like formations induced by infiltrated neutrophils in their lungs. Therefore, three COVID-19 patients at different ages (64, 33 and 27 years old) were treated with dornase alfa.</p>
      <p id="p0110">We observed significant improvement in breathing by the disappearance of dyspnoea after dornase alfa therapy. All of the patients had better oxygenation after dornase alfa, shown by their Sp<sc>o</sc>
<sub>2</sub> values. Increased coughing was observed after the first dornase alfa dose, most probably due to the resolving of viscous mucus, but this phenomenon was followed by the disappearance of coughing at the end of therapy. Also, after the last dornase alfa dose, decreasing respiratory rates for all patients were accepted as an improvement in pulmonary function. In addition to the improvement in the clinical data, we also observed a decrease in the inflammatory biomarkers like C-reactive protein and procalcitonin. To our knowledge, dornase alfa has no direct anti-inflammatory effects so these laboratory findings must be tested in further studies.</p>
      <p id="p0115">We detected radiological improvements in the thorax CT images that were compatible with better ventilation after dornase alfa therapy and this supported our clinical findings. Radiological improvement was significant for Case 1 and Case 3. However, persistent lesions were detected in Case 2, this also might be accepted as a response to therapy in this early phase of the disease that mostly progressed with radiological deterioration. On the other hand, we speculated that the comorbidities of cancer and COVID-19 in the same patient may have determined the difference in clinical improvement. Although it is apparent that only three patients are not enough to comment on the efficacy of dornase alfa, two independent clinical trials with dornase alfa on COVID-19 patients will evaluate its efficacy. One of them is led by the Agence Nationale de S&#xE9;curit&#xE9; du M&#xE9;dicament (EudraCT, 2020-001492-33) with the project named &#x2018;Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SARS-CoV-2/COVID-19&#x2019; that plans for 100 individuals with COVID-19 to be included. The second one is led by University College, London (ClinicalTrials.gov: NCT04359654) with the phase 2 project named &#x2018;Nebulised Dornase &#x391; for Treatment of COVID-19 (COVASE)&#x2019;, which will recruit 50 individuals with COVID-19. These large-scale clinical trials may prove the clinical efficacy of dornase alfa in the treatment of COVID-19.</p>
      <p id="p0120">As dornase alfa is routinely taken by cystic fibrosis patients, data about the impact of COVID-19 on individuals with cystic fibrosis could be helpful to comment on the efficacy of dornase alfa. A recent study of this subject, reported very few and less severe COVID-19-positive cystic fibrosis patients across Europe [<xref rid="bib42" ref-type="bibr">42</xref>]. These data are very interesting because they are not compatible with the reported eight times higher death rate in chronic respiratory diseases compared with the cases with no comorbidities (COVID-19 Fatality Rate by Comorbidity. <ext-link ext-link-type="uri" xlink:href="http://www.worldometers.info" id="intref0015">www.worldometers.info</ext-link>). Lower severity of COVID-19 in cystic fibrosis patients could be explained by the long-term antibiotic therapy, such as azithromycin, or by the extreme efforts of families to minimize social contacts [<xref rid="bib42" ref-type="bibr">42</xref>]. Also, dornase alfa is a regular therapy used by cystic fibrosis patients and this might be the reason for this promising result in COVID-19. Besides the patients presented in this study, we have data from two cystic fibrosis patients who recovered from COVID-19 without severe symptoms under regular dornase alfa therapy (personal communication).</p>
      <p id="p0125">All of these data gave rise to the thought that dornase alfa may have an anti-viral effect against SARS-CoV-2 infection. With this purpose, in our RTCA assay dornase alfa was co-incubated with SARS-CoV-2, and we determined that the infection and SARS-CoV-2 viral propogation on the Vero cells did not progress in increasing concentrations of dornase alfa pre-treatment. This preliminary <italic>in&#xA0;vitro</italic> data proposed that dornase alfa may have a possible anti-viral effect against SARS-CoV-2, which is yet to be studied in detail. Our <italic>in&#xA0;vitro</italic> tests have shown that the RNA genome can be degraded by pre-incubating the SARS-CoV-2 virus with dornase alfa. This result was confirmed by RTCA and cytopathic effect tests. These initial findings revealed that dornase alfa may interact directly with SARS-CoV-2.</p>
      <p id="p0130">In this study, we instantly report our preliminary data from the days of the pandemic on <italic>in&#xA0;vitro</italic> effects and <italic>in&#xA0;vivo</italic> anti-viral and nuclease activity of dornase alfa for the clearance of SARS-CoV-2 viral load and NETs in lungs, which can be added among the used drugs as a candidate for the treatment of COVID-19 patients. For these reasons, it is suggested that using dornase &#x391; in the early period will decrease the viral load and slow down the course of the disease. Here, we also anounce that we have just started our clinical trial (ClinicalTrials.gov Identifier: NCT04432987) with early application of dornase alfa in the treatment of COVID-19 and this study involves the first case results.</p>
    </sec>
    <sec sec-type="data-availability" id="sec5">
      <title>Availability of data and material</title>
      <p id="p0135">The patient data used to support the findings of the study are available from the corresponding author upon request.</p>
    </sec>
    <sec id="sec6">
      <title>Funding statement</title>
      <p id="p0140">All funding for the work was supported by <funding-source id="gs1">Acibadem Healthcare Group</funding-source>.</p>
    </sec>
    <sec id="sec7">
      <title>Author contributions</title>
      <p id="p0145">HKO, RZ, MK, CC and ASK performed the clinical treatments. KY, CH, MK MEY, ED, NB and NBP analysed the clinical data. CT, SD, BY, GS, DDK, SA and US performed the SARS-CoV-2 isolation, propagation, plaque assay and in&#xA0;vitro experiments. KY, CT and SD wrote the manuscript. EO led the clinical investigation and contributed to the design and interpretation of the data. EO was the project supervisor that developed the concept of anti-viral use of dornase alfa in COVID-19 infection. All authors have seen and approved the content and have contributed significantly to this work.</p>
    </sec>
    <sec id="sec8">
      <title>Consent for publication</title>
      <p id="p0150">This manuscript has not been submitted or accepted for publication elsewhere. The authors do not have any financial interests to report.</p>
    </sec>
    <sec id="sec9">
      <title>Conflicts of interest</title>
      <p id="p0155">The authors declare that there are no competing interests.</p>
    </sec>
  </body>
  <back>
    <ref-list id="cebib0010">
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal" id="sref1">
          <person-group person-group-type="author">
            <name>
              <surname>Pedersen</surname>
              <given-names>S.F.</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>Y.C.</given-names>
            </name>
          </person-group>
          <article-title>SARS-CoV-2: a storm is raging</article-title>
          <source>J Clin Invest</source>
          <volume>130</volume>
          <issue>5</issue>
          <year>2020</year>
          <fpage>2202</fpage>
          <lpage>2205</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI137647</pub-id>
          <pub-id pub-id-type="pmid">32217834</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal" id="sref2">
          <person-group person-group-type="author">
            <name>
              <surname>Matthay</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Zemans</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Zimmerman</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Arabi</surname>
              <given-names>Y.M.</given-names>
            </name>
            <name>
              <surname>Beitler</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Mercat</surname>
            </name>
          </person-group>
          <article-title>Acute respiratory distress syndrome</article-title>
          <source>Nat Rev Dis Prim</source>
          <volume>5</volume>
          <issue>1</issue>
          <year>2018</year>
          <fpage>18</fpage>
          <pub-id pub-id-type="doi">10.1038/s41572-019-0069-0</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal" id="sref3">
          <person-group person-group-type="author">
            <name>
              <surname>Potey</surname>
              <given-names>P.M.D.</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Lucas</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Dorward</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential</article-title>
          <source>J Pathol</source>
          <volume>247</volume>
          <issue>5</issue>
          <year>2019</year>
          <fpage>672</fpage>
          <lpage>685</lpage>
          <pub-id pub-id-type="doi">10.1002/path.5221</pub-id>
          <pub-id pub-id-type="pmid">30570146</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal" id="sref4">
          <person-group person-group-type="author">
            <name>
              <surname>Frantzeskaki</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Armaganidis</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Orfanos</surname>
              <given-names>S.E.</given-names>
            </name>
          </person-group>
          <article-title>Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation</article-title>
          <source>Respiration</source>
          <volume>93</volume>
          <issue>3</issue>
          <year>2017</year>
          <fpage>212</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="doi">10.1159/000453002</pub-id>
          <pub-id pub-id-type="pmid">27997925</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal" id="sref5">
          <person-group person-group-type="author">
            <name>
              <surname>Iba</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Raj</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation</article-title>
          <source>J Clin Med</source>
          <volume>8</volume>
          <issue>5</issue>
          <year>2019</year>
          <fpage>728</fpage>
          <pub-id pub-id-type="doi">10.3390/jcm8050728</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal" id="sref6">
          <person-group person-group-type="author">
            <name>
              <surname>Ward</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Fattahi</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>New strategies for treatment of infectious sepsis</article-title>
          <source>J Leukoc Biol</source>
          <volume>106</volume>
          <issue>1</issue>
          <year>2019</year>
          <fpage>187</fpage>
          <lpage>192</lpage>
          <pub-id pub-id-type="doi">10.1002/JLB.4MIR1118-425R</pub-id>
          <pub-id pub-id-type="pmid">30821872</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal" id="sref7">
          <person-group person-group-type="author">
            <name>
              <surname>Meng</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yalavarthi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kanthi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Mazza</surname>
              <given-names>L.F</given-names>
            </name>
            <name>
              <surname>Elfline</surname>
              <given-names>M.A</given-names>
            </name>
            <name>
              <surname>Luke</surname>
              <given-names>C.E</given-names>
            </name>
          </person-group>
          <article-title>In vivo role of neutrophil extracellular traps in antiphospholipid antibody&#x2013;mediated venous thrombosis</article-title>
          <source>Arthritis Rheumatol (Hoboken, N.J.)</source>
          <volume>69</volume>
          <issue>3</issue>
          <year>2017</year>
          <fpage>655</fpage>
          <lpage>667</lpage>
          <pub-id pub-id-type="doi">10.1002/art.39938</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal" id="sref8">
          <person-group person-group-type="author">
            <name>
              <surname>Yadav</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Tourdot</surname>
              <given-names>B.E.</given-names>
            </name>
            <name>
              <surname>Yalavarthi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>B.N.</given-names>
            </name>
          </person-group>
          <article-title>Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1&#x3B2;-driven venous thrombosis</article-title>
          <source>J Clin Invest</source>
          <volume>129</volume>
          <issue>7</issue>
          <year>2019</year>
          <fpage>2872</fpage>
          <lpage>2877</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI124804</pub-id>
          <pub-id pub-id-type="pmid">30990798</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal" id="sref9">
          <person-group person-group-type="author">
            <name>
              <surname>Twaddell</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Baines</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Grainge</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>P.G.</given-names>
            </name>
          </person-group>
          <article-title>The emerging role of neutrophil extracellular traps in respiratory disease</article-title>
          <source>Chest</source>
          <volume>156</volume>
          <issue>4</issue>
          <year>2019</year>
          <fpage>774</fpage>
          <lpage>782</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chest.2019.06.012</pub-id>
          <pub-id pub-id-type="pmid">31265835</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal" id="sref10">
          <person-group person-group-type="author">
            <name>
              <surname>Porto</surname>
              <given-names>B.N.</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>R.T.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps in pulmonary diseases: too much of a good thing?</article-title>
          <source>Front Immunol</source>
          <volume>7</volume>
          <year>2016</year>
          <fpage>311</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2016.00311</pub-id>
          <pub-id pub-id-type="pmid">27574522</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="journal" id="sref11">
          <person-group person-group-type="author">
            <name>
              <surname>Liberale</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Holy</surname>
              <given-names>E.W.</given-names>
            </name>
            <name>
              <surname>Akhmedov</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bonetti</surname>
              <given-names>N.R.</given-names>
            </name>
            <name>
              <surname>Nietlispach</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Matter</surname>
              <given-names>C.M.</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-1&#x3B2; mediates arterial thrombus formation via NET-associated tissue factor</article-title>
          <source>J Clin Med</source>
          <volume>8</volume>
          <issue>12</issue>
          <year>2019</year>
          <fpage>2072</fpage>
          <pub-id pub-id-type="doi">10.3390/jcm8122072</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <element-citation publication-type="journal" id="sref12">
          <person-group person-group-type="author">
            <name>
              <surname>Meher</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Spinosa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Pope</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Laubach</surname>
              <given-names>V.E.</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Novel role of IL (interleukin)-1&#x3B2; in neutrophil extracellular trap formation and abdominal aortic aneurysms</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <volume>38</volume>
          <issue>4</issue>
          <year>2018</year>
          <fpage>843</fpage>
          <lpage>853</lpage>
          <pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309897</pub-id>
          <pub-id pub-id-type="pmid">29472233</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <element-citation publication-type="journal" id="sref13">
          <person-group person-group-type="author">
            <name>
              <surname>Josefs</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Quezada</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Voisin</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps promote macrophage inflammation and impair atherosclerosis resolution in diabetic mice</article-title>
          <source>JCI Insight</source>
          <volume>5</volume>
          <issue>7</issue>
          <year>2020</year>
          <object-id pub-id-type="publisher-id">e134796</object-id>
          <pub-id pub-id-type="doi">10.1172/jci.insight.134796</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <element-citation publication-type="journal" id="sref14">
          <person-group person-group-type="author">
            <name>
              <surname>Lachowicz-Scroggins</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Dunican</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Charbit</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Raymond</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Looney</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>M.C.</given-names>
            </name>
          </person-group>
          <article-title>Extracellular DNA, neutrophil extracellular traps, and inflammasome activation in severe asthma</article-title>
          <source>Am J Respir Crit Care Med</source>
          <volume>199</volume>
          <issue>9</issue>
          <year>2019</year>
          <fpage>1076</fpage>
          <lpage>1085</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.201810-1869OC</pub-id>
          <pub-id pub-id-type="pmid">30888839</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <element-citation publication-type="journal" id="sref15">
          <person-group person-group-type="author">
            <name>
              <surname>Merza</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hartman</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hwaiz</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Renstr&#xF6;m</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps induce trypsin activation, inflammation, and tissue damage in mice with severe acute pancreatitis</article-title>
          <source>Gastroenterology</source>
          <volume>149</volume>
          <issue>7</issue>
          <year>2015</year>
          <fpage>1920</fpage>
          <lpage>1931</lpage>
          <comment>e8</comment>
          <pub-id pub-id-type="doi">10.1053/j.gastro.2015.08.026</pub-id>
          <pub-id pub-id-type="pmid">26302488</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <label>16</label>
        <element-citation publication-type="journal" id="sref16">
          <person-group person-group-type="author">
            <name>
              <surname>Ridker</surname>
              <given-names>P.M.</given-names>
            </name>
          </person-group>
          <article-title>From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection</article-title>
          <source>Circ Res</source>
          <volume>118</volume>
          <issue>1</issue>
          <year>2016</year>
          <fpage>145</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.306656</pub-id>
          <pub-id pub-id-type="pmid">26837745</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <element-citation publication-type="journal" id="sref17">
          <person-group person-group-type="author">
            <name>
              <surname>Perlman</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Dandekar</surname>
              <given-names>A.A.</given-names>
            </name>
          </person-group>
          <article-title>Immunopathogenesis of coronavirus infections: implications for SARS</article-title>
          <source>Nat Rev Immunol</source>
          <volume>5</volume>
          <issue>12</issue>
          <year>2005</year>
          <fpage>917</fpage>
          <lpage>927</lpage>
          <pub-id pub-id-type="doi">10.1038/nri1732</pub-id>
          <pub-id pub-id-type="pmid">16322745</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <element-citation publication-type="journal" id="sref18">
          <person-group person-group-type="author">
            <name>
              <surname>Blondonnet</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Constantin</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Sapin</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Jabaudon</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>A pathophysiologic approach to biomarkers in acute respiratory distress syndrome</article-title>
          <source>Dis Markers</source>
          <volume>2016</volume>
          <year>2016</year>
          <fpage>3501373</fpage>
          <pub-id pub-id-type="doi">10.1155/2016/3501373</pub-id>
          <pub-id pub-id-type="pmid">26980924</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <element-citation publication-type="journal" id="sref19">
          <person-group person-group-type="author">
            <name>
              <surname>Narasaraju</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Samy</surname>
              <given-names>R.P.</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Poh</surname>
              <given-names>W.P.</given-names>
            </name>
            <name>
              <surname>Liew</surname>
              <given-names>A.A.</given-names>
            </name>
          </person-group>
          <article-title>Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis</article-title>
          <source>Am J Pathol</source>
          <volume>179</volume>
          <issue>1</issue>
          <year>2011</year>
          <fpage>199</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajpath.2011.03.013</pub-id>
          <pub-id pub-id-type="pmid">21703402</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <element-citation publication-type="journal" id="sref20">
          <person-group person-group-type="author">
            <name>
              <surname>Caudrillier</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kessenbrock</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Gilliss</surname>
              <given-names>B.M.</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>J.X.</given-names>
            </name>
            <name>
              <surname>Marques</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Monestier</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury</article-title>
          <source>J Clin Invest</source>
          <volume>122</volume>
          <issue>7</issue>
          <year>2012</year>
          <fpage>2661</fpage>
          <lpage>2671</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI61303</pub-id>
          <pub-id pub-id-type="pmid">22684106</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <label>21</label>
        <element-citation publication-type="journal" id="sref21">
          <person-group person-group-type="author">
            <name>
              <surname>Shi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Shao</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <article-title>COVID-19 infection: the perspectives on immune responses</article-title>
          <source>Cell Death Differ</source>
          <volume>27</volume>
          <issue>5</issue>
          <year>2020</year>
          <fpage>1451</fpage>
          <lpage>1454</lpage>
          <pub-id pub-id-type="doi">10.1038/s41418-020-0530-3</pub-id>
          <pub-id pub-id-type="pmid">32205856</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <element-citation publication-type="journal" id="sref22">
          <person-group person-group-type="author">
            <name>
              <surname>Barnes</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Adrover</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Baxter-Stoltzfus</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Borczuk</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cools-Lartigue</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Targeting potential drivers of COVID-19: neutrophil extracellular traps</article-title>
          <source>J Exp Med</source>
          <volume>217</volume>
          <issue>6</issue>
          <year>2020</year>
          <object-id pub-id-type="publisher-id">e20200652</object-id>
          <pub-id pub-id-type="doi">10.1084/jem.20200652</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <label>23</label>
        <element-citation publication-type="journal" id="sref23">
          <person-group person-group-type="author">
            <name>
              <surname>Kolaczkowska</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Jenne</surname>
              <given-names>C.N.</given-names>
            </name>
            <name>
              <surname>Surewaard</surname>
              <given-names>B.G.</given-names>
            </name>
            <name>
              <surname>Thanabalasuriar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Sanz</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanisms of NET formation and degradation revealed by intravital imaging in the liver vasculature</article-title>
          <source>Nat Commun</source>
          <volume>6</volume>
          <year>2015</year>
          <fpage>6673</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms7673</pub-id>
          <pub-id pub-id-type="pmid">25809117</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <label>24</label>
        <element-citation publication-type="journal" id="sref24">
          <person-group person-group-type="author">
            <name>
              <surname>McIlroy</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Minahan</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Keely</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lott</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Hansbro</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Reduced deoxyribonuclease enzyme activity in response to high postinjury mitochondrial DNA concentration provides a therapeutic target for systemic inflammatory response syndrome</article-title>
          <source>J Trauma Acute Care Surg</source>
          <volume>85</volume>
          <issue>2</issue>
          <year>2018</year>
          <fpage>354</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="doi">10.1097/TA.0000000000001919</pub-id>
          <pub-id pub-id-type="pmid">30080781</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <element-citation publication-type="journal" id="sref25">
          <person-group person-group-type="author">
            <name>
              <surname>Fuchs</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Borowitz</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Nash</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>B.W.</given-names>
            </name>
          </person-group>
          <article-title>Effect of aerosolized recombinant human dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis</article-title>
          <source>N Engl J Med</source>
          <volume>331</volume>
          <issue>10</issue>
          <year>1994</year>
          <fpage>637</fpage>
          <lpage>642</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199409083311003</pub-id>
          <pub-id pub-id-type="pmid">7503821</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <element-citation publication-type="journal" id="sref26">
          <person-group person-group-type="author">
            <name>
              <surname>McCoy</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease</article-title>
          <source>Chest</source>
          <volume>110</volume>
          <issue>4</issue>
          <year>1996</year>
          <fpage>889</fpage>
          <lpage>895</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.110.4.889</pub-id>
          <pub-id pub-id-type="pmid">8874241</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <element-citation publication-type="journal" id="sref27">
          <person-group person-group-type="author">
            <name>
              <surname>Mart&#xED;nez-Alem&#xE1;n</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Campos-Garc&#xED;a</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Palma-Nicolas</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Hern&#xE1;ndez-Bello</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Gonz&#xE1;lez</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>S&#xE1;nchez-Gonz&#xE1;lez</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Understanding the entanglement: neutrophil extracellular traps (NETs) in cystic fibrosis</article-title>
          <source>Front Cell Infect Microbiol</source>
          <volume>7</volume>
          <year>2017</year>
          <fpage>104</fpage>
          <pub-id pub-id-type="doi">10.3389/fcimb.2017.00104</pub-id>
          <pub-id pub-id-type="pmid">28428948</pub-id>
        </element-citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <element-citation publication-type="journal" id="sref28">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Wen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Clinical and pathological characteristics of 2019 novel coronavirus disease ( COVID-19 ): a systematic reviews</article-title>
          <source>medRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1101/2020.02.20.20025601</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <label>29</label>
        <element-citation publication-type="journal" id="sref29">
          <person-group person-group-type="author">
            <name>
              <surname>Ta&#x15E;tan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Yurtsever</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Sir Karaku&#x15E;</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>D&#x130;lek Kan&#xC7;a&#x11E;i</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Dem&#x130;r</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Abanuz</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>SARS-CoV-2 isolation and propagation from Turkish COVID-19 patients</article-title>
          <source>Turk J Biol</source>
          <volume>44</volume>
          <year>2020</year>
          <fpage>192</fpage>
          <lpage>202</lpage>
          <pub-id pub-id-type="doi">10.3906/biy-2004-113</pub-id>
          <pub-id pub-id-type="pmid">32595356</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <element-citation publication-type="book" id="sref30">
          <person-group person-group-type="author">
            <name>
              <surname>Hoppe</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Lassen</surname>
              <given-names>E.D.</given-names>
            </name>
          </person-group>
          <chapter-title>Blood smears and the use of Wright&#x2019; s stain</chapter-title>
          <volume>40</volume>
          <year>1978</year>
          <publisher-name>Iowa State Univ Vet</publisher-name>
          <fpage>113</fpage>
          <lpage>116</lpage>
          <ext-link ext-link-type="uri" xlink:href="https://lib.dr.iastate.edu/iowastate_veterinarian" id="intref0025">https://lib.dr.iastate.edu/iowastate_veterinarian</ext-link>
        </element-citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <element-citation publication-type="journal" id="sref31">
          <person-group person-group-type="author">
            <name>
              <surname>Fiel</surname>
              <given-names>S.B.</given-names>
            </name>
            <name>
              <surname>Fuchs</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gonda</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>A.R.</given-names>
            </name>
          </person-group>
          <article-title>Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis</article-title>
          <source>Chest</source>
          <volume>108</volume>
          <issue>1</issue>
          <year>1995</year>
          <fpage>153</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.108.1.153</pub-id>
          <pub-id pub-id-type="pmid">7606951</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <element-citation publication-type="journal" id="sref32">
          <person-group person-group-type="author">
            <name>
              <surname>Papayannopoulos</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Staab</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Zychlinsky</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving dnase therapy</article-title>
          <source>PLoS One</source>
          <volume>6</volume>
          <issue>12</issue>
          <year>2011</year>
          <object-id pub-id-type="publisher-id">e28526</object-id>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0028526</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <element-citation publication-type="journal" id="sref33">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>SARS-CoV-2: an emerging coronavirus that causes a global threat</article-title>
          <source>Int J Biol Sci</source>
          <volume>16</volume>
          <issue>10</issue>
          <year>2020</year>
          <fpage>1678</fpage>
          <lpage>1685</lpage>
          <pub-id pub-id-type="doi">10.7150/ijbs.45053</pub-id>
          <pub-id pub-id-type="pmid">32226285</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <element-citation publication-type="journal" id="sref34">
          <person-group person-group-type="author">
            <name>
              <surname>Ratjen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Van Koningsbruggen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Breitenstein</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rietschel</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Nikolaizik</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha</article-title>
          <source>Pediatr Pulmonol</source>
          <volume>39</volume>
          <issue>1</issue>
          <year>2005</year>
          <fpage>1</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1002/ppul.20134</pub-id>
          <pub-id pub-id-type="pmid">15532079</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <element-citation publication-type="journal" id="sref35">
          <person-group person-group-type="author">
            <name>
              <surname>Jim&#xE9;nez-Alc&#xE1;zar</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rangaswamy</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Panda</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bitterling</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Simsek</surname>
              <given-names>Y.J.</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>A.T.</given-names>
            </name>
          </person-group>
          <article-title>Host DNases prevent vascular occlusion by neutrophil extracellular traps</article-title>
          <source>Science (New York, N.Y.)</source>
          <volume>358</volume>
          <issue>6367</issue>
          <year>2017</year>
          <fpage>1202</fpage>
          <lpage>1206</lpage>
        </element-citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <element-citation publication-type="journal" id="sref36">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Dornase alfa for cystic fibrosis</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1002/14651858.CD001127.pub4</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <label>37</label>
        <element-citation publication-type="journal" id="sref37">
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>Z.S.</given-names>
            </name>
            <name>
              <surname>Sweezey</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Grasemann</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Palaniyar</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Progression of cystic fibrosis lung disease from childhood to adulthood&#x202F;: neutrophils, neutrophil extracellular trap (NET) formation, and NET degradation</article-title>
          <source>Genes</source>
          <volume>10</volume>
          <issue>3</issue>
          <year>2019</year>
          <fpage>183</fpage>
          <pub-id pub-id-type="doi">10.3390/genes10030183</pub-id>
        </element-citation>
      </ref>
      <ref id="bib38">
        <label>38</label>
        <element-citation publication-type="journal" id="sref38">
          <person-group person-group-type="author">
            <name>
              <surname>Bowen</surname>
              <given-names>K.L.</given-names>
            </name>
          </person-group>
          <article-title>Erroneous leukocyte counts and cold agglutinins</article-title>
          <source>Lab Med</source>
          <volume>28</volume>
          <year>1997</year>
          <fpage>247</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="doi">10.1093/labmed/28.4.247</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <label>39</label>
        <element-citation publication-type="journal" id="sref39">
          <person-group person-group-type="author">
            <name>
              <surname>Jeffery</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps in canine immune-mediated hemolytic anemia</article-title>
          <source>ProQuest Diss Theses</source>
          <year>2016</year>
          <fpage>263</fpage>
          <ext-link ext-link-type="uri" xlink:href="https://search.proquest.com/docview/1845054372?accountid=26646%0Ahttp://link.periodicos.capes.gov.br/sfxlcl41?url_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&amp;genre=dissertations+&amp;+theses&amp;sid=ProQ:ProQuest+Dissertations+&amp;+Theses+Globa" id="intref0030">https://search.proquest.com/docview/1845054372?accountid=26646%0Ahttp://link.periodicos.capes.gov.br/sfxlcl41?url_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&amp;genre=dissertations+%26+theses&amp;sid=ProQ:ProQuest+Dissertations+%26+Theses+Globa</ext-link>
        </element-citation>
      </ref>
      <ref id="bib40">
        <label>40</label>
        <element-citation publication-type="journal" id="sref40">
          <person-group person-group-type="author">
            <name>
              <surname>Konstan</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Ratjen</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Effect of dornase alfa on in fl ammation and lung function: potential role in the early treatment of cystic fibrosis</article-title>
          <source>J&#xA0;Cyst Fibros</source>
          <volume>11</volume>
          <year>2012</year>
          <fpage>78</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2011.10.003</pub-id>
          <pub-id pub-id-type="pmid">22093951</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <label>41</label>
        <element-citation publication-type="journal" id="sref41">
          <person-group person-group-type="author">
            <name>
              <surname>Holshue</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>DeBolt</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lindquist</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lofy</surname>
              <given-names>K.H.</given-names>
            </name>
            <name>
              <surname>Wiesman</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bruce</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>First case of 2019 novel coronavirus in the United States</article-title>
          <source>N Engl J Med</source>
          <volume>382</volume>
          <year>2020</year>
          <fpage>929</fpage>
          <lpage>936</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa2001191</pub-id>
          <pub-id pub-id-type="pmid">32004427</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <label>42</label>
        <element-citation publication-type="journal" id="sref42">
          <person-group person-group-type="author">
            <name>
              <surname>Colombo</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Burgel</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Gartner</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>van Koningsbruggen-Rietschel</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Naehrlich</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Sermet-Gaudelus</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Impact of COVID-19 on people with cystic fibrosis</article-title>
          <source>Lancet Respir Med</source>
          <volume>8</volume>
          <issue>5</issue>
          <year>2020</year>
          <fpage>e35</fpage>
          <lpage>e36</lpage>
          <pub-id pub-id-type="doi">10.1016/s2213-2600(20)30177-6</pub-id>
          <pub-id pub-id-type="pmid">32304639</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="appsec1" sec-type="supplementary-material">
      <label>Appendix A</label>
      <title>Supplementary data</title>
      <p id="p0165">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title><p>FIG. S1.&#xA0;Assessing TCID<sub>50</sub> of SARS-CoV-2.</p><p>FIG. S2.&#xA0;<italic>In&#xA0;vitro</italic> clearance of NET formation by dornase alfa.</p></caption><media xlink:href="mmc1.pdf"><alt-text>Multimedia component 1</alt-text></media></supplementary-material>
</p>
    </sec>
    <ack id="ack0010">
      <title>Acknowledgement</title>
      <p>
<xref rid="fig7" ref-type="fig">Figure&#xA0;7</xref> of the study was created with <sc>BioRender</sc>.com.</p>
    </ack>
    <fn-group>
      <fn id="appsec2" fn-type="supplementary-material">
        <label>Appendix A</label>
        <p id="p0170">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.nmni.2020.100756" id="intref0020">https://doi.org/10.1016/j.nmni.2020.100756</ext-link>.</p>
      </fn>
    </fn-group>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id>
      <journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id>
      <journal-id journal-id-type="publisher-id">pharmaceutics</journal-id>
      <journal-title-group>
        <journal-title>Pharmaceutics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1999-4923</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32751886</article-id>
      <article-id pub-id-type="pmc">7463544</article-id>
      <article-id pub-id-type="doi">10.3390/pharmaceutics12080721</article-id>
      <article-id pub-id-type="publisher-id">pharmaceutics-12-00721</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chang</surname>
            <given-names>Kyung Hwa</given-names>
          </name>
          <xref ref-type="aff" rid="af1-pharmaceutics-12-00721">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moon</surname>
            <given-names>Sang-Hyub</given-names>
          </name>
          <xref ref-type="aff" rid="af1-pharmaceutics-12-00721">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6032-4686</contrib-id>
          <name>
            <surname>Yoo</surname>
            <given-names>Sun Kook</given-names>
          </name>
          <xref ref-type="aff" rid="af2-pharmaceutics-12-00721">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>Bong Joo</given-names>
          </name>
          <xref ref-type="aff" rid="af3-pharmaceutics-12-00721">3</xref>
          <xref ref-type="aff" rid="af4-pharmaceutics-12-00721">4</xref>
          <xref rid="c1-pharmaceutics-12-00721" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nam</surname>
            <given-names>Ki Chang</given-names>
          </name>
          <xref ref-type="aff" rid="af1-pharmaceutics-12-00721">1</xref>
          <xref rid="c1-pharmaceutics-12-00721" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-pharmaceutics-12-00721"><label>1</label>Department of Medical Engineering, Dongguk University College of Medicine, Goyang-si, Gyeonggi-do 10326, Korea; <email>chang9429@hotmail.com</email> (K.H.C.); <email>shnoom@naver.com</email> (S.-H.M.)</aff>
      <aff id="af2-pharmaceutics-12-00721"><label>2</label>Department of Medical Engineering, Yonsei University College of Medicine, Seoul 03722, Korea; <email>sunkyoo@yuhs.ac</email></aff>
      <aff id="af3-pharmaceutics-12-00721"><label>3</label>Department of Electrical &amp; Biological Physics, Kwangwoon University, Seoul 01897, Korea</aff>
      <aff id="af4-pharmaceutics-12-00721"><label>4</label>Institute of Biomaterials, Kwangwoon University, Seoul 01897, Korea</aff>
      <author-notes>
        <corresp id="c1-pharmaceutics-12-00721"><label>*</label>Correspondence: <email>parkbj@kw.ac.kr</email> (B.J.P.); <email>chadol@dongguk.ac.kr</email> (K.C.N.); Tel.: +82-2-940-8629 (B.J.P.); +82-31-961-5802 (K.C.N.)</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>7</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>8</month>
        <year>2020</year>
      </pub-date>
      <volume>12</volume>
      <issue>8</issue>
      <elocation-id>721</elocation-id>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>6</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2020 by the authors.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license license-type="open-access">
          <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Recent reports on mesh nebulizers suggest the possibility of stable nebulization of various therapeutic protein drugs. In this study, the in vitro performance and drug stability of jet and mesh nebulizers were examined for dornase alfa and compared with respect to their lung delivery efficiency in BALB/c mice. We compared four nebulizers: two jet nebulizers (PARI BOY SX with red and blue nozzles), a static mesh nebulizer (NE-U150), and a vibrating mesh nebulizer (NE-SM1). The enzymatic activity of dornase alfa was assessed using a kinetic fluorometric DNase activity assay. Both jet nebulizers had large residual volumes between 24% and 27%, while the volume of the NE-SM1 nebulizer was less than 2%. Evaluation of dornase alfa aerosols produced by the four nebulizers showed no overall loss of enzymatic activity or protein content and no increase in aggregation or degradation. The amount of dornase alfa delivered to the lungs was highest for the PARI BOY SX-red jet nebulizer. This result confirmed that aerosol droplet size is an important factor in determining the efficiency of dornase alfa delivery to the lungs. Further clinical studies and analysis are required before any conclusions can be drawn regarding the clinical safety and efficacy of these nebulizers.</p>
      </abstract>
      <kwd-group>
        <kwd>nebulizer</kwd>
        <kwd>dornase alfa</kwd>
        <kwd>Pulmozyme</kwd>
        <kwd>aerosol size</kwd>
        <kwd>output rate</kwd>
        <kwd>DNase I activity</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-pharmaceutics-12-00721">
      <title>1. Introduction</title>
      <p>Dornase alfa (proprietary name: Pulmozyme, from Genentech) is a highly purified solution of recombinant human pancreatic deoxyribonuclease I (rhDNase I), an enzyme that selectively cleaves DNA. It was found to improve the rheological properties of purulent cystic sputum from cystic fibrosis (CF) patients in vitro [<xref rid="B1-pharmaceutics-12-00721" ref-type="bibr">1</xref>]. The reduction of viscosity is due to a decrease in the length of DNA derived from human neutrophils, which infiltrate the airways to eliminate pathogenic bacteria. The long-term effects of dornase alfa on lung exacerbation and its short-term (not more than 14 d) and long-term effects on lung function have been studied in clinical trials. These trials showed that dornase alfa is well tolerated, significantly improves lung function, and reduces the risk of pulmonary exacerbations [<xref rid="B2-pharmaceutics-12-00721" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-12-00721" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-12-00721" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-12-00721" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-12-00721" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-12-00721" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-12-00721" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-12-00721" ref-type="bibr">9</xref>]. Thus, dornase alfa is currently used as a mucolytic agent to treat the leading cause of morbidity and mortality in CF. According to the guidelines issued for chronic respiratory medication in CF patients, chronic patients aged over 6 years should inhale a 2.5 mg single-use ampule once daily using a recommended nebulizer [<xref rid="B10-pharmaceutics-12-00721" ref-type="bibr">10</xref>].</p>
      <p>Nebulizers, which are mainly used for aerosol therapy, can agitate liquid medication to create small aerosol droplets that can rapidly deliver drugs directly to the lungs and thus enable local drug delivery for the topical treatment of respiratory diseases, reducing the risk of systemic side effects [<xref rid="B11-pharmaceutics-12-00721" ref-type="bibr">11</xref>]. In addition, nebulizers do not require coordination between inhalation and actuation; thus, they are useful for pediatric, elderly, ventilated, and non-conscious patients [<xref rid="B12-pharmaceutics-12-00721" ref-type="bibr">12</xref>]. There are three types of nebulizers&#x2014;jet, ultrasonic, and mesh nebulizers&#x2014;which differ in terms of their working principles. Jet nebulizers are generally considered the gold standard method in the clinical field for delivering medicines to patients requiring aerosol therapy [<xref rid="B13-pharmaceutics-12-00721" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-12-00721" ref-type="bibr">14</xref>]. Current product information on dornase alfa for aerosol therapy in CF patients only recommends six jet nebulizers and one vibrating mesh nebulizer [<xref rid="B15-pharmaceutics-12-00721" ref-type="bibr">15</xref>]. This is because jet nebulizers have been used to administer dornase alfa in all clinical studies except for one, in which the Pari eRapid system (a portable vibrating mesh nebulizer) was evaluated [<xref rid="B16-pharmaceutics-12-00721" ref-type="bibr">16</xref>].</p>
      <p>Jet and ultrasonic nebulizers have been developed as the primary type, but ultrasonic nebulizers are more expensive than jet nebulizers and tend to increase the temperature of the nebulized drug solution. Thus, they are considered inappropriate for the nebulization of thermolabile peptides and proteins. On the other hand, compressor-based jet nebulizer systems are inconvenient for patients because they require extra tubing, a heavy compressor, and long treatment times, and are also noisy to use and relatively inefficient due to their large residual volumes [<xref rid="B12-pharmaceutics-12-00721" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-12-00721" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-12-00721" ref-type="bibr">14</xref>]. Compared with jet and ultrasonic nebulizers, mesh nebulizers are more portable, far more convenient for patients, deliver all liquid in reservoirs (i.e., zero residual volume), and enable efficient, rapid, and reproducible delivery of small drug volumes to the lungs. In a clinical trial, the eRapid mesh nebulizer system was strongly preferred by patients over the standard jet nebulizer [<xref rid="B16-pharmaceutics-12-00721" ref-type="bibr">16</xref>].</p>
      <p>Mesh nebulizers can be divided into two types: static (passive) and vibrating (active) nebulizers. Static mesh nebulizers use a horn that vibrates ultrasonically against a static mesh, while vibrating mesh nebulizers use a mesh mounted in an ultrasonically vibrating piezo ring [<xref rid="B13-pharmaceutics-12-00721" ref-type="bibr">13</xref>,<xref rid="B17-pharmaceutics-12-00721" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-12-00721" ref-type="bibr">18</xref>]. Recently, the performance characteristics of mesh nebulizers have attracted considerable interest for the pulmonary delivery of expensive protein-based biopharmaceuticals. Several studies have reported successful nebulization of sensitive drugs, such as proteins and antibodies, by mesh nebulizers. These in vitro studies, which were performed using a breathing simulator, showed that the delivery efficiency of protein aerosols produced by mesh nebulizers is comparable to that of jet mesh nebulizers [<xref rid="B16-pharmaceutics-12-00721" ref-type="bibr">16</xref>,<xref rid="B19-pharmaceutics-12-00721" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-12-00721" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-12-00721" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-12-00721" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-12-00721" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-12-00721" ref-type="bibr">24</xref>]. However, they did not compare the dose delivered to the lungs using an in vivo model. Although a variety of mesh nebulizers are commercially available, only the eRapid nebulizer has been approved for use with dornase alfa.</p>
      <p>Mesh nebulizers utilize the same piezoelectric transducer used in ultrasonic nebulizers to create aerosol droplets. In static nebulizers, this piezo element is mounted in a horn, whereas in vibrating mesh nebulizers, it is combined with the mesh substrate [<xref rid="B25-pharmaceutics-12-00721" ref-type="bibr">25</xref>]. It has been reported that piezoelectric elements in ultrasound nebulizers can produce sufficient heat to cause protein denaturation and loss of activity [<xref rid="B26-pharmaceutics-12-00721" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-12-00721" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-12-00721" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-12-00721" ref-type="bibr">29</xref>]. Recent reports show that the temperature of the liquid in the reservoir of a mesh nebulizer increases during nebulization [<xref rid="B30-pharmaceutics-12-00721" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-12-00721" ref-type="bibr">31</xref>]. Therefore, detailed studies are needed to determine whether heat generated by mesh nebulizers during operation affects protein stability.</p>
      <p>This study was undertaken to investigate the in vitro performance of four commonly used home nebulizers&#x2014;two jet nebulizers (PARI BOY SX with red and blue nozzles), a static mesh nebulizer (NE-U150), and a vibrating mesh nebulizer (NE-SM1)&#x2014;and to compare their effects on enzyme activity, structural integrity, temperature change, and in vivo delivery efficiency, using dornase alfa as the test drug. Dornase alfa delivery efficiency was evaluated using spontaneously breathing mice without mechanical ventilation or breathing masks in a closed inhalation chamber.</p>
    </sec>
    <sec id="sec2-pharmaceutics-12-00721">
      <title>2. Materials and Methods</title>
      <sec id="sec2dot1-pharmaceutics-12-00721">
        <title>2.1. Materials and Nebulizers</title>
        <p>Commercially available nebulizer solutions of 2.5 mg/2.5 mL dornase alfa were acquired from Genentech, Inc (South San Francisco, CA, USA) by Material Transfer Agreements (ID: OR-215976). The DNaseAlert&#x2122; QC System was obtained from Thermo Fisher Scientific (Waltham, MA, USA). The DC protein assay kit and 4&#x2013;20% Mini-PROTEAN<sup>&#xAE;</sup> TGX&#x2122; Precast Protein Gels were obtained from Bio-Rad Laboratories (Hercules, CA, USA). Anti-DNase I and horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG were purchased from Abcam (Cambridge, MA, USA) and Cell Signaling Technology (Danvers, MA, USA), respectively</p>
        <p>Four home nebulizers were investigated; the operating modes and abbreviations used for each nebulizer are described in <xref rid="pharmaceutics-12-00721-t001" ref-type="table">Table 1</xref>. Since the recommended devices for dornase alfa were not approved in the Korean market, popular items were selected for this study among the nebulizers commonly used in the clinic. PARI BOY SX in this study is the closest model to PARI LC PLUS, which is one of the recommended devices for dornase alfa. The PARI BOY SX jet nebulizer was used with two types of nozzle (red and blue); both were supplied by the manufacturer. According to the manufacturer, the red nozzle attachment creates finer droplets than the blue nozzle.</p>
      </sec>
      <sec id="sec2dot2-pharmaceutics-12-00721">
        <title>2.2. Animals</title>
        <p>All animal experiments were conducted in accordance with guidelines issued by the Ethics Committee of Animal Service Center at Dongguk University (IACUC Number: 2019-010-1, 18 April 2019). Female BALB/c mice aged seven to eight weeks were obtained from Daehan Biolink (Eumseong, Korea). The mice were housed in standard cages and maintained under controlled, constant room temperature (RT) and humidity with a 12-h light/dark cycle. The animals had free access to both water and food.</p>
      </sec>
      <sec id="sec2dot3-pharmaceutics-12-00721">
        <title>2.3. Size of Nebulized Aerosol Droplets</title>
        <p>The aerosol size distributions were assessed using a Spraytec (Model #STP5311, Malvern instrument, Malvern, UK), which utilizes the laser diffraction method and has been demonstrated to be a reliable and time-saving method [<xref rid="B32-pharmaceutics-12-00721" ref-type="bibr">32</xref>]. In each experiment, saline and 2.5 mL aliquots of 1 mg/mL dornase alfa were placed in nebulizers. In order to measure aerosol droplet sizes, all nebulizers were placed into a Spraytec without mask adapters or mouthpieces. Aerosol droplet sizes were measured during nebulization for 1 min after an initial nebulization period of 30 s. Particle size distribution (Dv (10), Dv (50), (Dv (90)) was automatically calculated by Spraytec software version 3.1 (Malvern instrument, Malvern, UK, 2009). All determinations were performed in triplicate.</p>
      </sec>
      <sec id="sec2dot4-pharmaceutics-12-00721">
        <title>2.4. Residual Volumes, Nebulization Times, and Output Rates</title>
        <p>To estimate residual volumes, nebulization times, and output rates, all nebulizers were operated in accordance with the manufacturer&#x2019;s recommendations. Dornase alfa was kept on ice prior to nebulization. After filling the reservoir of each nebulizer with saline or dornase alfa, nebulizers were operated for the duration of nebulization: jet nebulizers were run continuously until 1 min after the beginning of sputtering, and mesh nebulizers were run until the end of the operating period. Nebulizer weights were measured before and after nebulization, and nebulization times were also recorded. Residual volumes were determined gravimetrically; evaporation was negligible [<xref rid="B33-pharmaceutics-12-00721" ref-type="bibr">33</xref>]. Upon completion of nebulization, the output rate of each nebulizer was calculated using the equation below. This process was repeated three times for each nebulizer.
<disp-formula id="FD1-pharmaceutics-12-00721"><mml:math id="mm1"><mml:mrow><mml:mrow><mml:mi>O</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>R</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>m</mml:mi><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>c</mml:mi><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>v</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mi>L</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>v</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mi>L</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>b</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mtext>&#xA0;</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula></p>
      </sec>
      <sec id="sec2dot5-pharmaceutics-12-00721">
        <title>2.5. Activity and Quantification of Dornase Alfa after Nebulization</title>
        <p>To measure dornase alfa activity after nebulization, control (non-nebulized dornase alfa) samples (nominally 100% dornase alfa) were generated by transferring dornase alfa ampule contents at 2&#x2013;8 &#xB0;C into microtubes. Dornase alfa aerosols were collected using disposable plastic bags during nebulization and immediately transferred to clean microtubes and stored at 2&#x2013;8 &#xB0;C until required for analysis. The enzymatic activities of dornase alfa samples were determined using a kinetic fluorometric DNase activity assay. Briefly, collected dornase alfa samples were diluted 250-fold in saline, and then a 5 &#x3BC;L aliquot was transferred into the well of an analyzer containing 75 &#x3BC;L of nuclease-free water, 10 &#x3BC;L of 1X NucleaseAlter buffer, and 10 &#x3BC;L of DNase Alert Substrate solution. Fluorescence intensity was measured at Ex/Em = 535/556 nm at 1 min intervals for 1 h using a SpectraMax M3 microplate reader (Molecular Devices, Sunnyvale, CA, USA). Assays were performed at 37 &#xB0;C. Relative DNase activity was calculated from the slopes of graphs of fluorescence intensity. The DNase activity of non-nebulized nominal dornase alfa was regarded as 100%, as shown in Table 4. The protein content of collected dornase alfa was measured with a DC protein assay kit using BSA as the standard. The absorbance values of the samples were measured after 15 min of incubation at RT at 750 nm using a SpectraMax M3 microplate reader.</p>
      </sec>
      <sec id="sec2dot6-pharmaceutics-12-00721">
        <title>2.6. Polyacrylamide Gel Electrophoresis (PAGE) of Dornase Alfa after Nebulization</title>
        <p>Electrophoresis was carried out using 4&#x2013;20% Mini-PROTEAN<sup>&#xAE;</sup> TGX&#x2122; Precast Gels (native polyacrylamide gels) or 15% sodium dodecyl-sulfate (SDS) polyacrylamide gels. Protein samples (10 &#x3BC;g/20 &#x3BC;L) for native and SDS polyacrylamide gel analyses were prepared using 5X native sample loading buffer and 5X SDS-PAGE sample loading buffer, respectively. The mixtures with 5X SDS-PAGE sample loading buffer were heat-treated for 5 min in a heating block before being loaded into SDS polyacrylamide gel. After separation by electrophoresis, gels were stained with Coomassie Brilliant Blue (CBB) solution containing 0.1% (w/v) CBB R-250, 50% (v/v) methanol, and 10% (v/v) acetic acid at RT overnight. Subsequently, the CBB-stained gels were placed in the destaining solution containing 40% (v/v) methanol and 10% (v/v) acetic acid several times. Images of gels were captured using a digital camera.</p>
      </sec>
      <sec id="sec2dot7-pharmaceutics-12-00721">
        <title>2.7. Temperature Measurement During Nebulization</title>
        <p>The temperature changes of dornase alfa during nebulization were measured with a K-type thermocouple probe using a FLUKE-87-5 digital multimeter (Fluke, Everett, WA, USA). For the two jet nebulizers and the vibrating mesh nebulizer, a thermocouple probe was placed at a height of 2 mm from the center of the reservoir base, whereas for the static nebulizer, the probe was placed 2 mm from the horn. Dornase alfa was stored on ice prior to nebulization. Each nebulizer was operated after loading 2.5 mL of cold dornase alfa in the reservoir. Temperatures were recorded at 1 min intervals during nebulization. During measurements, the temperature and relative humidity were set at 23 &#xB0;C and 43%, respectively.</p>
      </sec>
      <sec id="sec2dot8-pharmaceutics-12-00721">
        <title>2.8. Treatment of Mice with Dornase Alfa and Bronchoalveolar Lavage Fluid Collection</title>
        <p>The mice were exposed to dornase alfa (2.5 mg/2.5 mL) in a closed inhalation exposure chamber (<xref ref-type="fig" rid="pharmaceutics-12-00721-f001">Figure 1</xref>) that was designed specifically for exposure of three mice at once. The chamber consisted of clear acrylic sheets (3 mm in thickness) with external dimensions of 20 &#xD7; 20 &#xD7; 15 cm, an internal volume of 6 L, and three small holes for head-only exposure [<xref rid="B34-pharmaceutics-12-00721" ref-type="bibr">34</xref>]. Mice were randomly divided into five groups (<italic>n</italic> = 3/group), as follows: (i) untreated (negative control); (ii) nebulized by JN-PARIr; (iii) nebulized by JN-PARIb; (iv) nebulized by SMN-U150; (v) nebulized by VMN-SM1. Mice were anesthetized with intraperitoneal injections of ketamine (100 mg/kg) and xylazine (10 mg/kg) prior to undergoing nebulization. The delivery efficiency of each of the four nebulizers was examined under two different exposure conditions: (1) 2.5 mL of dornase alfa was placed in the reservoir and then nebulizers were operated for the duration of nebulization (until the onset of sputter or to dryness) or (2) to maintain a constant output, 2.5 mL or 3 mL of dornase alfa was charged into the jet nebulizer reservoir or mesh nebulizer reservoir, respectively, and then the nebulizers were run until the output volume reached 1.7 mL. Following dornase alfa exposure, bronchoalveolar lavage fluid (BALF) samples were harvested to assess the dornase alfa concentration in the lungs. The BALF samples were collected from each animal by cannulation of the exposed trachea and gentle flushing of the lungs with 0.7 mL of warm saline. BALF samples were centrifuged and supernatants were transferred to pre-cooled tubes and immediately frozen at &#x2212;70 &#xB0;C until required for analysis.</p>
      </sec>
      <sec id="sec2dot9-pharmaceutics-12-00721">
        <title>2.9. Determination of Dornase Alfa Levels in BALF</title>
        <p>Dornase alfa levels in BALF samples were examined by conventional Western blot analysis using anti-DNase I. Briefly, BALF samples and 10 ng of dornase alfa proteins (i.e., positive control) were loaded into SDS polyacrylamide gel and then gel electrophoresis was performed. After transfer to polyvinylidene difluoride membranes, dornase alfa proteins were detected with primary and HRP conjugated secondary antibodies and Immobilon Western detection reagents, as described previously [<xref rid="B35-pharmaceutics-12-00721" ref-type="bibr">35</xref>]. Chemiluminescence images were obtained and analyzed with ChemiDoc XRS + system and Image Lab software (Bio-Rad Laboratories, Hercules, CA, USA), respectively.</p>
      </sec>
      <sec id="sec2dot10-pharmaceutics-12-00721">
        <title>2.10. Statistical Analysis</title>
        <p>One-way analysis of variance followed by Dunnett&#x2019;s test was used to determine the significance of intergroup differences. Statistical analysis was performed using SigmaPlot software version 13 (Systat Software, San Jose, CA, USA, 2014). <italic>p</italic>-values of &lt;0.05 were considered to be statistically significant.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3-pharmaceutics-12-00721">
      <title>3. Results</title>
      <sec id="sec3dot1-pharmaceutics-12-00721">
        <title>3.1. Nebulizer Characterization and Performance</title>
        <p>To investigate the functional performance levels of jet and mesh nebulizers, we compared the mass median diameter (MMD) of aerosol droplets of saline or 2.5 mg/2.5 mL dornase alfa solution. The data showed that aerosol droplet sizes differed between nebulizers (<xref rid="pharmaceutics-12-00721-t002" ref-type="table">Table 2</xref>). However, the Dv (50) results of dornase alfa were similar or slightly greater than those of saline. The Dv (50) results of dornase alfa generated by JN-PARIr and JN-PARIb clearly showed a difference between nozzle types: 3.18 &#xB1; 0.08 &#xB5;m for the red nozzle and 4.99 &#xB1; 0.08 &#xB5;m for the blue nozzle. The size difference according to the nozzle is similar to the results shown by the manufacturer. The Dv (50) results of dornase alfa for SMN-U150 and VMN-SM1 were 7.23 &#xB1; 0.07 &#xB5;m and 5.93 &#xB1; 0.23 &#xB5;m, respectively. Thus, JN-PARIr generated the smallest droplets and SMN-U150 generated the largest.</p>
        <p>We examined the residual volumes, nebulization times, and output rates after filling reservoirs with saline or dornase alfa. <xref rid="pharmaceutics-12-00721-t003" ref-type="table">Table 3</xref> shows that the results for dornase alfa were similar to those for saline. Residual volumes for dornase alfa were approximately 24% for JN-PARIr and 27% for JN-PARIb, respectively, whereas the residual volume for VMN-SM1 was small enough to be negligible (<xref rid="pharmaceutics-12-00721-t003" ref-type="table">Table 3</xref>). Incomplete aerosolization of the drug solution in the reservoirs of jet nebulizers is already a well-known characteristic [<xref rid="B12-pharmaceutics-12-00721" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-12-00721" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-12-00721" ref-type="bibr">14</xref>]. The residual volume of SMN-U150 was found to be 15% higher than that of VMN-SM1, due to the protruding structure around the horn. The nebulization times of SMN-U150 for saline and dornase alfa were the shortest at 6.22 &#xB1; 0.076 and 6.47 &#xB1; 0.031 min, respectively, whereas JN-PARIr had the longest nebulization times (13.19 &#xB1; 0.072 min for saline and 13.30 &#xB1; 0.068 min for dornase alfa). The data showed that nebulization times varied between nebulizers. As a result, the nebulization time of JN-PARIr was 2-fold longer than that of SMN-U150. The output rates of dornase alfa for the JN-PARIr, JN-PARIb, SMN-U150, and VMN-SM1 nebulizers were 0.140 &#xB1; 0.002, 0.170 &#xB1; 0.004, 0.311 &#xB1; 0.002, and 0.238 &#xB1; 0.002 mL/min, respectively: the same order as that observed for aerosol droplet sizes (<xref rid="pharmaceutics-12-00721-t003" ref-type="table">Table 3</xref>). These results show that the mesh nebulizers had smaller residual volumes and shorter nebulization times than the jet nebulizers.</p>
      </sec>
      <sec id="sec3dot2-pharmaceutics-12-00721">
        <title>3.2. Assessment of Dornase Alfa Activity, Concentration, and Structural Integrity after Nebulization</title>
        <p>The enzyme activity of the collected dornase alfa aerosol from the four nebulizers was fully retained when compared with the non-nebulized nominal samples (<xref rid="pharmaceutics-12-00721-t004" ref-type="table">Table 4</xref>). Likewise, the protein concentrations in the collected samples and in non-nebulized nominal samples were similar.</p>
        <p>Finally, to investigate the structural integrity of dornase alfa in the collected aerosol samples, we performed two different gel electrophoresis tests. As demonstrated in <xref ref-type="fig" rid="pharmaceutics-12-00721-f002">Figure 2</xref>b, the SDS-PAGE results showed that the non-nebulized nominal sample had one major band at ~35 kDa, which concurs with previous SDS-PAGE and Western blot studies on dornase alfa [<xref rid="B1-pharmaceutics-12-00721" ref-type="bibr">1</xref>,<xref rid="B15-pharmaceutics-12-00721" ref-type="bibr">15</xref>]. However, native PAGE produced one major band larger than 35 kDa and a smear band between 40 and 60 kDa for the non-nebulized control, probably because dornase alfa is a glycoprotein and native PAGE was carried out without SDS (<xref ref-type="fig" rid="pharmaceutics-12-00721-f002">Figure 2</xref>a). Nevertheless, aggregated or degraded protein bands of dornase alfa were not observed under non-reducing or reducing conditions, which showed that the nebulization processes of the four nebulizers did not result in any aggregation or degradation of dornase alfa (<xref ref-type="fig" rid="pharmaceutics-12-00721-f002">Figure 2</xref>a,b). This in vitro analysis demonstrated that static and vibrating mesh nebulizers are capable of stably producing fully active dornase alfa aerosols in vitro without aggregation or degradation, similar to the jet nebulizers.</p>
      </sec>
      <sec id="sec3dot3-pharmaceutics-12-00721">
        <title>3.3. Investigation of Temperature Change in the Reservoir During the Operation of the Nebulizer</title>
        <p>Temperature changes in the reservoir during nebulization were measured, as these can affect protein activity and structure [<xref rid="B36-pharmaceutics-12-00721" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-12-00721" ref-type="bibr">37</xref>]. Temperature changes in the reservoirs of the four nebulizers during nebulization are shown in <xref ref-type="fig" rid="pharmaceutics-12-00721-f003">Figure 3</xref>. The temperature of the dornase alfa solution in the JN-PARIr and JN-PARIb reservoirs quickly increased to 16 &#xB0;C within 1 min, but remained at 16 &#xB0;C below RT until nebulization was complete. The temperatures of SMN-U150 and VMN-SM1 continuously increased to 27 and 30 &#xB0;C, respectively, higher than the RT. VMN-SM1 achieved a higher temperature because its nebulization time was greater than that of SMN-150, as shown in <xref rid="pharmaceutics-12-00721-t003" ref-type="table">Table 3</xref>. Thus, the mesh nebulizers can significantly increase the temperature of dornase alfa solution in the reservoir to above RT, whereas jet nebulizers do not.</p>
      </sec>
      <sec id="sec3dot4-pharmaceutics-12-00721">
        <title>3.4. Delivery Efficiency of Dornase Alfa in Mice</title>
        <p>Large molecules such as dornase alfa can be measured in BALF samples after exposure to dornase alfa, because they have little or no systemic absorption [<xref rid="B36-pharmaceutics-12-00721" ref-type="bibr">36</xref>]. Mice were exposed to the dornase alfa under two different exposure conditions: Exposure 1 and 2. In the case of Exposure 1, nebulizer outputs from the four nebulizers were different, resulting in different residual volumes, as shown in <xref rid="pharmaceutics-12-00721-t003" ref-type="table">Table 3</xref>. Thus, for Exposure 1, it is difficult to accurately compare the drug delivery efficiency because the residual volumes varied depending on the type of nebulizer. Exposure 2 was designed to make delivery efficiency easier to compare by setting the output to 1.7 mL for all four nebulizers. The output was set at 1.7 mL because the largest residual volume of JN-PARIb was measured at approximately 0.7 mL with 2.5 mL of dornase alfa (<xref rid="pharmaceutics-12-00721-t003" ref-type="table">Table 3</xref>). As shown in <xref ref-type="fig" rid="pharmaceutics-12-00721-f004">Figure 4</xref>a,b, the JN-PARIr nebulizer achieved a significantly higher level of dornase alfa in BALF than the other nebulizers under both Exposure 1 (JN-PARIr: 552, JN-PARIb: 248, SMN-U150: 133, VMN-SM1: 360 ng/mL) and Exposure 2 (JN-PARIr: 549, JN-PARIb: 252, SMN-U150: 125, VMN-SM1: 259 ng/mL), while SMN-150, which had the highest output rate and the shortest nebulization time, had the lowest delivery efficiency under both exposure conditions. In Exposure 1, the level of dornase alfa in BALF for the VMN-SM1 nebulizer was generally higher than that of the JN-PARIb nebulizer, but for Exposure 2, VMN-SM1 and JN-PARIb had similar delivery efficiencies. Although JN-PARIr had a high residual volume and a long nebulization time, it showed the highest dornase alfa delivery efficiency under both conditions. Interestingly, the pattern of efficiency for the delivery of dornase alfa into lungs at Exposure 2 was similar to the order of particle size of dornase alfa aerosol shown in <xref rid="pharmaceutics-12-00721-t002" ref-type="table">Table 2</xref>. These results indicate that the delivery efficiency of dornase alfa is more related to the droplet size than the nebulizer output.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec4-pharmaceutics-12-00721">
      <title>4. Discussion</title>
      <p>Dornase alfa is indicated for daily administration using a recommended nebulizer in conjunction with standard therapies for the management of CF patients to improve pulmonary function. Currently, product information on dornase alfa recommends only six jet nebulizer/compressor systems and one vibrating mesh nebulizer [<xref rid="B15-pharmaceutics-12-00721" ref-type="bibr">15</xref>]. These nebulizers generate different droplet sizes and have different output characteristics and dosing rates, which largely depends on the mode of operation.</p>
      <p>It has been well established that total and regional lung deposition of inhaled aerosols are determined by two key factors: droplet size and output [<xref rid="B37-pharmaceutics-12-00721" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-12-00721" ref-type="bibr">38</xref>]. In the present study, we investigated the in vitro performance and drug stability of jet and mesh nebulizers for dornase alfa, and then compared their delivery efficiency in a mouse model.</p>
      <p>The droplet sizes produced by jet nebulizers were generally smaller than those generated by mesh nebulizers (<xref rid="pharmaceutics-12-00721-t002" ref-type="table">Table 2</xref>). Interestingly, for jet nebulizers, the droplet sizes are directly proportional to the size of the nozzle [<xref rid="B39-pharmaceutics-12-00721" ref-type="bibr">39</xref>]. We found that the sizes of droplets produced by the four nebulizers studied were greater than those specified by the manufacturers. This was due to the use of different laser diffraction instruments or the use of mass median aerodynamic diameters (MMAD), which were measured using an air-driven cascade impactor [<xref rid="B32-pharmaceutics-12-00721" ref-type="bibr">32</xref>]. In fact, it has been shown that the MMDs of droplets as determined by laser diffraction measure larger than droplets measured by MMAD due to evaporation losses from small droplets at the plume edge [<xref rid="B40-pharmaceutics-12-00721" ref-type="bibr">40</xref>]. Therefore, the droplet sizes may vary slightly according to the particular analytical method used. According to the performance data shown in <xref rid="pharmaceutics-12-00721-t003" ref-type="table">Table 3</xref>, the residual volumes of JN-PARIr and JN-PARIb were significantly greater than those of mesh nebulizers, and this resulted in lower output rates. The nebulization time of JN-PARIr was the longest, while that of SMN-U150 was the shortest. Although the nebulization time of JN-PARIb was similar to that of VMN-SM1, its output rate was lower because JN-PARIb had a high residual volume. This result is consistent with previous studies that compared the performance of jet and mesh nebulizers [<xref rid="B41-pharmaceutics-12-00721" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-12-00721" ref-type="bibr">42</xref>].</p>
      <p>Measurements of enzyme activity, protein concentration, and structural integrity of dornase alfa after nebulization are essential because they can impact clinical outcomes significantly. Also, aggregation or degradation of a protein could decrease its activity or even result in the generation of an immunogenic protein [<xref rid="B43-pharmaceutics-12-00721" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-12-00721" ref-type="bibr">44</xref>]. The enzymatic activity and protein concentrations of collected dornase alfa aerosols from the four nebulizers were similar to those of non-nebulized nominal samples (<xref rid="pharmaceutics-12-00721-t004" ref-type="table">Table 4</xref>). In addition, the results of PAGE using native polyacrylamide gel and SDS polyacrylamide gel showed that no larger or smaller fragments of dornase alfa were observed after nebulization, which demonstrates that dornase alfa was nebulized effectively without aggregation or degradation by all four nebulizers. These results show that dornase alfa remains in its active form and is analytically unaltered following aerosolization in all four nebulizers.</p>
      <p>Various nebulizers have been developed to deliver small-molecule drugs to the lungs rather than peptides or proteins. It is well known that jet nebulizers generally decrease the reservoir&#x2019;s solution temperature during the first 2 min of operation, whereas ultrasonic nebulizers increase the temperature by ~20 &#xB0;C within a few minutes [<xref rid="B45-pharmaceutics-12-00721" ref-type="bibr">45</xref>]. Mesh nebulizers are based on further development of the ultrasonic nebulization principle to improve aerosol generation efficiency, speed of nebulization, and device handling, as well as to reduce residual volumes; however, optimizing protein stability during nebulization has not been not a primary concern [<xref rid="B31-pharmaceutics-12-00721" ref-type="bibr">31</xref>,<xref rid="B46-pharmaceutics-12-00721" ref-type="bibr">46</xref>]. As research began to deliver expensive proteins directly into the lungs using a nebulizer, researchers examined whether proteins were stably nebulized with various type of nebulizers, because aggregation and degradation of proteins can reduce protein activity or even result in immunogenicity [<xref rid="B43-pharmaceutics-12-00721" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-12-00721" ref-type="bibr">44</xref>].</p>
      <p>Mesh nebulizers are generally considered to enable aerosol generation at low shear, and thus are suitable for use with biopharmaceuticals. Several reports using small-molecule drugs have reported that mesh nebulizers show little or no change in the temperature of the reservoir solution. Since these studies use drugs stored at RT, most of the temperature changes start from RT [<xref rid="B47-pharmaceutics-12-00721" ref-type="bibr">47</xref>]. However, current reports issued to date on the heating of protein drugs are inconsistent. A recent study using cold storage proteins reported reservoir temperatures reaching more than 35 &#xB0;C at the end of nebulization [<xref rid="B31-pharmaceutics-12-00721" ref-type="bibr">31</xref>]. In the present study, we investigated the temperature changes of cold dornase alfa in the reservoir during the operation of the nebulizer (<xref ref-type="fig" rid="pharmaceutics-12-00721-f003">Figure 3</xref>), because dornase alfa, unlike small-molecule drugs, must be stored according to the manufacturer&#x2019;s recommended temperature (range 2&#x2013;8 &#xB0;C) until the point of administration. The results of temperature changes using 2.5 mL of cold dornase alfa solution clearly showed that static and vibrating mesh nebulizers increase the temperature inside the reservoir above RT during nebulization (<xref ref-type="fig" rid="pharmaceutics-12-00721-f003">Figure 3</xref>). Since dornase alfa has a high melting temperature of 67.4 &#xB0;C, its activity in aerosols produced by these nebulizers was maintained despite the reservoir temperature increasing to 30 &#xB0;C [<xref rid="B48-pharmaceutics-12-00721" ref-type="bibr">48</xref>]. This result shows that the longer the nebulization time, the greater the operating energy of the nebulizer, which can cause the reservoir temperature to rise significantly. Therefore, heat-sensitive proteins in particular should be considered for use alone or in combination with other drugs.</p>
      <p>Accurate knowledge of delivery efficiency to the lungs after drug administration by nebulizer is critical for establishing dose&#x2013;response correlations and optimizing the treatment outcomes [<xref rid="B49-pharmaceutics-12-00721" ref-type="bibr">49</xref>]. The amount of dornase alfa delivered by nebulizers has usually been determined by capturing aerosols with an absolute filter connected to an in vitro breathing simulator developed to simulate in vivo breathing [<xref rid="B20-pharmaceutics-12-00721" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-12-00721" ref-type="bibr">21</xref>]. However, this method has shortcomings in terms of determining the delivery efficiency to the lungs, as it involves collecting all of the aerosol generated, and thus does not accurately mimic mouth-to-lung delivery. Aerosol droplet size is one of the most important variables in terms of determining the dose deposited and the distribution of the drug in the lungs. Most therapeutic aerosols generate a wide range of droplet sizes. It has been well established that fine droplets of less than 5 &#xB5;m are deposited within the peripheral airways, whereas larger droplets typically impact the oropharynx and are eventually swallowed [<xref rid="B50-pharmaceutics-12-00721" ref-type="bibr">50</xref>]. In addition, clinical studies on dornase alfa have only evaluated pulmonary functions and did not define the aerosol dose of dornase alfa delivered to the lungs. Therefore, there is a need to evaluate the delivery efficiency of dornase alfa reaching the lungs by nebulizer using an in vivo model. In this study, we decided to use an in vivo mouse model to compare the lung delivery efficiency of nebulizers that utilize different operating principles, generate different aerosol droplet sizes, and have different residual volumes and output rates.</p>
      <p>Dornase alfa levels in the BALF samples obtained from mouse lungs under two different exposure conditions were not detectable using commercial hDNase I ELISA kits due to a mismatch between the recombinant protein and the coated antibody or detection antibody. In addition, therapeutic proteins generally have high molecular weights and cannot easily penetrate the capillaries in the lungs. Thus, they can be detected in BALF [<xref rid="B36-pharmaceutics-12-00721" ref-type="bibr">36</xref>]. When examining a nebulizer&#x2019;s drug delivery efficiency under in vitro or in vivo conditions, nebulizers are generally operated for the duration of nebulization. However, these conditions make it difficult to compare drug delivery efficiencies, because the output rate and nebulization time depend on the nebulizer type. In this study, to compare the delivery efficiency of dornase alfa, mice were exposed to dornase alfa under Exposure 1 (duration of nebulization) and Exposure 2 (constant output of 1.7 mL) conditions. Under both exposure conditions, the JN-PARIr nebulizer produced the highest level of dornase alfa in BALF (<xref ref-type="fig" rid="pharmaceutics-12-00721-f004">Figure 4</xref>a,b). On the other hand, the SMN-U150 nebulizer, which generated the largest aerosol droplets and had a lower residual volume and the highest output rate, indicated the lowest level of dornase alfa under both exposure conditions. The in vivo study of Exposure 2 (constant output of 1.7 mL), shown in <xref ref-type="fig" rid="pharmaceutics-12-00721-f004">Figure 4</xref>b, indicated that the efficiency of delivering dornase alfa to the lungs was overwhelmingly determined by the aerosol droplet size, which concurs with the findings of previous studies that used a higher lung deposition of aerosols with smaller particle sizes [<xref rid="B11-pharmaceutics-12-00721" ref-type="bibr">11</xref>].</p>
      <p>Although in vivo data are more relevant than in vitro data, our mouse model also has its limitations. Anesthetization may have caused a significant departure from clinical conditions, and airway branching in the human lung is relatively symmetric, whereas that of mouse lungs is distinctly asymmetric or monopodial [<xref rid="B50-pharmaceutics-12-00721" ref-type="bibr">50</xref>]. Despite these differences, mouse lungs are being increasingly used as surrogates of human lungs in studies on the deposition and risks posed by inhaled particles. Nevertheless, we caution that the limitations of the anesthetized mouse model should be considered when interpreting our data.</p>
    </sec>
    <sec sec-type="conclusions" id="sec5-pharmaceutics-12-00721">
      <title>5. Conclusions</title>
      <p>Our results showed no overall loss of enzymatic activity or protein content and no increase in aggregation or degradation following aerosolization by the four studied nebulizers. We also found the jet nebulizers had lower output rates than the mesh nebulizer, but produced smaller aerosol droplets, which resulted in higher efficiency of dornase alfa delivery to the lungs. Static and mesh nebulizers were found to increase the reservoir temperature to close to 30 &#xB0;C when nebulized with 2.5 mL of dornase alfa. Therefore, when using a mesh nebulizer to deliver protein biopharmaceuticals into the lungs, manufacturers should fully consider the prescribed medication volume and melting temperature. We suggest clinical and analytical studies be undertaken to confirm the compatibilities of medications and nebulizers.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>This study was supported financially by the Bio &amp; Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science &amp; ICT (grant numbers NRF-2015M3A9E2066855 and -2015M3A9E2066856).</p>
    </ack>
    <notes>
      <title>Author Contributions</title>
      <p>K.H.C., S.-H.M., B.J.P., and K.C.N. planned and performed the experiments; K.H.C., S.-H.M., and K.C.N. analyzed and calculated the data; K.H.C., S.-H.M., S.K.Y., B.J.P., and K.C.N. wrote, reviewed, and revised the paper. All authors have read and agreed to the published version of the manuscript.</p>
    </notes>
    <notes>
      <title>Funding</title>
      <p>This research received no external funding.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-pharmaceutics-12-00721">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shak</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Capon</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Hellmiss</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Marsters</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>C.L.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant human DNase 1 reduces the viscosity of cystic fibrosis sputum</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>1990</year>
          <volume>87</volume>
          <fpage>9188</fpage>
          <lpage>9192</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.87.23.9188</pub-id>
          <pub-id pub-id-type="pmid">2251263</pub-id>
        </element-citation>
      </ref>
      <ref id="B2-pharmaceutics-12-00721">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hubbard</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>McElvaney</surname>
              <given-names>N.G.</given-names>
            </name>
            <name>
              <surname>Birrer</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Shak</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>W.W.</given-names>
            </name>
            <name>
              <surname>Jolley</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Chernick</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Crystal</surname>
              <given-names>R.G.</given-names>
            </name>
          </person-group>
          <article-title>A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis</article-title>
          <source>N. Engl. J. Med.</source>
          <year>1992</year>
          <volume>326</volume>
          <fpage>812</fpage>
          <lpage>815</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199203193261207</pub-id>
          <pub-id pub-id-type="pmid">1538726</pub-id>
        </element-citation>
      </ref>
      <ref id="B3-pharmaceutics-12-00721">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aitken</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Shak</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study</article-title>
          <source>J. Am. Med. Assoc.</source>
          <year>1992</year>
          <volume>267</volume>
          <fpage>1947</fpage>
          <lpage>1951</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.1992.03480140073036</pub-id>
        </element-citation>
      </ref>
      <ref id="B4-pharmaceutics-12-00721">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramsey</surname>
              <given-names>B.W.</given-names>
            </name>
            <name>
              <surname>Astley</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Aitken</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Colin</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Dorkin</surname>
              <given-names>H.L.</given-names>
            </name>
            <name>
              <surname>Eisenberg</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Harwood</surname>
              <given-names>I.R.</given-names>
            </name>
            <name>
              <surname>Schidlow</surname>
              <given-names>D.V.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis</article-title>
          <source>Am. J. Respir. Crit. Care Med.</source>
          <year>1993</year>
          <volume>148</volume>
          <fpage>145</fpage>
          <lpage>151</lpage>
          <pub-id pub-id-type="doi">10.1164/ajrccm/148.1.145</pub-id>
        </element-citation>
      </ref>
      <ref id="B5-pharmaceutics-12-00721">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuchs</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Borowitz</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Nash</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>B.W.</given-names>
            </name>
            <name>
              <surname>Rosenstein</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Wohl</surname>
              <given-names>M.E.</given-names>
            </name>
          </person-group>
          <article-title>Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis</article-title>
          <source>N. Engl. J. Med.</source>
          <year>1994</year>
          <volume>331</volume>
          <fpage>637</fpage>
          <lpage>642</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199409083311003</pub-id>
          <pub-id pub-id-type="pmid">7503821</pub-id>
        </element-citation>
      </ref>
      <ref id="B6-pharmaceutics-12-00721">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shah</surname>
              <given-names>P.L.</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>S.F.</given-names>
            </name>
            <name>
              <surname>Geddes</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Hodson</surname>
              <given-names>M.E.</given-names>
            </name>
          </person-group>
          <article-title>Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis</article-title>
          <source>Respir. Med.</source>
          <year>1995</year>
          <volume>89</volume>
          <fpage>499</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="doi">10.1016/0954-6111(95)90126-4</pub-id>
          <pub-id pub-id-type="pmid">7480980</pub-id>
        </element-citation>
      </ref>
      <ref id="B7-pharmaceutics-12-00721">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCoy</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease</article-title>
          <source>Chest</source>
          <year>1996</year>
          <volume>110</volume>
          <fpage>889</fpage>
          <lpage>895</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.110.4.889</pub-id>
          <pub-id pub-id-type="pmid">8874241</pub-id>
        </element-citation>
      </ref>
      <ref id="B8-pharmaceutics-12-00721">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quan</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Tiddens</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Sy</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>McKenzie</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Wohl</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Konstabt</surname>
              <given-names>M.W.</given-names>
            </name>
          </person-group>
          <article-title>Pulmozyme Early Intervention Trial Study Group. A two-year randomized placebo-controlled trial of dornase alpha in young patients with cystic fibrosis with mild lung function abnormalities</article-title>
          <source>J. Pediatr.</source>
          <year>2001</year>
          <volume>139</volume>
          <fpage>813</fpage>
          <lpage>820</lpage>
          <pub-id pub-id-type="doi">10.1067/mpd.2001.118570</pub-id>
          <pub-id pub-id-type="pmid">11743506</pub-id>
        </element-citation>
      </ref>
      <ref id="B9-pharmaceutics-12-00721">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hodson</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Mckenzie</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Harms</surname>
              <given-names>H.K.</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mastella</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Navarro</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Strandvik</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Investigators of the Epidemiologic Registry of Cystic Fibrosis. Dornase alpha in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis</article-title>
          <source>Pediatr. Pulmonol.</source>
          <year>2003</year>
          <volume>36</volume>
          <fpage>427</fpage>
          <lpage>432</lpage>
          <pub-id pub-id-type="doi">10.1002/ppul.10348</pub-id>
          <pub-id pub-id-type="pmid">14520726</pub-id>
        </element-citation>
      </ref>
      <ref id="B10-pharmaceutics-12-00721">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flume</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>O&#x2019;Sullivan</surname>
              <given-names>B.P.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Goss</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Mogayzel</surname>
              <given-names>P.J.</given-names>
              <suffix>Jr.</suffix>
            </name>
            <name>
              <surname>Willey-Courand</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Bujan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Finder</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lester</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Quittell</surname>
              <given-names>L.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cystic Fibrosis Foundation, Pulmonary Therapies Committee</article-title>
          <source>Am. J. Respir. Crit. Care Med.</source>
          <year>2007</year>
          <volume>176</volume>
          <fpage>957</fpage>
          <lpage>969</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.200705-664OC</pub-id>
          <pub-id pub-id-type="pmid">17761616</pub-id>
        </element-citation>
      </ref>
      <ref id="B11-pharmaceutics-12-00721">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Labiris</surname>
              <given-names>N.R.</given-names>
            </name>
            <name>
              <surname>Dolovich</surname>
              <given-names>M.B.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications</article-title>
          <source>Br. J. Clin. Pharmacol.</source>
          <year>2003</year>
          <volume>56</volume>
          <fpage>588</fpage>
          <lpage>599</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.01892.x</pub-id>
          <pub-id pub-id-type="pmid">14616418</pub-id>
        </element-citation>
      </ref>
      <ref id="B12-pharmaceutics-12-00721">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ibrahim</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Garcia-Contreras</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Inhalation drug delivery devices: Technology update</article-title>
          <source>Med. Devices</source>
          <year>2015</year>
          <volume>12</volume>
          <fpage>131</fpage>
          <lpage>139</lpage>
        </element-citation>
      </ref>
      <ref id="B13-pharmaceutics-12-00721">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ari</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Jet, Ultrasonic, and Mesh Nebulizers: An Evaluation of Nebulizers for Better Clinical Outcomes</article-title>
          <source>Eurasian J. Pulmonol.</source>
          <year>2014</year>
          <volume>16</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.5152/ejp.2014.00087</pub-id>
        </element-citation>
      </ref>
      <ref id="B14-pharmaceutics-12-00721">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goralski</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>S.D.</given-names>
            </name>
          </person-group>
          <article-title>Breathing easier: Addressing the challenges of aerosolizing medications to infants and preschoolers</article-title>
          <source>Respir. Med.</source>
          <year>2014</year>
          <volume>108</volume>
          <fpage>1069</fpage>
          <lpage>1074</lpage>
          <pub-id pub-id-type="doi">10.1016/j.rmed.2014.06.004</pub-id>
          <pub-id pub-id-type="pmid">25012949</pub-id>
        </element-citation>
      </ref>
      <ref id="B15-pharmaceutics-12-00721">
        <label>15.</label>
        <element-citation publication-type="web">
          <article-title>Instructions for Use PULMOZYME<sup>&#xAE;</sup> (dornase alfa) Inhalation Solution</article-title>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.gene.com/download/pdf/pulmozyme_IFU.pdf">https://www.gene.com/download/pdf/pulmozyme_IFU.pdf</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-07-29">(accessed on 29 July 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B16-pharmaceutics-12-00721">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sawicki</surname>
              <given-names>G.S.</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Raimundo</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Trzaskoma</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Konstan</surname>
              <given-names>M.W.</given-names>
            </name>
          </person-group>
          <article-title>Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2015</year>
          <volume>14</volume>
          <fpage>777</fpage>
          <lpage>783</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2015.04.003</pub-id>
          <pub-id pub-id-type="pmid">25921451</pub-id>
        </element-citation>
      </ref>
      <ref id="B17-pharmaceutics-12-00721">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhand</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol</article-title>
          <source>Respir. Care</source>
          <year>2002</year>
          <volume>47</volume>
          <fpage>1406</fpage>
          <lpage>1416</lpage>
          <pub-id pub-id-type="pmid">12467499</pub-id>
        </element-citation>
      </ref>
      <ref id="B18-pharmaceutics-12-00721">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vecellio</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>The mesh nebuliser: A recent technical innovation for aerosol delivery</article-title>
          <source>Breathe</source>
          <year>2006</year>
          <volume>2</volume>
          <fpage>252</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="doi">10.1183/18106838.0203.252</pub-id>
        </element-citation>
      </ref>
      <ref id="B19-pharmaceutics-12-00721">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maillet</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Congy-Jolivet</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Le Guellec</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Vecellio</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Hamard</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Courty</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Courtois</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gauthier</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Diot</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Thibault</surname>
              <given-names>G.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization</article-title>
          <source>Pharm. Res.</source>
          <year>2008</year>
          <volume>25</volume>
          <fpage>1318</fpage>
          <lpage>1326</lpage>
          <pub-id pub-id-type="doi">10.1007/s11095-007-9481-3</pub-id>
          <pub-id pub-id-type="pmid">18030605</pub-id>
        </element-citation>
      </ref>
      <ref id="B20-pharmaceutics-12-00721">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Waldrep</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Dhand</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Aerosol delivery of recombinant human DNase I: In vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer</article-title>
          <source>Respir. Care</source>
          <year>2008</year>
          <volume>53</volume>
          <fpage>1703</fpage>
          <lpage>1708</lpage>
          <pub-id pub-id-type="pmid">19025706</pub-id>
        </element-citation>
      </ref>
      <ref id="B21-pharmaceutics-12-00721">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scherer</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Geller</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Owyang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Tservistas</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Boden</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Kesser</surname>
              <given-names>K.C.</given-names>
            </name>
            <name>
              <surname>Shire</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>A technical feasibility study of dornase alfa delivery with eFlow<sup>&#xAE;</sup> vibrating membrane nebulizers: Aerosol characteristics and physicochemical stability</article-title>
          <source>J. Pharm. Sci.</source>
          <year>2011</year>
          <volume>100</volume>
          <fpage>98</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="doi">10.1002/jps.22231</pub-id>
          <pub-id pub-id-type="pmid">20533437</pub-id>
        </element-citation>
      </ref>
      <ref id="B22-pharmaceutics-12-00721">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Germershaus</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>L&#xFC;hmann</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Beck-Broichsitter</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>H&#xF6;gger</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Meinel</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Insulin-like growth factor-I aerosol formulations for pulmonary delivery</article-title>
          <source>Eur. J. Pharm. Biopharm.</source>
          <year>2013</year>
          <volume>85</volume>
          <fpage>61</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejpb.2013.03.011</pub-id>
          <pub-id pub-id-type="pmid">23958318</pub-id>
        </element-citation>
      </ref>
      <ref id="B23-pharmaceutics-12-00721">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Respaud</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Marchand</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Parent</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Pelat</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Thullier</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Tournamille</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Viaud-Massuard</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Diot</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Si-Tahar</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vecellio</surname>
              <given-names>L.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of formulation on the stability and aerosol performance of a nebulized antibody</article-title>
          <source>MAbs</source>
          <year>2014</year>
          <volume>6</volume>
          <fpage>1347</fpage>
          <lpage>1355</lpage>
          <pub-id pub-id-type="doi">10.4161/mabs.29938</pub-id>
          <pub-id pub-id-type="pmid">25517319</pub-id>
        </element-citation>
      </ref>
      <ref id="B24-pharmaceutics-12-00721">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sweeney</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>McCloskey</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Cryan</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>MacLoughlin</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Effective nebulization of interferon-&#x3B3; using a novel vibrating mesh</article-title>
          <source>Respir. Res.</source>
          <year>2019</year>
          <volume>20</volume>
          <fpage>66</fpage>
          <pub-id pub-id-type="doi">10.1186/s12931-019-1030-1</pub-id>
          <pub-id pub-id-type="pmid">30943978</pub-id>
        </element-citation>
      </ref>
      <ref id="B25-pharmaceutics-12-00721">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pritchard</surname>
              <given-names>J.N.</given-names>
            </name>
            <name>
              <surname>Hatley</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>Denyer</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hollen</surname>
              <given-names>D.V.</given-names>
            </name>
          </person-group>
          <article-title>Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments</article-title>
          <source>Ther. Deliv.</source>
          <year>2018</year>
          <volume>9</volume>
          <fpage>121</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="doi">10.4155/tde-2017-0102</pub-id>
          <pub-id pub-id-type="pmid">29325508</pub-id>
        </element-citation>
      </ref>
      <ref id="B26-pharmaceutics-12-00721">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ari</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Fink</surname>
              <given-names>J.B.</given-names>
            </name>
          </person-group>
          <article-title>Guidelines for aerosol devices in infants, children and adults: Which to choose, why and how to achieve effective aerosol therapy?</article-title>
          <source>Expert Rev. Respir. Med.</source>
          <year>2011</year>
          <volume>5</volume>
          <fpage>561</fpage>
          <lpage>572</lpage>
          <pub-id pub-id-type="doi">10.1586/ers.11.49</pub-id>
          <pub-id pub-id-type="pmid">21859275</pub-id>
        </element-citation>
      </ref>
      <ref id="B27-pharmaceutics-12-00721">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ari</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Restrepo</surname>
              <given-names>R.D.</given-names>
            </name>
          </person-group>
          <article-title>American Association for Respiratory Care. Aerosol delivery device selection for spontaneously breathing patients: 2012</article-title>
          <source>Respir. Care</source>
          <year>2012</year>
          <volume>57</volume>
          <fpage>613</fpage>
          <lpage>626</lpage>
          <pub-id pub-id-type="doi">10.4187/respcare.01756</pub-id>
          <pub-id pub-id-type="pmid">22472501</pub-id>
        </element-citation>
      </ref>
      <ref id="B28-pharmaceutics-12-00721">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watts</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>McConville</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>R.O.</given-names>
            </name>
          </person-group>
          <article-title>III. Current therapies and technological advances in aqueous aerosol drug delivery</article-title>
          <source>Drug Dev. Ind. Pharm.</source>
          <year>2008</year>
          <volume>34</volume>
          <fpage>913</fpage>
          <lpage>922</lpage>
          <pub-id pub-id-type="doi">10.1080/03639040802144211</pub-id>
          <pub-id pub-id-type="pmid">18663654</pub-id>
        </element-citation>
      </ref>
      <ref id="B29-pharmaceutics-12-00721">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Ultrasonic nebulizers for pulmonary drug delivery</article-title>
          <source>Int. J. Pharm.</source>
          <year>1997</year>
          <volume>153</volume>
          <fpage>93</fpage>
          <lpage>104</lpage>
          <pub-id pub-id-type="doi">10.1016/S0378-5173(97)00105-1</pub-id>
        </element-citation>
      </ref>
      <ref id="B30-pharmaceutics-12-00721">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beck-Broichsitter</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kleimann</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Schmehl</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Betz</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Bakowsky</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Kissel</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Seeger</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers</article-title>
          <source>Eur. J. Pharm. Biopharm.</source>
          <year>2012</year>
          <volume>82</volume>
          <fpage>272</fpage>
          <lpage>280</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejpb.2012.07.004</pub-id>
          <pub-id pub-id-type="pmid">22820646</pub-id>
        </element-citation>
      </ref>
      <ref id="B31-pharmaceutics-12-00721">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hertel</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Friess</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Protein stability in pulmonary drug delivery via nebulization</article-title>
          <source>Adv. Drug Deliv. Rev.</source>
          <year>2015</year>
          <volume>93</volume>
          <fpage>79</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="doi">10.1016/j.addr.2014.10.003</pub-id>
          <pub-id pub-id-type="pmid">25312674</pub-id>
        </element-citation>
      </ref>
      <ref id="B32-pharmaceutics-12-00721">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zhan</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Effects of temperature and humidity on laser diffraction measurements to jet nebulizer and comparison with NGI</article-title>
          <source>AAPS PharmSciTech</source>
          <year>2016</year>
          <volume>17</volume>
          <fpage>380</fpage>
          <lpage>388</lpage>
          <pub-id pub-id-type="doi">10.1208/s12249-015-0346-5</pub-id>
          <pub-id pub-id-type="pmid">26169901</pub-id>
        </element-citation>
      </ref>
      <ref id="B33-pharmaceutics-12-00721">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tandon</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>McPeck</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Smaldone</surname>
              <given-names>G.C.</given-names>
            </name>
          </person-group>
          <article-title>Measuring nebulizer output aerosol production vs gravimetric analysis</article-title>
          <source>Chest</source>
          <year>1997</year>
          <volume>111</volume>
          <fpage>1361</fpage>
          <lpage>1365</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.111.5.1361</pub-id>
          <pub-id pub-id-type="pmid">9149595</pub-id>
        </element-citation>
      </ref>
      <ref id="B34-pharmaceutics-12-00721">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>K.H.</given-names>
            </name>
            <name>
              <surname>Moon</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>J.Y.</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>Y.S.</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>C.Y.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Nam</surname>
              <given-names>K.C.</given-names>
            </name>
          </person-group>
          <article-title>Comparison of Salbutamol Delivery Efficiency for Jet versus Mesh Nebulizer Using Mice</article-title>
          <source>Pharmaceutics</source>
          <year>2019</year>
          <volume>11</volume>
          <elocation-id>192</elocation-id>
          <pub-id pub-id-type="doi">10.3390/pharmaceutics11040192</pub-id>
          <pub-id pub-id-type="pmid">31010218</pub-id>
        </element-citation>
      </ref>
      <ref id="B35-pharmaceutics-12-00721">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Suo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Vega</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Giddens</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>W.R.</given-names>
            </name>
            <name>
              <surname>Jo</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: Role of bone morphogenic protein antagonists in inflammation and atherosclerosis</article-title>
          <source>Circulation</source>
          <year>2007</year>
          <volume>116</volume>
          <fpage>1258</fpage>
          <lpage>1266</lpage>
          <pub-id pub-id-type="pmid">17785623</pub-id>
        </element-citation>
      </ref>
      <ref id="B36-pharmaceutics-12-00721">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiel</surname>
              <given-names>S.B.</given-names>
            </name>
            <name>
              <surname>Fuchs</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gonda</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>A.R.</given-names>
            </name>
          </person-group>
          <article-title>Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group</article-title>
          <source>Chest</source>
          <year>1995</year>
          <volume>108</volume>
          <fpage>153</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.108.1.153</pub-id>
          <pub-id pub-id-type="pmid">7606951</pub-id>
        </element-citation>
      </ref>
      <ref id="B37-pharmaceutics-12-00721">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ryan</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Dolovich</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Obminski</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Cockcroft</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Juniper</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hargreave</surname>
              <given-names>F.E.</given-names>
            </name>
            <name>
              <surname>Newhouse</surname>
              <given-names>M.T.</given-names>
            </name>
          </person-group>
          <article-title>Standardization of inhalation provocation tests: Influence of nebulizer output, particle size, and method of inhalation</article-title>
          <source>J. Allergy Clin. Immunol.</source>
          <year>1981</year>
          <volume>67</volume>
          <fpage>156</fpage>
          <lpage>161</lpage>
          <pub-id pub-id-type="doi">10.1016/0091-6749(81)90012-9</pub-id>
          <pub-id pub-id-type="pmid">7451782</pub-id>
        </element-citation>
      </ref>
      <ref id="B38-pharmaceutics-12-00721">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Usmani</surname>
              <given-names>O.S.</given-names>
            </name>
            <name>
              <surname>Biddiscombe</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size</article-title>
          <source>Am. J. Respir. Crit. Care Med.</source>
          <year>2005</year>
          <volume>172</volume>
          <fpage>1497</fpage>
          <lpage>1504</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.200410-1414OC</pub-id>
          <pub-id pub-id-type="pmid">16192448</pub-id>
        </element-citation>
      </ref>
      <ref id="B39-pharmaceutics-12-00721">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khilnani</surname>
              <given-names>G.C.</given-names>
            </name>
            <name>
              <surname>Banga</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Aerosol therapy</article-title>
          <source>Indian J. Chest Dis. Allied Sci.</source>
          <year>2008</year>
          <volume>50</volume>
          <fpage>209</fpage>
          <lpage>220</lpage>
        </element-citation>
      </ref>
      <ref id="B40-pharmaceutics-12-00721">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwong</surname>
              <given-names>W.T.</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Coates</surname>
              <given-names>A.L.</given-names>
            </name>
          </person-group>
          <article-title>Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor</article-title>
          <source>J. Aerosol Med.</source>
          <year>2000</year>
          <volume>13</volume>
          <fpage>303</fpage>
          <lpage>314</lpage>
          <pub-id pub-id-type="doi">10.1089/jam.2000.13.303</pub-id>
          <pub-id pub-id-type="pmid">11262437</pub-id>
        </element-citation>
      </ref>
      <ref id="B41-pharmaceutics-12-00721">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>E.C.</given-names>
            </name>
            <name>
              <surname>Denyer</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kendrick</surname>
              <given-names>A.H.</given-names>
            </name>
          </person-group>
          <article-title>Comparison of twenty three nebulizer/compressor combinations for domiciliary use</article-title>
          <source>Eur. Respir. J.</source>
          <year>1995</year>
          <volume>8</volume>
          <fpage>1214</fpage>
          <lpage>1221</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.95.08071214</pub-id>
          <pub-id pub-id-type="pmid">7589407</pub-id>
        </element-citation>
      </ref>
      <ref id="B42-pharmaceutics-12-00721">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kendrick</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>E.C.</given-names>
            </name>
            <name>
              <surname>Denyer</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Nebulizers-fill volume, residual volume and matching of nebulizer to compressor</article-title>
          <source>Respir. Med.</source>
          <year>1995</year>
          <volume>89</volume>
          <fpage>157</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="doi">10.1016/0954-6111(95)90241-4</pub-id>
          <pub-id pub-id-type="pmid">7746906</pub-id>
        </element-citation>
      </ref>
      <ref id="B43-pharmaceutics-12-00721">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roberts</surname>
              <given-names>C.J.</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic protein aggregation: Mechanisms, design, and control</article-title>
          <source>Trends Biotechnol.</source>
          <year>2014</year>
          <volume>32</volume>
          <fpage>372</fpage>
          <lpage>380</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tibtech.2014.05.005</pub-id>
          <pub-id pub-id-type="pmid">24908382</pub-id>
        </element-citation>
      </ref>
      <ref id="B44-pharmaceutics-12-00721">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ratanji</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Derrick</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Dearman</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Kimber</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Immunogenicity of therapeutic proteins: Influence of aggregation</article-title>
          <source>J. Immunotoxicol.</source>
          <year>2014</year>
          <volume>11</volume>
          <fpage>99</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="doi">10.3109/1547691X.2013.821564</pub-id>
          <pub-id pub-id-type="pmid">23919460</pub-id>
        </element-citation>
      </ref>
      <ref id="B45-pharmaceutics-12-00721">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steckel</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Eskandar</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers</article-title>
          <source>Eur. J. Pharm. Sci.</source>
          <year>2003</year>
          <volume>19</volume>
          <fpage>443</fpage>
          <lpage>455</lpage>
          <pub-id pub-id-type="doi">10.1016/S0928-0987(03)00148-9</pub-id>
          <pub-id pub-id-type="pmid">12907295</pub-id>
        </element-citation>
      </ref>
      <ref id="B46-pharmaceutics-12-00721">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>K.H.</given-names>
            </name>
            <name>
              <surname>Moon</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Nam</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Fabrication and Characterization of Medical Mesh-Nebulizer for Aerosol Drug Delivery</article-title>
          <source>Appl. Sci.</source>
          <year>2018</year>
          <volume>8</volume>
          <elocation-id>604</elocation-id>
          <pub-id pub-id-type="doi">10.3390/app8040604</pub-id>
        </element-citation>
      </ref>
      <ref id="B47-pharmaceutics-12-00721">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sidler-Moix</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Di Paolo</surname>
              <given-names>E.R.</given-names>
            </name>
            <name>
              <surname>Dolci</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Berger-Gryllaki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Cotting</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Pannatier</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Physicochemical aspects and efficiency of albuterol nebulization: Comparison of three aerosol types in an in vitro pediatric model</article-title>
          <source>Respir. Care</source>
          <year>2015</year>
          <volume>60</volume>
          <fpage>38</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.4187/respcare.02490</pub-id>
          <pub-id pub-id-type="pmid">25516995</pub-id>
        </element-citation>
      </ref>
      <ref id="B48-pharmaceutics-12-00721">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>H.K.</given-names>
            </name>
            <name>
              <surname>Au-Yeung</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Gonda</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Effects of additives on heat denaturation of rhDNase in solutions</article-title>
          <source>Pharm. Res.</source>
          <year>1996</year>
          <volume>13</volume>
          <fpage>756</fpage>
          <lpage>761</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1016091030928</pub-id>
          <pub-id pub-id-type="pmid">8860433</pub-id>
        </element-citation>
      </ref>
      <ref id="B49-pharmaceutics-12-00721">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wells</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Guest</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hakizimana</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Si</surname>
              <given-names>X.A.</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>W.C.</given-names>
            </name>
            <name>
              <surname>Xi</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Visualization and quantification of nebulized aerosol deposition in mouth-lung casts under healthy and abnormal breathing conditions</article-title>
          <source>Lungs Breath.</source>
          <year>2018</year>
          <volume>2</volume>
          <fpage>1</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.15761/LBJ.1000127</pub-id>
        </element-citation>
      </ref>
      <ref id="B50-pharmaceutics-12-00721">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winkler-Heil</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Modeling particle deposition in the Balb/c mouse respiratory tract</article-title>
          <source>Inhal. Toxicol.</source>
          <year>2016</year>
          <volume>28</volume>
          <fpage>180</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="doi">10.3109/08958378.2016.1148801</pub-id>
          <pub-id pub-id-type="pmid">26986953</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="pharmaceutics-12-00721-f001" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>A head-only exposure chamber system for mice: (<bold>a</bold>) top view and (<bold>b</bold>) side view.</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00721-g001"/>
    </fig>
    <fig id="pharmaceutics-12-00721-f002" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Representative native PAGE (<bold>a</bold>) and SDS-PAGE (<bold>b</bold>) analyses of dornase alfa aerosols generated by the four nebulizers: molecular weight standard (<bold>lane M</bold>), non-nebulized nominal (<bold>lane 1</bold>), JN-PARIr (<bold>lane 2</bold>), JN-PARIb (<bold>lane 3</bold>), SMN-U150 (<bold>lane 4</bold>), and VMN-SM1 (<bold>lane 5</bold>).</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00721-g002"/>
    </fig>
    <fig id="pharmaceutics-12-00721-f003" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Plot of reservoir temperatures during nebulization by the JN-PARIr (<bold>green circle line</bold>), JN-PARIb (<bold>purple square line</bold>), SMN-U150 (<bold>red triangle line</bold>), and VMN-SM1 (<bold>blue diamond line</bold>) nebulizers. The black dashed lined indicates room temperature (RT).</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00721-g003"/>
    </fig>
    <fig id="pharmaceutics-12-00721-f004" orientation="portrait" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Representative Western blot images and levels of dornase alfa in bronchoalveolar lavage fluid (BALF) from mice treated using the four nebulizers. (<bold>a</bold>) Duration of nebulization with 2.5 mL of dornase alfa (Exposure 1); (<bold>b</bold>) Constant output at 1.7 mL (Exposure 2). Normal mice BALF (<bold>lane 1</bold>), JN-PARIr-treated mice (<bold>lane 2</bold>), JN-PARIb-treated mice (<bold>lane 3</bold>), SMN-U150-treated mice (<bold>lane 4</bold>), and VMN-SM1-treated mice (<bold>lane 5</bold>). Lane 6 shows the blot obtained for 10 ng of dornase alfa (<bold>lane 6</bold>). All values are means &#xB1; SD. * <italic>p</italic> &lt; 0.05 versus JN-PARIr.</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00721-g004"/>
    </fig>
    <table-wrap id="pharmaceutics-12-00721-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">pharmaceutics-12-00721-t001_Table 1</object-id>
      <label>Table 1</label>
      <caption>
        <p>Nebulizers used in the study.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mode of Operation</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Abbreviation in the Study</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Jet</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">PARI BOY SX-red nozzle (PARI GmbH, Starnberg, Germany)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">JN-PARIr</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PARI BOY SX-blue nozzle (PARI GmbH, Starnberg, Germany)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">JN-PARIb</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Static mesh</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">NE-U150 (Omron Healthcare, Kyoto, Japan)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">SMN-U150</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vibrating mesh</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE-SM1 NEPLUS (KTMED Co., Seoul, Korea)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VMN-SM1</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="pharmaceutics-12-00721-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">pharmaceutics-12-00721-t002_Table 2</object-id>
      <label>Table 2</label>
      <caption>
        <p>Aerosol droplet sizes for saline and dornase alfa generated by the four nebulizers.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Device</th>
            <th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Saline</th>
            <th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Dornase Alfa</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dv10 (&#xB5;m)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dv50 (&#xB5;m)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dv90 (&#xB5;m)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Span</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dv10 (&#xB5;m)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dv50 (&#xB5;m)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dv90 (&#xB5;m)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Span</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">JN-PARIr</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.64 &#xB1; 0.03</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.05 &#xB1; 0.08</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.30 &#xB1; 0.26</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.83 &#xB1; 0.01</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.55 &#xB1; 0.05</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.18 &#xB1; 0.08</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.08 &#xB1; 0.32</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.81 &#xB1; 0.01</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">JN-PARIb</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.89 &#xB1; 0.01</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.48 &#xB1; 0.01</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10.18 &#xB1; 0.18</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.86 &#xB1; 0.03</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.85 &#xB1; 0.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.99 &#xB1; 0.08</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">12.61 &#xB1; 0.29</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.93 &#xB1; 0.02</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">SMN-U150</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.77 &#xB1; 0.12</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.69 &#xB1; 0.09</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">16.74 &#xB1; 0.73</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.97 &#xB1; 0.10</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.02 &#xB1; 0.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.23 &#xB1; 0.07</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">16.69 &#xB1; 0.39</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.99 &#xB1; 0.03</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VMN-SM1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.17 &#xB1; 0.04</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.18 &#xB1; 0.18</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.60 &#xB1; 0.17</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.98 &#xB1; 0.07</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.39 &#xB1; 0.05</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.93 &#xB1; 0.23</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.64 &#xB1; 0.14</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.00 &#xB1; 0.08</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="pharmaceutics-12-00721-t003" orientation="portrait" position="float">
      <object-id pub-id-type="pii">pharmaceutics-12-00721-t003_Table 3</object-id>
      <label>Table 3</label>
      <caption>
        <p>Residual volumes, nebulization times, and output rates for the four nebulizers.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Device</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Residual Volume (mL)</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Nebulization Time (min)</th>
            <th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Output Rate (mL/min)</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saline</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dornase Alfa</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saline</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dornase Alfa</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saline</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dornase Alfa</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">JN-PARIr</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.595 &#xB1; 0.014</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.609 &#xB1; 0.024</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">13.19 &#xB1; 0.072</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">13.30 &#xB1; 0.068</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.143 &#xB1; 0.002</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.140 &#xB1; 0.002</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">JN-PARIb</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.639 &#xB1; 0.015</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.687 &#xB1; 0.027</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10.19 &#xB1; 0.066</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10.32 &#xB1; 0.183</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.181 &#xB1; 0.002</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.170 &#xB1; 0.004</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">SMN-U150</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.374 &#xB1; 0.011</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.385 &#xB1; 0.007</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.22 &#xB1; 0.076</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.47 &#xB1; 0.031</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.334 &#xB1; 0.008</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.311 &#xB1; 0.002</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VMN-SM1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.034 &#xB1; 0.005</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.047 &#xB1; 0.002</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.09 &#xB1; 0.036</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.15 &#xB1; 0.057</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.243 &#xB1; 0.001</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.238 &#xB1; 0.002</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="pharmaceutics-12-00721-t004" orientation="portrait" position="float">
      <object-id pub-id-type="pii">pharmaceutics-12-00721-t004_Table 4</object-id>
      <label>Table 4</label>
      <caption>
        <p>Dornase alfa activity and concentrations of nebulized samples expressed as percentages of non-nebulized nominals.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Device</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Enzyme Activity (%)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Protein Concentration (mg/mL)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Nominal</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">100</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.006 &#xB1; 0.001</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">JN-PARIr</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">99.53 &#xB1; 2.88</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.000 &#xB1; 0.011</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">JN-PARIb</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">98.63 &#xB1; 0.63</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.995 &#xB1; 0.025</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">SMN-U150</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">100.37 &#xB1; 1.32</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">0.995 &#xB1; 0.008</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VMN-SM1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.34 &#xB1; 1.12</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.995 &#xB1; 0.005</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>There were no statistically significant differences in the enzyme activity and protein concentration between the nominal and experimental groups (<italic>p</italic> &lt; 0.05).</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Mol Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Mol. Med</journal-id>
      <journal-title-group>
        <journal-title>Molecular Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1076-1551</issn>
      <issn pub-type="epub">1528-3658</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32993479</article-id>
      <article-id pub-id-type="pmc">7522910</article-id>
      <article-id pub-id-type="publisher-id">215</article-id>
      <article-id pub-id-type="doi">10.1186/s10020-020-00215-w</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Weber</surname>
            <given-names>Andrew G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chau</surname>
            <given-names>Alice S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Egeblad</surname>
            <given-names>Mikala</given-names>
          </name>
          <address>
            <email>egeblad@cshl.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6766-4352</contrib-id>
          <name>
            <surname>Barnes</surname>
            <given-names>Betsy J.</given-names>
          </name>
          <address>
            <email>bbarnes1@northwell.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Janowitz</surname>
            <given-names>Tobias</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.416477.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2168 3646</institution-id><institution>Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, </institution><institution>Northwell Health, </institution></institution-wrap>300 Community Drive, Manhasset, NY 11030 USA </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.240741.4</institution-id><institution-id institution-id-type="ISNI">0000 0000 9026 4165</institution-id><institution>Division of Allergy and Infectious Diseases, Department of Medicine, </institution><institution>University of Washington and the Center for Immunity and Immunotherapies, Seattle Children&#x2019;s Research Institute, </institution></institution-wrap>1900 9th Ave, Seattle, WA 98101 USA </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.225279.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0387 3667</institution-id><institution>Cancer Center, Cold Spring Harbor Laboratory, </institution></institution-wrap>1 Bungtown Road, Cold Spring Harbor, NY 11724 USA </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.257060.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2284 9943</institution-id><institution>Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, The Feinstein Institutes for Medical Research and the Departments of Molecular Medicine and Pediatrics, </institution><institution>Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, </institution></institution-wrap>350 Community Drive, Manhasset, NY 11030 USA </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.416477.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2168 3646</institution-id><institution>Northwell Health Cancer Institute, </institution></institution-wrap>450 Lakeville Road, New Hyde Park, NY 11042 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>29</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>26</volume>
      <elocation-id>91</elocation-id>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>6</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>9</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2020</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p id="Par1">Mechanically ventilated patients with COVID-19 have a mortality of 24&#x2013;53%, in part due to distal mucopurulent secretions interfering with ventilation. DNA from neutrophil extracellular traps (NETs) contribute to the viscosity of mucopurulent secretions and NETs are found in the serum of COVID-19 patients. Dornase alfa is recombinant human DNase 1 and is used to digest DNA in mucoid sputum. Here, we report a single-center case series where dornase alfa was co-administered with albuterol through an in-line nebulizer system.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p id="Par2">Demographic and clinical data were collected from the electronic medical records of five mechanically ventilated patients with COVID-19&#x2014;including three requiring veno-venous extracorporeal membrane oxygenation&#x2014;treated with nebulized in-line endotracheal dornase alfa and albuterol, between March 31 and April 24, 2020. Data on tolerability and response were analyzed.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p id="Par3">The fraction of inspired oxygen requirements was reduced for all five patients after initiating dornase alfa administration. All patients were successfully extubated, discharged from hospital and remain alive. No drug-associated toxicities were identified.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p id="Par4">Results suggest that dornase alfa will be well-tolerated by patients with severe COVID-19. Clinical trials are required to formally test the dosing, safety, and efficacy of dornase alfa in COVID-19, and several have been recently registered.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>SARS-CoV-2</kwd>
        <kwd>COVID-19</kwd>
        <kwd>Coronavirus</kwd>
        <kwd>Mucopurulent secretions</kwd>
        <kwd>Dornase alfa</kwd>
        <kwd>Neutrophil extracellular traps</kwd>
        <kwd>ARDS</kwd>
        <kwd>VV-ECMO</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>National Cancer Institute</institution>
          </funding-source>
          <award-id>5P30CA045508-30</award-id>
          <principal-award-recipient>
            <name>
              <surname>Janowitz</surname>
              <given-names>Tobias</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>Division of Cancer Epidemiology and Genetics, National Cancer Institute (US)</institution>
          </funding-source>
          <award-id>5P30CA045508-30</award-id>
          <principal-award-recipient>
            <name>
              <surname>Egeblad</surname>
              <given-names>Mikala</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id>
              <institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution>
            </institution-wrap>
          </funding-source>
          <award-id>1R01AR076242-01</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id>
              <institution>U.S. Department of Defense</institution>
            </institution-wrap>
          </funding-source>
          <award-id>W81XWH-18-1-0674</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id>
              <institution>National Institute of Allergy and Infectious Diseases</institution>
            </institution-wrap>
          </funding-source>
          <award-id>U54 AI 082973</award-id>
          <principal-award-recipient>
            <name>
              <surname>Chau</surname>
              <given-names>Alice S.</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p id="Par20">Critically ill patients with coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), progress to hypoxemic and then mixed respiratory failure, secondary to acute respiratory distress syndrome (ARDS) (Marini and Gattinoni <xref ref-type="bibr" rid="CR15">2020</xref>; Greenland et al. <xref ref-type="bibr" rid="CR12">2020</xref>). Approximately 79&#x2013;88% of patients admitted to the intensive care unit (ICU) with COVID-19 require intubation and mechanical ventilation, with a mortality of 24&#x2013;53% (Cummings et al. <xref ref-type="bibr" rid="CR6">2020</xref>; Grasselli et al. <xref ref-type="bibr" rid="CR11">2020</xref>; Richardson et al. <xref ref-type="bibr" rid="CR20">2020</xref>; Docherty et al. <xref ref-type="bibr" rid="CR7">2020</xref>). ARDS in COVID-19 is characterized by respiratory failure, in part attributable to distally located mucopurulent secretions.</p>
      <p id="Par21">Dornase alfa (Pulmozyme&#xAE;) is recombinant human DNase 1 and a safe mucolytic that is administered in nebulized form. It is FDA-approved in combination with standard therapies for patients with cystic fibrosis to improve sputum clearance and pulmonary function (Yang and Montgomery <xref ref-type="bibr" rid="CR25">2018</xref>). It is also used off-label as a mucolytic in other diseases, including ARDS (Morris and Mullan <xref ref-type="bibr" rid="CR18">2004</xref>; ClinicalTrials.gov [Internet] <xref ref-type="bibr" rid="CR5">2019</xref>). A mechanism by which dornase alfa might improve ventilation is by reducing the DNA-mediated viscosity of neutrophil-rich secretions (Papayannopoulos et al. <xref ref-type="bibr" rid="CR19">2011</xref>). There are multiple sources for the DNA in mucoid sputum, one of which is neutrophil extracellular traps (NETs). Recently, we collaboratively reported that in the discarded serum of patients with COVID-19, the levels of NETs were increased and correlated with lactate dehydrogenase (LDH), D-dimer, and C-reactive protein (CRP) levels (Zuo et al. <xref ref-type="bibr" rid="CR26">2020</xref>). Subsequently, NET-containing microthrombi and increased neutrophil-platelet infiltration in pulmonary autopsies from COVID-19 patients was reported (Becker <xref ref-type="bibr" rid="CR3">2020</xref>; Fox et al. <xref ref-type="bibr" rid="CR10">2020</xref>; Middleton et al. <xref ref-type="bibr" rid="CR17">2020</xref>; Schonrich et al. <xref ref-type="bibr" rid="CR21">2020</xref>; Tay et al. <xref ref-type="bibr" rid="CR22">2020</xref>; Varga et al. <xref ref-type="bibr" rid="CR24">2020</xref>; Leppkes et al. <xref ref-type="bibr" rid="CR14">2020</xref>). Notably, targeting NETs reduces mortality in animal models of acute lung injury (Barnes et al. <xref ref-type="bibr" rid="CR2">2020</xref>; Adrover et al. <xref ref-type="bibr" rid="CR1">2020</xref>; Caudrillier et al. <xref ref-type="bibr" rid="CR4">2012</xref>; Lefrancais et al. <xref ref-type="bibr" rid="CR13">2018</xref>; Thomas et al. <xref ref-type="bibr" rid="CR23">2012</xref>). Despite recognition that mucolytic treatment may be beneficial for patients with COVID-19 (12, (Earhart et al. <xref ref-type="bibr" rid="CR9">2020</xref>), administration of nebulized medications, such as dornase alfa, have been limited due to risk of viral aerosolization. If risk of viral aerosolization can be avoided, dornase alfa may benefit patients with severe COVID-19 by acting as a mucolytic and by reducing NET levels in the lungs, thereby improving oxygenation and ventilation. We report the clinical course, safety, and outcomes after nebulized in-line endotracheal dornase alfa treatment for five intubated and mechanically ventilated patients with PCR-confirmed COVID-19.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <p id="Par22">The Northwell Health institutional review board that focuses on COVID-19 research approved this case series as minimal-risk research using de-identified data from routine clinical practice. Data were collected from the enterprise health record (Sunrise Clinical Manager; Allscripts) reporting database, and included patient demographics, comorbidities, inpatient medications, laboratory studies, treatment, and outcomes. We further obtained longitudinal values of the fraction of inspired oxygen (FiO<sub>2</sub>) and of the arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>) as measures of respiratory function during treatment. Lung mechanics were assessed by obtaining mechanical power of the respiratory system (MP) and mean airway pressure (Paw). FiO<sub>2</sub> values of the circuit were reported for those patients who required veno-venous extracorporeal membrane oxygenation (VV-ECMO). Ferritin, CRP, LDH, and D-dimer were obtained as measures of systemic disease and inflammation. Not all patients had laboratory investigations on the same days in relation to the nebulized and co-administered dornase alfa and albuterol (nDA&#x2009;+&#x2009;A) treatment. In the following case synopses, each measurement is therefore followed by the day in relation to the first day of treatment with nDA&#x2009;+&#x2009;A (e.g.<italic>,</italic> d 2 for the second day of treatment with nDA&#x2009;+&#x2009;A or d&#x2009;&#x2212;&#x2009;1 for the day before nDA&#x2009;+&#x2009;A treatment was initiated). Relevant nDA toxicities (hoarseness, rash, hypersensitivity reactions and hemoptysis) were clinically monitored. Hoarseness was assessed post-intubation. Rash was assessed daily via physical exam. Hypersensitivity reactions were determined via physical exam, vital signs, and vasopressor requirements. Hemoptysis was assessed in intubated patients by endotracheal tube visual inspection.</p>
    </sec>
    <sec id="Sec3">
      <title>Results</title>
      <p id="Par23">Five patients treated with dornase alfa between March 31, 2020 and April 24, 2020 were identified. These patients had met the Berlin criteria for ARDS and were treated with ventilator strategies guided by the ARDSNet protocol at North Shore University Hospital within Northwell Health (Durante et al. <xref ref-type="bibr" rid="CR8">2002</xref>). These patients had been treated with dornase alfa because they required high levels of FiO<sub>2</sub> and had elevated ventilation demands. All patients received the same treatment doses: nebulized dornase alfa (2.5&#x2009;mg) co-administered twice daily with the short-acting &#x3B2;<sub>2</sub>-agonist albuterol (2.5&#x2009;mg) to improve delivery to the alveoli (referred to as nDA&#x2009;+&#x2009;A). Of note, &#x3B2;<sub>2</sub>-adrenoreceptor agonism may also inhibit NET formation by direct action on neutrophils (Marino et al. <xref ref-type="bibr" rid="CR16">2018</xref>). The treatment was administered with an Aerogen&#xAE; Solo in-line nebulizer to avoid open aerosol generation, which would place staff at risk of exposure to SARS-CoV-2.</p>
      <p id="Par24">The patient characteristics are summarized in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. Patients were treated with nDA&#x2009;+&#x2009;A between 3 to 25&#x2009;days. The most common characteristics of the patients included obesity (BMI&#x2009;&#x2265;&#x2009;30) and four of the patients had hypertension. Four patients received methylprednisolone dosed at 1-2&#x2009;mg/kg/day. All patients were treated with full dose or prophylactic dose anticoagulation for thrombosis. All other medications that were administered during the course of hospitalization were considered standard of care (STC) at the time of treatment and are summarized in Table S<xref rid="MOESM1" ref-type="media">1</xref>. No adverse events related to nDA&#x2009;+&#x2009;A treatment were observed for any of the patients throughout the duration of the study. The clinical course of the five patients treated with nDA&#x2009;+&#x2009;A is summarized in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>. Figures&#xA0;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref> display the longitudinal, ventilatory, and inflammatory markers for each patient.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient data from five patients with COVID-19 who received dornase alfa with albuterol March&#x2013;April, 2020</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th></tr></thead><tbody><tr><td colspan="6">Clinical Characteristics</td></tr><tr><td>&#x2003;Date of admission</td><td>29 March</td><td>4 April</td><td>16 March</td><td>16 March</td><td>26 March</td></tr><tr><td>&#x2003;Age</td><td>56</td><td>34</td><td>65</td><td>31</td><td>34</td></tr><tr><td>&#x2003;Gender</td><td>F</td><td>M</td><td>M</td><td>M</td><td>F</td></tr><tr><td>&#x2003;Ethnicity</td><td>Hispanic</td><td>White</td><td>Asian</td><td>Hispanic</td><td>Black</td></tr><tr><td>&#x2003;BMI</td><td>38</td><td>41</td><td>32</td><td>30</td><td>38</td></tr><tr><td>&#x2003;Date of ICU admission</td><td>31 March</td><td>4 April</td><td>16 March</td><td>18 March</td><td>26 March</td></tr><tr><td colspan="6">Comorbidities</td></tr><tr><td>&#x2003;Hypertension</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td/></tr><tr><td>&#x2003;Diabetes mellitus, type 2</td><td>Yes</td><td/><td/><td/><td/></tr><tr><td>&#x2003;Asthma</td><td>Yes</td><td/><td>Yes</td><td/><td>Yes</td></tr><tr><td>&#x2003;Hyperlipidemia</td><td/><td>Yes</td><td/><td/><td/></tr><tr><td>&#x2003;Migraine</td><td/><td/><td/><td/><td>Yes</td></tr><tr><td>&#x2003;Chronic gastritis</td><td/><td/><td/><td/><td>Yes</td></tr><tr><td colspan="6">ECMO</td></tr><tr><td>&#x2003;Date of ECMO initiation</td><td>&#x2013;</td><td>4 April</td><td>&#x2013;</td><td>27 March</td><td>28 March</td></tr><tr><td>&#x2003;Date of ECMO cessation</td><td>&#x2013;</td><td>16 April</td><td>&#x2013;</td><td>10 April</td><td>20 April</td></tr><tr><td colspan="6">Dornase alfa (DA)&#x2009;+&#x2009;albuterol (A) parameters</td></tr><tr><td colspan="6">Administration (DA: 2.5&#x2009;mg, A: 2.5&#x2009;mg, both twice daily using the Aerogen&#xAE; Solo nebulizer)</td></tr><tr><td>Date of DA&#x2009;+&#x2009;A initiation</td><td>9 April</td><td>4 April</td><td>31 March</td><td>1 April</td><td>31 March</td></tr><tr><td>Date of DA&#x2009;+&#x2009;A cessation</td><td>14 April</td><td>6 April</td><td>8 April</td><td>19 April</td><td>24 April</td></tr><tr><td>Toxicities</td><td>None</td><td>None</td><td>None</td><td>None</td><td>None</td></tr><tr><td colspan="6">Other COVID-19 treatment</td></tr><tr><td>&#x2003;Methylprednisolone</td><td>Yes</td><td>Yes</td><td/><td>Yes</td><td>Yes</td></tr><tr><td>&#x2003;Anakinra</td><td/><td>Yes</td><td/><td>Yes</td><td/></tr><tr><td>&#x2003;CytoSorb</td><td/><td/><td/><td/><td>Yes</td></tr><tr><td colspan="6">Anticoagulants <sup>a</sup></td></tr><tr><td>&#x2003;Enoxaparin</td><td>40&#x2009;mg BID</td><td>120&#x2009;mg BID</td><td>40&#x2009;mg BID</td><td>100&#x2009;mg BID</td><td>120&#x2009;mg BID</td></tr><tr><td>&#x2003;Argatroban</td><td/><td>Yes</td><td/><td>Yes</td><td>Yes</td></tr><tr><td>&#x2003;Heparin gtt</td><td/><td/><td>Yes</td><td/><td>Yes</td></tr><tr><td>Venous thromboembolism</td><td>None</td><td>None</td><td>None</td><td><p>Right SDVT</p><p>Right CVT</p></td><td>None</td></tr><tr><td>Current State</td><td>ICU discharge</td><td>ICU discharge</td><td>ICU discharge</td><td>ICU discharge</td><td>ICU discharge</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Patients were not on simultaneous anticoagulation therapies. <italic>BMI</italic> Body mass index, <italic>ICU</italic> Intensive care unit, <italic>ECMO</italic> Extracorporeal membrane oxygenation, <italic>BID</italic> Bis in die (twice a day), <italic>gtt</italic> Guttae (intravenous drip), <italic>SDVT</italic> Soleal deep vein thrombosis, <italic>CVT</italic> Cephalic vein thrombosis</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Overview of the clinical course of five patients treated with nebulized dornase alfa + albuterol (nDA&#x2009;+&#x2009;A)</p></caption><graphic xlink:href="10020_2020_215_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Patient-level data of respiratory function during treatment with nebulized dornase alfa + albuterol (nDA&#x2009;+&#x2009;A). Values were extracted from the medical records the day before and up to the seven days after the initiation of treatment. Values are graphed in black for patients after they ceased nDA&#x2009;+&#x2009;A treatment. Dashed lines indicate patients on VV-ECMO. Not all markers were measured daily for every patient. FiO<sub>2</sub>: fraction of inspired oxygen; PaCO<sub>2</sub>: partial pressure of carbon dioxide</p></caption><graphic xlink:href="10020_2020_215_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Patient-level data of systemic disease during treatment with nebulized dornase alfa + albuterol (nDA&#x2009;+&#x2009;A). Values were extracted from the medical records the day before and up to the seven days after the initiation of treatment. Values are graphed in black for patients after they ceased nDA&#x2009;+&#x2009;A treatment. Dashed lines indicate patients on VV-ECMO. Not all markers were measured daily for every patient. CRP: C-reactive protein; LDH: lactate dehydrogenase</p></caption><graphic xlink:href="10020_2020_215_Fig3_HTML" id="MO3"/></fig></p>
      <p id="Par25">Patient 1 is a 56-year-old Hispanic woman who presented in respiratory distress. Her respiratory status deteriorated over 48&#x2009;h, requiring intubation and transfer to the ICU. She was treated with nDA&#x2009;+&#x2009;A for 6 days, starting from day 10 of intubation. The FiO<sub>2</sub> requirement decreased from 70% (d&#x2009;&#x2212;&#x2009;1) to 30% (d 6), PaCO<sub>2</sub> from 58 (d&#x2009;&#x2212;&#x2009;1) to 37&#x2009;mmHg (d 7), ferritin from 1803 (d&#x2009;&#x2212;&#x2009;1) to 472&#x2009;ng/mL (d 6), and D-dimer from 1619 (d&#x2009;&#x2212;&#x2009;1) to 563&#x2009;ng/mL (d 6). MP had increased from 16.48 (d&#x2009;&#x2212;&#x2009;1) to 20.91&#x2009;J/minute (d 6), and Paw from 12 (d&#x2009;&#x2212;&#x2009;1) to 20 cmH<sub>2</sub>O (d 6). Minimal changes were noted in CRP and LDH. The patient underwent a tracheostomy after 23&#x2009;days of endotracheal intubation and was able to be decannulated 19&#x2009;days later. She was discharged to a rehabilitation facility after a total hospital stay of 82&#x2009;days.</p>
      <p id="Par26">Patient 2 is a 34-year-old white man who presented to the hospital in diabetic ketoacidosis without prior history of diabetes mellitus. He was intubated on admission and initiated on VV-ECMO. He received nDA&#x2009;+&#x2009;A for 3 days and was de-cannulated after 12&#x2009;days. No change in ECMO settings occurred during treatment time. The FiO<sub>2</sub> requirement decreased from 100% (d 0) to 80% (d 3), MP from 36.38 (d 0) to 12.03&#x2009;J/min (d 3), Paw from 36.38 (d 0) to 12.03 cmH<sub>2</sub>O (d 3), CRP from 14.14 (d 0) to 2.41&#x2009;mg/dL (d 3), ferritin from 12,281 (d 0) to 5453&#x2009;ng/mL (d 3), and D-dimer from 5210 (d 0) to 2099&#x2009;ng/mL (d 3). Minimal changes were noted in PaCO<sub>2</sub> and LDH. The patient was able to be extubated after 30&#x2009;days of endotracheal intubation (VV-ECMO the first 12&#x2009;days). He was discharged to a rehabilitation facility after a total hospital stay of 75&#x2009;days.</p>
      <p id="Par27">Patient 3 is a 65-year-old Asian man who was admitted directly to the ICU for respiratory distress and intubated 3 days later. Twelve days after intubation, he was started on 9 days of nDA&#x2009;+&#x2009;A treatment. The FiO<sub>2</sub> requirement decreased from 50% (d&#x2009;&#x2212;&#x2009;1) to 40% (d 7), PaCO<sub>2</sub> from 55 (d 0) to 43&#x2009;mmHg (d 6), and CRP from 22.07 (d 0) to 26.48&#x2009;mg/dL (d 6). Minimal changes were noted in MP, Paw, ferritin, LDH, and D-dimer. He was extubated 1 day after the completion of the nDA&#x2009;+&#x2009;A course. Five days later, he was re-intubated for an additional 4 days due to mental status changes and failure to protect his airway. The patient was extubated in ICU care 30&#x2009;days after his initial endotracheal intubation. He subsequently developed a right colonic and small bowel perforation requiring the placement of multiple drains. He required the initiation of total parenteral nutrition until he was able to tolerate enteral feeds. Surgery was never required. He was discharged to a rehabilitation facility after a total hospital stay of 97&#x2009;days.</p>
      <p id="Par28">Patient 4 is a 31-year-old Hispanic man who was intubated and transferred to the ICU from the Internal Medicine service 2 days after presenting with respiratory distress. Nine days after intubation, he was initiated on VV-ECMO. Five days after cannulation, he was started on the nDA&#x2009;+&#x2009;A treatment. After ten days, he was de-cannulated and remained intubated for ten days while continuing the nDA&#x2009;+&#x2009;A treatment. No change in ECMO settings occurred during treatment time. He was then extubated and discharged to the floor. The FiO<sub>2</sub> requirement decreased from 90% (d&#x2009;&#x2212;&#x2009;1) to 21% (d 7), Paw from 19 (d&#x2009;&#x2212;&#x2009;1) to 16 cmH<sub>2</sub>O (d 7), and LDH from 1054 (d&#x2009;&#x2212;&#x2009;1) to 451&#x2009;U/L (d 7). Ferritin initially decreased from 1669 (d&#x2009;&#x2212;&#x2009;1) to 387&#x2009;ng/mL (d 7). On day 15 of treatment, he developed methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) pneumonia and bacteremia. Ferritin thus increased to 1619&#x2009;ng/mL (d 13) prior to decreasing to 555&#x2009;ng/mL (d 19) with antibiotic treatment. Minimal changes were noted in MP, PaCO<sub>2</sub>, CRP, and D-dimer. He was transferred to an acute inpatient rehabilitation facility after a total hospital stay of 73&#x2009;days.</p>
      <p id="Par29">Patient 5 is a 34-year-old black woman who was intubated at an outside hospital, then transferred to the North Shore University Hospital ICU. Two days later, she was cannulated for VV-ECMO. She required VV-ECMO for 24&#x2009;days and was intubated for a total of 30&#x2009;days. She was treated with nDA&#x2009;+&#x2009;A for 25&#x2009;days starting on day 4 following cannulation for VV-ECMO. While on VV-ECMO for the first 5 days, CytoSorb therapy was applied. She was de-cannulated after 24&#x2009;days, extubated after 4&#x2009;days, and discharged to the floor. No change in ECMO settings occurred during treatment time. The FiO<sub>2</sub> requirement fell from 80% (d&#x2009;&#x2212;&#x2009;1) to 40% (d 7), ferritin from 1244 (d&#x2009;&#x2212;&#x2009;1) to 535&#x2009;ng/mL (d 7), and LDH from 844 (d&#x2009;&#x2212;&#x2009;1) to 693&#x2009;U/L (d 7). MP increased from 11.03 (d&#x2009;&#x2212;&#x2009;1) to 20.08&#x2009;J/minute (d 7), Paw from 15 (d&#x2009;&#x2212;&#x2009;1) to 22 cmH<sub>2</sub>O (d 7). Minimal changes were noted in PaCO<sub>2</sub>, CRP, and D-dimer. She declined rehabilitation therapy and was discharged home after a total hospital stay of 38&#x2009;days.</p>
    </sec>
    <sec id="Sec4">
      <title>Discussion</title>
      <p id="Par30">At the doses utilized, no nDA&#x2009;+&#x2009;A treatment-associated toxicities were identified. FiO<sub>2</sub> requirements decreased for all five patients 7 days after nDA&#x2009;+&#x2009;A treatment was initiated, while measures of lung mechanics varied. All patients were discharged from the hospital and remain alive at the time of submission of this report. During the time period that these patients were treated, ~&#x2009;25% mortality was reported during the first month for patients requiring ICU care within our hospital system (Richardson et al. <xref ref-type="bibr" rid="CR20">2020</xref>). We recognize that changes in FiO<sub>2</sub> levels, lung mechanics, and systemic inflammatory markers may be independent of the nDA&#x2009;+&#x2009;A treatment. Clinical trials are therefore required to test the dose range, safety, and efficacy of dornase alfa in patients with COVID-19 in this setting and possibly earlier in the disease course. Endpoints should include measurements of the effect on respiratory function and mechanics, as well as on systemic inflammation, coagulopathy, secondary infections, and the presence of NETs in plasma. Eight such trials were recently registered (<italic>NCT04359654, NCT04355364, NCT04432987, NCT04409925, NCT04445285, NCT04402944, NCT04402970, NCT04459325).</italic></p>
      <p id="Par31">Although it is not yet clear whether nebulized dornase alfa will have any effect on blood NET levels or systemic inflammation in COVID-19, a reduction in systemic inflammatory markers has been reported after use of dornase alfa in patients with cystic fibrosis (Yang and Montgomery <xref ref-type="bibr" rid="CR25">2018</xref>). We did note a reduction in CRP in two patients (patients 2 and 3) and a reduction in D-dimer in two patients (patients 1 and 2) during nDA&#x2009;+&#x2009;A treatment. LDH was reduced for the patients on VV-ECMO during nDA&#x2009;+&#x2009;A treatment, and ferritin was reduced in four out of five patients. Due to the small sample size and the common occurrence of secondary infections in ventilated patients with COVID-19, we are unable to comment on any potential relationship between nDA&#x2009;+&#x2009;A administration and the risk of secondary infections.</p>
    </sec>
    <sec id="Sec5">
      <title>Conclusions</title>
      <p id="Par32">This case report suggests that nebulized dornase alfa in combination with albuterol is a safe treatment option, supporting randomized, controlled clinical trials for mechanically ventilated patients with ARDS secondary to COVID-19, including for those on VV-ECMO&#x2014;a patient population with an urgent, unmet need for effective therapies.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <sec id="Sec11">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10020_2020_215_MOESM1_ESM.docx"><caption><p><bold>Additional file 1 Supplemental Table&#xA0;1.</bold> Additional medications that dornase alfa+albuterol-treated COVID-19 patients received while in the hospital.</p></caption></media></supplementary-material></p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ARDS</term>
          <def>
            <p id="Par5">Acute respiratory distress syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>BID</term>
          <def>
            <p id="Par6">Bis in die (twice daily)</p>
          </def>
        </def-item>
        <def-item>
          <term>COVID-19</term>
          <def>
            <p id="Par7">Coronavirus disease 2019</p>
          </def>
        </def-item>
        <def-item>
          <term>CRP</term>
          <def>
            <p id="Par8">C-reactive protein</p>
          </def>
        </def-item>
        <def-item>
          <term>d</term>
          <def>
            <p id="Par9">Day</p>
          </def>
        </def-item>
        <def-item>
          <term>FiO<sub>2</sub></term>
          <def>
            <p id="Par10">Fraction of inspired oxygen</p>
          </def>
        </def-item>
        <def-item>
          <term>gtt</term>
          <def>
            <p id="Par11">Guttae (intravenous drip)</p>
          </def>
        </def-item>
        <def-item>
          <term>ICU</term>
          <def>
            <p id="Par12">Intensive care unit</p>
          </def>
        </def-item>
        <def-item>
          <term>LDH</term>
          <def>
            <p id="Par13">Lactate dehydrogenase</p>
          </def>
        </def-item>
        <def-item>
          <term>MRSA</term>
          <def>
            <p id="Par14">Methicillin-resistant <italic>Staphylococcus aureus</italic></p>
          </def>
        </def-item>
        <def-item>
          <term>nDA&#x2009;+&#x2009;A</term>
          <def>
            <p id="Par15">Nebulized dornase alfa plus albuterol</p>
          </def>
        </def-item>
        <def-item>
          <term>NETs</term>
          <def>
            <p id="Par16">Neutrophil extracellular traps</p>
          </def>
        </def-item>
        <def-item>
          <term>PaCO<sub>2</sub></term>
          <def>
            <p id="Par17">Arterial partial pressure of carbon dioxide</p>
          </def>
        </def-item>
        <def-item>
          <term>SARS-CoV-19</term>
          <def>
            <p id="Par18">Severe acute respiratory syndrome coronavirus 2</p>
          </def>
        </def-item>
        <def-item>
          <term>VV-ECMO</term>
          <def>
            <p id="Par19">Veno-venous extracorporeal membrane oxygenation</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s10020-020-00215-w.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors thanks &#x201C;The NETwork to Target Neutrophils in COVID-19,&#x201D; Eric Gottesman, William Taylor, David Menon, and David Tuveson for helpful discussions, as well as the Northwell COVID-19 Research Consortium for facilitating the study.</p>
      <sec id="FPar1">
        <title>Disclaimer</title>
        <p id="Par33">The initial characteristics of 5700 patients from Northwell Health are presented elsewhere (Richardson et al. <xref ref-type="bibr" rid="CR20">2020</xref>). This case series presented in-depth results on the clinical status of five patients treated with dornase alfa that were not presented in that article.</p>
      </sec>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>Concept and design, analysis and interpretation of data, and drafting of the manuscript: A.G.W., A.S.C., M.E., B.J.B., and T.J. Data acquisition: A.G.W. and B.J.B. The authors read and approved the final manuscript.</p>
      <sec id="FPar2">
        <title>Authors&#x2019; information</title>
        <p id="Par34">Not applicable.</p>
      </sec>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>This work was supported by the William C. and Joyce C. O&#x2019;Neil Charitable Trust. In addition, M.E. and T.J. are supported by NIH grant 5P30CA045508&#x2013;30. B.J.B. is supported by NIH grant 1R01AR076242&#x2013;01 and DOD LRP W81XWH-18-1-0674. A.S.C. was supported by The Primary Immune Deficiency Treatment Consortium (U54 AI 082973), funded jointly by the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Allergy and Infectious Diseases (NIAID). The funding bodies had no role in the design of the study, in collection, analysis, and interpretation of data, or in writing the manuscript.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials</title>
      <p>All data generated or analyzed during this study are included within the article.</p>
    </notes>
    <notes id="FPar3">
      <title>Ethics approval and consent to participate</title>
      <p id="Par35">The Northwell Health institutional review board that focuses on COVID-19 research approved this case series as minimal-risk research using de-identified data from routine clinical practice. Informed consent to participate in the study was obtained from the participants or their health care proxies. The study has been registered as &#x201C;Dornase Alfa Administered to Patients With COVID-19 (DACOVID)&#x201D; at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> with <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT04387786.</p>
    </notes>
    <notes id="FPar4">
      <title>Consent for publication</title>
      <p id="Par36">Not applicable.</p>
    </notes>
    <notes id="FPar5" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par37">Mikala Egeblad is receiving lonodelestat from Santhera for preclinical studies, but has no financial relationship with Santhera. The other authors declare that they have no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adrover</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Aroca-Crevillen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Crainiciuc</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ostos</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rojas-Vega</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Rubio-Ponce</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Programmed 'disarming' of the neutrophil proteome reduces the magnitude of inflammation</article-title>
          <source>Nat Immunol</source>
          <year>2020</year>
          <volume>21</volume>
          <issue>2</issue>
          <fpage>135</fpage>
          <lpage>144</lpage>
          <pub-id pub-id-type="doi">10.1038/s41590-019-0571-2</pub-id>
          <pub-id pub-id-type="pmid">31932813</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <mixed-citation publication-type="other">Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652.</mixed-citation>
      </ref>
      <ref id="CR3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Becker</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>COVID-19 update: Covid-19-associated coagulopathy</article-title>
          <source>J Thromb Thrombolysis</source>
          <year>2020</year>
          <volume>50</volume>
          <issue>1</issue>
          <fpage>54</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1007/s11239-020-02134-3</pub-id>
          <pub-id pub-id-type="pmid">32415579</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caudrillier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kessenbrock</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gilliss</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>JX</given-names>
            </name>
            <name>
              <surname>Marques</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Monestier</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury</article-title>
          <source>J Clin Invest</source>
          <year>2012</year>
          <volume>122</volume>
          <issue>7</issue>
          <fpage>2661</fpage>
          <lpage>2671</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI61303</pub-id>
          <pub-id pub-id-type="pmid">22684106</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>ClinicalTrials.gov [Internet]</collab>
          </person-group>
          <source>Identifier NCT03368092, inhaled Dornase alpha to reduce respiratory failure after severe trauma (TRAUMADORNASE)</source>
          <year>2019</year>
          <publisher-loc>Bethesda</publisher-loc>
          <publisher-name>National Library of Medicine (US)</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR6">
        <mixed-citation publication-type="other">Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in new York City: a prospective cohort study. Lancet. 2020;395(10239):1763&#x2013;70.</mixed-citation>
      </ref>
      <ref id="CR7">
        <mixed-citation publication-type="other">Docherty AB, Harrison EM,&#xA0;Hardwick HE,&#xA0;Holden KA,&#xA0;Dondelinger F, Mersen L,&#xA0;et al. Features of 20,133 UK patients in hospital&#xA0;with COVID-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985.</mixed-citation>
      </ref>
      <ref id="CR8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Durante</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Turco</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rustichini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cosimini</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Giunta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hudson</surname>
              <given-names>LD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ARDSNet lower tidal volume Ventilatory strategy may generate intrinsic positive end-expiratory pressure in patients with acute respiratory distress syndrome</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2002</year>
          <volume>165</volume>
          <issue>9</issue>
          <fpage>1271</fpage>
          <lpage>1274</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.2105050</pub-id>
          <pub-id pub-id-type="pmid">11991877</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Earhart</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Holliday</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>HV</given-names>
            </name>
            <name>
              <surname>Schrum</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome</article-title>
          <source>New Microbes New Infect</source>
          <year>2020</year>
          <volume>35</volume>
          <fpage>100689</fpage>
          <pub-id pub-id-type="doi">10.1016/j.nmni.2020.100689</pub-id>
          <pub-id pub-id-type="pmid">32355564</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fox</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Akmatbekov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Harbert</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Quincy Brown</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vander Heide</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans</article-title>
          <source>Lancet Respir Med</source>
          <year>2020</year>
          <volume>8</volume>
          <issue>7</issue>
          <fpage>681</fpage>
          <lpage>686</lpage>
          <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30243-5</pub-id>
          <pub-id pub-id-type="pmid">32473124</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <mixed-citation publication-type="other">Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. Jama. 2020;323(16):1574&#x2013;81.</mixed-citation>
      </ref>
      <ref id="CR12">
        <mixed-citation publication-type="other">Greenland JR, Michelow MD, Wang L, London MJ. COVID-19 infection: implications for perioperative and critical care physicians. Anesthesiology. 2020;132(6):1346&#x2013;61.</mixed-citation>
      </ref>
      <ref id="CR13">
        <mixed-citation publication-type="other">Lefrancais E, Mallavia B, Zhuo H, Calfee CS, Looney MR. Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury. JCI Insight. 2018;3(3):e98178.</mixed-citation>
      </ref>
      <ref id="CR14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leppkes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Knopf</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Naschberger</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lindemann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Herrmann</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Vascular occlusion by neutrophil extracellular traps in COVID-19</article-title>
          <source>EBioMedicine.</source>
          <year>2020</year>
          <volume>58</volume>
          <fpage>102925</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102925</pub-id>
          <pub-id pub-id-type="pmid">32745993</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <mixed-citation publication-type="other">Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020;323(22):2329&#x2013;30.</mixed-citation>
      </ref>
      <ref id="CR16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marino</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Scanzano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pulze</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pinoli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rasini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Luini</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>beta2 -Adrenoceptors inhibit neutrophil extracellular traps in human polymorphonuclear leukocytes</article-title>
          <source>J Leukoc Biol</source>
          <year>2018</year>
          <volume>104</volume>
          <issue>3</issue>
          <fpage>603</fpage>
          <lpage>614</lpage>
          <pub-id pub-id-type="doi">10.1002/JLB.3A1017-398RR</pub-id>
          <pub-id pub-id-type="pmid">29668114</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <mixed-citation publication-type="other">Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil extracellular traps (NETs) contribute to Immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136(10):1169&#x2013;79.</mixed-citation>
      </ref>
      <ref id="CR18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morris</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mullan</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Use of dornase alfa in the management of ARDS</article-title>
          <source>Anaesthesia</source>
          <year>2004</year>
          <volume>59</volume>
          <issue>12</issue>
          <fpage>1249</fpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2044.2004.04018.x</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papayannopoulos</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Staab</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zychlinsky</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil Elastase enhances sputum Solubilization in cystic fibrosis patients receiving DNase therapy</article-title>
          <source>PLoS One</source>
          <year>2011</year>
          <volume>6</volume>
          <issue>12</issue>
          <fpage>e28526</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0028526</pub-id>
          <pub-id pub-id-type="pmid">22174830</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <mixed-citation publication-type="other">Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area. Jama. 2020;323(20):2052&#x2013;9.</mixed-citation>
      </ref>
      <ref id="CR21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schonrich</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Raftery</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Samstag</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Devilishly radical NETwork in COVID-19: oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression</article-title>
          <source>Adv Biol Regul</source>
          <year>2020</year>
          <volume>77</volume>
          <fpage>100741</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jbior.2020.100741</pub-id>
          <pub-id pub-id-type="pmid">32773102</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tay</surname>
              <given-names>MZ</given-names>
            </name>
            <name>
              <surname>Poh</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Renia</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>MacAry</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>LFP</given-names>
            </name>
          </person-group>
          <article-title>The trinity of COVID-19: immunity, inflammation and intervention</article-title>
          <source>Nat Rev Immunol</source>
          <year>2020</year>
          <volume>20</volume>
          <issue>6</issue>
          <fpage>363</fpage>
          <lpage>374</lpage>
          <pub-id pub-id-type="doi">10.1038/s41577-020-0311-8</pub-id>
          <pub-id pub-id-type="pmid">32346093</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Carbo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Martinod</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mazo</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Schatzberg</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice</article-title>
          <source>Blood.</source>
          <year>2012</year>
          <volume>119</volume>
          <issue>26</issue>
          <fpage>6335</fpage>
          <lpage>6343</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2012-01-405183</pub-id>
          <pub-id pub-id-type="pmid">22596262</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Varga</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Flammer</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Steiger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Haberecker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Andermatt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zinkernagel</surname>
              <given-names>AS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Endothelial cell infection and endotheliitis in COVID-19</article-title>
          <source>Lancet.</source>
          <year>2020</year>
          <volume>395</volume>
          <issue>10234</issue>
          <fpage>1417</fpage>
          <lpage>1418</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30937-5</pub-id>
          <pub-id pub-id-type="pmid">32325026</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Dornase alfa for cystic fibrosis</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2018</year>
          <volume>9</volume>
          <fpage>Cd001127</fpage>
          <pub-id pub-id-type="pmid">30187450</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <mixed-citation publication-type="other">Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">medRxiv</journal-id>
      <journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
      <journal-title-group>
        <journal-title>medRxiv</journal-title>
      </journal-title-group>
      <publisher>
        <publisher-name>Cold Spring Harbor Laboratory</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32511514</article-id>
      <article-id pub-id-type="pmc">7273282</article-id>
      <article-id pub-id-type="doi">10.1101/2020.05.13.20087734</article-id>
      <article-version-alternatives>
        <article-version article-version-type="status">preprint</article-version>
        <article-version article-version-type="number">1</article-version>
      </article-version-alternatives>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Weber</surname>
            <given-names>Andrew G.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chau</surname>
            <given-names>Alice S.</given-names>
          </name>
          <degrees>MD MSE</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Egeblad</surname>
            <given-names>Mikala</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref rid="CR1" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barnes</surname>
            <given-names>Betsy J.</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref rid="CR1" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Janowitz</surname>
            <given-names>Tobias</given-names>
          </name>
          <degrees>MD PhD</degrees>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Northwell Health, 300 Community Drive, Manhasset, NY, 11030</aff>
      <aff id="A2"><label>2</label>Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington and the Center for Immunity and Immunotherapies, Seattle Children&#x2019;s Research Institute, 1900 9<sup>th</sup> Ave, Seattle, WA 98101</aff>
      <aff id="A3"><label>3</label>Cancer Center, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724</aff>
      <aff id="A4"><label>4</label>Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, The Feinstein Institutes for Medical Research and the Departments of Molecular Medicine and Pediatrics, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 350 Community Drive, Manhasset, NY, 11030</aff>
      <aff id="A5"><label>5</label>Northwell Health Cancer Institute, 450 Lakeville Road, New Hyde Park, NY 11042</aff>
      <author-notes>
        <fn fn-type="con" id="FN1">
          <p id="P1"><bold>Authors&#x2019; contributions:</bold>
<italic>Concept and design, analysis and interpretation of data, and drafting of the manuscript:</italic> A.G.W., A.S.C., M.E., B.J.B., and T.J. <italic>Data acquisition:</italic> A.G.W. and B.J.B.</p>
        </fn>
        <corresp id="CR1"><label>*</label>Corresponding authors: Betsy J. Barnes (<email>bbarnes1@northwell.edu</email>) and Mikala Egeblad (<email>egeblad@cshl.edu</email>)</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>5</month>
        <year>2020</year>
      </pub-date>
      <elocation-id>2020.05.13.20087734</elocation-id>
      <permissions>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
          <license-p>It is made available under a <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">CC-BY-NC-ND 4.0 International license</ext-link>.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf">nihpp-2020.05.13.20087734.pdf</self-uri>
      <abstract id="ABS1">
        <sec id="S1">
          <title>Background</title>
          <p id="P2">Mechanically ventilated patients with coronavirus disease 2019 (COVID-19) have a mortality of 24&#x2013;53%, in part due to distal mucopurulent secretions interfering with ventilation. Dornase alfa is recombinant human DNase 1 and digests DNA in mucoid sputum. Nebulized dornase alfa is FDA-approved for cystic fibrosis treatment. DNA from neutrophil extracellular traps (NETs) contributes to the viscosity of mucopurulent secretions. NETs are found in the serum of patients with severe COVID-19, and targeting NETs reduces mortality in animal models of acute respiratory distress syndrome (ARDS). Thus, dornase alfa may be beneficial to patients with severe COVID-19&#x2014;acting as a mucolytic and targeting NETs. However, delivery of nebulized drugs can aerosolize SARS-CoV-2, which causes COVID-19, increasing the infection risk for staff. Here, we report a single center case series where dornase alfa was administered through an in-line nebulizer system to minimize risk of virus aerosolization.</p>
        </sec>
        <sec id="S2">
          <title>Methods</title>
          <p id="P3">Demographic, clinical data, and outcomes were collected from the electronic medical records of five mechanically ventilated patients with COVID-19&#x2014;including three requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO)&#x2014;treated with nebulized in-line endotracheal dornase alfa co-administered with albuterol (used to increase delivery to the alveoli), between March 31 and April 24, 2020. Data on tolerability and responses, including longitudinal values capturing respiratory function and inflammatory status, were analyzed.</p>
        </sec>
        <sec id="S3">
          <title>Results</title>
          <p id="P4">Following nebulized in-line administration of dornase alfa with albuterol, the fraction of inspired oxygen requirements was reduced for all five patients. All patients remain alive and two patients have been discharged from the intensive care unit. No drug associated toxicities were identified.</p>
        </sec>
        <sec id="S4">
          <title>Conclusions</title>
          <p id="P5">The results presented in this case series suggest that dornase alfa will be well-tolerated by critically ill patients with COVID-19. Clinical trials are required to formally test the dosing, safety, and efficacy of dornase alfa in COVID-19, and two have recently been registered (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04359654">NCT04359654</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04355364">NCT04355364</ext-link>). With this case series, we hope to contribute to the development of management approaches for critically ill patients with COVID-19.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>SARS-CoV-2</kwd>
        <kwd>COVID-19</kwd>
        <kwd>coronavirus</kwd>
        <kwd>mucopurulent secretions</kwd>
        <kwd>dornase alfa</kwd>
        <kwd>neutrophil extracellular traps</kwd>
        <kwd>ARDS</kwd>
        <kwd>VV-ECMO</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="S5">
      <title>BACKGROUND</title>
      <p id="P6">Critically ill patients with coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), progress to hypoxemic and then mixed respiratory failure, secondary to acute respiratory distress syndrome (ARDS) (<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>). Approximately 79&#x2013;88% of patients admitted to the intensive care unit (ICU) with COVID-19 require intubation and mechanical ventilation, with a mortality of 24&#x2013;53% (<xref rid="R3" ref-type="bibr">3</xref>&#x2013;<xref rid="R6" ref-type="bibr">6</xref>). ARDS in COVID-19 is characterized by ventilation failure, in part attributable to distally located mucopurulent secretions.</p>
      <p id="P7">Dornase alfa (Pulmozyme&#xAE;) is recombinant human DNase 1 and a safe mucolytic that is administered in nebulized form. It is FDA-approved in combination with standard therapies for patients with cystic fibrosis to improve sputum clearance and pulmonary function (<xref rid="R7" ref-type="bibr">7</xref>). It is also used off-label as a mucolytic in other diseases, including ARDS (<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>). A mechanism by which dornase alfa might improve ventilation is by reducing the DNA-mediated viscosity of neutrophil-rich secretions (<xref rid="R10" ref-type="bibr">10</xref>). There are multiple sources for the DNA in mucoid sputum, one of which is neutrophil extracellular traps (NETs). Recently, we collaboratively reported that in the discarded serum of patients with COVID-19, the levels of NETs were increased and were correlated with lactate dehydrogenase (LDH), D-dimer, and C-reactive protein (CRP) levels (<xref rid="R11" ref-type="bibr">11</xref>). Targeting NETs reduces mortality in animal models of ARDS (<xref rid="R12" ref-type="bibr">12</xref>). Despite recognition that mucolytic treatment may be beneficial for patients with COVID-19, administration of nebulized medications, such as dornase alfa, have been limited due to risk of viral aerosolization. If risk of viral aerosolization can be avoided, dornase alfa may benefit patients with severe COVID-19. by acting as a mucolytic and by reducing NET levels in the lungs, thereby improving oxygenation and ventilation. We report the clinical course, safety, and outcomes after nebulized in-line endotracheal dornase alfa treatment for five intubated and mechanically ventilated patients with PCR-confirmed COVID-19.</p>
    </sec>
    <sec id="S6">
      <title>METHODS</title>
      <p id="P8">The Northwell Health institutional review board that focuses on COVID-19 research approved this case series as minimal-risk research using de-identified data from routine clinical practice. Data were collected from the enterprise health record (Sunrise Clinical Manager; Allscripts) reporting database, and included patient demographics, comorbidities, inpatient medications, laboratory studies, treatment, and outcomes. We further obtained longitudinal values of FiO<sub>2</sub> and of the arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>) as measures of respiratory function during treatment. FiO<sub>2</sub> values of the circuit were reported for those patients who required veno-venous extracorporeal membrane oxygenation (VV-ECMO). Ferritin, CRP, LDH, and D-dimer were obtained as measures of systemic disease and inflammation. Not all patients had laboratory investigations on the same days in relation to the nDA+A treatment. In the following case synopses, each measurement is therefore followed by the day in relation to the first day of treatment with nDA+A (<italic>e.g.</italic> d 2 for the second day of treatment with nDA+A or d &#x2212;1 for the day before nDA+A treatment was initiated).</p>
    </sec>
    <sec id="S7">
      <title>RESULTS</title>
      <p id="P9">Five patients treated with dornase alfa between March 31, 2020 and April 24, 2020 were identified. These patients had met the Berlin criteria for ARDS and were treated with ventilator strategies guided by the ARDSNet protocol at North Shore University Hospital within Northwell Health (<xref rid="R13" ref-type="bibr">13</xref>). They had been treated with dornase alfa because they required high levels of fraction of inspired oxygen (FiO<sub>2</sub>) and had elevated ventilation demands. All patients received the same treatment doses: nebulized dornase alfa (2.5 mg) co-administered twice daily with the short-acting &#x3B2;<sub>2</sub>-agonist albuterol (2.5 mg, hereafter abbreviated as nDA+A) to improve delivery to the alveoli. Of note, &#x3B2;<sub>2</sub>-adrenoreceptor agonism may also inhibit NET formation by direct action on neutrophils (<xref rid="R14" ref-type="bibr">14</xref>). The treatment was administered with an Aerogen&#xAE; Solo in-line nebulizer to avoid open aerosol generation, which would place staff at risk of exposure to SARS-CoV-2.</p>
      <p id="P10">The patient characteristics are summarized in <xref rid="T1" ref-type="table">Table 1</xref>. Patients were treated with nDA+A between 3 to 25 days. The most common characteristics of the patients included obesity (BMI&#x2265;30) and four of the patients had hypertension. Four patients received methylprednisolone dosed at 1&#x2013;2mg/kg/day. All patients were treated with full dose or prophylactic dose anticoagulation for thrombosis. All other medications that were administered during the course of hospitalization are summarized in <xref rid="SD1" ref-type="supplementary-material">Table S1</xref>. The clinical course of the five patients treated with nDA+A is summarized in <xref rid="F1" ref-type="fig">Figure 1</xref>. <xref rid="F2" ref-type="fig">Figure 2</xref> and <xref rid="F3" ref-type="fig">3</xref> display the longitudinal, ventilatory, and inflammatory markers for each patient.</p>
      <p id="P11">Patient 1 is a 56-year-old Hispanic woman who presented in respiratory distress. Her respiratory status deteriorated over 48 hours, requiring intubation and transfer to the ICU. She was treated with nDA+A for six days, starting from day 9 of intubation. The FiO<sub>2</sub> requirement decreased from 70% (d &#x2212;1) to 30% (d 6), PaCO<sub>2</sub> from 58 (d &#x2212;1) to 37 mmHg (d 7), ferritin from 1,803 (d &#x2212;1) to 472 ng/mL (d 6), and D-dimer from 1,619 (d &#x2212;1) to 563 ng/mL (d 6). Minimal changes were noted in CRP and LDH. The patient underwent a tracheostomy after 23 days of endotracheal intubation and remains on an FiO<sub>2</sub> of 30% while pending return of mental status.</p>
      <p id="P12">Patient 2 is a 34-year-old white man who presented to the hospital in diabetic ketoacidosis without prior history of diabetes mellitus. He was intubated on admission and initiated on VV-ECMO. He received nDA+A for three days and was de-cannulated after 12 days. The FiO<sub>2</sub> requirement decreased from 100% (d 0) to 80% (d 3), CRP from 14.14 (d 0) to 2.41 mg/dL (d 3), ferritin from 12,281 (d 0) to 5,453 ng/mL (d 3), and D-dimer from 5,210 (d 0) to 2,099 ng/mL (d 3). Minimal changes were noted in PaCO<sub>2</sub> and LDH. The patient remains intubated.</p>
      <p id="P13">Patient 3 is a 65-year-old Asian man who was admitted directly to the ICU for respiratory distress and intubated three days later. Twelve days after intubation, he was started on nine days of nDA+A treatment. The FiO<sub>2</sub> requirement decreased from 50% (d &#x2212;1) to 40% (d 7), PaCO<sub>2</sub> from 55 (d 0) to 43 mmHg (d 6), and CRP from 22.07 (d 0) to 26.48 mg/dL (d 6). Minimal changes were noted in ferritin, LDH, and D-dimer. He was extubated one day after the completion of the nDA+A course. Six days later, he was re-intubated for an additional four days due to mental status changes and failure to protect his airway. The patient remains extubated in ICU care.</p>
      <p id="P14">Patient 4 is a 31-year-old Hispanic man who was intubated and transferred to the ICU from the Internal Medicine service two days after presenting with respiratory distress. Nine days after intubation, he was initiated on VV-ECMO. Five days after cannulation, he was started on the nDA+A treatment. After nine days, he was de-cannulated and remained intubated for ten days while continuing the nDA+A treatment. He was then extubated and discharged to the floor. The FiO<sub>2</sub> requirement decreased from 90% (d &#x2212;1) to 21% (d 7) and LDH from 1,054 (d &#x2212;1) to 451 U/L (d 7). Ferritin initially decreased from 1,669 (d &#x2212;1) to 387 ng/mL (d 7). On day 15 of treatment, he developed methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) pneumonia and bacteremia. Ferritin thus increased to 1,619 ng/mL (d 13) prior to decreasing to 555 ng/mL (d 19) with antibiotic treatment. Minimal changes were noted in PaCO<sub>2</sub>, CRP, and D-dimer.</p>
      <p id="P15">Patient 5 is a 34-year-old black woman who was intubated at an outside hospital, then transferred to the North Shore University Hospital ICU. Two days later, she was cannulated for VV-ECMO. She required VV-ECMO for 13 days and was intubated for a total of 29 days. She was treated with nDA+A for 25 days starting three days following intubation and cannulation. While on VV-ECMO for the first five days, CytoSorb therapy was applied. She was de-cannulated after 23 days, extubated after 4 days, and discharged to the floor. The FiO<sub>2</sub> requirement fell from 80% (d &#x2212;1) to 40% (d 7), ferritin from 1,244 (d &#x2212;1) to 535 ng/mL (d 7), and LDH from 844 (d &#x2212;1) to 693 U/L (d 7). Minimal changes were noted in PaCO<sub>2</sub>, CRP, and D-dimer.</p>
    </sec>
    <sec id="S8">
      <title>DISCUSSION</title>
      <p id="P16">At the doses utilized, no nDA+A treatment-associated toxicities were identified. FiO<sub>2</sub> requirements decreased for all five patients seven days after nDA+A treatment was initiated. All patients remain alive at the time of submission of this report, with two patients discharged from the ICU. We recognize that these FiO<sub>2</sub> changes may be independent of the nDA+A treatment. Clinical trials are therefore required to test the dose range, safety, and efficacy of dornase alfa in patients with COVID-19 in this setting and possibly earlier in the disease course. Endpoints should include measurements of the effect on respiratory function as well as on systemic inflammation, coagulopathy, secondary infections, and the presence of NETs in plasma. Two such trials were recently registered (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04359654">NCT04359654</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04355364">NCT04355364</ext-link>).</p>
      <p id="P17">It is not clear whether nebulized dornase alfa will have any effect on blood NET levels or systemic inflammation in COVID-19, but a reduction in systemic inflammatory markers has been reported after use of dornase alfa in patients with cystic fibrosis (<xref rid="R7" ref-type="bibr">7</xref>). We did note a reduction in CRP in two patients (patients 2 and 3) and a reduction in D-dimer in two patients (patients 1 and 2) during nDA+A treatment. LDH was reduced for the patients on VV-ECMO during nDA+A treatment, and ferritin was reduced in four out of five patients. Due to the small sample size and the common occurrence of secondary infections in ventilated patients with COVID-19, we are unable to comment on any potential relationship between nDA+A administration and the risk of secondary infections.</p>
    </sec>
    <sec id="S9">
      <title>CONCLUSIONS</title>
      <p id="P18">Nebulized dornase alfa in combination with albuterol may be a safe treatment option for mechanically ventilated patients with ARDS secondary to COVID-19, including for those on VV-ECMO&#x2014;a patient population with an urgent, unmet need for effective therapies.</p>
    </sec>
    <sec sec-type="supplementary-material" id="SM1">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>1</label>
        <media xlink:href="NIHPP2020.05.13.20087734-supplement-1.pdf" orientation="portrait" id="d38e368" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S10">
      <title>Acknowledgements:</title>
      <p id="P19">The authors thanks &#x201C;The NETwork to Target Neutrophils in COVID-19,&#x201D; Eric Gottesman, William Taylor, David Menon, and David Tuveson for helpful discussions, as well as the Northwell COVID-19 Research Consortium for facilitating the study.</p>
      <p id="P20">Funding: This work was supported by the William C. and Joyce C. O&#x2019;Neil Charitable Trust. In addition, M.E. and T.J. are supported by NIH grant 5P30CA045508-30. B.J.B. is supported by NIH grant 1R01AR076242-01 and DOD LRP W81XWH-18-1-0674. A.S.C. was supported by The Primary Immune Deficiency Treatment Consortium (U54 AI 082973), funded jointly by NCATS (write out) and the National Institute of Allergy and Infectious Diseases (NIAID). The funding bodies had no role in the design of the study; in collection, analysis, and interpretation of data; and in writing the manuscript.</p>
    </ack>
    <fn-group>
      <fn id="FN2">
        <p id="P21">Ethics approval and consent to participate:The Northwell Health institutional review board that focuses on COVID-19 research approved this case series as minimal-risk research using de-identified data from routine clinical practice. Informed consent to participate in the study was obtained from the participants or their health care proxies. The study has been registered as &#x201C;Dornase Alfa Administered to Patients With COVID-19 (DACOVID)&#x201D; at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> with <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04387786">NCT04387786</ext-link>.</p>
      </fn>
      <fn id="FN3">
        <p id="P22">Consent for publication: Not applicable.</p>
      </fn>
      <fn id="FN4">
        <p id="P23">Availability of supporting data: All data generated or analyzed during this study are included within the article.</p>
      </fn>
      <fn fn-type="COI-statement" id="FN5">
        <p id="P24">Competing interests: Mikala Egeblad is receiving lonodelestat from Santhera for preclinical studies, but has no financial relationship with Santhera. The other authors declare that they have no competing interests.</p>
      </fn>
      <fn id="FN6">
        <p id="P25">Authors&#x2019; information: Not applicable.</p>
      </fn>
      <fn id="FN7">
        <p id="P26" content-type="publisher-disclaimer">Disclaimer: The initial characteristics of 5,700 patients from Northwell Health are presented elsewhere (<xref rid="R5" ref-type="bibr">5</xref>). This case series presented in-depth results on the clinical status of five patients treated with dornase alfa that were not presented in that article.</p>
      </fn>
    </fn-group>
    <glossary>
      <title>LIST OF ABBREVIATIONS</title>
      <def-list>
        <def-item>
          <term>ARDS</term>
          <def>
            <p id="P27">acute respiratory distress syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>BID</term>
          <def>
            <p id="P28">bis in die (twice daily)</p>
          </def>
        </def-item>
        <def-item>
          <term>COVID-19</term>
          <def>
            <p id="P29">coronavirus disease 2019</p>
          </def>
        </def-item>
        <def-item>
          <term>CRP</term>
          <def>
            <p id="P30">C-reactive protein</p>
          </def>
        </def-item>
        <def-item>
          <term>d</term>
          <def>
            <p id="P31">day</p>
          </def>
        </def-item>
        <def-item>
          <term>FiO<sub>2</sub></term>
          <def>
            <p id="P32">fraction of inspired oxygen</p>
          </def>
        </def-item>
        <def-item>
          <term>gtt</term>
          <def>
            <p id="P33">guttae (intravenous drip)</p>
          </def>
        </def-item>
        <def-item>
          <term>ICU</term>
          <def>
            <p id="P34">intensive care unit</p>
          </def>
        </def-item>
        <def-item>
          <term>LDH</term>
          <def>
            <p id="P35">lactate dehydrogenase</p>
          </def>
        </def-item>
        <def-item>
          <term>MRSA</term>
          <def>
            <p id="P36">methicillin-resistant <italic>Staphylococcus aureus</italic></p>
          </def>
        </def-item>
        <def-item>
          <term>nDA+A</term>
          <def>
            <p id="P37">nebulized dornase alfa plus albuterol</p>
          </def>
        </def-item>
        <def-item>
          <term>NETs</term>
          <def>
            <p id="P38">neutrophil extracellular traps</p>
          </def>
        </def-item>
        <def-item>
          <term>PaCO<sub>2</sub></term>
          <def>
            <p id="P39">arterial partial pressure of carbon dioxide</p>
          </def>
        </def-item>
        <def-item>
          <term>SARS-CoV-19</term>
          <def>
            <p id="P40">severe acute respiratory syndrome coronavirus 2</p>
          </def>
        </def-item>
        <def-item>
          <term>VV-ECMO</term>
          <def>
            <p id="P41">veno-venous extracorporeal membrane oxygenation</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><name><surname>Marini</surname><given-names>JJ</given-names></name>, <name><surname>Gattinoni</surname><given-names>L</given-names></name>. <article-title>Management of COVID-19 Respiratory Distress</article-title>. <source>JAMA</source>. <year>2020</year>.</mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><name><surname>Greenland</surname><given-names>JR</given-names></name>, <name><surname>Michelow</surname><given-names>MD</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>London</surname><given-names>MJ</given-names></name>. <article-title>COVID-19 Infection: Implications for Perioperative and Critical Care Physicians</article-title>. <source>Anesthesiology</source>. <year>2020</year>.</mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><name><surname>Cummings</surname><given-names>MJ</given-names></name>, <name><surname>Baldwin</surname><given-names>MR</given-names></name>, <name><surname>Abrams</surname><given-names>D</given-names></name>, <name><surname>Jacobson</surname><given-names>SD</given-names></name>, <name><surname>Meyer</surname><given-names>BJ</given-names></name>, <name><surname>Balough</surname><given-names>EM</given-names></name>, <etal/>
<article-title>Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study</article-title>. <source>medRxiv</source>. <year>2020</year>:<comment>2020.04.15.20067157</comment>.</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><name><surname>Grasselli</surname><given-names>G</given-names></name>, <name><surname>Zangrillo</surname><given-names>A</given-names></name>, <name><surname>Zanella</surname><given-names>A</given-names></name>, <name><surname>Antonelli</surname><given-names>M</given-names></name>, <name><surname>Cabrini</surname><given-names>L</given-names></name>, <name><surname>Castelli</surname><given-names>A</given-names></name>, <etal/>
<article-title>Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region</article-title>, <source>Italy. Jama.</source>
<year>2020</year>.</mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><name><surname>Richardson</surname><given-names>S</given-names></name>, <name><surname>Hirsch</surname><given-names>JS</given-names></name>, <name><surname>Narasimhan</surname><given-names>M</given-names></name>, <name><surname>Crawford</surname><given-names>JM</given-names></name>, <name><surname>McGinn</surname><given-names>T</given-names></name>, <name><surname>Davidson</surname><given-names>KW</given-names></name>, <etal/>
<article-title>Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area</article-title>. <source>Jama</source>. <year>2020</year>.</mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><name><surname>Docherty</surname><given-names>AB</given-names></name>, <name><surname>Harrison</surname><given-names>EM</given-names></name>, <name><surname>Green</surname><given-names>CA</given-names></name>, <name><surname>Hardwick</surname><given-names>HE</given-names></name>, <name><surname>Pius</surname><given-names>R</given-names></name>, <name><surname>Norman</surname><given-names>L</given-names></name>, <etal/>
<article-title>Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol</article-title>. <source>medRxiv</source>. <year>2020</year>:<comment>2020.04.23.20076042</comment>.</mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>C</given-names></name>, <name><surname>Montgomery</surname><given-names>M</given-names></name>. <article-title>Dornase alfa for cystic fibrosis</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2018</year>;<volume>9</volume>:<fpage>Cd001127</fpage>.<pub-id pub-id-type="pmid">30187450</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><name><surname>Morris</surname><given-names>C</given-names></name>, <name><surname>Mullan</surname><given-names>B</given-names></name>. <article-title>Use of dornase alfa in the management of ARDS</article-title>. <source>Anaesthesia</source>. <year>2004</year>;<volume>59</volume>(<issue>12</issue>):<fpage>1249</fpage><bold>-. </bold></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="web"><collab>ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)</collab>. <source>2017 Dec 11. Identifier NCT03368092, Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma (TRAUMADORNASE)</source>; <year>2019</year>
<comment>Aug 21 [cited</comment>
<date-in-citation>2020 Apr 28</date-in-citation>]. <comment>Available</comment>
<bold>from:</bold>
<comment><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03368092">https://clinicaltrials.gov/ct2/show/NCT03368092</ext-link></comment>.</mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><name><surname>Papayannopoulos</surname><given-names>V</given-names></name>, <name><surname>Staab</surname><given-names>D</given-names></name>, <name><surname>Zychlinsky</surname><given-names>A</given-names></name>. <article-title>Neutrophil Elastase Enhances Sputum Solubilization in Cystic Fibrosis Patients Receiving DNase Therapy</article-title>. <source>PLOS ONE</source>. <year>2011</year>;<volume>6</volume>(<issue>12</issue>):<fpage>e28526</fpage>.<pub-id pub-id-type="pmid">22174830</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><name><surname>Zuo</surname><given-names>Y</given-names></name>, <name><surname>Yalavarthi</surname><given-names>S</given-names></name>, <name><surname>Shi</surname><given-names>H</given-names></name>, <name><surname>Gockman</surname><given-names>K</given-names></name>, <name><surname>Zuo</surname><given-names>M</given-names></name>, <name><surname>Madison</surname><given-names>JA</given-names></name>, <etal/>
<article-title>Neutrophil extracellular traps in COVID-19</article-title>. <source>JCI Insight</source>. <year>2020</year>.</mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><name><surname>Barnes</surname><given-names>BJ</given-names></name>, <name><surname>Adrover</surname><given-names>JM</given-names></name>, <name><surname>Baxter-Stoltzfus</surname><given-names>A</given-names></name>, <name><surname>Borczuk</surname><given-names>A</given-names></name>, <name><surname>Cools-Lartigue</surname><given-names>J</given-names></name>, <name><surname>Crawford</surname><given-names>JM</given-names></name>, <etal/>
<article-title>Targeting potential drivers of COVID-19: Neutrophil extracellular traps</article-title>. <source>Journal of Experimental Medicine</source>. <year>2020</year>;<volume>217</volume>(<issue>6</issue>).</mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><name><surname>Gd</surname><given-names>Durante</given-names></name>, <name><surname>Md</surname><given-names>Turco</given-names></name>, <name><surname>Rustichini</surname><given-names>L</given-names></name>, <name><surname>Cosimini</surname><given-names>P</given-names></name>, <name><surname>Giunta</surname><given-names>F</given-names></name>, <name><surname>Hudson</surname><given-names>LD</given-names></name>, <etal/>
<article-title>ARDSNet Lower Tidal Volume Ventilatory Strategy May Generate Intrinsic Positive End-Expiratory Pressure in Patients with Acute Respiratory Distress Syndrome</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2002</year>;<volume>165</volume>(<issue>9</issue>):<fpage>1271</fpage>&#x2013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">11991877</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><name><surname>Marino</surname><given-names>F</given-names></name>, <name><surname>Scanzano</surname><given-names>A</given-names></name>, <name><surname>Pulze</surname><given-names>L</given-names></name>, <name><surname>Pinoli</surname><given-names>M</given-names></name>, <name><surname>Rasini</surname><given-names>E</given-names></name>, <name><surname>Luini</surname><given-names>A</given-names></name>, <etal/>
<article-title>beta2 -Adrenoceptors inhibit neutrophil extracellular traps in human polymorphonuclear leukocytes</article-title>. <source>J Leukoc Biol</source>. <year>2018</year>;<volume>104</volume>(<issue>3</issue>):<fpage>603</fpage>&#x2013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">29668114</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1.</label>
      <caption>
        <p id="P99">Overview of the clinical course of five patients treated with nebulized dornase alfa + albuterol (nDA+A).</p>
      </caption>
      <graphic xlink:href="nihpp-2020.05.13.20087734-f0001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2.</label>
      <caption>
        <title>Patient-level data of respiratory function during treatment with nebulized dornase alfa + albuterol (nDA+A).</title>
        <p id="P42">Values were extracted from the medical records the day before and up to the seven days after the initiation of treatment. Values are graphed in black for patients after they ceased nDA+A treatment. Dashed lines indicate patients on VV-ECMO. Not all markers were measured daily for every patient. FiO<sub>2</sub>: fraction of inspired oxygen; PaCO<sub>2</sub>: partial pressure of carbon dioxide.</p>
      </caption>
      <graphic xlink:href="nihpp-2020.05.13.20087734-f0002"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Figure 3.</label>
      <caption>
        <title>Patient-level data of systemic disease during treatment with nebulized dornase alfa + albuterol (nDA+A).</title>
        <p id="P43">Values were extracted from the medical records the day before and up to the seven days after the initiation of treatment. Values are graphed in black for patients after they ceased nDA+A treatment. Dashed lines indicate patients on VV-ECMO. Not all markers were measured daily for every patient. CRP: C-reactive protein; LDH: lactate dehydrogenase.</p>
      </caption>
      <graphic xlink:href="nihpp-2020.05.13.20087734-f0003"/>
    </fig>
    <table-wrap id="T1" orientation="portrait" position="float">
      <label>Table 1.</label>
      <caption>
        <p id="P44">Patient data from five patients with COVID-19 who received dornase alfa with albuterol March&#x2013;April, 2020.</p>
      </caption>
      <table frame="box" rules="all">
        <colgroup span="1">
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
        </colgroup>
        <thead>
          <tr>
            <th align="center" valign="middle" rowspan="1" colspan="1">Patient</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">1</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">2</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">3</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">4</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">5</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="6" align="left" valign="middle" rowspan="1">
              <bold>Clinical Characteristics</bold>
            </td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Date of admission</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">29 March</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">16 March</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">16 March</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">26 March</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Age</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">56</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">34</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">65</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">31</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">34</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Gender</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">F</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">M</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">M</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">M</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">F</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Ethnicity</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Hispanic</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">White</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Asian</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Hispanic</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Black</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">BMI</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">38</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">41</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">32</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">30</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">38</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Date of ICU admission</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">31 March</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">16 March</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">18 March</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">26 March</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Comorbidities</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
          </tr>
          <tr style="border-top: hidden;border-bottom: hidden">
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Hypertension</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Diabetes mellitus, type 2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
          </tr>
          <tr style="border-top: hidden;border-bottom: hidden">
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Asthma</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Hyperlipidemia</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
          </tr>
          <tr style="border-top: hidden;border-bottom: hidden">
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Migraine</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Chronic gastritis</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
          </tr>
          <tr>
            <td colspan="6" align="left" valign="middle" rowspan="1">
              <bold>ECMO</bold>
            </td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Date of ECMO initiation</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">27 March</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">28 March</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Date of ECMO cessation</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">16 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">20 April</td>
          </tr>
          <tr>
            <td colspan="6" align="left" valign="middle" rowspan="1">
              <bold>Dornase alfa (DA) + albuterol (A) parameters</bold>
            </td>
          </tr>
          <tr>
            <td colspan="6" align="left" valign="middle" rowspan="1">Administration (DA: 2.5 mg, A: 2.5 mg, both twice daily using the Aerogen&#xAE; Solo nebulizer)</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Date of DA + A initiation</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">9 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">31 March</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">31 March</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Date of DA + A cessation</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">14 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">19 April</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">24 April</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">Toxicities</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">None</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">None</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">None</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">None</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">None</td>
          </tr>
          <tr style="border-bottom: hidden">
            <td align="left" valign="middle" rowspan="1" colspan="1">
              <bold>Other COVID-19 treatment</bold>
            </td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Methylprednisolone</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
          </tr>
          <tr style="border-top: hidden;border-bottom: hidden">
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Anakinra</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;CytoSorb</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
          </tr>
          <tr style="border-bottom: hidden">
            <td align="left" valign="middle" rowspan="1" colspan="1"><bold>Anticoagulants</bold>
<xref rid="TFN1" ref-type="table-fn">*</xref></td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Enoxaparin</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">40 mg BID</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">120 mg BID</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">40 mg BID</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">100 mg BID</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">120 mg BID</td>
          </tr>
          <tr style="border-top: hidden;border-bottom: hidden">
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Argatroban</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">&#x2003;Heparin gtt</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="middle" rowspan="1" colspan="1"/>
            <td align="center" valign="middle" rowspan="1" colspan="1">Yes</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">
              <bold>Venous thromboembolism</bold>
            </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">None</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">None</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">None</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Right SDVT Right CVT</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">None</td>
          </tr>
          <tr>
            <td align="left" valign="middle" rowspan="1" colspan="1">
              <bold>Current State</bold>
            </td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Recovery post tracheostomy</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Intubated</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Recovery</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ICU discharge (23 April)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">ICU discharge (28 April)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN1">
          <label>*</label>
          <p id="P45">Patients were not on simultaneous anticoagulation therapies. BMI: body mass index; ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation; BID: bis in die (twice a day); gtt: guttae (intravenous drip); SDVT: soleal deep vein thrombosis; CVT: cephalic vein thrombosis.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">New Microbes New Infect</journal-id>
      <journal-id journal-id-type="iso-abbrev">New Microbes New Infect</journal-id>
      <journal-title-group>
        <journal-title>New Microbes and New Infections</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2052-2975</issn>
      <publisher>
        <publisher-name>The Author(s). Published by Elsevier Ltd.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32355564</article-id>
      <article-id pub-id-type="pmc">7192073</article-id>
      <article-id pub-id-type="publisher-id">S2052-2975(20)30041-X</article-id>
      <article-id pub-id-type="doi">10.1016/j.nmni.2020.100689</article-id>
      <article-id pub-id-type="publisher-id">100689</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="au1">
          <name>
            <surname>Earhart</surname>
            <given-names>A.P.</given-names>
          </name>
          <email>apey5x@mail.missouri.edu</email>
          <xref rid="aff1" ref-type="aff">1</xref>
          <xref rid="cor2" ref-type="corresp">&#x2217;&#x2217;</xref>
        </contrib>
        <contrib contrib-type="author" id="au2">
          <name>
            <surname>Holliday</surname>
            <given-names>Z.M.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" id="au3">
          <name>
            <surname>Hofmann</surname>
            <given-names>H.V.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author" id="au4">
          <name>
            <surname>Schrum</surname>
            <given-names>A.G.</given-names>
          </name>
          <email>schruma@health.missouri.edu</email>
          <xref rid="aff3" ref-type="aff">3</xref>
          <xref rid="aff4" ref-type="aff">4</xref>
          <xref rid="aff5" ref-type="aff">5</xref>
          <xref rid="cor1" ref-type="corresp">&#x2217;</xref>
        </contrib>
        <aff id="aff1"><label>1)</label>Molecular Pathogenesis &amp; Therapeutics Program, University of Missouri Graduate School, Columbia, MO, USA</aff>
        <aff id="aff2"><label>2)</label>Pulmonary Disease, Critical Care Medicine, School of Medicine, University of Missouri, Columbia, MO, USA</aff>
        <aff id="aff3"><label>3)</label>Molecular Microbiology &amp; Immunology, University of Missouri, Columbia, MO, USA</aff>
        <aff id="aff4"><label>4)</label>Surgery, School of Medicine, University of Missouri, Columbia, MO, USA</aff>
        <aff id="aff5"><label>5)</label>Biomedical, Biological, &amp; Chemical Engineering, College of Engineering, University of Missouri, Columbia, MO, USA</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>&#x2217;</label><bold>Corresponding author:</bold> A.G. Schrum, M627 Medical Sciences Building, One Hospital Drive, Columbia, MO, 65212, USA. <email>schruma@health.missouri.edu</email></corresp>
        <corresp id="cor2"><label>&#x2217;&#x2217;</label><bold>Corresponding author:</bold> A.P. Earhart, M627 Medical Sciences Building, One Hospital Drive, Columbia, MO, 65212, USA. <email>apey5x@mail.missouri.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>30</day>
        <month>4</month>
        <year>2020</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>4</month>
        <year>2020</year>
      </pub-date>
      <volume>35</volume>
      <fpage>100689</fpage>
      <lpage>100689</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>4</month>
          <year>2020</year>
        </date>
        <date date-type="rev-recd">
          <day>22</day>
          <month>4</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>4</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2020 The Author(s)</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license>
          <license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
        </license>
      </permissions>
      <abstract id="abs0010">
        <p>We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be considered for clinical trials in treatment of severe COVID-19.</p>
      </abstract>
      <kwd-group id="kwrds0010">
        <title>Keywords</title>
        <kwd>acute respiratory distress syndrome</kwd>
        <kwd>COVID-19</kwd>
        <kwd>DNAse 1</kwd>
        <kwd>dornase alfa</kwd>
        <kwd>Neutrophil extracellular trap</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p id="p0010">Dornase alfa (Pulmozyme; Genentech, South San Francisco, CA, USA) is recombinant human deoxyribonuclease I, the only drug in its class that acts as a mucolytic by cleaving extracellular chromosomal DNA from neutrophil extracellular traps (NET) and other cell-free DNA. The drug's on-label clinical use is to reduce the viscosity and quantity of airway mucus in individuals with cystic fibrosis, thereby improving mucociliary clearance [<xref rid="bib1" ref-type="bibr">1</xref>]. Dornase alfa is commonly used in individuals with cystic fibrosis, including those with severe complications requiring mechanical ventilation in intensive care units, and is compatible with co-administration of other routine drugs including antibiotics. Off-label use of dornase alfa includes reports treating acute respiratory distress syndrome (ARDS), where the drug can lead to mucus plug clearance and accelerated recovery in humans and mice [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib3" ref-type="bibr">3</xref>]. A controlled clinical trial for treating ARDS with dornase alfa is currently underway [<xref rid="bib4" ref-type="bibr">4</xref>]. In the Critical Care setting, rare and minor adverse effects associated with dornase alfa include voice alteration and rash [<xref rid="bib1" ref-type="bibr">1</xref>].</p>
    <p id="p0015">The cellular and molecular mechanisms proposed for dornase alfa activity in severely distressed lungs of individuals with cystic fibrosis and many ARDS patients are as follows. Inflammation results in neutrophilia and neutrophil infiltration in the lungs, where these cells produce NETs, largely comprised of sticky, large chromosomal DNA that physically reinforces airway mucus viscosity and accumulation [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>]. Thick mucus that clears poorly can lead to airway obstruction, bronchiectasis, lung injury, hypoxia and respiratory failure. Dornase alfa facilitates airway clearance by breaking up reinforcement of mucus by NETs, by far the greatest source of extracellular DNA in inflamed lungs [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>].</p>
    <p id="p0020">Severe cases of coronavirus disease 2019 (COVID-19) have shown an inflammatory neutrophil and mucus-mediated airway exclusion pathway with striking similarities to that described above (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>
). Unlike mild COVID-19, which is often associated with fever and upper-airway symptoms, individuals with severe COVID-19 often progress to an ARDS condition: hypoxaemic respiratory failure associated with neutrophilia and neutrophil infiltration in the lungs, thick mucus in bronchi, and bronchiectasis [<xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>]. Because lung neutrophilia in ARDS is generally known to involve high NET production [<xref rid="bib5" ref-type="bibr">5</xref>], we feel it is rational to hypothesize that NETs contribute to severe pathology in COVID-19. Indeed, lung neutrophilia and NET production have been shown to contribute to the development of ARDS in other severe viral respiratory infections, including H1N1 influenza [<xref rid="bib11" ref-type="bibr">11</xref>].<fig id="fig1"><label>Fig.&#xA0;1</label><caption><p>Model of how dornase alfa-sensitive neutrophil extracellular traps (NETs) from neutrophils may reinforce mucus accumulation, rigidity and airway occlusion in severe coronavirus disease 2019 (COVID-19). (a) Viral infection causes inflammation and respiratory distress (darkened lungs). Lung-infiltrating neutrophils produce NETs whose large quantities of chromosomal, extracellular DNA are susceptible to degradation by dornase alfa (recombinant human deoxyribonuclease I, right). (b) Close up view of alveoli. Without dornase alfa treatment (left), NETs reinforce the accumulation and rigidity of mucus that can increase lung injury and reduce oxygenation. Dornase alfa treatment (right) reduces NET-mediated reinforcement of mucus, making it less rigid (lighter yellow) and facilitating mucus clearance, so reducing lung injury and increasing gas exchange. (c) The rate at which recovery from severe COVID-19 occurs naturally (left, thin arrow) might be increased by dornase alfa treatment (right, thicker arrow). Figure&#xA0;was created with BioRender.</p></caption><alt-text id="alttext0010">Fig.&#xA0;1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p>
    <p id="p0025">We postulate that nebulized dornase alfa may effectively treat a deleterious effect of NETs in the airways and so promote recovery in individuals with COVID-19-related ARDS (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>). Dornase alfa can be easily administered to mechanically ventilated patients and is well tolerated in intensive care unit settings. Anecdotally, an individual with COVID-19 who had been intubated for 5 days was given 3 days of nebulized dornase alfa (2.5 mg twice daily) with continued standard intensive care unit care. Improvements in oxygenation and lung compliance were observed comparing before with after the 3-day period (changes: arterial oxygen partial pressure (PaO2)/fractional inspired oxygen (FiO2)&#xA0;=&#xA0;P/F, 212 to 305; FiO2, 65% to 40%; positive end-expiratory pressure (PEEP), 20 to 14). Four additional days were followed by extubation and six more days in hospital before the patient was considered recovered and discharged home. At this juncture of a rapidly evolving pandemic associated with high mortality in severely ill individuals and the concepts discussed above, we suggest the consideration of including inhaled dornase alfa in clinical trials for severe COVID-19 associated with ARDS.</p>
    <sec id="sec1">
      <title>Funding</title>
      <p id="p0030">AE and AGS were supported by the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100007165</institution-id><institution>University of Missouri</institution></institution-wrap></funding-source> Biomedical Innovation recruitment funds, and AGS was supported by <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>NIH</institution></institution-wrap></funding-source> grant R01GM103841.</p>
    </sec>
    <sec id="sec2">
      <title>Author contributions</title>
      <p id="p0035">AE contributed to conceptualization, investigation and writing the original draft; ZMH contributed to investigation, writing, review and editing; and HVH and AGS contributed to writing, review, editing and supervision.</p>
    </sec>
    <sec id="sec3">
      <title>Conflicts of interest</title>
      <p id="p0040">The authors declare no conflicts of interest and no relation with Genentech, Inc.</p>
    </sec>
  </body>
  <back>
    <ref-list id="cebib0010">
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal" id="sref1">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Dornase &#x3B1; for cystic fibrosis</article-title>
          <source>Cochrane Database Syst Rev</source>
          <volume>9</volume>
          <year>2018</year>
          <fpage>CD001127</fpage>
          <pub-id pub-id-type="pmid">30187450</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal" id="sref2">
          <person-group person-group-type="author">
            <name>
              <surname>Morris</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mullan</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Use of dornase &#x3B1; in the management of ARDS</article-title>
          <source>Anaesthesia</source>
          <volume>59</volume>
          <year>2004</year>
          <fpage>1249</fpage>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal" id="sref3">
          <person-group person-group-type="author">
            <name>
              <surname>Riethmueller</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Borth-Bruhns</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kumpf</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vonthein</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wiskirchen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children</article-title>
          <source>Pediatr Pulmonol</source>
          <volume>41</volume>
          <year>2006</year>
          <fpage>61</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">16265663</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal" id="sref4">
          <person-group person-group-type="author">
            <name>
              <surname>Pottecher</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Noll</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Borel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Audibert</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Gette</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase &#x3B1; to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients</article-title>
          <source>Trials</source>
          <volume>21</volume>
          <year>2020</year>
          <fpage>274</fpage>
          <pub-id pub-id-type="pmid">32183886</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal" id="sref5">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>O.Z.</given-names>
            </name>
            <name>
              <surname>Palaniyar</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>NET balancing: a problem in inflammatory lung diseases</article-title>
          <source>Front Immunol</source>
          <volume>4</volume>
          <year>2013</year>
          <fpage>1</fpage>
          <pub-id pub-id-type="pmid">23355837</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal" id="sref6">
          <person-group person-group-type="author">
            <name>
              <surname>Martinez-Aleman</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Campos-Garcia</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Palma-Nicolas</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Hernandez-Bello</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Sanchez-Gonzalez</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Understanding the entanglement: neutrophil extracellular traps (NETs) in cystic fibrosis</article-title>
          <source>Front Cell Infect Microbiol</source>
          <volume>7</volume>
          <year>2017</year>
          <fpage>104</fpage>
          <pub-id pub-id-type="pmid">28428948</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="book" id="sref7">
          <person-group person-group-type="author">
            <collab>World Health</collab>
          </person-group>
          <chapter-title>Organization report of the WHO&#x2014;China joint mission on coronavirus disease 2019 (COVID-19)</chapter-title>
          <year>2020</year>
          <publisher-name>WHO</publisher-name>
          <publisher-loc>Geneva</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal" id="sref8">
          <person-group person-group-type="author">
            <name>
              <surname>Ye</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review</article-title>
          <source>Eur Radiol</source>
          <year>2020</year>
          <comment>epub ahead of print. PubMed PMID: 32193638</comment>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal" id="sref9">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis</article-title>
          <source>Resp Res</source>
          <volume>21</volume>
          <issue>1</issue>
          <year>2020</year>
          <fpage>74</fpage>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal" id="sref10">
          <person-group person-group-type="author">
            <name>
              <surname>Barnes</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Adrover</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Baxter-Stoltzfus</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Borczuk</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cools-Lartigue</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Targeting potential drivers of COVID-19: neutrophil extracellular traps</article-title>
          <source>J&#xA0;Exp Med</source>
          <volume>217</volume>
          <issue>6</issue>
          <year>2020</year>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="journal" id="sref11">
          <person-group person-group-type="author">
            <name>
              <surname>Narasaraju</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Samy</surname>
              <given-names>R.P.</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Poh</surname>
              <given-names>W.P.</given-names>
            </name>
            <name>
              <surname>Liew</surname>
              <given-names>A.A.</given-names>
            </name>
          </person-group>
          <article-title>Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis</article-title>
          <source>Am J Pathol</source>
          <volume>179</volume>
          <year>2011</year>
          <fpage>199</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="pmid">21703402</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack id="ack0010">
      <title>Acknowledgements</title>
      <p>We thank William Boyan (Pulmonary Critical Care, Providence Medical Group, Olympia, Washington) and Eva Carmona, Patricio Escalante and Tobias Peikert (Pulmonary &amp; Critical Care, Mayo Clinic, Rochester, Minnesota) for helpful discussions.</p>
    </ack>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Trials</journal-id>
      <journal-id journal-id-type="iso-abbrev">Trials</journal-id>
      <journal-title-group>
        <journal-title>Trials</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1745-6215</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32560746</article-id>
      <article-id pub-id-type="pmc">7303591</article-id>
      <article-id pub-id-type="publisher-id">4488</article-id>
      <article-id pub-id-type="doi">10.1186/s13063-020-04488-8</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8395-6312</contrib-id>
          <name>
            <surname>Desilles</surname>
            <given-names>J. P.</given-names>
          </name>
          <address>
            <email>jpdesilles@for.paris</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gregoire</surname>
            <given-names>C.</given-names>
          </name>
          <address>
            <email>cgregoire@for.paris</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Le Cossec</surname>
            <given-names>C.</given-names>
          </name>
          <address>
            <email>clecossec@for.paris</email>
          </address>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lambert</surname>
            <given-names>J.</given-names>
          </name>
          <address>
            <email>jlambert@for.paris</email>
          </address>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mophawe</surname>
            <given-names>O.</given-names>
          </name>
          <address>
            <email>omophawe@for.paris</email>
          </address>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Losser</surname>
            <given-names>M. R.</given-names>
          </name>
          <address>
            <email>mr.losser@chru-nancy.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lambiotte</surname>
            <given-names>F.</given-names>
          </name>
          <address>
            <email>lambiotte-f@ch-valenciennes.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Le Tacon</surname>
            <given-names>S.</given-names>
          </name>
          <address>
            <email>s.le-tacon@chr-metz-thionville.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cantier</surname>
            <given-names>M.</given-names>
          </name>
          <address>
            <email>mcantier@for.paris</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Engrand</surname>
            <given-names>N.</given-names>
          </name>
          <address>
            <email>nengrand@for.paris</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Trouiller</surname>
            <given-names>P.</given-names>
          </name>
          <address>
            <email>ptrouiller@for.paris</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pottecher</surname>
            <given-names>J.</given-names>
          </name>
          <address>
            <email>julien.pottecher@chru-strasbourg.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff9">9</xref>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.419339.5</institution-id><institution>Biological Resource Center, Interventional Neuroradiology Department, </institution><institution>Rothschild Foundation Hospital, </institution></institution-wrap>Paris, France </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.5842.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 2558</institution-id><institution>Laboratory of Vascular Translational Science, U1148 INSERM, </institution><institution>Universit&#xE9; de Paris, </institution></institution-wrap>Paris, France </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Program in Cellular and Molecular Medicine, Boston Children&#x2019;s Hospital, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA 02115 USA </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.419339.5</institution-id><institution>Intensive Care Department, </institution><institution>Rothschild Foundation Hospital, </institution></institution-wrap>Paris, France </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.419339.5</institution-id><institution>Clinical Research Unit, </institution><institution>Rothschild Foundation Hospital, </institution></institution-wrap>Paris, France </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.410527.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1765 1301</institution-id><institution>CHRU Nancy, P&#xF4;le d&#x2019;Anesth&#xE9;sie-R&#xE9;animation, </institution></institution-wrap>29 Avenue de Lattre de Tassigny, 54000 Nancy, France </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.418063.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0594 4203</institution-id><institution>Service de R&#xE9;animation Polyvalente, </institution><institution>Centre Hospitalier de Valenciennes, </institution></institution-wrap>Avenue D&#xE9;sandrouin, 59322 Valenciennes, France </aff>
        <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.489915.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9617 2608</institution-id><institution>CHR Metz-Thionville-Site de Mercy, Service de R&#xE9;animation Polyvalente, </institution></institution-wrap>1 All&#xE9;e du Ch&#xE2;teau, 57350 Ars-Laquenexy, France </aff>
        <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.412201.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0593 6932</institution-id><institution>H&#xF4;pitaux Universitaires de Strasbourg, H&#xF4;pital de Hautepierre, Service d&#x2019;Anesth&#xE9;sie-R&#xE9;animation Chirurgicale, </institution></institution-wrap>1 Avenue Moli&#xE8;re, 67098 Strasbourg, France </aff>
        <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.11843.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 9291</institution-id><institution>Universit&#xE9; de Strasbourg, Facult&#xE9; de M&#xE9;decine, F&#xE9;d&#xE9;ration de M&#xE9;decine Translationnelle de Strasbourg (FMTS), EA3072, </institution></institution-wrap>Strasbourg, France </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>6</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>19</day>
        <month>6</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>21</volume>
      <elocation-id>548</elocation-id>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>5</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>6</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2020</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Objectives</title>
          <p id="Par1">Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for the treatment of cystic fibrosis, which cleaves extracellular DNA and may break up cell-free DNA, loosening sticky mucus in the distal airways and reducing NETs-induced toxicity on alveolar pneumocytes. The COVIDornase trial intends to define the impact of aerosolized intra-tracheal dornase alfa administration on the severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus thinner and looser, promoting improved clearance of secretions and reduce extracellular double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the lungs.</p>
        </sec>
        <sec>
          <title>Trial design</title>
          <p id="Par2">COVIDornase is a prospective, randomized, controlled, 2-arm (1:1 ratio), multicentric, open-label clinical trial.</p>
        </sec>
        <sec>
          <title>Participants</title>
          <p id="Par3">The study will recruit mechanically ventilated patients hospitalized in the intensive care unit (ICU) in the recruiting centres (at the time of writing: The Rothschild foundation hospital in Paris, the Strasbourg university hospitals, and Metz-Thionville hospital) who have been diagnosed with COVID-19 and meet ARDS criteria.</p>
        </sec>
        <sec>
          <title>Inclusion criteria</title>
          <p id="Par4">- Adult patient (age &#x2265; 18 years old);</p>
          <p id="Par5">- Hospitalized in ICU;</p>
          <p id="Par6">- With severe COVID-19 pneumonia and ARDS according to Berlin criteria (PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 300 and PEEP &gt; 5 cmH<sub>2</sub>O);</p>
          <p id="Par7">- Intubated for less than 8 days;</p>
          <p id="Par8">- With an anticipated duration of mechanical ventilation &gt; 48 hours;</p>
          <p id="Par9">- Carrier of an arterial catheter;</p>
          <p id="Par10">- For whom 4 PaO<sub>2</sub>/FiO<sub>2</sub> values over the preceding 24 hours are available;</p>
        </sec>
        <sec>
          <title>Non-inclusion criteria</title>
          <p id="Par11">- Known hypersensitivity to dornase alfa or any of its excipients;</p>
          <p id="Par12">- Pregnant or breastfeeding status;</p>
          <p id="Par13">- Patient under legal protection.</p>
        </sec>
        <sec>
          <title>Intervention and comparator</title>
          <p id="Par14"><bold>Intervention 1,</bold> Study group</p>
          <p id="Par15">Dornase alfa (Pulmozyme&#xAE;, Roche, Switzerland) will be administered by aerosol, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer (Aerogen Solo&#xAE;, Aerogen, Ireland). The remainder of the management will be performed in accordance with good clinical practice, including mechanical ventilation (protective ventilation, PEEP &gt; 5 cmH<sub>2</sub>O, tracheal balloon pressure check every 4 hours or automatic device, 30&#xB0; head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure &lt; 30 cmH<sub>2</sub>O), neuromuscular blockers if necessary, prone position if PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 150, early enteral nutrition, glycemic control and a sedation protocol based on the RASS score.</p>
          <p id="Par16"><bold>Intervention 2,</bold> Comparator</p>
          <p id="Par17">Patients will receive usual care in accordance with good practice (as detailed above), without aerosols.</p>
        </sec>
        <sec>
          <title>Main outcomes</title>
          <p id="Par18">The primary outcome is the occurrence of at least one grade improvement between D<sub>0</sub> (inclusion) and D<sub>7</sub> in the ARDS scale severity (Berlin criteria). For instance from &#x201C;severe&#x201D; to &#x201C;moderate&#x201D; or from &#x201C;moderate&#x201D; to &#x201C;mild&#x201D;.</p>
        </sec>
        <sec>
          <title>Randomisation</title>
          <p id="Par19">All consecutive patients meeting the inclusion criteria will be randomised 1:1 using an eCRF-based, computer-generated randomisation table, either to the dornase alfa arm or to the control arm. An interim analysis will be performed after inclusion of 20 patients. Inclusions may be stopped at the interim analysis per data safety and monitoring board (DSMB) advice, if statistical analyses conclude on the futility or efficacy of the intervention or by other DSMB decision.</p>
        </sec>
        <sec>
          <title>Blinding (masking)</title>
          <p id="Par20">The participants and caregivers will not be blinded to study group assignment. Those assessing the outcomes will be blinded to study group assignment.</p>
        </sec>
        <sec>
          <title>Numbers to be randomised (sample size)</title>
          <p id="Par21">Fifty patients will be randomized to each group, 100 patients in total.</p>
        </sec>
        <sec>
          <title>Trial Status</title>
          <p id="Par22">Protocol version number 2, April 29<sup>th</sup>, 2020. Recruitment is ongoing. The trial started recruitment on the 21<sup>st</sup> April 2020. We estimate recruitment will finish August 21<sup>st</sup> 2020.</p>
        </sec>
        <sec>
          <title>Trial registration</title>
          <p id="Par23">The trial was registered in ClinicalTrials.gov on 21 April 2020, updated on 8 May 2020. Trial registration number is <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04355364">NCT04355364</ext-link>.</p>
        </sec>
        <sec>
          <title>Full protocol</title>
          <p id="Par24">The full protocol is attached as an additional file, accessible from the Trials website (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated. This Letter serves as a summary of the key elements of the full protocol.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>COVID-19</kwd>
        <kwd>Randomised controlled trial</kwd>
        <kwd>Lung damage</kwd>
        <kwd>Neutrophil extracellular traps</kwd>
        <kwd>ARDS</kwd>
        <kwd>Dornase alfa</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <sec id="Sec1">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13063_2020_4488_MOESM1_ESM.pdf"><caption><p><bold>Additional file 1.</bold> Full Study Protocol.</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s13063-020-04488-8.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>Not applicable.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>JPD, CG, CLC and JP conceived the study, coordinated its design, drafted and wrote the manuscript. JPD, CG, CLC, JL, OM, MRL, FL, SLT, MC, NE, PT and JP read and were involved in critical appraisal and revision of the manuscript. CLC and JL provided statistical expertise. All authors approved the final manuscript prior to submission.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>Aerogen (Ireland) will provide nebulizers to the study centers. Roche (Switzerland) will provide dornase alfa to the study centers.</p>
      <p>Funders will have no role in the study&#x2019;s design, collection, management, analysis and interpretation of data, writing of the report and the decision to submit the report for publication conception or in the data analysis.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials</title>
      <p>Study documents will be de-identified, stored in each recruitment centre and kept for at least 15 years in a locked, secure office, according to French law. All personnel involved in data analysis will be masked. Only the principal investigators, the DSMB and the statisticians will have access to the final data set. The data sets used and analysed during the current study will be available from the corresponding author on reasonable request, after publication of the main core article.</p>
    </notes>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par25">The Comit&#xE9; de Protection des Personnes Ouest IV-Nantes approved the study on April 4<sup>th</sup>, 2020 (Reference: CPP 39/20_1, file number 20.4.01.46248). We therefore certify that the COVIDornase trial has received ethical approval from the appropriate ethical committee.</p>
      <p id="Par26">Inclusion will be feasible after patient approval, next of kin approval or emergency consent procedure (according to French law). Subsequent confirmation of consent will be obtained from the relatives and from the patient as soon as possible.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par27">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par28">The authors declare that they have no competing interests.</p>
    </notes>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Future Virol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Future Virol</journal-id>
      <journal-id journal-id-type="publisher-id">FVL</journal-id>
      <journal-title-group>
        <journal-title>Future Virology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1746-0794</issn>
      <issn pub-type="epub">1746-0808</issn>
      <publisher>
        <publisher-name>Future Medicine Ltd</publisher-name>
        <publisher-loc>London, UK</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">7543042</article-id>
      <article-id pub-id-type="doi">10.2217/fvl-2020-0119</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>In&#xA0;silico</italic> analysis of
protein/peptide-based inhalers against SARS-CoV-2</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6592-9812</contrib-id>
          <name>
            <surname>Salman</surname>
            <given-names>Saad</given-names>
          </name>
          <xref ref-type="corresp" rid="COR1">*</xref>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0413-0673</contrib-id>
          <name>
            <surname>Shah</surname>
            <given-names>Fahad Hassan</given-names>
          </name>
          <xref ref-type="aff" rid="AFF2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chaudhry</surname>
            <given-names>Maham</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tariq</surname>
            <given-names>Muniba</given-names>
          </name>
          <xref ref-type="aff" rid="AFF3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1491-3305</contrib-id>
          <name>
            <surname>Akbar</surname>
            <given-names>Muhammad Yasir</given-names>
          </name>
          <xref ref-type="aff" rid="AFF4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Adnan</surname>
            <given-names>Muhammad</given-names>
          </name>
          <xref ref-type="aff" rid="AFF1">
            <sup>1</sup>
          </xref>
        </contrib>
        <aff id="AFF1"><label>1</label><sup>1</sup>Department of Pharmacy, The University of Lahore,
Islamabad Campus, Islamabad, Federal&#xA0;44000, Pakistan</aff>
        <aff id="AFF2"><label>2</label><sup>2</sup>Centre of Biotechnology &amp; Microbiology, University
of Peshawar, Khyber Pakhtunkhwa, Pakistan</aff>
        <aff id="AFF3"><label>3</label><sup>3</sup>Diet &amp; Nutritional Sciences, The University of
Lahore, Islamabad Campus, Islamabad, Federal&#xA0;44000, Pakistan</aff>
        <aff id="AFF4"><label>4</label><sup>4</sup>Department of Bioinformatics, Quaid-e-Azam University,
Islamabad, Federal&#xA0;44000, Pakistan</aff>
      </contrib-group>
      <author-notes>
        <corresp id="COR1"><label>*</label>Author for correspondence: <email xlink:href="mailto:saad.salman@pharm.uol.edu.pk">saad.salman@pharm.uol.edu.pk</email></corresp>
      </author-notes>
      <pub-date publication-format="electronic" date-type="pub">
        <day>08</day>
        <month>10</month>
        <year>2020</year>
      </pub-date>
      <pub-date publication-format="print" date-type="pub">
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>08</day>
        <month>10</month>
        <year>2020</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <elocation-id>10.2217/fvl-2020-0119</elocation-id>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>4</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>9</month>
          <year>2020</year>
        </date>
        <date date-type="online">
          <day>08</day>
          <month>10</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2020 Future Medicine Ltd</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license license-type="open-access">
          <license-p>This work is licensed under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/"> Creative
Commons Attribution 4.0 License</ext-link></license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:title="pdf" xlink:href="fvl-2020-0119.pdf"/>
      <abstract>
        <p><bold>Aim:</bold> Peptide/protein-based inhalers are excessively used to
treat respiratory disorders. The molecular docking was performed for these
inhalers including human neutralizing S230 light chain-antibody (monoclonal
antibodies [mAbs]), alpha-1-antitrypsin (AAT), short-palate-lung and
nasal-epithelial clone-1-derived peptides (SPLUNC1)&#xA0;and dornase-alfa (DA)
against spike glycoprotein of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) to assess their inhibitory activity. <bold>Materials &amp;
methods:</bold> HawkDock was used to dock these biologics against SARS-CoV-2
spike-glycoprotein. <bold>Results:</bold> Results showed that DA, AAT and
mAb&#xA0;were quite active against spike glycoprotein with a binding free
energy of -26.35 and -22.94 kcal/mol. <bold>Conclusion:</bold> mAB and
AAT combined with DA can be used in the treatment of coronavirus disease of 2019
as a potential anti-SARS-CoV-2 agent.</p>
      </abstract>
      <abstract abstract-type="graphical">
        <title>Graphical abstract</title>
        <p>
          <inline-graphic xlink:href="fvl-2020-0119GA.jpg"/>
        </p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords:&#x2002;</title>
        <kwd>COVID-19</kwd>
        <kwd>dornase-alfa</kwd>
        <kwd>inhalers</kwd>
        <kwd>monoclonal antibody</kwd>
        <kwd>short-palate-lung and nasal-epithelial clone-1-derived peptides</kwd>
      </kwd-group>
      <counts>
        <page-count count="8"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>Coronavirus disease of 2019 (COVID-19) is an acute respiratory disorder that is similar
to severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS)
[<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>].
The origin and evolution of COVID-19 are of immense importance for the drug discovery
and prevention of the epidemic. There are 28&#xA0;proteins that encode by SARS-CoV-2,
out of which, 16 are for replication, four are structural proteins responsible for viral
packaging and pathogenesis while the remaining are the accessory proteins. The
structural proteins are spike, membrane, nucleocapsid&#xA0;and envelope protein [<xref rid="B3" ref-type="bibr">3</xref>]. SARS-CoV-2 exploits crown-shaped spike
glycoprotein to interact with the ACE-2 receptor to gain entry inside the host cell. The
virus then reproduces to form abundant copies which on maturation burst open the
infected cell and releases viral progenies which in turn attack other surrounding cells
ultimately reaching the brain. SARS COV-2 spike glycoprotein consists of two subunits
that are the S1 and S2. The S1 subunit consists of receptor binding domain
(RBD)&#xA0;that binds with the host cell receptor to ACE-2. The second subunit is S2
which arbitrate fusion between viral and plasma membrane of host. It contains
protrusions that allow the virus to bind a receptor on the host cell.</p>
    <p>SARS-CoV-2 is transmitted by droplets and contact between a healthy individual and an
infected person [<xref rid="B4" ref-type="bibr">4</xref>]. The spike glycoprotein is a
142.3&#xA0;kDa protein present on the surface of the virion that facilitates
interaction by employing their 319&#x2013;591 number amino acid residues to interact
with the ACE-2 receptor. After attachment, the infection develops, and the human
body&#x2019;s immediate response is to produce an immune response against the infection
and also to modulate the mucous secretion in the surrounding epithelial cells to deter
the attachment of other freshly produced SARS-CoV-2 progenies. Both SARS-CoV-2 and mucus
aggravate disease progression by contributing to the production of a cough. It is
imperative to develop aerosols that could help in the prevention and control of the
disease.</p>
    <p>Aerosols composed of monoclonal antibodies (mAbs) are commonly used for respiratory
disorders, such as asthma [<xref rid="B5" ref-type="bibr">5</xref>]. mAbs are composed
of transgenic animals or phage display technology, which benefit in several ways as to
curtail immunogenicity, increase effector function and delay their serum half-life
[<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>].
Cystic fibrosis (CF) airways manifest increased neutrophil elastase activity, which can
likely destroy the lung, and also cleave and activate ENaC intensifying mucus
dehydration and expediating&#xA0;mucociliary clearance. Alpha-1-antitrypsin (AAT) is
an endogenous neutrophil elastase (NE) inhibitor that, by blocking NE, can improve
pulmonary function [<xref rid="B8" ref-type="bibr">8</xref>]. The drug dornase-alfa (DA)
for CF reduces DNA length, hydrolyzes DNA polymer and makes a good mucolytic agent.
Making DA a drug of choice for CF&#xA0;that is well tolerated, helps in the
amelioration of lung function and reduces sputum viscosity [<xref rid="B7" ref-type="bibr">7</xref>]. So, short-palate lung and nasal-epithelial clone-1-derived
peptides (SPLUNC1) could be utilized in CF for the inhibition of ENaC [<xref rid="B8" ref-type="bibr">8</xref>] and regulation of Th2 inflammation [<xref rid="B9" ref-type="bibr">9</xref>]. SPX-101 is novel protease-resistant
peptide&#xA0;that inhibits&#xA0;ENaC, regulates mucosal secretions, and ameliorates
rehydration [<xref rid="B10" ref-type="bibr">10</xref>]. However, the use of
protein/peptide-based inhalers does have toxicogenic and immunogenic responses in
the body [<xref rid="B11" ref-type="bibr">11</xref>]. The administration of these agents
could be debilitating, if the dose is not controlled or with their chronic use [<xref rid="B12" ref-type="bibr">12</xref>]. Some of these protein/peptide-based
inhalers can precipitate pulmonary toxicity, cytokine-release syndrome, serum sickness,
tumor lysis syndrome, toxic pulmonary-amyloid aggregates, antibodies generation and
acute anaphylaxis, anaphylactoid reactions and in rare cases progressive multifocal
leukoencephalopathy [<xref rid="B13" ref-type="bibr">13&#x2013;15</xref>].
Although the safety and efficacy of DA [<xref rid="B16" ref-type="bibr">16</xref>],
SPLUNC1 [<xref rid="B17" ref-type="bibr">17</xref>], AAT [<xref rid="B18" ref-type="bibr">18</xref>] and mAb&#xA0;[<xref rid="B19" ref-type="bibr">19</xref>] are
well established, still the detailed studies regarding their toxic and antigenic
profiles remain elusive. These four inhalers containing mAb, DA, AAT and SPLUNC1 were
tested through molecular docking against SARS-CoV-2 spike glycoprotein, their toxicity,
antigenicity, water solubility and resistance to gastric enzymatic activity
were&#xA0;evaluated.</p>
    <sec sec-type="materials|methods" id="S0001">
      <title>Materials &amp; methods</title>
      <sec id="S0002">
        <title>Molecular docking</title>
        <p>The protein ligands alpha-1-antitrypsin (PDB ID:1ATU), DA (human recombinant
DNAse-I (PDB ID: 4AWN), angiotensin-converting enzyme-2 (ACE-2) (PDB ID:1R4L),
human palate, lung and nasal epithelium clone protein (4N4X) and human
neutralizing S230 light chain antibody (6NB6) and COVID spike protein (PDB
ID:6VSB) was obtained from Protein Data Bank [<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>]. These protein
structures were further refined with Modrefiner [<xref rid="B22" ref-type="bibr">22</xref>] and HawkDOCK [<xref rid="B23" ref-type="bibr">23</xref>] was
then used for docking studies coupled with Discovery Studio 4.0 for the
visualization of docked complexes.</p>
      </sec>
      <sec id="S0003">
        <title>Toxicity assessment</title>
        <p>To assess the <italic>in&#xA0;silico</italic> toxicity analysis of the
protein/peptide-based inhalers, the UniProt database was used for the
protein/peptide sequences. The toxicity was analyzed by utilizing
ToxinPred [<xref rid="B24" ref-type="bibr">24</xref>] while the prediction of
allergenicity was calculated by utilizing AllerTop [<xref rid="B24" ref-type="bibr">24</xref>]. Also, these samples were subjected to
<italic>in&#xA0;silico</italic> prediction of gastrointestinal digestion
resistance by utilizing PeptideCutter [<xref rid="B25" ref-type="bibr">25</xref>]. The water solubility of these inhalers was checked through peptide
property calculator, in order to establish its water solubility. The proposed
mechanism of DA, SPLUNC1 and mAb&#xA0;in asthma and CF&#xA0;are given in
<xref ref-type="fig" rid="F1">Figure&#xA0;1</xref>.</p>
        <fig id="F1" orientation="portrait" position="float">
          <label>Figure 1.<x xml:space="preserve"> </x></label>
          <caption>
            <title>Pathophysiology of asthma and cystic fibrosis.</title>
            <p><bold>(A)</bold>&#xA0;SPLUNC1 is a protein that consists of the ENaC
inhibitory domain-S18 region. SPLUNC1-derived peptide, which serves in
CF airways as an ENaC inhibitor, help in the regulation of lung
function.&#xA0;<bold>(B)</bold> CF has high levels of DNA and
actin in the lung lumen, which are discharged by necrotic neutrophils.
Dnase1 cleaves extracellular DNA in the lung lumen reducing DNA length
and sputum viscosity is decreased. mAbs get attached to a wide variety
of proteins with high affinity and specificity. In asthma, they bind to
IgE and FecRI resulting in reduced exacerbations. I&#x2013;III: these
three agents fight against SARS-CoV-2 by either binding (I, II) or
blocking (III) its passage to reach out to the
ACE-2&#xA0;receptor.</p>
            <p>CF: Cystic fibrosis; mAb: Monoclonal antibody.</p>
          </caption>
          <graphic xlink:href="figure1"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="results" id="S0004">
      <title>Results</title>
      <sec id="S0005">
        <title>Docking analysis</title>
        <p>Protein&#x2013;protein interaction (PPI) of COVID-19 spike glycoprotein with
alpha-1-antitrypsin (1atu), dornase-alfa (4AWN), angiotensin-converting enzyme-2
(ACE-2) (PDB ID:1R4L), human palate, lung and nasal epithelium clone protein
(SPLUNC1) (4n4x) and human neutralizing the S230 light chain antibody was
evaluated through HawkDock. The algorithm of HawkDock is composed of ATTRACT and
HawkRank, which allows flexible protein&#x2013;protein docking combined with
MM/GBSA free energy decomposition of key protein residues involved in the
interaction [<xref rid="B23" ref-type="bibr">23</xref>]. Prior to PPI, we
selected chain-A of SARS-CoV-2 receptor binding domain as the rest of the chain
had identical sequence as compared with the rest of the protein chains (B, C).
Our strategy was to dock these selected proteins in the 319th to 591st number of
amino acids within the chain-A of SARS-CoV-2 spike glycoprotein. These amino
acids interact with the human ACE-2 receptor which facilitates their entry
inside the brain, hence inflicting neuronal and neurovascular disruption in
affected patients [<xref rid="B26" ref-type="bibr">26</xref>]. After successful
docking process execution, the top 10&#xA0;models were downloaded and analyzed
for amino acid interaction between SARS-CoV-2 spike receptor and protein ligands
and for the type of bond formed by each other. The hydrogen bonds in PPI holds
the participating amino acid residues of one protein in bond formation with the
other protein more vigorous than van der Waals forces [<xref rid="B27" ref-type="bibr">27</xref>]. By analyzing individual docked models, it was observed
that, human neutralizing S230 light chain amino acid residues; serine 24 and
serine 30 established H-bonds with the arginine 365, phenylalanine 388, tyrosine
267 of SARS-CoV-2 spike protein whereas valine 1 of S230 formed a H-bond with
the tyrosine 312 having -22.94 kcal/mol of binding free energy
(<named-content content-type="suppl">Supplementary Figure
1</named-content>). On the other hand, ACE-2 formed van der Waal interaction
with SARS-CoV-2 spike proteins with the binding free energy lower than mAb S230
as summarized in <xref rid="T1" ref-type="table">Table&#xA0;1</xref>. DA
protein created H-bond with leucine 390, alanine 313 and valine 266 with the
binding energy of -26.35 kcal/mol (<named-content content-type="suppl">Supplementary Figure 2</named-content>) whereas alpha 1 antitrypsin protein
residue valine 107 created H-bond with arginine 271 (-27.6 kcal/mol
binding free energy) of SARS-CoV-2 spike protein (<named-content content-type="suppl">Supplementary Figure 3</named-content>) while both MBP-
and S-18 peptide of human palate, lung and nasal epithelium clone protein
(SPLUNC1) established only van der Waals interaction with the receptor protein
having free energy of -21.8 and -40.34 kcal/mol (<named-content content-type="suppl">Supplementary Figures 4 &amp; 5</named-content>).
The results are summarized in <xref rid="T1" ref-type="table">Table&#xA0;1</xref>.</p>
        <table-wrap id="T1" orientation="portrait" position="float">
          <label>Table 1.<x xml:space="preserve"> </x></label>
          <caption>
            <title>Summary of protein&#x2013;protein interaction results obtained
from HawkDock.</title>
          </caption>
          <!--OASIS TABLE HERE-->
          <table frame="hsides" rules="groups">
            <colgroup>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
            </colgroup>
            <thead valign="top">
              <tr>
                <th align="left">Ligand (PDB
ID)</th>
                <th align="left">Docked ligand-receptor
(6VSB)</th>
                <th align="left">Model, docking
score</th>
                <th align="left">Residues involved in
H-Bonding (black) and van der Waal interaction
(red)</th>
                <th align="left">BFE,
kcal/mol</th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td align="left">6NB6</td>
                <td align="left">
                  <inline-graphic xlink:href="fvl-2020-0119T1a.gif"/>
                </td>
                <td align="left">Model 10,
-4086.50</td>
                <td align="left">VALB1:TYRA312, SERB24:
PHEA388, SERB30: ARGA365-TYR267</td>
                <td align="left">-22.94</td>
              </tr>
              <tr>
                <td align="left">4AWN</td>
                <td align="left">
                  <inline-graphic xlink:href="fvl-2020-0119T1b.gif"/>
                </td>
                <td align="left">Model 01,
-4132.90</td>
                <td align="left">TRPB269: VALA266,
LYSB272: ALAA313, HISB392: LEUA390</td>
                <td align="left">-26.35</td>
              </tr>
              <tr>
                <td align="left">1ATU</td>
                <td align="left">
                  <inline-graphic xlink:href="fvl-2020-0119T1c.gif"/>
                </td>
                <td align="left">Model 09,
-4547.20</td>
                <td align="left">VALB107:
ARGA271</td>
                <td align="left">-27.6</td>
              </tr>
              <tr>
                <td align="left">4N4X</td>
                <td align="left">
                  <inline-graphic xlink:href="fvl-2020-0119T1d.gif"/>
                </td>
                <td align="left">Model 01,
4721.21</td>
                <td align="left">VALB454: ASNA361,
ARGB455:HIEA392, ASPB456: TYRA360, LYSB457: LEUA363,
GLNB458: ALAA393 GLYB466</td>
                <td align="left">-21.8</td>
              </tr>
              <tr>
                <td align="left">1R4L</td>
                <td align="left">
                  <inline-graphic xlink:href="fvl-2020-0119T1e.gif"/>
                </td>
                <td align="left">Model-10,</td>
                <td align="left">VAL-B346: LEU-A367,
THRB-316: TYRA-360, METB-314: TYRA-378, VALB-280: PROA-318,
SERB-494: VAL-A321GLNB-287: ARGA-500, ALA-B283:VALA-527,
LYSB-345: LYSA-573</td>
                <td align="left">-22.54</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>6NB6, chain L: Human neutralizing S230 light chain; 4AWN:
Dornase-alfa; 1ATU: Alpha-1-antitrypsin 4N4X-MBP-fused human
SPLUNC1; 6VSB, CHAIN A: COVID-19 spike glycoprotein; 1R4L: Inhibitor
bound human angiotensin-converting enzyme-related carboxypeptidase
(ACE-2). Residues involved in H-bonds (yellow) and VDW (red) ligand
B: receptor A, binding free. A separate docking study was conducted
for specific-S18 of SPLUNC1 peptide chain demonstrated a van der
Waals interaction with 6VSB and a free binding energy of -40.34
(kcal/mol) (<named-content content-type="suppl">Supplementary
Figure 5</named-content>).</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="S0006">
        <title>Results of toxicity assessment</title>
        <p>None of proteins/peptides: 6NB6, 4AWN, 1ATU, 4N4X and 1R4L demonstrate any
kind of toxicity or allergic response <italic>in&#xA0;silico</italic>. Only
SPLUNC1 demonstrated a 33.3% allergenic response in the
<italic>in&#xA0;silico</italic> model. Apart from the specific S18 of
SPLUNC1 peptide chain, they were nontoxic and nonallergenic. (<xref rid="T2" ref-type="table">Table&#xA0;2</xref>) None of the proteins
demonstrated resistance to the digestive enzymes. The purpose of conducting the
resistance to digestive enzymes test was to check the fate of these inhalers as
ultimately, they reach to the stomach and may cause adverse drug reactions.
These inhalers were checked against the enzymes, such as trypsin, pepsin (pH
&gt;&#xA0;2) and chymotrypsin. These inhalers are not able to protect
themselves from these digestive enzymes, and are broken down in the stomach, and
so cannot illicit unwanted physiological effects. The poor solubility of these
inhalers may be due to the fact that all of them are protein/peptides and
are hydrophobic in nature. The greater the aqueous solubility of these drugs,
the&#xA0;greater will be the chance for these inhalers to illicit a response
in the systemic circulation [<xref rid="B28" ref-type="bibr">28</xref>].</p>
        <table-wrap id="T2" orientation="portrait" position="float">
          <label>Table 2.<x xml:space="preserve"> </x></label>
          <caption>
            <title>Results of toxicity, allergenicity, digestion resistance and
water solubility of protein/peptide-based
inhalers.</title>
          </caption>
          <!--OASIS TABLE HERE-->
          <table frame="hsides" rules="groups">
            <colgroup>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
            </colgroup>
            <thead valign="top">
              <tr>
                <th align="left">Ligand (PDB
ID)</th>
                <th align="left">Toxicity</th>
                <th align="left">Allergenicity</th>
                <th align="left">Digestion
resistance</th>
                <th align="left">Water
solubility</th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td align="left">6NB6</td>
                <td align="left">Nontoxin</td>
                <td align="left">Nonallergen</td>
                <td align="left">No</td>
                <td align="left">Poor</td>
              </tr>
              <tr>
                <td align="left">4AWN</td>
                <td align="left">Nontoxin</td>
                <td align="left">Nonallergen</td>
                <td align="left">No</td>
                <td align="left">Poor</td>
              </tr>
              <tr>
                <td align="left">1ATU</td>
                <td align="left">Nontoxin</td>
                <td align="left">Nonallergen</td>
                <td align="left">No</td>
                <td align="left">Poor</td>
              </tr>
              <tr>
                <td align="left">4N4X</td>
                <td align="left">Nontoxin</td>
                <td align="left">33.3%</td>
                <td align="left">No</td>
                <td align="left">Poor</td>
              </tr>
              <tr>
                <td align="left">4NAX-S18</td>
                <td align="left">Nontoxin</td>
                <td align="left">Nonallergen</td>
                <td align="left">No</td>
                <td align="left">Poor</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>6NB6, chain L: Human neutralizing S230 light chain; 4AWN:
Dornase-alfa; 1ATU: Alpha-1-antitrypsin 4N4X-MBP-fused human
SPLUNC1; 4NAX-S18: Specific S18 of SPLUNC1 peptide chain.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
    </sec>
    <sec sec-type="discussion" id="S0007">
      <title>Discussion</title>
      <p>SARS-CoV-2 spike glycoprotein is of great concern within the scientist community.
These proteins can only reproduce by entering the cells. Blocking such entry might
be of great interest in terms of treatment and that could be a way of preventing
SARS-CoV-2 infection and flattening the disease curve [<xref rid="B4" ref-type="bibr">4</xref>]. We attempted to address this issue by analyzing a variety of
protein/peptide-based inhalers/antimucolytic agents and previously
utilized mAb&#xA0;(used in asthma) to observe their possible interaction with the
SARS-CoV-2 spike protein. Both mAb&#xA0;and DA established H-bonds with spike
protein employed by SARS-CoV-2 for attachment. However, in comparison with DA, the
mAb&#xA0;and AAT showed considerable H-interaction with the SARS-CoV-2 spike
protein. CF and chronic obstructive pulmonary disease (COPD) have high levels of DNA
and actin in the lung lumen, which are discharged by necrotic neutrophils. The DNA
population and actin alter mucus rheology as well as increase mucociliary clearance.
Another way to boost mucociliary clearance in CF is to decrease mucus viscosity by
cleaving extracellular DNA in infectious lungs. DA is a recombinant version of human
DNase-1-protein which is used as a therapeutic moiety for CF [<xref rid="B7" ref-type="bibr">7</xref>]. Dnase1 cleaves extracellular DNA in the lung lumen, which
results in reduced DNA length/concentration and decreased sputum viscosity
[<xref rid="B6" ref-type="bibr">6</xref>]. This agent can also help in the
treatment of COVID-19. SPLUNC1, on the other hand, does not demonstrate good
interaction with the spike protein but does inhibit ENaC by inducing endocytosis
incongruous to traditional ion channel antagonists which the block ENaC&#x2019;s
pore [<xref rid="B8" ref-type="bibr">8</xref>]. Regulation of ENaC fails because of
SPLUNC1 in the CF lung, so, SPLUNC1-derived peptide acts in CF airways as an ENaC
inhibitor. This regulates CF airway surface liquid hydration, boost mucociliary
clearance and decrease infection, and inflammation [<xref rid="B6" ref-type="bibr">6</xref>]. These peptides are heat stable and with maximum binding efficiency
to accomplish a greater contact area with their target proteins. S18-derived
peptides do not readily cross the respiratory epithelium. They do not reach the
kidney, where they might cause hyperkalemia because S18-derived peptides are
protease-resistant as seen with small-molecule ENaC antagonists like amiloride.
Chronic inhalation therapy results in local immunogenicity and irritation from the
peptides involved, but it has been well established that SPLUNC1-derived peptides
did not precipitate immunogenicity [<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B8" ref-type="bibr">8</xref>]. Our study highlights the toxic and antigenic
profiles of the corresponding inhalers. Although the safety and efficacy of these
inhalers, such as DA, SPLUNC1, AAT and mAbs were established already [<xref rid="B16" ref-type="bibr">16&#x2013;19</xref>], we report the
<italic>in&#xA0;silico</italic> antigenicity of SPLUNC1 protein while bearing
in mind the potential side effects of mAbs [<xref rid="B13" ref-type="bibr">13</xref>]. Therefore, they could be utilized in the COVID-19 therapy and as an
adjuvant.</p>
      <p>Antibodies with therapeutic and diagnostic potential for SARS and MERS have already
been identified [<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B26" ref-type="bibr">26</xref>]. The preparation of particular variants of antibodies that
attach to SARS and MERS viruses are patented in 61 out of 99 registered agents. In
42 patents the S-protein in the viral infection exhibits an immune response. The
scrutiny of patents associated with the establishment of therapeutic antibodies for
SARS has been provided by Liu <italic>et al.</italic> [<xref rid="B29" ref-type="bibr">29</xref>]. These antibodies are 90% in opposition to S
proteins along its RBD. Moreover, compared with chemical drugs, mAbs bind to
multiple places on viral surfaces. This gives them an edge over chemical drugs.
mAbs&#xA0;become&#xA0;attached to a wide variety of proteins with high affinity
and specificity. After breakdown, the products are amino acids, so the resultant
compounds are not toxic [<xref rid="B6" ref-type="bibr">6</xref>]. An exciting
property of the mAbs is that they cling to their physical and immunological
properties after the aerosolization, which implies that it is only a matter of time
before mAb&#xA0;inhalation is exploited therapeutically. mAb&#xA0;and DA might
synergistically clear the mucus, alleviate coughing and modulate the immune response
toward the virion of the spike glycoprotein eventually disrupting the viral
attachment. These inhalers could be used in in low-income countries where people
cannot afford convalescent plasma therapy and where there is a shortage of
inhalers/nebulizers.</p>
      <p>On 24&#xA0;March 2020, different pharmacists across the USA reported a shortage of
metered-dose inhalers [<xref rid="B30" ref-type="bibr">30</xref>]. Unfortunately,
despite the demand, the production of these inhalers has not kept pace. The problem
was further aggravated by people stocking up on inhalers due to fear of the
pandemic. However, despite their usefulness, these inhalers&#xA0;are not commonly
available in pharmacies due to shortage of supplies. Pharmaceutical companies and
health regulatory authorities in all the countries should ensure a proper supply of
these inhalers.</p>
    </sec>
    <sec sec-type="conclusions" id="S0008">
      <title>Conclusion</title>
      <p>Because of the apparent devastating situation caused by COVID-19, computational
studies can help in a quick drug repurposing analysis. mAb&#xA0;and DA
demonstrated efficient binding with the spike protein of SARS-CoV-2. The
protein/peptide-based inhalers are valuable assets due to their prolonged
action, higher potency, lower systematic availability and minimum toxicity.
Therapeutics for COVID-19 are in the infancy stage and no US&#xA0;FDA approved
vaccine is available. During the pandemic, the use of protein/peptide-based
inhalers along with other vaccines for SARS and MERS could mitigate the disease and
serve as both therapeutic and prevention.</p>
    </sec>
    <sec id="S0009">
      <title>Future perspective&#xA0;&amp; recommendations</title>
      <p>The general instructions for the use of these protein/peptide-based inhalers
are:<list list-type="bullet"><list-item><p>Follow all the manual instructions that are given by the manufacturers
regarding the use and cleaning of the inhalers, compressors and
nebulizers.</p></list-item><list-item><p>These inhalers are usually present in solution form in
plastic/glass ampoules.</p></list-item><list-item><p>Air compressor is connected to a Jet nebulizer or eRapid&#x2122;
nebulizer system to convert the drug (Pulmozyme<sup>&#xAE;</sup>) into
minutely small particles [<xref rid="B31" ref-type="bibr">31</xref>].</p></list-item><list-item><p>The patients should breathe in the spray through a mouthpiece for about
10&#x2013;15&#xA0;min or until all the nebulizer cup is emptied.</p></list-item><list-item><p>PARI BABY&#x2122; nebulizer must be used if the patient is unable to
inhale or exhale.</p></list-item><list-item><p>Never utilize a discolored or cloudy inhalation solution.</p></list-item><list-item><p>Use it every day till your condition is ameliorated upon the direction of
the physician.</p></list-item><list-item><p>The frequency/dose of the drug should be calculated by the
pharmacist on an individual basis according to the strength of the drug,
severity of the symptoms, disease progression and body mass index.</p></list-item><list-item><p>Precautions should be taken to avoid drug&#x2013;drug and
drug&#x2013;food interactions.</p></list-item><list-item><p>If you forget to take the medicine, do so when you remember, unless you
are near the time of&#xA0;your following dose. In this case, do not
take the dose you have missed, but return to the original schedule.
Never double the doses.</p></list-item><list-item><p>Administer one drug at a time and do not mix it with any other agents
[<xref rid="B31" ref-type="bibr">31</xref>].</p></list-item><list-item><p>The prescribers are advised not to switch between the inhaler types
during the treatment unless otherwise required.</p></list-item></list></p>
      <p>During the pandemic, certain areas of the world are experiencing shortages of the
inhalers but it is not because of production problems. The spike in demand is due to
patient overflow and the use of inhalers for respiratory difficulties experienced by
the suspected and confirmed cases of the COVID-19. It is also due to the panic among
the people and pharmacists who are ordering inhalers which are ultimately not needed
in such high quantities. Other reasons according to the FDA are regulatory and
logistical challenges in different countries. The manufacturers are not given
incentives to produce economical inhalers [<xref rid="B32" ref-type="bibr">32</xref>]. This report provided some solutions to this issue including:<list list-type="bullet"><list-item><p>Contracts with private companies to ensure a reliable supply of the
inhalers.</p></list-item><list-item><p>Incentives should be given to the manufacturers who provide a sustainable
supply of good quality inhalers.</p></list-item><list-item><p>Public sessions and seminars should be held to promote awareness of the
impact of drug shortage on patients.</p></list-item></list></p>
      <p>Different hospitals are moving away from the nebulizer use in order to avoid the
spread of SARS-CoV2. So, the doctors are suggesting using these inhalers at home
[<xref rid="B30" ref-type="bibr">30</xref>]. Virtual screening of the inhalers
should be subjected to clinical trials before the issuance of the necessary medical
recommendations. The <italic>in silico</italic> studies cannot completely replace
the experimental studies, so we do not favor using these
protein/peptide-based inhalers while first-line therapy options are
available, nor do we advise readers to do so. But given the shortage of albuterol
and other inhalers according to the&#xA0;FDA, the use of these peptide-based
inhalers could be appropriate in the future.</p>
      <boxed-text id="BB1" position="float" orientation="portrait">
        <caption>
          <title>Summary points</title>
        </caption>
        <list list-type="bullet">
          <list-item>
            <p>Molecular docking analysis of protein/peptide-based inhalers
revealed that the S230 light chain antibody and dornase-alfa
demonstrated a strong affinity for SARS-CoV-2 spike protein.</p>
          </list-item>
          <list-item>
            <p>The binding free energy of the S230 light chain antibody and dornase-alfa
were -22.94 and -26.35 kcal/mol indicating highly stable bonding
with the spike receptor.</p>
          </list-item>
          <list-item>
            <p>Toxicity assessment of these inhalers suggest that they can be used as
anti-spike attachment agents, except for SPLUNC1, which showed a
33.3% allergic reaction <italic>in silico</italic>.</p>
          </list-item>
          <list-item>
            <p>S230 light chain antibody, dornase-alfa and short-palate lung and
nasal-epithelial clone-1-derived peptides are capable of impeding virus
interaction with the human host cell.</p>
          </list-item>
        </list>
      </boxed-text>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data">
        <media xlink:href="fvl-2020-0119.s1.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <title>Supplementary data</title>
      <p>To view the supplementary data that accompany this paper please visit the journal
website at: <ext-link ext-link-type="uri" xlink:href="http://www.futuremedicine.com/doi/suppl/10.2217/fvl-2020-0119">www.futuremedicine.com/doi/suppl/10.2217/fvl-2020-0119</ext-link></p>
    </ack>
    <ack>
      <title>Author contributions</title>
      <p>All authors equally contributed for this study.</p>
    </ack>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors&#xA0;thanked Caleac for proofreading and editing the research design of
this article.</p>
    </ack>
    <ack>
      <title>Financial &amp; competing interests disclosure</title>
      <p>The authors have no relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript. This includes employment,
consultancies, honoraria, stock ownership or options, expert testimony, grants or
patents received or pending, or royalties.</p>
      <p>No writing assistance was utilized in the production of this manuscript.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Lane</surname><given-names>HC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Redfield</surname><given-names>RR</given-names></name></person-group>
<article-title>Covid-19 &#x2013; navigating the uncharted</article-title>.
<source>N. Engl. J. Med.</source>
<volume>382</volume>(<issue>13</issue>),
<fpage>1268</fpage>&#x2013;<lpage>1269</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">32109011</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salman</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Shah</surname><given-names>FH</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Idrees</surname><given-names>J</given-names></name></person-group>
<etal/>
<article-title>Virtual screening of immunomodulatory medicinal compounds as
promising anti-SARS-COV-2 inhibitors</article-title>. <source>Future
Virol.</source>
<volume>15</volume>(<issue>5</issue>),
<fpage>267</fpage>&#x2013;<lpage>275</lpage>
(<year>2020</year>).</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Guo</surname><given-names>D</given-names></name></person-group>
<article-title>Emerging coronaviruses: genome structure, replication, and
pathogenesis</article-title>. <source>J. Med. Virol.</source>
<volume>92</volume>(<issue>4</issue>),
<fpage>418</fpage>&#x2013;<lpage>423</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">31967327</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Du</surname><given-names>R</given-names></name></person-group>
<etal/>
<article-title>Clinical course and risk factors for mortality of adult
inpatients with COVID-19 in Wuhan, China: a retrospective cohort
study</article-title>. <source>Lancet</source>
<volume>395</volume>(<issue>10229</issue>),
<fpage>1054</fpage>&#x2013;<lpage>1062</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roback</surname><given-names>JD</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Guarner</surname><given-names>J</given-names></name></person-group>
<article-title>Convalescent plasma to treat COVID-19: possibilities and
challenges</article-title>. <source>JAMA</source>
<volume>323</volume>(<issue>16</issue>),
<fpage>1561</fpage>&#x2013;<lpage>1562</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">32219429</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fellner</surname><given-names>RC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Terryah</surname><given-names>ST</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tarran</surname><given-names>R</given-names></name></person-group>
<article-title>Inhaled protein/peptide-based therapies for
respiratory disease</article-title>. <source>Mol. Cell. Pediatr.</source>
<volume>3</volume>(<issue>1</issue>), <fpage>16</fpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">27098663</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Montgomery</surname><given-names>M</given-names></name></person-group>
<article-title>Dornase alfa for cystic fibrosis</article-title>.
<source>Cochrane Database Syst. Rev.</source>
<volume>9</volume>(<issue>9</issue>), <fpage>CD001127</fpage>
(<year>2018</year>).<pub-id pub-id-type="pmid">30187450</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Webster</surname><given-names>MJ</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Reidel</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tan</surname><given-names>CD</given-names></name></person-group>
<etal/>
<article-title>SPLUNC1 degradation by the cystic fibrosis mucosal environment
drives airway surface liquid dehydration</article-title>. <source>Eur.
Respir. J.</source>
<volume>52</volume>(<issue>4</issue>), <fpage>1800668</fpage>
(<year>2018</year>).<pub-id pub-id-type="pmid">30190268</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tarran</surname><given-names>R</given-names></name></person-group>
<article-title>Lung epithelial derived SPLUNC1 regulates Th2 inflammation in
allergic asthma</article-title>. <source>J. Allergy Clin. Immunol.</source>
<volume>141</volume>(<issue>Suppl. 2</issue>), <fpage>AB108</fpage>
(<year>2018</year>).</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sesma</surname><given-names>JI</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wu</surname><given-names>B</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Stuhlmiller</surname><given-names>TJ</given-names></name></person-group>
<etal/>
<article-title>SPX-101 is stable in and retains function after exposure to
cystic fibrosis sputum</article-title>. <source>J. Cyst. Fibros.</source>
<volume>18</volume>(<issue>2</issue>),
<fpage>244</fpage>&#x2013;<lpage>250</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">29936069</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lip</surname><given-names>Kwok
PC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Chan</surname><given-names>HK</given-names></name></person-group>
<source>Chapter 2 &#x2013; Pulmonary Delivery of Peptides and
Proteins.</source>
<publisher-name>Elsevier</publisher-name>, <publisher-loc>Amsterdam, The
Netherlands</publisher-loc>, <fpage>23</fpage>&#x2013;<lpage>46</lpage>
(<year>2011</year>).</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adjei</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gupta</surname><given-names>P</given-names></name></person-group>
<article-title>Pulmonary delivery of therapeutic peptides and
proteins</article-title>. <source>J. Control. Rel.</source>
<volume>29</volume>(<issue>3</issue>),
<fpage>361</fpage>&#x2013;<lpage>373</lpage>
(<year>1994</year>).</mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansel</surname><given-names>TT</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kropshofer</surname><given-names>H</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Singer</surname><given-names>T</given-names></name></person-group>
<etal/>
<article-title>The safety and side effects of monoclonal
antibodies</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>9</volume>(<issue>4</issue>),
<fpage>325</fpage>&#x2013;<lpage>338</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20305665</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasagna-Reeves</surname><given-names>CA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Clos</surname><given-names>AL</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Midoro-Hiriuti</surname><given-names>T</given-names></name></person-group>
<etal/>
<article-title>Inhaled insulin forms toxic pulmonary amyloid
aggregates</article-title>. <source>Endocrinology</source>
<volume>151</volume>(<issue>10</issue>),
<fpage>4717</fpage>&#x2013;<lpage>4724</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20685871</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agu</surname><given-names>RU</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ugwoke</surname><given-names>MI</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Armand</surname><given-names>M</given-names></name></person-group>
<etal/>
<article-title>The lung as a route for systemic delivery of therapeutic proteins
and peptides</article-title>. <source>Respir. Res.</source>
<volume>2</volume>(<issue>4</issue>),
<fpage>198</fpage>&#x2013;<lpage>209</lpage>
(<year>2001</year>).<pub-id pub-id-type="pmid">11686885</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>KH</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Allen</surname><given-names>GC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kelley</surname><given-names>PE</given-names></name></person-group>
<etal/>
<article-title>Dornase alfa ototoxic effects in animals and efficacy in the
treatment of clogged tympanostomy tubes in children: a preclinical study and
a randomized clinical trial</article-title>. <source>JAMA Otolaryngol. Neck
Surg.</source>
<volume>144</volume>(<issue>9</issue>),
<fpage>776</fpage>&#x2013;<lpage>780</lpage>
(<year>2018</year>).</mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terryah</surname><given-names>ST</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Fellner</surname><given-names>RC</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name></person-group>
<etal/>
<article-title>Evaluation of a SPLUNC1-derived peptide for the treatment of
cystic fibrosis lung disease</article-title>. <source>Am. J.
Physiol.</source>
<volume>314</volume>(<issue>1</issue>),
<fpage>L192</fpage>&#x2013;<lpage>205</lpage>
(<year>2017</year>).</mixed-citation>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stolk</surname><given-names>J</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Tov</surname><given-names>N</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Chapman</surname><given-names>KR</given-names></name></person-group>
<etal/>
<article-title>Efficacy and safety of inhaled alpha-1-antitrypsin in patients
with severe alpha-1-antitrypsin deficiency and frequent exacerbations of
chronic obstructive pulmonary disease</article-title>. <source>Eur. Respir.
J.</source>
<volume>54</volume>(<issue>5</issue>), <fpage>1900673</fpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">31467115</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edris</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>De</surname><given-names>Feyter
S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Maes</surname><given-names>T</given-names></name></person-group>
<etal/>
<article-title>Monoclonal antibodies in Type 2 asthma: a systematic review and
network meta-analysis</article-title>. <source>Respir. Res.</source>
<volume>20</volume>(<issue>1</issue>), <fpage>179</fpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">31395084</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Thiessen</surname><given-names>PA</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Bolton</surname><given-names>EE</given-names></name></person-group>
<etal/>
<article-title>PubChem substance and compound databases</article-title>.
<source>Nucleic Acids Res.</source>
<volume>44</volume>(<issue>D1</issue>),
<fpage>D1202</fpage>&#x2013;<lpage>D1213</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">26400175</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrapp</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Corbett</surname><given-names>KS</given-names></name></person-group>
<etal/>
<article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion
conformation</article-title>. <source>Science</source>
<volume>367</volume>(<issue>6483</issue>),
<fpage>1260</fpage>&#x2013;<lpage>1263</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">32075877</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group>
<article-title>Improving the physical realism and structural accuracy of
protein models by a two-step atomic-level energy
minimization</article-title>. <source>Biophys. J.</source>
<volume>101</volume>(<issue>10</issue>),
<fpage>2525</fpage>&#x2013;<lpage>2534</lpage>
(<year>2011</year>).<pub-id pub-id-type="pmid">22098752</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>G</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wang</surname><given-names>E</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group>
<etal/>
<article-title>HawkDock: a web server to predict and analyze the
protein&#x2013;protein complex based on computational docking and
MM/GBSA</article-title>. <source>Nucleic Acids Res.</source>
<volume>47</volume>(<issue>W1</issue>),
<fpage>W322</fpage>&#x2013;<lpage>W330</lpage>
(<year>2019</year>).<pub-id pub-id-type="pmid">31106357</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kapoor</surname><given-names>P</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Chaudhary</surname><given-names>K</given-names></name></person-group>
<etal/>
<article-title><italic>In silico</italic> approach for predicting toxicity of
peptides and proteins</article-title>. <source>PLoS ONE</source>
<volume>8</volume>(<issue>9</issue>),
<fpage>e73957</fpage>&#x2013;<lpage>e73957</lpage>
(<year>2013</year>).<pub-id pub-id-type="pmid">24058508</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25.</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Gasteiger</surname><given-names>E</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Hoogland</surname><given-names>C</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gattiker</surname><given-names>A</given-names></name></person-group>
<etal/>
<source>Protein Identification and Analysis Tools on the ExPASy Server BT
&#x2013; The Proteomics Protocols Handbook.</source>
<publisher-name>SpringerLink</publisher-name>,
<publisher-loc>Switzerland</publisher-loc>,
<fpage>571</fpage>&#x2013;<lpage>607</lpage>
(<year>2005</year>).</mixed-citation>
      </ref>
      <ref id="B26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baig</surname><given-names>AM</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Khaleeq</surname><given-names>A</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Ali</surname><given-names>U</given-names></name></person-group>
<etal/>
<article-title>Evidence of the COVID-19 virus targeting the CNS: tissue
distribution, host&#x2013;virus interaction, and proposed neurotropic
mechanisms</article-title>. <source>ACS Chem. Neurosci.</source>
<volume>11</volume>(<issue>7</issue>),
<fpage>995</fpage>&#x2013;<lpage>998</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">32167747</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Oezguen</surname><given-names>N</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Urvil</surname><given-names>P</given-names></name></person-group>
<etal/>
<article-title>Regulation of protein-ligand binding affinity by hydrogen bond
pairing</article-title>. <source>Sci. Adv.</source>
<volume>2</volume>(<issue>3</issue>), <fpage>e1501240</fpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">27051863</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savjani</surname><given-names>KT</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Gajjar</surname><given-names>AK</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Savjani</surname><given-names>JK</given-names></name></person-group>
<article-title>Drug solubility: importance and enhancement
techniques</article-title>. <source>ISRN Pharm.</source>
<volume>2012</volume>, <fpage>195727</fpage>
(<year>2012</year>).<pub-id pub-id-type="pmid">22830056</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group>
<etal/>
<article-title>Research and development on therapeutic agents and vaccines for
COVID-19 and related human coronavirus diseases</article-title>. <source>ACS
Cent. Sci.</source>
<volume>6</volume>(<issue>3</issue>),
<fpage>315</fpage>&#x2013;<lpage>331</lpage>
(<year>2020</year>).<pub-id pub-id-type="pmid">32226821</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30.</label>
        <mixed-citation publication-type="other"><collab>US Pharmacist</collab>.
<article-title>COVID-19 pandemic sparking inhaler shortages</article-title>.
<ext-link ext-link-type="uri" xlink:href="http://www.uspharmacist.com/article/covid19-pandemic-sparking-inhaler-shortages">www.uspharmacist.com/article/covid19-pandemic-sparking-inhaler-shortages</ext-link></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagener</surname><given-names>JS</given-names></name><x xml:space="preserve">, </x><name name-style="western"><surname>Kupfer</surname><given-names>O</given-names></name></person-group>
<article-title>Dornase alfa (pulmozyme)</article-title>. <source>Curr. Opin.
Pulm. Med.</source>
<volume>18</volume>(<issue>6</issue>),
<fpage>609</fpage>&#x2013;<lpage>614</lpage>
(<year>2012</year>).<pub-id pub-id-type="pmid">22990660</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32.</label>
        <mixed-citation publication-type="other"><collab>US Food and Drug Administration
(FDA)</collab>. <article-title>Drug shortages: root causes and potential
solutions</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/drugs/drug-shortages/report-drug-shortages-root-causes-and-potential-solutions">www.fda.gov/drugs/drug-shortages/report-drug-shortages-root-causes-and-potential-solutions</ext-link></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32746902</article-id>
      <article-id pub-id-type="pmc">7398294</article-id>
      <article-id pub-id-type="publisher-id">5210</article-id>
      <article-id pub-id-type="doi">10.1186/s13104-020-05210-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1601-6854</contrib-id>
          <name>
            <surname>Jiang</surname>
            <given-names>Chuan</given-names>
          </name>
          <address>
            <email>cjiangmd@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Xie</surname>
            <given-names>Meng</given-names>
          </name>
          <address>
            <email>Simon.m.xie@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cervellione</surname>
            <given-names>Kelly</given-names>
          </name>
          <address>
            <email>kcervell@jhmc.org</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thurm</surname>
            <given-names>Craig</given-names>
          </name>
          <address>
            <email>cthurm1@jhmc.org</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.414915.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0414 4052</institution-id><institution>Department of Medicine-Division of Pulmonary Medicine, </institution><institution>Jamaica Hospital Medical Center, </institution></institution-wrap>Jamaica, NY 11418 USA </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.414915.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0414 4052</institution-id><institution>Department of Clinical Research, </institution><institution>Jamaica Hospital Medical Center, </institution></institution-wrap>Jamaica, NY 11418 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>3</day>
        <month>8</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>3</day>
        <month>8</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>13</volume>
      <elocation-id>368</elocation-id>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>6</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2020</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Objective</title>
          <p id="Par1">The use of intrapleural tissue plasminogen activator (tPA) and dornase alfa (DNase) is common in the management of pleural space infection. We review our experience with the efficacy and safety of this therapy. We performed a single center, retrospective study of consecutive patients with complicated parapneumonic effusion or empyema who received tPA/DNase therapy. Treatment success was defined as radiographic and clinical improvement in pleural space infection that precluded the need for surgical intervention, and the absence of mortality related to pleural infection.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p id="Par2">Fifty-six patients received concurrent once daily tPA/DNase therapy (median 3&#xA0;days) from July 2014 to July 2019. Fifty-two patients (92.9%) had treatment success. Median duration of chest tube therapy was 10&#xA0;days and length of stay was 15&#xA0;days. Significant pleural bleeding requiring transfusion therapy occurred in five patients (8.9%). Of these, three patients (5.4%) required operative intervention. Concurrent once daily administration of tPA/DNase in patients with pleural infection yielded comparable rates of treatment success as compared to twice daily concurrent or sequential administration. However, adverse events highlight potential safety concerns with using once daily concurrent administration of tPA/DNAse.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Parapneumonic effusion</kwd>
        <kwd>Empyema</kwd>
        <kwd>Fibrinolytic therapy</kwd>
        <kwd>Pleural disease</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par14">Empyema and complicated parapneumonic effusions (CPE) are estimated to cost the United States healthcare system at least 500 million dollars a year [<xref ref-type="bibr" rid="CR1">1</xref>] and the former is associated with a mortality of at least 15% [<xref ref-type="bibr" rid="CR2">2</xref>]. Fibrinolytic therapy for intrapleural infections has been available since 1949, when it was initially described by Tillet and Sherry, as a therapy to facilitate improved drainage of infected pleural effusions [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
      <p id="Par15">The use of intrapleural alteplase (tPA) and dornase alfa (DNase) in the management of complicated parapneumonic effusions and empyema was demonstrated to improve chest tube drainage, reduce the requirement for thoracic surgical intervention, and reduce hospital length of stay as compared to placebo and alteplase use alone [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
      <p id="Par16">Intrapleural hemorrhage requiring blood transfusion was observed in 3.8% of the patients receiving combination therapy [<xref ref-type="bibr" rid="CR4">4</xref>]. In a &#x201C;real world&#x201D; study, pleural bleeding requiring blood transfusion also occurred at a similar 1.8% rate [<xref ref-type="bibr" rid="CR5">5</xref>]. At our institution, we utilized a once daily concurrent administration technique and experienced good clinical efficacy. However, we observed a higher rate of significant pleural bleeding as compared to the above studies.</p>
    </sec>
    <sec id="Sec2">
      <title>Main text</title>
      <sec id="Sec3">
        <title>Methods</title>
        <p id="Par17">We reviewed the charts of all patients admitted to our hospital with complicated parapneumonic effusion or empyema from January 1, 2014 to July 1, 2019. Patients were identified using ICD codes and pharmacy records. Patients were included if there was: (1) a complicated parapneumonic effusion defined by a non-purulent effusion in a patient with pleural fluid pH less than or equal to 7.2, pleural fluid glucose less than 60&#xA0;mg/dL, pleural fluid lactate dehydrogenase (LDH) greater than 1000&#xA0;IU/L, and/or radiographic evidence of loculations; or (2) empyema defined by purulent pleural fluid or microbiological identification within the fluid [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
        <p id="Par18">The dose of DNase (Pulmozyme; Genetech, South San Francisco, CA) was 5&#xA0;mg in 30&#xA0;mL of sterile water and the dose of tPA (Activase; Genetech, South San Francisco, CA) was 10&#xA0;mg in 10&#xA0;mL of 0.9% NaCl. Concurrent administration (i.e. injection of tPA followed by DNase one after the other) of these agents was followed by a 10&#xA0;mL saline flush. The chest tube was clamped for 60&#xA0;min before it was opened to a gravity bag. Routine therapy was given once daily. The total number of days of administration was at the discretion of the treating physician.</p>
        <p id="Par19">In contrast, the sequential administration method refers to: (1) the administration of tPA followed by a 10- to 25-mL flush of saline followed by a 60&#xA0;min clamp, (2) an unclamp followed by a 60&#xA0;min open drainage period, (3) the administration of DNase followed by a 10- to 25-mL flush of saline followed by another 60&#xA0;min clamp, and (4) an unclamp to open drainage.</p>
        <p id="Par20">Electronic medical records were reviewed for patient demographics, clinical characteristics, treatment, outcomes, and safety. The primary efficacy outcome was treatment success, which was defined as clinical and radiologic improvement without the need for surgical intervention or mortality. Clinical and radiographic improvement were assessed by documentation by the treating physician. Radiographic improvement was defined as significant improvement of the opacified hemithorax on chest x-ray. Other clinical outcome measures included need for operative intervention for treatment failure, need for operative intervention for pleural bleeding complications, mortality related to pleural infection or bleeding complications, cumulative volume of pleural fluid drainage, length of chest tube therapy, and length of hospital stay.</p>
        <p id="Par21">Incidence of major bleeding was defined according to the International Society of Thrombosis and Haemostasis [<xref ref-type="bibr" rid="CR7">7</xref>] as (1) Fatal bleeding, and/or (2) Symptomatic bleeding in a critical organ such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, intrathoracic, pericardial, or intramuscular with compartment syndrome, and/or (3) Bleeding causing a fall of hemoglobin of 2&#xA0;g/dL or more leading to a transfusion of two or more units of packed red blood cells (pRBC).</p>
        <p id="Par22">Further, we defined &#x201C;pleural bleeding&#x201D; as a change in chest tube drainage to a bloody appearance accompanied by signs and symptoms of bleeding (i.e. worsening respiratory symptoms, incident pleuritic chest pain, worsening radiographic appearance, and/or decrease in serum hemoglobin values). Evidence of pleural bleeding found during surgery was also considered &#x201C;pleural bleeding.&#x201D;</p>
        <p id="Par23">Statistical analysis was performed using Microsoft Excel. Descriptive statistics for continuous data are expressed as mean (standard deviation [SD]) if normally distributed and as median (interquartile range [IQR]) if non-normally distributed; for categorical data statistics are expressed as N (%). The study was approved by the Jamaica Hospital Medical Center Institutional Review Board (IRB# 1527223).</p>
      </sec>
      <sec id="Sec4">
        <title>Results</title>
        <sec id="Sec5">
          <title>Patients</title>
          <p id="Par24">Our study included 56 patients with CPE or empyema who received concurrent tPA/DNase therapy. All patients meeting inclusion criteria during the defined time period were included. Complete data was available for all patients. The baseline demographics and pre-existing medical conditions of these patients are outlined in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. The mean age was 64.8 (&#xB1;&#x2009;16.2) years with 64.2% being male. Twenty-one patients (37.5%) were on an antiplatelet agent or anticoagulant. Only five (8.9%) were on full dose anticoagulation for a pre-existing indication.<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Patient demographics and comorbidities</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Mean age (SD), year</td><td align="left">64.8 (16.2)</td></tr><tr><td align="left">Male, n (%)</td><td align="left">36 (64.2)</td></tr><tr><td align="left" colspan="2">Racial background, n (%)</td></tr><tr><td align="left">&#xA0;Caucasian</td><td align="left">21 (37.5)</td></tr><tr><td align="left">&#xA0;Black</td><td align="left">11 (19.6)</td></tr><tr><td align="left">&#xA0;Hispanic</td><td align="left">10 (17.9)</td></tr><tr><td align="left">&#xA0;Asian</td><td align="left">12 (21.4)</td></tr><tr><td align="left">&#xA0;Other/mixed</td><td align="left">2 (3.6)</td></tr><tr><td align="left" colspan="2">Comorbidities, n (%)</td></tr><tr><td align="left">&#xA0;Hypertension</td><td align="left">39 (69.6)</td></tr><tr><td align="left">&#xA0;Diabetes mellitus</td><td align="left">26 (46.4)</td></tr><tr><td align="left">&#xA0;Coronary artery disease</td><td align="left">13 (23.2)</td></tr><tr><td align="left">&#xA0;Chronic kidney disease</td><td align="left">12 (21.4)</td></tr><tr><td align="left">&#xA0;Gastroesophageal reflux disease/peptic ulcer disease</td><td align="left">10 (17.9)</td></tr><tr><td align="left">&#xA0;Congestive heart failure</td><td align="left">10 (17.9)</td></tr><tr><td align="left">&#xA0;Cerebrovascular accident</td><td align="left">9 (16.1)</td></tr><tr><td align="left">&#xA0;End stage renal disease on hemodialysis</td><td align="left">8 (14.3)</td></tr><tr><td align="left">&#xA0;Atrial fibrillation</td><td align="left">7 (12.5)</td></tr><tr><td align="left">&#xA0;Asthma</td><td align="left">4 (7.1)</td></tr><tr><td align="left">&#xA0;Substance related condition</td><td align="left">4 (7.1)</td></tr><tr><td align="left">&#xA0;Chronic obstructive pulmonary disease</td><td align="left">3 (5.4)</td></tr><tr><td align="left">&#xA0;Valvular heart disease</td><td align="left">2 (3.6)</td></tr><tr><td align="left">&#xA0;Hepatitis B or C</td><td align="left">1 (1.8)</td></tr><tr><td align="left">&#xA0;Common variable immunodeficiency</td><td align="left">1 (1.8)</td></tr><tr><td align="left">&#xA0;Bronchiectasis</td><td align="left">0</td></tr><tr><td align="left">&#xA0;Active malignancy</td><td align="left">0</td></tr><tr><td align="left" colspan="2">Anticoagulation or antiplatelet medications prior to admission, n (%)</td></tr><tr><td align="left">&#xA0;Aspirin only</td><td align="left">12 (21.4)</td></tr><tr><td align="left">&#xA0;Aspirin and clopidogrel</td><td align="left">4 (7.1)</td></tr><tr><td align="left">&#xA0;Rivaroxaban</td><td align="left">2 (3.6)</td></tr><tr><td align="left">&#xA0;Apixaban</td><td align="left">1 (1.8)</td></tr><tr><td align="left">&#xA0;Enoxaparin</td><td align="left">1 (1.8)</td></tr><tr><td align="left">&#xA0;Warfarin</td><td align="left">1 (1.8)</td></tr></tbody></table></table-wrap></p>
          <p id="Par25">Clinical, radiographic, microbiological, and treatment data are shown in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>. Evidence of loculations on CT chest imaging were noted in 78.6% of the patients. Purulence of pleural fluid was noted in 30.4% of patients and 46.4% of the sampled effusions yielded a positive bacterial culture. The predominant microorganisms isolated were <italic>Streptococcus milleri</italic> (n&#x2009;=&#x2009;8) and <italic>Staphylococcus aureus</italic> (n&#x2009;=&#x2009;9; methicillin sensitive, n&#x2009;=&#x2009;5; methicillin resistant n&#x2009;=&#x2009;4). The majority of patients received three or fewer doses of tPA/DNase (92%). The reasons for using fewer than three doses varied on a case by case basis, including rapid resolution of clinical and radiographic features (n&#x2009;=&#x2009;6), patient refusal due to intractable chest pain (n&#x2009;=&#x2009;3), and change in hemodynamics (n&#x2009;=&#x2009;2).<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Clinical data</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Presence of loculations on CT scan, n (%)</td><td char="(" align="char">44 (78.6)</td></tr><tr><td align="left" colspan="2">Number of chest tubes placed</td></tr><tr><td align="left">&#xA0;1 chest tube placed, n (%)</td><td char="(" align="char">53 (94.6)</td></tr><tr><td align="left">&#xA0;2 chest tubes placed, n (%)</td><td char="(" align="char">3 (5.4)</td></tr><tr><td align="left" colspan="2">Size of chest tubes placed</td></tr><tr><td align="left">&#xA0;32 French, n (%)</td><td char="(" align="char">3 (5.1)</td></tr><tr><td align="left">&#xA0;12 French, n (%)</td><td char="(" align="char">7 (12.5)</td></tr><tr><td align="left">&#xA0;10 French, n (%)</td><td char="(" align="char">39 (69.6)</td></tr><tr><td align="left">&#xA0;8 French, n (%)</td><td char="(" align="char">10 (17.8)</td></tr><tr><td align="left">Purulent pleural fluid, n (%)</td><td char="(" align="char">17 (30.4)</td></tr><tr><td align="left">Positive pleural fluid culture, n (%)</td><td char="(" align="char">26 (46.4)</td></tr><tr><td align="left" colspan="2">Organisms found on pleural fluid culture</td></tr><tr><td align="left">&#xA0;<italic>Streptococcus milleri</italic></td><td char="(" align="char">8 (30.8)</td></tr><tr><td align="left">&#xA0;<italic>Klebsiella pneumoniae</italic></td><td char="(" align="char">5 (19.2)</td></tr><tr><td align="left">&#xA0;<italic>Staphylococcus aureus</italic>, methicillin sensitive</td><td char="(" align="char">5 (19.2)</td></tr><tr><td align="left">&#xA0;<italic>Staphylococcus aureus</italic>, methicillin resistant</td><td char="(" align="char">4 (15.4)</td></tr><tr><td align="left">&#xA0;<italic>Escherichia coli</italic></td><td char="(" align="char">3 (11.5)</td></tr><tr><td align="left">&#xA0;<italic>Streptococcus pneumoniae</italic></td><td char="(" align="char">2 (7.7)</td></tr><tr><td align="left">&#xA0;<italic>Enterobacter aerogenes</italic></td><td char="(" align="char">1 (3.8)</td></tr><tr><td align="left">&#xA0;<italic>Enterococcus faecium</italic></td><td char="(" align="char">1 (3.8)</td></tr><tr><td align="left">&#xA0;<italic>Gemella</italic> sp</td><td char="(" align="char">1 (3.8)</td></tr><tr><td align="left">Median pleural fluid pH (IQR)</td><td char="(" align="char">7.08 (6.87&#x2013;7.18)</td></tr><tr><td align="left">Median pleural fluid lactate dehydrogenase (IQR), IU/L</td><td char="(" align="char">4456.5 (1975.8&#x2013;12,762.5)</td></tr><tr><td align="left">Median peripheral leukocyte count (IQR), &#xD7;&#x2009;10<sup>9</sup>/L</td><td char="(" align="char">15.9 (12.6&#x2013;20.5)</td></tr><tr><td align="left">Median ESR (IQR), mm/h</td><td char="(" align="char">83.5 (57.5&#x2013;101.3)</td></tr><tr><td align="left">Median CRP (IQR), mg/L</td><td char="(" align="char">8.25 (4.8&#x2013;16.6)</td></tr><tr><td align="left" colspan="2">Antibiotics, n (%)<sup>a</sup></td></tr><tr><td align="left">&#xA0;Vancomycin</td><td char="(" align="char">37 (66.1)</td></tr><tr><td align="left">&#xA0;Piperacillin&#x2013;tazobactam</td><td char="(" align="char">35 (62.5)</td></tr><tr><td align="left">&#xA0;Ceftaroline</td><td char="(" align="char">17 (30.4)</td></tr><tr><td align="left">&#xA0;Meropenem</td><td char="(" align="char">15 (26.8)</td></tr><tr><td align="left">&#xA0;Metronidazole</td><td char="(" align="char">9 (16.1)</td></tr><tr><td align="left">&#xA0;Levofloxacin</td><td char="(" align="char">9 (16.1)</td></tr><tr><td align="left">&#xA0;Ceftriaxone</td><td char="(" align="char">8 (14.3)</td></tr><tr><td align="left">&#xA0;Azithromycin</td><td char="(" align="char">7 (12.5)</td></tr><tr><td align="left">&#xA0;Ampicillin&#x2013;sulbactam</td><td char="(" align="char">7 (12.5)</td></tr><tr><td align="left">&#xA0;Tigecycline</td><td char="(" align="char">7 (12.5)</td></tr><tr><td align="left">&#xA0;Clindamycin</td><td char="(" align="char">4 (7.1)</td></tr><tr><td align="left">&#xA0;Doxycycline</td><td char="(" align="char">3 (5.4)</td></tr><tr><td align="left">&#xA0;Linezolid</td><td char="(" align="char">3 (5.4)</td></tr><tr><td align="left">&#xA0;Aztreonam</td><td char="(" align="char">2 (3.6)</td></tr><tr><td align="left">&#xA0;Daptomycin</td><td char="(" align="char">1 (1.8)</td></tr><tr><td align="left">&#xA0;Penicillin</td><td char="(" align="char">1 (1.8)</td></tr><tr><td align="left">&#xA0;Polymixin B</td><td char="(" align="char">1 (1.8)</td></tr><tr><td align="left" colspan="2">Number of intrapleural administrations of alteplase/dornase alfa, n (%)</td></tr><tr><td align="left">&#xA0;One</td><td char="(" align="char">5 (8.9)</td></tr><tr><td align="left">&#xA0;Two</td><td char="(" align="char">6 (10.7)</td></tr><tr><td align="left">&#xA0;Three</td><td char="(" align="char">40 (71.4)</td></tr><tr><td align="left">&#xA0;Four</td><td char="(" align="char">1 (1.8)</td></tr><tr><td align="left">&#xA0;Five</td><td char="(" align="char">1 (1.8)</td></tr><tr><td align="left">&#xA0;Six</td><td char="(" align="char">3 (5.4)</td></tr><tr><td align="left">Patients who received the first dose of intrapleural treatment in under 24&#xA0;h after chest tube insertion, n (%)</td><td char="(" align="char">37 (66.1)</td></tr><tr><td align="left">Median days from chest tube insertion to first dose of intrapleural treatment (IQR)</td><td char="(" align="char">1 (0&#x2013;2)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> All patients received more than one antibiotic during treatment</p></table-wrap-foot></table-wrap></p>
        </sec>
        <sec id="Sec6">
          <title>Outcomes</title>
          <p id="Par26">Outcome data is presented in Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>. Fifty-two out of fifty-six (92.9%) of the patients experienced treatment success. The median number of days from chest tube insertion to first dose of intrapleural treatment was 1&#xA0;day (IQR, 0&#x2013;2) with 66.1% receiving the first dose of intrapleural tPA/DNase within 24&#xA0;h. The median chest tube outputs at 24&#xA0;h and 72&#xA0;h after intrapleural therapy were 447.5&#xA0;mL (IQR, 177.5&#x2013;769.8) and 1470&#xA0;mL (IQR, 717.5&#x2013;1989.8), respectively. Median chest tube duration was 10&#xA0;days (IQR, 7&#x2013;14) and median hospital length of stay was 15&#xA0;days (IQR, 11&#x2013;28).<table-wrap id="Tab3"><label>Table&#xA0;3</label><caption><p>Clinical outcomes and adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Treatment outcomes</th><th align="left">Data</th></tr></thead><tbody><tr><td align="left">Treatment success, n (%)</td><td char="(" align="char">52 (92.9)</td></tr><tr><td align="left">Surgical intervention for treatment failure (VATS with decortication), n (%)</td><td char="(" align="char">2 (3.6)</td></tr><tr><td align="left">30&#xA0;day mortality due to pleural infection, n (%)</td><td char="(" align="char">2 (3.6)</td></tr><tr><td align="left">30&#xA0;day readmission rate, n (%)</td><td char="(" align="char">0 (0)</td></tr><tr><td align="left">Median hospital stay (IQR)</td><td char="(" align="char">15 (11&#x2013;28)</td></tr><tr><td align="left">Median cumulative volume of pleural drainage 24&#xA0;h after first dose of intrapleural therapy (IQR), mL</td><td char="(" align="char">447.5 (177.5&#x2013;769.75)</td></tr><tr><td align="left">Median cumulative volume of pleural drainage 48&#xA0;h after first dose of intrapleural therapy (IQR), mL</td><td char="(" align="char">995 (520&#x2013;1445.5)</td></tr><tr><td align="left">Median cumulative volume of pleural drainage 72&#xA0;h after first dose of intrapleural therapy (IQR), mL</td><td char="(" align="char">1470 (717.5&#x2013;1989.75)</td></tr><tr><td align="left">Median days of chest tube in pleural cavity (IQR)</td><td char="(" align="char">10 (7&#x2013;14)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Bleeding outcomes</th></tr></thead><tbody><tr><td align="left">Pleural bleeding</td><td char="(" align="char">9 (16.1)</td></tr><tr><td align="left">Pleural bleeding requiring&#x2009;&#x2265;&#x2009;2U pRBC transfusion</td><td char="(" align="char">5 (8.9)</td></tr><tr><td align="left">Gastrointestinal bleeding</td><td char="(" align="char">0 (0)</td></tr><tr><td align="left">Intracranial bleeding</td><td char="(" align="char">0 (0)</td></tr><tr><td align="left">Other bleeding</td><td char="(" align="char">0 (0)</td></tr><tr><td align="left">Mean hemoglobin loss (SD), g/dL</td><td char="(" align="char">3.5 (1.1)</td></tr><tr><td align="left">Median units of pRBC transfusion in patients transfused (IQR)</td><td char="(" align="char">2 (2&#x2013;5)</td></tr><tr><td align="left">Surgical intervention for pleural bleeding, n (%)</td><td char="(" align="char">3 (5.4)</td></tr><tr><td align="left">30&#xA0;day mortality due to pleural bleeding, n (%)</td><td char="(" align="char">0 (0)</td></tr></tbody></table></table-wrap></p>
          <p id="Par27">Four patients (7.1%) experienced treatment failure, 2 of which received surgical intervention. These two patients underwent video assisted thoracoscopic surgery (VATS) with decortication and both were successfully discharged and survived beyond 30&#xA0;days. The other two patients with treatment failure had refractory septic shock and were not considered operative candidates.</p>
        </sec>
        <sec id="Sec7">
          <title>Adverse events</title>
          <p id="Par28">Nine patients (16.1%) experienced pleural bleeding as defined in &#x201C;<xref rid="Sec3" ref-type="sec">Methods</xref>&#x201D; section. Of these, only five (8.9% of all patients) developed pleural bleeding significant enough to require transfusion of at least 2 units of pRBC. Three of these five patients (5.4% of all patients) required surgical intervention with VATS for evacuation of hematoma. No patients experienced major bleeding at any other predefined sites.</p>
          <p id="Par29">All nine patients who experienced pleural bleeding received three or more doses of tPA/DNase. Mean hemoglobin loss was 3.5&#xA0;g/dL (&#xB1;&#x2009;1.1) and the median units of pRBC transfusions was 2 units (IQR 2&#x2013;5). There was no mortality related to pleural bleeding at 30&#xA0;days. Of the five patients requiring &#x2265;&#x2009;2 units of pRBC, one was on full dose anticoagulation (rivaroxaban), which was held for 2&#xA0;days prior to chest tube insertion but was resumed during the time this patient received fibrinolytic therapy. Three patients were on aspirin alone. In comparison, of the 47 patients who had no evidence of pleural bleeding while receiving tPA/DNase, 21 patients (44.7%) were on some form of antiplatelet agent or an anticoagulant (12 patients on aspirin alone, 4 patients on aspirin and clopidogrel, 1 patient on rivaroxaban, 1 patient on apixaban, 1 patient on enoxaparin, and 1 patient on warfarin).</p>
          <p id="Par30">The 30-day mortality rate due to pleural infection was 3.6% (2 out of 56 patients). These two patients both received three doses of tPA/DNase and passed away at days 14 and 27. Both were in the intensive care unit setting with septic shock due to empyema and acute respiratory failure requiring mechanical ventilation.</p>
        </sec>
      </sec>
      <sec id="Sec8">
        <title>Discussion</title>
        <p id="Par31">Empyema and CPE are associated with significant morbidity and mortality [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Intrapleural administration of tPA (with or without DNase) at 10&#xA0;mg has been reported to lead to pleural bleeding at rates between 1.8 and 12.0% [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR13">13</xref>]. Based on one pharmacologic study, the bleeding risk of intrapleural tPA appears to be dose dependent [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
        <p id="Par32">The MIST-2 trial [<xref ref-type="bibr" rid="CR4">4</xref>], which utilized 10&#xA0;mg of alteplase and 5&#xA0;mg of dornase alfa twice daily, demonstrated a 3.8% rate of pleural bleeding. However, a retrospective study using the same dosing regimen [<xref ref-type="bibr" rid="CR13">13</xref>], led to a pleural bleeding rate of 5.4%. There is conflicting data as to whether reducing the dose of tPA will lead to a reduction in pleural bleeding [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p>
        <p id="Par33">Conversely, a study utilizing extended tPA/DNase dosing (mean 9.8 doses) in patients who were not surgical candidates, demonstrated a similar efficacy rate as six doses but a higher pleural bleeding rate at 10% [<xref ref-type="bibr" rid="CR16">16</xref>]. Two studies investigated the effect of concurrent administration of tPA and DNase. One study showed comparable treatment success rates but an increased rate in pleural bleeding as compared to MIST-2 [<xref ref-type="bibr" rid="CR13">13</xref>]. The other showed treatment success comparable to MIST-2 trial but with no pleural bleeding [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
        <p id="Par34">Our data shows that a concurrent once daily dosing strategy was associated with a similar rate of treatment success as previous studies that utilized a twice daily, sequential dosing strategy. Rates of treatment failure requiring VATS decortication in our cohort (5.4%) were comparable to the rates found in previous studies of 4.0 to 9.6% [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Given apparent similarities in the clinical and biochemical characteristics of our patient cohort in comparison to these other studies, it is reasonable to conclude that a once daily concurrent dosing regimen is as effective as twice daily concurrent dosing.</p>
        <p id="Par35">Although our treatment success rate was comparable to that of previously reported studies, our patients experienced a longer duration of chest tube therapy and length of hospital stay compared to prior studies. This raises the possibility that the reduced dosing or the concurrent administration of medications leads to a longer duration of drainage time before completion of therapy. Alternatively, this could reflect variations in local treatment practices or the absence of rigid protocols of a clinical trial setting that may have led to earlier removal of chest tubes.</p>
        <p id="Par36">Despite using a lower total dose of alteplase, our study revealed an overall pleural bleeding rate of 16.1%. The rate of pleural bleeding requiring at least 2 units of pRBC was 8.9% (5 patients). Three patients (5.4%) required VATS for hematoma evacuation. This stands in contrast to previous studies which showed overall rates of pleural bleeding ranging from 0 to 5.4% and no reports of pleural bleeding requiring VATS for hematoma evacuation [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. The use of antiplatelet or anticoagulant medications may have led to the increased bleeding rate. Further, we speculate there may be a synergistic effect of concurrent administration of tPA/DNase leading to the increased pleural bleeding rate.</p>
      </sec>
      <sec id="Sec9">
        <title>Conclusion</title>
        <p id="Par37">In this single center, retrospective study of patients presenting with complicated parapneumonic effusion or empyema, the use of once daily concurrently administered tPA/DNAse led to comparable rates of the primary efficacy outcome of treatment success as prior studies utilizing twice daily concurrent or sequential dosing.</p>
      </sec>
    </sec>
    <sec id="Sec10">
      <title>Limitations</title>
      <p>
        <list list-type="bullet">
          <list-item>
            <p id="Par38">This retrospective design and relatively small sample size limits definitive conclusions.</p>
          </list-item>
          <list-item>
            <p id="Par39">A component of our definition of clinical success included physician assessment, which is subjective in nature.</p>
          </list-item>
          <list-item>
            <p id="Par40">Assessment of radiographic improvement was based on radiologist interpretation and not by objective quantitative means, such as CT volumetry.</p>
          </list-item>
        </list>
      </p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CPE</term>
          <def>
            <p id="Par3">Complicated parapneumonic effusion</p>
          </def>
        </def-item>
        <def-item>
          <term>CRP</term>
          <def>
            <p id="Par4">C-reactive protein</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p id="Par5">Computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>DNase</term>
          <def>
            <p id="Par6">Dornase alfa</p>
          </def>
        </def-item>
        <def-item>
          <term>ESR</term>
          <def>
            <p id="Par7">Erythrocyte Sedimentation Rate</p>
          </def>
        </def-item>
        <def-item>
          <term>IQR</term>
          <def>
            <p id="Par8">Inter-quartile range</p>
          </def>
        </def-item>
        <def-item>
          <term>LDH</term>
          <def>
            <p id="Par9">Lactate dehydrogenase</p>
          </def>
        </def-item>
        <def-item>
          <term>pRBC</term>
          <def>
            <p id="Par10">Packed red blood cell</p>
          </def>
        </def-item>
        <def-item>
          <term>tPA</term>
          <def>
            <p id="Par11">Tissue plasminogen activator</p>
          </def>
        </def-item>
        <def-item>
          <term>SD</term>
          <def>
            <p id="Par12">Standard deviation</p>
          </def>
        </def-item>
        <def-item>
          <term>VATS</term>
          <def>
            <p id="Par13">Video assisted thoracoscopic surgery</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher's Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors acknowledge Louis Cosenza BS, MS for his efforts in compiling the list of eligible patients from our hospital&#x2019;s pharmacy database.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>CJ takes responsibility for the content of the manuscript, including the data analysis and writing of the manuscript. MX and KC had full access to all of the data in the study and took responsibility for the accurate collection and analysis of the data. CJ, MX, KC, and CT all contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript. All authors read and approved the final manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>No funding was required for the performance of this study.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials</title>
      <p>The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.</p>
    </notes>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par41">The study was approved by the Jamaica Hospital Medical Center Institutional Review Board (IRB# 1527223). Our medical center is located within the United States of America.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par42">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par43">All authors report no financial disclosures or ethical conflicts of interest regarding this study.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Kozower</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>Surgical spectrum in the management of empyemas</article-title>
          <source>Thorac Surg Clin</source>
          <year>2012</year>
          <volume>22</volume>
          <fpage>431</fpage>
          <lpage>440</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thorsurg.2012.04.007</pub-id>
          <pub-id pub-id-type="pmid">22789604</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shen</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Bribriesco</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Crabtree</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The American Association for Thoracic Surgery Consensus guidelines for the management of empyema</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <year>2017</year>
          <volume>153</volume>
          <fpage>e129</fpage>
          <lpage>e146</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jtcvs.2017.01.030</pub-id>
          <pub-id pub-id-type="pmid">28274565</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tucker</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Idell</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Plasminogen-plasmin system in the pathogenesis and treatment of lung and pleural injury</article-title>
          <source>Semin Thromb Hemost</source>
          <year>2013</year>
          <volume>39</volume>
          <fpage>373</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0033-1334486</pub-id>
          <pub-id pub-id-type="pmid">23504608</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahman</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Maskell</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intrapleural use of tissue plasminogen activator and DNase in pleural infection</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>365</volume>
          <fpage>518</fpage>
          <lpage>526</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1012740</pub-id>
          <pub-id pub-id-type="pmid">21830966</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piccolo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pitman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bhatnagar</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection: an effective and safe alternative to surgery</article-title>
          <source>Ann Am Thorac Soc</source>
          <year>2014</year>
          <volume>11</volume>
          <issue>9</issue>
          <fpage>1419</fpage>
          <lpage>1425</lpage>
          <pub-id pub-id-type="doi">10.1513/AnnalsATS.201407-329OC</pub-id>
          <pub-id pub-id-type="pmid">25296241</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Porcel</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Distinguishing complicated from uncomplicated parapneumonic effusion</article-title>
          <source>Curr Opin Pulm Med</source>
          <year>2015</year>
          <volume>21</volume>
          <fpage>346</fpage>
          <lpage>351</lpage>
          <pub-id pub-id-type="doi">10.1097/MCP.0000000000000164</pub-id>
          <pub-id pub-id-type="pmid">26016577</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schulman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kearon</surname>
              <given-names>C</given-names>
            </name>
            <collab>The Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis</collab>
          </person-group>
          <article-title>Definition of major bleeding in clinical investigations of antihemostatic medicine products in non-surgical patients</article-title>
          <source>J Thromb Haemost</source>
          <year>2005</year>
          <volume>3</volume>
          <fpage>692</fpage>
          <lpage>694</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2005.01204.x</pub-id>
          <pub-id pub-id-type="pmid">15842354</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Semenkovich</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Olsen</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Puri</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Kozower</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>Current statement of empyema management</article-title>
          <source>Ann Thorac Surg</source>
          <year>2018</year>
          <volume>105</volume>
          <issue>6</issue>
          <fpage>1589</fpage>
          <lpage>1596</lpage>
          <pub-id pub-id-type="doi">10.1016/j.athoracsur.2018.02.027</pub-id>
          <pub-id pub-id-type="pmid">29550205</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mehta</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Biswas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Penley</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Cope</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jantz</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Management of intrapleural sepsis with once daily use of tissue plasminogen activator and deoxyribonuclease</article-title>
          <source>Respiration</source>
          <year>2016</year>
          <volume>91</volume>
          <fpage>101</fpage>
          <lpage>106</lpage>
          <pub-id pub-id-type="doi">10.1159/000443334</pub-id>
          <pub-id pub-id-type="pmid">26761711</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aleman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Porcel</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Alegre</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic PLeural Effusions an<italic>d Empyema</italic>: a prospective randomized study</article-title>
          <source>Lung</source>
          <year>2015</year>
          <volume>193</volume>
          <fpage>993</fpage>
          <lpage>1000</lpage>
          <pub-id pub-id-type="doi">10.1007/s00408-015-9807-6</pub-id>
          <pub-id pub-id-type="pmid">26423784</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Skeete</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Rutherford</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Schlidt</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Abrams</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>PB</given-names>
            </name>
          </person-group>
          <article-title>Intrapleural tissue plasminogen activator for complicated pleural <italic>Effusio</italic>ns</article-title>
          <source>J Trauma</source>
          <year>2004</year>
          <volume>57</volume>
          <fpage>1178</fpage>
          <lpage>1183</lpage>
          <pub-id pub-id-type="doi">10.1097/01.TA.0000141879.67441.52</pub-id>
          <pub-id pub-id-type="pmid">15625447</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thommi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Shehan</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Robison</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Backemeyer</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>McLeay</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>A double blind randomized crossover trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions</article-title>
          <source>Respir Med</source>
          <year>2012</year>
          <volume>106</volume>
          <fpage>716</fpage>
          <lpage>723</lpage>
          <pub-id pub-id-type="doi">10.1016/j.rmed.2012.02.005</pub-id>
          <pub-id pub-id-type="pmid">22398159</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Majid</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kheir</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Folch</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Concurrent intrapleural instillation of tissue plasminogen activator and DNase for pleural infection. A single center experience</article-title>
          <source>Ann ATS</source>
          <year>2016</year>
          <volume>13</volume>
          <issue>9</issue>
          <fpage>1512</fpage>
          <lpage>1518</lpage>
          <pub-id pub-id-type="doi">10.1513/AnnalsATS.201602-127OC</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Popowicz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bintcliffe</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>De Fonseka</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dose de-escalation of intrapleural tissue plasminogen activator therapy for pleural infection: the ADAPT project</article-title>
          <source>Ann Am Thorac Soc</source>
          <year>2017</year>
          <volume>14</volume>
          <issue>6</issue>
          <fpage>929</fpage>
          <lpage>936</lpage>
          <pub-id pub-id-type="doi">10.1513/AnnalsATS.201609-673OC</pub-id>
          <pub-id pub-id-type="pmid">28324671</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Innabi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Surana</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alzghoul</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Meena</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Rethinking the doses of tissue plasminogen activator and deoxyribonuclease administered concurrently for intrapleural therapy for complicated pleural effusion and empyema</article-title>
          <source>Cureus</source>
          <year>2018</year>
          <volume>19</volume>
          <issue>2</issue>
          <fpage>e2214</fpage>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">McClune JR, Wilshire CL, Gorden JA, et al. Safety and efficacy of intrapleural tissue plasminogen activator and DNase during extended use in complicated pleural space infections. Can Respir J. 2016, Article ID 9796768, 6 pages.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Laryngoscope Investig Otolaryngol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Laryngoscope Investig Otolaryngol</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)2378-8038</journal-id>
      <journal-id journal-id-type="publisher-id">LIO2</journal-id>
      <journal-title-group>
        <journal-title>Laryngoscope Investigative Otolaryngology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2378-8038</issn>
      <publisher>
        <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
        <publisher-loc>Hoboken, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32596478</article-id>
      <article-id pub-id-type="pmc">7314487</article-id>
      <article-id pub-id-type="doi">10.1002/lio2.401</article-id>
      <article-id pub-id-type="publisher-id">LIO2401</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Review</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Allergy, Rhinology, and Immunology</subject>
          <subj-group subj-group-type="heading">
            <subject>Reviews</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Chronic rhinosinusitis in patients with cystic fibrosis&#x2014;Current management and new treatments</article-title>
        <alt-title alt-title-type="left-running-head">Johnson et al.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="lio2401-cr-0001" contrib-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>Brian Jake</given-names>
          </name>
          <degrees>MD</degrees>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4092-8164</contrib-id>
          <xref ref-type="aff" rid="lio2401-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="lio2401-cr-0002" contrib-type="author">
          <name>
            <surname>Choby</surname>
            <given-names>Garret W.</given-names>
          </name>
          <degrees>MD</degrees>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3745-2727</contrib-id>
          <xref ref-type="aff" rid="lio2401-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="lio2401-cr-0003" contrib-type="author" corresp="yes">
          <name>
            <surname>O'Brien</surname>
            <given-names>Erin K.</given-names>
          </name>
          <degrees>MD</degrees>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4891-9548</contrib-id>
          <xref ref-type="aff" rid="lio2401-aff-0001">
<sup>1</sup>
</xref>
          <address>
            <email>obrien.erin@mayo.edu</email>
          </address>
        </contrib>
      </contrib-group>
      <aff id="lio2401-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Otorhinolaryngology</named-content>
<institution>Mayo Clinic</institution>
<city>Rochester</city>
<named-content content-type="country-part">Minnesota</named-content>
<country country="US">USA</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/> Erin K. O'Brien MD, Department of Otorhinolaryngology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.<break/>
Email: <email>obrien.erin@mayo.edu</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>6</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>6</month>
        <year>2020</year>
      </pub-date>
      <volume>5</volume>
      <issue>3</issue>
      <issue-id pub-id-type="doi">10.1002/lio2.v5.3</issue-id>
      <fpage>368</fpage>
      <lpage>374</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>12</month>
          <year>2019</year>
        </date>
        <date date-type="rev-recd">
          <day>27</day>
          <month>4</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>5</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 The American Laryngological, Rhinological and Otological Society, Inc. <copyright-statement>-->
        <copyright-statement content-type="article-copyright">&#xA9; 2020 The Authors. <italic>Laryngoscope Investigative Otolaryngology</italic> published by Wiley Periodicals, Inc. on behalf of The Triological Society.</copyright-statement>
        <license license-type="creativeCommonsBy-nc-nd">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x2010;commercial and no modifications or adaptations are made.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:LIO2-5-368.pdf"/>
      <abstract>
        <title>Abstract</title>
        <sec id="lio2401-sec-0001">
          <title>Objectives</title>
          <p>The purpose of this article is to provide a state&#x2010;of&#x2010;the&#x2010;art review of the literature and summarize the latest publications on medical and surgical treatment of cystic fibrosis (CF) chronic rhinosinusitis (CRS), with an emphasis on describing recent advancements in cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies.</p>
        </sec>
        <sec id="lio2401-sec-0002">
          <title>Methods</title>
          <p>A comprehensive literature review was conducted utilizing the PubMed database with search phrases detailed within the body of the article. Abstracts were reviewed to include publications detailing medical, surgical, and CFTR modulating therapies for CF CRS. Findings from studies not previously reviewed and publications regarding CFTR modulators were emphasized.</p>
        </sec>
        <sec id="lio2401-sec-0003">
          <title>Results</title>
          <p>No clear guidelines for treatment of CF CRS are available. Nasal saline rinses, topical steroids, topical antibiotics, and topical dornase alfa are reported medical therapies. Ivacaftor has some sinonasal symptomatic benefit. A new triple therapy CFTR modulator, elexacaftor/tezacaftor/ivacaftor, is capable of treating 90% of patients with CF and has shown the greatest FEV1 improvement of any CFTR modulator yet. There is no clear consensus on surgical indications or technique, though aggressive surgery in recalcitrant disease has shown some symptomatic benefit. Endoscopic sinus surgery after lung transplantation may benefit some patients in whom the sinuses serve as a reservoir for recurrent pulmonary infections by decreasing rates of bronchiolitis obliterans syndrome and improving 5 year survival.</p>
        </sec>
        <sec id="lio2401-sec-0004">
          <title>Conclusion</title>
          <p>As lifespan increases for patients with CF, further investigation into medical therapy, CFTR modulator sinonasal outcomes, and surgical technique and outcomes for CF CRS is needed.</p>
        </sec>
        <sec id="lio2401-sec-0005">
          <title>Level of Evidence</title>
          <p>5.</p>
        </sec>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="lio2401-kwd-0001">CF</kwd>
        <kwd id="lio2401-kwd-0002">CFTR modulator</kwd>
        <kwd id="lio2401-kwd-0003">chronic rhinosinusitis</kwd>
        <kwd id="lio2401-kwd-0004">cystic fibrosis</kwd>
        <kwd id="lio2401-kwd-0005">endoscopic sinus surgery</kwd>
        <kwd id="lio2401-kwd-0006">sinus disease</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <page-count count="7"/>
        <word-count count="6538"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>June 2020</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.4 mode:remove_FC converted:24.06.2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="lio2401-cit-9001">
<string-name>
<surname>Johnson</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Choby</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>EK</given-names>
</string-name>. <article-title>Chronic rhinosinusitis in patients with cystic fibrosis&#x2014;Current management and new treatments</article-title>. <source xml:lang="en">Laryngoscope Investigative Otolaryngology</source>. <year>2020</year>;<volume>5</volume>:<fpage>368</fpage>&#x2013;<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1002/lio2.401</pub-id>
</mixed-citation>
</p>
    </notes>
  </front>
  <body id="lio2401-body-0001">
    <sec id="lio2401-sec-0006">
      <label>1</label>
      <title>INTRODUCTION</title>
      <p>Cystic fibrosis (CF) is an autosomal recessive disease caused by defective CF transmembrane conductance regulator (CFTR) protein. Mutations in the CFTR gene result in impaired chloride transport to the luminal surface of mucosal epithelium, aberrations in sodium and water resorption, and ultimately, viscous secretions in multiple organs. CF affects 30&#x2009;000 Americans with nearly 1000 new cases diagnosed yearly. The thickened and tenacious mucus causes disease in the upper and lower airways, gastrointestinal tract, and genitourinary system.<xref rid="lio2401-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="lio2401-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> Research focus and treatment development has been heavily centered on the lungs, as pulmonary disease is the main driver of mortality in CF.<xref rid="lio2401-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> However, sinonasal disease is important in patients with CF, both as a source of symptomatic quality of life burden and as a reservoir for pulmonary disease.<xref rid="lio2401-bib-0003" ref-type="ref">
<sup>3</sup>
</xref>
</p>
    </sec>
    <sec id="lio2401-sec-0007">
      <label>2</label>
      <title>METHODS</title>
      <p>The PubMed database was utilized to review current published literature regarding CF chronic rhinosinusitis (CRS). The following search phrases were used: &#x201C;cystic fibrosis chronic rhinosinusitis,&#x201D; &#x201C;cystic fibrosis chronic rhinosinusitis medical,&#x201D; &#x201C;cystic fibrosis chronic rhinosinusitis surgical,&#x201D; &#x201C;cystic fibrosis ivacaftor,&#x201D; &#x201C;cystic fibrosis lumacaftor,&#x201D; &#x201C;cystic fibrosis tezacaftor,&#x201D; and &#x201C;cystic fibrosis elexacaftor.&#x201D; This article aims to review current CF CRS medical and surgical therapies, and present evidence on new CFTR modulators.</p>
      <sec id="lio2401-sec-0008">
        <label>2.1</label>
        <title>Sinonasal manifestations of <styled-content style="fixed-case" toggle="no">CF</styled-content>
</title>
        <p>In the nasal cavity and paranasal sinuses, CF induces chronic disease due to compromise of mucociliary clearance (MCC). The viscous epithelial secretions and inspissated mucus can lead to CRS via impaired MCC, recurrent and/or persistent infection, intramucosal microabscesses, and TH1 mediated and neutrophil predominant inflammation.<xref rid="lio2401-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> This is in contrast to the TH2 mediated inflammation of more common forms of nasal polyposis.<xref rid="lio2401-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> Though less than 20% of CF patients self&#x2010;report CRS symptoms, 2/3 have polyposis and up to 100% of CF patients have radiographic or endoscopic evidence of sinonasal inflammation.<xref rid="lio2401-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="lio2401-bib-0002" ref-type="ref">
<sup>2</sup>
</xref>, <xref rid="lio2401-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> Radiographic imaging of the paranasal sinuses in patients with CF tends to demonstrate bony demineralization, medialization of the lateral nasal wall, sinus opacification, paranasal sinus bone sclerosis, and sinus hypoplasia/under pneumatization (Figures <xref rid="lio2401-fig-0001" ref-type="fig">1</xref> and <xref rid="lio2401-fig-0002" ref-type="fig">2</xref>).<xref rid="lio2401-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> Furthermore, among patients with CF, those with more severe genotypes have worse disease on sinus computed tomography (CT) scan and more often have sinus hypoplasia/aplasia compared to those with less severe genotypes.<xref rid="lio2401-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> Adults with CF CRS have significantly worse Lund&#x2010;Kennedy (LK) scores compared to those without CF, but endoscopic findings are similar in CF patients regardless of the presence of CRS symptoms.<xref rid="lio2401-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> The discordance of objective findings and symptoms creates difficulty in diagnosing and treating patients with CF CRS. However, a recent prospective study of 33 post&#x2010;endoscopic sinus surgery (ESS) patients with CF CRS and diverse lung function found that CRS exacerbation was associated with an odds ratio of 2.07 for having a pulmonary exacerbation recorded at the next visit.<xref rid="lio2401-bib-0007" ref-type="ref">
<sup>7</sup>
</xref> Given the common findings of significant objective disease on imaging and endoscopy, acute change in sinonasal symptomatology may alert the clinician to impending pulmonary exacerbation.</p>
        <fig fig-type="FIGURE" xml:lang="en" id="lio2401-fig-0001" orientation="portrait" position="float">
          <label>FIGURE 1</label>
          <caption>
            <p>Computed tomography (CT) scan CT findings of a patient with CF CRS. Note the poor pneumatization of the frontal, maxillary, and sphenoid sinuses, as well as the sclerotic/osteitic boney remodeling. CF, cystic fibrosis; CRS, chronic rhinosinusitis</p>
          </caption>
          <graphic id="nlm-graphic-1" xlink:href="LIO2-5-368-g001"/>
        </fig>
        <fig fig-type="FIGURE" xml:lang="en" id="lio2401-fig-0002" orientation="portrait" position="float">
          <label>FIGURE 2</label>
          <caption>
            <p>Sagittal CT computed tomography (CT) scan findings of a patient with CF CRS. Note the poor pneumatization of the frontal, maxillary, and sphenoid sinuses, as well as the sclerotic/osteitic boney remodeling. CF, cystic fibrosis; CRS, chronic rhinosinusitis</p>
          </caption>
          <graphic id="nlm-graphic-3" xlink:href="LIO2-5-368-g002"/>
        </fig>
        <p>As understanding of the disease and subsequent therapies, including lung transplantation, continue to improve, the life expectancy of CF patients has increased. For people with CF born between 2012 and 2017, median projected survival age is 43.6&#x2009;years, compared to 32.7 for those born from 2002 to 2007.<xref rid="lio2401-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> As a direct result of this increased life span, more patients with CF are requiring long&#x2010;term management of their CRS and nasal polyposis.</p>
      </sec>
      <sec id="lio2401-sec-0009">
        <label>2.2</label>
        <title>Genetics</title>
        <p>Mutations in the CFTR gene cause abnormal transcription or translation and affect functional chloride transport at the cell membrane.<xref rid="lio2401-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> Nearly 2000 genetic variants have been identified, with the most common mutation being F508del.<xref rid="lio2401-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> Eighty&#x2010;six percent of patients with CF carry at least one copy of this mutation, and no other allelic variant is found in more than 5% of patients.<xref rid="lio2401-bib-0002" ref-type="ref">
<sup>2</sup>
</xref>, <xref rid="lio2401-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> Mutations are grouped into one of five classes, based on the type of defect caused: synthetic, trafficking, channel gating, channel conductance, and transcription levels.<xref rid="lio2401-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> Classes I to III are considered minimal function CFTR mutations and cause more severe phenotypes, while those in IV to V have residual function in CFTR and cause less severe phenotypes.<xref rid="lio2401-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> The definitions of minimal and residual function have been based on the disease severity generally associated with these genotypes, as well as their responsiveness to CFTR modulating therapies.<xref rid="lio2401-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>, <xref rid="lio2401-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> Patients with residual function CFTR exhibit the typical spectrum of CF disease, yet disease that progresses much more slowly than those with minimal function CFTR.<xref rid="lio2401-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>, <xref rid="lio2401-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> Though this classification system provides a framework for understanding loss of function of CFTR based on the mutation, it has become clear that individual CFTR mutations alone do not completely predict the disease phenotype.<xref rid="lio2401-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> For example, F508del leads to misfolding and degradation of the protein product, aberrant chloride channel function, and reduced quantity of protein translated.<xref rid="lio2401-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> It has also been found that variants of other genes, distinct from CFTR, can modify CF phenotype and influence onset of CF&#x2010;related sequelae.<xref rid="lio2401-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> Though all of this information highlights the complexity of the disease, it also has allowed for a paradigm shift in treatment&#x2014;from treating the sequelae of CF to correcting and potentiating the genetic cause of disease.</p>
      </sec>
      <sec id="lio2401-sec-0010">
        <label>2.3</label>
        <title>
<styled-content style="fixed-case" toggle="no">CFTR</styled-content> heterozygotes</title>
        <p>Heterozygosity of CFTR alleles does not cause the full spectrum of CF disease if there is one normal CFTR allele, but one CFTR mutation can lead to CF&#x2010;like disease in at least one of the classically affected organ systems.<xref rid="lio2401-bib-0012" ref-type="ref">
<sup>12</sup>
</xref> Interestingly, it is not only the loss of a copy of wild&#x2010;type CFTR that is problematic for carriers of CFTR mutations. F508del, the most common CFTR mutant, has a dominant negative effect that impairs processing of the wild&#x2010;type protein and limits its expression and function.<xref rid="lio2401-bib-0012" ref-type="ref">
<sup>12</sup>
</xref> Compared to the general population, CFTR carriers more commonly report CRS symptoms (36% vs 14%, <italic>P</italic>&#x2009;&lt;&#x2009;.05) and were found more commonly in a population of patients with CRS (7% vs 2%, <italic>P</italic>&#x2009;&lt;&#x2009;.04).<xref rid="lio2401-bib-0013" ref-type="ref">
<sup>13</sup>
</xref>, <xref rid="lio2401-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> Though patients with a single CFTR mutation are five times more likely to have CRS, most have normal sweat chloride levels (SCLs) and nasal potential difference (NPD) similar to patients without CF.<xref rid="lio2401-bib-0013" ref-type="ref">
<sup>13</sup>
</xref> Normal values on routine testing and the absence of the classic constellation of CF symptoms may limit recognition of these patients. Suspicion of a CRS patient harboring a CFTR mutation should be increased if the patient has: juvenile nasal polyposis, purulent chronic pansinusitis, chronic superinfection of nasal polyposis, hypoplastic frontal and maxillary sinuses, chronic pulmonary symptoms, or infertility.<xref rid="lio2401-bib-0015" ref-type="ref">
<sup>15</sup>
</xref>, <xref rid="lio2401-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> As new CF therapies arise, identification of CFTR heterozygotes may allow for better management of this subset of patients with CRS.</p>
      </sec>
      <sec id="lio2401-sec-0011">
        <label>2.4</label>
        <title>Medical therapies</title>
        <p>For 75&#x2009;years, treatment for CF has centered around targeting end&#x2010;organ manifestations.<xref rid="lio2401-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> In CF CRS, this is no different, as the mainstay of medical treatment includes nasal saline rinses with steroids and/or antibiotics.<xref rid="lio2401-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="lio2401-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> Though nasal rinses with normal (0.9%) saline alone have no clear evidence for benefit in CF, they are used to topically deliver beneficial steroids and antibiotics.<xref rid="lio2401-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> Topical steroids improve polyposis and sinonasal endoscopic appearance in patients with CF CRS, but studies on their effect on symptoms have mixed results.<xref rid="lio2401-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> Though their symptomatic effect is unclear, topical steroids can be used safely with minimal systemic effects.<xref rid="lio2401-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> Topical and oral antibiotics are often used during pulmonary exacerbations but have also been investigated for daily use. Topical colistin and tobramycin have been shown to reduce bacterial load, and tobramycin decreased rate of reoperation 1 year postoperatively.<xref rid="lio2401-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="lio2401-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> In a study of nine patients, six patients used aerosolized tobramycin and experienced improved SNOT&#x2010;20 scores compared to 0.9% saline.<xref rid="lio2401-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> Two larger trials are currently examining the daily use of antibiotics. Oral aztreonam alone is being compared to oral and nasally inhaled aztreonam, with SNOT&#x2010;20 scores as a secondary outcome being investigated in 30 patients.<xref rid="lio2401-bib-0019" ref-type="ref">
<sup>19</sup>
</xref> Nebulized, nasally inhaled tobramycin vs nebulized 0.9% saline is being examined with secondary outcomes including SNOT&#x2010;20 score and several other sinus specific symptoms in 86 patients.<xref rid="lio2401-bib-0020" ref-type="ref">
<sup>20</sup>
</xref> Topical dornase alfa (DA), a recombinant DNase, improves CRS symptoms and lung function by cleaving extracellular neutrophil DNA.<xref rid="lio2401-bib-0021" ref-type="ref">
<sup>21</sup>
</xref> It has been shown to improve sinonasal symptoms (compared to saline rinses), post&#x2010;ESS outcomes, lung function, and prevent pulmonary exacerbations.<xref rid="lio2401-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="lio2401-bib-0003" ref-type="ref">
<sup>3</sup>
</xref>, <xref rid="lio2401-bib-0004" ref-type="ref">
<sup>4</sup>
</xref>, <xref rid="lio2401-bib-0021" ref-type="ref">
<sup>21</sup>
</xref> The main drawback to widespread utilization of both daily topical antibiotics and DA in CF CRS is the cost, with approximate yearly cost of $13&#x2009;972 to $27&#x2009;944 for DA and $12&#x2009;315 to $26&#x2009;366 for colistin, aztreonam, and tobramycin.<xref rid="lio2401-bib-0022" ref-type="ref">
<sup>22</sup>
</xref>
</p>
        <p>CFTR modulators work at the molecular level to increase transmission of CFTR to the epithelial cell membrane (corrector) or improve function of CFTR (potentiator). Functionally, they augment the defect caused by CFTR mutations. In the context of the currently available modulators, CFTR mutations can be thought of as those that cause misprocessing and prevent trafficking (minimal function) and those that lower activity of CFTR at the epithelial surface (residual function).<xref rid="lio2401-bib-0023" ref-type="ref">
<sup>23</sup>
</xref>
</p>
        <p>The first modulator shown to be effective was ivacaftor (Vertex Pharmaceuticals). It functions as a &#x201C;potentiator&#x201D; by increasing the time that activated CFTR channels at the cell surface remain open, and was first proven to benefit patients with the second most common CFTR mutation, G551D (representing 5% of patients).<xref rid="lio2401-bib-0004" ref-type="ref">
<sup>4</sup>
</xref>, <xref rid="lio2401-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> G551D is a class III mutation that allows for transport of CFTR to the epithelial membrane, but causes CFTR gating dysfunction and thus is a residual function mutation.<xref rid="lio2401-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>, <xref rid="lio2401-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> When initially studied in patients 12&#x2009;years and older, ivacaftor showed improvements in FEV1, improved pulmonary symptoms, decreased pulmonary exacerbations, decreased SCL, and improved weight gain.<xref rid="lio2401-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> This was followed up with a study in patients aged 6 to 11 that showed improvement in FEV1, SCL, and weight gain.<xref rid="lio2401-bib-0024" ref-type="ref">
<sup>24</sup>
</xref> Despite a pretreatment mean FEV1 of 84.7% in these young patients, treatment with ivacaftor led to a 12.6% mean increase in FEV1, indicating benefit of intervention in patients with minimal loss of pulmonary function.<xref rid="lio2401-bib-0024" ref-type="ref">
<sup>24</sup>
</xref>
</p>
        <p>In addition to pulmonary outcomes, ivacaftor is the only modulator with published data regarding rhinologic outcomes. In 2014 and 2015, three case reports of one patient each and a case series of 12 patients' response to ivacaftor were published. The case series patients all had at least one copy of G551D, and the case reports covered three different mutations&#x2014;F508del/G551D, G551D/P205S (P205S is type I, mild phenotype mutation), and F508del/S1215N (S1215N is a type III mutation).<xref rid="lio2401-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>, <xref rid="lio2401-bib-0026" ref-type="ref">
<sup>26</sup>
</xref>, <xref rid="lio2401-bib-0027" ref-type="ref">
<sup>27</sup>
</xref>, <xref rid="lio2401-bib-0028" ref-type="ref">
<sup>28</sup>
</xref>, <xref rid="lio2401-bib-0029" ref-type="ref">
<sup>29</sup>
</xref> All three individual case reports detailed improvement or resolution of sinus symptoms, improvement of sinus CT, and increased FEV1, while the case series of 12 reported only improved CT appearance.<xref rid="lio2401-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>, <xref rid="lio2401-bib-0026" ref-type="ref">
<sup>26</sup>
</xref>, <xref rid="lio2401-bib-0027" ref-type="ref">
<sup>27</sup>
</xref>, <xref rid="lio2401-bib-0028" ref-type="ref">
<sup>28</sup>
</xref>
</p>
        <p>A prospective study by McCormick et al showed improvements in the subcategories of rhinology (rhinorrhea, postnasal drip, thick nasal discharge), sleep function (difficulty falling asleep, waking up at night, and lack of a good night's sleep), and psychological function (fatigue, reduced concentration, sadness) on SNOT&#x2010;20 scores for CF patients initiating ivacaftor.<xref rid="lio2401-bib-0030" ref-type="ref">
<sup>30</sup>
</xref> While statistically significant, the improvements did not meet the minimal clinically important difference, which was attributed to the low self&#x2010;reporting of symptoms in CF CRS patients.<xref rid="lio2401-bib-0030" ref-type="ref">
<sup>30</sup>
</xref> Recently, Cho et al published two studies showing benefits of ivacaftor in&#x2009;vitro. The first found synergistic effects of resveratrol (a potentiator) and ivacaftor on chloride transport in G551D human sinonasal epithelium.<xref rid="lio2401-bib-0031" ref-type="ref">
<sup>31</sup>
</xref> The second reported reduction of Pseudomonas biofilms utilizing a ciprofloxacin&#x2010;ivacaftor coated biodegradable nasal stent.<xref rid="lio2401-bib-0032" ref-type="ref">
<sup>32</sup>
</xref> The authors of this study plan to next conduct a study of the coated stents to assess effect on biofilms in&#x2009;vivo.<xref rid="lio2401-bib-0032" ref-type="ref">
<sup>32</sup>
</xref>
</p>
        <p>Another class of CFTR modulator, lumacaftor (a &#x201C;corrector&#x201D;), was found to correct misprocessing of F508del CFTR and increase trafficking of the protein to the cell surface.<xref rid="lio2401-bib-0033" ref-type="ref">
<sup>33</sup>
</xref> In patients homozygous for F508del, lumacaftor&#x2010;ivacaftor improved FEV1, decreased pulmonary exacerbations, improved BMI, and improved quality of life on the Cystic Fibrosis Questionnaire&#x2010;Revised (CFQ&#x2010;R).<xref rid="lio2401-bib-0033" ref-type="ref">
<sup>33</sup>
</xref> Though sinus outcomes were not explicitly analyzed, examination of the supplementary appendix revealed significantly less nasal congestion in the treatment arm of the TRAFFIC trial (one of the two randomized control trials in the study).<xref rid="lio2401-bib-0033" ref-type="ref">
<sup>33</sup>
</xref> This decrease in nasal congestion was not found in the other trial, TRANSPORT, so further study of this modulator combination therapy on sinonasal outcomes is warranted. Lumacaftor&#x2010;ivacaftor has also been shown to improve NPD in patients homozygous for F508del, but none of the studies examined or reported sinonasal outcomes.<xref rid="lio2401-bib-0034" ref-type="ref">
<sup>34</sup>
</xref>, <xref rid="lio2401-bib-0035" ref-type="ref">
<sup>35</sup>
</xref>, <xref rid="lio2401-bib-0036" ref-type="ref">
<sup>36</sup>
</xref>
</p>
        <p>For patients heterozygous for F508del and a residual function allele, tezacaftor (a corrector) plus ivacaftor was found to improve FEV1 and CFQ&#x2010;R when compared to placebo and ivacaftor alone.<xref rid="lio2401-bib-0010" ref-type="ref">
<sup>10</sup>
</xref> In this trial, nasal congestion was not significantly different between placebo and treatment groups.<xref rid="lio2401-bib-0010" ref-type="ref">
<sup>10</sup>
</xref> Searching for studies examining rhinologic outcomes of tezacaftor&#x2010;ivacaftor within the PubMed database yielded no results.</p>
        <p>Recently, a major breakthrough in CFTR modulator therapy was made by adding the next generation corrector elexacaftor (Vertex Pharmaceuticals) to tezacaftor&#x2010;ivacaftor.<xref rid="lio2401-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> Elexacaftor&#x2010;tezacaftor&#x2010;ivacaftor displayed significant improvement in FEV1, CFQ&#x2010;R, decreased pulmonary exacerbations, and normalized SCLs in patients heterozygous for F508del and a minimal function allele.<xref rid="lio2401-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> To this point, ivacaftor for patients with G551D has set the benchmark for CFTR modulator therapy, with an increase of 10.6% in FEV1.<xref rid="lio2401-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> Elexacaftor&#x2010;tezacaftor&#x2010;ivacaftor improved upon this standard, by showing a 13.8% increase in FEV1.<xref rid="lio2401-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> By improving these measures in patients with F508del/minimal function alleles, elexacaftor&#x2010;tezacaftor&#x2010;ivacaftor showed that it could modulate disease for patients with F508del, regardless of their second allele.<xref rid="lio2401-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> This new medication has raised the bar for CFTR modulator therapy efficacy (with regard to FEV1 improvement) and extends CFTR modulator therapy to nearly 90% of people with CF.<xref rid="lio2401-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> In this study and its supplemental appendix, the only reported outcome related to the sinonasal cavity was a nonsignificant difference between therapy and placebo in &#x201C;nasopharyngitis.&#x201D;<xref rid="lio2401-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> A currently ongoing clinical trial aims to examine the effect of the new medication on sinus disease in 70 patients with CF.<xref rid="lio2401-bib-0037" ref-type="ref">
<sup>37</sup>
</xref> With such strong early data, further research into this therapy is needed, and its effects on all aspects of CF disease should be explored. One area of potential high impact is the lung transplant CF patient. With such great FEV1 improvement, triple therapy could potentially improve postlung transplant outcomes, survival, or even change the trajectory of patients who previously would have received lung transplant.</p>
        <p>Sinonasal outcomes have only been directly studied for ivacaftor.<xref rid="lio2401-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>, <xref rid="lio2401-bib-0026" ref-type="ref">
<sup>26</sup>
</xref>, <xref rid="lio2401-bib-0027" ref-type="ref">
<sup>27</sup>
</xref>, <xref rid="lio2401-bib-0028" ref-type="ref">
<sup>28</sup>
</xref>, <xref rid="lio2401-bib-0030" ref-type="ref">
<sup>30</sup>
</xref> Given the efficacy of CFTR modulators on pulmonary disease, increasing lifespan, and prevalence of sinus disease in patients with CF, further investigation of CFTR modulators and other therapies effects on sinus outcomes is warranted. However, one potential barrier to the study and use of CFTR modulators is cost. All of the aforementioned therapies cost roughly $300&#x2009;000 per year.<xref rid="lio2401-bib-0022" ref-type="ref">
<sup>22</sup>
</xref>, <xref rid="lio2401-bib-0038" ref-type="ref">
<sup>38</sup>
</xref>
</p>
      </sec>
      <sec id="lio2401-sec-0012">
        <label>2.5</label>
        <title>Surgical therapy</title>
        <p>Sinus surgery for patients with CF has been established to be a safe procedure for both children and adults, and pediatric facial growth is not affected by sinus surgery.<xref rid="lio2401-bib-0039" ref-type="ref">
<sup>39</sup>
</xref>, <xref rid="lio2401-bib-0040" ref-type="ref">
<sup>40</sup>
</xref>, <xref rid="lio2401-bib-0041" ref-type="ref">
<sup>41</sup>
</xref>, <xref rid="lio2401-bib-0042" ref-type="ref">
<sup>42</sup>
</xref> Patients may undergo multiple sinus procedures and have altered anatomy, but the coupling of CT scan with intraoperative navigation has been important advancement in the surgical management of these patients.<xref rid="lio2401-bib-0004" ref-type="ref">
<sup>4</sup>
</xref>, <xref rid="lio2401-bib-0043" ref-type="ref">
<sup>43</sup>
</xref> There is currently no clear consensus on indications for ESS in patients with CF CRS, although 20% to 60% undergo ESS.<xref rid="lio2401-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> Two recent studies examined patient characteristics predictive of ESS. Brook et al found that patients with severe CFTR mutations and previous ESS were more likely to undergo ESS compared to those with mild CFTR mutations and no history of ESS.<xref rid="lio2401-bib-0044" ref-type="ref">
<sup>44</sup>
</xref> Ayoub et al found early ESS (vs ESS later or medical therapy) was predicted by Lund Mackay CT score, SNOT&#x2010;22, previous ESS, nasal polyposis, and lower FEV1 at presentation.<xref rid="lio2401-bib-0045" ref-type="ref">
<sup>45</sup>
</xref> With their findings, they offer a SNOT&#x2010;22 score of &gt;39 and an FEV1 of &lt;68.7% at presentation to predict the need for ESS at any time point.<xref rid="lio2401-bib-0045" ref-type="ref">
<sup>45</sup>
</xref>
</p>
        <p>Surgical technique for ESS in patients with CF CRS is also without clear evidence of a best practice, though some sinus specific protocols have been published. For the maxillary sinus, several variations of a wide maxillary antrostomy have been promoted as safe and with improved mucus clearance.<xref rid="lio2401-bib-0046" ref-type="ref">
<sup>46</sup>
</xref> Recently, modified endoscopic medial maxillectomy has been recommended with significant improvements in symptom score, endoscopic appearance, and decreased pulmonary exacerbations.<xref rid="lio2401-bib-0046" ref-type="ref">
<sup>46</sup>
</xref> Though FEV1 was unchanged, the authors state that the procedure also allows for better access to the maxillary sinus, including in&#x2010;office debridement, improved clearance of mucus with rinses, and increased penetrance of topical therapies.<xref rid="lio2401-bib-0046" ref-type="ref">
<sup>46</sup>
</xref> Utilizing endoscopic maxillary mega&#x2010;antrostomy, 74% of patients reported complete resolution of symptoms while 26% reported partial symptomatic improvement.<xref rid="lio2401-bib-0047" ref-type="ref">
<sup>47</sup>
</xref>, <xref rid="lio2401-bib-0048" ref-type="ref">
<sup>48</sup>
</xref> Patients with CF made up nearly 25% of this cohort, and this has become the authors' standard protocol for management of the maxillary sinus in patients with CF CRS.<xref rid="lio2401-bib-0047" ref-type="ref">
<sup>47</sup>
</xref>, <xref rid="lio2401-bib-0048" ref-type="ref">
<sup>48</sup>
</xref> Regardless of technique, poor pneumatization of the maxillary sinus and under&#x2010;mineralized/hypoplastic uncinate processes in patients with CF are important surgical considerations when addressing the maxillary sinus.<xref rid="lio2401-bib-0004" ref-type="ref">
<sup>4</sup>
</xref>
</p>
        <p>Evidence on specific surgical technique for the ethmoid, sphenoid, and frontal sinuses is lacking. Anatomically, concha bullosa and Haller cells were less common in patients with CF, while Onodi cells were more common.<xref rid="lio2401-bib-0049" ref-type="ref">
<sup>49</sup>
</xref> In children, a low ethmoid roof compared to patients without CF was noted, though this was not true for adults.<xref rid="lio2401-bib-0049" ref-type="ref">
<sup>49</sup>
</xref> Regarding the frontal sinus, two patients with CF CRS and persistent symptoms after multiple ESS had good symptomatic improvement after modified endoscopic Lothrop (Draf III) frontal sinus surgery.<xref rid="lio2401-bib-0050" ref-type="ref">
<sup>50</sup>
</xref> Overall, very little data are available on surgical approaches for CF CRS.</p>
        <p>In three systematic reviews of ESS for CF CRS, adults and children consistently experienced symptomatic benefit, but no clear improvement in FEV1 was demonstrated.<xref rid="lio2401-bib-0040" ref-type="ref">
<sup>40</sup>
</xref>, <xref rid="lio2401-bib-0051" ref-type="ref">
<sup>51</sup>
</xref>, <xref rid="lio2401-bib-0052" ref-type="ref">
<sup>52</sup>
</xref> Data on endoscopy score, CT appearance, hospitalization, and antibiotic use were mixed.<xref rid="lio2401-bib-0040" ref-type="ref">
<sup>40</sup>
</xref>, <xref rid="lio2401-bib-0051" ref-type="ref">
<sup>51</sup>
</xref>, <xref rid="lio2401-bib-0052" ref-type="ref">
<sup>52</sup>
</xref> Necessity of ESS prior to or after lung transplant (LuTx) is a subject of debate. There is growing evidence to support the sinonasal cavity and the lungs as a unified airway with translocation of bacteria from the sinuses as a source of colonization or infection of the lungs.<xref rid="lio2401-bib-0053" ref-type="ref">
<sup>53</sup>
</xref>, <xref rid="lio2401-bib-0054" ref-type="ref">
<sup>54</sup>
</xref>, <xref rid="lio2401-bib-0055" ref-type="ref">
<sup>55</sup>
</xref>, <xref rid="lio2401-bib-0056" ref-type="ref">
<sup>56</sup>
</xref> Regarding ESS prior to LuTX, one paper reported 87% of patients' lungs were recolonized (mean 19&#x2009;days after ESS) with <italic>Pseudomonas aeruginosa</italic> post&#x2010;transplant and no survival benefit when compared to centers where patients did not undergo ESS before transplantation.<xref rid="lio2401-bib-0057" ref-type="ref">
<sup>57</sup>
</xref> There was no standardized surgical procedure in this cohort and postsurgical sinus care was unclear.<xref rid="lio2401-bib-0057" ref-type="ref">
<sup>57</sup>
</xref> Four papers reported outcomes of ESS shortly after LuTX, three of which came from University of Zurich and followed essentially the same protocol. This initially consisted of maxillary antrostomy, ethmoidectomy, sphenoidotomy, and Draf I frontal sinusotomy (with daily postoperative isotonic saline rinses) after recovery from LuTX and 2&#x2009;weeks of culture&#x2010;directed antibiotic therapy.<xref rid="lio2401-bib-0058" ref-type="ref">
<sup>58</sup>
</xref> Later, the authors generally describe more aggressive surgery to remove all septations in sinuses, including removal of the floor of the sphenoid sinus and the middle turbinate.<xref rid="lio2401-bib-0059" ref-type="ref">
<sup>59</sup>
</xref> The authors advocate that this allows for better drainage of the sinuses and improved penetrance of nasal rinses, with no adverse effects.<xref rid="lio2401-bib-0059" ref-type="ref">
<sup>59</sup>
</xref> After ESS, these three studies reported a correlation between negative sinus culture and negative lung culture, though there was a 59% to 68% rate of persistent nasal colonization.<xref rid="lio2401-bib-0058" ref-type="ref">
<sup>58</sup>
</xref>, <xref rid="lio2401-bib-0059" ref-type="ref">
<sup>59</sup>
</xref>, <xref rid="lio2401-bib-0060" ref-type="ref">
<sup>60</sup>
</xref> The earliest paper from this group reported rates of bronchiolitis obliterans syndrome (BOS) comparable to patients without CF who undergo LuTx and lower rates of tracheobronchitis and pneumonia in cases of successful sinus surgery (defined by obtaining three or less sinus aspirates with bacterial counts greater than 10<sup>4</sup>).<xref rid="lio2401-bib-0058" ref-type="ref">
<sup>58</sup>
</xref> Their 2013 paper reported that patients with negative bronchoalveolar lavage and nasal aspirates had improved survival at 5&#x2009;years after LuTx (86% vs 57%) with fewer patients having BOS stages 1 and 2 (as defined by FEV1 66%&#x2010;80% and 51%&#x2010;65% of baseline, respectively).<xref rid="lio2401-bib-0060" ref-type="ref">
<sup>60</sup>
</xref>, <xref rid="lio2401-bib-0061" ref-type="ref">
<sup>61</sup>
</xref> Overall, these studies indicate that ESS after LuTx may have some benefit, especially to patients in whom bacterial eradication can be achieved.</p>
        <p>A 2019 paper evaluated nine patients who underwent various forms of ESS (with daily postoperative saline rinses) after LuTx and 1 week of preoperative IV antibiotics.<xref rid="lio2401-bib-0062" ref-type="ref">
<sup>62</sup>
</xref> Compared to 14 patients who had LuTx without ESS, those who had ESS had improved nasal obstruction, rhinorrhea, SNOT&#x2010;22 score, and LK score.<xref rid="lio2401-bib-0062" ref-type="ref">
<sup>62</sup>
</xref> Another 2019 paper investigated 20 patients who underwent 36 ESS at least a year after LuTx.<xref rid="lio2401-bib-0063" ref-type="ref">
<sup>63</sup>
</xref> In that cohort, antibiotic use was decreased in the 6 months after ESS compared to 6 months preoperatively, but no difference was found in length of hospitalizations or FEV1.<xref rid="lio2401-bib-0063" ref-type="ref">
<sup>63</sup>
</xref> Similarly, a 2020 paper evaluated complete ESS (bilateral maxillary antrostomy of any size, bilateral total ethmoidectomy, bilateral sphenoidotomy, and bilateral Draf IIa or IIb frontal sinusotomy) vs limited ESS (any procedure less than above) in patients with CF CRS. In their retrospective review, they found that use of oral antibiotics was reduced in the complete ESS group, but found no difference in IV antibiotic use, hospital admission frequency or length, or rate of change in FEV1.<xref rid="lio2401-bib-0064" ref-type="ref">
<sup>64</sup>
</xref>
</p>
      </sec>
    </sec>
    <sec id="lio2401-sec-0013">
      <label>3</label>
      <title>CONCLUSION</title>
      <p>The lifespan of patients with CF has greatly increased over the past 20&#x2009;years due to improvement in treatment of end&#x2010;organ disease. Management of CF CRS, however, remains challenging. At this time, there are no consensus guidelines regarding treatment of CF CRS. However, the CF Foundation is currently developing guidelines for Otorhinolaryngology care, which will be an excellent resource to standardize the care of patients with CF CRS.</p>
      <p>Currently, common medical therapies for CF CRS include saline rinses, topical steroids, DA, topical antibiotics during exacerbation, and CFTR modulators in appropriate patients. Beginning in 2012, targeted therapies such as ivacaftor (a potentiator) sparked a new wave of treatment for CF, directly modulating the dysfunctional protein that defines the disease. Correctors (increase trafficking to cell membrane) have been added since then, now with a triple combination therapy expansion that can be applied to treat nearly 90% of CF patients. There is no definitive agreement on surgical indications or technique, though aggressive surgery in recalcitrant disease has shown some symptomatic benefit. ESS after lung transplant appears to benefit patients in whom sinus bacteria are eradicated by decreasing pulmonary infections, decreasing rates of BOS, and improving 5 year survival. As treatment for CF expands and patients with CF live longer, further investigation is required to examine the effects of these medications on sinus disease. As CFTR modulators are increasingly utilized, the treatment paradigm of CF CRS may change. However, the otolaryngologist will remain critical to the multidisciplinary care team by providing longitudinal care for the rhinologic, otologic, and upper airway needs of patients with CF.</p>
    </sec>
    <sec sec-type="COI-statement" id="lio2401-sec-0014">
      <title>CONFLICT OF INTEREST</title>
      <p>The authors declare no potential conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ref-list id="lio2401-bibl-0001" content-type="cited-references">
      <title>REFERENCES</title>
      <ref id="lio2401-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0001">
<string-name>
<surname>Tipirneni</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Woodworth</surname>
<given-names>BA</given-names>
</string-name>. <article-title>Medical and surgical advancements in the management of cystic fibrosis chronic rhinosinusitis</article-title>. <source xml:lang="en">Curr Otorhinolaryngol Rep</source>. <year>2017</year>;<volume>5</volume>(<issue>1</issue>):<fpage>24</fpage>&#x2010;<lpage>34</lpage>.<pub-id pub-id-type="pmid">28989817</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="book" id="lio2401-cit-0002">
<collab collab-type="authors">CF Foundation</collab>
. <source xml:lang="en">2017 Annual Data Report</source>. <publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>Cystic Fibrosis Foundation Patient Registry</publisher-name>; <year>2018</year>.</mixed-citation>
      </ref>
      <ref id="lio2401-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0003">
<string-name>
<surname>Zheng</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Safi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gudis</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Surgical management of chronic rhinosinusitis in cystic fibrosis</article-title>. <source xml:lang="en">Med Sci</source>. <year>2019</year>;<volume>7</volume>(<issue>4</issue>):57.</mixed-citation>
      </ref>
      <ref id="lio2401-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0004">
<string-name>
<surname>Safi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Dimango</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Keating</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gudis</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Chronic rhinosinusitis in cystic fibrosis: diagnosis and medical management</article-title>. <source xml:lang="en">Med Sci</source>. <year>2019</year>;<volume>7</volume>(<issue>2</issue>):32.</mixed-citation>
      </ref>
      <ref id="lio2401-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0005">
<string-name>
<surname>Halderman</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>London</surname>
<given-names>NR</given-names>
</string-name>, et al. <article-title>Impact of high&#x2010; versus low&#x2010;risk genotype on sinonasal radiographic disease in cystic fibrosis</article-title>. <source xml:lang="en">Laryngoscope</source>. <year>2019</year>;<volume>129</volume>(<issue>4</issue>):<fpage>788</fpage>&#x2010;<lpage>793</lpage>.<pub-id pub-id-type="pmid">30549259</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0006">
<string-name>
<surname>Casserly</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Harrison</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>O'Connell</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>O'Donovan</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Plant</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>O'Sullivan</surname>
<given-names>P</given-names>
</string-name>. <article-title>Nasal endoscopy and paranasal sinus computerised tomography (CT) findings in an Irish cystic fibrosis adult patient group</article-title>. <source xml:lang="en">Eur Arch Otorhinolaryngol</source>. <year>2015</year>;<volume>272</volume>(<issue>11</issue>):<fpage>3353</fpage>&#x2010;<lpage>3359</lpage>.<pub-id pub-id-type="pmid">25537816</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0007">
<string-name>
<surname>Zemke</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Nouraie</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Clinical predictors of cystic fibrosis chronic rhinosinusitis severity</article-title>. <source xml:lang="en">Int Forum Allergy Rhinol</source>. <year>2019</year>;<volume>9</volume>(<issue>7</issue>):<fpage>759</fpage>&#x2010;<lpage>765</lpage>.<pub-id pub-id-type="pmid">31162888</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0008">
<string-name>
<surname>Cutting</surname>
<given-names>GR</given-names>
</string-name>. <article-title>Cystic fibrosis genetics: from molecular understanding to clinical application</article-title>. <source xml:lang="en">Nat Rev Genet</source>. <year>2015</year>;<volume>16</volume>(<issue>1</issue>):<fpage>45</fpage>&#x2010;<lpage>56</lpage>.<pub-id pub-id-type="pmid">25404111</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0009">
<string-name>
<surname>Clancy</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Jain</surname>
<given-names>M</given-names>
</string-name>. <article-title>Personalized medicine in cystic fibrosis: dawning of a new era</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2012</year>;<volume>186</volume>(<issue>7</issue>):<fpage>593</fpage>&#x2010;<lpage>597</lpage>.<pub-id pub-id-type="pmid">22723294</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0010">
<string-name>
<surname>Rowe</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Daines</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ringshausen</surname>
<given-names>FC</given-names>
</string-name>, et al. <article-title>Tezacaftor&#x2010;ivacaftor in residual&#x2010;function heterozygotes with cystic fibrosis</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>21</issue>):<fpage>2024</fpage>&#x2010;<lpage>2035</lpage>.<pub-id pub-id-type="pmid">29099333</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0011">
<string-name>
<surname>Middleton</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Mall</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Drevinek</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Elexacaftor&#x2010;tezacaftor&#x2010;ivacaftor for cystic fibrosis with a single Phe508del allele</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2019</year>;<volume>381</volume>(<issue>19</issue>):<fpage>1809</fpage>&#x2010;<lpage>1819</lpage>.<pub-id pub-id-type="pmid">31697873</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0012">
<string-name>
<surname>Tucker</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Fortenberry</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Zsembery</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schwiebert</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Schwiebert</surname>
<given-names>EM</given-names>
</string-name>. <article-title>The DeltaF508&#x2010;CFTR mutation inhibits wild&#x2010;type CFTR processing and function when co&#x2010;expressed in human airway epithelia and in mouse nasal mucosa</article-title>. <source xml:lang="en">BMC Physiol</source>. <year>2012</year>;<volume>12</volume>:<fpage>12</fpage>.<pub-id pub-id-type="pmid">22999299</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0013">
<string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Moylan</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Leopold</surname>
<given-names>DA</given-names>
</string-name>, et al. <article-title>Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population</article-title>. <source xml:lang="en">JAMA</source>. <year>2000</year>;<volume>284</volume>(<issue>14</issue>):<fpage>1814</fpage>&#x2010;<lpage>1819</lpage>.<pub-id pub-id-type="pmid">11025834</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0014">
<string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McWilliams</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cutting</surname>
<given-names>GR</given-names>
</string-name>. <article-title>Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation</article-title>. <source xml:lang="en">Arch Otolaryngol Head Neck Surg</source>. <year>2005</year>;<volume>131</volume>(<issue>3</issue>):<fpage>237</fpage>&#x2010;<lpage>240</lpage>.<pub-id pub-id-type="pmid">15781764</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0015">
<string-name>
<surname>Coste</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Girodon</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Louis</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Atypical sinusitis in adults must lead to looking for cystic fibrosis and primary ciliary dyskinesia</article-title>. <source xml:lang="en">Laryngoscope</source>. <year>2004</year>;<volume>114</volume>(<issue>5</issue>):<fpage>839</fpage>&#x2010;<lpage>843</lpage>.<pub-id pub-id-type="pmid">15126740</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0016">
<string-name>
<surname>Calton</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Koripella</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Willis</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Le</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Chiu</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>EH</given-names>
</string-name>. <article-title>Paranasal sinus size is decreased in CFTR heterozygotes with chronic rhinosinusitis</article-title>. <source xml:lang="en">Int Forum Allergy Rhinol</source>. <year>2017</year>;<volume>7</volume>(<issue>3</issue>):<fpage>256</fpage>&#x2010;<lpage>260</lpage>.<pub-id pub-id-type="pmid">27860385</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0017">
<string-name>
<surname>Mainz</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Schadlich</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Schien</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway <italic>Pseudomonas aeruginosa</italic> colonization: results of a randomized, double&#x2010;blind, placebo&#x2010;controlled pilot study</article-title>. <source xml:lang="en">Drug des Devel Ther</source>. <year>2014</year>;<volume>8</volume>:<fpage>209</fpage>&#x2010;<lpage>217</lpage>.</mixed-citation>
      </ref>
      <ref id="lio2401-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0018">
<string-name>
<surname>Moss</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>King</surname>
<given-names>VV</given-names>
</string-name>. <article-title>Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Reduction in recurrence requiring surgery</article-title>. <source xml:lang="en">Arch Otolaryngol Head Neck Surg</source>. <year>1995</year>;<volume>121</volume>(<issue>5</issue>):<fpage>566</fpage>&#x2010;<lpage>572</lpage>.<pub-id pub-id-type="pmid">7727092</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="miscellaneous" id="lio2401-cit-0019">Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT02730793">https://ClinicalTrials.gov/show/NCT02730793</ext-link>. Accessed December 5, 2019.</mixed-citation>
      </ref>
      <ref id="lio2401-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="miscellaneous" id="lio2401-cit-0020">Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT02888730">https://ClinicalTrials.gov/show/NCT02888730</ext-link>. Accessed December 5, 2019.</mixed-citation>
      </ref>
      <ref id="lio2401-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0021">
<string-name>
<surname>Mainz</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Schien</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schiller</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double&#x2010;blind placebo&#x2010;controlled cross&#x2010;over trial</article-title>. <source xml:lang="en">J Cyst Fibros</source>. <year>2014</year>;<volume>13</volume>(<issue>4</issue>):<fpage>461</fpage>&#x2010;<lpage>470</lpage>.<pub-id pub-id-type="pmid">24594542</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="miscellaneous" id="lio2401-cit-0022">
<collab collab-type="authors">Health CAfDaTi</collab>
. <italic>Table 11 Cost Comparison Table for Drugs Used for Cystic Fibrosis. Common Drug Review</italic> Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; <year>2015</year>.</mixed-citation>
      </ref>
      <ref id="lio2401-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0023">
<string-name>
<surname>Ramsey</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McElvaney</surname>
<given-names>NG</given-names>
</string-name>, et al. <article-title>A CFTR potentiator in patients with cystic fibrosis and the G551D mutation</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>18</issue>):<fpage>1663</fpage>&#x2010;<lpage>1672</lpage>.<pub-id pub-id-type="pmid">22047557</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0024">
<string-name>
<surname>Davies</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Wainwright</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Canny</surname>
<given-names>GJ</given-names>
</string-name>, et al. <article-title>Efficacy and safety of ivacaftor in patients aged 6 to 11&#x2009;years with cystic fibrosis with a G551D mutation</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2013</year>;<volume>187</volume>(<issue>11</issue>):<fpage>1219</fpage>&#x2010;<lpage>1225</lpage>.<pub-id pub-id-type="pmid">23590265</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0025">
<string-name>
<surname>Chang</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>XX</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>VS</given-names>
</string-name>, et al. <article-title>Medical reversal of chronic sinusitis in a cystic fibrosis patient with ivacaftor</article-title>. <source xml:lang="en">Int Forum Allergy Rhinol</source>. <year>2015</year>;<volume>5</volume>(<issue>2</issue>):<fpage>178</fpage>&#x2010;<lpage>181</lpage>.<pub-id pub-id-type="pmid">25363320</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0026">
<string-name>
<surname>Sheikh</surname>
<given-names>SI</given-names>
</string-name>, <string-name>
<surname>Long</surname>
<given-names>FR</given-names>
</string-name>, <string-name>
<surname>McCoy</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ryan&#x2010;Wenger</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Hayes</surname>
<given-names>D</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation</article-title>. <source xml:lang="en">Clin Otolaryngol</source>. <year>2015</year>;<volume>40</volume>(<issue>1</issue>):<fpage>16</fpage>&#x2010;<lpage>21</lpage>.<pub-id pub-id-type="pmid">25145599</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0027">
<string-name>
<surname>Vreede</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Berkhout</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Sprij</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Fokkens</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Heijerman</surname>
<given-names>HG</given-names>
</string-name>. <article-title>Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N</article-title>. <source xml:lang="en">J Cyst Fibros</source>. <year>2015</year>;<volume>14</volume>(<issue>3</issue>):<fpage>412</fpage>&#x2010;<lpage>413</lpage>.<pub-id pub-id-type="pmid">25169789</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0028">
<string-name>
<surname>Hayes</surname>
<given-names>D</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>McCoy</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Sheikh</surname>
<given-names>SI</given-names>
</string-name>. <article-title>Improvement of sinus disease in cystic fibrosis with ivacaftor therapy</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2014</year>;<volume>190</volume>(<issue>4</issue>):<fpage>468</fpage>.<pub-id pub-id-type="pmid">25127305</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0029">
<string-name>
<surname>Chillon</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Casals</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nunes</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gimenez</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Perez Ruiz</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Estivill</surname>
<given-names>X</given-names>
</string-name>. <article-title>Identification of a new missense mutation (P205S) in the first transmembrane domain of the CFTR gene associated with a mild cystic fibrosis phenotype</article-title>. <source xml:lang="en">Hum Mol Genet</source>. <year>1993</year>;<volume>2</volume>(<issue>10</issue>):<fpage>1741</fpage>&#x2010;<lpage>1742</lpage>.<pub-id pub-id-type="pmid">7505694</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0030">
<string-name>
<surname>McCormick</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>DY</given-names>
</string-name>, <string-name>
<surname>Lampkin</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Ivacaftor improves rhinologic, psychologic, and sleep&#x2010;related quality of life in G551D cystic fibrosis patients</article-title>. <source xml:lang="en">Int Forum Allergy Rhinol</source>. <year>2019</year>;<volume>9</volume>(<issue>3</issue>):<fpage>292</fpage>&#x2010;<lpage>297</lpage>.<pub-id pub-id-type="pmid">30472785</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0031">
<string-name>
<surname>Zhang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lazrak</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Resveratrol and ivacaftor are additive CFTR potentiators: therapeutic implications for CF sinus disease</article-title>. <source xml:lang="en">Pediatr Pulm</source>. <year>2018</year>;<volume>53</volume>:<fpage>161</fpage>&#x2010;<lpage>161</lpage>.</mixed-citation>
      </ref>
      <ref id="lio2401-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0032">
<string-name>
<surname>Cho</surname>
<given-names>DY</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Mackey</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>In&#x2010;vitro evaluation of a ciprofloxacin&#x2010; and ivacaftor&#x2010;coated sinus stent against <italic>Pseudomonas aeruginosa</italic> biofilms</article-title>. <source xml:lang="en">Int Forum Allergy Rhinol</source>. <year>2019</year>;<volume>9</volume>(<issue>5</issue>):<fpage>486</fpage>&#x2010;<lpage>492</lpage>.<pub-id pub-id-type="pmid">30702211</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0033">
<string-name>
<surname>Wainwright</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Elborn</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Ramsey</surname>
<given-names>BW</given-names>
</string-name>, et al. <article-title>Lumacaftor&#x2010;ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2015</year>;<volume>373</volume>(<issue>3</issue>):<fpage>220</fpage>&#x2010;<lpage>231</lpage>.<pub-id pub-id-type="pmid">25981758</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0034">
<string-name>
<surname>Masson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schneider&#x2010;Futschik</surname>
<given-names>EK</given-names>
</string-name>, <string-name>
<surname>Baatallah</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Predictive factors for lumacaftor/ivacaftor clinical response</article-title>. <source xml:lang="en">J Cyst Fibros</source>. <year>2019</year>;<volume>18</volume>(<issue>3</issue>):<fpage>368</fpage>&#x2010;<lpage>374</lpage>.<pub-id pub-id-type="pmid">30595473</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0035">
<string-name>
<surname>Graeber</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Dopfer</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Naehrlich</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Effects of lumacaftor&#x2010;ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in Phe508del homozygous patients with cystic fibrosis</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2018</year>;<volume>197</volume>(<issue>11</issue>):<fpage>1433</fpage>&#x2010;<lpage>1442</lpage>.<pub-id pub-id-type="pmid">29327948</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0036">
<string-name>
<surname>Pranke</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Hatton</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Simonin</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators</article-title>. <source xml:lang="en">Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>7375</fpage>.<pub-id pub-id-type="pmid">28785019</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="miscellaneous" id="lio2401-cit-0037">Impact of Triple Combination CFTR Therapy on Sinus Disease. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT04056702">https://ClinicalTrials.gov/show/NCT04056702</ext-link>. Accessed December 5, 2019.</mixed-citation>
      </ref>
      <ref id="lio2401-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0038">
<string-name>
<surname>Mahase</surname>
<given-names>E</given-names>
</string-name>. <article-title>Cystic fibrosis: triple therapy shows promising results</article-title>. <source xml:lang="en">BMJ</source>. <year>2019</year>;<volume>367</volume>:<elocation-id>l6347</elocation-id>.<pub-id pub-id-type="pmid">31685479</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0039">
<string-name>
<surname>Tumin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hayes</surname>
<given-names>D</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Kirkby</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Tobias</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>McKee</surname>
<given-names>C</given-names>
</string-name>. <article-title>Safety of endoscopic sinus surgery in children with cystic fibrosis</article-title>. <source xml:lang="en">Int J Pediatr Otorhinolaryngol</source>. <year>2017</year>;<volume>98</volume>:<fpage>25</fpage>&#x2010;<lpage>28</lpage>.<pub-id pub-id-type="pmid">28583497</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0040">
        <label>40</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0040">
<string-name>
<surname>Macdonald</surname>
<given-names>KI</given-names>
</string-name>, <string-name>
<surname>Gipsman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Magit</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Endoscopic sinus surgery in patients with cystic fibrosis: a systematic review and meta&#x2010;analysis of pulmonary function</article-title>. <source xml:lang="en">Rhinology</source>. <year>2012</year>;<volume>50</volume>(<issue>4</issue>):<fpage>360</fpage>&#x2010;<lpage>369</lpage>.<pub-id pub-id-type="pmid">23181249</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0041">
        <label>41</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0041">
<string-name>
<surname>Schulte</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Kasperbauer</surname>
<given-names>JL</given-names>
</string-name>. <article-title>Safety of paranasal sinus surgery in patients with cystic fibrosis</article-title>. <source xml:lang="en">Laryngoscope</source>. <year>1998</year>;<volume>108</volume>(<issue>12</issue>):<fpage>1813</fpage>&#x2010;<lpage>1815</lpage>.<pub-id pub-id-type="pmid">9851496</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0042">
        <label>42</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0042">
<string-name>
<surname>Van Peteghem</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Clement</surname>
<given-names>PA</given-names>
</string-name>. <article-title>Influence of extensive functional endoscopic sinus surgery (FESS) on facial growth in children with cystic fibrosis. Comparison of 10 cephalometric parameters of the midface for three study groups</article-title>. <source xml:lang="en">Int J Pediatr Otorhinolaryngol</source>. <year>2006</year>;<volume>70</volume>(<issue>8</issue>):<fpage>1407</fpage>&#x2010;<lpage>1413</lpage>.<pub-id pub-id-type="pmid">16621034</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0043">
        <label>43</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0043">
<string-name>
<surname>Fuchsmann</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ayari</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Reix</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Contribution of CT&#x2010;assisted navigation and microdebriders to endoscopic sinus surgery in cystic fibrosis</article-title>. <source xml:lang="en">Int J Pediatr Otorhinolaryngol</source>. <year>2008</year>;<volume>72</volume>(<issue>3</issue>):<fpage>343</fpage>&#x2010;<lpage>349</lpage>.<pub-id pub-id-type="pmid">18178261</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0044">
        <label>44</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0044">
<string-name>
<surname>Brook</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Maxfield</surname>
<given-names>AZ</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sedaghat</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Holbrook</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Gray</surname>
<given-names>ST</given-names>
</string-name>. <article-title>Factors influencing the need for endoscopic sinus surgery in adult patients with cystic fibrosis</article-title>. <source xml:lang="en">Am J Rhinol Allergy</source>. <year>2017</year>;<volume>31</volume>(<issue>1</issue>):<fpage>44</fpage>&#x2010;<lpage>47</lpage>.<pub-id pub-id-type="pmid">28234153</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0045">
        <label>45</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0045">
<string-name>
<surname>Ayoub</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Thamboo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Habib</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Nayak</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>PH</given-names>
</string-name>. <article-title>Determinants and outcomes of upfront surgery versus medical therapy for chronic rhinosinusitis in cystic fibrosis</article-title>. <source xml:lang="en">Int Forum Allergy Rhinol</source>. <year>2017</year>;<volume>7</volume>(<issue>5</issue>):<fpage>450</fpage>&#x2010;<lpage>458</lpage>.<pub-id pub-id-type="pmid">28218486</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0046">
        <label>46</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0046">
<string-name>
<surname>Virgin</surname>
<given-names>FW</given-names>
</string-name>, <string-name>
<surname>Rowe</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Wade</surname>
<given-names>MB</given-names>
</string-name>, et al. <article-title>Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitis</article-title>. <source xml:lang="en">Am J Rhinol Allergy</source>. <year>2012</year>;<volume>26</volume>(<issue>1</issue>):<fpage>70</fpage>&#x2010;<lpage>75</lpage>.<pub-id pub-id-type="pmid">22391086</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0047">
        <label>47</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0047">
<string-name>
<surname>Costa</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Psaltis</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Nayak</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>PH</given-names>
</string-name>. <article-title>Long&#x2010;term outcomes of endoscopic maxillary mega&#x2010;antrostomy for refractory chronic maxillary sinusitis</article-title>. <source xml:lang="en">Int Forum Allergy Rhinol</source>. <year>2015</year>;<volume>5</volume>(<issue>1</issue>):<fpage>60</fpage>&#x2010;<lpage>65</lpage>.<pub-id pub-id-type="pmid">25312656</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0048">
        <label>48</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0048">
<string-name>
<surname>Cho</surname>
<given-names>DY</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>PH</given-names>
</string-name>. <article-title>Results of endoscopic maxillary mega&#x2010;antrostomy in recalcitrant maxillary sinusitis</article-title>. <source xml:lang="en">Am J Rhinol</source>. <year>2008</year>;<volume>22</volume>(<issue>6</issue>):<fpage>658</fpage>&#x2010;<lpage>662</lpage>.<pub-id pub-id-type="pmid">19178809</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0049">
        <label>49</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0049">
<string-name>
<surname>Eggesbo</surname>
<given-names>HB</given-names>
</string-name>, <string-name>
<surname>Sovik</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dolvik</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Eiklid</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kolmannskog</surname>
<given-names>F</given-names>
</string-name>. <article-title>CT characterization of developmental variations of the paranasal sinuses in cystic fibrosis</article-title>. <source xml:lang="en">Acta Radiol</source>. <year>2001</year>;<volume>42</volume>(<issue>5</issue>):<fpage>482</fpage>&#x2010;<lpage>493</lpage>.<pub-id pub-id-type="pmid">11552886</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0050">
        <label>50</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0050">
<string-name>
<surname>Jaberoo</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Pulido</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Saleh</surname>
<given-names>HA</given-names>
</string-name>. <article-title>Modified Lothrop procedure in cystic fibrosis patients: does it have a role?</article-title>
<source xml:lang="en">J Laryngol Otol</source>. <year>2013</year>;<volume>127</volume>(<issue>7</issue>):<fpage>666</fpage>&#x2010;<lpage>669</lpage>.<pub-id pub-id-type="pmid">23750749</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0051">
        <label>51</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0051">
<string-name>
<surname>Liang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Higgins</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Ishman</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Boss</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Benke</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>SY</given-names>
</string-name>. <article-title>Surgical management of chronic rhinosinusitis in cystic fibrosis: a systematic review</article-title>. <source xml:lang="en">Int Forum Allergy Rhinol</source>. <year>2013</year>;<volume>3</volume>(<issue>10</issue>):<fpage>814</fpage>&#x2010;<lpage>822</lpage>.<pub-id pub-id-type="pmid">23839953</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0052">
        <label>52</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0052">
<string-name>
<surname>Vlastarakos</surname>
<given-names>PV</given-names>
</string-name>, <string-name>
<surname>Fetta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Segas</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Maragoudakis</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Nikolopoulos</surname>
<given-names>TP</given-names>
</string-name>. <article-title>Functional endoscopic sinus surgery improves sinus&#x2010;related symptoms and quality of life in children with chronic rhinosinusitis: a systematic analysis and meta&#x2010;analysis of published interventional studies</article-title>. <source xml:lang="en">Clin Pediatr</source>. <year>2013</year>;<volume>52</volume>(<issue>12</issue>):<fpage>1091</fpage>&#x2010;<lpage>1097</lpage>.</mixed-citation>
      </ref>
      <ref id="lio2401-bib-0053">
        <label>53</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0053">
<string-name>
<surname>Mainz</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Hentschel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schien</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Sinonasal persistence of <italic>Pseudomonas aeruginosa</italic> after lung transplantation</article-title>. <source xml:lang="en">J Cyst Fibros</source>. <year>2012</year>;<volume>11</volume>(<issue>2</issue>):<fpage>158</fpage>&#x2010;<lpage>161</lpage>.<pub-id pub-id-type="pmid">22133899</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0054">
        <label>54</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0054">
<string-name>
<surname>Morlacchi</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Greer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tudorache</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>The burden of sinus disease in cystic fibrosis lung transplant recipients</article-title>. <source xml:lang="en">Transpl Infect Dis</source>. <year>2018</year>;<volume>20</volume>(<issue>5</issue>):<elocation-id>e12924</elocation-id>.<pub-id pub-id-type="pmid">29797646</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0055">
        <label>55</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0055">
<string-name>
<surname>Choi</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>TZ</given-names>
</string-name>, <string-name>
<surname>Honeybrook</surname>
<given-names>AL</given-names>
</string-name>, et al. <article-title>Correlation between sinus and lung cultures in lung transplant patients with cystic fibrosis</article-title>. <source xml:lang="en">Int Forum Allergy Rhinol</source>. <year>2018</year>;<volume>8</volume>(<issue>3</issue>):<fpage>389</fpage>&#x2010;<lpage>393</lpage>.<pub-id pub-id-type="pmid">29240302</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0056">
        <label>56</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0056">
<string-name>
<surname>Pletcher</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Cope</surname>
<given-names>EK</given-names>
</string-name>. <article-title>Loss of microbial niche specificity between the upper and lower airways in patients with cystic fibrosis</article-title>. <source xml:lang="en">Laryngoscope</source>. <year>2019</year>;<volume>129</volume>(<issue>3</issue>):<fpage>544</fpage>&#x2010;<lpage>550</lpage>.<pub-id pub-id-type="pmid">30284279</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0057">
        <label>57</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0057">
<string-name>
<surname>Leung</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Rachakonda</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Weill</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>PH</given-names>
</string-name>. <article-title>Effects of sinus surgery on lung transplantation outcomes in cystic fibrosis</article-title>. <source xml:lang="en">Am J Rhinol</source>. <year>2008</year>;<volume>22</volume>(<issue>2</issue>):<fpage>192</fpage>&#x2010;<lpage>196</lpage>.<pub-id pub-id-type="pmid">18416979</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0058">
        <label>58</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0058">
<string-name>
<surname>Holzmann</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Speich</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kaufmann</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10&#x2010;year experience</article-title>. <source xml:lang="en">Transplantation</source>. <year>2004</year>;<volume>77</volume>(<issue>1</issue>):<fpage>134</fpage>&#x2010;<lpage>136</lpage>.<pub-id pub-id-type="pmid">14724449</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0059">
        <label>59</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0059">
<string-name>
<surname>Vital</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hofer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Boehler</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Holzmann</surname>
<given-names>D</given-names>
</string-name>. <article-title>Posttransplant sinus surgery in lung transplant recipients with cystic fibrosis: a single institutional experience</article-title>. <source xml:lang="en">Eur Arch Otorhinolaryngol</source>. <year>2013</year>;<volume>270</volume>(<issue>1</issue>):<fpage>135</fpage>&#x2010;<lpage>139</lpage>.<pub-id pub-id-type="pmid">22460525</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0060">
        <label>60</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0060">
<string-name>
<surname>Vital</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hofer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Benden</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Holzmann</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Boehler</surname>
<given-names>A</given-names>
</string-name>. <article-title>Impact of sinus surgery on pseudomonal airway colonization, bronchiolitis obliterans syndrome and survival in cystic fibrosis lung transplant recipients</article-title>. <source xml:lang="en">Respiration</source>. <year>2013</year>;<volume>86</volume>(<issue>1</issue>):<fpage>25</fpage>&#x2010;<lpage>31</lpage>.<pub-id pub-id-type="pmid">22922656</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0061">
        <label>61</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0061">
<string-name>
<surname>Estenne</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maurer</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Boehler</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria</article-title>. <source xml:lang="en">J Heart Lung Transplant</source>. <year>2002</year>;<volume>21</volume>(<issue>3</issue>):<fpage>297</fpage>&#x2010;<lpage>310</lpage>.<pub-id pub-id-type="pmid">11897517</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0062">
        <label>62</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0062">
<string-name>
<surname>Luparello</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lazio</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Voltolini</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Borchi</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Taccetti</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Maggiore</surname>
<given-names>G</given-names>
</string-name>. <article-title>Outcomes of endoscopic sinus surgery in adult lung transplant patients with cystic fibrosis</article-title>. <source xml:lang="en">Eur Arch Otorhinolaryngol</source>. <year>2019</year>;<volume>276</volume>(<issue>5</issue>):<fpage>1341</fpage>&#x2010;<lpage>1347</lpage>.<pub-id pub-id-type="pmid">30689038</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0063">
        <label>63</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0063">
<string-name>
<surname>Cheng</surname>
<given-names>TZ</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Honeybrook</surname>
<given-names>AL</given-names>
</string-name>, et al. <article-title>Decreased antibiotic utilization after sinus surgery in cystic fibrosis patients with lung transplantation</article-title>. <source xml:lang="en">Am J Rhinol Allergy</source>. <year>2019</year>;<volume>33</volume>(<issue>4</issue>):<fpage>354</fpage>&#x2010;<lpage>358</lpage>.<pub-id pub-id-type="pmid">30781973</pub-id></mixed-citation>
      </ref>
      <ref id="lio2401-bib-0064">
        <label>64</label>
        <mixed-citation publication-type="journal" id="lio2401-cit-0064">
<string-name>
<surname>Lee</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sykes</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rizvi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tullis</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Complete versus limited endoscopic sinus surgery for chronic rhinosinusitis in adults with cystic fibrosis</article-title>. <source xml:lang="en">Otolaryngol Head Neck Surg</source>. <year>2020</year>;<volume>162</volume>(<issue>4</issue>):<fpage>572</fpage>&#x2010;<lpage>580</lpage>.<pub-id pub-id-type="pmid">32093566</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Paul Pediatr</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rev Paul Pediatr</journal-id>
      <journal-id journal-id-type="publisher-id">rpp</journal-id>
      <journal-title-group>
        <journal-title>Revista Paulista de Pediatria</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0103-0582</issn>
      <issn pub-type="epub">1984-0462</issn>
      <publisher>
        <publisher-name>Sociedade de Pediatria de S&#xE3;o Paulo</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32520296</article-id>
      <article-id pub-id-type="pmc">7274532</article-id>
      <article-id pub-id-type="doi">10.1590/1984-0462/2020/38/2018338</article-id>
      <article-id pub-id-type="other">00441</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>TREATMENT ADHERENCE AMONG CHILDREN AND ADOLESCENTS IN A CYSTIC
FIBROSIS REFERENCE CENTER</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>ADES&#xC3;O AO TRATAMENTO DA FIBROSE C&#xCD;STICA ENTRE CRIAN&#xC7;AS E
ADOLESCENTES DE UM CENTRO DE REFER&#xCA;NCIA</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2748-8689</contrib-id>
          <name>
            <surname>Bonfim</surname>
            <given-names>Bianca Sampaio</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0561-766X</contrib-id>
          <name>
            <surname>de Melo</surname>
            <given-names>Valmir Machado</given-names>
            <suffix>Filho</suffix>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7650-1627</contrib-id>
          <name>
            <surname>Fontenelle</surname>
            <given-names>Fernanda Matos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4916-8483</contrib-id>
          <name>
            <surname>Souza</surname>
            <given-names>Edna L&#xFA;cia</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
          <xref ref-type="corresp" rid="c1">*</xref>
        </contrib>
        <aff id="aff1">
<label>a</label>Universidade Federal da Bahia, Salvador, BA, Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1"><label>*</label>Corresponding author. E-mail:
<email>souza.ednalucia@gmail.com</email> (E.L. Souza)</corresp>
        <fn fn-type="COI-statement" id="fn2">
          <p>The authors declare no conflict of interests.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>05</day>
        <month>6</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>38</volume>
      <elocation-id>e2018338</elocation-id>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>11</month>
          <year>2018</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>2</month>
          <year>2019</year>
        </date>
        <date date-type="online">
          <day>21</day>
          <month>5</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <abstract>
        <title>ABSTRACT</title>
        <sec>
          <title>Objective:</title>
          <p> To evaluate the level of self-referenced treatment adherence (TA) and its
association with clinical and sociodemographic variables in patients with
cystic fibrosis assisted at a reference center, as well as compare the level
of self-referenced TA with that presumed by the multidisciplinary team.</p>
        </sec>
        <sec>
          <title>Methods:</title>
          <p> This is a cross-sectional study that included children and adolescents aged
between 0-20 years with cystic fibrosis. Adolescents older than 14 years or
their guardians, when younger than 14 years old, were interviewed using a
standardized questionnaire. Professionals from the multidisciplinary clinic
filled out another form with their impressions of the patients&#x2019; TA. Clinical
and laboratory data were obtained in the medical records. The TA was
considered satisfactory if the total adherence index (TAI) was equal or
higher than 80%.</p>
        </sec>
        <sec>
          <title>Results:</title>
          <p> 53 patients were included with a median age of 112 months. The mean TAI was
83.2%. The mean TAIs for dornase alfa, pancreatic enzymes, continued use of
inhaled tobramycin, vitamins supplements, nutritional supplements and
dietary orientation was respectively: 86.1; 96.6; 78.6; 88.1; 51.8 and 78%.
Children younger than 14 years presented better TA (p=0.021). The
correlation between the self-referenced TA and the one presumed by the
multidisciplinary team ranged from 0,117 to 0.402, being higher for
Psychology and Nutrition professionals.</p>
        </sec>
        <sec>
          <title>Conclusions:</title>
          <p> The TAI was high particularly among children younger than 14 years. There
was a positive correlation between the self-referenced TA and the one
presumed by the Psychology (p=0.032) and the nutrition (p=0.012)
professionals.</p>
        </sec>
      </abstract>
      <trans-abstract xml:lang="pt">
        <title>RESUMO</title>
        <sec>
          <title>Objetivo:</title>
          <p> Avaliar o grau de ades&#xE3;o ao tratamento (AT) autorreferida e pesquisar sua
associa&#xE7;&#xE3;o com vari&#xE1;veis cl&#xED;nicas e sociodemogr&#xE1;ficas em pacientes com
fibrose c&#xED;stica (FC) de um centro de refer&#xEA;ncia e comparar o grau de AT
autorreferida com o presumido pela equipe multidisciplinar.</p>
        </sec>
        <sec>
          <title>M&#xE9;todos:</title>
          <p> Estudo transversal, incluindo crian&#xE7;as e adolescentes com FC entre zero e 20
anos. Foram realizadas entrevistas com os adolescentes maiores de 14 anos ou
com os respons&#xE1;veis dos mais jovens, utilizando-se formul&#xE1;rio padronizado.
Profissionais do centro preencheram outro formul&#xE1;rio com suas impress&#xF5;es da
AT dos pacientes. Registraram-se dados cl&#xED;nicos por meio da revis&#xE3;o de
prontu&#xE1;rios. A AT foi considerada satisfat&#xF3;ria se o &#xED;ndice de ades&#xE3;o global
(IAG) fosse igual ou superior a 80%.</p>
        </sec>
        <sec>
          <title>Resultados:</title>
          <p> Foram inclu&#xED;dos 53 pacientes, com mediana de idade de 112 meses. O IAG m&#xE9;dio
foi de 83,2%. Os &#xED;ndices de ades&#xE3;o &#xE0; terap&#xEA;utica (IAT) m&#xE9;dios para
alfadornase, enzimas pancre&#xE1;ticas, tobramicina inalat&#xF3;ria de uso cont&#xED;nuo,
suplementos vitam&#xED;nicos, suplementos nutricionais e orienta&#xE7;&#xF5;es diet&#xE9;ticas
foram, respectivamente, 86,1; 96,6; 78,6; 88,1; 51,8 e 78%. Crian&#xE7;as com
idade inferior a 14 anos apresentaram melhor AT (p=0,021). As correla&#xE7;&#xF5;es
entre a AT autorreferida e a presumida pelos profissionais variaram de 0,117
a 0,402, sendo maiores para a psicologia e a nutri&#xE7;&#xE3;o.</p>
        </sec>
        <sec>
          <title>Conclus&#xF5;es:</title>
          <p> A taxa global de AT foi elevada, principalmente para menores de 14 anos.
Houve correla&#xE7;&#xE3;o positiva entre a AT autorreferida e as avalia&#xE7;&#xF5;es da
psicologia (p=0,032) e da nutri&#xE7;&#xE3;o (p=0,012).</p>
        </sec>
      </trans-abstract>
      <kwd-group>
        <title>Keywords:</title>
        <kwd>Cystic fibrosis</kwd>
        <kwd>Medication adherence</kwd>
        <kwd>Patient compliance</kwd>
        <kwd>Pediatrics</kwd>
        <kwd>Therapeutics</kwd>
      </kwd-group>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave:</title>
        <kwd>Fibrose c&#xED;stica</kwd>
        <kwd>Ades&#xE3;o &#xE0; medica&#xE7;&#xE3;o</kwd>
        <kwd>Coopera&#xE7;&#xE3;o do paciente</kwd>
        <kwd>Pediatria</kwd>
        <kwd>Terap&#xEA;utica</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="8"/>
        <equation-count count="0"/>
        <ref-count count="27"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Cystic fibrosis (CF) is the most common genetic disease in Caucasians, being
characterized by multisystem clinical manifestations and requiring a complex
therapeutic regimen, which may include the use of bronchodilators, mucolytics,
antibiotics, vitamin supplements, enzyme replacement therapy (ETR), insulin and,
more recently, protein modulators of Cystic Fibrosis Transmembrane Conductance
Regulator (CFTR). In addition, dietary specifications and daily respiratory physical
therapy sessions are required.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B2" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref> The therapeutic regimen of these patients has, on average, seven components
and require 108 to 180 minutes per day,<xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>,</sup>
<xref rid="B5" ref-type="bibr">
<sup>5</sup>
</xref> which makes treatment adherence (TA) difficult. The World Health
Organization (WHO) defines TA as the extent to which an individual&#x2019;s behavior
(regarding medication use, adherence to diet, lifestyle changes etc.) coincides with
the recommendation agreed between them and the health professional.<xref rid="B6" ref-type="bibr">
<sup>6</sup>
</xref>
</p>
      <p>Overall, absence of TA has a major impact on health costs,<xref rid="B7" ref-type="bibr">
<sup>7</sup>
</xref> which may reach US$ 100 billion annually for the United States, accounting
for 10% of hospital admissions and 23% of total home admissions.<xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref> Noncompliance in CF also contributes to increase in hospital stay, increased
occurrence of pulmonary exacerbations, and loss of pulmonary function - the leading
cause of premature death related to the disease.<xref rid="B9" ref-type="bibr">
<sup>9</sup>
</xref> The overall rate of TA in CF varies from 31 to 79%.<xref rid="B7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref> Multiple factors potentially influencing TA have been reported in the
literature, such as parental supervision, severity of disease, bond with the health
team, age, perceived repercussions of non-adherence, priorities competing with
adherence, gender, forgetfulness, privacy concerns,<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref> among others.</p>
      <p>A thorough understanding of TA and related factors requires studying diverse
populations. In Brazil, studies on TA in CF are scarce, with a percentage of high-TA
patients ranging from 59 to 81.6%.<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>,</sup>
<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref> Therefore, the present study has the following objectives: to determine the
degree of self-reported TA related to medication, respiratory physical therapy, and
the diet recommended for CF patients from a referral center; to evaluate how TA
varies according to clinical and sociodemographic data; and to compare the degree of
compliance reported by patients with that assumed by the multidisciplinary team.</p>
    </sec>
    <sec sec-type="methods">
      <title>METHOD</title>
      <p>A cross-sectional study was conducted with patients (aged zero to 20 years old)
assisted at a pediatric referral center for CF treatment. Patients are treated, on
average, every three months, by a team of physicians and professionals in the areas
of physical therapy, nutrition, pharmacy, social assistance, and psychology, aiming
to develop individualized and integral care, which enables a close contact with
patient, encouraging health promotion in this context. Some of the regularly
medications (dornase alfa, pancreatic enzymes, and inhaled tobramycin) prescribed
for CF are made available by the Unified Health System (SUS) and handed to patients
at the center itself after each routine consultation. Thus, patients do not travel
or have additional costs to access medication.</p>
      <p>Data were collected during routine outpatient consultations in interviews conducted
by the same researcher, in a private place, protecting patient privacy, from
February 2015 to August 2016. Forms were filled out with variables possibly related
to TA (available with corresponding author), questions about medication use, and
socioeconomic data. For those under 14 years old, the questions were addressed to
their guardians, while those over 14 were interviewed directly. The evaluation of
each patient&#x2019;s TA was also requested by professional of physical therapy, nutrition,
pharmacy, psychology and pneumology (forms available with corresponding author),
giving them a score from one (minimum TA) to ten (maximum TA), based on their
impressions when seeing the participant.</p>
      <p>Initially, the questionnaires were randomly applied to 12 patients in order to verify
their practical feasibility and identify the main adjustments to be made (pilot
study). Due to the low level of understanding by patients, we opted to interview the
adolescents or guardians, depending on the age group.</p>
      <p>In terms of casuistry, all children and adolescents aged zero to 20 years with a
confirmed diagnosis of CF were included by two positive sweat tests (Chlorine &#x2265;60
mEq/L) and/or identification of two pathological CFTR gene mutations, and also six
patients with CF-compatible clinic and questionable sweat test, who were regularly
taking CF treatment medications. All patients should be followed up for at least six
months at the referral center. Exclusion criteria were withdrawal from participation
in the study and absence of continuous use of specific CF medications. After
applying these criteria, the final sample was constituted of 53 patients. This
project was approved by the Research Ethics Committee of the institution in which it
was conducted, Opinion No. 843.869, of October 23, 2014. Free and informed consent
forms were obtained from the guardians or patients, depending on the age group, and
terms of assent, where relevant.</p>
      <p>The different treatment protocols were evaluated, seeking to identify differences in
adherence rates between them. During the interviews, information regarding the
patients&#x2019; socioeconomic conditions was obtained, as well as the difficulties they
reported facing in adhering to treatment.</p>
      <p>During review of medical records, the following clinical data were collected:</p>
      <p>
<list list-type="bullet"><list-item><p>Forced expiratory volume in the first second (FEV<sub>1</sub>) of the
best spirometry of the year of the interview or most recent of each
patient eligible for the exam.</p></list-item><list-item><p>Most recent anthropometric data, dating closest to the interview day
(body mass index - BMI, expressed in kg/m<sup>2</sup>), plus Z scores
for BMI/age (patients older than 5 years) and weight/height Z score
(under five).</p></list-item><list-item><p>Shwachman-Kulczycki score of the same year of interview or most recent.
This score is an instrument for clinical and functional assessment of CF
patients, divided into four categories - general activity, physical
examination, nutrition and radiological findings - with a final score
ranging from 20 to 100 points.<xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref>
</p></list-item><list-item><p>Hospital cycles of intravenous antibiotics in the past two years.</p></list-item><list-item><p>Age of patients at diagnosis.</p></list-item></list>
</p>
      <p>The degree of TA was calculated using the Therapy Adherence Index (TAI), obtained for
each of the treatment protocols used by the patient through the following operation:
TAI=frequency of use by the patient/standard frequency of use (x100), where the
frequencies used by patients corresponded to the following self-reported data during
interviews with them:</p>
      <p>
<list list-type="bullet"><list-item><p>Number of times of inhaled dornase alfa administration per week.</p></list-item><list-item><p>Total meals using pancreatic enzymes per day.</p></list-item><list-item><p>Number of meals in which oil or olive oil is used per day.</p></list-item><list-item><p>Number of spoons of nutritional supplements per day.</p></list-item><list-item><p>Number of drops of the vitamin supplement used per day.</p></list-item><list-item><p>Inhaled Tobramycin: total inhaled ampoules on alternate months for
patients receiving continuous antibiotic therapy every other month.</p></list-item></list>
</p>
      <p>The overall adherence index (OAI) was calculated as the arithmetic mean of the
percentages obtained for each treatment protocol. TA was considered satisfactory for
patients with OAI from 80% and unsatisfactory below this percentage. The AT
(satisfactory or unsatisfactory) was then compared with the estimated adherence
scores indicated by the health professionals.</p>
      <p>The data obtained were recorded in a standard form and stored in a database in the
Statistical Package for the Social Sciences (SPSS), version 20 (SPSS<sup>&#xAE;</sup>,
Chicago, IL, USA). Descriptive data were expressed as simple and relative
frequencies of the studied qualitative variables, as well as means, standard
deviation (SD), median or minimum and maximum values for quantitative variables.
Income was expressed as median and interquartile range. Continuous variables with
normal distribution were expressed as means and SD; and those with non-normal
distribution, as median and interquartile range. The normality of numerical
variables was verified by descriptive statistics, graphical analysis and the
Shapiro-Wilk test.</p>
      <p>For the association between adherence (satisfactory and unsatisfactory) and
sociodemographic and clinical data (categorical variables), the chi-square test was
used, assuming the presence of association if p&lt;0.05. For the correlation between
OAI and TA perception scores of different professionals (pharmacy, psychology,
physiotherapy, pediatric pneumology, and nutrition), the Spearman&#x2019;s correlation was
used. Correlations were classified according to the following criteria:</p>
      <p>
<list list-type="bullet"><list-item><p>between 1.00 and 0.90 (very high correlation);</p></list-item><list-item><p>between 0.90 and 0.70 (high correlation);</p></list-item><list-item><p>between 0.70 and 0.40 (moderate correlation);</p></list-item><list-item><p>between 0.40 and 0.20 (weak correlation);</p></list-item><list-item><p>between 0.20 and 0.00 (very weak correlation).<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
</p></list-item></list>
</p>
    </sec>
    <sec sec-type="results">
      <title>RESULTS</title>
      <p>Fifty-three patients were included in the study, 30 of them (56.6%) being males. One
patient was excluded because, despite having been diagnosed with the disease, he was
oligosymptomatic and did not use any of the medications in study. The median age of
patients was 112 (13-231) months. From all patients, 33 (62.3%) lived in cities in
the countryside of the State. <xref rid="t1" ref-type="table">Table 1</xref>
presents other socioeconomic information and data on clinical variables studied. The
primary caregivers were the mother and the father of 36 (67.9%) and three (5.7%)
patients, respectively. In four cases (7.6%), individuals with other degrees of
kinship has this function. Among the 43 caregivers, 12 (27.9%) had incomplete
primary education; seven (16.3%) had complete elementary school; 19 (44.2%) had
complete high school; and five (11.6%), had complete higher education. Ten patients
(18.9%) were mainly responsible for the management of the therapeutic regimen
(self-care). The median monthly family income was R$ 1,000 (R$ 300 - R$ 4,000,000),
with 19 (38.5%) families receiving up to one minimum wage per month. School dropout
(minimum of three months without going to school) was reported for four patients, in
all cases due to clinical complications of the disease.</p>
      <p>
<table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Clinical and socioeconomic data of the patients.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Socioeconomic profile of patients</th><th align="center" rowspan="1" colspan="1">n (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Social assistance beneficiaries</td><td align="center" rowspan="1" colspan="1">11 (20.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Receiving benefit for patients with chronic
diseases</td><td align="center" rowspan="1" colspan="1">32 (60.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">School dropout</td><td align="center" rowspan="1" colspan="1">4 (7.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical profile of patients</td><td align="center" rowspan="1" colspan="1">Mean (SD)</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (%)<sup>a</sup>
</td><td align="center" rowspan="1" colspan="1">84.9% (17.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)<sup>b</sup>
</td><td align="center" rowspan="1" colspan="1">16.7 (3.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of hospital admissions for intravenous
antibiotic therapy</td><td align="center" rowspan="1" colspan="1">0.3 (0.6)<sup>c</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Shwachman-Kulczycki Score</td><td align="center" rowspan="1" colspan="1">85.1 (13.6)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>SD: standard deviation; FEV<sub>1</sub>: forced expiratory volume in
the first second; BMI: body mass index; <sup>a</sup>data available
only for 35 patients (spirometry is performed only on patients from
seven years of age), median FEV<sub>1</sub> of 85%;
<sup>b</sup>median BMI = 16.08 kg/m<sup>2</sup>; <sup>c</sup>median
number of hospital admissions was zero.</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>Among patients, 20 (37.7%) reported assisted respiratory physical therapy, of which
45% (n=9) did it only once a week, while the others (55%) did it twice or more times
a week. Twenty-three patients (43.4%) were on home respiratory physical therapy,
with frequencies ranging from sporadic (n=3; 13%) to daily (n=5; 21.7%); while 17
(73.9%) patients were on home physical therapy twice or more times a week.</p>
      <p>The mean OAI was 83.2% (SD=15.3). <xref rid="t2" ref-type="table">Table 2</xref>
lists the TAI for the different forms of treatment and the main difficulties related
to adherence reported by the interviewees. Of these, 27 (50.9%) reported
forgetfulness of treatment. Among them, the medications most frequently overlooked
were dornase alfa (10 patients - 37%) and vitamin supplementation (25.9%, n=7),
while pancreatic enzymes were reported by 66.7% (n=18) as the least frequently
forgotten.</p>
      <p>
<table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Patients&#x2019; adherence rates and main difficulties identified.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Treatment modality (number of patients using
them)</th><th align="center" rowspan="1" colspan="1">Mean TAI (SD)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Dornase alfa (n=39)</td><td align="center" rowspan="1" colspan="1">86.1% (29.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pancreatic enzymes (n=45)</td><td align="center" rowspan="1" colspan="1">96.6% (9.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhaled Tobramycin for Continuous Use (n=5)</td><td align="center" rowspan="1" colspan="1">78.6% (29.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vitamin Supplements (n=52)</td><td align="center" rowspan="1" colspan="1">88.1% (28.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nutritional Supplements (n=14)</td><td align="center" rowspan="1" colspan="1">51.8% (50.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Oil addition to food (n=52)</td><td align="center" rowspan="1" colspan="1">77.0% (32.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nutritional guidelines (n=53)</td><td align="center" rowspan="1" colspan="1">78.0% (16.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Difficulties related to adherence reported by
patients</td><td align="center" rowspan="1" colspan="1">n (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">No time</td><td align="center" rowspan="1" colspan="1">7 (3.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Too many medications in the therapeutic
routine</td><td align="center" rowspan="1" colspan="1">8 (15.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Poor access to medications or supplements</td><td align="center" rowspan="1" colspan="1">26 (49.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">No understanding of how to use medications</td><td align="center" rowspan="1" colspan="1">1 (1.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Feeling of embarrassment when using medications in
front of other people</td><td align="center" rowspan="1" colspan="1">11 (20.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Reduction of pancreatic enzymes for weight
loss</td><td align="center" rowspan="1" colspan="1">2 (3.8)</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>TAI: therapeutic adherence index; SD: standard deviation.</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>Due to changes in the staff composition at the institution, the assessment of
patients&#x2019; TA by health professionals included only those who entered the outpatient
clinic until 2014 (n=39). As not all patients were on psychological counseling, only
29 of them were included in the assessment of this specialty. In the areas of
nutrition, pharmacy and pulmonology, a form was not filled in, resulting in a final
sample of 38 patients. The mean scores provided by the team were 7.7&#xB1;1.6 by
pulmonology; 7.0&#xB1;1.0 by physical therapy; 6.9&#xB1;0.29 by psychology; 6.8&#xB1;2.4 by
nutrition; and 6.3&#xB1;2.0 by pharmacy.</p>
      <p>When assessing the association between TA and sociodemographic and clinical
variables, a statistically significant association between satisfactory TA and age
below 14 years was found (p=0.021). The evaluation on the association between TA and
the other variables, on the other hand, resulted not statistically significant
(<xref rid="t3" ref-type="table">Table 3</xref>). There was a statistically
significant positive correlation between the scores of psychologists (p=0.032) and
nutritionists (p=0.012), which did not occur in the other areas (<xref rid="t4" ref-type="table">Table 4</xref>).</p>
      <p>
<table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Association between adherence to treatment and
clinical/sociodemographic variables.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="2"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variables</th><th align="center" colspan="2" rowspan="1">Adherence: n (%)</th><th align="center" rowspan="2" colspan="1">p-value <sup>a</sup>
</th></tr><tr><th align="center" rowspan="1" colspan="1">Satisfactory</th><th align="center" rowspan="1" colspan="1">Unsatisfactory</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Age</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x2265;14 years</td><td align="center" rowspan="1" colspan="1">6 (17.6)</td><td align="center" rowspan="1" colspan="1">9 (47.4)</td><td align="center" rowspan="2" colspan="1">0.021</td></tr><tr><td align="left" rowspan="1" colspan="1">&lt;14 years</td><td align="center" rowspan="1" colspan="1">28 (82.4)</td><td align="center" rowspan="1" colspan="1">10 (52.6)</td></tr><tr><td align="left" colspan="4" rowspan="1">Gender</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">16 (47.1)</td><td align="center" rowspan="1" colspan="1">7 (36.8)</td><td align="center" rowspan="2" colspan="1">0.472</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">18 (52.9)</td><td align="center" rowspan="1" colspan="1">12 (63.2)</td></tr><tr><td align="left" colspan="4" rowspan="1">Family income<sup>b</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&lt;1 minimum wage</td><td align="center" rowspan="1" colspan="1">2 (5.9)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="3" colspan="1">0.333</td></tr><tr><td align="left" rowspan="1" colspan="1">1-2 minimum wages</td><td align="center" rowspan="1" colspan="1">21 (61.8)</td><td align="center" rowspan="1" colspan="1">15 (78.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&gt;2 minimum wages</td><td align="center" rowspan="1" colspan="1">11 (32.3)</td><td align="center" rowspan="1" colspan="1">4 (21.1)</td></tr><tr><td align="left" colspan="4" rowspan="1">Age at diagnosis</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x2264;12 months</td><td align="center" rowspan="1" colspan="1">14 (41.2)</td><td align="center" rowspan="1" colspan="1">4 (21.1)</td><td align="center" rowspan="2" colspan="1">0.226</td></tr><tr><td align="left" rowspan="1" colspan="1">&gt;12 months</td><td align="center" rowspan="1" colspan="1">20 (58.8)</td><td align="center" rowspan="1" colspan="1">15 (78.9)</td></tr><tr><td align="left" colspan="4" rowspan="1">Schooling</td></tr><tr><td align="left" rowspan="1" colspan="1">Incomplete elementary school</td><td align="center" rowspan="1" colspan="1">7 (23.4)</td><td align="center" rowspan="1" colspan="1">3 (23.0)</td><td align="center" rowspan="3" colspan="1">0.154</td></tr><tr><td align="left" rowspan="1" colspan="1">Complete primary education</td><td align="center" rowspan="1" colspan="1">4 (13.3)</td><td align="center" rowspan="1" colspan="1">5 (38.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Complete high school or more</td><td align="center" rowspan="1" colspan="1">19 (63.3)</td><td align="center" rowspan="1" colspan="1">5 (38.5)</td></tr><tr><td align="left" colspan="4" rowspan="1">Benefits from the Government</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">23 (67.6)</td><td align="center" rowspan="1" colspan="1">13 (68.4)</td><td align="center" rowspan="2" colspan="1">0.954</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">11 (32.4)</td><td align="center" rowspan="1" colspan="1">6 (31.6)</td></tr><tr><td align="left" colspan="4" rowspan="1">Poor access to medications</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">15 (44.1)</td><td align="center" rowspan="1" colspan="1">11 (57.9)</td><td align="center" rowspan="2" colspan="1">0.336</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">19 (55.9)</td><td align="center" rowspan="1" colspan="1">8 (42.1)</td></tr><tr><td align="left" colspan="4" rowspan="1">Schwachman score</td></tr><tr><td align="left" rowspan="1" colspan="1">86-100</td><td align="center" rowspan="1" colspan="1">17 (50.0)</td><td align="center" rowspan="1" colspan="1">6 (31.6)</td><td align="center" rowspan="4" colspan="1">0.448</td></tr><tr><td align="left" rowspan="1" colspan="1">71-85</td><td align="center" rowspan="1" colspan="1">12 (35.3)</td><td align="center" rowspan="1" colspan="1">7 (36.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">56-70</td><td align="center" rowspan="1" colspan="1">4 (11.8)</td><td align="center" rowspan="1" colspan="1">5 (26.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">41-55</td><td align="center" rowspan="1" colspan="1">1 (2.9)</td><td align="center" rowspan="1" colspan="1">1 (5.3)</td></tr><tr><td align="left" colspan="4" rowspan="1">FEV<sub>1</sub>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x2265;80</td><td align="center" rowspan="1" colspan="1">13 (70.6)</td><td align="center" rowspan="1" colspan="1">11 (68.8)</td><td align="center" rowspan="4" colspan="1">0.559</td></tr><tr><td align="left" rowspan="1" colspan="1">60-79</td><td align="center" rowspan="1" colspan="1">4 (26.5)</td><td align="center" rowspan="1" colspan="1">5 (31.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">40-60</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&lt;40</td><td align="center" rowspan="1" colspan="1">1 (2.9)</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="4" rowspan="1">BMI or weight/height</td></tr><tr><td align="left" rowspan="1" colspan="1">Risk/overweight</td><td align="center" rowspan="1" colspan="1">6 (17.6)</td><td align="center" rowspan="1" colspan="1">1 (5.3)</td><td align="center" rowspan="3" colspan="1">0.261</td></tr><tr><td align="left" rowspan="1" colspan="1">Eutrophic</td><td align="center" rowspan="1" colspan="1">27 (79.4)</td><td align="center" rowspan="1" colspan="1">16 (84.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Thinness</td><td align="center" rowspan="1" colspan="1">1 (3.0)</td><td align="center" rowspan="1" colspan="1">2 (10.5)</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>FEV<sub>1</sub>: forced expiratory volume in the first second; BMI:
body mass index; <sup>a</sup>chi-square test; <sup>b</sup>a minimum
wage corresponded to R$ 788.00 (U$ 215.31).</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>
<table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Evaluation of the association between the notes provided by the
team&#x2019;s health professionals, referring to the assessment of patients&#x2019;
adherence to treatment (n = 38), with self-reported global adherence
rates.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Field</th><th align="center" rowspan="1" colspan="1">
<bold>R</bold>
</th><th align="center" rowspan="1" colspan="1">p-value<sup><italic>a</italic></sup>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Pharmacy</td><td align="center" rowspan="1" colspan="1">0.210</td><td align="center" rowspan="1" colspan="1">0.206</td></tr><tr><td align="left" rowspan="1" colspan="1">Physical therapy</td><td align="center" rowspan="1" colspan="1">0.117</td><td align="center" rowspan="1" colspan="1">0.479</td></tr><tr><td align="left" rowspan="1" colspan="1">Psychology</td><td align="center" rowspan="1" colspan="1">0.399</td><td align="center" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" rowspan="1" colspan="1">Nutrition</td><td align="center" rowspan="1" colspan="1">0.402</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Pneumology</td><td align="center" rowspan="1" colspan="1">0.162</td><td align="center" rowspan="1" colspan="1">0.332</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>
<sup>a</sup>Spearman&#x2019;s correlation.</p></fn></table-wrap-foot></table-wrap>
</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>There was a high rate of global TA (83.2%) in this study, compared to the variations
from 31 to 79% described in the literature,<xref rid="B7" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref> which may be due to the age group studied. Previous studies have shown
better TA in CF among children compared to adolescents.<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>,</sup>
<xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref> Among the possible causes for higher rates of TA in childhood, there would
be a lower rate of participation of parents in the administration of treatment
during adolescence, a moment of transition in which one&#x2019;s perceptions about their
own disease are established, in addition to several personal, professional and
social changes and challenges in which the clinical progression of CF can have a
direct impact, thus influencing TA.<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>,</sup>
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref> It is essential, therefore, to emphasize the relevance of family
participation in the adaptation of adolescents to their therapeutic routine, without
compromising the development their individual autonomy. The age at diagnosis, in
turn, was not significantly associated with TA, as previously described in the
literature.<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
</p>
      <p>The present study covered very low-income patients and, even so, high rates of global
TA were found. The routine of supplying and dispensing medications, available at the
center, is probably an important factor that contributed to this phenomenon. The
importance of a multidisciplinary team with close contact with patients should also
be emphasized, enabling multiple approaches that promote a better TA. The patient&#x2019;s
solid relationship with the health team as an important facilitator of TA has been
previously described.<xref rid="B22" ref-type="bibr">
<sup>22</sup>
</xref>
<sup>,</sup>
<xref rid="B23" ref-type="bibr">
<sup>23</sup>
</xref>
</p>
      <p>In this study, adherence to ETR was the highest (96.6%), in addition to being
indicated as the drug category that was less frequently overlooked by participants.
These data are in agreement with that described in another Brazilian study, in which
96.3% of the patients were in the group of high adherence to this therapy.<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref> The reported adherence to ERT is within the percentages reported in other
studies (27,4 to 96.5%).<xref rid="B9" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref> The greater adherence to ERT is possibly due to steatorrhea and other
immediate consequences of not using enzymes.<xref rid="B24" ref-type="bibr">
<sup>24</sup>
</xref> The perception of signs and symptoms is an important factor in raising
awareness of patients for TA. Difficulties regarding this adherence in asymptomatic
pediatric patients have already been detected in previous studies.<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
</p>
      <p>The adherence to respiratory physical therapy was very low in this research, inferior
to data in the literature, which indicate TA rates from 36 to 91% for this treatment
modality.<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref> In the present study, low family income and residence in the countryside of
the State (62.3% of patients), where the availability of physical therapy services
is poor, must have contributed to the low adherence to this modality. Even in the
capital, difficulties were reported for regular monitoring by these professionals.
Among patients who did not undergo assisted respiratory physical therapy, 72.7%
(n=24) reported difficulties in getting monitored by a physical therapist, which
reflects the problems of access to the health system. Unfortunately, this center
does not provide outpatient physical therapy follow-up; it is only available during
outpatient consultations or hospital admissions.</p>
      <p>The average scores given by the health professionals ranged from 6.3 to 7.7. Arias
Llorente et al., in 2008, also evaluated the opinion of health professionals
(nurses, pulmonologists and gastroenterologists) regarding TA of patients, reporting
35.1% (physiotherapy) to 70.4% (digestive tract medications).<xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref> In that study, however, the methodology for assessing TA by professionals
differed from the one used in the present study, making comparisons difficult, which
is a common problem due to the diversity of strategies reported in the literature to
classify and analyze TA.<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
</p>
      <p>There was a positive association between TA scores provided by psychology and
nutrition professionals and the self-reported OAI. Such data possibly stems from
aspects intrinsic to the routine of care of these professionals, which can provide
more accurate information about the degree of dedication of patients to the proposed
therapeutic regime. Nutritional assessment, for example, includes obtaining regular
food records. Psychology, in turn, is dedicated to addressing in-depth psychosocial
issues critical to TA. However, it is worth mentioning that these correlations,
although statistically significant, were weak. On the other hand, there was a
positive correlation between the scores attributed by other professionals and TA,
although it was not statistically significant, possibly due to the small sample
size. Therefore, further studies are needed to assess this issue.</p>
      <p>There are several methods of measuring TA available.<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref> Modi et al., In 2006, carried out a study that evaluated adherence through
different methods and compared them with electronic monitoring, which would
correspond to the most accurate form of investigation, and found that the
self-reported approach had very different results in relation to the other methods,
overestimating adherence.<xref rid="B26" ref-type="bibr">
<sup>26</sup>
</xref> Thus, the self-reported method used in the present study may have
contributed to the high adherence percentages. It is noteworthy, however, that a
previous study, using a more accurate measurement methodology, reported a high rate
of adherence in pediatric CF patients, suggesting that TA may be higher among
them.<xref rid="B27" ref-type="bibr">
<sup>27</sup>
</xref> Ball et al., in 2013, investigated adherence to inhaled medications using
electronic monitoring in patients aged 11 to 17 years and reported an adherence rate
greater than 75% in half of them.<xref rid="B27" ref-type="bibr">
<sup>27</sup>
</xref> Thus, it is also possible that the high TA observed in this study is not due
to the measurement method, but rather to the age group of patients. In addition, the
positive correspondence between psychology and nutrition assessments and patients&#x2019;
self-assessment may indicate greater reliability of the self-reported TA in this
study.</p>
      <p>We can list the following methodological limitations of the present study:</p>
      <p>
<list list-type="bullet"><list-item><p>the small number of patients studied;</p></list-item><list-item><p>the age group of the population, in which the most severe clinical
manifestations of the disease were not so common, as well as the wide
age range of the patients;</p></list-item><list-item><p>the fact that the study covers a single reference center;</p></list-item><list-item><p>the self-reported methodology for measuring TA;</p></list-item><list-item><p>the change in the composition of the service team, which made it
difficult to collect the opinion of health professionals regarding the
TA.</p></list-item></list>
</p>
      <p>Thus, additional studies with a larger number of participants are needed, as well as
different tools for measuring TA in CF, which has several peculiarities due to the
complexity of treatment and the chronic character of the disease.</p>
      <p>To conclude, it appears that the overall rate of TA was high, although TA was
unsatisfactory in certain therapeutic modalities, such as nutritional guidelines and
continuous inhaled tobramycin. Adherence to respiratory physical therapy was very
low, in fact lower than previous reports in the literature. There was a satisfactory
association between age below 14 years and TA. The average scores attributed to
patients&#x2019; TA by professionals from the reference center varied little between
different areas of health, with the pharmacy providing the lowest average and
pneumology, the highest. There was a positive correlation only between TA scores
inferred by psychology and nutrition professionals compared to TA self-reported by
patients/guardians. The results point to the importance of monitoring TA in chronic
diseases, particularly among adolescents.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <title>Funding</title>
      <fn fn-type="financial-disclosure" id="fn1">
        <p>This work had a partial contribution from the Foundation for the Support of
Research in the State of Bahia (Funda&#xE7;&#xE3;o de Amparo &#xE0; Pesquisa da Bahia) (PPSUS
020/2013), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quittner</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Saez-Flores</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>The psychological burden of cystic fibrosis</article-title>
          <source>Curr Opin Pulm Med</source>
          <year>2016</year>
          <volume>22</volume>
          <fpage>187</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="doi">10.1097/MCP.0000000000000244</pub-id>
          <pub-id pub-id-type="pmid">26814144</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abbott</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Measuring and reporting quality of life outcomes in clinical
trials in cystic fibrosis: a critical review</article-title>
          <source>Health Qual Life Outcomes</source>
          <year>2005</year>
          <volume>3</volume>
          <issue>19</issue>
          <fpage>https://doi.org/10.1186/1477</fpage>
          <lpage>https://doi.org/10.7525-3-19</lpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Graeber</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Dopfer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Naehrlich</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gyulumyan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scheuermann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hirtz</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of lumacaftor/ivacaftor therapy on CFTR function in
Phe508del homozygous patients with cystic fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2018</year>
          <volume>197</volume>
          <fpage>1433</fpage>
          <lpage>1442</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.201710-1983OC</pub-id>
          <pub-id pub-id-type="pmid">29327948</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conway</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pond</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hamnett</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Compliance with treatment in adult patients with cystic
fibrosis</article-title>
          <source>Thorax</source>
          <year>1996</year>
          <volume>51</volume>
          <fpage>29</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="doi">10.1136/thx.51.1.29</pub-id>
          <pub-id pub-id-type="pmid">8658364</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sawicki</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>WM</given-names>
            </name>
          </person-group>
          <article-title>High treatment burden in adults with cystic fibrosis: challenges
to disease self-management</article-title>
          <source>J Cyst Fibros</source>
          <year>2009</year>
          <volume>8</volume>
          <fpage>91</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2008.09.007</pub-id>
          <pub-id pub-id-type="pmid">18952504</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <comment>[homepage on the Internet]</comment>
          <source>Adherence to long-term therapies: evidence for action</source>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>WHO</publisher-name>
          <year>2003</year>
          <date-in-citation content-type="access-date" iso-8601-date="2018-08-10">2018 Aug
10</date-in-citation>
          <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1">http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quittner</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marynchenko</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chopra</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Signorovitch</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yushkina</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pulmonary medication adherence and health-care use in cystic
fibrosis</article-title>
          <source>Chest</source>
          <year>2014</year>
          <volume>146</volume>
          <fpage>142</fpage>
          <lpage>151</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.13-1926</pub-id>
          <pub-id pub-id-type="pmid">24480974</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vermeire</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hearnshaw</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>van Royen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Denekens</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Patient adherence to treatment: three decades of research. A
comprehensive review</article-title>
          <source>J Clin Pharm Ther</source>
          <year>2001</year>
          <volume>26</volume>
          <fpage>331</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2710.2001.00363.x</pub-id>
          <pub-id pub-id-type="pmid">11679023</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Narayanan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mainz</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Gala</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tabori</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Grossoehme</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Adherence to therapies in cystic fibrosis: a targeted literature
review</article-title>
          <source>Expert Rev Respir Med</source>
          <year>2017</year>
          <volume>11</volume>
          <fpage>129</fpage>
          <lpage>145</lpage>
          <pub-id pub-id-type="doi">10.1080/17476348.2017.1280399</pub-id>
          <pub-id pub-id-type="pmid">28107795</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Donohoe</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fullen</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Adherence of subjects with cystic fibrosis to their home program:
a systematic review</article-title>
          <source>Respir Care</source>
          <year>2014</year>
          <volume>59</volume>
          <fpage>1731</fpage>
          <lpage>1746</lpage>
          <pub-id pub-id-type="doi">10.4187/respcare.02990</pub-id>
          <pub-id pub-id-type="pmid">25233386</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oddleifson</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Sawicki</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Adherence and recursive perception among young adults with cystic
fibrosis</article-title>
          <source>Anthropol Med</source>
          <year>2017</year>
          <volume>24</volume>
          <fpage>65</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.1080/13648470.2017.1278865</pub-id>
          <pub-id pub-id-type="pmid">28292207</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dziuban</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Saab-Abazeed</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chaudhry</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Streetman</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Nasr</surname>
              <given-names>SZ</given-names>
            </name>
          </person-group>
          <article-title>Identifying barriers to treatment adherence and related
attitudinal patterns in adolescents with cystic fibrosis</article-title>
          <source>Pediatr Pulmonol</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>450</fpage>
          <lpage>458</lpage>
          <pub-id pub-id-type="doi">10.1002/ppul.21195</pub-id>
          <pub-id pub-id-type="pmid">20425852</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simon</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Horky</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Nick</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Riekert</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Body satisfaction, nutritional adherence, and quality of life in
youth with cystic fibrosis</article-title>
          <source>Pediatr Pulmonol</source>
          <year>2011</year>
          <volume>46</volume>
          <fpage>1085</fpage>
          <lpage>1092</lpage>
          <pub-id pub-id-type="doi">10.1002/ppul.21477</pub-id>
          <pub-id pub-id-type="pmid">21626713</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sawicki</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Heller</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Demars</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>WM</given-names>
            </name>
          </person-group>
          <article-title>Motivating adherence among adolescents with cystic fibrosis:
youth and parent perspectives</article-title>
          <source>Pediatr Pulmonol</source>
          <year>2015</year>
          <volume>50</volume>
          <fpage>127</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="doi">10.1002/ppul.23017</pub-id>
          <pub-id pub-id-type="pmid">24616259</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dalcin</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Rampon</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pasin</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Ramon</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Abrah&#xE3;o</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>VZ</given-names>
            </name>
          </person-group>
          <article-title>Adherence to treatment in patients with cystic
fibrosis</article-title>
          <source>J Bras Pneumol</source>
          <year>2007</year>
          <volume>33</volume>
          <fpage>663</fpage>
          <lpage>670</lpage>
          <pub-id pub-id-type="doi">10.1590/s1806-37132007000600009</pub-id>
          <pub-id pub-id-type="pmid">18200366</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feiten</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Farias</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Rovedder</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Camargo</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Dalcin</surname>
              <given-names>PT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Respiratory therapy: a problem among children and adolescents
with cystic fibrosis</article-title>
          <source>J Bras Pneumol</source>
          <year>2016</year>
          <volume>42</volume>
          <fpage>29</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1590/S1806-37562016000000068</pub-id>
          <pub-id pub-id-type="pmid">26982038</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flores</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Teixeira</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Rovedder</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Ziegler</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dalcin</surname>
              <given-names>PT</given-names>
            </name>
          </person-group>
          <article-title>Adherence to airway clearance therapies by adult cystic fibrosis
patients</article-title>
          <source>Respir Care</source>
          <year>2013</year>
          <volume>58</volume>
          <fpage>279</fpage>
          <lpage>285</lpage>
          <pub-id pub-id-type="doi">10.4187/respcare.01389</pub-id>
          <pub-id pub-id-type="pmid">22782067</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shwachman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kulczycki</surname>
              <given-names>LL</given-names>
            </name>
          </person-group>
          <article-title>Long-term study of one hundred five patients with cystic
fibrosis; studies made over a five- to fourteen-year period</article-title>
          <source>AMA J Dis Child</source>
          <year>1958</year>
          <volume>96</volume>
          <fpage>6</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1001/archpedi.1958.02060060008002</pub-id>
          <pub-id pub-id-type="pmid">13544726</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Pestana</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Gageiro</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
          <source>An&#xE1;lise de dados para as Ci&#xEA;ncias Sociais: a complementaridade do
SPSS</source>
          <edition>5</edition>
          <publisher-loc>Lisboa</publisher-loc>
          <publisher-name>S&#xED;labo</publisher-name>
          <year>2008</year>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shakkottai</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kidwell</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Townsend</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nasr</surname>
              <given-names>SZ</given-names>
            </name>
          </person-group>
          <article-title>A five-year retrospective analysis of adherence in cystic
fibrosis</article-title>
          <source>Pediatr Pulmonol</source>
          <year>2015</year>
          <volume>50</volume>
          <fpage>1224</fpage>
          <lpage>1229</lpage>
          <pub-id pub-id-type="doi">10.1002/ppul.23307</pub-id>
          <pub-id pub-id-type="pmid">26346919</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arias Llorente</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Buoso&#xF1;o Garc&#xED;a</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>D&#xED;az Mart&#xED;n</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Treatment compliance in children and adults with cystic
fibrosis</article-title>
          <source>J Cyst Fibros</source>
          <year>2008</year>
          <volume>7</volume>
          <fpage>359</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2008.01.003</pub-id>
          <pub-id pub-id-type="pmid">18304896</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>George</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rand-Giovannetti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Eakin</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Borrelli</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zettler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Riekert</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Perceptions of barriers and facilitators: self-management
decisions by older adolescents and adults with CF</article-title>
          <source>J Cyst Fibros</source>
          <year>2010</year>
          <volume>9</volume>
          <fpage>425</fpage>
          <lpage>432</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2010.08.016</pub-id>
          <pub-id pub-id-type="pmid">20846910</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riekert</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Eakin</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Bilderback</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ridge</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>BC</given-names>
            </name>
          </person-group>
          <article-title>Opportunities for cystic fibrosis care teams to support treatment
adherence</article-title>
          <source>J Cyst Fibros</source>
          <year>2015</year>
          <volume>14</volume>
          <fpage>142</fpage>
          <lpage>148</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2014.10.003</pub-id>
          <pub-id pub-id-type="pmid">25459564</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dodd</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Understanding non-compliance with treatment in adults with cystic
fibrosis</article-title>
          <source>J R Soc Med</source>
          <year>2000</year>
          <volume>93</volume>
          <issue>38</issue>
          <fpage>2</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">10911812</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mooney</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Downey</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Pharmacists&#x2019; perspectives on monitoring adherence to treatment in
Cystic Fibrosis</article-title>
          <source>Int J Clin Pharm</source>
          <year>2016</year>
          <volume>38</volume>
          <fpage>296</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="doi">10.1007/s11096-015-0239-4</pub-id>
          <pub-id pub-id-type="pmid">26715548</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Modi</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Geller</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Quittner</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>A multi-method assessment of treatment adherence for children
with cystic fibrosis</article-title>
          <source>J Cyst Fibros</source>
          <year>2006</year>
          <volume>5</volume>
          <fpage>177</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2006.03.002</pub-id>
          <pub-id pub-id-type="pmid">16679071</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ball</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Southern</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>McCormack</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Duff</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Brownlee</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>McNamara</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Adherence to nebulised therapies in adolescents with cystic
fibrosis is best on week-days during school term-time</article-title>
          <source>J Cyst Fibros</source>
          <year>2013</year>
          <volume>12</volume>
          <fpage>440</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2012.12.012</pub-id>
          <pub-id pub-id-type="pmid">23369661</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Paediatr Respir Rev</journal-id>
      <journal-id journal-id-type="iso-abbrev">Paediatr Respir Rev</journal-id>
      <journal-title-group>
        <journal-title>Paediatric Respiratory Reviews</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1526-0542</issn>
      <issn pub-type="epub">1526-0550</issn>
      <publisher>
        <publisher-name>Elsevier Ltd.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32653467</article-id>
      <article-id pub-id-type="pmc">7297155</article-id>
      <article-id pub-id-type="pii">S1526-0542(20)30092-0</article-id>
      <article-id pub-id-type="doi">10.1016/j.prrv.2020.06.007</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Mini-symposium: Diagnosis and management of pulmonary lymphatic disorders</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rational use of mucoactive medications to treat pediatric airway disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="au005">
          <name>
            <surname>Linssen</surname>
            <given-names>R.S.N.</given-names>
          </name>
          <xref rid="af005" ref-type="aff">a</xref>
          <xref rid="fn1" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author" id="au010">
          <name>
            <surname>Ma</surname>
            <given-names>J.</given-names>
          </name>
          <xref rid="af010" ref-type="aff">b</xref>
          <xref rid="fn1" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author" id="au015">
          <name>
            <surname>Bem</surname>
            <given-names>R.A.</given-names>
          </name>
          <xref rid="af005" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author" id="au020">
          <name>
            <surname>Rubin</surname>
            <given-names>B.K.</given-names>
          </name>
          <xref rid="af010" ref-type="aff">b</xref>
          <xref rid="cor1" ref-type="corresp">&#x204E;</xref>
        </contrib>
        <aff id="af005"><label>a</label>Pediatric Intensive Care Unit, Amsterdam UMC, Emma Children&#x2019;s Hospital, Location AMC, Amsterdam, the Netherlands</aff>
        <aff id="af010"><label>b</label>Pediatric Pulmonary Medicine, Children&#x2019;s Hospital of Richmond, Virginia Commonwealth University, United States</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>&#x204E;</label>Corresponding author at: Dept. of Pediatrics, Virginia Commonwealth University School of Medicine, Children's Hospital of Richmond at VCU, 1000 East Broad St, Richmond, VA 23298, USA.</corresp>
        <fn id="fn1">
          <label>1</label>
          <p id="np005">These authors contributed equally.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>16</day>
        <month>6</month>
        <year>2020</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>6</month>
        <year>2020</year>
      </pub-date>
      <volume>36</volume>
      <fpage>8</fpage>
      <lpage>14</lpage>
      <permissions>
        <copyright-statement>&#xA9; 2020 Elsevier Ltd. All rights reserved.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
        </license>
      </permissions>
      <abstract id="ab005">
        <p>Many airway diseases in children, notably bronchiolitis, cystic fibrosis (CF), non-CF bronchiectasis including primary ciliary dyskinesia, pneumonia, and severe asthma are associated with retention of airway secretions. Medications to improve secretions clearance, the mucoactive medications, are employed to treat these diseases with varying degrees of success. This manuscript reviews evidence for the use of these medications and future directions of study.</p>
      </abstract>
      <kwd-group id="kg005">
        <title>Abbreviations</title>
        <kwd>AAP, American Academy of Pediatrics</kwd>
        <kwd>CF, cystic fibrosis</kwd>
        <kwd>CFTR, cystic fibrosis transmembrane ion regulator</kwd>
        <kwd>ENaC, epithelial sodium channel</kwd>
        <kwd>ERK, extracellular regulating kinase</kwd>
        <kwd>HS, hyperosmolar saline</kwd>
        <kwd>NAC, N-acetyl <sc>l</sc>-cysteine</kwd>
        <kwd>PICU, pediatric intensive care unit</kwd>
        <kwd>RSV, respiratory syncytial virus</kwd>
        <kwd>tPA, tissue plasminogen activator</kwd>
      </kwd-group>
      <kwd-group id="kg010">
        <title>Keywords</title>
        <kwd>Sputum</kwd>
        <kwd>Mucoactive medications</kwd>
        <kwd>Mucolytics</kwd>
        <kwd>Cystic fibrosis</kwd>
        <kwd>Dornase</kwd>
        <kwd>Airway diseases</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s0005">
      <title>Introduction: Definitions and taxonomy</title>
      <p id="p0005">Normal mucus is the lining fluid that protects the airway by entrapping and clearing inhaled particulate matter, and prevents fluid loss from the airway surface. Normal mucus is comprised of approximately 95% water, with polymeric mucins particularly MUC5B secreted from submucosal glands and MUC5AC secreted from mucous or goblet cells, providing the gel structure <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0010" ref-type="bibr">[2]</xref>. The mucous gel layer sits atop a periciliary layer of lower viscosity that contains attached mucins. The polymeric mucins form a gel through entanglement of long mucin chains. There is a relative paucity of cross-linking among discrete mucin polymers (<xref rid="f0005" ref-type="fig">Fig. 1</xref>
and <xref rid="t0005" ref-type="table">Table 1</xref>
).<fig id="f0005"><label>Fig. 1</label><caption><p>(A) Regulators of goblet cell mucus secretion. Anticholinergics decrease mucus secretion by inhibition of neutrophil elastase driven mucin production (11). Anti-inflammatory agents such as corticosteroids and macrolides decrease mucus hypersecretion in airway inflammation. (B) Mucolytic agents break down mucus network structures to favorable biophysical properties for improved mucociliary clearance. Dornase-alfa hydrolyzes extracellular DNA in sputum and N-acetylcysteine reduces disulfide bonds in mucus networks. (C) Airway surface liquid (ASL) rehydrators reverse ASL height reduction to improve mucociliary clearance. These also increase mucus secretion as expectorators hypertonic saline and dry powder mannitol rehydrate ASL by hyperosmolar action. Epithelial sodium channel (ENaC) inhibitors prevent ASL depletion by hyperabsorption of sodium and water through ENaC.</p></caption><graphic xlink:href="gr1_lrg"/></fig><table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Mucus therapies in cystic fibrosis lung disease management.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Therapy</th><th>Mechanism</th><th>Form of Administration</th></tr></thead><tbody><tr><td>Hypertonic Saline</td><td>Restoration of ASL Height</td><td>Aerosol mist</td></tr><tr><td>Mannitol</td><td>Restoration of ASL Height</td><td>Dry-power inhalation</td></tr><tr><td>ENaC Inhibitors</td><td>Restoration of ASL Height</td><td>N/A</td></tr><tr><td>Dornase alfa</td><td>DNA hydrolysis</td><td>Aerosol mist</td></tr><tr><td>N-acetylcysteine</td><td>Disulfide bond</td><td>Aerosol mist</td></tr></tbody></table></table-wrap></p>
      <p id="p0010">During infection and inflammation, airway secretions also contain inflammatory and shed epithelial cells, particulates, microorganisms, secreted peptides and products of inflammation. This complex mix is called <italic>phlegm</italic> when it is in the airway and <italic>sputum</italic> when expectorated <xref rid="b0015" ref-type="bibr">[3]</xref>. Mucoactive drugs are meant to improve the clearance as well as decrease the production of phlegm. In some disorders, as discussed later, airways are obstructed by atypical secretions, such as lymphatic leakage as in plastic bronchitis. In some diseases, notably CF, reduction in the height of the periciliary fluid layer and increased adhesivity of the mucous gel can lead to poor mucus clearance causing accumulation within the airway that eventually can become infected phlegm.</p>
      <p id="p0015">Mucoactive medications are defined by their presumed mechanism of action <xref rid="b0020" ref-type="bibr">[4]</xref>. The term mucolytic, a medication that breaks down polymer bonds within the secretions, has sometimes been incorrectly used interchangeably with the term mucoactive medication. <italic>Mucolytics</italic> can be classic mucolytics that break down mucins at the cross-linked disulfide bonds across adjacent cysteine residues. These classic mucolytics, of which N-acetyl L-cysteine (NAC) is the archetype, contain free sulfhydryl (thiol) groups that hydrolyze these disulfide bonds. Peptide mucolytics of which dornase alfa (Pulmozyme, Genentech, South San Francisco) is the archetype, depolymerize the secondary gel network comprised of polymeric DNA and filamentous (F-) actin. Because F-actin inhibits the effectiveness of dornase alfa, studies are underway evaluating the potential use of actin-protected dornase for more effective depolymerization of the DNA network (eg alidornase).</p>
      <p id="p0020">
<italic>Expectorants</italic> are medications that increase the water content of secretions with the goal of improving clearance. One of the most widely studied of these is guaifenesin, but nearly all studies have shown guaifenesin and related compounds are no more effective than placebo <xref rid="b0025" ref-type="bibr">[5]</xref>. Hyperosmolar medications such as hypertonic saline (HS) or dry powder mannitol are effective in increasing the hydration or fluid content of airway secretions and improving airway clearance in diseases such as CF and non-CF bronchiectasis <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>.</p>
      <p id="p0025">
<italic>Mucokinetic</italic> medications are intended to improve the effectiveness of ciliary propulsion or cough in secretion clearance. Although beta-agonists such as salbutamol increase ciliary beat frequency, there is little evidence that they are effective mucokinetic drugs <xref rid="b0040" ref-type="bibr">[8]</xref>. It could also be argued that by inducing effective coughing, hyperosmolar medications also have mucokinetic properties. Inhaled surfactant decreases the adhesivity of airway secretions, which potentially improves the effectiveness of ciliary and cough clearance <xref rid="b0045" ref-type="bibr">[9]</xref>.</p>
      <p id="p0030">
<italic>Mucoregulatory</italic> medications decrease secretions by inhibiting mucus production or by decreasing inflammation. These medications include macrolide antibiotics that decrease mucin production by inhibiting the extracellular regulating kinase ERK1/2 <xref rid="b0050" ref-type="bibr">[10]</xref>, anticholinergic medications that may decrease mucus production by inhibiting neutrophil elastase driven mucin production <xref rid="b0055" ref-type="bibr">[11]</xref>, and corticosteroids which can decrease airway inflammation.</p>
      <p id="p0035">
<italic>Mucospicic</italic> drugs (e.g. tetracycline) increase secretion viscosity. Secretions that are too thin might not be well cleared either by cough or by cilia, which is why mucus exists as a gel. Some patients, such as those with bronchorrhea, have extremely thin and liquid-like mucus. Mucospicic drugs may improve mucus clearance in these patients.</p>
    </sec>
    <sec id="s0010">
      <title>Viral bronchiolitis</title>
      <p id="p0040">Viral bronchiolitis is a clinical diagnosis in children characterized by obstructive dyspnea with increased respiratory effort, cough and - sometimes in young infants- apnea <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>. It is most frequently caused by respiratory syncytial virus (RSV), but other respiratory viruses such as human metapneumovirus, bocavirus, human rhinovirus, para-influenza virus, coronavirus, enterovirus can be implicated as well <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>. The pathobiology of bronchiolitis consists of edema of the small airways, increased local mucus production, and epithelial cell injury (necrosis and apoptosis) with ciliary dysfunction <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>. The sloughing of dead airway cells together with an influx of leukocytes contributes to the thick mucus plugs that obstruct the smaller airways. Due to their small airways, especially young infants are prone to airway obstruction and at increased risk for hospitalization <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>. Treatment for bronchiolitis is mainly supportive and as such there is need for an effective treatment targeting airway mucus obstruction.</p>
      <p id="p0045">The mucus plugs obstructing airways in viral bronchiolitis contain a large amount of polymerized, extracellular DNA <xref rid="b0100" ref-type="bibr">[20]</xref>. As such, the use of the mucolytic dornase alfa, has been of interest <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>. Two randomized, placebo-controlled studies of nebulized dornase alfa in hospitalized children with mild to moderate bronchiolitis and a Cochrane review did not show a decrease in length of hospital stay or respiratory effort <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>. However, one study did show an improvement in chest radiograph defined atelectasis compared to placebo in young children with severe bronchiolitis <xref rid="b0100" ref-type="bibr">[20]</xref>. Although chest X-ray abnormalities as a single finding are clinically less relevant, this finding is consistent with case series of mechanically ventilated children that reported radiological and clinical improvement after the use of dornase alfa <xref rid="b0125" ref-type="bibr">[25]</xref>. A more prominent role for mucus plugging in the severe cases of bronchiolitis is suggested. For example: large amounts of neutrophils have been shown to be present in the airway of children who were mechanically ventilated or died from severe bronchiolitis <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref> and excessive formation of neutrophil extracellular traps may contribute to increased DNA content in mucus, further increasing its viscoelasticity <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>. The current guideline from the American Academy of Pediatrics (AAP) on the treatment of bronchiolitis does not include a recommendation for using dornase alfa <xref rid="b0155" ref-type="bibr">[31]</xref>. Future studies might focus on the use of dornase alfa in severe bronchiolitis and the possibilities for combined use with other aerosol agents to enhance small airway deposition.</p>
      <p id="p0050">The mucolytic NAC can be administered either by nebulization or orally, but has a low bioavailability as it undergoes first pass metabolism <xref rid="b0160" ref-type="bibr">[32]</xref>. Although the use of NAC is carefully being explored for respiratory diseases in experimental settings, the clinical use of NAC for respiratory diseases is not recommended <xref rid="b0165" ref-type="bibr">[33]</xref>. Despite one abstract reporting improvement of clinical severity scores when comparing nebulized NAC to salbutamol in children with viral bronchiolitis (full text article could not be retrieved), no studies have evaluated the role of NAC in viral bronchiolitis patients <xref rid="b0170" ref-type="bibr">[34]</xref>. A possible beneficial effect for NAC can be hypothesized, as NAC functions as a free radical scavenger with anti-oxidative properties <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref>. Oxidative stress is implicated in the pathophysiology of bronchiolitis. Laboratory studies showed increased levels of intracellular H<sub>2</sub>O<sub>2</sub> in pulmonary epithelial cells after RSV infection <xref rid="b0185" ref-type="bibr">[37]</xref> and the addition of NAC to RSV infected airway cultures reduces MUC5AC expression <italic>in vitro</italic>
<xref rid="b0185" ref-type="bibr">[37]</xref>.</p>
      <p id="p0055">Nebulized HS decreases mucus plugging through the osmotic hydration of mucus, improving mucociliary clearance <xref rid="b0190" ref-type="bibr">[38]</xref> and stimulates effective cough through an irritant effect. The use of 3% HS has been extensively studied in viral bronchiolitis. An in 2017 updated Cochrane review on a total of 4195 children, showed that the use of nebulized hypertonic saline compared to normal (0.9%) saline resulted in a slightly shorter length of hospitalization, but also reported low quality evidence <xref rid="b0195" ref-type="bibr">[39]</xref>, <xref rid="b0200" ref-type="bibr">[40]</xref>. Three randomized trials have been published since 2017. From them, only one study showed clinical improvement after three days of HS compared to one day of HS treatment but was underpowered <xref rid="b0205" ref-type="bibr">[41]</xref>, while two trials showed no beneficial effects for HS treatment compared to standard supportive care <xref rid="b0210" ref-type="bibr">[42]</xref>, <xref rid="b0215" ref-type="bibr">[43]</xref>. In most studies, HS was administered in combination with bronchodilator agents because of the fear for HS induced bronchospasms. But a retrospective cohort study focusing on the use of 3% HS without bronchodilators reported only one bronchospasm among 377 included children <xref rid="b0220" ref-type="bibr">[44]</xref>. In severe bronchiolitis, one retrospective study including 104 children admitted to pediatric intensive care unit (PICU) for mechanical ventilation reported both a decreased duration of respiratory support and length of PICU stay in favor of HS <xref rid="b0225" ref-type="bibr">[45]</xref>. Again, this might implicate a more prominent role for mucus obstruction in the pathobiology of viral bronchiolitis in children necessitating PICU admission. The AAP guideline on the treatment of bronchiolitis takes a neutral position on this topic and does not give recommendations on the use of HS in hospitalized children <xref rid="b0155" ref-type="bibr">[31]</xref>.</p>
      <p id="p0060">Although children suffering from bronchiolitis may present with wheezing in the acute phase, the respiratory distress originates from to small airway inflammation with extensive mucus plugging and (in most cases) not from bronchospasms. Randomized controlled trials show no significant benefits from nebulized albuterol for bronchiolitis and a Cochrane review from 2014 reported no benefits in terms of oxygen saturation or clinical scores <xref rid="b0230" ref-type="bibr">[46]</xref>. A single study evaluating the effects of epinephrine, levalbuterol, and racemic albuterol/salbutamol in mechanically ventilated children with bronchiolitis found a statistically significant, but clinically futile effect on airway peak pressures <xref rid="b0235" ref-type="bibr">[47]</xref>. As such, the AAP advises against the use of bronchodilators for viral bronchiolitis <xref rid="b0155" ref-type="bibr">[31]</xref> and a recent clinical study reporting no negatively affected clinical outcome after decreased use of albuterol affirms this recommendation <xref rid="b0240" ref-type="bibr">[48]</xref>.</p>
      <p id="p0065">Surfactant (mucokinetic) is essential for normal small airway function and prevention of alveolar collapse. In health, surfactant decreases the adhesive interaction between the cilia and mucus. This enables effective mucociliary clearance as it allows the cilia to beat without becoming entangled in the airway mucus <xref rid="b0245" ref-type="bibr">[49]</xref>. A decreased amount of airway phosphatidylcholine and impaired surfactant function in children suffering from bronchiolitis is reported <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0255" ref-type="bibr">[51]</xref>. This may be worse in severe cases of children who are in need of mechanical ventilation, as they suffer from more extensive airway inflammation <xref rid="b0260" ref-type="bibr">[52]</xref>. A relationship between clinical recovery from bronchiolitis and improved surfactant activity is suggested <xref rid="b0260" ref-type="bibr">[52]</xref>. To date, no clinical trials on the efficacy of exogenous surfactant administration in children hospitalized for mild to moderate bronchiolitis have been published. For children admitted to the PICU for bronchiolitis necessitating invasive ventilation, three randomized controlled trials have been published. A 2015 Cochrane review indicated favorable effect for duration of mechanical ventilation and PICU stay <xref rid="b0260" ref-type="bibr">[52]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>, but only included a low number of subjects. The current AAP guideline does not include a recommendation regarding the use of nebulized surfactant for bronchiolitis <xref rid="b0155" ref-type="bibr">[31]</xref>.</p>
    </sec>
    <sec id="s0015">
      <title>Plastic bronchitis</title>
      <p id="p0070">Plastic bronchitis is a rare airway disorder defined by the presence of cohesive (rubbery) and branching casts that fill the airways <xref rid="b0270" ref-type="bibr">[54]</xref>. This is different from mucus plugging where large, friable, non-branching phlegm contains mucin, inflammatory cells, and often bacteria. Although mucus plugs can be quite large, they do not have the extensive branching characteristics and rubbery texture of plastic bronchitis casts. They represent completely different etiologies. As one example, although extensive mucus plugging is common in patients with both CF and non-CF bronchiectasis, plastic bronchitis has never been reliably reported in patients with either of these disorders.</p>
      <p id="p0075">Plastic bronchitis is now identified as either being lymphatic or non-lymphatic in origin. The older classification systems that include inflammatory vs. non-inflammatory casts or Type 1 vs. Type 2 plastic bronchitis <xref rid="b0275" ref-type="bibr">[55]</xref> were abandoned over 15&#x202F;years ago when it was demonstrated that all forms of plastic bronchitis have some degree of inflammation. However, it is true that the non-lymphatic (or eosinophilic) plastic bronchitis has more inflammatory cells than classic or lymphatic plastic bronchitis <xref rid="b0280" ref-type="bibr">[56]</xref>.</p>
      <p id="p0080">Lymphatic plastic bronchitis appears to be the most common form of this disorder. It is most often reported in children and young adults with congenital heart disease, often after Fontan surgery and repair of single ventricle physiology. Plastic bronchitis is reported to occur in 3&#x2013;4 % of these patients although the prevalence is probably under recognized <xref rid="b0265" ref-type="bibr">[53]</xref>. As well described in another paper in this issue by Dr. Itkin and colleagues, there are characteristic abnormalities of the thoracic duct and lymphatic drainage that lead to plastic bronchitis when pulmonary vascular pressures are compromised.</p>
      <p id="p0085">Plastic bronchitis casts can be seen in some patients with sickle cell acute chest syndrome <xref rid="b0285" ref-type="bibr">[57]</xref>, primary lymphatic abnormalities, and following primary lymphatic malignancy. These lymphatic associated casts contain some cells, almost no fibrin, but extensive and congealed lymph. Because of this, classic mucolytics, peptide mucolytics, and fibrinolytic drugs are only partially effective in treating this disorder.</p>
      <p id="p0090">Eosinophilic plastic bronchitis produces branching casts that contain eosinophils and eosinophil degradation products including Charcot-Leyden crystals. Eosinophilic plastic bronchitis tends to occur in older children and young adults most of whom have a history of asthma and allergies <xref rid="b0265" ref-type="bibr">[53]</xref>. These casts tend to occur in one branch of the airway and to reoccur only in that airway branch. Although this condition bears some resemblance to severe asthma where there is extensive mucus obstruction, even those patients have asthma tend to have relatively mild disease. In some respects, this disease is more like other eosinophilic diseases such as eosinophilic esophagitis.</p>
      <p id="p0095">It has been difficult to evaluate the effectiveness of mucoactive medications for the treatment of plastic bronchitis. There are relatively few subjects available for study in any one center leading to reports of individual case interventions. Also, the frequent confusion between plastic bronchitis and mucus plugging in those less familiar with these conditions makes it unclear which disorder has been treated.</p>
      <p id="p0100">Lymphatic plastic bronchitis does not respond to either classic or peptide mucolytics which should not be surprising as there appears to be little if any polymeric mucin or DNA in these casts. Tissue plasminogen activator (tPA) has been used acutely to degrade casts in patients with airway obstruction who are unable to tolerate bronchoscopy <xref rid="b0290" ref-type="bibr">[58]</xref>. However, tPA should be considered a temporizing measure as it leads to extensive airway inflammation.</p>
      <p id="p0105">Tissue Factor activation has been associated with plastic bronchitis and so inhaled heparin has been used as chronic therapy to act both as an anti-inflammatory agent and to inhibit Tissue Factor. This therapy has met with variable success and appears to be most effective as a temporizing measure to prevent the formation of casts following bronchoscopic removal. There is no evidence for the effectiveness of inhaled hypertonic saline, NAC, steroids, salbutamol, or other medications for the treatment of lymphatic plastic bronchitis.</p>
      <p id="p0110">Eosinophilic or non-lymphatic plastic bronchitis often responds to corticosteroids administered in high dose or as pulse therapy. There is no proven effectiveness for the use of NAC, dornase alfa, hypertonic saline or other mucoactive medications for the treatment of non-lymphatic plastic bronchitis. Although it is possible that some of the newer biologics, particularly those that inhibit eosinophils, may be effective treatment of non-lymphatic plastic bronchitis, to our knowledge this has not been studied.</p>
    </sec>
    <sec id="s0020">
      <title>Cystic fibrosis and Non-Cystic fibrosis bronchiectasis</title>
      <p id="p0115">A major feature of cystic fibrosis lung disease is mucus accumulation resulting in airway obstruction. Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane ion regulator (CFTR) protein gene, resulting in decreased chloride and bicarbonate secretion at the apical cell membrane of airway epithelial cells. This decreased anion secretion, coupled with CFTR-mediated increased sodium absorption via the epithelial sodium channel (ENaC), results in higher partial osmotic pressure and compression of the airway surface liquid height <xref rid="b0295" ref-type="bibr">[59]</xref>. This reduction of the airway surface liquid height results in reduced ciliary beat frequency and thus impaired mucociliary clearance, in turn resulting in mucus plug formation and small airway obstruction <xref rid="b0295" ref-type="bibr">[59]</xref>. These changes in the airway mucus clearance, together with the primary CFTR defect, result in repeated cycles of infection and inflammation, bronchiectasis, and progressive loss of lung function <xref rid="b0300" ref-type="bibr">[60]</xref>. Ameliorating these CFTR dysfunction related changes to airway mucus is thus an important therapeutic strategy in CF.</p>
      <p id="p0120">The first class of therapeutics addressing abnormal airway mucus in CF is those that directly hydrate the mucus. Depletion of the airway surface liquid occurs through decreased CFTR&#x2010;mediated fluid secretion with concomitant fluid absorption via the epithelial sodium channel (ENaC). Thus, one therapeutic strategy in CF lung disease is &#x201C;rehydration&#x201D; of the airway surface liquid by inhaling hyperosmolar agents. The premise of this class of therapies is that the airway surface liquid is pulled into the airway from the osmotic gradient generated <xref rid="b0305" ref-type="bibr">[61]</xref>. The most widely used is aerosol hypertonic saline as a 7% sodium chloride solution <xref rid="b0310" ref-type="bibr">[62]</xref>. Hypertonic saline, administered as an inhalation therapy twice daily, increases mucociliary clearance but not lung function in adults with CF <xref rid="b0315" ref-type="bibr">[63]</xref>
<bold>.</bold> In a double-blind, randomized control trial of inhaled hypertonic saline and isotonic saline in adults with CF, hypertonic saline failed to improve lung function but resulted in reduction of pulmonary exacerbations <xref rid="b0320" ref-type="bibr">[64]</xref>. More recently, in the Saline Hypertonic in Preschoolers (SHIP) study, inhaled hypertonic saline was shown to improve the lung clearance Index, a marker of ventilation homogeneity, in children with CF aged 3&#x2013;6&#x202F;years <xref rid="b0325" ref-type="bibr">[65]</xref>. Mannitol, which is a monosaccharide and is inhaled as a dry powder, has also been used in a similar fashion in CF and it improves lung function <xref rid="b0330" ref-type="bibr">[66]</xref>, <xref rid="b0335" ref-type="bibr">[67]</xref> and surface properties of CF sputum <xref rid="b0340" ref-type="bibr">[68]</xref>. In non-CF bronchiectasis, the role of inhaled hyperosmolar therapy is less clear. Hypertonic saline failed to improvements in exacerbation rate, lung function, and quality of life when compared to inhaled isotonic saline in a 12-month clinical trial <xref rid="b0345" ref-type="bibr">[69]</xref>. Similarly, dry powder mannitol failed show improvement in function or respiratory symptom assessment over placebo <xref rid="b0350" ref-type="bibr">[70]</xref>
<bold>.</bold>
</p>
      <p id="p0125">Another therapeutic strategy to rehydrate the airway surface liquid is targeting the epithelial sodium channel (ENaC). ENaC is an ion channel expressed on the apical surface of airway epithelial cells that conducts the resorption of sodium ions and water from the epithelial lumen into the epithelial cell <xref rid="b0355" ref-type="bibr">[71]</xref>. In a CFTR deficient state there is evidence to suggest hyperabsorption of sodium and water via ENaC, which results in further depletion of the airway surface liquid <xref rid="b0360" ref-type="bibr">[72]</xref>. There are ongoing efforts to develop ENaC inhibitors as potential therapeutics in CF to improve airway mucus and mucus clearance, though none are approved at the time of this review article.</p>
      <p id="p0130">CF airway mucus has abnormal viscoelastic properties <xref rid="b0365" ref-type="bibr">[73]</xref> in part due to increased DNA and filamentous actin <xref rid="b0370" ref-type="bibr">[74]</xref>. Another therapeutic strategy to improve airway mucus properties and enhance mucus clearance is to &#x201C;thin&#x201D; airway secretions with mucolytic and sputum-lytic agents. Dornase alfa has been widely adopted as an inhaled therapy in CF. Dornase alfa improves CF airway mucus properties by enzymatically degrading DNA, resulting in a decrease in mucus viscosity <xref rid="b0105" ref-type="bibr">[21]</xref> and improvement in lung function <xref rid="b0375" ref-type="bibr">[75]</xref>. While dornase alfa has been shown to be clinically beneficial in CF lung disease, it has been shown to be harmful in non-CF bronchiectasis, with increased risk of exacerbations and decrease in lung function when compared to placebo <xref rid="b0380" ref-type="bibr">[76]</xref>. Another proposed mucolytic therapy in CF is N-acetylcysteine, which disrupts the mucus architecture through hydrolysis of the disulfide bonds tethering mucus strands. However, there are no studies to date to show clinical benefit in CF lung disease <xref rid="b0385" ref-type="bibr">[77]</xref>.</p>
    </sec>
    <sec id="s0025">
      <title>Asthma</title>
      <p id="p0135">Asthma is a common, chronic inflammatory disorder of the airways that is primarily associated with bronchial hyperresponsiveness and intermittent airflow obstruction. Mucus hypersecretion and airway obstruction by mucus plugs often contribute to disease symptoms, in particular during exacerbations and especially with severe, life-threatening or fatal asthma attacks <xref rid="b0390" ref-type="bibr">[78]</xref>, <xref rid="b0395" ref-type="bibr">[79]</xref>, <xref rid="b0400" ref-type="bibr">[80]</xref>. Current, well-established, asthma medications, including both controller and reliever therapies such as <inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mi>&#x3B2;</mml:mi></mml:math></inline-formula>2-agonists <xref rid="b0405" ref-type="bibr">[81]</xref>, <xref rid="b0410" ref-type="bibr">[82]</xref>, <xref rid="b0415" ref-type="bibr">[83]</xref>, anticholinergics <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0420" ref-type="bibr">[84]</xref>, <xref rid="b0425" ref-type="bibr">[85]</xref>, <xref rid="b0430" ref-type="bibr">[86]</xref>, and corticosteroids <xref rid="b0435" ref-type="bibr">[87]</xref> have putative mucoregulatory activities. However, in the clinical evaluation of these agents, any direct mucoregulatory effects (e.g. reduction of mucus secretion or occurrence of mucus plugs) will be difficult to distinguish from their other more primary bronchodilator and/or immunomodulatory functions. On the other hand, macrolides, have been shown to decrease mucus secretion both <italic>in vitro</italic> and <italic>in vivo</italic>
<xref rid="b0440" ref-type="bibr">[88]</xref>, and may have a role as an anti-inflammatory to treat asthma, but their clinical benefit in both children and adults with chronic asthma has not been established <xref rid="b0445" ref-type="bibr">[89]</xref>.</p>
      <p id="p0140">Mucolytic agents, including dornase alfa and NAC, are not used in the management of asthma. There is no evidence of a clinical benefit of dornase alfa in children <xref rid="b0450" ref-type="bibr">[90]</xref> or adults <xref rid="b0455" ref-type="bibr">[91]</xref> with moderate to severe asthma. Nevertheless, some clinicians appear to use dornase alfa in mechanically ventilated children,<xref rid="b0460" ref-type="bibr">[92]</xref> fueled by case reports showing improvement agent <xref rid="b0465" ref-type="bibr">[93]</xref>, <xref rid="b0470" ref-type="bibr">[94]</xref>. The administration of NAC in asthma has met with very limited success, as more recently assessed in a systematic review and meta-analysis.<xref rid="b0475" ref-type="bibr">[95]</xref> Although expectorants, such as hypertonic saline, which is frequently used for sputum induction during bronchial challenge, have been shown to improve mucociliary and cough clearance in asthmatics in small studies, <xref rid="b0480" ref-type="bibr">[96]</xref>, <xref rid="b0485" ref-type="bibr">[97]</xref> these agents are currently not recommended in asthma management and indeed are known to induce mucus secretion and bronchospasm.</p>
      <p id="p0145">Although these findings reduce the likelihood that mucoactive agents in current use will play a role in the pharmacological approach to (pediatric) asthma, increasing insight into asthma endotypes (e.g. allergic, non-allergic, neutrophilic, cough-dominant etc), in which different immune cells (e.g. eosinophils vs neutrophils) function as the primary drivers of asthma pathophysiology, may establish the relative importance of mucus in defining clinical signs of illness, particularly in T17 dominant (non-eosinophilic) asthma. As such, the concept of secretory hyperresponsiveness, which has strong links to IL-13 and neutrophil elastase mediated responses, <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0490" ref-type="bibr">[98]</xref>, <xref rid="b0495" ref-type="bibr">[99]</xref> may serve as an anchor point for the use of mucoactive agents in asthma.</p>
    </sec>
    <sec id="s0030">
      <title>Pediatric critical care: Mechanically ventilated children</title>
      <p id="p0150">Children with acute respiratory failure undergoing invasive mechanical ventilation in the pediatric intensive care unit (PICU) comprise a patient group highly vulnerable for airway obstruction by phlegm. Airway obstruction in these children increases the risk of atelectasis, ventilator-associated pneumonia and need for high peak airway pressures. At the same time, an indwelling endotracheal tube provides an opportunity for new local drug delivery for mucoactive agents <xref rid="b0500" ref-type="bibr">[100]</xref>, <xref rid="b0505" ref-type="bibr">[101]</xref>.</p>
      <p id="p0155">Disappointingly, few randomized controlled studies have so far studied the effectiveness of mucoactive agents during invasive mechanical ventilation in an either specific or general PICU population. McKinley et al. have investigated the effect of no saline versus 0.225% or 0.9% saline installation before routine endotracheal suction to remove phlegm in 427 children receiving ventilator support <xref rid="b0510" ref-type="bibr">[102]</xref>. However, in this non-blinded trial, no statistically significant differences in duration of mechanical ventilation, oxygen therapy or PICU stay between the groups were found. Similarly, Shein et al. have focused on expectorants by studying routine nebulization with hypertonic (3%) saline versus normal (0.9%) saline in a pilot study <xref rid="b0515" ref-type="bibr">[103]</xref>. With a very small sample size (n&#x202F;=&#x202F;18), they found no differences between the groups for a number of outcomes, including duration of mechanical ventilation or chest X-ray atelectasis score, as well as respiratory mechanics parameters before and after intervention. Finally, Riethmueller and co-workers studied the mucolytic agent aldornasfa versus normal saline in 88 mechanically ventilated children with an age of 0&#x2013;2&#x202F;years after cardiac surgery <xref rid="b0520" ref-type="bibr">[104]</xref>. Nebulization with dornase alfa resulted in a statistically significant reduction in duration of ventilator support by approximately one day, as well as a trend (p&#x202F;=&#x202F;0.051) towards improved chest X-ray atelectasis scores. However, the primary endpoint of this study, re-intubation incidence, was not significantly different between the groups.</p>
      <p id="p0160">These results do not make any recommendations on routine mucoactive medication strategies for PICU patients possible. They merely reveal the need for further randomized trials in this field. With this, we need to realize that subgroups of PICU patients either with or without active respiratory inflammation and infection may react differently to expectorants versus pure mucolytics. As such, better insight into the dynamics of mucus and phlegm viscoelastic properties and contents (e.g. extracellular DNA, proteins) during the course of mechanical ventilation for pediatric critical illnesses is highly relevant.</p>
    </sec>
    <sec id="s0035">
      <title>Conclusion &amp; future research directions</title>
      <p id="p0165">A characteristic of many airway diseases is secretion retention. Although various mucoactive medications, with diverse mechanisms of action, have been studied as potential therapies, there are few well controlled clinical studies supporting their use; especially for older medications. There has been a renewed interest in testing existing drugs and developing new medications targeting specific abnormalities in mucus clearance. This is driven, in large part, by a better understanding of the importance of secretion clearance and the mechanism(s) of action of mucoactive medications as well as a better understanding of how mucus secretion and clearance changes with disease type and disease activity.</p>
    </sec>
    <sec id="s0040">
      <title>Educational aims</title>
      <p id="p0170">The reader will be able to:<list list-type="simple" id="l0005"><list-item id="o0005"><label>&#x2022;</label><p id="p0175">Understand the classification of mucoactive medications based upon their proposed mechanism of action</p></list-item><list-item id="o0010"><label>&#x2022;</label><p id="p0180">Identify medications that have been approved for secretion clearance therapy and their specific indications</p></list-item><list-item id="o0015"><label>&#x2022;</label><p id="p0185">Appreciate how to evaluate the effectiveness of mucoactive medications for different airway diseases</p></list-item><list-item id="o0020"><label>&#x2022;</label><p id="p0190">Recognize that medications that are effective for one disease may not be effective or may even be harmful for treating other diseases.</p></list-item></list>
</p>
    </sec>
    <sec id="s0045">
      <title>Author contributions</title>
      <p id="p0195">Linssen, RSN: contributed to the writing of the manuscript.</p>
      <p id="p0200">Ma, J: contributed to the writing of the manuscript.</p>
      <p id="p0205">Bem, RA: contributed to the writing of the manuscript.</p>
      <p id="p0210">Rubin, BK: contributed to the design of the study, contributed to the writing of the manuscript.</p>
    </sec>
  </body>
  <back>
    <ref-list id="bi005">
      <title>References</title>
      <ref id="b0005">
        <label>1</label>
        <element-citation publication-type="journal" id="h0005">
          <person-group person-group-type="author">
            <name>
              <surname>Voynow</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Mucins, mucus, and sputum</article-title>
          <source>Chest</source>
          <volume>135</volume>
          <issue>2</issue>
          <year>2009</year>
          <fpage>505</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="pmid">19201713</pub-id>
        </element-citation>
      </ref>
      <ref id="b0010">
        <label>2</label>
        <element-citation publication-type="journal" id="h0010">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Voynow</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Mucins, mucus, and goblet cells</article-title>
          <source>Chest</source>
          <volume>154</volume>
          <issue>1</issue>
          <year>2018</year>
          <fpage>169</fpage>
          <lpage>176</lpage>
          <pub-id pub-id-type="pmid">29170036</pub-id>
        </element-citation>
      </ref>
      <ref id="b0015">
        <label>3</label>
        <element-citation publication-type="journal" id="h0015">
          <person-group person-group-type="author">
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Mucus, phlegm, and sputum in cystic fibrosis</article-title>
          <source>Respir Care</source>
          <volume>54</volume>
          <issue>6</issue>
          <year>2009</year>
          <fpage>726</fpage>
          <lpage>732</lpage>
          <comment>discussion 32</comment>
          <pub-id pub-id-type="pmid">19467160</pub-id>
        </element-citation>
      </ref>
      <ref id="b0020">
        <label>4</label>
        <element-citation publication-type="book" id="h0020">
          <person-group person-group-type="author">
            <name>
              <surname>Bk</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <chapter-title>Taxonomy of mucoactive medications</chapter-title>
          <year>2004</year>
          <publisher-name>Marcel Dekker, Inc</publisher-name>
          <publisher-loc>New York</publisher-loc>
        </element-citation>
      </ref>
      <ref id="b0025">
        <label>5</label>
        <element-citation publication-type="journal" id="h0025">
          <person-group person-group-type="author">
            <name>
              <surname>Hoffer-Schaefer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rozycki</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Yopp</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Guaifenesin has no effect on sputum volume or sputum properties in adolescents and adults with acute respiratory tract infections</article-title>
          <source>Respir Care</source>
          <volume>59</volume>
          <issue>5</issue>
          <year>2014</year>
          <fpage>631</fpage>
          <lpage>636</lpage>
          <pub-id pub-id-type="pmid">24003241</pub-id>
        </element-citation>
      </ref>
      <ref id="b0030">
        <label>6</label>
        <element-citation publication-type="journal" id="h0030">
          <person-group person-group-type="author">
            <name>
              <surname>Nevitt</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Thornton</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Dwyer</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Inhaled mannitol for cystic fibrosis</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2020;5(5):</year>
          <fpage>Cd008649</fpage>
          <pub-id pub-id-type="pmid">32358807</pub-id>
        </element-citation>
      </ref>
      <ref id="b0035">
        <label>7</label>
        <element-citation publication-type="journal" id="h0035">
          <person-group person-group-type="author">
            <name>
              <surname>Wark</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>V.M.</given-names>
            </name>
          </person-group>
          <article-title>Nebulised hypertonic saline for cystic fibrosis</article-title>
          <source>Cochrane Database Syst Rev</source>
          <volume>9</volume>
          <issue>9</issue>
          <year>2018</year>
          <fpage>Cd001506</fpage>
          <pub-id pub-id-type="pmid">30260472</pub-id>
        </element-citation>
      </ref>
      <ref id="b0040">
        <label>8</label>
        <element-citation publication-type="journal" id="h0040">
          <person-group person-group-type="author">
            <name>
              <surname>Isawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Teshima</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ebina</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Anazawa</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Konno</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Effect of bronchodilation on the deposition and clearance of radioaerosol in bronchial asthma in remission</article-title>
          <source>J Nuclear Med</source>
          <volume>28</volume>
          <issue>12</issue>
          <year>1987</year>
          <fpage>1901</fpage>
          <lpage>1906</lpage>
        </element-citation>
      </ref>
      <ref id="b0045">
        <label>9</label>
        <element-citation publication-type="journal" id="h0045">
          <person-group person-group-type="author">
            <name>
              <surname>Anzueto</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Jubran</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ohar</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Piquette</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Rennard</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Colice</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial</article-title>
          <source>JAMA</source>
          <volume>278</volume>
          <issue>17</issue>
          <year>1997</year>
          <fpage>1426</fpage>
          <lpage>1431</lpage>
          <pub-id pub-id-type="pmid">9356001</pub-id>
        </element-citation>
      </ref>
      <ref id="b0050">
        <label>10</label>
        <element-citation publication-type="journal" id="h0050">
          <person-group person-group-type="author">
            <name>
              <surname>Shinkai</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>G.H.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <volume>290</volume>
          <issue>1</issue>
          <year>2006</year>
          <fpage>L75</fpage>
          <lpage>L85</lpage>
          <pub-id pub-id-type="pmid">16085674</pub-id>
        </element-citation>
      </ref>
      <ref id="b0055">
        <label>11</label>
        <element-citation publication-type="journal" id="h0055">
          <person-group person-group-type="author">
            <name>
              <surname>Komiya</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kawano</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Suzaki</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Akaba</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kadota</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Tiotropium inhibits mucin production stimulated by neutrophil elastase but not by IL-13</article-title>
          <source>Pulm Pharmacol Ther</source>
          <volume>48</volume>
          <year>2018</year>
          <fpage>161</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="pmid">29158154</pub-id>
        </element-citation>
      </ref>
      <ref id="b0060">
        <label>12</label>
        <element-citation publication-type="journal" id="h0060">
          <person-group person-group-type="author">
            <name>
              <surname>Meissner</surname>
              <given-names>H.C.</given-names>
            </name>
          </person-group>
          <article-title>Viral bronchiolitis in children</article-title>
          <source>N Engl J Med</source>
          <volume>374</volume>
          <issue>1</issue>
          <year>2016</year>
          <fpage>62</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">26735994</pub-id>
        </element-citation>
      </ref>
      <ref id="b0065">
        <label>13</label>
        <element-citation publication-type="journal" id="h0065">
          <person-group person-group-type="author">
            <name>
              <surname>Florin</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Plint</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Zorc</surname>
              <given-names>J.J.</given-names>
            </name>
          </person-group>
          <article-title>Viral bronchiolitis</article-title>
          <source>The Lancet</source>
          <volume>389</volume>
          <issue>10065</issue>
          <year>2017</year>
          <fpage>211</fpage>
          <lpage>224</lpage>
        </element-citation>
      </ref>
      <ref id="b0070">
        <label>14</label>
        <element-citation publication-type="journal" id="h0070">
          <person-group person-group-type="author">
            <name>
              <surname>Pickles</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>DeVincenzo</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis</article-title>
          <source>J Pathol</source>
          <volume>235</volume>
          <issue>2</issue>
          <year>2015</year>
          <fpage>266</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="pmid">25302625</pub-id>
        </element-citation>
      </ref>
      <ref id="b0075">
        <label>15</label>
        <element-citation publication-type="journal" id="h0075">
          <person-group person-group-type="author">
            <name>
              <surname>Bem</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Domachowske</surname>
              <given-names>J.B.</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>H.F.</given-names>
            </name>
          </person-group>
          <article-title>Animal models of human respiratory syncytial virus disease</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <volume>301</volume>
          <issue>2</issue>
          <year>2011</year>
          <fpage>L148</fpage>
          <lpage>L156</lpage>
          <pub-id pub-id-type="pmid">21571908</pub-id>
        </element-citation>
      </ref>
      <ref id="b0080">
        <label>16</label>
        <element-citation publication-type="journal" id="h0080">
          <person-group person-group-type="author">
            <name>
              <surname>Terry</surname>
              <given-names>P.B.</given-names>
            </name>
            <name>
              <surname>Traystman</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>The clinical significance of collateral ventilation</article-title>
          <source>Ann Am Thorac Soc</source>
          <volume>13</volume>
          <issue>12</issue>
          <year>2016</year>
          <fpage>2251</fpage>
          <lpage>2257</lpage>
          <pub-id pub-id-type="pmid">27739872</pub-id>
        </element-citation>
      </ref>
      <ref id="b0085">
        <label>17</label>
        <element-citation publication-type="journal" id="h0085">
          <person-group person-group-type="author">
            <name>
              <surname>Hall</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Blumkin</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Staat</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>A.F.</given-names>
            </name>
          </person-group>
          <article-title>Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age</article-title>
          <source>Pediatrics</source>
          <volume>132</volume>
          <issue>2</issue>
          <year>2013</year>
          <fpage>e341</fpage>
          <lpage>e348</lpage>
          <pub-id pub-id-type="pmid">23878043</pub-id>
        </element-citation>
      </ref>
      <ref id="b0090">
        <label>18</label>
        <element-citation publication-type="journal" id="h0090">
          <person-group person-group-type="author">
            <name>
              <surname>Hall</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Iwane</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Blumkin</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Staat</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>The burden of respiratory syncytial virus infection in young children</article-title>
          <source>N Engl J Med</source>
          <volume>360</volume>
          <issue>6</issue>
          <year>2009</year>
          <fpage>588</fpage>
          <lpage>598</lpage>
          <pub-id pub-id-type="pmid">19196675</pub-id>
        </element-citation>
      </ref>
      <ref id="b0095">
        <label>19</label>
        <mixed-citation publication-type="other" id="h0095">Fujiogi M, Goto T, Yasunaga H, Fujishiro J, Mansbach JM, Camargo CA, Jr., et al. Trends in Bronchiolitis Hospitalizations in the United States: 2000-2016. Pediatrics. 2019;144(6).</mixed-citation>
      </ref>
      <ref id="b0100">
        <label>20</label>
        <element-citation publication-type="journal" id="h0100">
          <person-group person-group-type="author">
            <name>
              <surname>Nasr</surname>
              <given-names>S.Z.</given-names>
            </name>
            <name>
              <surname>Strouse</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Soskolne</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Maxvold</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>Garver</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis</article-title>
          <source>Chest</source>
          <volume>120</volume>
          <issue>1</issue>
          <year>2001</year>
          <fpage>203</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="pmid">11451839</pub-id>
        </element-citation>
      </ref>
      <ref id="b0105">
        <label>21</label>
        <element-citation publication-type="journal" id="h0105">
          <person-group person-group-type="author">
            <name>
              <surname>Shak</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Capon</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Hellmiss</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Marsters</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>C.L.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum</article-title>
          <source>PNAS</source>
          <volume>87</volume>
          <issue>23</issue>
          <year>1990</year>
          <fpage>9188</fpage>
          <lpage>9192</lpage>
          <pub-id pub-id-type="pmid">2251263</pub-id>
        </element-citation>
      </ref>
      <ref id="b0110">
        <label>22</label>
        <element-citation publication-type="journal" id="h0110">
          <person-group person-group-type="author">
            <name>
              <surname>Fuchs</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Borowitz</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Nash</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>B.W.</given-names>
            </name>
          </person-group>
          <article-title>Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group</article-title>
          <source>N Engl J Med</source>
          <volume>331</volume>
          <issue>10</issue>
          <year>1994</year>
          <fpage>637</fpage>
          <lpage>642</lpage>
          <pub-id pub-id-type="pmid">7503821</pub-id>
        </element-citation>
      </ref>
      <ref id="b0115">
        <label>23</label>
        <element-citation publication-type="journal" id="h0115">
          <person-group person-group-type="author">
            <name>
              <surname>Boogaard</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hulsmann</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>van Veen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Vaessen-Verberne</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Yap</surname>
              <given-names>Y.N.</given-names>
            </name>
            <name>
              <surname>Sprij</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant human deoxyribonuclease in infants with respiratory syncytial virus bronchiolitis</article-title>
          <source>Chest</source>
          <volume>131</volume>
          <issue>3</issue>
          <year>2007</year>
          <fpage>788</fpage>
          <lpage>795</lpage>
          <pub-id pub-id-type="pmid">17356094</pub-id>
        </element-citation>
      </ref>
      <ref id="b0120">
        <label>24</label>
        <element-citation publication-type="journal" id="h0120">
          <person-group person-group-type="author">
            <name>
              <surname>Enriquez</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>I.W.</given-names>
            </name>
            <name>
              <surname>Mellis</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>W.Y.</given-names>
            </name>
          </person-group>
          <article-title>Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months</article-title>
          <source>Cochrane Database Syst Rev</source>
          <volume>11</volume>
          <year>2012</year>
          <fpage>CD008395</fpage>
          <pub-id pub-id-type="pmid">23152257</pub-id>
        </element-citation>
      </ref>
      <ref id="b0125">
        <label>25</label>
        <element-citation publication-type="journal" id="h0125">
          <person-group person-group-type="author">
            <name>
              <surname>Merkus</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>de Hoog</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>van Gent</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>de Jongste</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis</article-title>
          <source>Eur Respir J</source>
          <volume>18</volume>
          <issue>4</issue>
          <year>2001</year>
          <fpage>734</fpage>
          <lpage>737</lpage>
          <pub-id pub-id-type="pmid">11716180</pub-id>
        </element-citation>
      </ref>
      <ref id="b0130">
        <label>26</label>
        <element-citation publication-type="journal" id="h0130">
          <source>Mod Pathol</source>
          <volume>20</volume>
          <issue>1</issue>
          <year>2007</year>
          <fpage>108</fpage>
          <lpage>119</lpage>
          <pub-id pub-id-type="pmid">17143259</pub-id>
        </element-citation>
      </ref>
      <ref id="b0135">
        <label>27</label>
        <element-citation publication-type="journal" id="h0135">
          <person-group person-group-type="author">
            <name>
              <surname>Geerdink</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Hennus</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Westerlaken</surname>
              <given-names>G.H.A.</given-names>
            </name>
            <name>
              <surname>Abrahams</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Albers</surname>
              <given-names>K.I.</given-names>
            </name>
            <name>
              <surname>Walk</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>LAIR-1 limits neutrophil extracellular trap formation in viral bronchiolitis</article-title>
          <source>J Allergy Clin Immunol</source>
          <volume>141</volume>
          <issue>2</issue>
          <year>2018</year>
          <fpage>811</fpage>
          <lpage>814</lpage>
          <pub-id pub-id-type="pmid">29050972</pub-id>
        </element-citation>
      </ref>
      <ref id="b0140">
        <label>28</label>
        <mixed-citation publication-type="other" id="h0140">Cortjens B, Ingelse SA, Calis JC, Vlaar AP, Koenderman L, Bem RA, et al. Neutrophil subset responses in infants with severe viral respiratory infection. (1521-7035 (Electronic)).</mixed-citation>
      </ref>
      <ref id="b0145">
        <label>29</label>
        <mixed-citation publication-type="other" id="h0145">Cortjens B, de Boer OJ, de Jong R, Antonis AF, Sabogal Pineros YS, Lutter R, et al. Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease. (1096-9896 (Electronic)).</mixed-citation>
      </ref>
      <ref id="b0150">
        <label>30</label>
        <mixed-citation publication-type="other" id="h0150">Cortjens B, de Jong R, Bonsing JG, van Woensel JBM, Antonis AFG, Bem RA. Local dornase alfa treatment reduces NETs-induced airway obstruction during severe RSV infection. (1468-3296 (Electronic)).</mixed-citation>
      </ref>
      <ref id="b0155">
        <label>31</label>
        <element-citation publication-type="journal" id="h0155">
          <person-group person-group-type="author">
            <name>
              <surname>Ralston</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Lieberthal</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Meissner</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Alverson</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Baley</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Gadomski</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis</article-title>
          <source>Pediatrics</source>
          <volume>134</volume>
          <issue>5</issue>
          <year>2014</year>
          <fpage>e1474</fpage>
          <lpage>e1502</lpage>
          <pub-id pub-id-type="pmid">25349312</pub-id>
        </element-citation>
      </ref>
      <ref id="b0160">
        <label>32</label>
        <element-citation publication-type="journal" id="h0160">
          <person-group person-group-type="author">
            <name>
              <surname>Balsamo</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lanata</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Egan</surname>
              <given-names>C.G.</given-names>
            </name>
          </person-group>
          <article-title>Mucoactive drugs</article-title>
          <source>Eur Respir Rev</source>
          <volume>19</volume>
          <issue>116</issue>
          <year>2010</year>
          <fpage>127</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="pmid">20956181</pub-id>
        </element-citation>
      </ref>
      <ref id="b0165">
        <label>33</label>
        <mixed-citation publication-type="other" id="h0165">Banerjee S, McCormack S. Acetylcysteine for Patients Requiring Mucous Secretion Clearance: A Review of Clinical Effectiveness and Safety. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright (c) 2019 Canadian Agency for Drugs and Technologies in Health.; 2019.</mixed-citation>
      </ref>
      <ref id="b0170">
        <label>34</label>
        <element-citation publication-type="journal" id="h0170">
          <person-group person-group-type="author">
            <name>
              <surname>Naz</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Raza</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Ijaz</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Kazi</surname>
              <given-names>M.Y.</given-names>
            </name>
          </person-group>
          <article-title>Effectiveness of nebulized N-acetylcysteine solution in children with acute bronchiolitis</article-title>
          <source>J College Phys Surg-Pakistan: JCPSP</source>
          <volume>24</volume>
          <issue>6</issue>
          <year>2014</year>
          <fpage>408</fpage>
          <lpage>411</lpage>
        </element-citation>
      </ref>
      <ref id="b0175">
        <label>35</label>
        <element-citation publication-type="journal" id="h0175">
          <person-group person-group-type="author">
            <name>
              <surname>Aldini</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Altomare</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Baron</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Vistoli</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Carini</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Borsani</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why</article-title>
          <source>Free Radic Res</source>
          <volume>52</volume>
          <issue>7</issue>
          <year>2018</year>
          <fpage>751</fpage>
          <lpage>762</lpage>
          <pub-id pub-id-type="pmid">29742938</pub-id>
        </element-citation>
      </ref>
      <ref id="b0180">
        <label>36</label>
        <element-citation publication-type="journal" id="h0180">
          <person-group person-group-type="author">
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Aerosol medications for treatment of mucus clearance disorders</article-title>
          <source>Respir Care</source>
          <volume>60</volume>
          <issue>6</issue>
          <year>2015</year>
        </element-citation>
      </ref>
      <ref id="b0185">
        <label>37</label>
        <element-citation publication-type="journal" id="h0185">
          <person-group person-group-type="author">
            <name>
              <surname>Mata</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Morcillo</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gimeno</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Cortijo</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)</article-title>
          <source>Biochem Pharmacol</source>
          <volume>82</volume>
          <issue>5</issue>
          <year>2011</year>
          <fpage>548</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="pmid">21635874</pub-id>
        </element-citation>
      </ref>
      <ref id="b0190">
        <label>38</label>
        <element-citation publication-type="journal" id="h0190">
          <person-group person-group-type="author">
            <name>
              <surname>Mandelberg</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Amirav</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale</article-title>
          <source>Pediatr Pulmonol</source>
          <volume>45</volume>
          <issue>1</issue>
          <year>2010</year>
          <fpage>36</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">20014350</pub-id>
        </element-citation>
      </ref>
      <ref id="b0195">
        <label>39</label>
        <element-citation publication-type="journal" id="h0195">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Mendoza-Sassi</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Wainwright</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Klassen</surname>
              <given-names>T.P.</given-names>
            </name>
          </person-group>
          <article-title>Nebulised hypertonic saline solution for acute bronchiolitis in infants</article-title>
          <source>Cochrane Database Syst Rev</source>
          <volume>12</volume>
          <year>2017</year>
          <fpage>CD006458</fpage>
          <pub-id pub-id-type="pmid">29265171</pub-id>
        </element-citation>
      </ref>
      <ref id="b0200">
        <label>40</label>
        <element-citation publication-type="journal" id="h0200">
          <person-group person-group-type="author">
            <name>
              <surname>Harrison</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Angoulvant</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>House</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Gajdos</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Ralston</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <article-title>Hypertonic saline in bronchiolitis and type I Error: A trial sequential analysis</article-title>
          <source>Pediatrics</source>
          <volume>142</volume>
          <issue>3</issue>
          <year>2018</year>
        </element-citation>
      </ref>
      <ref id="b0205">
        <label>41</label>
        <element-citation publication-type="journal" id="h0205">
          <person-group person-group-type="author">
            <name>
              <surname>Beal</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Barbier</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Thoret</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rubio</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bonnet</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mazet</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Nebulized hypertonic saline 3% for 1 versus 3 days in hospitalized bronchiolitis: a blinded non-inferiority randomized controlled trial</article-title>
          <source>BMC Pediatr</source>
          <volume>19</volume>
          <issue>1</issue>
          <year>2019</year>
          <fpage>417</fpage>
          <pub-id pub-id-type="pmid">31699072</pub-id>
        </element-citation>
      </ref>
      <ref id="b0210">
        <label>42</label>
        <element-citation publication-type="journal" id="h0210">
          <person-group person-group-type="author">
            <name>
              <surname>Morikawa</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Miura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Furuhata</surname>
              <given-names>M.Y.</given-names>
            </name>
            <name>
              <surname>Morino</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Omori</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Otsuka</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Nebulized hypertonic saline in infants hospitalized with moderately severe bronchiolitis due to RSV infection: A multicenter randomized controlled trial</article-title>
          <source>Pediatr Pulmonol</source>
          <volume>53</volume>
          <issue>3</issue>
          <year>2018</year>
          <fpage>358</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="pmid">29327810</pub-id>
        </element-citation>
      </ref>
      <ref id="b0215">
        <label>43</label>
        <element-citation publication-type="journal" id="h0215">
          <person-group person-group-type="author">
            <name>
              <surname>Jaquet-Pilloud</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Verga</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gehri</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pauchard</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>Nebulised hypertonic saline in moderate-to-severe bronchiolitis: a randomised clinical trial</article-title>
          <source>Arch Dis Child</source>
          <volume>105</volume>
          <issue>3</issue>
          <year>2020</year>
          <fpage>236</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="pmid">31488402</pub-id>
        </element-citation>
      </ref>
      <ref id="b0220">
        <label>44</label>
        <element-citation publication-type="journal" id="h0220">
          <person-group person-group-type="author">
            <name>
              <surname>Bhilare</surname>
              <given-names>N.V.</given-names>
            </name>
            <name>
              <surname>Dhaneshwar</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Sinha</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Kandhare</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Bodhankar</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <article-title>Novel thioester prodrug of N-acetylcysteine for odor masking and bioavailability enhancement</article-title>
          <source>Curr Drug Deliv</source>
          <volume>13</volume>
          <issue>4</issue>
          <year>2016</year>
          <fpage>611</fpage>
          <lpage>620</lpage>
          <pub-id pub-id-type="pmid">26338258</pub-id>
        </element-citation>
      </ref>
      <ref id="b0225">
        <label>45</label>
        <element-citation publication-type="journal" id="h0225">
          <person-group person-group-type="author">
            <name>
              <surname>Stobbelaar</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kool</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>de Kruijf</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Van Hoorenbeeck</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Jorens</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>De Dooy</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Nebulised hypertonic saline in children with bronchiolitis admitted to the paediatric intensive care unit: A retrospective study</article-title>
          <source>J Paediatr Child Health</source>
          <volume>55</volume>
          <issue>9</issue>
          <year>2019</year>
          <fpage>1125</fpage>
          <lpage>1132</lpage>
          <pub-id pub-id-type="pmid">30645038</pub-id>
        </element-citation>
      </ref>
      <ref id="b0230">
        <label>46</label>
        <element-citation publication-type="journal" id="h0230">
          <person-group person-group-type="author">
            <name>
              <surname>Gadomski</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Scribani</surname>
              <given-names>M.B.</given-names>
            </name>
          </person-group>
          <article-title>Bronchodilators for bronchiolitis</article-title>
          <source>Cochrane Database Syst Rev</source>
          <volume>6</volume>
          <year>2014</year>
          <fpage>CD001266</fpage>
        </element-citation>
      </ref>
      <ref id="b0235">
        <label>47</label>
        <element-citation publication-type="journal" id="h0235">
          <person-group person-group-type="author">
            <name>
              <surname>Levin</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Slogic</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Jarvis</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Leiter</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>A prospective randomized controlled blinded study of three bronchodilators in infants with respiratory syncytial virus bronchiolitis on mechanical ventilation</article-title>
          <source>Pediatric Critic Care Med</source>
          <volume>9</volume>
          <issue>6</issue>
          <year>2008</year>
          <fpage>598</fpage>
          <lpage>604</lpage>
        </element-citation>
      </ref>
      <ref id="b0240">
        <label>48</label>
        <element-citation publication-type="journal" id="h0240">
          <person-group person-group-type="author">
            <name>
              <surname>Dunn</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Muthu</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Burlingame</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Gahman</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>McCloskey</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tyler</surname>
              <given-names>L.M.</given-names>
            </name>
          </person-group>
          <article-title>Reducing albuterol use in children with bronchiolitis</article-title>
          <source>Pediatrics</source>
          <volume>145</volume>
          <issue>1</issue>
          <year>2020</year>
        </element-citation>
      </ref>
      <ref id="b0245">
        <label>49</label>
        <element-citation publication-type="journal" id="h0245">
          <person-group person-group-type="author">
            <name>
              <surname>Girod</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Galabert</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lecuire</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zahm</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Puchelle</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases</article-title>
          <source>Pediatr Pulmonol</source>
          <volume>13</volume>
          <issue>1</issue>
          <year>1992</year>
          <fpage>22</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">1589308</pub-id>
        </element-citation>
      </ref>
      <ref id="b0250">
        <label>50</label>
        <element-citation publication-type="journal" id="h0250">
          <person-group person-group-type="author">
            <name>
              <surname>Skelton</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Darowski</surname>
              <given-names>P.H.M.</given-names>
            </name>
            <name>
              <surname>Chetcuti</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>L.W.</given-names>
            </name>
            <name>
              <surname>Harwood</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Abnormal surfactant composition and activity in severe bronchiolitis</article-title>
          <source>Acta Paediatr</source>
          <volume>88</volume>
          <year>1999</year>
          <fpage>942</fpage>
          <lpage>946</lpage>
          <pub-id pub-id-type="pmid">10519333</pub-id>
        </element-citation>
      </ref>
      <ref id="b0255">
        <label>51</label>
        <element-citation publication-type="journal" id="h0255">
          <person-group person-group-type="author">
            <name>
              <surname>LeVine</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Lotze</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Stroud</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>O'Donnell</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Whitsett</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Surfactant content in children with inflammatory lung disease</article-title>
          <source>Crit Care Med</source>
          <volume>24</volume>
          <issue>6</issue>
          <year>1996</year>
          <fpage>1062</fpage>
          <lpage>1067</lpage>
          <pub-id pub-id-type="pmid">8681574</pub-id>
        </element-citation>
      </ref>
      <ref id="b0260">
        <label>52</label>
        <element-citation publication-type="journal" id="h0260">
          <person-group person-group-type="author">
            <name>
              <surname>Jat</surname>
              <given-names>K.R.</given-names>
            </name>
            <name>
              <surname>Chawla</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Surfactant therapy for bronchiolitis in critically ill infants</article-title>
          <source>Cochrane Database Syst Rev</source>
          <volume>8</volume>
          <year>2015</year>
          <fpage>CD009194</fpage>
        </element-citation>
      </ref>
      <ref id="b0265">
        <label>53</label>
        <element-citation publication-type="journal" id="h0265">
          <person-group person-group-type="author">
            <name>
              <surname>Davison</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ventre</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Luchetti</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis</article-title>
          <source>Pediatric Critical Care Med</source>
          <volume>5</volume>
          <issue>5</issue>
          <year>2004</year>
          <fpage>482</fpage>
          <lpage>489</lpage>
        </element-citation>
      </ref>
      <ref id="b0270">
        <label>54</label>
        <mixed-citation publication-type="other" id="h0270">Rubin BK IM. Plastic Bronchitis. 2nd ed., 2019.</mixed-citation>
      </ref>
      <ref id="b0275">
        <label>55</label>
        <element-citation publication-type="journal" id="h0275">
          <person-group person-group-type="author">
            <name>
              <surname>Seear</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hui</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Magee</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Bohn</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Cutz</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Bronchial casts in children: a proposed classification based on nine cases and a review of the literature</article-title>
          <source>Am J Respir Crit Care Med</source>
          <volume>155</volume>
          <issue>1</issue>
          <year>1997</year>
          <fpage>364</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="pmid">9001337</pub-id>
        </element-citation>
      </ref>
      <ref id="b0280">
        <label>56</label>
        <element-citation publication-type="journal" id="h0280">
          <person-group person-group-type="author">
            <name>
              <surname>Madsen</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Plastic bronchitis: new insights and a classification scheme</article-title>
          <source>Paediatr Respir Rev</source>
          <volume>6</volume>
          <issue>4</issue>
          <year>2005</year>
          <fpage>292</fpage>
          <lpage>300</lpage>
          <pub-id pub-id-type="pmid">16298313</pub-id>
        </element-citation>
      </ref>
      <ref id="b0285">
        <label>57</label>
        <element-citation publication-type="journal" id="h0285">
          <person-group person-group-type="author">
            <name>
              <surname>Moser</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Nussbaum</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>Plastic bronchitis and the role of bronchoscopy in the acute chest syndrome of sickle cell disease</article-title>
          <source>Chest</source>
          <volume>120</volume>
          <issue>2</issue>
          <year>2001</year>
          <fpage>608</fpage>
          <lpage>613</lpage>
          <pub-id pub-id-type="pmid">11502666</pub-id>
        </element-citation>
      </ref>
      <ref id="b0290">
        <label>58</label>
        <element-citation publication-type="journal" id="h0290">
          <person-group person-group-type="author">
            <name>
              <surname>Gibb</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Blount</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Nielson</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Church</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Management of plastic bronchitis with topical tissue-type plasminogen activator</article-title>
          <source>Pediatrics</source>
          <volume>130</volume>
          <issue>2</issue>
          <year>2012</year>
          <fpage>e446</fpage>
          <lpage>e450</lpage>
          <pub-id pub-id-type="pmid">22802609</pub-id>
        </element-citation>
      </ref>
      <ref id="b0295">
        <label>59</label>
        <element-citation publication-type="journal" id="h0295">
          <person-group person-group-type="author">
            <name>
              <surname>Boucher</surname>
              <given-names>R.C.</given-names>
            </name>
          </person-group>
          <article-title>Airway surface dehydration in cystic fibrosis: pathogenesis and therapy</article-title>
          <source>Annu Rev Med</source>
          <volume>58</volume>
          <issue>1</issue>
          <year>2007</year>
          <fpage>157</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="pmid">17217330</pub-id>
        </element-citation>
      </ref>
      <ref id="b0300">
        <label>60</label>
        <element-citation publication-type="journal" id="h0300">
          <person-group person-group-type="author">
            <name>
              <surname>Fahy</surname>
              <given-names>J.V.</given-names>
            </name>
            <name>
              <surname>Dickey</surname>
              <given-names>B.F.</given-names>
            </name>
          </person-group>
          <article-title>Airway mucus function and dysfunction</article-title>
          <source>N Engl J Med</source>
          <volume>363</volume>
          <issue>23</issue>
          <year>2010</year>
          <fpage>2233</fpage>
          <lpage>2247</lpage>
          <pub-id pub-id-type="pmid">21121836</pub-id>
        </element-citation>
      </ref>
      <ref id="b0305">
        <label>61</label>
        <element-citation publication-type="journal" id="h0305">
          <person-group person-group-type="author">
            <name>
              <surname>Mall</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>Unplugging mucus in cystic fibrosis and chronic obstructive pulmonary disease</article-title>
          <source>Ann Am Thorac Soc</source>
          <volume>13</volume>
          <issue>Suppl. 2</issue>
          <year>2016</year>
          <fpage>S177</fpage>
          <lpage>S185</lpage>
          <pub-id pub-id-type="pmid">27115954</pub-id>
        </element-citation>
      </ref>
      <ref id="b0310">
        <label>62</label>
        <element-citation publication-type="journal" id="h0310">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Regnis</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bautovich</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Bye</surname>
              <given-names>P.T.</given-names>
            </name>
          </person-group>
          <article-title>Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <volume>153</volume>
          <issue>5</issue>
          <year>1996</year>
          <fpage>1503</fpage>
          <lpage>1509</lpage>
          <pub-id pub-id-type="pmid">8630593</pub-id>
        </element-citation>
      </ref>
      <ref id="b0315">
        <label>63</label>
        <element-citation publication-type="journal" id="h0315">
          <person-group person-group-type="author">
            <name>
              <surname>Donaldson</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>W.D.</given-names>
            </name>
            <name>
              <surname>Zeman</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Knowles</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Tarran</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Boucher</surname>
              <given-names>R.C.</given-names>
            </name>
          </person-group>
          <article-title>Mucus clearance and lung function in cystic fibrosis with hypertonic saline</article-title>
          <source>N Engl J Med</source>
          <volume>354</volume>
          <issue>3</issue>
          <year>2006</year>
          <fpage>241</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="pmid">16421365</pub-id>
        </element-citation>
      </ref>
      <ref id="b0320">
        <label>64</label>
        <element-citation publication-type="journal" id="h0320">
          <person-group person-group-type="author">
            <name>
              <surname>Elkins</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Harbour</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Moriarty</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>G.B.</given-names>
            </name>
          </person-group>
          <article-title>A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis</article-title>
          <source>N Engl J Med</source>
          <volume>354</volume>
          <issue>3</issue>
          <year>2006</year>
          <fpage>229</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="pmid">16421364</pub-id>
        </element-citation>
      </ref>
      <ref id="b0325">
        <label>65</label>
        <element-citation publication-type="journal" id="h0325">
          <person-group person-group-type="author">
            <name>
              <surname>Ratjen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Stanojevic</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kronmal</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Hinckley Stukovsky</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Jorgensen</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial</article-title>
          <source>Lancet Respir Med</source>
          <volume>7</volume>
          <issue>9</issue>
          <year>2019</year>
          <fpage>802</fpage>
          <lpage>809</lpage>
          <pub-id pub-id-type="pmid">31178421</pub-id>
        </element-citation>
      </ref>
      <ref id="b0330">
        <label>66</label>
        <element-citation publication-type="journal" id="h0330">
          <person-group person-group-type="author">
            <name>
              <surname>Jaques</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Daviskas</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Turton</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>McKay</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Stirling</surname>
              <given-names>R.G.</given-names>
            </name>
          </person-group>
          <article-title>Inhaled mannitol improves lung function in cystic fibrosis</article-title>
          <source>Chest</source>
          <volume>133</volume>
          <issue>6</issue>
          <year>2008</year>
          <fpage>1388</fpage>
          <lpage>1396</lpage>
          <pub-id pub-id-type="pmid">18339790</pub-id>
        </element-citation>
      </ref>
      <ref id="b0335">
        <label>67</label>
        <element-citation publication-type="journal" id="h0335">
          <person-group person-group-type="author">
            <name>
              <surname>Aitken</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Bellon</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>De Boeck</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Flume</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>H.G.</given-names>
            </name>
            <name>
              <surname>Geller</surname>
              <given-names>D.E.</given-names>
            </name>
          </person-group>
          <article-title>Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study</article-title>
          <source>Am J Respir Crit Care Med</source>
          <volume>185</volume>
          <issue>6</issue>
          <year>2012</year>
          <fpage>645</fpage>
          <lpage>652</lpage>
          <pub-id pub-id-type="pmid">22198974</pub-id>
        </element-citation>
      </ref>
      <ref id="b0340">
        <label>68</label>
        <element-citation publication-type="journal" id="h0340">
          <person-group person-group-type="author">
            <name>
              <surname>Daviskas</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Jaques</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Charlton</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis</article-title>
          <source>Chest</source>
          <volume>137</volume>
          <issue>4</issue>
          <year>2010</year>
          <fpage>861</fpage>
          <lpage>868</lpage>
          <pub-id pub-id-type="pmid">19880909</pub-id>
        </element-citation>
      </ref>
      <ref id="b0345">
        <label>69</label>
        <element-citation publication-type="journal" id="h0345">
          <person-group person-group-type="author">
            <name>
              <surname>Nicolson</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Stirling</surname>
              <given-names>R.G.</given-names>
            </name>
            <name>
              <surname>Borg</surname>
              <given-names>B.M.</given-names>
            </name>
            <name>
              <surname>Button</surname>
              <given-names>B.M.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Holland</surname>
              <given-names>A.E.</given-names>
            </name>
          </person-group>
          <article-title>The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis</article-title>
          <source>Respir Med</source>
          <volume>106</volume>
          <issue>5</issue>
          <year>2012</year>
          <fpage>661</fpage>
          <lpage>667</lpage>
          <pub-id pub-id-type="pmid">22349069</pub-id>
        </element-citation>
      </ref>
      <ref id="b0350">
        <label>70</label>
        <element-citation publication-type="journal" id="h0350">
          <person-group person-group-type="author">
            <name>
              <surname>Bilton</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Daviskas</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Kolbe</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Stirling</surname>
              <given-names>R.G.</given-names>
            </name>
          </person-group>
          <article-title>Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis</article-title>
          <source>Chest</source>
          <volume>144</volume>
          <issue>1</issue>
          <year>2013</year>
          <fpage>215</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="pmid">23429964</pub-id>
        </element-citation>
      </ref>
      <ref id="b0355">
        <label>71</label>
        <element-citation publication-type="journal" id="h0355">
          <person-group person-group-type="author">
            <name>
              <surname>Hanukoglu</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Hanukoglu</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Epithelial sodium channel (ENaC) family: Phylogeny, structure-function, tissue distribution, and associated inherited diseases</article-title>
          <source>Gene</source>
          <volume>579</volume>
          <issue>2</issue>
          <year>2016</year>
          <fpage>95</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="pmid">26772908</pub-id>
        </element-citation>
      </ref>
      <ref id="b0360">
        <label>72</label>
        <element-citation publication-type="journal" id="h0360">
          <person-group person-group-type="author">
            <name>
              <surname>Althaus</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art</article-title>
          <source>Current Mol Pharmacol</source>
          <volume>6</volume>
          <issue>1</issue>
          <year>2013</year>
          <fpage>3</fpage>
          <lpage>12</lpage>
        </element-citation>
      </ref>
      <ref id="b0365">
        <label>73</label>
        <element-citation publication-type="journal" id="h0365">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Voynow</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Cystic fibrosis sputum rheology correlates with both acute and longitudinal changes in lung function</article-title>
          <source>Chest</source>
          <volume>154</volume>
          <issue>2</issue>
          <year>2018</year>
          <fpage>370</fpage>
          <lpage>377</lpage>
          <pub-id pub-id-type="pmid">29559310</pub-id>
        </element-citation>
      </ref>
      <ref id="b0370">
        <label>74</label>
        <element-citation publication-type="journal" id="h0370">
          <person-group person-group-type="author">
            <name>
              <surname>Henke</surname>
              <given-names>M.O.</given-names>
            </name>
            <name>
              <surname>Ratjen</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Mucolytics in cystic fibrosis</article-title>
          <source>Paediatr Respir Rev</source>
          <volume>8</volume>
          <issue>1</issue>
          <year>2007</year>
          <fpage>24</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="pmid">17419975</pub-id>
        </element-citation>
      </ref>
      <ref id="b0375">
        <label>75</label>
        <element-citation publication-type="journal" id="h0375">
          <person-group person-group-type="author">
            <name>
              <surname>Aitken</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Shak</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study</article-title>
          <source>JAMA</source>
          <volume>267</volume>
          <issue>14</issue>
          <year>1992</year>
          <fpage>1947</fpage>
          <lpage>1951</lpage>
          <pub-id pub-id-type="pmid">1548827</pub-id>
        </element-citation>
      </ref>
      <ref id="b0380">
        <label>76</label>
        <element-citation publication-type="journal" id="h0380">
          <person-group person-group-type="author">
            <name>
              <surname>O'Donnell</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>A.F.</given-names>
            </name>
            <name>
              <surname>Ilowite</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Fick</surname>
              <given-names>R.B.</given-names>
            </name>
          </person-group>
          <article-title>Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group</article-title>
          <source>Chest</source>
          <volume>113</volume>
          <issue>5</issue>
          <year>1998</year>
          <fpage>1329</fpage>
          <lpage>1334</lpage>
          <pub-id pub-id-type="pmid">9596315</pub-id>
        </element-citation>
      </ref>
      <ref id="b0385">
        <label>77</label>
        <mixed-citation publication-type="other" id="h0385">YCM Duijvestijn PLP Brand Systematic review of N-acetylcysteine in cystic fibrosis 88 1 1999 38 41 10.1111/apa.1999.88.issue-1 10.1111/j.1651-2227.1999.tb01265.x http://doi.wiley.com/10.1111/apa.1999.88.issue-1 http://doi.wiley.com/10.1111/j.1651-2227.1999.tb01265.x.</mixed-citation>
      </ref>
      <ref id="b0390">
        <label>78</label>
        <element-citation publication-type="journal" id="h0390">
          <person-group person-group-type="author">
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Tomkiewicz</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Fahy</surname>
              <given-names>J.V.</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>F.H.</given-names>
            </name>
          </person-group>
          <article-title>Histopathology of fatal asthma: drowning in mucus</article-title>
          <source>Pediatr Pulmonol</source>
          <issue>Suppl 23</issue>
          <year>2001</year>
          <fpage>88</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="pmid">11886162</pub-id>
        </element-citation>
      </ref>
      <ref id="b0395">
        <label>79</label>
        <element-citation publication-type="journal" id="h0395">
          <person-group person-group-type="author">
            <name>
              <surname>Rogers</surname>
              <given-names>D.F.</given-names>
            </name>
          </person-group>
          <article-title>Airway mucus hypersecretion in asthma: an undervalued pathology?</article-title>
          <source>Curr Opin Pharmacol</source>
          <volume>4</volume>
          <issue>3</issue>
          <year>2004</year>
          <fpage>241</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="pmid">15140415</pub-id>
        </element-citation>
      </ref>
      <ref id="b0400">
        <label>80</label>
        <element-citation publication-type="journal" id="h0400">
          <person-group person-group-type="author">
            <name>
              <surname>Kuyper</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Pare</surname>
              <given-names>P.D.</given-names>
            </name>
            <name>
              <surname>Hogg</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Lambert</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Ionescu</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Woods</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of airway plugging in fatal asthma</article-title>
          <source>Am J Med</source>
          <volume>115</volume>
          <issue>1</issue>
          <year>2003</year>
          <fpage>6</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">12867228</pub-id>
        </element-citation>
      </ref>
      <ref id="b0405">
        <label>81</label>
        <element-citation publication-type="journal" id="h0405">
          <person-group person-group-type="author">
            <name>
              <surname>Delavoie</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Molinari</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Milliot</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Zahm</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Coraux</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Michel</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Salmeterol restores secretory functions in cystic fibrosis airway submucosal gland serous cells</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <volume>40</volume>
          <issue>4</issue>
          <year>2009</year>
          <fpage>388</fpage>
          <lpage>397</lpage>
          <pub-id pub-id-type="pmid">18931328</pub-id>
        </element-citation>
      </ref>
      <ref id="b0410">
        <label>82</label>
        <element-citation publication-type="journal" id="h0410">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rennard</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD</article-title>
          <source>Chest</source>
          <volume>120</volume>
          <issue>1</issue>
          <year>2001</year>
          <fpage>258</fpage>
          <lpage>270</lpage>
          <pub-id pub-id-type="pmid">11451847</pub-id>
        </element-citation>
      </ref>
      <ref id="b0415">
        <label>83</label>
        <element-citation publication-type="journal" id="h0415">
          <person-group person-group-type="author">
            <name>
              <surname>Lazarus</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Basbaum</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Gold</surname>
              <given-names>W.M.</given-names>
            </name>
          </person-group>
          <article-title>Localization of cAMP in dog and cat trachea: effects of beta-adrenergic agonists</article-title>
          <source>Am J Physiol</source>
          <volume>247</volume>
          <issue>5 Pt 1</issue>
          <year>1984</year>
          <fpage>C327</fpage>
          <lpage>C334</lpage>
          <pub-id pub-id-type="pmid">6093565</pub-id>
        </element-citation>
      </ref>
      <ref id="b0420">
        <label>84</label>
        <element-citation publication-type="journal" id="h0420">
          <person-group person-group-type="author">
            <name>
              <surname>Arai</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Kondo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Izumo</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Tamaoki</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice</article-title>
          <source>Eur Respir J</source>
          <volume>35</volume>
          <issue>5</issue>
          <year>2010</year>
          <fpage>1164</fpage>
          <lpage>1171</lpage>
          <pub-id pub-id-type="pmid">19897560</pub-id>
        </element-citation>
      </ref>
      <ref id="b0425">
        <label>85</label>
        <element-citation publication-type="journal" id="h0425">
          <person-group person-group-type="author">
            <name>
              <surname>Meltzer</surname>
              <given-names>E.O.</given-names>
            </name>
          </person-group>
          <article-title>Intranasal anticholinergic therapy of rhinorrhea</article-title>
          <source>J Allergy Clin Immunol</source>
          <volume>90</volume>
          <issue>6 Pt 2</issue>
          <year>1992</year>
          <fpage>1055</fpage>
          <lpage>1064</lpage>
          <pub-id pub-id-type="pmid">1460208</pub-id>
        </element-citation>
      </ref>
      <ref id="b0430">
        <label>86</label>
        <element-citation publication-type="journal" id="h0430">
          <person-group person-group-type="author">
            <name>
              <surname>Yuta</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Baraniuk</surname>
              <given-names>J.N.</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic approaches to mucus hypersecretion</article-title>
          <source>Curr Allergy Asthma Rep</source>
          <volume>5</volume>
          <issue>3</issue>
          <year>2005</year>
          <fpage>243</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="pmid">15842963</pub-id>
        </element-citation>
      </ref>
      <ref id="b0435">
        <label>87</label>
        <element-citation publication-type="journal" id="h0435">
          <person-group person-group-type="author">
            <name>
              <surname>Agnew</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Bateman</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Pavia</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Clarke</surname>
              <given-names>S.W.</given-names>
            </name>
          </person-group>
          <article-title>Peripheral airways mucus clearance in stable asthma is improved by oral corticosteroid therapy</article-title>
          <source>Bull Eur Physiopathol Respirat</source>
          <volume>20</volume>
          <issue>3</issue>
          <year>1984</year>
          <fpage>295</fpage>
          <lpage>301</lpage>
          <pub-id pub-id-type="pmid">6743872</pub-id>
        </element-citation>
      </ref>
      <ref id="b0440">
        <label>88</label>
        <element-citation publication-type="journal" id="h0440">
          <person-group person-group-type="author">
            <name>
              <surname>Kanoh</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of action and clinical application of macrolides as immunomodulatory medications</article-title>
          <source>Clin Microbiol Rev</source>
          <volume>23</volume>
          <issue>3</issue>
          <year>2010</year>
          <fpage>590</fpage>
          <lpage>615</lpage>
          <pub-id pub-id-type="pmid">20610825</pub-id>
        </element-citation>
      </ref>
      <ref id="b0445">
        <label>89</label>
        <element-citation publication-type="journal" id="h0445">
          <person-group person-group-type="author">
            <name>
              <surname>Kew</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Undela</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kotortsi</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Ferrara</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Macrolides for chronic asthma</article-title>
          <source>Cochrane Database Syst Rev</source>
          <volume>9</volume>
          <year>2015</year>
          <fpage>CD002997</fpage>
        </element-citation>
      </ref>
      <ref id="b0450">
        <label>90</label>
        <element-citation publication-type="journal" id="h0450">
          <person-group person-group-type="author">
            <name>
              <surname>Boogaard</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Smit</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Schornagel</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Vaessen-Verberne</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Kouwenberg</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Hekkelaan</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant human deoxyribonuclease for the treatment of acute asthma in children</article-title>
          <source>Thorax</source>
          <volume>63</volume>
          <issue>2</issue>
          <year>2008</year>
          <fpage>141</fpage>
          <lpage>146</lpage>
          <pub-id pub-id-type="pmid">17675321</pub-id>
        </element-citation>
      </ref>
      <ref id="b0455">
        <label>91</label>
        <element-citation publication-type="journal" id="h0455">
          <person-group person-group-type="author">
            <name>
              <surname>Silverman</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Dalipi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kline</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lesser</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: a pilot study</article-title>
          <source>Respir Med</source>
          <volume>106</volume>
          <issue>8</issue>
          <year>2012</year>
          <fpage>1096</fpage>
          <lpage>1102</lpage>
          <pub-id pub-id-type="pmid">22580235</pub-id>
        </element-citation>
      </ref>
      <ref id="b0460">
        <label>92</label>
        <element-citation publication-type="journal" id="h0460">
          <person-group person-group-type="author">
            <name>
              <surname>Snoek</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Brierley</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Mucolytics for intubated asthmatic children: a national survey of United kingdom paediatric intensive care consultants</article-title>
          <source>Crit Care Res Pract</source>
          <volume>2015</volume>
          <year>2015</year>
          <object-id pub-id-type="publisher-id">396107</object-id>
        </element-citation>
      </ref>
      <ref id="b0465">
        <label>93</label>
        <element-citation publication-type="journal" id="h0465">
          <person-group person-group-type="author">
            <name>
              <surname>Patel</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Harrison</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Durward</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Murdoch</surname>
              <given-names>I.A.</given-names>
            </name>
          </person-group>
          <article-title>Intratracheal recombinant human deoxyribonuclease in acute life-threatening asthma refractory to conventional treatment</article-title>
          <source>Br J Anaesth</source>
          <volume>84</volume>
          <issue>4</issue>
          <year>2000</year>
          <fpage>505</fpage>
          <lpage>507</lpage>
          <pub-id pub-id-type="pmid">10823105</pub-id>
        </element-citation>
      </ref>
      <ref id="b0470">
        <label>94</label>
        <element-citation publication-type="journal" id="h0470">
          <person-group person-group-type="author">
            <name>
              <surname>Durward</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Forte</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Shemie</surname>
              <given-names>S.D.</given-names>
            </name>
          </person-group>
          <article-title>Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus</article-title>
          <source>Crit Care Med</source>
          <volume>28</volume>
          <issue>2</issue>
          <year>2000</year>
          <fpage>560</fpage>
          <lpage>562</lpage>
          <pub-id pub-id-type="pmid">10708200</pub-id>
        </element-citation>
      </ref>
      <ref id="b0475">
        <label>95</label>
        <element-citation publication-type="journal" id="h0475">
          <person-group person-group-type="author">
            <name>
              <surname>Tarrant</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Le Maitre</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Steward</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Button</surname>
              <given-names>B.M.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>B.R.</given-names>
            </name>
          </person-group>
          <article-title>Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis</article-title>
          <source>Respirology</source>
          <volume>22</volume>
          <issue>6</issue>
          <year>2017</year>
          <fpage>1084</fpage>
          <lpage>1092</lpage>
          <pub-id pub-id-type="pmid">28397992</pub-id>
        </element-citation>
      </ref>
      <ref id="b0480">
        <label>96</label>
        <element-citation publication-type="journal" id="h0480">
          <person-group person-group-type="author">
            <name>
              <surname>Daviskas</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Eberl</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>I.H.</given-names>
            </name>
          </person-group>
          <article-title>Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction</article-title>
          <source>Respir Med</source>
          <volume>104</volume>
          <issue>11</issue>
          <year>2010</year>
          <fpage>1645</fpage>
          <lpage>1653</lpage>
          <pub-id pub-id-type="pmid">20576419</pub-id>
        </element-citation>
      </ref>
      <ref id="b0485">
        <label>97</label>
        <element-citation publication-type="journal" id="h0485">
          <person-group person-group-type="author">
            <name>
              <surname>Daviskas</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Gonda</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Eberl</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Meikle</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Seale</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects</article-title>
          <source>Eur Respir J</source>
          <volume>9</volume>
          <issue>4</issue>
          <year>1996</year>
          <fpage>725</fpage>
          <lpage>732</lpage>
          <pub-id pub-id-type="pmid">8726937</pub-id>
        </element-citation>
      </ref>
      <ref id="b0490">
        <label>98</label>
        <element-citation publication-type="journal" id="h0490">
          <person-group person-group-type="author">
            <name>
              <surname>Kanoh</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tanabe</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <article-title>IL-13-induced MUC5AC production and goblet cell differentiation is steroid resistant in human airway cells</article-title>
          <source>Clin Experiment Allergy</source>
          <volume>41</volume>
          <issue>12</issue>
          <year>2011</year>
          <fpage>1747</fpage>
          <lpage>1756</lpage>
        </element-citation>
      </ref>
      <ref id="b0495">
        <label>99</label>
        <element-citation publication-type="journal" id="h0495">
          <person-group person-group-type="author">
            <name>
              <surname>Rubin</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Priftis</surname>
              <given-names>K.N.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Henke</surname>
              <given-names>M.O.</given-names>
            </name>
          </person-group>
          <article-title>Secretory hyperresponsiveness and pulmonary mucus hypersecretion</article-title>
          <source>Chest</source>
          <volume>146</volume>
          <issue>2</issue>
          <year>2014</year>
          <fpage>496</fpage>
          <lpage>507</lpage>
          <pub-id pub-id-type="pmid">25091755</pub-id>
        </element-citation>
      </ref>
      <ref id="b0500">
        <label>100</label>
        <element-citation publication-type="journal" id="h0500">
          <person-group person-group-type="author">
            <name>
              <surname>Krause</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>von Bismarck</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Oppermann</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Ankermann</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Bronchoscopic surfactant administration in pediatric patients with persistent lobar atelectasis</article-title>
          <source>Respiration</source>
          <volume>75</volume>
          <issue>1</issue>
          <year>2008</year>
          <fpage>100</fpage>
          <lpage>104</lpage>
          <pub-id pub-id-type="pmid">16205052</pub-id>
        </element-citation>
      </ref>
      <ref id="b0505">
        <label>101</label>
        <element-citation publication-type="journal" id="h0505">
          <person-group person-group-type="author">
            <name>
              <surname>Hendriks</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>de Hoog</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lequin</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Devos</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Merkus</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>DNase and atelectasis in non-cystic fibrosis pediatric patients</article-title>
          <source>Critical Care (London, England)</source>
          <volume>9</volume>
          <issue>4</issue>
          <year>2005</year>
          <fpage>R351</fpage>
          <lpage>R356</lpage>
        </element-citation>
      </ref>
      <ref id="b0510">
        <label>102</label>
        <element-citation publication-type="journal" id="h0510">
          <person-group person-group-type="author">
            <name>
              <surname>McKinley</surname>
              <given-names>D.F.</given-names>
            </name>
            <name>
              <surname>Kinney</surname>
              <given-names>S.B.</given-names>
            </name>
            <name>
              <surname>Copnell</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Shann</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Long-term effects of saline instilled during endotracheal suction in pediatric intensive care: a randomized trial</article-title>
          <source>Am J Crit Care</source>
          <volume>27</volume>
          <issue>6</issue>
          <year>2018</year>
          <fpage>486</fpage>
          <lpage>494</lpage>
          <pub-id pub-id-type="pmid">30385540</pub-id>
        </element-citation>
      </ref>
      <ref id="b0515">
        <label>103</label>
        <element-citation publication-type="journal" id="h0515">
          <person-group person-group-type="author">
            <name>
              <surname>Shein</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Deakins</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Weinert</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>Prophylactic use of nebulized hypertonic saline in mechanically ventilated children: a randomized blinded pilot study</article-title>
          <source>Respir Care</source>
          <volume>61</volume>
          <issue>5</issue>
          <year>2016</year>
          <fpage>586</fpage>
          <lpage>592</lpage>
          <pub-id pub-id-type="pmid">26732142</pub-id>
        </element-citation>
      </ref>
      <ref id="b0520">
        <label>104</label>
        <element-citation publication-type="journal" id="h0520">
          <person-group person-group-type="author">
            <name>
              <surname>Riethmueller</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Borth-Bruhns</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kumpf</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vonthein</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wiskirchen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children</article-title>
          <source>Pediatr Pulmonol</source>
          <volume>41</volume>
          <issue>1</issue>
          <year>2006</year>
          <fpage>61</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">16265663</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack id="ak005">
      <sec id="s0050">
        <title>Acknowledgements</title>
        <p id="p0215">None.</p>
      </sec>
      <sec id="s0055">
        <title>Funding</title>
        <p id="p0220">None.</p>
      </sec>
      <sec id="s0060">
        <title>Declarations of interest</title>
        <p id="p0225">None.</p>
      </sec>
    </ack>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Mol Biomed</journal-id>
      <journal-title-group>
        <journal-title>Molecular Biomedicine</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2662-8651</issn>
      <publisher>
        <publisher-name>Springer Singapore</publisher-name>
        <publisher-loc>Singapore</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">7595758</article-id>
      <article-id pub-id-type="publisher-id">14</article-id>
      <article-id pub-id-type="doi">10.1186/s43556-020-00014-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Developing inhaled protein therapeutics for lung diseases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Matthews</surname>
            <given-names>Abigail A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ee</surname>
            <given-names>Pui Lai Rachel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0750-7336</contrib-id>
          <name>
            <surname>Ge</surname>
            <given-names>Ruowen</given-names>
          </name>
          <address>
            <email>dbsgerw@nus.edu.sg</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution>Department of Biological Sciences, </institution><institution>Faculty of Science, National University of Singapore, </institution></institution-wrap>16 Science drive 4, Singapore, 117558 Singapore </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution>Department of Pharmacy, </institution><institution>National University of Singapore, </institution></institution-wrap>18 Science Drive 4, Singapore, 117543 Singapore </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution>NUS Graduate School for Integrative Sciences and Engineering, </institution></institution-wrap>21 Lower Kent Ridge Road, Singapore, 119077 Singapore </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>10</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>30</day>
        <month>10</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2020</year>
      </pub-date>
      <volume>1</volume>
      <issue>1</issue>
      <elocation-id>11</elocation-id>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>8</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>10</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2020</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">Biologic therapeutics such as protein/polypeptide drugs are conventionally administered systemically via intravenous injection for the treatment of diseases including lung diseases, although this approach leads to low target site accumulation and the potential risk for systemic side effects. In comparison, topical delivery of protein drugs to the lung via inhalation is deemed to be a more effective approach for lung diseases, as proteins would directly reach the target in the lung while exhibiting poor diffusion into the systemic circulation, leading to higher lung drug retention and efficacy while minimising toxicity to other organs. This review examines the important considerations and challenges in designing an inhaled protein therapeutics for local lung delivery: the choice of inhalation device, structural changes affecting drug deposition in diseased lungs, clearance mechanisms affecting an inhaled protein drug&#x2019;s lung accumulation, protein stability, and immunogenicity. Possible approaches to overcoming these issues will also be discussed.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Inhalation</kwd>
        <kwd>Proteins</kwd>
        <kwd>Biologics</kwd>
        <kwd>Drug delivery</kwd>
        <kwd>Lung diseases</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>Singapore Ministry of Education</institution>
          </funding-source>
          <award-id>MOE2017-T2-2-122</award-id>
          <principal-award-recipient>
            <name>
              <surname>Ge</surname>
              <given-names>Ruowen</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par35">Biological drugs are revolutionising the treatment and management of many serious illnesses including cancer, autoimmune disorders, and rare genetic diseases, with about a third of all new drug approvals by the Food and Drug Administration (FDA) consisting of biological drugs [<xref ref-type="bibr" rid="CR1">1</xref>]. However, over the past decades, the development of inhaled therapeutics for the treatment of respiratory diseases has largely been focused on small molecules (corticosteroids, &#x3B2;2 agonists, and muscarinic antagonists), with only one inhaled protein biologic drug Pulmozyme&#xAE; being approved by the FDA to date [<xref ref-type="bibr" rid="CR2">2</xref>]. In the treatment of lung diseases via inhalation therapy, biological drugs such as proteins/polypeptides offer many advantages over small molecule drugs. Proteins delivered via the pulmonary route could accumulate in the lungs while having a poor ability to traverse the air-blood barrier due to their large molecular weight. This would result in higher target site accumulation (airway epithelial cells, alveolar macrophages, neutrophils etc) and minimise systemic toxicity, as compared to small molecule drugs that would pass easily into the systemic circulation after reaching the lungs [<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref>]. In addition, protein therapeutics display higher potencies (picomolar to femtomolar range) than small molecules (nanomolar range), as well as highly specific receptor binding to reduce off-target effects [<xref ref-type="bibr" rid="CR5">5</xref>]. Notably, although peptide drugs (&lt;&#x2009;5&#x2009;kDa or&#x2009;&lt;&#x2009;40&#x2013;50 amino acids in length) share some of the characteristics with protein/polypeptide drugs such as both are composed of amino acids linked via peptide bond and both having high target specificity, most of peptide drugs are much smaller in sizes, conferring them with some distinct differences including less enzyme stability, higher tissue penetration ability etc. In addition, many peptide drugs harbour chemical modifications in the form of peptidomimetics and/or cyclization, and some have direct cell membrane penetrating ability. These peptide drugs are not covered in this review.</p>
      <p id="Par36">Protein therapeutics are conventionally administered via the systemic route, although this has proven to be an inefficient approach for drug delivery to the lung, not mentioning the additional danger of exposing the rest of the body vulnerable to toxicity [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. For instance, monoclonal antibodies (mAbs) are found at higher levels (500&#x2013;10,000 times more) in serum than in bronchoalveolar lavage (BAL) fluid following intravenous administration, a trend that has been demonstrated in all species [<xref ref-type="bibr" rid="CR4">4</xref>]. By the same token, protein therapeutics delivered via the airways also pass poorly from the lungs into the systemic circulation. For example, only low amounts of anti-VEGF-A G6&#x2013;31 mAb (5.1%) and cetuximab (11%), an anti-EGFR mAb, were present in the serum after aerosol delivery in mouse models of lung cancer [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. This means that high concentrations of the protein drug can be attained in the lung via pulmonary delivery, suggesting that lower doses of inhaled protein can have an equivalent or even superior therapeutic effect for lung diseases when compared to the higher doses that would be needed from systemic administration [<xref ref-type="bibr" rid="CR9">9</xref>]. Indeed, it was reported that the nebulised effective dose of AvidinOX-anchored biotinylated cetuximab was 1/25,000 of the intravenous effective dose in a mouse model of advanced metastatic lung cancer [<xref ref-type="bibr" rid="CR10">10</xref>]. Although higher pulmonary levels of protein therapeutics can be achieved through inhalation compared to systemic administration, this could be offset by the short residence time of proteins in the lung compared to plasma. Proteins and antibodies are mostly cleared from the lungs within 24&#x2009;h, while plasma half-lives of full-length antibodies following intravenous injection can reach 3&#x2009;weeks and more [<xref ref-type="bibr" rid="CR11">11</xref>]. Nevertheless, there are strategies that can be employed to increase the local residence time of protein therapeutics in the lungs, and these will be discussed in detail later on in this review. Besides improving pharmacokinetic and toxicity profiles of protein therapeutics, the inhalation route is non-invasive and allows for self-administration, which could improve patient compliance [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p>
      <p id="Par37">In 1993, Pulmozyme&#xAE; (dornase alfa/deoxyribonuclease I), was introduced for the treatment of cystic fibrosis [<xref ref-type="bibr" rid="CR9">9</xref>]. It has been almost three decades since then, and no other inhaled protein therapeutics for topical treatment of a lung disease has reached the market, despite the aforementioned advantages that inhaled proteins possess. Presently, and to the best of our knowledge, ten inhaled protein therapeutics are being assessed in clinical trials for the treatment of a range of lung diseases including asthma, cystic fibrosis, lung cancer, COPD and COVID-19 (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR13">13</xref>&#x2013;<xref ref-type="bibr" rid="CR18">18</xref>]. There are also protein therapeutics such as mAbs that are in the preclinical stages [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In order to drive more of these therapies into clinical development and eventually to the market, it is crucial to take into account the challenges unique to the development of these agents into potential treatments so that they may be utilised successfully for pulmonary delivery. In this review, we will discuss the challenges in developing an inhaled protein therapeutic for lung diseases, as well as approaches that could help to circumvent these issues. The focus of this review is on the pulmonary delivery of protein drugs for local action in the lung, however, examples of inhaled proteins for systemic action will be mentioned wherever relevant.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inhaled protein drugs currently in clinical development for lung diseases</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Protein</th><th rowspan="2">Drug Name</th><th rowspan="2">Sponsor(s)</th><th rowspan="2">Disease(s)</th><th rowspan="2">Development Phase</th><th rowspan="2">Type of inhaler</th><th>Clinical trial no./</th></tr><tr><th>Reference</th></tr></thead><tbody><tr><td rowspan="2"><bold>Alpha-1 antitrypsin</bold> (52&#x2009;kDa)</td><td>Alpha-1 antitrypsin</td><td>Rabin Medical Center</td><td>Bronchiolitis obliterable syndrome (BOS) after lung transplantation</td><td>Phase II unknown status</td><td>&#x2013;</td><td>NCT01394835</td></tr><tr><td>Kamada-AAT</td><td>Kamada</td><td>Alpha-1 antitrypsin deficiency</td><td>Phase III ongoing</td><td>Mesh nebuliser (PARI eFlow&#xAE; system)</td><td>NCT04204252</td></tr><tr><td rowspan="2"><bold>Anticalin&#xAE; protein (IL-4R&#x3B1; antagonist)</bold> (~&#x2009;18&#x2009;kDa)</td><td>PRS-060/AZD1402</td><td>Pieris Australia Pty Ltd</td><td>Asthma</td><td>Phase I ongoing</td><td>&#x2013;</td><td>NCT03574805</td></tr><tr><td>&#x2013;</td><td>AstraZeneca</td><td>Asthma</td><td>Phase I completed (2019)</td><td>DPI (Plastiape Monodose inhaler,) vs. Mesh nebuliser (Philips InnoSpire Go)</td><td>NCT03921268</td></tr><tr><td><bold>Anti &#x2013;human thymic stromal lymphopoietin (TSLP) mAb fragment (Fab)</bold> (46&#x2009;kDa)</td><td>CSJ117</td><td>Novartis</td><td>Asthma</td><td>Phase IIb ongoing</td><td>&#x2013;</td><td>NCT04410523</td></tr><tr><td rowspan="4"><bold>Deoxyribo-nuclease I (DNase I)</bold> (37&#x2009;kDa)</td><td>AIR DNase&#x2122;/ Alidornase alfa/ PRX-110</td><td>Protalix</td><td>Cystic fibrosis</td><td>Phase II completed (2017)</td><td>Vibrating mesh nebuliser (Philips I-neb&#xAE; AAD system)</td><td>NCT02722122 [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td>Pulmozyme&#xAE;</td><td>University Hospital, Strasbourg, France</td><td>Acute respiratory distress syndrome (ARDS)</td><td>Phase III ongoing</td><td>Vibrating mesh nebuliser (Aerogen&#xAE; Solo device)</td><td>NCT03368092</td></tr><tr><td>Pulmozyme&#xAE;</td><td>Fondation Ophtalmolo-gique Adolphe de Rothschild</td><td>ARDS in coronavirus disease 2019 (COVID-19)</td><td>Phase III ongoing</td><td>Nebuliser</td><td>NCT04355364</td></tr><tr><td>rhDNase</td><td>National Jewish Health</td><td>Neutrophilic asthma</td><td>Phase I/II ongoing</td><td>Nebuliser</td><td>NCT03994380</td></tr><tr><td rowspan="6"><bold>Granulocyte macrophage colony-stimulating factor (GM-CSF)</bold> (14&#x2009;kDa)</td><td>rhGM-CSF</td><td><p>Dai Huaping</p><p>China-Japan Friendship Hospital</p></td><td>Autoimmune pulmonary alveolar proteinosis (aPAP)</td><td>Phase II ongoing</td><td>&#x2013;</td><td>NCT03316651</td></tr><tr><td>Molgramostim</td><td>University of Giessin</td><td>ARDS</td><td>Phase II ongoing</td><td>&#x2013;</td><td>NCT02595060</td></tr><tr><td>Molgramostim</td><td>Savara Inc</td><td>aPAP</td><td>Phase III ongoing</td><td><p>Mesh nebuliser</p><p>(PARI eFlow&#xAE; system)</p></td><td>NCT03482752 [<xref ref-type="bibr" rid="CR15">15</xref>]</td></tr><tr><td>Molgramostim</td><td>Savara Inc.</td><td>Nontuberculous mycobacterial (NTM) infections</td><td>Phase II ongoing</td><td>Mesh nebuliser (PARI eFlow&#xAE; system)</td><td>NCT03597347</td></tr><tr><td>Sargramostim/Leukine&#xAE;</td><td>Children&#x2019;s Hospital Medical Center (Cincinnati)</td><td>aPAP</td><td>Phase I ongoing</td><td>&#x2013;</td><td>NCT03006146</td></tr><tr><td>Sargramostim/Leukine&#xAE;</td><td>IRCCS Policlinico S. Matteo</td><td>aPAP</td><td>Phase II/III unknown status</td><td>Vibrating mesh nebuliser (AKITA<sup>2</sup>&#xAE;)</td><td>NCT00901511 [<xref ref-type="bibr" rid="CR16">16</xref>]</td></tr><tr><td rowspan="2"><bold>Interferon beta-1a (IFN&#x3B2;-1a)</bold> (22&#x2009;kDa)</td><td>SNG001</td><td>Synairgen Research Ltd.</td><td>Chronic Obstructive Pulmonary Disease (COPD)</td><td>Phase II ongoing</td><td>&#x2013;</td><td>NCT03570359</td></tr><tr><td>SNG001</td><td>Synairgen Research Ltd.</td><td>COVID-19</td><td>Phase II ongoing</td><td>&#x2013;</td><td>[<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td><bold>Interleukin-2 (IL-2)</bold> (15&#x2009;kDa)</td><td>Aldesleukin</td><td>MD Anderson Cancer Center</td><td>Lung metastases</td><td>Phase I/II ongoing</td><td>&#x2013;</td><td>NCT01590069</td></tr><tr><td><bold>Lactoferrin (in combination with hypothiocyanite)</bold> (80&#x2009;kDa)</td><td>ALX-009</td><td>Alaxia SAS</td><td>Cystic fibrosis/Bronchiectasis</td><td>Phase I ongoing</td><td>Nebuliser</td><td>NCT02598999</td></tr><tr><td rowspan="4"><bold>Sialidase</bold> (46&#x2009;kDa)</td><td>DAS181</td><td>Renmin Hospital of Wuhan University/Ansun Biopharma</td><td>Severe COVID-19</td><td>N.A. (Compassionate use) ongoing</td><td>Nebuliser</td><td>NCT04324489</td></tr><tr><td>DAS181</td><td>Ansun Biopharma</td><td>Lower tract parainfluenza (PIV) infection/ COVID-19 substudy</td><td>Phase III ongoing</td><td>Vibrating mesh nebuliser (Aerogen&#xAE; Solo device)</td><td>NCT03808922 [<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td>DAS181</td><td>Ansun Biopharma</td><td>COVID-19</td><td>Phase II/III ongoing</td><td>Vibrating mesh nebuliser (Aerogen&#xAE; Solo device)</td><td>NCT04354389 [<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td>DAS181</td><td>Ansun Biopharma</td><td>Influenza/SAD-RV infections (including COVID-19)</td><td>Phase II ongoing</td><td>Vibrating mesh nebuliser (Aerogen&#xAE; Solo device)</td><td>NCT04298060 [<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td><bold>Tissue plasminogen activator</bold> (70&#x2009;kDa)</td><td>Alteplase</td><td>University of Michigan</td><td>Plastic bronchitis</td><td>Phase II ongoing</td><td>Nebuliser</td><td>NCT02315898</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec2">
      <title>Challenges and considerations in the development of protein therapeutics for local lung delivery</title>
      <sec id="Sec3">
        <title>Choice and limitations of drug delivery device</title>
        <p id="Par38">There are mainly three classes of inhalation devices namely dry powder inhalers (DPIs), nebulisers, and metered dose inhalers (MDIs). DPIs deliver drug as a solid aerosol, and powder formulations possess inherent stability and shelf life benefits [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. However, the temperature and shear stress during the manufacturing processes needed to produce powders (e.g. freeze drying, spray drying) could lead to protein degradation [<xref ref-type="bibr" rid="CR21">21</xref>]. DPIs have been used for the marketed inhalable insulin formulations Exubera&#xAE; (approved in 2006, but was discontinued after 1&#x2009;year due to large device size, high pricing, and safety concerns) and Afrezza&#xAE; (still commercially available) [<xref ref-type="bibr" rid="CR22">22</xref>]. Moreover, DPIs have shown promising results in studies assessing their use for inhaled protein formulations. For example, Weers et al. (2019) showed that dry powder formulations of CSJ117 (anti-thymic stromal lymphopoietin (TSLP) mAb fragment) could achieve a total lung dose (TLD) of about 95% of the delivered dose (DD) with the use of particle engineering techniques such as via the introduction of surface corrugation through the addition of trileucine [<xref ref-type="bibr" rid="CR23">23</xref>].</p>
        <p id="Par39">Nebulisers (jet, ultrasonic, and mesh) generate aerosol droplets from a liquid solution of the drug [<xref ref-type="bibr" rid="CR4">4</xref>]. The first and only inhaled protein formulation approved for pulmonary delivery to date, Pulmozyme&#xAE;, is administered via jet nebuliser. Nebulised formulations are less expensive to produce and test, because the manufacturing process for these formulations does not include extra drying steps. Nevertheless, prolonged storage of proteins in liquid solutions can lead to protein instability through degradation pathways (i.e. deamidation and hydrolysis), temperature and pH changes, and aggregation (through agitation of the aqueous carrier) [<xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, across all nebuliser types, the process of nebulisation exposes the protein to physical stresses such as shearing forces and heat, as well as the large air-liquid interface (ALI) that could alter protein conformation and/or structure through denaturation, chemical modifications (oxidation, deamidation), and aggregation [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Device-specific limitations such as the shear forces generated by jet nebulisers, and the temperature increases that occur in ultrasonic nebulisers, can also lead to protein degradation. Jet and ultrasonic nebulisers actually recycle 99% of the primary aerosol, and a molecule would typically be subjected to 10&#x2013;15&#x2009;cycles of nebulisation before leaving the nebuliser as a secondary aerosol [<xref ref-type="bibr" rid="CR24">24</xref>]. This subjects the molecules to high shear stress in these devices, resulting in the denaturation of proteins, with the extent of protein denaturation and degradation varies depending on the characteristics of the individual protein [<xref ref-type="bibr" rid="CR25">25</xref>]. For example, for jet nebulizer delivery of LDH and urease, there is a log-linear degradation with a fraction of protein degraded with every recirculation [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In contrast, IgG and G-CSF has a rapid initial decline in native proteins in the first 5&#x2013;10&#x2009;min [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. For ultrasonic nebulizers, heating resulting from ultrasonic radiation in addition to aerosol recirculation generated various protein denaturation and degradation in different proteins [<xref ref-type="bibr" rid="CR25">25</xref>]. For example, the degradation of LDH with ultrasonic nebulizer presented a sigmoidal progression instead, indicating different denaturation process and factors involved from jet nebulizers [<xref ref-type="bibr" rid="CR29">29</xref>]. By comparison, vibrating mesh nebulisers employ single-pass technology, ensuring that there is no recirculation of droplets into the reservoir; they do not alter solution temperature, and produce less shear forces inside the drug reservoir during nebulisation, making them more suitable for the delivery of protein therapeutics [<xref ref-type="bibr" rid="CR24">24</xref>&#x2013;<xref ref-type="bibr" rid="CR31">31</xref>]. In fact, several studies have reported that jet and ultrasonic nebulisers produce lower levels of activity, lower amounts of protein monomers (because of partial degradation), and more aggregates (with or without excipients). On the other hand, mesh nebulisers appear to maintain protein integrity to a greater extent than other nebulisers [<xref ref-type="bibr" rid="CR32">32</xref>]. Safe aerosolisation with mesh nebulisers has already been demonstrated in several studies of labile drugs including proteins and mAbs [<xref ref-type="bibr" rid="CR33">33</xref>&#x2013;<xref ref-type="bibr" rid="CR38">38</xref>]. The detailed designs and comparisons of various types of nebulizers have been reviewed previously and we will not elaborate further here [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>&#x2013;<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p>
        <p id="Par40">Recently, nanoengineered particles using metal-phenolic networks (MPNs) with highly defined physical properties have been used to encapsulate both small molecule and macromolecules including proteins for pulmonary delivery via nebulisation. Intratracheal nebulization delivery of FITC-labelled bovine serum albumin (BSA, 65&#x2009;kDa) in mice demonstrated that these capsules are biocompatible and biodegradable, showing &gt;&#x2009;85% of the capsules in the lung after 20&#x2009;h, while only &lt;&#x2009;4% remaining after 30&#x2009;days without causing obvious lung inflammation or toxicity. Although still in early stage of development, these MPN particles may revolutionize the nebulization delivery of protein drugs and provide a more protected environment for effective pulmonary delivery [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
        <p id="Par41">Moreover, new generation nebulisers are being developed such as surface acoustic wave (SAW) nebulisers and the more recent HYDRA (HYbriD Resonant Acoustics) nebulisers that provide new platforms for inhaled drug delivery. SAW use surface waves to generate aerosols which can preserve macromolecule integrity that has been shown to be efficient in aerosolising proteins [<xref ref-type="bibr" rid="CR41">41</xref>]. HYDRA uses a hybrid combination of surface and bulk sound waves to generate the aerosol droplets, and can overcome the low nebulisation rate of SAW nebulisers and conventional nebulisers, while also avoiding the potential damage to proteins due to high shear (jet nebulisation) or cavitation (ultrasonic nebulisation). The first human lung deposition study using a prototype HYDRA nebuliser has been reported recently, indicating successful lung deposition of a radiolabelled small molecule [<xref ref-type="bibr" rid="CR42">42</xref>]. It is probable that HYDRA nebulisers may be developed for pulmonary protein drug delivery.</p>
        <p id="Par42">MDIs deliver drug through an aerosol burst, and allow for the controlled delivery of specific amounts of drug to the lungs [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. However, as with nebulisers, the use of aqueous solutions is not ideal for protein storage [<xref ref-type="bibr" rid="CR22">22</xref>]. There are also concerns that the hydrofluoroalkane (HFA) propellants used in MDIs could denature proteins [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Despite this concern, there are examples of studies showing that proteins can remain stable in HFA-containing MDI formulations. Quinn et al. (1999) utilised Raman spectroscopy to analyse the secondary conformations of lysozyme in the HFA propellants tetrafluoroethane (HFA 134a) and heptafluoropropane (HFA 227), demonstrating that structural integrity of lysozyme was preserved in both HFAs, and that there is potential for proteins to be developed as MDI formulations without compromising their conformational stability [<xref ref-type="bibr" rid="CR44">44</xref>]. Moreover, Liao et al. (2005) demonstrated that spray-dried lysozyme and catalase that were stabilised with excipients (sugars and/or 80% polyvinyl alcohol) and then stored in HFA 134a at room temperature for 6&#x2009;months showed retention of biological activity [<xref ref-type="bibr" rid="CR45">45</xref>].</p>
        <p id="Par43">When choosing an inhalation device, it is important to be cognisant of the fact that not all devices in the same category are equivalent. For instance, although it is generally accepted that there is minimal heating of the drug reservoir in vibrating mesh nebulisers, and that heating occurs to a lesser degree than in ultrasonic nebulisers, considerable temperature increases have been reported in some brands of vibrating mesh nebulisers (PARI eFlow&#xAE;, AKITA<sup>2</sup> APIXNEB&#xAE;, and Aeroneb Go), with temperatures of up to 40&#xB0;C being reached towards the end of nebulisation [<xref ref-type="bibr" rid="CR24">24</xref>]. Therefore, it is essential to choose the inhalation device carefully, bearing in mind that the best device type is the one that confers the most stability to the protein drug formulation. Soft mist inhaler (SMI), which also generate aerosols from liquid, is the newest type of inhaler which does not use any propellent. As only one medicine Respimat uses SMI, its suitability for protein drug delivery is not clear.</p>
        <p id="Par44">Another factor to consider is the aerodynamic diameter of aerosol particles, which is critical to control where the particles will be deposited in the respiratory track after inhalation. To be therapeutically effective, the drug containing particles need to be deposited into the correct location within the respiratory track. For example, for therapeutics for COPD, drugs need to be delivered to the deep lung (the alveolar space) for which it requires the aerodynamic diameter of the particles to be between 1 and 5&#x2009;&#x3BC;m. Larger size particles will generally be deposited in the oropharyngeal region and be ingested, while small particles &lt;&#x2009;1&#x2009;&#x3BC;m may be exhaled during the next breathing cycle. Thus, suitable aerosol particle sizes need to be selected for precise drug delivery into the lung to enhance drug efficacy while simultaneously reducing harmful side effects [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      </sec>
      <sec id="Sec4">
        <title>Structural changes in diseased lungs</title>
        <p id="Par45">The respiratory tract comprises of a series of branching airways, which can be categorised into two parts: the conducting zone and the respiratory zone. The conducting zone consists of the trachea, bronchi, bronchioles, and terminal bronchioles. The airway wall in the conducting zone is too thick for diffusion and this region does not contain alveoli. As such, no gas exchange takes place here, and the purposes of the conducting zone include transmitting air to the respiratory zone, as well as to warm, moisture and cleaning the inspired air. The respiratory zone consists of respiratory bronchioles, alveolar ducts, and alveolar sacs, and facilitates gas exchange between the air and the bloodstream. Alveoli can occasionally be found in the walls of the respiratory bronchioles, and are abundant in the alveolar ducts and alveolar sacs [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Given the branched structure of the lungs, it is not only important to achieve high deposition rates, but also to obtain an appropriate deposition pattern for the respiratory disease in question i.e. the protein therapeutic would not only need to reach the lung, but would also need to reach the correct target site within the lung. For instance, a therapeutic for asthma would have to reach the large airway, as asthma mainly affects the bronchi, while a drug for emphysema in COPD would need to go deeper and reach the small airways of the lung because emphysema affects the alveolar region [<xref ref-type="bibr" rid="CR47">47</xref>].</p>
        <p id="Par46">The amount and pattern of lung deposition is not only affected by the device and the characteristics of the inhaled drug (particle size and physicochemical properties of the formulation), but also by factors that are influenced by the specific disease state, including breathing patterns, lung geometry (i.e. airway diameter, number of alveoli) and structure, and nasal, oral, and pharyngeal anatomy [<xref ref-type="bibr" rid="CR45">45</xref>]. These factors need to be considered, and if possible, alterations to the drug formulation can be made to address these issues. For example, in certain lung pathologies (for instance cystic fibrosis, COPD, and chronic sinusitis), the airway mucus becomes thicker. It has been reported that the thickness of the mucus layer ranges from 2 to 30&#x2009;&#x3BC;m in normal lungs to more than 260&#x2009;&#x3BC;m in cystic fibrosis and other obstructive airway diseases [<xref ref-type="bibr" rid="CR48">48</xref>]. This presents a physical barrier that the protein drug would need to penetrate to reach its target site in the lung and exert its effects. The addition of anti-adhesive molecules (e.g. polyethylene glycol, PEG) in the formulation may help to promote the translocation of the protein drug through the thickened mucus, although it should be noted that the adhesive properties of PEG depend on PEG molecular weight (MW) [<xref ref-type="bibr" rid="CR12">12</xref>]. While high MW PEGs display mucoadhesive properties, low MW PEGs are able to prevent mucoadhesion, with PEGs of MW up to 40&#x2009;kDa able to provide effective mucus penetration [<xref ref-type="bibr" rid="CR49">49</xref>&#x2013;<xref ref-type="bibr" rid="CR51">51</xref>].</p>
        <p id="Par47">Notably, as macromolecules, proteins have a relatively poor ability to penetrate the epithelial layer to reach the deep parenchyma lung. However, depending on the molecular weight and aerosol characteristics, a portion of the proteins would be able to reach the abluminal side of the epithelium or the air-blood interface in the thin alveolar wall, triggering local or even systemic immune signalling that may provide beneficial therapeutic effect in some cases [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
      </sec>
      <sec id="Sec5">
        <title>Clearance mechanisms in the lung</title>
        <p id="Par48">A good lung deposition pattern would be worthless if the protein therapeutic cannot withstand the lung&#x2019;s clearance mechanisms. Inhaled proteins would be subjected to clearance by three mechanisms. The first clearance mechanism is mucociliary clearance (MCC), which is the coordinated beating of cilia lining the nasal cavity, trachea, and bronchi, in order to move the mucus towards the larynx/pharynx, thereby pushing dust, microorganisms, and insoluble particles that are trapped in the mucus out of the lungs and into the upper airways to eventually be swallowed [<xref ref-type="bibr" rid="CR46">46</xref>]. The surface lining of the airways in normal lungs consists of an aqueous layer adjacent to the epithelium and a surfactant containing film layer at the air-liquid interface. The peri-ciliary aqueous layer has a relatively low viscosity, while the surfactant film layer is more viscous. The surfactant film plays an important role in the displacement of airway particles towards the epithelium where they will be immersed and retained. The extent of particle immersion depends on the surface tension of the film. The lower the surface tension, the greater the immersion of particles into the aqueous layer adjacent to the epithelium [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. It is possible that some protein monomers could quickly reach the stagnant aqueous layer and not be subjected to MCC. On the other hand, some protein monomers would become aggregated during the inhalation delivery process and the aggregates may stay with the surfactant film layer at the air-liquid interface for some time for MCC to take effect. Anti-adhesive formulations (achieved by using lower MW PEGs for example) could be used to circumvent MCC clearance of inhaled therapeutics, thus increasing their lung accumulation. The mucus-penetrating ability of such PEGs has already been demonstrated in multiple studies [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR54">54</xref>&#x2013;<xref ref-type="bibr" rid="CR61">61</xref>].</p>
        <p id="Par49">The second clearance mechanism is macrophage uptake, which is the primary clearance mechanism in the alveoli. Proteins are taken up by alveolar macrophages in the deep lung via pinocytosis, and the uptake of particles is size dependent [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Large proteins (&#x2265; 40&#x2009;kDa) would have more time to be engulfed by alveolar macrophages by virtue of their slower transport and absorption across the alveolo-capillary barrier, while small proteins and peptides (&#x2264; 25&#x2009;kDa) are absorbed rapidly from the airspaces and thus, may not be impacted by alveolar macrophage uptake as much. In essence, pinocytosis by alveolar macrophages could become significant for macromolecules with MW&#x2009;&gt;&#x2009;40&#x2009;kDa [<xref ref-type="bibr" rid="CR62">62</xref>]. The use of excipients can help to reduce clearance of large proteins by alveolar macrophages. For example, Koussoroplis et al. (2014) showed that PEGylation conferred increased residence time to antibody fragments anti-IL-17A F (ab&#x2032;)2 and anti-IL-13 Fab&#x2032; (unconjugated F (ab&#x2032;)2 was 98&#x2009;kDa and unconjugated Fab&#x2032; was 47&#x2009;kDa), and that the effect was due to mucoadhesion as well as evasion of alveolar macrophage uptake [<xref ref-type="bibr" rid="CR11">11</xref>]. Protein PEGylation may potentially also alter its deposition pattern in the respiratory track, due to changes in molecular weight, hydrophilicity etc. However, systemic analyses of the effect of PEGylation on protein deposition pattern in the respiratory track are still needed in order to know if a consistent deposition pattern and behaviour can be reached based on how PEGylation is achieved.</p>
        <p id="Par50">The third clearance mechanism is absorption into the systemic circulation. After deposition in the alveolar region, aerosol drug particles may dissolve in pulmonary epithelial lining fluid if the drug is water-soluble, and become available for systemic absorption and clearance [<xref ref-type="bibr" rid="CR46">46</xref>]. For the purpose of topical lung treatment, the goal would be to minimise systemic absorption, which is greatly influenced by protein MW. The bioavailability of a protein after absorption from the lung decreases as protein MW increases. Small peptides are absorbed rapidly from the lungs with 20&#x2013;50% of the bioavailability for subcutaneous injection [<xref ref-type="bibr" rid="CR63">63</xref>]. Proteins with MW of 6&#x2013;50&#x2009;kDa exhibit moderate absorption, with bioavailability ranging from 10 to 40%, although it should be noted that pulmonary absorption studies in animals may lead to an overestimation of bioavailability. For example, systemic bioavailability after aerosol administration in animals for growth hormone (GH) and interferon &#x3B1; (IFN&#x3B1;) was 45% and 70% respectively, compared to only 3&#x2013;10% in humans [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Large MW antibodies (~&#x2009;150&#x2009;kDa) are not significantly absorbed across the lung, and bioavailability is negligible (&lt;&lt;&#x2009;10%) unless an active transport system is included [<xref ref-type="bibr" rid="CR63">63</xref>]. Apart from high protein MW, the presence of obstructive lung diseases (e.g. asthma, COPD, cystic fibrosis) can also reduce systemic absorption and bioavailability of proteins and other drugs [<xref ref-type="bibr" rid="CR46">46</xref>]. For example, Henry et al. (2003) reported that healthy subjects had significantly higher area under the curve (AUC) and mean maximum concentration (C<sub>max</sub>) after insulin inhalation than asthma patients, indicating that less insulin was absorbed into the systemic circulation in asthma patients [<xref ref-type="bibr" rid="CR65">65</xref>]. In addition, Diderichsen et al. (2013) reported that the C<sub>max</sub> of an inhaled long acting &#x3B2;<sub>2</sub> agonist (PF-00610355) was found to be reduced by 31% and 52% for COPD and asthma patients respectively, compared to healthy volunteers [<xref ref-type="bibr" rid="CR66">66</xref>]. Additional possibility for the lower systemic absorption of drugs in lung disease patients could be due to altered drug deposition pattern in the diseased lung, for which further studies are needed. Regardless the underlying mechanisms, effective local lung retention of protein drugs may not be a major issue for the successful inhalation treatment of obstructive lung diseases, since the protein can be relatively well retained in the lungs.</p>
      </sec>
      <sec id="Sec6">
        <title>Protein stability and immunogenicity</title>
        <p id="Par51">Inhaled protein therapeutics may undergo various degradation mechanisms during production, processing and/or storage. These degradation pathways may be physical (denaturation and non-covalent aggregation) or chemical (mainly covalent aggregation, deamidation, oxidation and/or glycation).</p>
        <p id="Par52">Denaturation is the result of physical stresses including low/high temperatures, high salt concentrations, organic solvents, and air/water or ice/water interfaces. Removal of the stressor may be spontaneously reversible (for some single domain proteins), but is usually irreversible for most of the larger multi-domain proteins [<xref ref-type="bibr" rid="CR67">67</xref>]. Surface-induced aggregation is one of the common mechanisms of non-covalent aggregation, and one example of when it occurs is during the process of nebulisation [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. As most proteins are amphiphilic and surface active, they have a tendency towards adsorption at the ALI. Upon adsorption, conformation changes may occur, exposing hydrophobic residues to the interface to avoid contact with water, thus leading to aggregation and unfolding, which are the main factors contributing to protein instability [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Chemical degradation of proteins (deamidation, oxidation, glycation) may also cause aggregation (either covalent or non-covalent) [<xref ref-type="bibr" rid="CR67">67</xref>].</p>
        <p id="Par53">Aggregation has been extensively studied but chemical modifications have not, despite having implications on biological activity and immunogenicity [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Aggregation can result from both physical and chemical pathways; therefore, it is useful to also evaluate chemical changes in inhaled proteins. Most studies assessing stability of inhaled protein formulations focus on formation of aggregates, while studies that also examine chemical changes are few and far between. One study did, however, consider chemical changes when evaluating the technical feasibility of delivering dornase alfa using perforated vibrating membrane devices for nebulisation. In this study, besides detecting protein aggregates, stability was also evaluated by measuring the percent deamidation of dornase alfa at Asn<sub>74</sub> (the main chemical change for the protein), which was shown to be inversely proportional to dornase alfa potency [<xref ref-type="bibr" rid="CR35">35</xref>]. Another study looked at methionine 59 oxidation [Met(o)] of nebulised insulin-like growth factor-1 (IGF-I), and how that correlated with aggregate formation and bioactivity. Highly aggregated samples displayed a complete loss of bioactivity, while samples with complete oxidation but minimal aggregation showed partial retention of bioactivity. Limited Met(o) formation and no aggregation was observed following delivery with air-jet or vibrating mesh nebulisers [<xref ref-type="bibr" rid="CR36">36</xref>]. Bandi et al. (2019) conducted a study to compare the effects of deamidation and oxidation on interferon alpha-2a (IFNA2a), as deamidation of asparagine and glutamine residues, and oxidation of methionine residues are two of the most common chemical alterations that occur in pharmaceutical proteins that could compromise their efficacy and safety [<xref ref-type="bibr" rid="CR68">68</xref>]. These findings revealed that deamidation destabilised IFNA2a and enhanced its tendency to aggregate under stressful conditions, and reduced its function to a greater extent than oxidation. This is the first study that quantitatively compared the effects between deamidation and oxidation of a therapeutic protein [<xref ref-type="bibr" rid="CR68">68</xref>]. It would be a good strategy to conduct such studies early on in the development of therapeutic protein candidates in order to identify the chemical modifications that a particular protein would be susceptible to, and to test out various excipients that could resolve specific stability issues.</p>
        <p id="Par54">The protein therapeutic also needs to remain stable after reaching the lung, which can be challenging due to the high numbers of serine proteases and aminopeptidases present in the lung mucosa [<xref ref-type="bibr" rid="CR69">69</xref>&#x2013;<xref ref-type="bibr" rid="CR72">72</xref>]. These proteases could degrade protein drugs even before they reach their target sites within the lung. The use of appropriate excipients in the formulation such as PEG, could help to enhance protein resistance to proteolysis by these lung proteases. For example, Zhang et al. (2014) evaluated the stability of fibronectin (FN) preferentially PEGylated at lysine residues using different MW PEGs [2&#x2009;kDa (PEG2), 5&#x2009;kDa (PEG5) or 10&#x2009;kDa (PEG10)] against the protease &#x3B1;-chymotrypsin. They showed that PEGylation protected FN from proteolysis and that PEG MW positively correlated with proteolytic stability (i.e. after 30&#x2009;min of proteolysis, 4%, 34%, 43% and 65% of the starting amounts of native FN, FN-PEG2, FN-PEG5 and FN-PEG10 respectively were remaining) [<xref ref-type="bibr" rid="CR73">73</xref>].</p>
        <p id="Par55">One must also be aware of the possibility of protein aggregates forming in the lungs. Lasagna-Reeves et al. [<xref ref-type="bibr" rid="CR74">74</xref>] demonstrated that mice exposed to inhaled insulin (Exubera&#xAE;) in a chamber twice daily for 1 week developed amyloid aggregates of insulin in both the proximal and distal airways, as well as the lung parenchyma (epithelium and muscle layer of the bronchi, bronchioles, and in the alveolar lining cells). The formation of insulin aggregates coincided with a significant decrease in respiratory flow rates, and also with caspase-9 activation. Previous studies investigating the link between changes in pulmonary function and inhaled insulin use focused on formation of anti-insulin antibodies, or pulmonary inflammation and subsequent airway remodelling, but none of the published works before this looked at insulin aggregation in the lungs as a contributor to pulmonary dysfunction after inhaled insulin use [<xref ref-type="bibr" rid="CR74">74</xref>]. Indeed, Exubera&#xAE; was reported to cause cough, dyspnea, increased sputum and epistaxis [<xref ref-type="bibr" rid="CR75">75</xref>]. This example highlights the possibility of inhaled proteins forming aggregates in the lungs, and thus the need for toxicity testing and safety studies examining this possibility to be done early on in the development of an inhaled protein candidate, during preclinical studies.</p>
        <p id="Par56">In addition, proteins and other macromolecules have the potential to induce immunogenicity, with the production of anti-drug antibodies (ADAs) as the main immune response [<xref ref-type="bibr" rid="CR5">5</xref>]. The development of ADAs in patients can alter pharmacokinetics, drastically reduce efficacy, and can also lead to severe adverse events or even lethal consequences [<xref ref-type="bibr" rid="CR76">76</xref>]. Immunogenicity is also linked to protein stability, as the presence of aggregates can render the protein immunogenic. As aggregates are typically composed of denatured molecules, they would exhibit no or decreased activity, but at the same time, aggregates are usually immunogenic leading to ADAs with important clinical implications [<xref ref-type="bibr" rid="CR4">4</xref>]. Aggregates are believed to be recognised and processed via non-specific uptake by antigen presenting cells and specific uptake by B cells. They may unmask neo&#x2212;/cryptic/repetitive epitopes, and these differences may influence the mechanism by which they activate the immune system [<xref ref-type="bibr" rid="CR76">76</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Approaches to address the challenges in formulating inhaled protein therapeutics</title>
      <sec id="Sec8">
        <title>Usage of excipients</title>
        <p id="Par57">Currently, only a few excipients have been approved by the FDA for inhalation due to a dearth of toxicological studies for inhaled excipients [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. There is also very limited number of excipients that are approved by FDA for biologics, rendering formulators limited choices to improve protein formulations when excipients are searched on the FDA&#x2019;s Inactive Ingredient Database Guidance. Furthermore, very few novel excipients have been investigated for biologic products; most are cyclodextrin-based excipients [<xref ref-type="bibr" rid="CR77">77</xref>]. As such, there is a need for more extensive toxicity testing to identify novel excipients for pulmonary delivery. For excipients already known to increase protein stability, a trial and error approach needs to be taken in determining their suitability for a particular protein formulation, as an excipient may work for one protein but not for another for various reasons including sequence differences [<xref ref-type="bibr" rid="CR15">15</xref>]. Excipients that are commonly used in liquid formulations (nebulisers and MDIs) include buffering or pH adjusting agents, and surfactants, and those that are commonly used in dry powder formulations (DPIs) include sugars, polyols, and amino acids [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR78">78</xref>].</p>
        <p id="Par58">Buffering or pH adjusting agents such as sodium chloride, sodium citrate, hydrochloric acid, sodium hydroxide, and citric acid, are added to maintain the pH of the formulation. It is important to choose the right buffering agent at an appropriate concentration, as most proteins in solution only remain stable within a narrow pH range. Different buffer systems and concentrations can also affect the aggregation pattern of proteins [<xref ref-type="bibr" rid="CR67">67</xref>]. Kim et al. [<xref ref-type="bibr" rid="CR79">79</xref>] analysed the stability of a fusion protein, etanercept (marketed Enbrel&#xAE;), with changing pH and buffer concentrations. Increasing the pH of etanercept from pH&#x2009;6.6 to 8.6 resulted in a decrease in protein size and increase in aggregation. Under high buffer concentrations (30&#x2009;mM Tris buffer), changes in protein size was reduced and irreversible aggregation was not observed, while in lower buffer concentrations (10&#x2009;mM Tris buffer), larger aggregates (~&#x2009;1&#x2009;&#x3BC;m) were observed across the pH range [<xref ref-type="bibr" rid="CR79">79</xref>].</p>
        <p id="Par59">Surfactants (polysorbates, sorbitan esters, oleic acid, and soy lecithin) are frequently used to prevent aggregate formation, and they work by displacing protein molecules from the ALI [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Polysorbates are the most commonly used surfactants, and are already being used to preclude aggregation in formulations of intravenously administered antibodies [<xref ref-type="bibr" rid="CR34">34</xref>]. Polysorbate 80 has been reported to lead to stabilisation in various inhaled protein formulations including those for granulocyte-colony stimulating factor (G-CSF), lactate dehydrogenase (LDH), tissue plasminogen activator (t-Pa) and aviscumine (recombinant mistletoe lectin) [<xref ref-type="bibr" rid="CR68">68</xref>]. The ability of polysorbates and other surfactants to stabilise a protein and hinder aggregate formation is contingent on the protein-to-surfactant ratio. Respaud et al. [<xref ref-type="bibr" rid="CR34">34</xref>] examined the effects of various antibody and surfactant (polysorbate 20) concentrations to optimise the protein-to-surfactant ratio for a nebulised antibody formulation. The authors determined that high concentrations of either surfactant or protein could minimise the formation of medium and large-sized aggregates, without significantly affecting the volume mean diameter (VMD) of the aerosol cloud, ensuring suitability for inhalation. Therefore, including surfactants and raising protein concentration to enhance the stability of inhaled protein formulations is a viable strategy, although it should be noted that this approach needs to be evaluated and optimised for each drug and device pairing being developed into an inhaled protein formulation [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
        <p id="Par60">Sugars (sucrose, trehalose, raffinose and lactose) and polyols (mannitol) stabilise proteins through the preferential hydration of proteins via steric repulsion of sugar/polyol molecules from the native protein [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Lactose is often used as a drug carrier in DPIs, however, it may not be suitable for proteins because it is a reducing sugar, and it could interact with amino groups in proteins (Maillard reaction) [<xref ref-type="bibr" rid="CR67">67</xref>]. On the other hand, non-reducing sugars such as sucrose, trehalose and raffinose would not undergo the Maillard reaction with proteins, and thus could be used as alternatives to lactose [<xref ref-type="bibr" rid="CR81">81</xref>]. Sellers et al. [<xref ref-type="bibr" rid="CR82">82</xref>] demonstrated that sucrose could help to improve the stability of a dry powder formulation of LDH. Supercritical fluid (SCF) drying of LDH without excipients lead to irreversible loss of activity (only 15% recovered after rehydration). Inclusion of 10% (w/w) sucrose during dehydration lead to an increase in activity recovered (to ~&#x2009;60%), and there was almost complete retention of activity when polysorbate 20 was added in addition to sucrose [<xref ref-type="bibr" rid="CR82">82</xref>]. Trehalose and raffinose are currently not approved for any administration routes, but have been evaluated in experimental studies with promising results. For instance, &#xD3;g&#xE1;in et al. [<xref ref-type="bibr" rid="CR81">81</xref>] incorporated lysozyme into nanoporous microparticles of trehalose and raffinose. Lysozyme showed good retention of specific activity after storage for 12&#x2009;weeks at either 4&#xB0;C (98.2&#x2009;&#xB1;&#x2009;7.1% for lysozyme:trehalose and 99.1&#x2009;&#xB1;&#x2009;7.1% for lyzosyme:raffinose) or 25&#xB0;C (92.5&#x2009;&#xB1;&#x2009;7.1% for lysozyme:trehalose and 90.8&#x2009;&#xB1;&#x2009;7.1% for lyzosyme:raffinose) [<xref ref-type="bibr" rid="CR81">81</xref>]. Mannitol was used as an excipient in the formulation of Exubera&#xAE; (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR80">80</xref>].
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Excipients used in marketed inhaled protein formulations</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Product</th><th>Device type</th><th>Active Pharmaceutical Ingredient (API)</th><th>Excipients</th></tr></thead><tbody><tr><td>Pulmozyme&#xAE; (approved 1993)</td><td>Jet nebuliser</td><td>Dornase alfa (DNase I)</td><td>sodium chloride, calcium chloride dihydrate</td></tr><tr><td>Exubera&#xAE; (approved 2006, discontinued 2007)</td><td>DPI</td><td>Insulin human</td><td>mannitol, sodium citrate, glycine, sodium hydroxide</td></tr><tr><td>Afrezza&#xAE; (approved 2014)</td><td>DPI</td><td>Insulin human</td><td>fumaryl diketopiperazine, polysorbate 80</td></tr></tbody></table></table-wrap></p>
        <p id="Par61">Small amino acids (histidine, arginine, alanine, glycine, lysine, isoleucine) are also used as stabilisers, and they work by the &#x201C;water substitution mechanism&#x201D; in which the amino acids hydrogen bond with the protein during drying to preserve the native protein structure in the dried state [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. Ajmera and Scherlie&#x3B2; [<xref ref-type="bibr" rid="CR84">84</xref>] screened different amino acids and their combinations for their ability to stabilize catalase during spray drying. When various ratios of arginine, glycine and histidine were mixed with catalase, some formulations were able to maintain close to 100% catalase activity [<xref ref-type="bibr" rid="CR84">84</xref>]. Despite encouraging results in studies such as this one, there is a lack of data on the local toxicity of the various amino acids following inhalation, which could limit their use. However, as they are endogenous substances, they may not present major safety issues for local lung delivery [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR85">85</xref>].</p>
        <p id="Par62">The polyol, PEG, could be used for both liquid and powder formulations of inhaled proteins. Small MW PEGs (&lt;&#x2009;10&#x2009;kDa) are often used as excipients in oral, intravenous and nasal formulations. Larger PEGs (up to 40&#x2009;kDa) may be used in PEGylated biopharmaceuticals, and safety testing for these formulations are done during development on a case-by-case basis [<xref ref-type="bibr" rid="CR86">86</xref>]. PEGylation is a commonly used method to enhance solubility and stability, as well as to decrease immunogenicity of bioactive drugs including but not limited to proteins, peptides, antibody fragments, and enzymes, and is achieved by the covalent or noncovalent conjugation of PEG to the biomolecule [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. PEGylation can also help to reduce clearance and increase lung accumulation and residence time of inhaled protein therapeutics. For instance, conjugation of a PEG chain to two antibody fragments (anti- IL-17A F (ab&#x2032;)2 and anti-IL-13 Fab&#x2032;) increased their levels in mouse lungs following intranasal administration. Forty-eight hours post-administration, levels of unconjugated antibody fragments in the lungs had dropped to 10% and 14% of the original deposited dose of F (ab&#x2032;)2 and Fab&#x2032; respectively, while this value was 40% for both PEGylated fragments [<xref ref-type="bibr" rid="CR11">11</xref>]. Furthermore, conjugation of a PEG chain to an anti-IL-17A Fab&#x2019; antibody fragment increased pulmonary retention in all three species tested (mice, rats, and rabbits) following intratracheal administration. Unconjugated fragments were cleared from the lungs within 24&#x2009;h while large amounts of PEGylated fragments still remained for up to 48&#x2009;h [<xref ref-type="bibr" rid="CR89">89</xref>].</p>
      </sec>
      <sec id="Sec9">
        <title>Encapsulation in carriers</title>
        <p id="Par63">The two biggest challenges in developing particle systems for pulmonary drug delivery are to maintain colloidal stability during aerosolisation and to achieve high delivery efficacy. Encapsulation of proteins in carriers could provide multiple benefits such as protection from enzymatic degradation and specific targeting to the site of action through targeting ligands [<xref ref-type="bibr" rid="CR5">5</xref>]. Furthermore, carriers may also be used to provide sustained drug release, accumulating in the lungs and releasing therapeutic levels of the protein drug over extended periods of time. This would enhance efficacy while averting peaks in local drug concentrations that could cause pulmonary toxicity [<xref ref-type="bibr" rid="CR90">90</xref>]. Proteins, including insulin, calcitonin, and IgG, have already been loaded into various carriers such as microparticles, liposomes, and solid lipid nanoparticles [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. Indeed, Afrezza&#xAE; uses Technosphere&#xAE; technology, in which fumaryl diketopiperazine (FDKP), an excipient added into the formulation, self-assembles into microspheres, entrapping the insulin. Upon reaching the alveolar zone of the lung, the Technosphere&#xAE; particles rapidly dissolve in the pH-neutral environment and release the insulin for systemic absorption [<xref ref-type="bibr" rid="CR75">75</xref>]. Although this approach has not been extensively explored for topical lung delivery of proteins, and more work needs to be done on the use of carriers for the purpose of systemic delivery of proteins through the lungs, some promising results have been reported that support further development of this approach. Tawfeek et al. [<xref ref-type="bibr" rid="CR92">92</xref>] encapsulated a model mucinolytic enzyme, &#x3B1;-chymotrypsin (which is very sensitive to unfolding and formulation conditions), in a novel biodegradable PEG-co-polyester microparticle carrier. The encapsulated &#x3B1;-chymotrypsin exhibited retention of enzymatic activity and the results indicated suitability of the carrier for potential use in the delivery of macromolecules as DPI formulations for the treatment of lung diseases [<xref ref-type="bibr" rid="CR92">92</xref>]. In another study by Osman et al. [<xref ref-type="bibr" rid="CR93">93</xref>], various surface modifications were made to DNase I loaded microparticles using different excipients in order to provide higher lung deposition, enzyme stability and biological activity. Surface modifying the microparticles with polyglutamic acid (PGA) or dextran was found to provide high inhalation indices (emitted fraction (EF), respirable particle fraction (RP), and effective inhalation index (EI)) and increased mucolytic activity in cystic fibrosis sputum. This could be explained by the resulting surfaces of the particles after modification with PGA (rough dented surfaces) or dextran (dimpled surfaces). Compared to spherical particles with similar physical properties, corrugated particles have surface asperities that could reduce the true contact area between particles, decreasing powder cohesiveness and enhancing aerosol performance [<xref ref-type="bibr" rid="CR93">93</xref>].</p>
        <p id="Par64">Advancements in drug-loaded capsules for pulmonary delivery have been made in both inhalable dry powder or liquid drug formulations [<xref ref-type="bibr" rid="CR94">94</xref>&#x2013;<xref ref-type="bibr" rid="CR96">96</xref>]. For dry powder drug particles, precise control of the particle size has been reported using the Particle Replication In Nonwetting Templates (PRINT) technology [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. For control of aerodynamic particle size in liquid aerosols such as in nebulized liquid formulation, the recently reported MPNs have presented promising possibilities. MPN-based drug-loaded capsules with highly defined physical properties can be generated for both macromolecular protein drugs and small molecule chemical drugs [<xref ref-type="bibr" rid="CR54">54</xref>]. These new developments may transform inhalation drug delivery in the near future.</p>
        <p id="Par65">One drawback with the use of carriers is their rapid uptake by alveolar macrophages [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. Phagocytosis of carriers by alveolar macrophages can result in fast clearance and reduced residence time, limiting the therapeutic efficacy of the carrier-associated drug. This would be an issue for the treatment of chronic lung diseases such as asthma and COPD, where the goal of using a carrier system would be to achieve controlled and continuous drug release over an extended period of time. However, various formulation design strategies may be employed to reduce the uptake of particulate carriers by alveolar macrophages including modulation of particle size, shape, surface charge and surface coating [<xref ref-type="bibr" rid="CR101">101</xref>]. Studies on the use of various polymer coatings demonstrate reduced alveolar macrophage uptake of coated carriers. For example, Jones et al. [<xref ref-type="bibr" rid="CR102">102</xref>] showed that respirable microspheres coated with dipalmitoyl phosphatidylcholine (DPPC; a major component of lung surfactant) were able to significantly reduce phagocytic uptake by NR8383 in cultured alveolar macrophages compared to uncoated microspheres. The uptake of DPPC coated microspheres was found to be only 24.1&#x2009;&#xB1;&#x2009;7.86%, 31.9&#x2009;&#xB1;&#x2009;3.74% or 36.6&#x2009;&#xB1;&#x2009;3.66%, of the uptake of uncoated microspheres for ratios of 5, 10 or excess microspheres per NR8383 cell respectively [<xref ref-type="bibr" rid="CR102">102</xref>]. Furthermore, Shen et al. [<xref ref-type="bibr" rid="CR103">103</xref>] demonstrated that surface coating of hydrogel nano- and microparticles with PEG showed significantly reduced uptake by alveolar macrophages both in vitro (in MH-S cells) and in vivo (in mice) compared to unPEGylated particles of the respective size. At 24&#x2009;h post-dose, the fold difference between PEGylated and unPEGylated 80&#x2009;&#xD7;&#x2009;320&#x2009;nm, 1.5&#x2009;&#x3BC;m, and 6&#x2009;&#x3BC;m particles in bronchioalveolar lavage fluid (BALF), was 1.5, 3.4 and 3.7 respectively [<xref ref-type="bibr" rid="CR103">103</xref>]. On the other hand, drug-loaded particles may be advantageous for anti-tuberculosis drugs as efficient uptake of drugs into alveolar macrophages could potentially enhance the drug&#x2019;s efficacy to kill the parasitic <italic>Mycobacterium tuberculosis</italic> that hide inside the cells [<xref ref-type="bibr" rid="CR104">104</xref>].</p>
        <p id="Par66">If the usage of a carrier is to be included in the protein formulation, it should be noted that the formulation (i.e. combination of protein and carrier) would need to be optimised together with the choice of device, as the chosen carrier may not work well with all inhalation device types. For instance, liposomes may be delivered to the lungs either by dry powder inhalation or nebulisation of a liposome suspension. However, nebulised solutions of liposomes may cause instability as nebulisation has been reported to disrupt liposomal structure, leading to the release of loaded drug. These issues can be avoided with the use of dry powders of liposomes instead [<xref ref-type="bibr" rid="CR90">90</xref>]. Hence, although this review has presented a general overview for the various aspects of protein formulation design (such as choice of device, excipients), it is important to test out the formulation and device together to determine which combination works best.</p>
      </sec>
    </sec>
    <sec id="Sec10">
      <title>Concluding remarks</title>
      <p id="Par67">This review analyses the various obstacles that an inhaled protein drug would need to overcome in order to reach the lungs and exert its therapeutic effects. These obstacles include the physical and chemical stresses experienced by the protein during production/storage/aerosolisation, the need to overcome mucociliary clearance and physical barriers arising from disease conditions in order to reach target sites within the lung, and the need to remain stable in spite of the presence of abundant proteases, and to evade clearance by alveolar macrophages after reaching the lungs (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). All of these threats to the integrity of the protein need to be carefully considered, so that pre-emptive measures can be taken while designing the protein formulation to ensure its therapeutic efficacy. Nevertheless, although the information provided here may serve as general considerations in developing pulmonary protein therapeutics, empirical testing of the formulation together with the device should still be performed to determine the best combination for a particular protein.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Major challenges for targeting inhaled protein therapeutics to the lungs for local action. Targeted deposition sites within the lung (large or small airways) will vary depending on the specific lung disease being treated. (Created with <ext-link ext-link-type="uri" xlink:href="http://biorender.com">BioRender.com</ext-link>)</p></caption><graphic xlink:href="43556_2020_14_Fig1_HTML" id="MO1"/></fig></p>
      <p id="Par68">Several key areas will require further investigation in order to support the development of more successful inhaled protein therapies, and maintaining the stability of the inhaled protein is of paramount importance. Firstly, more studies could look at other instability issues beyond protein aggregation. In depth studies on the specific chemical modifications that a protein would be susceptible to, such as the one conducted by Bandi et al. (2019), could be carried out on therapeutic protein candidates so that they may be developed into stable and effective treatments [<xref ref-type="bibr" rid="CR68">68</xref>]. Moreover, the scarcity of FDA-approved excipients for inhaled therapeutics further limits drug developers, and expanding this list through increased toxicological testing of new excipients would provide more options for formulation design. Finally, innovative approaches such as the use of novel carrier systems should be employed for the purpose of topical lung delivery, as carrier systems could greatly enhance the stability and pharmacokinetic profile of proteins. These approaches would greatly benefit the field of pulmonary drug delivery, and will ultimately allow more inhaled protein therapeutics to reach the clinic.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>API</term>
          <def>
            <p id="Par2">Active pharmaceutical ingredient</p>
          </def>
        </def-item>
        <def-item>
          <term>ADAs</term>
          <def>
            <p id="Par3">Anti-drug antibodies</p>
          </def>
        </def-item>
        <def-item>
          <term>AUC</term>
          <def>
            <p id="Par4">Area under the curve</p>
          </def>
        </def-item>
        <def-item>
          <term>BSA</term>
          <def>
            <p id="Par5">Bovine serum albumin</p>
          </def>
        </def-item>
        <def-item>
          <term>COPD</term>
          <def>
            <p id="Par6">Chronic obstructive pulmonary disease</p>
          </def>
        </def-item>
        <def-item>
          <term>DD</term>
          <def>
            <p id="Par7">Delivered dose</p>
          </def>
        </def-item>
        <def-item>
          <term>DPPC</term>
          <def>
            <p id="Par8">Dipalmitoyl phosphatidylcholine</p>
          </def>
        </def-item>
        <def-item>
          <term>DPIs</term>
          <def>
            <p id="Par9">Dry powder inhalers</p>
          </def>
        </def-item>
        <def-item>
          <term>EI</term>
          <def>
            <p id="Par10">Effective inhalation index</p>
          </def>
        </def-item>
        <def-item>
          <term>EF</term>
          <def>
            <p id="Par11">Emitted&#xA0;Fraction</p>
          </def>
        </def-item>
        <def-item>
          <term>FN</term>
          <def>
            <p id="Par12">Fibronectin</p>
          </def>
        </def-item>
        <def-item>
          <term>FDA</term>
          <def>
            <p id="Par13">Food and Drug Administration</p>
          </def>
        </def-item>
        <def-item>
          <term>FDKP</term>
          <def>
            <p id="Par14">Fumaryl diketopiperazine</p>
          </def>
        </def-item>
        <def-item>
          <term>G-CSF</term>
          <def>
            <p id="Par15">Granulocyte-colony stimulating factor</p>
          </def>
        </def-item>
        <def-item>
          <term>HYDRA</term>
          <def>
            <p id="Par16">HYbriD Resonant Acoustics</p>
          </def>
        </def-item>
        <def-item>
          <term>HFA</term>
          <def>
            <p id="Par17">Hydrofluoroalkane</p>
          </def>
        </def-item>
        <def-item>
          <term>IGF-I</term>
          <def>
            <p id="Par18">Insulin-like growth factor-1</p>
          </def>
        </def-item>
        <def-item>
          <term>LDH</term>
          <def>
            <p id="Par19">Lactate dehydrogenase</p>
          </def>
        </def-item>
        <def-item>
          <term>MDIs</term>
          <def>
            <p id="Par20">Metered dose inhalers</p>
          </def>
        </def-item>
        <def-item>
          <term>MPNs</term>
          <def>
            <p id="Par21">Metal-phenolic networks</p>
          </def>
        </def-item>
        <def-item>
          <term>Cmax</term>
          <def>
            <p id="Par22">Mean maximum concentration</p>
          </def>
        </def-item>
        <def-item>
          <term>MW</term>
          <def>
            <p id="Par23">Molecular weight</p>
          </def>
        </def-item>
        <def-item>
          <term>mAbs</term>
          <def>
            <p id="Par24">Monoclonal antibodies</p>
          </def>
        </def-item>
        <def-item>
          <term>MCC</term>
          <def>
            <p id="Par25">Mucociliary clearance</p>
          </def>
        </def-item>
        <def-item>
          <term>PRINT</term>
          <def>
            <p id="Par26">Particle Replication In Nonwetting Templates</p>
          </def>
        </def-item>
        <def-item>
          <term>PEG</term>
          <def>
            <p id="Par27">Polyethylene glycol</p>
          </def>
        </def-item>
        <def-item>
          <term>PGA</term>
          <def>
            <p id="Par28">Polyglutamic acid</p>
          </def>
        </def-item>
        <def-item>
          <term>RP</term>
          <def>
            <p id="Par29">Respirable particle fraction</p>
          </def>
        </def-item>
        <def-item>
          <term>SMI</term>
          <def>
            <p id="Par30">Soft mist inhaler</p>
          </def>
        </def-item>
        <def-item>
          <term>SCF</term>
          <def>
            <p id="Par31">Supercritical fluid</p>
          </def>
        </def-item>
        <def-item>
          <term>TSLP</term>
          <def>
            <p id="Par32">Thymic stromal lymphopoietin</p>
          </def>
        </def-item>
        <def-item>
          <term>TLD</term>
          <def>
            <p id="Par33">Total lung dose</p>
          </def>
        </def-item>
        <def-item>
          <term>VMD</term>
          <def>
            <p id="Par34">Volume mean diameter</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>NA.</p>
      <sec id="FPar1">
        <title>Code availability</title>
        <p id="Par69">NA.</p>
      </sec>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>Abigail Matthews performed the literature search and drafted the manuscript. Ruowen Ge obtained the funding, advised on the contents and revised the manuscript. Pui Lai Rachel Ee provided comments and suggestions. The author(s) read and approved the final manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>Funding support for this work is provided by the grant MOE2017-T2&#x2013;2-122 awarded to Ruowen Ge from Singapore Ministry of Education, Republic of Singapore.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials</title>
      <p>NA.</p>
    </notes>
    <notes id="FPar2">
      <title>Ethics approval and consent to participate</title>
      <p id="Par70">NA.</p>
    </notes>
    <notes id="FPar3">
      <title>Consent for publication</title>
      <p id="Par71">All authors concur with this publication.</p>
    </notes>
    <notes id="FPar4" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par72">Ruowen Ge is the scientific founder of NovoBreeze Therapeutics Co. Ltd., Ningbo, China. Other authors declare no competing interest.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">Gottlieb S. Capturing the benefits of competition for patients. U.S. Food and Drug Administration. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/speeches-fda-officials/capturing-benefits-competition-patients-03072018">https://www.fda.gov/news-events/speeches-fda-officials/capturing-benefits-competition-patients-03072018</ext-link>. Published March 7, 2018.</mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strong</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rapeport</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Current approaches to the discovery of novel inhaled medicines</article-title>
          <source>Drug Discov Today</source>
          <year>2018</year>
          <volume>23</volume>
          <issue>10</issue>
          <fpage>1705</fpage>
          <lpage>1717</lpage>
          <pub-id pub-id-type="doi">10.1016/j.drudis.2018.05.017</pub-id>
          <pub-id pub-id-type="pmid">29775668</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="other">Fellner RC, Terryah ST, Tarran R. Inhaled protein/peptide-based therapies for respiratory disease. Mol Cell Pediatr. 2016;3(1). 10.1186/s40348-016-0044-8.</mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Respaud</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vecellio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Diot</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Heuz&#xE9;-Vourc&#x2019;H</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Nebulization as a delivery method for mAbs in respiratory diseases</article-title>
          <source>Expert Opin Drug Deliv.</source>
          <year>2015</year>
          <volume>12</volume>
          <issue>6</issue>
          <fpage>1027</fpage>
          <lpage>1039</lpage>
          <pub-id pub-id-type="doi">10.1517/17425247.2015.999039</pub-id>
          <pub-id pub-id-type="pmid">25557066</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Osman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kaneko</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Carini</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Saleem</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies</article-title>
          <source>Expert Opin Drug Deliv.</source>
          <year>2018</year>
          <volume>15</volume>
          <issue>8</issue>
          <fpage>821</fpage>
          <lpage>834</lpage>
          <pub-id pub-id-type="doi">10.1080/17425247.2018.1502267</pub-id>
          <pub-id pub-id-type="pmid">30021074</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="other">S&#xE9;cher T, Mayor A, Heuz&#xE9;-Vourc'h N. Inhalation of immuno-therapeutics/&#x2212;prophylactics to fight respiratory tract infections: an appropriate drug at the right place! Front Immunol. 2019;10. 10.3389/fimmu.2019.02760.</mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herv&#xE9;</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rabbe</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Guilleminault</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schlick</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Azzopardi</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations</article-title>
          <source>MAbs.</source>
          <year>2014</year>
          <volume>6</volume>
          <issue>6</issue>
          <fpage>1638</fpage>
          <lpage>1648</lpage>
          <pub-id pub-id-type="doi">10.4161/mabs.34454</pub-id>
          <pub-id pub-id-type="pmid">25484066</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maillet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guilleminault</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lemari&#xE9;</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lerondel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Azzopardi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Montharu</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The airways, a novel route for delivering monoclonal antibodies to treat lung tumors</article-title>
          <source>Pharm Res</source>
          <year>2011</year>
          <volume>28</volume>
          <issue>9</issue>
          <fpage>2147</fpage>
          <lpage>2156</lpage>
          <pub-id pub-id-type="doi">10.1007/s11095-011-0442-5</pub-id>
          <pub-id pub-id-type="pmid">21491145</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borghardt</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kloft</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes</article-title>
          <source>Can Respir J</source>
          <year>2018</year>
          <volume>2018</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1155/2018/2732017</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santis</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Rosi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Anastasi</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Chiapparino</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Albertoni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Leoni</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated cetuximab</article-title>
          <source>Oncotarget.</source>
          <year>2014</year>
          <volume>5</volume>
          <issue>19</issue>
          <fpage>9239</fpage>
          <lpage>9255</lpage>
          <pub-id pub-id-type="doi">10.18632/oncotarget.2409</pub-id>
          <pub-id pub-id-type="pmid">25238453</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koussoroplis</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Paulissen</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tyteca</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Goldansaz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Todoroff</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barilly</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract</article-title>
          <source>J Control Release</source>
          <year>2014</year>
          <volume>187</volume>
          <fpage>91</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.05.021</pub-id>
          <pub-id pub-id-type="pmid">24845126</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smaldone</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
          <article-title>Repurposing of gamma interferon via inhalation delivery</article-title>
          <source>Adv Drug Deliv Rev</source>
          <year>2018</year>
          <volume>133</volume>
          <fpage>87</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1016/j.addr.2018.06.004</pub-id>
          <pub-id pub-id-type="pmid">29886069</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerem</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Blau</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shteinberg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Efrati</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Alon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dekel</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>WS01.2 phase II clinical trial results of alidornase alfa for the treatment of cystic fibrosis</article-title>
          <source>J Cyst Fibros</source>
          <year>2017</year>
          <volume>16</volume>
          <fpage>S1</fpage>
          <pub-id pub-id-type="doi">10.1016/s1569-1993(17)30157-1</pub-id>
          <pub-id pub-id-type="pmid">28986025</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="other">Nanus M. Protalix BioTherapeutics announces phase II clinical trial results for alidornase alfa in cystic fibrosis presented at the 40th European Cystic Fibrosis Society Conference. Protalix BioTherapeutics. <ext-link ext-link-type="uri" xlink:href="https://protalixbiotherapeutics.gcs-web.com/news-releases/news-release-details/protalix-biotherapeutics-announces-phase-ii-clinical-trial">https://protalixbiotherapeutics.gcs-web.com/news-releases/news-release-details/protalix-biotherapeutics-announces-phase-ii-clinical-trial</ext-link>. Published June 7, 2017.</mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bodier-Montagutelli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mayor</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vecellio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Respaud</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Heuz&#xE9;-Vourc&#x2019;H</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Designing inhaled protein therapeutics for topical lung delivery: what are the next steps?</article-title>
          <source>Expert Opin Drug Deliv.</source>
          <year>2018</year>
          <volume>15</volume>
          <issue>8</issue>
          <fpage>729</fpage>
          <lpage>736</lpage>
          <pub-id pub-id-type="doi">10.1080/17425247.2018.1503251</pub-id>
          <pub-id pub-id-type="pmid">30025210</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campo</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mariani</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Paracchini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Piloni</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kadija</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Salvaterra</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Inhaled GM-CSF in a pulmonary alveolar proteinosis patient refractory to plasmapheresis combined with multiple whole lung lavages</article-title>
          <source>Arch Pulmonol Respir Care</source>
          <year>2017</year>
          <volume>3</volume>
          <issue>1</issue>
          <fpage>016</fpage>
          <lpage>019</lpage>
          <pub-id pub-id-type="doi">10.17352/aprc.000018</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="other">FDAnews. Synairgen doses first patient in COVID-19 trial. <ext-link ext-link-type="uri" xlink:href="https://www.fdanews.com/articles/196457-synairgen-doses-first-patient-in-covid-19-trial">https://www.fdanews.com/articles/196457-synairgen-doses-first-patient-in-covid-19-trial</ext-link>. Published March 31, 2020.</mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="other">BioSpace. Ansun Biopharma enrolls first patient in proof of concept trial of DAS181 for the treatment of COVID-19. BioSpace. <ext-link ext-link-type="uri" xlink:href="https://www.biospace.com/article/releases/ansun-biopharma-enrolls-first-patient-in-proof-of-concept-trial-of-das181-for-the-treatment-of-covid-19/">https://www.biospace.com/article/releases/ansun-biopharma-enrolls-first-patient-in-proof-of-concept-trial-of-das181-for-the-treatment-of-covid-19/</ext-link>. Published April 15, 2020.</mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leyva-Grado</surname>
              <given-names>VH</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Yondola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Palese</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2015</year>
          <volume>59</volume>
          <issue>7</issue>
          <fpage>4162</fpage>
          <lpage>4172</lpage>
          <pub-id pub-id-type="doi">10.1128/aac.00290-15</pub-id>
          <pub-id pub-id-type="pmid">25941218</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>S&#xE9;cher</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dalonneau</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Parent</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Azzopardi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Paintaud</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration</article-title>
          <source>J Control Release</source>
          <year>2019</year>
          <volume>303</volume>
          <fpage>24</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jconrel.2019.04.005</pub-id>
          <pub-id pub-id-type="pmid">30981816</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morales</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Fathe</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Brunaugh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ferrati</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Montenegro-Nicolini</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes</article-title>
          <source>AAPS J</source>
          <year>2017</year>
          <volume>19</volume>
          <issue>3</issue>
          <fpage>652</fpage>
          <lpage>668</lpage>
          <pub-id pub-id-type="doi">10.1208/s12248-017-0054-z</pub-id>
          <pub-id pub-id-type="pmid">28194704</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anselmo</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Gokarn</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mitragotri</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Non-invasive delivery strategies for biologics</article-title>
          <source>Nat Rev Drug Discov</source>
          <year>2018</year>
          <volume>18</volume>
          <issue>1</issue>
          <fpage>19</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1038/nrd.2018.183</pub-id>
          <pub-id pub-id-type="pmid">30498202</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weers</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Son</surname>
              <given-names>Y-J</given-names>
            </name>
            <name>
              <surname>Glusker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Haynes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kadrichu</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Idealhalers versus realhalers: is it possible to bypass deposition in the upper respiratory tract?</article-title>
          <source>J Aerosol Med Pulm Drug Deliv.</source>
          <year>2019</year>
          <volume>32</volume>
          <issue>2</issue>
          <fpage>55</fpage>
          <lpage>69</lpage>
          <pub-id pub-id-type="doi">10.1089/jamp.2018.1497</pub-id>
          <pub-id pub-id-type="pmid">30481087</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hertel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pohl</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Friess</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>That&#x2019;s cool! &#x2013; nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer</article-title>
          <source>Eur J Pharm Biopharm</source>
          <year>2014</year>
          <volume>87</volume>
          <issue>2</issue>
          <fpage>357</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejpb.2014.03.001</pub-id>
          <pub-id pub-id-type="pmid">24662437</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hertel</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Friess</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Protein stability in pulmonary drug delivery via nebulization</article-title>
          <source>Adv Drug Deliv Rev</source>
          <year>2015</year>
          <volume>93</volume>
          <fpage>79</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="doi">10.1016/j.addr.2014.10.003</pub-id>
          <pub-id pub-id-type="pmid">25312674</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niven</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Ip</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Mittelman</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Farrar</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Arakawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Prestrelski</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Protein nebulization: I. stability of lactate dehydrogenase and recombinant granulocyte-colony stimulating factor to air-jet nebulization</article-title>
          <source>Int J Pharm</source>
          <year>1994</year>
          <volume>109</volume>
          <issue>1</issue>
          <fpage>17</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1016/0378-5173(94)90117-1</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>F&#xE4;ngmark</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Carpin</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Stability of urease during aerosolization</article-title>
          <source>J Aerosol Sci</source>
          <year>1998</year>
          <volume>29</volume>
          <issue>3</issue>
          <fpage>279</fpage>
          <lpage>288</lpage>
          <pub-id pub-id-type="doi">10.1016/s0021-8502(97)10010-6</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>F&#xE4;ngmark</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Carpin</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Protein nebulization</article-title>
          <source>J Aerosol Sci</source>
          <year>1996</year>
          <volume>27</volume>
          <fpage>S231</fpage>
          <lpage>S232</lpage>
          <pub-id pub-id-type="doi">10.1016/0021-8502(96)00188-7</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niven</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Ip</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Mittelman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Prestrelski</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Arakawa</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Some factors associated with the ultrasonic nebulization of proteins</article-title>
          <source>Pharm Res</source>
          <year>1995</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>53</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="doi">10.1023/a:1016282502954</pub-id>
          <pub-id pub-id-type="pmid">7724488</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Finlay</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Nebulizers for drug delivery to the lungs</article-title>
          <source>Expert Opin Drug Deliv.</source>
          <year>2014</year>
          <volume>12</volume>
          <issue>6</issue>
          <fpage>889</fpage>
          <lpage>900</lpage>
          <pub-id pub-id-type="doi">10.1517/17425247.2015.995087</pub-id>
          <pub-id pub-id-type="pmid">25534396</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Mcconville</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>The function and performance of aqueous aerosol devices for inhalation therapy</article-title>
          <source>J Pharm Pharmacol</source>
          <year>2016</year>
          <volume>68</volume>
          <issue>5</issue>
          <fpage>556</fpage>
          <lpage>578</lpage>
          <pub-id pub-id-type="doi">10.1111/jphp.12541</pub-id>
          <pub-id pub-id-type="pmid">27061412</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Longest</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Spence</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hindle</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Devices for improved delivery of nebulized pharmaceutical aerosols to the lungs</article-title>
          <source>J Aerosol Med Pulm Drug Deliv</source>
          <year>2019</year>
          <volume>32</volume>
          <issue>5</issue>
          <fpage>317</fpage>
          <lpage>339</lpage>
          <pub-id pub-id-type="doi">10.1089/jamp.2018.1508</pub-id>
          <pub-id pub-id-type="pmid">31287369</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forde</surname>
              <given-names>&#xC9;</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sweeney</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fitzgerald-Hughes</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Macloughlin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Devocelle</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Vibrating mesh nebulisation of pro-antimicrobial peptides for use in cystic fibrosis</article-title>
          <source>Pharmaceutics.</source>
          <year>2019</year>
          <volume>11</volume>
          <issue>5</issue>
          <fpage>239</fpage>
          <pub-id pub-id-type="doi">10.3390/pharmaceutics11050239</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Respaud</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Marchand</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Parent</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pelat</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Thullier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tournamille</surname>
              <given-names>J-F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of formulation on the stability and aerosol performance of a nebulized antibody</article-title>
          <source>MAbs.</source>
          <year>2014</year>
          <volume>6</volume>
          <issue>5</issue>
          <fpage>1347</fpage>
          <lpage>1355</lpage>
          <pub-id pub-id-type="doi">10.4161/mabs.29938</pub-id>
          <pub-id pub-id-type="pmid">25517319</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scherer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Geller</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Owyang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tservistas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boden</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A technical feasibility study of dornase alfa delivery with eFlow&#xAE; vibrating membrane nebulizers: aerosol characteristics and physicochemical stability</article-title>
          <source>J Pharm Sci</source>
          <year>2011</year>
          <volume>100</volume>
          <issue>1</issue>
          <fpage>98</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="doi">10.1002/jps.22231</pub-id>
          <pub-id pub-id-type="pmid">20533437</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Germershaus</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>L&#xFC;hmann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Beck-Broichsitter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>H&#xF6;gger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Meinel</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Insulin-like growth factor-I aerosol formulations for pulmonary delivery</article-title>
          <source>Eur J Pharm Biopharm</source>
          <year>2013</year>
          <volume>85</volume>
          <issue>1</issue>
          <fpage>61</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejpb.2013.03.011</pub-id>
          <pub-id pub-id-type="pmid">23958318</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Respaud</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Marchand</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pelat</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tchou-Wong</surname>
              <given-names>K-M</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Parent</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin</article-title>
          <source>J Control Release</source>
          <year>2016</year>
          <volume>234</volume>
          <fpage>21</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jconrel.2016.05.018</pub-id>
          <pub-id pub-id-type="pmid">27173943</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sweeney</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mccloskey</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Cryan</surname>
              <given-names>S-A</given-names>
            </name>
            <name>
              <surname>Macloughlin</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Effective nebulization of interferon-&#x3B3; using a novel vibrating mesh</article-title>
          <source>Respir Res</source>
          <year>2019</year>
          <volume>20</volume>
          <fpage>66</fpage>
          <pub-id pub-id-type="doi">10.1186/s12931-019-1030-1</pub-id>
          <pub-id pub-id-type="pmid">30943978</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elphick</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hollen</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Pritchard</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Nikander</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hardaker</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Hatley</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Factors to consider when selecting a nebulizer for a new inhaled drug product development program</article-title>
          <source>Expert Opin Drug Deliv</source>
          <year>2015</year>
          <volume>12</volume>
          <issue>8</issue>
          <fpage>1375</fpage>
          <lpage>1387</lpage>
          <pub-id pub-id-type="doi">10.1517/17425247.2015.1014339</pub-id>
          <pub-id pub-id-type="pmid">25758911</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ju</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cortez-Jugo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>TY</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Tsantikos</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Engineering of nebulized metal&#x2013;phenolic capsules for controlled pulmonary deposition</article-title>
          <source>Adv Sci</source>
          <year>2020</year>
          <volume>7</volume>
          <issue>6</issue>
          <fpage>1902650</fpage>
          <pub-id pub-id-type="doi">10.1002/advs.201902650</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cortez-Jugo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Qi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rajapaksa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Friend</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Yeo</surname>
              <given-names>LY</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform</article-title>
          <source>Biomicrofluidics.</source>
          <year>2015</year>
          <volume>9</volume>
          <issue>5</issue>
          <fpage>052603</fpage>
          <pub-id pub-id-type="doi">10.1063/1.4917181</pub-id>
          <pub-id pub-id-type="pmid">25945147</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwok</surname>
              <given-names>PCL</given-names>
            </name>
            <name>
              <surname>Mcdonnell</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Knight</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mckay</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Butler</surname>
              <given-names>SP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>In vivo deposition study of a new generation nebuliser utilising hybrid resonant acoustic (HYDRA) technology</article-title>
          <source>Int J Pharm</source>
          <year>2020</year>
          <volume>580</volume>
          <fpage>119196</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119196</pub-id>
          <pub-id pub-id-type="pmid">32145340</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shoyele</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Slowey</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery</article-title>
          <source>Int J Pharm</source>
          <year>2006</year>
          <volume>314</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2006.02.014</pub-id>
          <pub-id pub-id-type="pmid">16563674</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quinn</surname>
              <given-names>&#xC9;&#xC1;</given-names>
            </name>
            <name>
              <surname>Forbes</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Oliver</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Mckenzie</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Purewal</surname>
              <given-names>TS</given-names>
            </name>
          </person-group>
          <article-title>Protein conformational stability in the hydrofluoroalkane propellants tetrafluoroethane and heptafluoropropane analysed by Fourier transform Raman spectroscopy</article-title>
          <source>Int J Pharm</source>
          <year>1999</year>
          <volume>186</volume>
          <issue>1</issue>
          <fpage>31</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="doi">10.1016/s0378-5173(99)00135-0</pub-id>
          <pub-id pub-id-type="pmid">10469921</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ganguly</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Carlander</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Garessus</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Frid&#xE9;n</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eriksson</surname>
              <given-names>UG</given-names>
            </name>
            <name>
              <surname>Tehler</surname>
              <given-names>U</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Computational modeling of lung deposition of inhaled particles in chronic obstructive pulmonary disease (COPD) patients: identification of gaps in knowledge and data</article-title>
          <source>Crit Rev Toxicol</source>
          <year>2019</year>
          <volume>49</volume>
          <issue>2</issue>
          <fpage>160</fpage>
          <lpage>173</lpage>
          <pub-id pub-id-type="doi">10.1080/10408444.2019.1584153</pub-id>
          <pub-id pub-id-type="pmid">31012388</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Y-B</given-names>
            </name>
            <name>
              <surname>Watts</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>RO</given-names>
            </name>
          </person-group>
          <article-title>The impact of pulmonary diseases on the fate of inhaled medicines&#x2014;a review</article-title>
          <source>Int J Pharm</source>
          <year>2014</year>
          <volume>461</volume>
          <issue>1&#x2013;2</issue>
          <fpage>112</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.11.042</pub-id>
          <pub-id pub-id-type="pmid">24291124</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karra</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Swindle</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Drug delivery for traditional and emerging airway models</article-title>
          <source>Organs-on-a-Chip.</source>
          <year>2019</year>
          <volume>1</volume>
          <fpage>100002</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ooc.2020.100002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roy</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Vij</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Nanodelivery in airway diseases: challenges and therapeutic applications</article-title>
          <source>Nanomedicine.</source>
          <year>2010</year>
          <volume>6</volume>
          <issue>2</issue>
          <fpage>237</fpage>
          <lpage>244</lpage>
          <pub-id pub-id-type="doi">10.1016/j.nano.2009.07.001</pub-id>
          <pub-id pub-id-type="pmid">19616124</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Y-Y</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Suk</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Pace</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cone</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hanes</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that &#x201C;slip&#x201D; through the human mucus barrier</article-title>
          <source>Angew Chem Int Ed Engl.</source>
          <year>2008</year>
          <volume>47</volume>
          <issue>50</issue>
          <fpage>9726</fpage>
          <lpage>9729</lpage>
          <pub-id pub-id-type="doi">10.1002/anie.200803526</pub-id>
          <pub-id pub-id-type="pmid">18979480</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Dawson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>SK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2009</year>
          <volume>106</volume>
          <issue>46</issue>
          <fpage>19268</fpage>
          <lpage>19273</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0905998106</pub-id>
          <pub-id pub-id-type="pmid">19901335</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maisel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Chattopadhyay</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cone</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ensign</surname>
              <given-names>LM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nanoparticles coated with high molecular weight PEG penetrate mucus and provide uniform vaginal and colorectal distribution in vivo</article-title>
          <source>Nanomedicine.</source>
          <year>2016</year>
          <volume>11</volume>
          <issue>11</issue>
          <fpage>1337</fpage>
          <lpage>1343</lpage>
          <pub-id pub-id-type="doi">10.2217/nnm-2016-0047</pub-id>
          <pub-id pub-id-type="pmid">27171816</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sch&#xFC;rch</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gehr</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hof</surname>
              <given-names>VI</given-names>
            </name>
            <name>
              <surname>Geiser</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Surfactant displaces particles toward the epithelium in airways and alveoli</article-title>
          <source>Respir Physiol</source>
          <year>1990</year>
          <volume>80</volume>
          <issue>1</issue>
          <fpage>17</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1016/0034-5687(90)90003-h</pub-id>
          <pub-id pub-id-type="pmid">2367749</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schurch</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gehr</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary surfactant: surface properties and function of alveolar and airway surfactant</article-title>
          <source>Pure Appl Chem</source>
          <year>1992</year>
          <volume>64</volume>
          <issue>11</issue>
          <fpage>1745</fpage>
          <lpage>1750</lpage>
          <pub-id pub-id-type="doi">10.1351/pac199264111745</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forier</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Messiaen</surname>
              <given-names>A-S</given-names>
            </name>
            <name>
              <surname>Raemdonck</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Deschout</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rejman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Baets</surname>
              <given-names>FD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy</article-title>
          <source>Nanomedicine.</source>
          <year>2013</year>
          <volume>8</volume>
          <issue>6</issue>
          <fpage>935</fpage>
          <lpage>949</lpage>
          <pub-id pub-id-type="doi">10.2217/nnm.12.129</pub-id>
          <pub-id pub-id-type="pmid">23035662</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Chisholm</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhuang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protein nanocages that penetrate airway mucus and tumor tissue</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2017</year>
          <volume>114</volume>
          <issue>32</issue>
          <fpage>E6595</fpage>
          <lpage>E6602</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1705407114</pub-id>
          <pub-id pub-id-type="pmid">28739953</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Boylan</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Suk</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hwangbo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schuster</surname>
              <given-names>BS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Use of single-site-functionalized PEG dendrons to prepare gene vectors that penetrate human mucus barriers</article-title>
          <source>Angew Chem Int Ed Engl</source>
          <year>2013</year>
          <volume>52</volume>
          <issue>14</issue>
          <fpage>3985</fpage>
          <lpage>3988</lpage>
          <pub-id pub-id-type="doi">10.1002/anie.201208556</pub-id>
          <pub-id pub-id-type="pmid">23460577</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lai</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>O'hanlon</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Harrold</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Man</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y-Y</given-names>
            </name>
            <name>
              <surname>Cone</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2007</year>
          <volume>104</volume>
          <issue>5</issue>
          <fpage>1482</fpage>
          <lpage>1487</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0608611104</pub-id>
          <pub-id pub-id-type="pmid">17244708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mastorakos</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>ALD</given-names>
            </name>
            <name>
              <surname>Chisholm</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Boyle</surname>
              <given-names>MP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2015</year>
          <volume>112</volume>
          <issue>28</issue>
          <fpage>8720</fpage>
          <lpage>8725</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1502281112</pub-id>
          <pub-id pub-id-type="pmid">26124127</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Osman</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Chisholm</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy</article-title>
          <source>J Control Release</source>
          <year>2018</year>
          <volume>285</volume>
          <fpage>35</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jconrel.2018.07.001</pub-id>
          <pub-id pub-id-type="pmid">30004000</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suk</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Trehan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Cebotaru</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Woodward</surname>
              <given-names>OM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier</article-title>
          <source>J Control Release</source>
          <year>2014</year>
          <volume>178</volume>
          <fpage>8</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.01.007</pub-id>
          <pub-id pub-id-type="pmid">24440664</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suk</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y-Y</given-names>
            </name>
            <name>
              <surname>Ensign</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Zeitlin</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Boyle</surname>
              <given-names>MP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles</article-title>
          <source>Biomaterials.</source>
          <year>2009</year>
          <volume>30</volume>
          <issue>13</issue>
          <fpage>2591</fpage>
          <lpage>2597</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biomaterials.2008.12.076</pub-id>
          <pub-id pub-id-type="pmid">19176245</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandes</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Vanbever</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Preclinical models for pulmonary drug delivery</article-title>
          <source>Expert Opin Drug Deliv.</source>
          <year>2009</year>
          <volume>6</volume>
          <issue>11</issue>
          <fpage>1231</fpage>
          <lpage>1245</lpage>
          <pub-id pub-id-type="doi">10.1517/17425240903241788</pub-id>
          <pub-id pub-id-type="pmid">19852680</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cipolla</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Gonda</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Formulation technology to repurpose drugs for inhalation delivery</article-title>
          <source>Drug Discov Today Ther Strateg</source>
          <year>2011</year>
          <volume>8</volume>
          <issue>3&#x2013;4</issue>
          <fpage>123</fpage>
          <lpage>130</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ddstr.2011.07.001</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cipolla</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Will pulmonary drug delivery for systemic application ever fulfill its rich promise?</article-title>
          <source>Expert Opin Drug Deliv.</source>
          <year>2016</year>
          <volume>13</volume>
          <issue>10</issue>
          <fpage>1337</fpage>
          <lpage>1340</lpage>
          <pub-id pub-id-type="doi">10.1080/17425247.2016.1218466</pub-id>
          <pub-id pub-id-type="pmid">27464271</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henry</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Mudaliar</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Iii</surname>
              <given-names>WCH</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>An</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects</article-title>
          <source>Diabetes Care</source>
          <year>2003</year>
          <volume>26</volume>
          <issue>3</issue>
          <fpage>764</fpage>
          <lpage>769</lpage>
          <pub-id pub-id-type="doi">10.2337/diacare.26.3.764</pub-id>
          <pub-id pub-id-type="pmid">12610035</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diderichsen</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Cleton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ribbing</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Characterizing systemic exposure of inhaled drugs: application to the long-acting &#x3B2;2-agonist PF-00610355</article-title>
          <source>Clin Pharmacokinet</source>
          <year>2013</year>
          <volume>52</volume>
          <issue>6</issue>
          <fpage>443</fpage>
          <lpage>452</lpage>
          <pub-id pub-id-type="doi">10.1007/s40262-013-0048-7</pub-id>
          <pub-id pub-id-type="pmid">23494982</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Depreter</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pilcer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Amighi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Inhaled proteins: challenges and perspectives</article-title>
          <source>Int J Pharm</source>
          <year>2013</year>
          <volume>447</volume>
          <issue>1&#x2013;2</issue>
          <fpage>251</fpage>
          <lpage>280</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.02.031</pub-id>
          <pub-id pub-id-type="pmid">23499756</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bandi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Upadhyay</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Mallela</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>2D NMR analysis of the effect of asparagine deamidation versus methionine oxidation on the structure, stability, aggregation, and function of a therapeutic protein</article-title>
          <source>Mol Pharm</source>
          <year>2019</year>
          <volume>16</volume>
          <issue>11</issue>
          <fpage>4621</fpage>
          <lpage>4635</lpage>
          <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00719</pub-id>
          <pub-id pub-id-type="pmid">31483994</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jaspers</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2015</year>
          <volume>308</volume>
          <issue>12</issue>
          <fpage>L1189&#x2013;L1201</fpage>
          <pub-id pub-id-type="doi">10.1152/ajplung.00028.2015</pub-id>
          <pub-id pub-id-type="pmid">25888573</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <mixed-citation publication-type="other">Chakraborti S, Sarkar J, Pramanik PK, Chakraborti T. Role of proteases in lung disease: a brief overview. In: Proteases in human diseases. 2017:333&#x2013;74. 10.1007/978-981-10-3162-5_16.</mixed-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pandey</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>De</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mishra</surname>
              <given-names>PK</given-names>
            </name>
          </person-group>
          <article-title>Role of proteases in chronic obstructive pulmonary disease</article-title>
          <source>Front Pharmacol</source>
          <year>2017</year>
          <volume>8</volume>
          <fpage>512</fpage>
          <pub-id pub-id-type="doi">10.3389/fphar.2017.00512</pub-id>
          <pub-id pub-id-type="pmid">28848433</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greene</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Mcelvaney</surname>
              <given-names>NG</given-names>
            </name>
          </person-group>
          <article-title>Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery</article-title>
          <source>Br J Pharmacol</source>
          <year>2009</year>
          <volume>158</volume>
          <issue>4</issue>
          <fpage>1048</fpage>
          <lpage>1058</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00448.x</pub-id>
          <pub-id pub-id-type="pmid">19845686</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Perez-Luna</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Karuri</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>PEGylation of lysine residues improves the proteolytic stability of fibronectin while retaining biological activity</article-title>
          <source>Biotechnol J</source>
          <year>2014</year>
          <volume>9</volume>
          <issue>8</issue>
          <fpage>1033</fpage>
          <lpage>1043</lpage>
          <pub-id pub-id-type="doi">10.1002/biot.201400115</pub-id>
          <pub-id pub-id-type="pmid">24803071</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lasagna-Reeves</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Clos</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Midoro-Hiriuti</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Goldblum</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Kayed</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Inhaled insulin forms toxic pulmonary amyloid aggregates</article-title>
          <source>Endocrinology.</source>
          <year>2010</year>
          <volume>151</volume>
          <issue>10</issue>
          <fpage>4717</fpage>
          <lpage>4724</lpage>
          <pub-id pub-id-type="doi">10.1210/en.2010-0457</pub-id>
          <pub-id pub-id-type="pmid">20685871</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Almeida</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Grenha</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>das Neves</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sarmento</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Technosphere&#xAE;: an inhalation system for pulmonary delivery of biopharmaceuticals</article-title>
          <source>Mucosal delivery of biopharmaceuticals</source>
          <year>2014</year>
          <publisher-loc>Boston</publisher-loc>
          <publisher-name>Springer</publisher-name>
          <fpage>483</fpage>
          <lpage>498</lpage>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Filipe</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Jiskoot</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Basmeleh</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Halim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schellekens</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Brinks</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice</article-title>
          <source>MAbs.</source>
          <year>2012</year>
          <volume>4</volume>
          <issue>6</issue>
          <fpage>740</fpage>
          <lpage>752</lpage>
          <pub-id pub-id-type="doi">10.4161/mabs.22066</pub-id>
          <pub-id pub-id-type="pmid">22951518</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Samra</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bhambhani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pipkin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zimmerer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Joshi</surname>
              <given-names>SB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The effects of substituted cyclodextrins on the colloidal and conformational stability of selected proteins</article-title>
          <source>J Pharm Sci</source>
          <year>2010</year>
          <volume>99</volume>
          <issue>6</issue>
          <fpage>2800</fpage>
          <lpage>2818</lpage>
          <pub-id pub-id-type="doi">10.1002/jps.22053</pub-id>
          <pub-id pub-id-type="pmid">20049940</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pilcer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Amighi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Formulation strategy and use of excipients in pulmonary drug delivery</article-title>
          <source>Int J Pharm</source>
          <year>2010</year>
          <volume>392</volume>
          <issue>1&#x2013;2</issue>
          <fpage>1</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2010.03.017</pub-id>
          <pub-id pub-id-type="pmid">20223286</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>An</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Shim</surname>
              <given-names>WS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of pH and buffer concentration on the thermal stability of etanercept using DSC and DLS</article-title>
          <source>Biol Pharm Bull</source>
          <year>2014</year>
          <volume>37</volume>
          <issue>5</issue>
          <fpage>808</fpage>
          <lpage>816</lpage>
          <pub-id pub-id-type="doi">10.1248/bpb.b13-00926</pub-id>
          <pub-id pub-id-type="pmid">24790003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hou</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Shu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Practical, regulatory and clinical considerations for development of inhalation drug products</article-title>
          <source>Asian J Pharm Sci</source>
          <year>2015</year>
          <volume>10</volume>
          <issue>6</issue>
          <fpage>490</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajps.2015.08.008</pub-id>
        </element-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>&#xD3;g&#xE1;in</surname>
              <given-names>ON</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tajber</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Corrigan</surname>
              <given-names>OI</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Particle engineering of materials for oral inhalation by dry powder inhalers. I&#x2014;particles of sugar excipients (trehalose and raffinose) for protein delivery</article-title>
          <source>Int J Pharm</source>
          <year>2011</year>
          <volume>405</volume>
          <issue>1&#x2013;2</issue>
          <fpage>23</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2010.11.039</pub-id>
          <pub-id pub-id-type="pmid">21129458</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sellers</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Sievers</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Carpenter</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO2-assisted aerosolization</article-title>
          <source>J Pharm Sci</source>
          <year>2001</year>
          <volume>90</volume>
          <issue>6</issue>
          <fpage>785</fpage>
          <lpage>797</lpage>
          <pub-id pub-id-type="doi">10.1002/jps.1032</pub-id>
          <pub-id pub-id-type="pmid">11357179</pub-id>
        </element-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Pikal</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of protein stabilization in the solid state</article-title>
          <source>J Pharm Sci</source>
          <year>2009</year>
          <volume>98</volume>
          <issue>9</issue>
          <fpage>2886</fpage>
          <lpage>2908</lpage>
          <pub-id pub-id-type="doi">10.1002/jps.21825</pub-id>
          <pub-id pub-id-type="pmid">19569054</pub-id>
        </element-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ajmera</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scherlie&#xDF;</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Stabilisation of proteins via mixtures of amino acids during spray drying</article-title>
          <source>Int J Pharm</source>
          <year>2014</year>
          <volume>463</volume>
          <issue>1</issue>
          <fpage>98</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.01.002</pub-id>
          <pub-id pub-id-type="pmid">24412336</pub-id>
        </element-citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Okuda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>X-Y</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>H-K</given-names>
            </name>
          </person-group>
          <article-title>Amorphous powders for inhalation drug delivery</article-title>
          <source>Adv Drug Deliv Rev</source>
          <year>2016</year>
          <volume>100</volume>
          <fpage>102</fpage>
          <lpage>115</lpage>
          <pub-id pub-id-type="doi">10.1016/j.addr.2016.01.002</pub-id>
          <pub-id pub-id-type="pmid">26780404</pub-id>
        </element-citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guichard</surname>
              <given-names>M-J</given-names>
            </name>
            <name>
              <surname>Leal</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Vanbever</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals</article-title>
          <source>Curr Opin Colloid Interface Sci</source>
          <year>2017</year>
          <volume>31</volume>
          <fpage>43</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cocis.2017.08.001</pub-id>
        </element-citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swierczewska</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>What is the future of PEGylated therapies?</article-title>
          <source>Expert Opin Emerg Drugs</source>
          <year>2015</year>
          <volume>20</volume>
          <issue>4</issue>
          <fpage>531</fpage>
          <lpage>536</lpage>
          <pub-id pub-id-type="doi">10.1517/14728214.2015.1113254</pub-id>
          <pub-id pub-id-type="pmid">26583759</pub-id>
        </element-citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <mixed-citation publication-type="other">Bel&#xE9;n LH, Rangel-Yagui CDO, Lissabet JFB, Effer B, Lee-Estevez M, Pessoa A, et al. From synthesis to characterization of site-selective PEGylated proteins. Front Pharmacol. 2019;10. 10.3389/fphar.2019.01450.</mixed-citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freches</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Patil</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Franco</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Uyttenhove</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Heywood</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vanbever</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>PEGylation prolongs the pulmonary retention of an anti-IL-17A fab&#x2019; antibody fragment after pulmonary delivery in three different species</article-title>
          <source>Int J Pharm</source>
          <year>2017</year>
          <volume>521</volume>
          <issue>1&#x2013;2</issue>
          <fpage>120</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.02.021</pub-id>
          <pub-id pub-id-type="pmid">28192159</pub-id>
        </element-citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loira-Pastoriza</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Todoroff</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vanbever</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Delivery strategies for sustained drug release in the lungs</article-title>
          <source>Adv Drug Deliv Rev</source>
          <year>2014</year>
          <volume>75</volume>
          <fpage>81</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="doi">10.1016/j.addr.2014.05.017</pub-id>
          <pub-id pub-id-type="pmid">24915637</pub-id>
        </element-citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pontes</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Grenha</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Multifunctional nanocarriers for lung drug delivery</article-title>
          <source>Nanomaterials.</source>
          <year>2020</year>
          <volume>10</volume>
          <issue>2</issue>
          <fpage>183</fpage>
          <pub-id pub-id-type="doi">10.3390/nano10020183</pub-id>
        </element-citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tawfeek</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Iftikhar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mohammed</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Shabir</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Somavarapu</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dry powder inhalation of macromolecules using novel PEG-co-polyester microparticle carriers</article-title>
          <source>Int J Pharm</source>
          <year>2013</year>
          <volume>441</volume>
          <issue>1&#x2013;2</issue>
          <fpage>611</fpage>
          <lpage>619</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.10.036</pub-id>
          <pub-id pub-id-type="pmid">23124106</pub-id>
        </element-citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Osman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jamal</surname>
              <given-names>KTA</given-names>
            </name>
            <name>
              <surname>Kan</surname>
              <given-names>P-L</given-names>
            </name>
            <name>
              <surname>Awad</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mortada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>El-Shamy</surname>
              <given-names>A-E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhalable DNase I microparticles engineered with biologically active excipients</article-title>
          <source>Pulm Pharmacol Ther</source>
          <year>2013</year>
          <volume>26</volume>
          <issue>6</issue>
          <fpage>700</fpage>
          <lpage>709</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pupt.2013.07.010</pub-id>
          <pub-id pub-id-type="pmid">23933140</pub-id>
        </element-citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El-Sherbiny</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>El-Baz</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Yacoub</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Inhaled nano- and microparticles for drug delivery</article-title>
          <source>Glob Cardiol Sci Pract</source>
          <year>2015</year>
          <volume>2015</volume>
          <issue>1</issue>
          <fpage>2</fpage>
          <pub-id pub-id-type="doi">10.5339/gcsp.2015.2</pub-id>
          <pub-id pub-id-type="pmid">26779496</pub-id>
        </element-citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sung</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Pulliam</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Nanoparticles for drug delivery to the lungs</article-title>
          <source>Trends Biotechnol</source>
          <year>2007</year>
          <volume>25</volume>
          <issue>12</issue>
          <fpage>563</fpage>
          <lpage>570</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tibtech.2007.09.005</pub-id>
          <pub-id pub-id-type="pmid">17997181</pub-id>
        </element-citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yhee</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Im</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nho</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Advanced therapeutic strategies for chronic lung disease using nanoparticle-based drug delivery</article-title>
          <source>J Clin Med</source>
          <year>2016</year>
          <volume>5</volume>
          <issue>9</issue>
          <fpage>82</fpage>
          <pub-id pub-id-type="doi">10.3390/jcm5090082</pub-id>
        </element-citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <mixed-citation publication-type="other">Wilson EM, Luft JC, Desimone JM. Formulation of high-performance dry powder aerosols for pulmonary protein delivery. Pharm Res. 2018;35(10). 10.1007/s11095-018-2452-z.</mixed-citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mack</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fromen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tully</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications</article-title>
          <source>J Drug Deliv</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1155/2012/941243</pub-id>
        </element-citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lim</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Tiemann</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Hunstad</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Elsabahy</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wooley</surname>
              <given-names>KL</given-names>
            </name>
          </person-group>
          <article-title>Polymeric nanoparticles in development for treatment of pulmonary infectious diseases</article-title>
          <source>Wiley Interdiscip Rev Nanomed Nanobiotechnol</source>
          <year>2016</year>
          <volume>8</volume>
          <issue>6</issue>
          <fpage>842</fpage>
          <lpage>871</lpage>
          <pub-id pub-id-type="doi">10.1002/wnan.1401</pub-id>
          <pub-id pub-id-type="pmid">27016134</pub-id>
        </element-citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Geiser</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Update on macrophage clearance of inhaled micro- and nanoparticles</article-title>
          <source>J Aerosol Med Pulm Drug Deliv.</source>
          <year>2010</year>
          <volume>23</volume>
          <issue>4</issue>
          <fpage>207</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="doi">10.1089/jamp.2009.0797</pub-id>
          <pub-id pub-id-type="pmid">20109124</pub-id>
        </element-citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ahsan</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome</article-title>
          <source>Eur J Pharm Biopharm</source>
          <year>2015</year>
          <volume>89</volume>
          <fpage>163</fpage>
          <lpage>174</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejpb.2014.12.001</pub-id>
          <pub-id pub-id-type="pmid">25497488</pub-id>
        </element-citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dickinson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gumbleton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kellaway</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages</article-title>
          <source>Int J Pharm</source>
          <year>2002</year>
          <volume>236</volume>
          <issue>1&#x2013;2</issue>
          <fpage>65</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="doi">10.1016/s0378-5173(02)00016-9</pub-id>
          <pub-id pub-id-type="pmid">11891071</pub-id>
        </element-citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shen</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Fromen</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Kai</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Luft</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Rahhal</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>GR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Distribution and cellular uptake of PEGylated polymeric particles in the lung towards cell-specific targeted delivery</article-title>
          <source>Pharm Res</source>
          <year>2015</year>
          <volume>32</volume>
          <issue>10</issue>
          <fpage>3248</fpage>
          <lpage>3260</lpage>
          <pub-id pub-id-type="doi">10.1007/s11095-015-1701-7</pub-id>
          <pub-id pub-id-type="pmid">26002743</pub-id>
        </element-citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Traini</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Drug delivery for tuberculosis: is inhaled therapy the key to success?</article-title>
          <source>Ther Deliv</source>
          <year>2017</year>
          <volume>8</volume>
          <issue>10</issue>
          <fpage>819</fpage>
          <lpage>821</lpage>
          <pub-id pub-id-type="doi">10.4155/tde-2017-0050</pub-id>
          <pub-id pub-id-type="pmid">28944739</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1663-9812</issn>
      <publisher>
        <publisher-name>Frontiers Media S.A.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33162887</article-id>
      <article-id pub-id-type="pmc">7583590</article-id>
      <article-id pub-id-type="doi">10.3389/fphar.2020.572009</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Pharmacology</subject>
          <subj-group>
            <subject>Review</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chiang</surname>
            <given-names>Chih-Chao</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn003">
            <sup>&#x2020;</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/723359"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Korinek</surname>
            <given-names>Michal</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn003">
            <sup>&#x2020;</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/442713"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>Wei-Jen</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn003">
            <sup>&#x2020;</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/723396"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hwang</surname>
            <given-names>Tsong-Long</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
          <xref ref-type="aff" rid="aff9">
            <sup>9</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn001">
            <sup>*</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/104196"/>
        </contrib>
      </contrib-group>
      <aff id="aff1"><sup>1</sup><institution>Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University</institution>, <addr-line>Taoyuan</addr-line>, <country>Taiwan</country></aff>
      <aff id="aff2"><sup>2</sup><institution>Puxin Fengze Chinese Medicine Clinic</institution>, <addr-line>Taoyuan</addr-line>, <country>Taiwan</country></aff>
      <aff id="aff3"><sup>3</sup><institution>Graduate Institute of Natural Products, College of Medicine, Chang Gung University</institution>, <addr-line>Taoyuan</addr-line>, <country>Taiwan</country></aff>
      <aff id="aff4"><sup>4</sup><institution>Research Center for Chinese Herbal Medicine, Research Center for Food and Cosmetic Safety, and Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology</institution>, <addr-line>Taoyuan</addr-line>, <country>Taiwan</country></aff>
      <aff id="aff5"><sup>5</sup><institution>Department of Biotechnology, College of Life Science, Kaohsiung Medical University</institution>, <addr-line>Kaohsiung</addr-line>, <country>Taiwan</country></aff>
      <aff id="aff6"><sup>6</sup><institution>School of Traditional Chinese Medicine, College of Medicine, Chang Gung University</institution>, <addr-line>Taoyuan</addr-line>, <country>Taiwan</country></aff>
      <aff id="aff7"><sup>7</sup><institution>Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital</institution>, <addr-line>Taoyuan</addr-line>, <country>Taiwan</country></aff>
      <aff id="aff8"><sup>8</sup><institution>Department of Anesthesiology, Chang Gung Memorial Hospital</institution>, <addr-line>Taoyuan</addr-line>, <country>Taiwan</country></aff>
      <aff id="aff9"><sup>9</sup><institution>Department of Chemical Engineering, Ming Chi University of Technology</institution>, <addr-line>New Taipei City</addr-line>, <country>Taiwan</country></aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Siddappa N. Byrareddy, University of Nebraska Omaha, United States</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Betsy J. Barnes, Feinstein Institute for Medical Research, United States; Hitendra S. Chand, Florida International University, United States</p>
        </fn>
        <corresp id="fn001">*Correspondence: Tsong-Long Hwang, <email xlink:href="mailto:htl@mail.cgu.edu.tw" xlink:type="simple">htl@mail.cgu.edu.tw</email></corresp>
        <fn fn-type="other" id="fn002">
          <p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p>
        </fn>
        <fn fn-type="equal" id="fn003">
          <p>&#x2020;These authors have contributed equally to this work</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>09</day>
        <month>10</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>09</day>
        <month>10</month>
        <year>2020</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>11</volume>
      <elocation-id>572009</elocation-id>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>6</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>9</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 Chiang, Korinek, Cheng and Hwang</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Chiang, Korinek, Cheng and Hwang</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>This review describes targeting neutrophils as a potential therapeutic strategy for acute respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID-19), a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutrophil counts are significantly elevated in patients with COVID-19 and significantly correlated with disease severity. The neutrophil-to-lymphocyte ratio can serve as a clinical marker for predicting fatal complications related to ARDS in patients with COVID-19. Neutrophil-associated inflammation plays a critical pathogenic role in ARDS. The effector functions of neutrophils, acting as respiratory burst oxidants, granule proteases, and neutrophil extracellular traps, are linked to the pathogenesis of ARDS. Hence, neutrophils can not only be used as pathogenic markers but also as candidate drug targets for COVID-19 associated ARDS.</p>
      </abstract>
      <kwd-group>
        <kwd>coronavirus disease 2019</kwd>
        <kwd>severe acute respiratory syndrome coronavirus 2</kwd>
        <kwd>acute respiratory distress syndrome</kwd>
        <kwd>neutrophils</kwd>
        <kwd>neutrophil extracellular trap</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source id="cn001">Ministry of Science and Technology, Taiwan<named-content content-type="fundref-id">10.13039/501100004663</named-content></funding-source>
          <award-id rid="cn001">MOST 108-2320-B-255-003-MY3, MOST 109-2327-B-255-001, MOST 109-2327-B-182-002</award-id>
        </award-group>
        <award-group>
          <funding-source id="cn002">Chang Gung Memorial Hospital<named-content content-type="fundref-id">10.13039/100012553</named-content></funding-source>
          <award-id rid="cn002">BMRP450, CORPG5K0031</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="1"/>
        <equation-count count="0"/>
        <ref-count count="155"/>
        <page-count count="14"/>
        <word-count count="5565"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped, nonsegmented, positive-sense RNA &#x3B2;-coronavirus, is the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic (<xref rid="B44" ref-type="bibr">Guo et al., 2020</xref>). SARS-CoV-2 is primarily transmitted by respiratory droplets and airway secretions through close contact with infected individuals (<xref rid="B66" ref-type="bibr">Lee and Hsueh, 2020</xref>). The main manifestations of COVID-19 are fever, cough, dyspnea, sore throat, fatigue, diarrhea (<xref rid="B40" ref-type="bibr">Guan et al., 2020</xref>), headache, nausea, vomiting (<xref rid="B72" ref-type="bibr">Li Y. C. et al., 2020</xref>), anosmia (loss of smell), and ageusia (loss of taste) (<xref rid="B131" ref-type="bibr">Vaira et al., 2020</xref>). Severe complications include acute respiratory distress syndrome (ARDS), septic shock, coagulation dysfunction, and multiple organ failure (<xref rid="B135" ref-type="bibr">Wang et al., 2020</xref>). The elderly (&gt;65 years of age) and individuals with underlying secondary diseases, such as chronic obstructive pulmonary disease (COPD), cardiovascular disease, hypertension, and diabetes mellitus, tend to have severe complications and higher mortality rates (<xref rid="B145" ref-type="bibr">Yang et al., 2020</xref>). An effective therapy for COVID-19 remains under investigation (<xref rid="B80" ref-type="bibr">Lu, 2020</xref>).</p>
      <p>Neutrophils are pivotal effector cells in the innate immune defense against infections in humans. Neutrophils migrate to infected tissues in multiple ways including rolling, adhesion, crawling, and transmigration. Subsequently, they are activated and exert inflammatory responses, such as phagocytosis, respiratory burst with superoxide anion production, degranulation with protease release, and NETosis with neutrophil extracellular trap (NET) formation (<xref rid="B73" ref-type="bibr">Liew and Kubes, 2019</xref>). Neutrophil inflammatory responses may be considered a double-edged sword; although they protect against infection, they also cause severe tissue damage. Activated neutrophils are involved in many acute and chronic inflammatory diseases as well as autoimmune disorders, such as respiratory diseases (ARDS, COPD, and asthma), cardiovascular diseases (atherosclerosis and thrombosis) (<xref rid="B94" ref-type="bibr">N&#xE9;meth et al., 2020</xref>), gastrointestinal diseases (inflammatory bowel disease and autoimmune hepatitis) (<xref rid="B51" ref-type="bibr">Honda and Kubes, 2018</xref>), neurological diseases (multiple sclerosis and Alzheimer&#x2019;s disease) (<xref rid="B32" ref-type="bibr">Dong et al., 2018</xref>; <xref rid="B139" ref-type="bibr">Woodberry et al., 2018</xref>), skin diseases (psoriasis and Beh&#xE7;et&#x2019;s disease) (<xref rid="B109" ref-type="bibr">Safi et al., 2018</xref>; <xref rid="B28" ref-type="bibr">Chiang et al., 2019</xref>), and metabolic diseases (diabetes mellitus and obesity) (<xref rid="B124" ref-type="bibr">Talukdar et al., 2012</xref>; <xref rid="B19" ref-type="bibr">Brotfain et al., 2015</xref>).</p>
      <p>During the incubation period and nonsevere stage of COVID-19, the host immune system successfully destroys the virus and protects against disease progression. However, in the severe stage, SARS-CoV-2 replicates rapidly and causes massive tissue damage, particularly in the lungs. Thereafter, the destroyed cells cause a dysregulated inflammatory response and cytokine storm, leading to ARDS and other severe complications (<xref rid="B112" ref-type="bibr">Shi H. et al., 2020</xref>). Therefore, therapeutic strategies targeting hyperactivated neutrophils may be useful for treating COVID-19 associated ARDS. It has been suggested that a combination of antiviral and anti-inflammatory therapies effectively inhibit SARS-CoV-2 activity and reduce dysregulated immune reactions in COVID-19 (<xref rid="B117" ref-type="bibr">Stebbing et al., 2020</xref>).</p>
      <p>In this review, we describe the roles of neutrophils in COVID-19 associated ARDS and provide an overview of suitable therapeutic strategies for targeting neutrophils. The particular focus is on clinical drugs and clinical trial drugs shown to affect neutrophil function (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>).</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Drugs targeting neutrophils.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">Drug</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Neutrophil <break/>Target</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Clinical Stage</th>
              <th valign="top" align="left" rowspan="1" colspan="1">Approved Indication (Approved target)</th>
              <th valign="top" align="left" rowspan="1" colspan="1">Clinical Trial (Disease, Phase)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Clinical Trial for COVID-19 (Phase)<sup>1</sup></th>
              <th valign="top" align="center" rowspan="1" colspan="1">Reference</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Sivelestat (Elaspol, ONO 5046)</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>NE</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Korea and Japan-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Acute lung injury, ARDS (elastase)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B2" ref-type="bibr">Aikawa and Kawasaki, 2014</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Alvelestat (AZD9668)</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>NE</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT03636347<break/>(COPD, phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B13" ref-type="bibr">Barnes et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>BAY 85-8501</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>NE</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT01818544<break/>(non-CF bronchiectasis, phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B136" ref-type="bibr">Watz et al., 2019</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Lonodelestat (POL6014)</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>NE</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT03748199<break/>(CF, phase 1)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B14" ref-type="bibr">Barth et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>CHF6333</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>NE</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT03056326, NCT04010799<break/>(non-CF bronchiectasis, phase 1)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B37" ref-type="bibr">Gramegna et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Elafin</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>NE</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT02944279<break/>(ARDS, phase 1)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B13" ref-type="bibr">Barnes et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold><italic>N</italic>-Acetylcysteine</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Respiratory burst and ROS</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Mucolytic (glutathione synthetase)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04419025 (phase 4)<break/>NCT04455243 (phase 3) NCT04374461<break/>(phase 2)<break/>and 3 more</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B6" ref-type="bibr">Allegra et al., 2002</xref>; <xref rid="B150" ref-type="bibr">Zhang et al., 2017</xref>; <xref rid="B9" ref-type="bibr">Andreou et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Brensocatib (AZD7986)</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>DPP1</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT03218917<break/>(non-CF bronchiectasis, phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">EudraCT 2020-001643-13 (phase 3)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B99" ref-type="bibr">Palm&#xE9;r et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Dipyridamole</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>PDEs</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Prevention of postoperative thromboembolism, stroke (PDEs, adenosine receptor)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04410328 (phase 3) NCT04424901 (phase 2) NCT04391179<break/>(phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B4" ref-type="bibr">Ali et al., 2019</xref>; <xref rid="B77" ref-type="bibr">Liu et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Pentoxifylline</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>PDEs</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Blood flow (PDEs, adenosine receptor)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04433988<break/>(phase 1 and 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B48" ref-type="bibr">Hendry et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Roflumilast</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>PDE4</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">COPD (PDE4)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B101" ref-type="bibr">Phillips, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Apremilast</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>PDE4</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Psoriasis</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04488081 (phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B104" ref-type="bibr">Queiro Silva et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>CHF6001</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>PDE4</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT02986321<break/>(COPD, phase 2), NCT01689571<break/>(asthma, phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B113" ref-type="bibr">Singh et al., 2019</xref>; <xref rid="B101" ref-type="bibr">Phillips, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Crisaborole</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>PDE4</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Atopic dermatitis</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B46" ref-type="bibr">Hashim et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Ensifentrine (RPL554)</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>PDE4</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04027439 (COPD, phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04527471 (phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">Cazzola et al., 2019</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Disulfiram</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>GSDMD</bold><break/>(NETs)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Chronic alcoholism (aldehyde dehydrogenase)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04485130<break/>(phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B78" ref-type="bibr">Lobo-Galo et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Dornase alfa (Pulmozyme, rhDNase I)</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>DNAse</bold><break/>(NETs)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CF (DNA)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04402970<break/>(phase 3)<break/>NCT04359654<break/>(phase 2)<break/>NCT04355364<break/>(phase 3)<break/>EudraCT 2020-001492-33 (phase 3)<break/>and 5 more</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B137" ref-type="bibr">Weber et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>BMS-986253 (Humax IL-8)</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>IL-8</bold> (mAb)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT03400332 (cancer, phase 1 and 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04347226<break/>(phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B16" ref-type="bibr">Bilusic et al., 2019</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>AZD5069</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>CXCR2</bold> (receptor for IL-8)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT01255592 (bronchiectasis, phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B96" ref-type="bibr">Nicholls et al., 2015</xref>; <xref rid="B30" ref-type="bibr">Cullberg et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Danirixin (GSK1325756)</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>CXCR2</bold> (receptor for IL-8)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT03034967 (COPD, phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B81" ref-type="bibr">Madan et al., 2019</xref>; <xref rid="B14" ref-type="bibr">Barth et al., 2020</xref>; <xref rid="B65" ref-type="bibr">Lazaar et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Navarixin (SCH527123)</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>CXCR2</bold> (receptor for IL-8)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Clinical trial</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT00688467<break/>(allergen-induced asthma, phase 2)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B50" ref-type="bibr">Holz et al., 2010</xref>; <xref rid="B128" ref-type="bibr">Todd et al., 2016</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Ixekizumab</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>IL-17A</bold> (mAb)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Psoriasis (IL-17A)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B20" ref-type="bibr">Bulat et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Secukinumab</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>IL-17A</bold> (mAb)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Autoimmune diseases, RA, and psoriasis (IL-17A)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04403243<break/>(phase 2)<break/>EudraCT 2020-001246-18 (phase 4)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B20" ref-type="bibr">Bulat et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Brodalumab</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>IL-17A receptor</bold> (mAb)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Autoimmune diseases, RA, and psoriasis (IL-17A receptor)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B20" ref-type="bibr">Bulat et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Anakinra</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>IL-1</bold> receptor (mAb)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Autoimmune diseases (IL-1)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04330638 (phase 3) NCT04364009 (phase 3)<break/>EudraCT 2020-001963-10 (phase 3)<break/>and 14 more</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B132" ref-type="bibr">Van De Veerdonk and Netea, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Canakinumab</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>IL-1&#x3B2;</bold> (mAb)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Autoimmune diseases (IL-1)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04362813 (phase 3)<break/>EudraCT 2020-001370-30 (phase 3)<break/>and 4 more</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B102" ref-type="bibr">Prieto-Pe&#xF1;a and Dasgupta, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Rilonacept</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>IL-1&#x3B2;</bold> (mAb)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Autoimmune diseases (IL-1)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B102" ref-type="bibr">Prieto-Pe&#xF1;a and Dasgupta, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Tocilizumab</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>IL-6 receptor</bold> (mAb)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Autoimmune diseases (IL-6 receptor)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04317092<break/>(phase 2)<break/>NCT04320615 (phase 3)<break/>EudraCT 2020-001903-17 (phase 3)<break/>and 38 more</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B41" ref-type="bibr">Guaraldi et al., 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Sarilumab (Kevzara)</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1"><bold>IL-6 receptor</bold> (mAb)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">FDA-approved</td>
              <td valign="top" align="left" rowspan="1" colspan="1">RA<break/>(IL-6 receptor)</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">NCT04315298<break/>(phase 2 and 3)<break/>EudraCT 2020-001531-27 (phase 2)<break/>and 10 more</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">Lu et al., 2020</xref>)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p><sup>1</sup>Updated on 1<sup>st</sup> September 2020 via <uri xlink:type="simple" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</uri> (US national clinical trials) and <uri xlink:type="simple" xlink:href="https://www.clinicaltrialsregister.eu">https://www.clinicaltrialsregister.eu</uri> (EU clinical trials). Additional completed or ongoing clinical trial studies in COVID-19 using the drug as main intervention are indicated. ARDS, acute respiratory distress syndrome; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; CXCR2, chemokine receptor 2; DPP1, dipeptidyl peptidase 1; GSDMD, gasdermin D; IL, interleukin; mAb, monoclonal antibody; NE, neutrophil elastase; NET, neutrophil extracellular trap; PDE, phosphodiesterase; RA, rheumatic arthritis; ROS, reactive oxygen species.</p>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="s2">
      <title>General Characteristics of COVID-19 Associated ARDS</title>
      <p>ARDS is a critical noncardiogenic pulmonary edema caused by alveolar infection or inflammation. Patients who develop ARDS suffer from a series of nonspecific manifestations, such as cough, shortness of breath, dyspnea, tachycardia, or cyanosis of the nail bed (<xref rid="B122" ref-type="bibr">Sweeney and Mcauley, 2016</xref>). If respiratory failure occurs, patients require endotracheal intubation and mechanical ventilation. The mortality rate is approximately 30%&#x2013;40% (<xref rid="B118" ref-type="bibr">Stevens et al., 2018</xref>). ARDS is diagnosed using the Berlin criteria, i.e., acute onset or worsening within one week, bilateral lung infiltrates upon chest X-ray or computed tomography scan, origin exclusive of heart failure or volume overload, disease severity based on desaturation values (severe: arterial oxygen tension/inspired oxygen fraction (PaO<sub>2</sub>/FiO<sub>2</sub>) &#x2264; 100 mmHg, moderate: PaO<sub>2</sub>/FiO<sub>2</sub> 100 to &#x2264; 200 mmHg, and mild: PaO<sub>2</sub>/FiO<sub>2</sub> 200 to &#x2264; 300 mmHg), and minimum positive end-expiratory pressure (PEEP) of 5&#xA0;cm H<sub>2</sub>O for mechanical ventilation (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>) (<xref rid="B106" ref-type="bibr">Ranieri et al., 2012</xref>). Patients with pneumonia, sepsis, gastric aspiration, or chest trauma may readily develop ARDS. Respiratory viruses, such as influenza virus, Middle East respiratory syndrome-related coronavirus (MERS), SARS-CoV, rhinovirus, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, and adenoviruses may cause viral pneumonia and severe ARDS (<xref rid="B110" ref-type="bibr">Shah and Wunderink, 2017</xref>). SARS-CoV-2 emerged in 2019 and caused the COVID-19 outbreak. Patients with COVID-19 may experience lethal pneumonia and ARDS (<xref rid="B10" ref-type="bibr">Badraoui et al., 2020</xref>; <xref rid="B153" ref-type="bibr">Zhou P. et al., 2020</xref>). Matthay et al. provided a list of recommended treatments for patients with ARDS caused by COVID-19 including adjustment of the tidal volume to 6 ml/kg predicted weight, maintenance of the plateau airway pressure at &lt;30&#xA0;cm H<sub>2</sub>O, neuromuscular blockade for patient-ventilator dyssynchrony, maintenance of a prone position during ventilation for severe ARDS, maintenance of a negative fluid balance of 0.5&#x2013;1.0 L/day, and antibiotic administration for secondary bacterial and fungal infections (<xref rid="B84" ref-type="bibr">Matthay et al., 2020</xref>). Extracorporeal membrane oxygenation (ECMO) for ARDS related to COVID-19 requires careful patient selection, intensive care, and secondary infection prevention to rescue lung injury in severe cases of ARDS (<xref rid="B86" ref-type="bibr">Mi et al., 2018</xref>; <xref rid="B105" ref-type="bibr">Ramanathan et al., 2020</xref>).</p>
      <fig id="f1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Targeting neutrophils for COVID-19 associated ARDS. Precise diagnosis of SARS-CoV-2 infection and effective management of COVID-19 are important. Application of antiviral therapy together with suppression of overly active neutrophilic inflammation appears to be a promising strategy for treating patients with COVID-19 associated ARDS. ARDS, acute respiratory distress syndrome; BW, body weight; COVID-19, coronavirus disease 2019; CT, computed tomography; ECMO, extracorporeal membrane oxygenation; EOLIA, ECMO to rescue lung injury in severe ARDS; FiO<sub>2</sub>, inspired oxygen fraction; ACE2, angiotensin-converting enzyme 2; NET, neutrophil extracellular trap; PaO<sub>2</sub>, arterial oxygen tension; PEEP, positive end-expiratory pressure; PMN, polymorphonuclear leukocyte; RBD, receptor binding domain; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.</p>
        </caption>
        <graphic xlink:href="fphar-11-572009-g001"/>
      </fig>
    </sec>
    <sec id="s3">
      <title>Contribution of Neutrophils to COVID-19 Associated ARDS</title>
      <p>SARS-CoV-2 employs human angiotensin-converting enzyme 2 (hACE2) as an entry receptor for invading host (<xref rid="B153" ref-type="bibr">Zhou P. et al., 2020</xref>). The hACE2 receptor is abundant in the respiratory airway, blood vessels, kidney, and intestine (<xref rid="B72" ref-type="bibr">Li Y. C. et al., 2020</xref>). Viral RNAs serve as pathogen-associated molecular patterns (PAMPs) and are sensed by Toll-like receptors (TLRs) such as TLR3, TLR7, TLR8, and TLR9. This results in the production of interferon &#x3B1; and &#x3B2;, along with various proinflammatory cytokines (<xref rid="B56" ref-type="bibr">Kawai and Akira, 2010</xref>). Lung inflammation initiated by proinflammatory macrophages and neutrophils causes ARDS, a critical issue in the severe form of COVID-19 (<xref rid="B112" ref-type="bibr">Shi H. et al., 2020</xref>). Patients with severe COVID-19 exhibit dysregulated immune responses, such as decreased lymphocyte levels, but increased neutrophil levels (<xref rid="B103" ref-type="bibr">Qin et al., 2020</xref>). The neutrophil count in patients with pneumonia was found higher than in patients with only mild acute respiratory disease related to COVID-19 (<xref rid="B63" ref-type="bibr">Lai et al., 2020</xref>). The remarkably elevated neutrophil count was found to serve as a marker for poor prognosis in a retrospective review of 25 deaths related to SARS-CoV-2 (<xref rid="B71" ref-type="bibr">Li X. et al., 2020</xref>). In another retrospective analysis of 95 patients with COVID-19, an increased neutrophil count was related to disease severity and reflected an overt inflammatory response causing complications (<xref rid="B151" ref-type="bibr">Zhang et al., 2020</xref>). The neutrophil-to-lymphocyte ratio was significantly elevated in patients with severe COVID-19 based on a meta-analysis. Furthermore, this ratio could be used as a marker for predicting whether more severe complications such as ARDS would arise (<xref rid="B62" ref-type="bibr">Lagunas-Rangel, 2020</xref>). Finally, neutrophils are suggested as a target for immunopathologic complications in severe COVID-19 patients (<xref rid="B129" ref-type="bibr">Tomar et al., 2020</xref>). The elevated neutrophil count in COVID-19 patients and its significant correlation with disease severity indicates the importance of neutrophils in the management of COVID-19. The elevated neutrophil count is not only an abnormal laboratory finding but also a characteristic feature that should be further evaluated to develop treatments for patients infected with SARS-CoV-2.</p>
      <p>Cellular invasion of SARS-CoV-2 reduces hACE2 expression, thereby promoting the recruitment of neutrophils (<xref rid="B129" ref-type="bibr">Tomar et al., 2020</xref>). Possible strategies for developing anti-SARS-CoV-2 drugs include targeting the ACE2 receptor, the spike (S) protein receptor binding domain, the macrodomain (Mac1), and the main protease (Mpro, 3CLpro) (<xref rid="B3" ref-type="bibr">Alhammad et al., 2020</xref>; <xref rid="B130" ref-type="bibr">Ton et al., 2020</xref>; <xref rid="B154" ref-type="bibr">Zhu et al., 2020</xref>). Neutrophils were widespread in the alveoli in COVID-19 patients (<xref rid="B155" ref-type="bibr">Zuo et al., 2020</xref>). In rats, excessive neutrophil migration to the lungs caused severe lung hemorrhage and increased microvascular permeability. Therefore, neutrophils participate in viral clearance while contributing to pathological symptoms in rat respiratory coronavirus infection (<xref rid="B45" ref-type="bibr">Haick et al., 2014</xref>). Moreover, neutrophils play a pivotal role in the cytokine storm (<xref rid="B127" ref-type="bibr">Tisoncik et al., 2012</xref>). In COVID-19 patients, neutrophils secrete interleukin (IL)-6 <italic>via</italic> a TLR8-mediated mechanism leading to a cytokine storm and subsequent lung damage (<xref rid="B89" ref-type="bibr">Mohamed et al., 2020</xref>). IL-1&#x3B2; and NETs form a feedback loop, which contribute to the pathogenesis of ARDS in COVID-19 patients (<xref rid="B146" ref-type="bibr">Yaqinuddin and Kashir, 2020</xref>). SARS-CoV-2 may invade nerves and aggravate respiratory failure (<xref rid="B72" ref-type="bibr">Li Y.C. et al., 2020</xref>). Neutrophil reactive oxygen species (ROS) and NETs participate in demyelination of the central neural system in mice with neurological diseases and coronavirus infection (<xref rid="B27" ref-type="bibr">Cheng et al., 2019</xref>). Therefore, treatments targeting excessive neutrophil activation may improve pathological neutrophilic inflammation during COVID-19 infection complicated by ARDS and nerve invasion.</p>
    </sec>
    <sec id="s4">
      <title>Targeting Neutrophils May Improve the Treatment of ARDS Caused by SARS-COV-2 Infection</title>
      <p>Neutrophil infiltration is the defining hallmark of ARDS (<xref rid="B149" ref-type="bibr">Zemans and Matthay, 2017</xref>). Elevated neutrophils and neutrophil-derived microparticles are found in bronchoalveolar lavage fluid from patients with ARDS (<xref rid="B91" ref-type="bibr">Nakos et al., 1998</xref>; <xref rid="B42" ref-type="bibr">Guervilly et al., 2011</xref>). In ARDS patients, macrophages secrete CXCL8 (IL-8) to activate a circulating neutrophil recruitment cascade <italic>via</italic> C-X-C chemokine receptor 1 (CXCR1) receptors. CXCL8 levels are also correlated with the severity and outcome of ARDS (<xref rid="B88" ref-type="bibr">Miller et al., 1992</xref>; <xref rid="B39" ref-type="bibr">Groeneveld et al., 1995</xref>). CXC chemokines including CXCL1/2, CXCL8, CXCL5, CXCL12, and CXCL15 are responsible for neutrophil recruitment to the lungs during lung injury. However, their blockade would not completely prevent neutrophil recruitment, which indicates a rather complicated mechanism operating during immune activation (<xref rid="B149" ref-type="bibr">Zemans and Matthay, 2017</xref>). The SARS-CoV S protein stimulates lung epithelial cells to release IL-8 <italic>via</italic> activation of MAPK and AP-1, the IL-8 promoter (<xref rid="B24" ref-type="bibr">Chang et al., 2004</xref>). Epithelial membrane protein 2 (Emp2) of alveolar epithelial type 1 cells is important for the regulation of neutrophil migration in ARDS. Emp2 knock-out mice displayed decreased neutrophil influx to the lungs and an improved survival rate of bacterial pneumonia (<xref rid="B74" ref-type="bibr">Lin et al., 2020</xref>). Therefore, anti-EMP2 diabodies may be helpful in treating ARDS by mitigating neutrophil infiltration. Moreover, CCL2 (monocyte chemoattractant protein-1, MCP-1) and CCL7 are increased in the lungs of patients with ARDS (<xref rid="B15" ref-type="bibr">Bhatia et al., 2012</xref>; <xref rid="B85" ref-type="bibr">Mercer et al., 2014</xref>). Extravasated neutrophils exhibit elevated CCL2 and CCL7 binding to CCR2 receptors. Proteinase-activated receptors (PARs) are present on epithelial cells, monocytes, macrophages, and vascular endothelial cells, and their activation leads to the release of proinflammatory mediators including the cytokines TNF, IL-1&#x3B2;, IL-2, and IL-6, and the chemokines CXCL8 (IL-8) and CCL2, all of which are associated with ARDS pathogenesis. Modulating the CC chemokine response <italic>via</italic> antagonism of PAR1 signaling or by blocking these chemokines directly, may represent a treatment model for excessive neutrophilia and tissue damage associated with ARDS (<xref rid="B85" ref-type="bibr">Mercer et al., 2014</xref>). The level of neutrophil-derived calprotectin, along with other acute inflammatory markers, is correlated with pulmonary severity caused by SARS-CoV-2, which indicates that neutrophils are drivers of the thrombo-inflammatory storm, not just bystanders (<xref rid="B111" ref-type="bibr">Shi Y. et al., 2020</xref>). Mitochondrial formyl peptides are elevated in ARDS patients (<xref rid="B33" ref-type="bibr">Dorward et al., 2017</xref>) and formyl peptides are known to drive neutrophils in ARDS. Formyl peptide receptors (FPRs) play an important role in the activation of neutrophils (<xref rid="B141" ref-type="bibr">Yang and Hwang, 2016</xref>; <xref rid="B25" ref-type="bibr">Chen et al., 2017</xref>), and FPR-1 expression is elevated in lung injury and fibrosis (<xref rid="B68" ref-type="bibr">Leslie et al., 2020</xref>). Several FPR1 antagonists were discovered previously in our lab including the clinical drug propofol (<xref rid="B143" ref-type="bibr">Yang et al., 2013</xref>; <xref rid="B76" ref-type="bibr">Liu et al., 2017</xref>; <xref rid="B144" ref-type="bibr">Yang et al., 2017</xref>; <xref rid="B26" ref-type="bibr">Chen et al., 2018</xref>) that may have potential in the development of the treatment for COVID-19 associated ARDS.</p>
      <p>NETs are composed of sticky chromatin decorated with various granular components (<xref rid="B148" ref-type="bibr">Zawrotniak and Rapala-Kozik, 2013</xref>). Interestingly, sputum viscosity is correlated with the level of NETs (<xref rid="B100" ref-type="bibr">Papayannopoulos et al., 2011</xref>; <xref rid="B83" ref-type="bibr">Manzenreiter et al., 2012</xref>). Mucokinetic drugs that preserve viscoelasticity, not mucolytics, were recommended for the management of cystic fibrosis (<xref rid="B49" ref-type="bibr">Henke and Ratjen, 2007</xref>). This could also be applied to ARDS in COVID-19 patients. NET level was found related to the polarization of proinflammatory M1 macrophages in ARDS patients; furthermore, NET inhibitors repressed NET formation and reduced M1 macrophage markers in a mouse model of acute lung injury (<xref rid="B115" ref-type="bibr">Song et al., 2019</xref>). Phagocytosis of NETs by macrophages is impaired in ARDS (<xref rid="B38" ref-type="bibr">Gr&#xE9;goire et al., 2018</xref>). Activation of the AMP-activated protein kinase (AMPK) pathway stimulates macrophage efferocytosis (<xref rid="B11" ref-type="bibr">Bae et al., 2011</xref>). Therefore, drugs interacting with AMPK, such as metformin, may reduce ARDS severity (<xref rid="B38" ref-type="bibr">Gr&#xE9;goire et al., 2018</xref>). Moreover, NET levels in the plasma are known to be correlated with ARDS mortality (<xref rid="B67" ref-type="bibr">Lefran&#xE7;ais et al., 2018</xref>). NETs consist of neutrophil-extruded DNA coated with histones, neutrophil elastase (NE), and myeloperoxidase (MPO). Peptidylarginine deiminase 4 (PAD4), NE, and gasdermin D along with free DNA, all participate in the NET formation (<xref rid="B93" ref-type="bibr">Nathan, 2020</xref>). NETs are prevalent in blood, trachea, and lung specimens of COVID-19 patients (<xref rid="B133" ref-type="bibr">Veras et al., 2020</xref>). Moreover, SARS-CoV-2 stimulates neutrophils from healthy donors into forming NETs, which can cause apoptosis in respiratory epithelial cells <italic>in vitro</italic> (<xref rid="B98" ref-type="bibr">Oubihi and Wang, 2020</xref>). High levels of plasma MPO-DNA complex and aberrant NET formation are correlated with severe ARDS in COVID-19 (<xref rid="B87" ref-type="bibr">Middleton et al., 2020</xref>; <xref rid="B155" ref-type="bibr">Zuo et al., 2020</xref>). Also, elevated levels of cell-free DNA were observed in COVID-19 patients (n = 50), as well as highly specific markers of NETs, such as MPO-DNA and citrullinated histone H3 (Cit-H3), along with other typical markers (C-reactive protein, D-dimer, neutrophil count, etc.) (<xref rid="B155" ref-type="bibr">Zuo et al., 2020</xref>). NETs contributed to microthrombi through platelet-neutrophil interactions in COVID-19 associated ARDS, and neonatal NET-Inhibitory Factor (nNIF) could block NET formation induced by COVID-19 plasma. This represents a potential therapeutic intervention for COVID-19 (<xref rid="B87" ref-type="bibr">Middleton et al., 2020</xref>). PAD4 is a predominant driver of histone citrullination in NETs (<xref rid="B138" ref-type="bibr">Wong and Wagner, 2018</xref>). Currently, several PAD4 inhibitors were demonstrated to inhibit NET formation <italic>in vitro</italic>. Among them, Cl-amidine (<xref rid="B61" ref-type="bibr">Kusunoki et al., 2016</xref>), GSK484 (<xref rid="B69" ref-type="bibr">Lewis et al., 2015</xref>), and BMS-P5 (<xref rid="B70" ref-type="bibr">Li M. et al., 2020</xref>) may have future development potential. Therefore, inhibition of neutrophil activation and NET formation may be beneficial in COVID-19-associated ARDS.</p>
    </sec>
    <sec id="s5">
      <title>Drugs Targeting Neutrophils for COVID-19 ASSOCIATED ARDS</title>
      <p>Currently, there are several clinical drugs indicated for use in respiratory diseases that affect neutrophil function, but other drugs should also be considered for the treatment of ARDS in COVID-19. A summary of commercially available approved drugs or those in clinical trials, allocated to different groups based on their specific target in neutrophils, is provided (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref>, <xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>).</p>
      <fig id="f2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Drugs targeting neutrophils for COVID-19 associated ARDS. Clinical drugs (in red) and clinical trial drugs (in blue) are displayed with their targets in neutrophils. In COVID-19 infection, the release of SARS-CoV-2 RNA in lungs serves as PAMP and induces complicated immune reactions leading to ARDS and respiratory failure. Under these circumstances, neutrophils recruited to the site of infection participate in the elimination of SARS-CoV-2, but they also contribute to the pathogenesis of ARDS. Therefore, the commercial drugs targeting neutrophils might be considered as novel candidates to treat COVID-19 associated ARDS. ARDS, acute respiratory distress syndrome; CXCR, C-X-C chemokine receptor; DPP1, dipeptidyl peptidase 1; GSDMD, gasdermin D; IL, interleukin; NE, neutrophil elastase; NET, neutrophil extracellular trap; NOX, NADPH oxidase; PDE, phosphodiesterase; PMN, polymorphonuclear leukocyte; ROS, reactive oxygen species.</p>
        </caption>
        <graphic xlink:href="fphar-11-572009-g002"/>
      </fig>
      <sec id="s5_1">
        <title>Neutrophil Elastase Inhibitors</title>
        <p>Neutrophil elastase (NE) contributes to the invasion of SARS-CoV-2 into host cells and can also damage lung tissue directly, thus participating in the pathogenesis of COVID-19 associated ARDS (<xref rid="B126" ref-type="bibr">Thierry, 2020</xref>). Moreover, NE is an important component and plays an important role in NETosis. For instance, the administration of elastase inhibitors such as sivelestat (<xref rid="B58" ref-type="bibr">Kim et al., 2014</xref>) and BAY 85-8501 (<xref rid="B134" ref-type="bibr">Von Nussbaum et al., 2015</xref>) ameliorated acute lung injury in mice. Currently, sivelestat is the only approved NE inhibitor for the treatment of ARDS in Korea and Japan (<xref rid="B2" ref-type="bibr">Aikawa and Kawasaki, 2014</xref>). There are several other NE inhibitors in different stages of clinical trials including alvelestat (AZD9668, COPD, phase 2, US national clinical trial number NCT03636347) (<xref rid="B119" ref-type="bibr">Stockley et al., 2013</xref>), BAY 85-8501 (noncystic fibrosis bronchiectasis, phase 2, NCT01818544), (<xref rid="B136" ref-type="bibr">Watz et al., 2019</xref>), lonodelestat (POL6014, cystic fibrosis, phase 1, NCT03748199) (<xref rid="B14" ref-type="bibr">Barth et al., 2020</xref>), CHF6333 (noncystic fibrosis bronchiectasis, phase 1, NCT03056326, NCT04010799) (<xref rid="B37" ref-type="bibr">Gramegna et al., 2017</xref>), and elafin (ARDS, phase 1, NCT02944279) (<xref rid="B13" ref-type="bibr">Barnes et al., 2020</xref>). In a meta-analysis study, sivelestat failed to improve the survival of patients with ARDS (<xref rid="B123" ref-type="bibr">Tagami et al., 2014</xref>). However, a retrospective cohort study with 66 ARDS patients demonstrated that sivelestat treatment yields positive outcomes (<xref rid="B82" ref-type="bibr">Maki et al., 2020</xref>). In particular, aerosol- or nebulizer-dosed NE inhibitors significantly improved their efficacy and lowered adverse effects (<xref rid="B14" ref-type="bibr">Barth et al., 2020</xref>). Thus, prompt administration of NE inhibitors may be helpful in severe COVID-19 patients with ARDS (<xref rid="B89" ref-type="bibr">Mohamed et al., 2020</xref>).</p>
      </sec>
      <sec id="s5_2">
        <title>Respiratory Burst Inhibitor</title>
        <p><italic>N</italic>-Acetylcysteine is a potential therapeutic in the treatment of COVID-19 (<xref rid="B9" ref-type="bibr">Andreou et al., 2020</xref>). It is a mucolytic drug with antioxidant activity that is used in respiratory diseases (<xref rid="B90" ref-type="bibr">Mokhtari et al., 2017</xref>) and skin diseases (<xref rid="B1" ref-type="bibr">Adil et al., 2018</xref>), as well as an antidote in acetaminophen overdose (<xref rid="B90" ref-type="bibr">Mokhtari et al., 2017</xref>). Moreover, <italic>N</italic>-acetylcysteine inhibited the respiratory burst in activated neutrophils <italic>in vitro</italic> (<xref rid="B6" ref-type="bibr">Allegra et al., 2002</xref>) and in patients in the intensive care unit (<xref rid="B47" ref-type="bibr">Heller et al., 2001</xref>). Furthermore, <italic>N</italic>-acetylcysteine alleviated acute lung injury <italic>in vivo</italic> under various conditions (<xref rid="B5" ref-type="bibr">Alkan et al., 2006</xref>; <xref rid="B29" ref-type="bibr">Chuang et al., 2007</xref>; <xref rid="B75" ref-type="bibr">Liu et al., 2008</xref>; <xref rid="B147" ref-type="bibr">Yubero et al., 2012</xref>; <xref rid="B43" ref-type="bibr">Guo et al., 2019</xref>), and inhibited lung fibrosis <italic>in vivo</italic> (<xref rid="B60" ref-type="bibr">Kulshrestha et al., 2020</xref>) with limited patient outcomes, according to a meta-analysis study (<xref rid="B121" ref-type="bibr">Sun et al., 2016</xref>). In another meta-analysis study, <italic>N</italic>-acetylcysteine treatment of ARDS patients shortened their stay in the intensive care unit (<xref rid="B150" ref-type="bibr">Zhang et al., 2017</xref>). Finally, it has also been suggested that <italic>N</italic>-acetylcysteine should be used in combination with other drugs to manage ARDS (<xref rid="B43" ref-type="bibr">Guo et al., 2019</xref>; <xref rid="B9" ref-type="bibr">Andreou et al., 2020</xref>; <xref rid="B52" ref-type="bibr">Horowitz and Freeman, 2020</xref>). Currently, several clinical trials with <italic>N</italic>-acetylcysteine to treat COVID-19 (NCT04419025, NCT04455243, NCT04374461, etc.) are ongoing. Based on the above, we believe that <italic>N</italic>-acetylcysteine may be helpful in treating ARDS caused by SARS-CoV-2 <italic>via</italic> its antioxidant and anti-respiratory burst activity.</p>
      </sec>
      <sec id="s5_3">
        <title>Dipeptidyl Peptidase 1 Inhibitor</title>
        <p>Dipeptidyl peptidase 1 (DPP1), also known as cathepsin C, is a cysteine dipeptidyl aminopeptidase that activates serine proteases such as NE during maturation of neutrophils. Excessive serine protease activity causes various inflammatory lung diseases such as ARDS and contributes to COPD and asthma. Brensocatib (also called INS1007 or AZD7986), a DPP1 inhibitor, was found to reduce NE activity in healthy humans (<xref rid="B99" ref-type="bibr">Palm&#xE9;r et al., 2018</xref>) and is now in clinical trials for bronchiectasis (NCT03218917) and COVID-19 (EU clinical trial number EudraCT 2020-001643-13). The administration of DPP1 inhibitors may prevent ARDS progression caused by SARS-CoV-2 (<xref rid="B59" ref-type="bibr">Korkmaz et al., 2020</xref>). Thus, DPP1 inhibitors are of interest in treating COVID-19 associated ARDS.</p>
      </sec>
      <sec id="s5_4">
        <title>PDE4 Inhibitors</title>
        <p>Phosphodiesterases (PDEs) belong to the class of enzymes that metabolize the intracellular second messenger cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). In particular, cAMP-specific PDE4 type is widely present in immune cells including neutrophils and contributes to neutrophil-mediated lung inflammation (<xref rid="B12" ref-type="bibr">Baillie et al., 2019</xref>). There are currently three FDA-approved PDE4 inhibitors: roflumilast for COPD (<xref rid="B101" ref-type="bibr">Phillips, 2020</xref>), apremilast for psoriasis (<xref rid="B104" ref-type="bibr">Queiro Silva et al., 2020</xref>), and crisaborole for atopic dermatitis (<xref rid="B46" ref-type="bibr">Hashim et al., 2020</xref>). Other drugs such as CHF6001 (NCT02986321 for COPD and NCT01689571 for asthma) (<xref rid="B113" ref-type="bibr">Singh et al., 2019</xref>), and ensifentrine (RPL554, NCT04027439 for COPD) (<xref rid="B23" ref-type="bibr">Cazzola et al., 2019</xref>) are awaiting phase 3 clinical trials. However, many of the experimental drugs were discontinued in clinical trials due to side effects (<xref rid="B101" ref-type="bibr">Phillips, 2020</xref>). Several PDE inhibitors have been proposed to be suitable drugs for COVID-19 treatment (<xref rid="B36" ref-type="bibr">Giorgi et al., 2020</xref>). Thus, we suggest their clinical consideration in COVID-19 associated ARDS. In light of the above, clinical trials targeting COVID-19 using apremilast (NCT04488081) or ensifentrine (NCT04527471) have been initiated.</p>
        <p>Dipyridamole is an FDA-approved nonspecific PDE inhibitor used for thrombosis and was discovered to inhibit NET formation (<xref rid="B4" ref-type="bibr">Ali et al., 2019</xref>). Dipyridamole acts by&#xA0;increasing intracellular cAMP levels and blocking adenosine reuptake in cells, thereby leading to its antiplatelet and vasodilatory effects (<xref rid="B125" ref-type="bibr">Tan et al., 2019</xref>). In a trial including 31 COVID-19 patients, dipyridamole showed improvement in severe cases with significantly reduced D-dimer levels (<xref rid="B77" ref-type="bibr">Liu et al., 2020</xref>). Currently, several COVID-related trials are ongoing for dipyridamole (NCT04410328, NCT04424901, NCT04391179). Another FDA-approved nonspecific PDE inhibitor, pentoxifylline, is a derivative of caffeine. Pentoxifylline stimulates blood flow, inhibits platelets, and has immunomodulatory and anti-inflammatory properties. Pentoxifylline also inhibits neutrophil adhesion (<xref rid="B17" ref-type="bibr">Bone, 1992</xref>). It is currently in ongoing clinical trials for COVID-19 (NCT04433988). Along with specific PDE4 inhibitors, dipyridamole and pentoxifylline may represent suitable candidates for further anti-COVID-19 development (<xref rid="B48" ref-type="bibr">Hendry et al., 2020</xref>).</p>
      </sec>
      <sec id="s5_5">
        <title>Gasdermin D Inhibitor</title>
        <p>Disulfiram, an FDA-approved gasdermin D inhibitor, blocks SARS-CoV-2 replication <italic>in silico</italic> (<xref rid="B78" ref-type="bibr">Lobo-Galo et al., 2020</xref>). Moreover, disulfiram was shown to abrogate gasdermin D pore formation by covalent bonding to Cys191/Cys192 (<xref rid="B53" ref-type="bibr">Hu et al., 2020</xref>). Gasdermin D is important in the formation of NETs (<xref rid="B114" ref-type="bibr">Sollberger et al., 2018</xref>). Therefore, disulfiram has the potential to reduce NET-related pathogenesis in ARDS caused by SARS-CoV-2. Currently, a clinical trial is ongoing on the potential use of disulfiram in COVID-19 (NCT04485130).</p>
      </sec>
      <sec id="s5_6">
        <title>DNase Inhibitors</title>
        <p>Application of DNase I to mice with severe bacterial pneumonia and acute lung injury reduced NET formation and improved their survival rate (<xref rid="B67" ref-type="bibr">Lefran&#xE7;ais et al., 2018</xref>). Administration of dornase alfa, an FDA-approved recombinant human DNAse I, using a nebulizer in severe COVID-19 associated ARDS patients may help lyse the sputum and improve disease progression (<xref rid="B13" ref-type="bibr">Barnes et al., 2020</xref>; <xref rid="B137" ref-type="bibr">Weber et al., 2020</xref>). Currently, there are several COVID-19 clinical trials using dornase alfa (NCT04402970, NCT04359654, NCT04355364, EudraCT 2020-001492-33, etc.) (<xref rid="B31" ref-type="bibr">Desilles et al., 2020</xref>). Another promising DNase inhibitor, AIR DNAse&#x2122;, is currently undergoing phase 2 clinical trials in cystic fibrosis patients (NCT02605590, NCT02722122).</p>
      </sec>
      <sec id="s5_7">
        <title>Chemokine-Related Drugs (IL-8, IL-17, IL-1&#x3B2; and IL-6)</title>
        <p>IL-8 secreted by macrophages and lung epithelial cells is a neutrophil chemoattractant. Moreover, IL-8 contributes to neutrophil activation and NET formation after binding to CXCR2 on neutrophils, thereby causing hyperinflammation. Interestingly, anti-IL-8 monoclonal antibody BMS-986253 (Humax IL-8), developed as an anti-tumor treatment (<xref rid="B16" ref-type="bibr">Bilusic et al., 2019</xref>), is currently in clinical trial for COVID-19 (NCT04347226). AZD5069 (<xref rid="B96" ref-type="bibr">Nicholls et al., 2015</xref>; <xref rid="B30" ref-type="bibr">Cullberg et al., 2018</xref>), danirixin (<xref rid="B81" ref-type="bibr">Madan et al., 2019</xref>; <xref rid="B65" ref-type="bibr">Lazaar et al., 2020</xref>), and navarixin (SCH527123) (<xref rid="B50" ref-type="bibr">Holz et al., 2010</xref>; <xref rid="B128" ref-type="bibr">Todd et al., 2016</xref>) are available CXCR2 inhibitors that ameliorate neutrophil activation in pulmonary diseases including bronchiectasis, virus-associated lung infection, COPD and asthma. Therefore, they may represent valuable drugs for the treatment of ARDS in COVID-19 patients (<xref rid="B92" ref-type="bibr">Narasaraju et al., 2020</xref>). However, the development of the CXCR2 antagonist QBM076 was terminated for safety reasons (NCT01972776).</p>
        <p>IL-17A is a proinflammatory cytokine involved in inflammation and immune responses; thus, blocking its effect is beneficial in treating neutrophilic inflammatory diseases. Ixekizumab (NCT03099538) and secukinumab (NCT03099980) are monoclonal antibodies (mAb) against IL-17A that prevent its interaction with the IL-17A receptor. In particular, IL-17A antagonists have been used for the treatment of rheumatoid arthritis and psoriasis (<xref rid="B28" ref-type="bibr">Chiang et al., 2019</xref>). Brodalumab (NCT04249713) binds with a high affinity to interleukin IL-17 receptor A, thereby inhibiting IL-17 proinflammatory cytokines (<xref rid="B20" ref-type="bibr">Bulat et al., 2020</xref>). Secukinumab is currently tested in coronavirus trials (NCT04403243, EudraCT 2020-001246-18).</p>
        <p>Anakinra is a IL-1 receptor inhibitor, while canakinumab and rilonacept are IL-1&#x3B2; inhibitors (<xref rid="B102" ref-type="bibr">Prieto-Pe&#xF1;a and Dasgupta, 2020</xref>). Anakinra was reported in the treatment of COVID-19 (<xref rid="B132" ref-type="bibr">Van De Veerdonk and Netea, 2020</xref>). Subcutaneous administration of anakinra reduced mortality and lowered the need for advanced respiratory support in severe COVID-19 patients (<xref rid="B54" ref-type="bibr">Huet et al., 2020</xref>); however, several limitations were observed (<xref rid="B57" ref-type="bibr">Khan et al., 2020</xref>). There are currently several clinical trials in relation to COVID-19 on anakinra (NCT04330638, NCT04364009, etc.) and canakinumab (NCT04362813, etc.).</p>
        <p>Tocilizumab, an IL-6 receptor inhibitor, reduced the level of serum C-reactive protein and ameliorated pulmonary computed tomography appearances in patients with COVID-19 (<xref rid="B41" ref-type="bibr">Guaraldi et al., 2020</xref>; <xref rid="B116" ref-type="bibr">Soy et al., 2020</xref>; <xref rid="B140" ref-type="bibr">Xu et al., 2020</xref>). A plethora of clinical trials using tocilizumab is currently ongoing in relation to COVID-19 (Actemra, Roche, NCT04317092, NCT04320615, etc.). Similarly, several clinical trials for another IL-6 receptor inhibitor, sarilumab (Kevzara, Regeneron, NCT04315298, etc.), have been initiated (<xref rid="B79" ref-type="bibr">Lu et al., 2020</xref>).</p>
      </sec>
      <sec id="s5_8">
        <title>Other Drugs</title>
        <p>Corticosteroids are recommended by the US National Institutes of Health (NIH) for use in COVID-19 patients who are being mechanically ventilated or require oxygen supplementation (<uri xlink:type="simple" xlink:href="https://www.covid19treatmentguidelines.nih.gov">https://www.covid19treatmentguidelines.nih.gov</uri>). However, there are several concerns, and corticoids were previously not recommended in patients with ARDS related to viral pneumonia (<xref rid="B95" ref-type="bibr">Ni et al., 2019</xref>). Corticosteroids also reduce the level of neutrophil-derived secreted IL-1 receptor antagonist (sIL-1Ra), which leads to increased IL-1&#x3B2; expression (<xref rid="B64" ref-type="bibr">Langereis et al., 2011</xref>). Hence, corticosteroids have proinflammatory effects in neutrophils. Corticosteroids are generally thought to weakly suppress neutrophilic inflammation, although several research groups reported them to inhibit the neutrophil respiratory burst and interfere with neutrophil recruitment (<xref rid="B120" ref-type="bibr">Strausbaugh and Rosen, 2001</xref>; <xref rid="B108" ref-type="bibr">Ronchetti et al., 2018</xref>; <xref rid="B107" ref-type="bibr">Ricci et al., 2019</xref>). For instance, corticosteroids do not improve neutrophilic inflammation in corticosteroid-resistant asthma or COPD (<xref rid="B142" ref-type="bibr">Yang et al., 2012</xref>; <xref rid="B108" ref-type="bibr">Ronchetti et al., 2018</xref>).</p>
        <p>Dapsone, colchicine, and olanzapine were suggested as potential adjuvant therapies in ARDS caused by SARS-CoV-2 (<xref rid="B7" ref-type="bibr">Altschuler and Kast, 2020</xref>). Dapsone has anti-neutrophilic activity through its inhibition of IL-8 mediated chemotaxis and thus may be therapeutic in COVID-19 associated ARDS (<xref rid="B34" ref-type="bibr">Farouk and Salman, 2020</xref>; <xref rid="B55" ref-type="bibr">Kast, 2020</xref>). Colchicine, a neutrophil microtubule polymerization inhibitor, reduces IL-1 production and is undergoing several clinical trials for COVID-19 (NCT04322682 and 18 more) (<xref rid="B116" ref-type="bibr">Soy et al., 2020</xref>). Olanzapine is an antipsychotic drug targeting the histamine 1 receptor, thereby reducing IL-6 generation (<xref rid="B7" ref-type="bibr">Altschuler and Kast, 2020</xref>).</p>
        <p>Hydroxychloroquine and azithromycin were reported as effective anti-SARS-CoV-2 agents (<xref rid="B97" ref-type="bibr">Ohe et al., 2020</xref>; <xref rid="B152" ref-type="bibr">Zhou D. et al., 2020</xref>). Fujita et al. demonstrated that hydroxychloroquine significantly inhibited IL-1&#x3B2; production in activated human neutrophils <italic>in vitro</italic> (<xref rid="B35" ref-type="bibr">Fujita et al., 2019</xref>). Hydroxychloroquine inhibited NET formation and ameliorated the hypercoagulation state in mice with orthotopic pancreatic adenocarcinoma. A chemotherapy regimen with hydroxychloroquine prior to surgery improved the rate of perioperative venous thromboembolism in a clinical trial (<xref rid="B18" ref-type="bibr">Boone et al., 2018</xref>). With respect to the effect of azithromycin on neutrophils, Bystrzycka et al. revealed that azithromycin decreased NET release in activated neutrophils <italic>in vitro</italic> (<xref rid="B21" ref-type="bibr">Bystrzycka et al., 2017</xref>). Anderson et al. demonstrated that azithromycin inhibited neutrophil migration in dextran sulfate sodium-induced mice (<xref rid="B8" ref-type="bibr">Anderson et al., 2019</xref>). However, Cavalcanti et al. showed that hydroxychloroquine and azithromycin did not alter disease progression in patients with mild-to-moderate COVID-19 (<xref rid="B22" ref-type="bibr">Cavalcanti et al., 2020</xref>). The World Health Organization does not recommend the use of hydroxychloroquine and azithromycin due to the controversial outcomes of several trials.</p>
      </sec>
    </sec>
    <sec id="s6">
      <title>Conclusion</title>
      <p>ARDS is the most lethal complication of COVID-19. Neutrophils, although involved in the elimination of SARS-CoV-2, also participate in the pathogenesis of COVID-19 associated ARDS. Suppression of aberrant neutrophil activation may provide an effective strategy for treating COVID-19 associated ARDS. Several clinical drugs that target neutrophils can be chosen for further therapeutic use in ARDS associated with SARS-CoV-2 infection.</p>
    </sec>
    <sec id="s7">
      <title>Author Contributions</title>
      <p>C-CC, MK, and W-JC wrote the manuscript. T-LH conceived the study and edited the manuscript. All authors contributed to the article and approved the submitted version.</p>
    </sec>
    <sec sec-type="funding-information" id="s8">
      <title>Funding</title>
      <p>This work was supported by grants from the Ministry of Science and Technology (MOST 108-2320-B-255-003-MY3, MOST 109-2327-B-255-001,&#xA0;and MOST 109-2327-B-182-002) and Chang Gung Memorial Hospital (BMRP450, and CORPG5K0031). The funding sources had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.</p>
    </sec>
    <sec id="s9">
      <title>Conflict of Interest</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>This manuscript was edited by Editage. The figures were supported by BioRender.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adil</surname><given-names>M.</given-names></name><name><surname>Amin</surname><given-names>S. S.</given-names></name><name><surname>Mohtashim</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>N-acetylcysteine in dermatology</article-title>. <source>Indian J. Dermatol. Venereol. Leprol.</source>
<volume>84</volume>, <fpage>652</fpage>&#x2013;<lpage>659</lpage>. <pub-id pub-id-type="doi">10.4103/ijdvl.IJDVL_33_18</pub-id>
<pub-id pub-id-type="pmid">30246706</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aikawa</surname><given-names>N.</given-names></name><name><surname>Kawasaki</surname><given-names>Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome</article-title>. <source>Ther. Clin. Risk Manage.</source>
<volume>10</volume>, <fpage>621</fpage>&#x2013;<lpage>629</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S65066</pub-id>
</mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alhammad</surname><given-names>Y. M. O.</given-names></name><name><surname>Kashipathy</surname><given-names>M. M.</given-names></name><name><surname>Roy</surname><given-names>A.</given-names></name><name><surname>Johnson</surname><given-names>D. K.</given-names></name><name><surname>Mcdonald</surname><given-names>P.</given-names></name><name><surname>Battaile</surname><given-names>K. P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The SARS-CoV-2 conserved macrodomain is a highly efficient ADP-ribosylhydrolase enzyme</article-title>. <source>bioRxiv</source>
<volume>2020</volume><elocation-id>05.11.089375</elocation-id>. <pub-id pub-id-type="doi">10.1101/2020.05.11.0893755</pub-id>
</mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ali</surname><given-names>R. A.</given-names></name><name><surname>Gandhi</surname><given-names>A. A.</given-names></name><name><surname>Meng</surname><given-names>H.</given-names></name><name><surname>Yalavarthi</surname><given-names>S.</given-names></name><name><surname>Vreede</surname><given-names>A. P.</given-names></name><name><surname>Estes</surname><given-names>S. K.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome</article-title>. <source>Nat. Commun.</source>
<volume>10</volume>, <fpage>1916</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-09801-x</pub-id>
<pub-id pub-id-type="pmid">31015489</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alkan</surname><given-names>A.</given-names></name><name><surname>Ero&#x11F;lu</surname><given-names>F.</given-names></name><name><surname>Ero&#x11F;lu</surname><given-names>E.</given-names></name><name><surname>Ergin</surname><given-names>C.</given-names></name><name><surname>Cer&#xE7;i</surname><given-names>C.</given-names></name><name><surname>Alsancak</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Protective effects of N-acetylcysteine and erdosteine on hemorrhagic shock-induced acute lung injury</article-title>. <source>Eur. J. Emerg. Med.</source>
<volume>13</volume>, <fpage>281</fpage>&#x2013;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1097/00063110-200610000-00007</pub-id>
<pub-id pub-id-type="pmid">16969233</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allegra</surname><given-names>L.</given-names></name><name><surname>Dal Sasso</surname><given-names>M.</given-names></name><name><surname>Bovio</surname><given-names>C.</given-names></name><name><surname>Massoni</surname><given-names>C.</given-names></name><name><surname>Fonti</surname><given-names>E.</given-names></name><name><surname>Braga</surname><given-names>P. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations</article-title>. <source>Arzneimittelforschung</source>
<volume>52</volume>, <fpage>669</fpage>&#x2013;<lpage>676</lpage>. <pub-id pub-id-type="doi">10.1055/s-0031-1299949</pub-id>
<pub-id pub-id-type="pmid">12404881</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Altschuler</surname><given-names>E. L.</given-names></name><name><surname>Kast</surname><given-names>R. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)</article-title>. <source>Med. Hypotheses</source>
<volume>141</volume>, <elocation-id>109774</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.mehy.2020.109774</pub-id>
<pub-id pub-id-type="pmid">32344275</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>S. J.</given-names></name><name><surname>Lockhart</surname><given-names>J. S.</given-names></name><name><surname>Estaki</surname><given-names>M.</given-names></name><name><surname>Quin</surname><given-names>C.</given-names></name><name><surname>Hirota</surname><given-names>S. A.</given-names></name><name><surname>Alston</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Effects of azithromycin on behavior, pathologic signs, and changes in cytokines, chemokines, and neutrophil migration in C57BL/6 mice exposed to dextran sulfate sodium</article-title>. <source>Comp. Med.</source>
<volume>69</volume>, <fpage>4</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.30802/AALAS-CM-18-000001</pub-id>
<pub-id pub-id-type="pmid">30545428</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andreou</surname><given-names>A.</given-names></name><name><surname>Trantza</surname><given-names>S.</given-names></name><name><surname>Filippou</surname><given-names>D.</given-names></name><name><surname>Sipsas</surname><given-names>N.</given-names></name><name><surname>Tsiodras</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19: The potential role of copper and N-acetylcysteine (NAC) in a combination of candidate antiviral treatments against SARS-CoV-2</article-title>. <source>In Vivo</source>
<volume>34</volume>, <fpage>1567</fpage>&#x2013;<lpage>1588</lpage>. <pub-id pub-id-type="doi">10.21873/invivo.11946</pub-id>
<pub-id pub-id-type="pmid">32503814</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Badraoui</surname><given-names>R.</given-names></name><name><surname>Alrashedi</surname><given-names>M. M.</given-names></name><name><surname>El-May</surname><given-names>M. V.</given-names></name><name><surname>Bardakci</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19</article-title>. <source>J. Biomol. Struct. Dyn.</source>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1080/07391102.2020.1803139</pub-id> Online ahead of print.
</mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bae</surname><given-names>H. B.</given-names></name><name><surname>Zmijewski</surname><given-names>J. W.</given-names></name><name><surname>Deshane</surname><given-names>J. S.</given-names></name><name><surname>Tadie</surname><given-names>J. M.</given-names></name><name><surname>Chaplin</surname><given-names>D. D.</given-names></name><name><surname>Takashima</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>AMP-activated protein kinase enhances the phagocytic ability of macrophages and neutrophils</article-title>. <source>FASEB J.</source>
<volume>25</volume>, <fpage>4358</fpage>&#x2013;<lpage>4368</lpage>. <pub-id pub-id-type="doi">10.1096/fj.11-190587</pub-id>
<pub-id pub-id-type="pmid">21885655</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baillie</surname><given-names>G. S.</given-names></name><name><surname>Tejeda</surname><given-names>G. S.</given-names></name><name><surname>Kelly</surname><given-names>M. P.</given-names></name></person-group> (<year>2019</year>). <article-title>Therapeutic targeting of 3&#x2019;,5&#x2019;-cyclic nucleotide phosphodiesterases: inhibition and beyond</article-title>. <source>Nat. Rev. Drug Discovery</source>
<volume>18</volume>, <fpage>770</fpage>&#x2013;<lpage>796</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-019-0033-4</pub-id>
<pub-id pub-id-type="pmid">31388135</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barnes</surname><given-names>B. J.</given-names></name><name><surname>Adrover</surname><given-names>J. M.</given-names></name><name><surname>Baxter-Stoltzfus</surname><given-names>A.</given-names></name><name><surname>Borczuk</surname><given-names>A.</given-names></name><name><surname>Cools-Lartigue</surname><given-names>J.</given-names></name><name><surname>Crawford</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Targeting potential drivers of COVID-19: Neutrophil extracellular traps</article-title>. <source>J. Exp. Med.</source>
<volume>217</volume> (<issue>6</issue>), <elocation-id>e20200652</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1084/jem.20200652</pub-id>
<pub-id pub-id-type="pmid">32302401</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barth</surname><given-names>P.</given-names></name><name><surname>Bruijnzeel</surname><given-names>P.</given-names></name><name><surname>Wach</surname><given-names>A.</given-names></name><name><surname>Sellier Kessler</surname><given-names>O.</given-names></name><name><surname>Hooftman</surname><given-names>L.</given-names></name><name><surname>Zimmermann</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis</article-title>. <source>J. Cyst. Fibros.</source>
<volume>19</volume>, <fpage>299</fpage>&#x2013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcf.2019.08.020</pub-id>
<pub-id pub-id-type="pmid">31501052</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>M.</given-names></name><name><surname>Zemans</surname><given-names>R. L.</given-names></name><name><surname>Jeyaseelan</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Role of chemokines in the pathogenesis of acute lung injury</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source>
<volume>46</volume>, <fpage>566</fpage>&#x2013;<lpage>572</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2011-0392TR</pub-id>
<pub-id pub-id-type="pmid">22323365</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bilusic</surname><given-names>M.</given-names></name><name><surname>Heery</surname><given-names>C. R.</given-names></name><name><surname>Collins</surname><given-names>J. M.</given-names></name><name><surname>Donahue</surname><given-names>R. N.</given-names></name><name><surname>Palena</surname><given-names>C.</given-names></name><name><surname>Madan</surname><given-names>R. A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors</article-title>. <source>J. Immunother. Cancer</source>
<volume>7</volume>, <fpage>240</fpage>. <pub-id pub-id-type="doi">10.1186/s40425-019-0706-x</pub-id>
<pub-id pub-id-type="pmid">31488216</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bone</surname><given-names>R. C.</given-names></name></person-group> (<year>1992</year>). <article-title>Inhibitors of complement and neutrophils: a critical evaluation of their role in the treatment of sepsis</article-title>. <source>Crit. Care Med.</source>
<volume>20</volume>, <fpage>891</fpage>&#x2013;<lpage>898</lpage>. <pub-id pub-id-type="doi">10.1097/00003246-199206000-00029</pub-id>
<pub-id pub-id-type="pmid">1597046</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boone</surname><given-names>B. A.</given-names></name><name><surname>Murthy</surname><given-names>P.</given-names></name><name><surname>Miller-Ocuin</surname><given-names>J.</given-names></name><name><surname>Doerfler</surname><given-names>W. R.</given-names></name><name><surname>Ellis</surname><given-names>J. T.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps</article-title>. <source>BMC Cancer</source>
<volume>18</volume>, <fpage>678</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-018-4584-2</pub-id>
<pub-id pub-id-type="pmid">29929491</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brotfain</surname><given-names>E.</given-names></name><name><surname>Hadad</surname><given-names>N.</given-names></name><name><surname>Shapira</surname><given-names>Y.</given-names></name><name><surname>Avinoah</surname><given-names>E.</given-names></name><name><surname>Zlotnik</surname><given-names>A.</given-names></name><name><surname>Raichel</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Neutrophil functions in morbidly obese subjects</article-title>. <source>Clin. Exp. Immunol.</source>
<volume>181</volume>, <fpage>156</fpage>&#x2013;<lpage>163</lpage>. <pub-id pub-id-type="doi">10.1111/cei.12631</pub-id>
<pub-id pub-id-type="pmid">25809538</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Bulat</surname><given-names>V.</given-names></name><name><surname>Situm</surname><given-names>M.</given-names></name><name><surname>Azdajic</surname><given-names>M. D.</given-names></name><name><surname>Likic</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential role of IL-17 blocking agents in the treatment of severe COVID-19</article-title>? <source>Br. J. Clin. Pharmacol.</source> &#xA0;<pub-id pub-id-type="doi">10.1111/bcp.14437</pub-id> Online ahead of print.
</mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bystrzycka</surname><given-names>W.</given-names></name><name><surname>Manda-Handzlik</surname><given-names>A.</given-names></name><name><surname>Sieczkowska</surname><given-names>S.</given-names></name><name><surname>Moskalik</surname><given-names>A.</given-names></name><name><surname>Demkow</surname><given-names>U.</given-names></name><name><surname>Ciepiela</surname><given-names>O.</given-names></name></person-group> (<year>2017</year>). <article-title>Azithromycin and chloramphenicol diminish neutrophil extracellular traps (NETs) release</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>18</volume> (<issue>12</issue>), <fpage>2666</fpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/ijms18122666</pub-id> Online ahead of print.
</mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Cavalcanti</surname><given-names>A. B.</given-names></name><name><surname>Zampieri</surname><given-names>F. G.</given-names></name><name><surname>Rosa</surname><given-names>R. G.</given-names></name><name><surname>Azevedo</surname><given-names>L. C. P.</given-names></name><name><surname>Veiga</surname><given-names>V. C.</given-names></name><name><surname>Avezum</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19</article-title>. <source>N. Engl. J. Med.</source> &#xA0;<pub-id pub-id-type="doi">10.1056/NEJMoa2019014</pub-id>
</mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M.</given-names></name><name><surname>Calzetta</surname><given-names>L.</given-names></name><name><surname>Rogliani</surname><given-names>P.</given-names></name><name><surname>Matera</surname><given-names>M. G.</given-names></name></person-group> (<year>2019</year>). <article-title>Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD</article-title>. <source>Expert Opin. Investig. Drugs</source>
<volume>28</volume>, <fpage>827</fpage>&#x2013;<lpage>833</lpage>. <pub-id pub-id-type="doi">10.1080/13543784.2019.1661990</pub-id>
</mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y. J.</given-names></name><name><surname>Liu</surname><given-names>C. Y.</given-names></name><name><surname>Chiang</surname><given-names>B. L.</given-names></name><name><surname>Chao</surname><given-names>Y. C.</given-names></name><name><surname>Chen</surname><given-names>C. C.</given-names></name></person-group> (<year>2004</year>). <article-title>Induction of IL-8 release in lung cells via activator protein-1 by recombinant baculovirus displaying severe acute respiratory syndrome-coronavirus spike proteins: identification of two functional regions</article-title>. <source>J. Immunol.</source>
<volume>173</volume>, <fpage>7602</fpage>&#x2013;<lpage>7614</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.173.12.7602</pub-id>
<pub-id pub-id-type="pmid">15585888</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Bao</surname><given-names>Z.</given-names></name><name><surname>Gong</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>P.</given-names></name><name><surname>Yoshimura</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>J. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Regulation of inflammation by members of the formyl-peptide receptor family</article-title>. <source>J. Autoimmun.</source>
<volume>85</volume>, <fpage>64</fpage>&#x2013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2017.06.012</pub-id>
<pub-id pub-id-type="pmid">28689639</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>C. Y.</given-names></name><name><surname>Tsai</surname><given-names>Y. F.</given-names></name><name><surname>Huang</surname><given-names>W. J.</given-names></name><name><surname>Chang</surname><given-names>S. H.</given-names></name><name><surname>Hwang</surname><given-names>T. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Propofol inhibits endogenous formyl peptide-induced neutrophil activation and alleviates lung injury</article-title>. <source>Free Radic. Biol. Med.</source>
<volume>129</volume>, <fpage>372</fpage>&#x2013;<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.09.048</pub-id>
<pub-id pub-id-type="pmid">30312762</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Skinner</surname><given-names>D. D.</given-names></name><name><surname>Lane</surname><given-names>T. E.</given-names></name></person-group> (<year>2019</year>). <article-title>Innate immune responses and viral-induced neurologic disease</article-title>. <source>J. Clin. Med.</source>
<volume>8</volume> (<issue>1</issue>), <fpage>3</fpage>. <pub-id pub-id-type="doi">10.3390/jcm8010003</pub-id>
</mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiang</surname><given-names>C. C.</given-names></name><name><surname>Cheng</surname><given-names>W. J.</given-names></name><name><surname>Korinek</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>C. Y.</given-names></name><name><surname>Hwang</surname><given-names>T. L.</given-names></name></person-group> (<year>2019</year>). <article-title>Neutrophils in psoriasis</article-title>. <source>Front. Immunol.</source>
<volume>10</volume>, <elocation-id>2376</elocation-id>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.02376</pub-id>
<pub-id pub-id-type="pmid">31649677</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chuang</surname><given-names>I. C.</given-names></name><name><surname>Liu</surname><given-names>D. D.</given-names></name><name><surname>Kao</surname><given-names>S. J.</given-names></name><name><surname>Chen</surname><given-names>H. I.</given-names></name></person-group> (<year>2007</year>). <article-title>N-acetylcysteine attenuates the acute lung injury caused by phorbol myristate acetate in isolated rat lungs</article-title>. <source>Pulm. Pharmacol. Ther.</source>
<volume>20</volume>, <fpage>726</fpage>&#x2013;<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1016/j.pupt.2006.08.010</pub-id>
<pub-id pub-id-type="pmid">17071120</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cullberg</surname><given-names>M.</given-names></name><name><surname>Arfvidsson</surname><given-names>C.</given-names></name><name><surname>Larsson</surname><given-names>B.</given-names></name><name><surname>Malmgren</surname><given-names>A.</given-names></name><name><surname>Mitchell</surname><given-names>P.</given-names></name><name><surname>Wahlby Hamren</surname><given-names>U.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Pharmacokinetics of the oral selective CXCR2 antagonist AZD5069: a summary of eight phase I studies in healthy volunteers</article-title>. <source>Drugs R. D.</source>
<volume>18</volume>, <fpage>149</fpage>&#x2013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1007/s40268-018-0236-x</pub-id>
<pub-id pub-id-type="pmid">29856004</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Desilles</surname><given-names>J. P.</given-names></name><name><surname>Gregoire</surname><given-names>C.</given-names></name><name><surname>Le Cossec</surname><given-names>C.</given-names></name><name><surname>Lambert</surname><given-names>J.</given-names></name><name><surname>Mophawe</surname><given-names>O.</given-names></name><name><surname>Losser</surname><given-names>M. R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial</article-title>. <source>Trials</source>
<volume>21</volume>, <fpage>548</fpage>. <pub-id pub-id-type="doi">10.1186/s13063-020-04488-8</pub-id>
<pub-id pub-id-type="pmid">32560746</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Lagarde</surname><given-names>J.</given-names></name><name><surname>Xicota</surname><given-names>L.</given-names></name><name><surname>Corne</surname><given-names>H.</given-names></name><name><surname>Chantran</surname><given-names>Y.</given-names></name><name><surname>Chaigneau</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Neutrophil hyperactivation correlates with Alzheimer&#x2019;s disease progression</article-title>. <source>Ann. Neurol.</source>
<volume>83</volume>, <fpage>387</fpage>&#x2013;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1002/ana.25159</pub-id>
<pub-id pub-id-type="pmid">29369398</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorward</surname><given-names>D. A.</given-names></name><name><surname>Lucas</surname><given-names>C. D.</given-names></name><name><surname>Doherty</surname><given-names>M. K.</given-names></name><name><surname>Chapman</surname><given-names>G. B.</given-names></name><name><surname>Scholefield</surname><given-names>E. J.</given-names></name><name><surname>Conway Morris</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Novel role for endogenous mitochondrial formylated peptide-driven formyl peptide receptor 1 signalling in acute respiratory distress syndrome</article-title>. <source>Thorax</source>
<volume>72</volume>, <fpage>928</fpage>&#x2013;<lpage>936</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2017-210030</pub-id>
<pub-id pub-id-type="pmid">28469031</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farouk</surname><given-names>A.</given-names></name><name><surname>Salman</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Dapsone and doxycycline could be potential treatment modalities for COVID-19</article-title>. <source>Med. Hypotheses</source>
<volume>140</volume>, <elocation-id>109768</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.mehy.2020.109768</pub-id>
<pub-id pub-id-type="pmid">32339778</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fujita</surname><given-names>Y.</given-names></name><name><surname>Matsuoka</surname><given-names>N.</given-names></name><name><surname>Temmoku</surname><given-names>J.</given-names></name><name><surname>Furuya</surname><given-names>M. Y.</given-names></name><name><surname>Asano</surname><given-names>T.</given-names></name><name><surname>Sato</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Hydroxychloroquine inhibits IL-1&#x3B2; production from amyloid-stimulated human neutrophils</article-title>. <source>Arthritis Res. Ther.</source>
<volume>21</volume>, <fpage>250</fpage>. <pub-id pub-id-type="doi">10.1186/s13075-019-2040-6</pub-id>
<pub-id pub-id-type="pmid">31775905</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giorgi</surname><given-names>M.</given-names></name><name><surname>Cardarelli</surname><given-names>S.</given-names></name><name><surname>Ragusa</surname><given-names>F.</given-names></name><name><surname>Saliola</surname><given-names>M.</given-names></name><name><surname>Biagioni</surname><given-names>S.</given-names></name><name><surname>Poiana</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Phosphodiesterase inhibitors: could they be beneficial for the treatment of COVID-19</article-title>? <source>Int. J. Mol. Sci.</source>
<volume>21</volume>, <fpage>5338</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21155338</pub-id>
</mixed-citation>
      </ref>
      <ref id="B37">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gramegna</surname><given-names>A.</given-names></name><name><surname>Amati</surname><given-names>F.</given-names></name><name><surname>Terranova</surname><given-names>L.</given-names></name><name><surname>Sotgiu</surname><given-names>G.</given-names></name><name><surname>Tarsia</surname><given-names>P.</given-names></name><name><surname>Miglietta</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Neutrophil elastase in bronchiectasis</article-title>. <source>Respir. Res.</source>
<volume>18</volume>, <fpage>211</fpage>&#x2013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1186/s12931-017-0691-x</pub-id>
<pub-id pub-id-type="pmid">29258516</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gr&#xE9;goire</surname><given-names>M.</given-names></name><name><surname>Uhel</surname><given-names>F.</given-names></name><name><surname>Lesouhaitier</surname><given-names>M.</given-names></name><name><surname>Gacouin</surname><given-names>A.</given-names></name><name><surname>Guirriec</surname><given-names>M.</given-names></name><name><surname>Mourcin</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS</article-title>. <source>Eur. Respir. J.</source>
<volume>52</volume>, <fpage>1702590</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.02590-2017</pub-id>
<pub-id pub-id-type="pmid">29946009</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Groeneveld</surname><given-names>A. B.</given-names></name><name><surname>Raijmakers</surname><given-names>P. G.</given-names></name><name><surname>Hack</surname><given-names>C. E.</given-names></name><name><surname>Thijs</surname><given-names>L. G.</given-names></name></person-group> (<year>1995</year>). <article-title>Interleukin 8-related neutrophil elastase and the severity of the adult respiratory distress syndrome</article-title>. <source>Cytokine</source>
<volume>7</volume>, <fpage>746</fpage>&#x2013;<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1006/cyto.1995.0089</pub-id>
<pub-id pub-id-type="pmid">8580386</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guan</surname><given-names>W. J.</given-names></name><name><surname>Ni</surname><given-names>Z. Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W. H.</given-names></name><name><surname>Ou</surname><given-names>C. Q.</given-names></name><name><surname>He</surname><given-names>J. X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical characteristics of coronavirus cisease 2019 in China</article-title>. <source>N. Engl. J. Med.</source>
<volume>382</volume>, <fpage>1708</fpage>&#x2013;<lpage>1720</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id>
<pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guaraldi</surname><given-names>G.</given-names></name><name><surname>Meschiari</surname><given-names>M.</given-names></name><name><surname>Cozzi-Lepri</surname><given-names>A.</given-names></name><name><surname>Milic</surname><given-names>J.</given-names></name><name><surname>Tonelli</surname><given-names>R.</given-names></name><name><surname>Menozzi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Tocilizumab in patients with severe COVID-19: a retrospective cohort study</article-title>. <source>Lancet Rheumatol.</source>
<volume>2</volume>, <fpage>e474</fpage>&#x2013;<lpage>e484</lpage>. <pub-id pub-id-type="doi">10.1016/S2665-9913(20)30173-9</pub-id>
<pub-id pub-id-type="pmid">32835257</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guervilly</surname><given-names>C.</given-names></name><name><surname>Lacroix</surname><given-names>R.</given-names></name><name><surname>Forel</surname><given-names>J. M.</given-names></name><name><surname>Roch</surname><given-names>A.</given-names></name><name><surname>Camoin-Jau</surname><given-names>L.</given-names></name><name><surname>Papazian</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome</article-title>. <source>Crit. Care</source>
<volume>15</volume>, <fpage>R31</fpage>. <pub-id pub-id-type="doi">10.1186/cc9978</pub-id>
<pub-id pub-id-type="pmid">21244685</pub-id></mixed-citation>
      </ref>
      <ref id="B43">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>D. W.</given-names></name><name><surname>Wang</surname><given-names>C. Y.</given-names></name><name><surname>Shih</surname><given-names>H. C.</given-names></name></person-group> (<year>2019</year>). <article-title>N-acetylcysteine and atorvastatin alleviates lung injury due to ischemia-reperfusion injury in rats</article-title>. <source>J. Chin. Med. Assoc.</source>
<volume>82</volume>, <fpage>909</fpage>&#x2013;<lpage>914</lpage>. <pub-id pub-id-type="doi">10.1097/JCMA.0000000000000193</pub-id>
<pub-id pub-id-type="pmid">31567653</pub-id></mixed-citation>
      </ref>
      <ref id="B44">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y. R.</given-names></name><name><surname>Cao</surname><given-names>Q. D.</given-names></name><name><surname>Hong</surname><given-names>Z. S.</given-names></name><name><surname>Tan</surname><given-names>Y. Y.</given-names></name><name><surname>Chen</surname><given-names>S. D.</given-names></name><name><surname>Jin</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status</article-title>. <source>Mil. Med. Res.</source>
<volume>7</volume>, <fpage>11</fpage>. <pub-id pub-id-type="doi">10.1186/s40779-020-00240-0</pub-id>
<pub-id pub-id-type="pmid">32169119</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haick</surname><given-names>A. K.</given-names></name><name><surname>Rzepka</surname><given-names>J. P.</given-names></name><name><surname>Brandon</surname><given-names>E.</given-names></name><name><surname>Balemba</surname><given-names>O. B.</given-names></name><name><surname>Miura</surname><given-names>T. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Neutrophils are needed for an effective immune response against pulmonary rat coronavirus infection, but also contribute to pathology</article-title>. <source>J. Gen. Virol.</source>
<volume>95</volume>, <fpage>578</fpage>&#x2013;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.061986-0</pub-id>
<pub-id pub-id-type="pmid">24323639</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hashim</surname><given-names>P. W.</given-names></name><name><surname>Chima</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>H. J.</given-names></name><name><surname>Bares</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>C. J.</given-names></name><name><surname>Singer</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial</article-title>. <source>J. Am. Acad. Dermatol.</source>
<volume>82</volume>, <fpage>360</fpage>&#x2013;<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2019.06.1288</pub-id>
<pub-id pub-id-type="pmid">31279028</pub-id></mixed-citation>
      </ref>
      <ref id="B47">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heller</surname><given-names>A. R.</given-names></name><name><surname>Groth</surname><given-names>G.</given-names></name><name><surname>Heller</surname><given-names>S. C.</given-names></name><name><surname>Breitkreutz</surname><given-names>R.</given-names></name><name><surname>Nebe</surname><given-names>T.</given-names></name><name><surname>Quintel</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>N-acetylcysteine reduces respiratory burst but augments neutrophil phagocytosis in intensive care unit patients</article-title>. <source>Crit. Care Med.</source>
<volume>29</volume>, <fpage>272</fpage>&#x2013;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1097/00003246-200102000-00009</pub-id>.
<pub-id pub-id-type="pmid">11246305</pub-id></mixed-citation>
      </ref>
      <ref id="B48">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hendry</surname><given-names>B. M.</given-names></name><name><surname>Stafford</surname><given-names>N.</given-names></name><name><surname>Arnold</surname><given-names>A. D.</given-names></name><name><surname>Sangwaiya</surname><given-names>A.</given-names></name><name><surname>Manglam</surname><given-names>V.</given-names></name><name><surname>Rosen</surname><given-names>S. D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Hypothesis: pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients</article-title>. <source>Pharmacol. Res. Perspect.</source>
<volume>8</volume>, <fpage>e00631</fpage>. <pub-id pub-id-type="doi">10.1002/prp2.631</pub-id>
<pub-id pub-id-type="pmid">32715661</pub-id></mixed-citation>
      </ref>
      <ref id="B49">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henke</surname><given-names>M. O.</given-names></name><name><surname>Ratjen</surname><given-names>F.</given-names></name></person-group> (<year>2007</year>). <article-title>Mucolytics in cystic fibrosis</article-title>. <source>Paediatr. Respir. Rev.</source>
<volume>8</volume>, <fpage>24</fpage>&#x2013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.prrv.2007.02.009</pub-id>
<pub-id pub-id-type="pmid">17419975</pub-id></mixed-citation>
      </ref>
      <ref id="B50">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holz</surname><given-names>O.</given-names></name><name><surname>Khalilieh</surname><given-names>S.</given-names></name><name><surname>Ludwig-Sengpiel</surname><given-names>A.</given-names></name><name><surname>Watz</surname><given-names>H.</given-names></name><name><surname>Stryszak</surname><given-names>P.</given-names></name><name><surname>Soni</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</article-title>. <source>Eur. Respir. J.</source>
<volume>35</volume>, <fpage>564</fpage>&#x2013;<lpage>570</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00048509</pub-id>
<pub-id pub-id-type="pmid">19643947</pub-id></mixed-citation>
      </ref>
      <ref id="B51">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Honda</surname><given-names>M.</given-names></name><name><surname>Kubes</surname><given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>Neutrophils and neutrophil extracellular traps in the liver and gastrointestinal system</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source>
<volume>15</volume>, <fpage>206</fpage>&#x2013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1038/nrgastro.2017.183</pub-id>
<pub-id pub-id-type="pmid">29382950</pub-id></mixed-citation>
      </ref>
      <ref id="B52">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>R. I.</given-names></name><name><surname>Freeman</surname><given-names>P. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials</article-title>. <source>Med. Hypotheses</source>
<volume>143</volume>, <elocation-id>109851</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.mehy.2020.109851</pub-id>
<pub-id pub-id-type="pmid">32534175</pub-id></mixed-citation>
      </ref>
      <ref id="B53">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>J. J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation</article-title>. <source>Nat. Immunol.</source>
<volume>21</volume>, <fpage>736</fpage>&#x2013;<lpage>745</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-020-0669-6</pub-id>
<pub-id pub-id-type="pmid">32367036</pub-id></mixed-citation>
      </ref>
      <ref id="B54">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huet</surname><given-names>T.</given-names></name><name><surname>Beaussier</surname><given-names>H.</given-names></name><name><surname>Voisin</surname><given-names>O.</given-names></name><name><surname>Jouveshomme</surname><given-names>S.</given-names></name><name><surname>Dauriat</surname><given-names>G.</given-names></name><name><surname>Lazareth</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Anakinra for severe forms of COVID-19: a cohort study</article-title>. <source>Lancet Rheumatol.</source>
<volume>2</volume>, <fpage>e393</fpage>&#x2013;<lpage>e400</lpage>. <pub-id pub-id-type="doi">10.1016/S2665-9913(20)30164-8</pub-id>
<pub-id pub-id-type="pmid">32835245</pub-id></mixed-citation>
      </ref>
      <ref id="B55">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kast</surname><given-names>R. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Dapsone as treatment adjunct in ARDS</article-title>. <source>Exp. Lung Res.</source>
<volume>46</volume>, <fpage>157</fpage>&#x2013;<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1080/01902148.2020.1753266</pub-id>
<pub-id pub-id-type="pmid">32286085</pub-id></mixed-citation>
      </ref>
      <ref id="B56">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors</article-title>. <source>Nat. Immunol.</source>
<volume>11</volume>, <fpage>373</fpage>&#x2013;<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1863</pub-id>
<pub-id pub-id-type="pmid">20404851</pub-id></mixed-citation>
      </ref>
      <ref id="B57">
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Khan</surname><given-names>A. R.</given-names></name><name><surname>Soneja</surname><given-names>M.</given-names></name><name><surname>George</surname><given-names>N.</given-names></name><name><surname>Wig</surname><given-names>N.</given-names></name></person-group> (<year>2020</year>). <article-title>Anakinra for severe forms of COVID-19</article-title>. <source>Lancet Rheumatol.</source> &#xA0;<pub-id pub-id-type="doi">10.1016/S2665-9913(20)30271-X</pub-id>
</mixed-citation>
      </ref>
      <ref id="B58">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>D. H.</given-names></name><name><surname>Chung</surname><given-names>J. H.</given-names></name><name><surname>Son</surname><given-names>B. S.</given-names></name><name><surname>Kim</surname><given-names>Y. J.</given-names></name><name><surname>Lee</surname><given-names>S. G.</given-names></name></person-group> (<year>2014</year>). <article-title>Effect of a neutrophil elastase inhibitor on ventilator-induced lung injury in rats</article-title>. <source>J.&#xA0;Thorac. Dis.</source>
<volume>6</volume>, <fpage>1681</fpage>&#x2013;<lpage>1689</lpage>. <pub-id pub-id-type="doi">10.3978/j.issn.2072-1439.2014.11.10</pub-id>
<pub-id pub-id-type="pmid">25589960</pub-id></mixed-citation>
      </ref>
      <ref id="B59">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Korkmaz</surname><given-names>B.</given-names></name><name><surname>Lesner</surname><given-names>A.</given-names></name><name><surname>Marchand-Adam</surname><given-names>S.</given-names></name><name><surname>Moss</surname><given-names>C.</given-names></name><name><surname>Jenne</surname><given-names>D. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Lung protection by cathepsin C inhibition: a new hope for COVID-19 and ARDS</article-title>? <source>J. Med. Chem.</source>
<volume>7</volume>, <fpage>2020</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00776</pub-id>
</mixed-citation>
      </ref>
      <ref id="B60">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kulshrestha</surname><given-names>R.</given-names></name><name><surname>Pandey</surname><given-names>A.</given-names></name><name><surname>Jaggi</surname><given-names>A.</given-names></name><name><surname>Bansal</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Beneficial effects of N-acetylcysteine on protease-antiprotease balance in attenuating bleomycin-induced pulmonary fibrosis in rats</article-title>. <source>Iran. J. Basic Med. Sci.</source>
<volume>23</volume>, <fpage>396</fpage>&#x2013;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.22038/IJBMS.2020.39031.9261</pub-id>
<pub-id pub-id-type="pmid">32440328</pub-id></mixed-citation>
      </ref>
      <ref id="B61">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kusunoki</surname><given-names>Y.</given-names></name><name><surname>Nakazawa</surname><given-names>D.</given-names></name><name><surname>Shida</surname><given-names>H.</given-names></name><name><surname>Hattanda</surname><given-names>F.</given-names></name><name><surname>Miyoshi</surname><given-names>A.</given-names></name><name><surname>Masuda</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Peptidylarginine deiminase inhibitor suppresses neutrophil extracellular trap formation and MPO-ANCA production</article-title>. <source>Front. Immunol.</source>
<volume>7</volume>:<elocation-id>227</elocation-id>. <pub-id pub-id-type="doi">10.3389/fimmu.2016.00227</pub-id>
<pub-id pub-id-type="pmid">27375623</pub-id></mixed-citation>
      </ref>
      <ref id="B62">
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Lagunas-Rangel</surname><given-names>F. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis</article-title>. <source>J. Med. Virol.</source> &#xA0;<pub-id pub-id-type="doi">10.1002/jmv.25819</pub-id>
</mixed-citation>
      </ref>
      <ref id="B63">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lai</surname><given-names>C. C.</given-names></name><name><surname>Liu</surname><given-names>Y. H.</given-names></name><name><surname>Wang</surname><given-names>C. Y.</given-names></name><name><surname>Wang</surname><given-names>Y. H.</given-names></name><name><surname>Hsueh</surname><given-names>S. C.</given-names></name><name><surname>Yen</surname><given-names>M. Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths</article-title>. <source>J. Microbiol. Immunol. Infect.</source>
<volume>53</volume>, <fpage>404</fpage>&#x2013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmii.2020.02.012</pub-id>
<pub-id pub-id-type="pmid">32173241</pub-id></mixed-citation>
      </ref>
      <ref id="B64">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Langereis</surname><given-names>J. D.</given-names></name><name><surname>Oudijk</surname><given-names>E. J.</given-names></name><name><surname>Schweizer</surname><given-names>R. C.</given-names></name><name><surname>Lammers</surname><given-names>J. W.</given-names></name><name><surname>Koenderman</surname><given-names>L.</given-names></name><name><surname>Ulfman</surname><given-names>L. H.</given-names></name></person-group> (<year>2011</year>). <article-title>Steroids induce a disequilibrium of secreted interleukin-1 receptor antagonist and interleukin-1&#x3B2; synthesis by human neutrophils</article-title>. <source>Eur. Respir. J.</source>
<volume>37</volume>, <fpage>406</fpage>&#x2013;<lpage>415</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00170409</pub-id>
<pub-id pub-id-type="pmid">20650986</pub-id></mixed-citation>
      </ref>
      <ref id="B65">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lazaar</surname><given-names>A. L.</given-names></name><name><surname>Miller</surname><given-names>B. E.</given-names></name><name><surname>Donald</surname><given-names>A. C.</given-names></name><name><surname>Keeley</surname><given-names>T.</given-names></name><name><surname>Ambery</surname><given-names>C.</given-names></name><name><surname>Russell</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial</article-title>. <source>Respir. Res.</source>
<volume>21</volume>, <fpage>149</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-020-01401-4</pub-id>
<pub-id pub-id-type="pmid">32532258</pub-id></mixed-citation>
      </ref>
      <ref id="B66">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>P. I.</given-names></name><name><surname>Hsueh</surname><given-names>P. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV</article-title>. <source>J. Microbiol. Immunol. Infect.</source>
<volume>53</volume>, <fpage>365</fpage>&#x2013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmii.2020.02.001</pub-id>
<pub-id pub-id-type="pmid">32035811</pub-id></mixed-citation>
      </ref>
      <ref id="B67">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lefran&#xE7;ais</surname><given-names>E.</given-names></name><name><surname>Mallavia</surname><given-names>B.</given-names></name><name><surname>Zhuo</surname><given-names>H.</given-names></name><name><surname>Calfee</surname><given-names>C. S.</given-names></name><name><surname>Looney</surname><given-names>M. R.</given-names></name></person-group> (<year>2018</year>). <article-title>Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury</article-title>. <source>JCI Insight</source>
<volume>3</volume> (<issue>3</issue>), <elocation-id>e98178</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1172/jci.insight.98178</pub-id>
</mixed-citation>
      </ref>
      <ref id="B68">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leslie</surname><given-names>J.</given-names></name><name><surname>Millar</surname><given-names>B. J.</given-names></name><name><surname>Del Carpio Pons</surname><given-names>A.</given-names></name><name><surname>Burgoyne</surname><given-names>R. A.</given-names></name><name><surname>Frost</surname><given-names>J. D.</given-names></name><name><surname>Barksby</surname><given-names>B. S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis</article-title>. <source>JCI Insight</source>
<volume>5</volume> (<issue>4</issue>), <elocation-id>e125937</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1172/jci.insight.125937</pub-id>
</mixed-citation>
      </ref>
      <ref id="B69">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>H. D.</given-names></name><name><surname>Liddle</surname><given-names>J.</given-names></name><name><surname>Coote</surname><given-names>J. E.</given-names></name><name><surname>Atkinson</surname><given-names>S. J.</given-names></name><name><surname>Barker</surname><given-names>M. D.</given-names></name><name><surname>Bax</surname><given-names>B. D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation</article-title>. <source>Nat. Chem. Biol.</source>
<volume>11</volume>, <fpage>189</fpage>&#x2013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.1735</pub-id>
<pub-id pub-id-type="pmid">25622091</pub-id></mixed-citation>
      </ref>
      <ref id="B70">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>C.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Strnad</surname><given-names>J.</given-names></name><name><surname>Bernabei</surname><given-names>L.</given-names></name><name><surname>Vogl</surname><given-names>D. T.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A novel peptidylarginine deiminase 4 (PAD4) inhibitor BMS-P5 blocks formation of neutrophil extracellular traps and delays progression of multiple myeloma</article-title>. <source>Mol. Cancer Ther.</source>
<volume>19</volume>, <fpage>1530</fpage>&#x2013;<lpage>1538</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-19-1020</pub-id>
<pub-id pub-id-type="pmid">32371579</pub-id></mixed-citation>
      </ref>
      <ref id="B71">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Xiang</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China</article-title>. <source>Int. J. Infect. Dis.</source>
<volume>94</volume>, <fpage>128</fpage>&#x2013;<lpage>132</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.ijid.2020.03.053</pub-id>
<pub-id pub-id-type="pmid">32251805</pub-id></mixed-citation>
      </ref>
      <ref id="B72">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Y. C.</given-names></name><name><surname>Bai</surname><given-names>W. Z.</given-names></name><name><surname>Hashikawa</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients</article-title>. <source>J.&#xA0;Med. Virol.</source>
<volume>92</volume>, <fpage>552</fpage>&#x2013;<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25728</pub-id>
<pub-id pub-id-type="pmid">32104915</pub-id></mixed-citation>
      </ref>
      <ref id="B73">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liew</surname><given-names>P. X.</given-names></name><name><surname>Kubes</surname><given-names>P.</given-names></name></person-group> (<year>2019</year>). <article-title>The neutrophil&#x2019;s role during health and disease</article-title>. <source>Physiol. Rev.</source>
<volume>99</volume>, <fpage>1223</fpage>&#x2013;<lpage>1248</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00012.2018</pub-id>
<pub-id pub-id-type="pmid">30758246</pub-id></mixed-citation>
      </ref>
      <ref id="B74">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>W. C.</given-names></name><name><surname>Gowdy</surname><given-names>K. M.</given-names></name><name><surname>Madenspacher</surname><given-names>J. H.</given-names></name><name><surname>Zemans</surname><given-names>R. L.</given-names></name><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Lyons-Cohen</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Epithelial membrane protein 2 governs transepithelial migration of neutrophils into the airspace</article-title>. <source>J. Clin. Invest.</source>
<volume>130</volume>, <fpage>157</fpage>&#x2013;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1172/JCI127144</pub-id>
<pub-id pub-id-type="pmid">31550239</pub-id></mixed-citation>
      </ref>
      <ref id="B75">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>D. D.</given-names></name><name><surname>Kao</surname><given-names>S. J.</given-names></name><name><surname>Chen</surname><given-names>H. I.</given-names></name></person-group> (<year>2008</year>). <article-title>N-acetylcysteine attenuates acute lung injury induced by fat embolism</article-title>. <source>Crit. Care Med.</source>
<volume>36</volume>, <fpage>565</fpage>&#x2013;<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1097/01.CCM.0000299737.24338.5C</pub-id>
<pub-id pub-id-type="pmid">18216605</pub-id></mixed-citation>
      </ref>
      <ref id="B76">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>F. C.</given-names></name><name><surname>Yu</surname><given-names>H. P.</given-names></name><name><surname>Syu</surname><given-names>Y. T.</given-names></name><name><surname>Fang</surname><given-names>J. Y.</given-names></name><name><surname>Lin</surname><given-names>C. F.</given-names></name><name><surname>Chang</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Honokiol suppresses formyl peptide-induced human neutrophil activation by blocking formyl peptide receptor 1</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>, <fpage>6718</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-07131-w</pub-id>
<pub-id pub-id-type="pmid">28751674</pub-id></mixed-citation>
      </ref>
      <ref id="B77">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19</article-title>. <source>Acta Pharm. Sin. B</source>
<volume>10</volume> (<issue>7</issue>), <fpage>1205</fpage>&#x2013;<lpage>1215</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.apsb.2020.04.008</pub-id>
<pub-id pub-id-type="pmid">32318327</pub-id></mixed-citation>
      </ref>
      <ref id="B78">
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Lobo-Galo</surname><given-names>N.</given-names></name><name><surname>Terrazas-L&#xF3;pez</surname><given-names>M.</given-names></name><name><surname>Mart&#xED;nez-Mart&#xED;nez</surname><given-names>A.</given-names></name><name><surname>D&#xED;az-S&#xE1;nchez</surname><given-names>A. G.</given-names></name></person-group> (<year>2020</year>). <article-title>FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication</article-title>. <source>J. Biomol. Struct. Dyn.</source>
<fpage>1</fpage>&#x2013;<lpage>9</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1080/07391102.2020.1764393</pub-id>
</mixed-citation>
      </ref>
      <ref id="B79">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>C. C.</given-names></name><name><surname>Chen</surname><given-names>M. Y.</given-names></name><name><surname>Lee</surname><given-names>W. S.</given-names></name><name><surname>Chang</surname><given-names>Y. L.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential therapeutic agents against COVID-19: What we know so far</article-title>. <source>J. Chin. Med. Assoc.</source>
<volume>83</volume>, <fpage>534</fpage>&#x2013;<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1097/JCMA.0000000000000318</pub-id>
<pub-id pub-id-type="pmid">32243270</pub-id></mixed-citation>
      </ref>
      <ref id="B80">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Drug treatment options for the 2019-new coronavirus, (2019-nCoV)</article-title>. <source>Biosci. Trends</source>
<volume>14</volume>, <fpage>69</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.5582/bst.2020.01020</pub-id>
<pub-id pub-id-type="pmid">31996494</pub-id></mixed-citation>
      </ref>
      <ref id="B81">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Madan</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Yates</surname><given-names>P.</given-names></name><name><surname>Washburn</surname><given-names>M. L.</given-names></name><name><surname>Roberts</surname><given-names>G.</given-names></name><name><surname>Peat</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Efficacy and safety of danirixin (GSK1325756) co-administered with standard-of-care antiviral (oseltamivir): a phase 2b, global, randomized study of adults hospitalized with influenza</article-title>. <source>Open Forum Infect. Dis.</source>
<volume>6</volume>, <elocation-id>ofz163</elocation-id>. <pub-id pub-id-type="doi">10.1093/ofid/ofz163</pub-id>
<pub-id pub-id-type="pmid">31041358</pub-id></mixed-citation>
      </ref>
      <ref id="B82">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maki</surname><given-names>C.</given-names></name><name><surname>Inoue</surname><given-names>Y.</given-names></name><name><surname>Ishihara</surname><given-names>T.</given-names></name><name><surname>Hirano</surname><given-names>Y.</given-names></name><name><surname>Kondo</surname><given-names>Y.</given-names></name><name><surname>Sueyoshi</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Evaluation of appropriate indications for the use of sivelestat sodium in acute respiratory distress syndrome: a retrospective cohort study</article-title>. <source>Acute Med. Surg.</source>
<volume>7</volume>, <fpage>e471</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/ams2.471</pub-id>
<pub-id pub-id-type="pmid">31988783</pub-id></mixed-citation>
      </ref>
      <ref id="B83">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manzenreiter</surname><given-names>R.</given-names></name><name><surname>Kienberger</surname><given-names>F.</given-names></name><name><surname>Marcos</surname><given-names>V.</given-names></name><name><surname>Schilcher</surname><given-names>K.</given-names></name><name><surname>Krautgartner</surname><given-names>W. D.</given-names></name><name><surname>Obermayer</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Ultrastructural characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy</article-title>. <source>J. Cyst. Fibros.</source>
<volume>11</volume>, <fpage>84</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcf.2011.09.008</pub-id>
<pub-id pub-id-type="pmid">21996135</pub-id></mixed-citation>
      </ref>
      <ref id="B84">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matthay</surname><given-names>M. A.</given-names></name><name><surname>Aldrich</surname><given-names>J. M.</given-names></name><name><surname>Gotts</surname><given-names>J. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Treatment for severe acute respiratory distress syndrome from COVID-19</article-title>. <source>Lancet Respir. Med.</source>
<volume>8</volume>, <fpage>433</fpage>&#x2013;<lpage>434</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30127-2</pub-id>
<pub-id pub-id-type="pmid">32203709</pub-id></mixed-citation>
      </ref>
      <ref id="B85">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mercer</surname><given-names>P. F.</given-names></name><name><surname>Williams</surname><given-names>A. E.</given-names></name><name><surname>Scotton</surname><given-names>C. J.</given-names></name><name><surname>Jos&#xE9;</surname><given-names>R. J.</given-names></name><name><surname>Sulikowski</surname><given-names>M.</given-names></name><name><surname>Moffatt</surname><given-names>J. D.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Proteinase-activated receptor-1, CCL2, and CCL7 regulate acute neutrophilic lung inflammation</article-title>. <source>Am. J. Respir. Cell Mol. Biol.</source>
<volume>50</volume>, <fpage>144</fpage>&#x2013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2013-0142OC</pub-id>
<pub-id pub-id-type="pmid">23972264</pub-id></mixed-citation>
      </ref>
      <ref id="B86">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mi</surname><given-names>M. Y.</given-names></name><name><surname>Matthay</surname><given-names>M. A.</given-names></name><name><surname>Morris</surname><given-names>A. H.</given-names></name></person-group> (<year>2018</year>). <article-title>Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome</article-title>. <source>N. Engl. J. Med.</source>
<volume>379</volume>, <fpage>884</fpage>&#x2013;<lpage>887</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMclde1804601</pub-id>
<pub-id pub-id-type="pmid">30157406</pub-id></mixed-citation>
      </ref>
      <ref id="B87">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Middleton</surname><given-names>E. A.</given-names></name><name><surname>He</surname><given-names>X. Y.</given-names></name><name><surname>Denorme</surname><given-names>F.</given-names></name><name><surname>Campbell</surname><given-names>R. A.</given-names></name><name><surname>Ng</surname><given-names>D.</given-names></name><name><surname>Salvatore</surname><given-names>S. P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome</article-title>. <source>Blood</source>
<volume>136</volume> (<issue>10</issue>), <fpage>1169</fpage>&#x2013;<lpage>1179</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1182/blood.2020007008</pub-id>
<pub-id pub-id-type="pmid">32597954</pub-id></mixed-citation>
      </ref>
      <ref id="B88">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>E. J.</given-names></name><name><surname>Cohen</surname><given-names>A. B.</given-names></name><name><surname>Nagao</surname><given-names>S.</given-names></name><name><surname>Griffith</surname><given-names>D.</given-names></name><name><surname>Maunder</surname><given-names>R. J.</given-names></name><name><surname>Martin</surname><given-names>T. R.</given-names></name><etal/></person-group> (<year>1992</year>). <article-title>Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality</article-title>. <source>Am. Rev. Respir. Dis.</source>
<volume>146</volume>, <fpage>427</fpage>&#x2013;<lpage>432</lpage>. <pub-id pub-id-type="doi">10.1164/ajrccm/146.2.427</pub-id>
<pub-id pub-id-type="pmid">1489135</pub-id></mixed-citation>
      </ref>
      <ref id="B89">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>M. M. A.</given-names></name><name><surname>El-Shimy</surname><given-names>I. A.</given-names></name><name><surname>Hadi</surname><given-names>M. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Neutrophil elastase inhibitors: a potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications</article-title>? <source>Crit. Care</source>
<volume>24</volume>, <fpage>311</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-020-03023-0</pub-id>
<pub-id pub-id-type="pmid">32513225</pub-id></mixed-citation>
      </ref>
      <ref id="B90">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mokhtari</surname><given-names>V.</given-names></name><name><surname>Afsharian</surname><given-names>P.</given-names></name><name><surname>Shahhoseini</surname><given-names>M.</given-names></name><name><surname>Kalantar</surname><given-names>S. M.</given-names></name><name><surname>Moini</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>A review on various uses of N-acetyl cysteine</article-title>. <source>Cell J.</source>
<volume>19</volume>, <fpage>11</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.22074/cellj.2016.4872</pub-id>
<pub-id pub-id-type="pmid">28367412</pub-id></mixed-citation>
      </ref>
      <ref id="B91">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakos</surname><given-names>G.</given-names></name><name><surname>Kitsiouli</surname><given-names>E. I.</given-names></name><name><surname>Tsangaris</surname><given-names>I.</given-names></name><name><surname>Lekka</surname><given-names>M. E.</given-names></name></person-group> (<year>1998</year>). <article-title>Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components</article-title>. <source>Intensive Care Med.</source>
<volume>24</volume>, <fpage>296</fpage>&#x2013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1007/s001340050571</pub-id>
<pub-id pub-id-type="pmid">9609406</pub-id></mixed-citation>
      </ref>
      <ref id="B92">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Narasaraju</surname><given-names>T.</given-names></name><name><surname>Tang</surname><given-names>B. M.</given-names></name><name><surname>Herrmann</surname><given-names>M.</given-names></name><name><surname>Muller</surname><given-names>S.</given-names></name><name><surname>Chow</surname><given-names>V. T. K.</given-names></name><name><surname>Radic</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Neutrophilia and NETopathy as key pathologic drivers of progressive lung impairment in patients with COVID-19</article-title>. <source>Front. Pharmacol.</source>
<volume>11</volume>:<elocation-id>870</elocation-id>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00870</pub-id>
<pub-id pub-id-type="pmid">32581816</pub-id></mixed-citation>
      </ref>
      <ref id="B93">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nathan</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Neutrophils and COVID-19: Nots, NETs, and knots</article-title>. <source>J. Exp. Med.</source>
<volume>21</volume> (<issue>9</issue>), <fpage>e20201439.7</fpage>. <pub-id pub-id-type="doi">10.1084/jem.20201439</pub-id>
</mixed-citation>
      </ref>
      <ref id="B94">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>N&#xE9;meth</surname><given-names>T.</given-names></name><name><surname>Sperandio</surname><given-names>M.</given-names></name><name><surname>M&#xF3;csai</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Neutrophils as emerging therapeutic&#xA0;targets</article-title>. <source>Nat. Rev. Drug Discovery</source>
<volume>19</volume>, <fpage>253</fpage>&#x2013;<lpage>275</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-019-0054-z</pub-id>
<pub-id pub-id-type="pmid">31969717</pub-id></mixed-citation>
      </ref>
      <ref id="B95">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ni</surname><given-names>Y. N.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>B. M.</given-names></name><name><surname>Liang</surname><given-names>Z. A.</given-names></name></person-group> (<year>2019</year>). <article-title>The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis</article-title>. <source>Crit. Care</source>
<volume>23</volume>, <fpage>99</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-019-2395-8</pub-id>
<pub-id pub-id-type="pmid">30917856</pub-id></mixed-citation>
      </ref>
      <ref id="B96">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>D. J.</given-names></name><name><surname>Wiley</surname><given-names>K.</given-names></name><name><surname>Dainty</surname><given-names>I.</given-names></name><name><surname>Macintosh</surname><given-names>F.</given-names></name><name><surname>Phillips</surname><given-names>C.</given-names></name><name><surname>Gaw</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>353</volume>, <fpage>340</fpage>&#x2013;<lpage>350</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.114.221358</pub-id>
<pub-id pub-id-type="pmid">25736418</pub-id></mixed-citation>
      </ref>
      <ref id="B97">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ohe</surname><given-names>M.</given-names></name><name><surname>Shida</surname><given-names>H.</given-names></name><name><surname>Jodo</surname><given-names>S.</given-names></name><name><surname>Kusunoki</surname><given-names>Y.</given-names></name><name><surname>Seki</surname><given-names>M.</given-names></name><name><surname>Furuya</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Macrolide treatment for COVID-19: will this be the way forward</article-title>? <source>Biosci. Trends</source>
<volume>14</volume>, <fpage>159</fpage>&#x2013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.5582/bst.2020.03058</pub-id>
<pub-id pub-id-type="pmid">32249257</pub-id></mixed-citation>
      </ref>
      <ref id="B98">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oubihi</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Caught by NETs</article-title>. <source>Nat. Rev. Immunol.</source>
<volume>20</volume>, <fpage>462</fpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-0384-4</pub-id>
</mixed-citation>
      </ref>
      <ref id="B99">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Palm&#xE9;r</surname><given-names>R.</given-names></name><name><surname>M&#xE4;enp&#xE4;&#xE4;</surname><given-names>J.</given-names></name><name><surname>Jauhiainen</surname><given-names>A.</given-names></name><name><surname>Larsson</surname><given-names>B.</given-names></name><name><surname>Mo</surname><given-names>J.</given-names></name><name><surname>Russell</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Dipeptidyl Peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>104</volume>, <fpage>1155</fpage>&#x2013;<lpage>1164</lpage>. <pub-id pub-id-type="doi">10.1002/cpt.1053</pub-id>
<pub-id pub-id-type="pmid">29484635</pub-id></mixed-citation>
      </ref>
      <ref id="B100">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Papayannopoulos</surname><given-names>V.</given-names></name><name><surname>Staab</surname><given-names>D.</given-names></name><name><surname>Zychlinsky</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy</article-title>. <source>PloS One</source>
<volume>6</volume>, <elocation-id>e28526</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0028526</pub-id>
<pub-id pub-id-type="pmid">22174830</pub-id></mixed-citation>
      </ref>
      <ref id="B101">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Phillips</surname><given-names>J. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases</article-title>. <source>Front. Pharmacol.</source>
<volume>11</volume>, <elocation-id>259</elocation-id>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00259</pub-id>
<pub-id pub-id-type="pmid">32226383</pub-id></mixed-citation>
      </ref>
      <ref id="B102">
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Prieto-Pe&#xF1;a</surname><given-names>D.</given-names></name><name><surname>Dasgupta</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update</article-title>. <source>Pol. Arch. Intern. Med.</source>
<pub-id pub-id-type="doi">10.20452/pamw.15438</pub-id>
</mixed-citation>
      </ref>
      <ref id="B103">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qin</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Dysregulation of immune response in patients with COVID-19 in Wuhan, China</article-title>. <source>Clin. Infect. Dis.</source>
<volume>71</volume>, <fpage>762</fpage>&#x2013;<lpage>768</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa248</pub-id>
<pub-id pub-id-type="pmid">32161940</pub-id></mixed-citation>
      </ref>
      <ref id="B104">
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Queiro Silva</surname><given-names>R.</given-names></name><name><surname>Armesto</surname><given-names>S.</given-names></name><name><surname>Gonz&#xE1;lez Vela</surname><given-names>C.</given-names></name><name><surname>Naharro Fern&#xE1;ndez</surname><given-names>C.</given-names></name><name><surname>Gonz&#xE1;lez-Gay</surname><given-names>M. A.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain</article-title>. <source>Dermatol. Ther.</source>
<elocation-id>e13961</elocation-id>. <pub-id pub-id-type="doi">10.1111/dth.13961</pub-id>
<pub-id pub-id-type="pmid">32618402</pub-id></mixed-citation>
      </ref>
      <ref id="B105">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramanathan</surname><given-names>K.</given-names></name><name><surname>Antognini</surname><given-names>D.</given-names></name><name><surname>Combes</surname><given-names>A.</given-names></name><name><surname>Paden</surname><given-names>M.</given-names></name><name><surname>Zakhary</surname><given-names>B.</given-names></name><name><surname>Ogino</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases</article-title>. <source>Lancet Respir. Med.</source>
<volume>8</volume>, <fpage>518</fpage>&#x2013;<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30121-1</pub-id>
<pub-id pub-id-type="pmid">32203711</pub-id></mixed-citation>
      </ref>
      <ref id="B106">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ranieri</surname><given-names>V. M.</given-names></name><name><surname>Rubenfeld</surname><given-names>G. D.</given-names></name><name><surname>Thompson</surname><given-names>B. T.</given-names></name><name><surname>Ferguson</surname><given-names>N. D.</given-names></name><name><surname>Caldwell</surname><given-names>E.</given-names></name><name><surname>Fan</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Acute respiratory distress syndrome: the Berlin Definition</article-title>. <source>JAMA</source>
<volume>307</volume>, <fpage>2526</fpage>&#x2013;<lpage>2533</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2012.5669</pub-id>
<pub-id pub-id-type="pmid">22797452</pub-id></mixed-citation>
      </ref>
      <ref id="B107">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ricci</surname><given-names>E.</given-names></name><name><surname>Ronchetti</surname><given-names>S.</given-names></name><name><surname>Gabrielli</surname><given-names>E.</given-names></name><name><surname>Pericolini</surname><given-names>E.</given-names></name><name><surname>Gentili</surname><given-names>M.</given-names></name><name><surname>Roselletti</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>GILZ restrains neutrophil activation by inhibiting the MAPK pathway</article-title>. <source>J. Leukoc. Biol.</source>
<volume>105</volume>, <fpage>187</fpage>&#x2013;<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1002/JLB.3AB0718-255R</pub-id>
<pub-id pub-id-type="pmid">30371949</pub-id></mixed-citation>
      </ref>
      <ref id="B108">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ronchetti</surname><given-names>S.</given-names></name><name><surname>Ricci</surname><given-names>E.</given-names></name><name><surname>Migliorati</surname><given-names>G.</given-names></name><name><surname>Gentili</surname><given-names>M.</given-names></name><name><surname>Riccardi</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>How glucocorticoids affect the neutrophil life</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>19</volume> (<issue>12</issue>), <fpage>4090</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19124090</pub-id>
</mixed-citation>
      </ref>
      <ref id="B109">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Safi</surname><given-names>R.</given-names></name><name><surname>Kallas</surname><given-names>R.</given-names></name><name><surname>Bardawil</surname><given-names>T.</given-names></name><name><surname>Mehanna</surname><given-names>C. J.</given-names></name><name><surname>Abbas</surname><given-names>O.</given-names></name><name><surname>Hamam</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Beh&#xE7;et&#x2019;s disease</article-title>. <source>J. Dermatol. Sci.</source>
<volume>92</volume>, <fpage>143</fpage>&#x2013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1016/j.jdermsci.2018.08.010</pub-id>
<pub-id pub-id-type="pmid">30237006</pub-id></mixed-citation>
      </ref>
      <ref id="B110">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shah</surname><given-names>R. D.</given-names></name><name><surname>Wunderink</surname><given-names>R. G.</given-names></name></person-group> (<year>2017</year>). <article-title>Viral pneumonia and acute respiratory distress syndrome</article-title>. <source>Clin. Chest Med.</source>
<volume>38</volume>, <fpage>113</fpage>&#x2013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccm.2016.11.013</pub-id>
<pub-id pub-id-type="pmid">28159154</pub-id></mixed-citation>
      </ref>
      <ref id="B111">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Zuo</surname><given-names>Y.</given-names></name><name><surname>Yalavarthi</surname><given-names>S.</given-names></name><name><surname>Gockman</surname><given-names>K.</given-names></name><name><surname>Zuo</surname><given-names>M.</given-names></name><name><surname>Madison</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Neutrophil calprotectin identifies severe pulmonary disease in COVID-19</article-title>. <source>Medrxiv Preprint Server Health Sci.</source>
<volume>2020</volume>. &#xA0;<pub-id pub-id-type="doi">10.1101/2020.05.06.20093070</pub-id>
</mixed-citation>
      </ref>
      <ref id="B112">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Shao</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Gan</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19 infection: the perspectives on immune responses</article-title>. <source>Cell Death Differ.</source>
<volume>27</volume> (<issue>5</issue>), <fpage>1451</fpage>&#x2013;<lpage>1454</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-020-0530-3</pub-id>
<pub-id pub-id-type="pmid">32205856</pub-id></mixed-citation>
      </ref>
      <ref id="B113">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>D.</given-names></name><name><surname>Beeh</surname><given-names>K. M.</given-names></name><name><surname>Colgan</surname><given-names>B.</given-names></name><name><surname>Kornmann</surname><given-names>O.</given-names></name><name><surname>Leaker</surname><given-names>B.</given-names></name><name><surname>Watz</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD</article-title>. <source>Respir. Res.</source>
<volume>20</volume>, <fpage>180</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-019-1142-7</pub-id>
<pub-id pub-id-type="pmid">31399091</pub-id></mixed-citation>
      </ref>
      <ref id="B114">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sollberger</surname><given-names>G.</given-names></name><name><surname>Choidas</surname><given-names>A.</given-names></name><name><surname>Burn</surname><given-names>G. L.</given-names></name><name><surname>Habenberger</surname><given-names>P.</given-names></name><name><surname>Di Lucrezia</surname><given-names>R.</given-names></name><name><surname>Kordes</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Gasdermin D plays a vital role in the generation of neutrophil extracellular traps</article-title>. <source>Sci. Immunol.</source>
<volume>3</volume> (<issue>26</issue>), <elocation-id>eaar6689</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1126/sciimmunol.aar6689</pub-id>
<pub-id pub-id-type="pmid">30143555</pub-id></mixed-citation>
      </ref>
      <ref id="B115">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Dai</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>NETs promote ALI/ARDS inflammation by regulating alveolar macrophage polarization</article-title>. <source>Exp. Cell Res.</source>
<volume>382</volume>, <fpage>111486</fpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2019.06.031</pub-id>
<pub-id pub-id-type="pmid">31255598</pub-id></mixed-citation>
      </ref>
      <ref id="B116">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soy</surname><given-names>M.</given-names></name><name><surname>Keser</surname><given-names>G.</given-names></name><name><surname>Atag&#xFC;nd&#xFC;z</surname><given-names>P.</given-names></name><name><surname>Tabak</surname><given-names>F.</given-names></name><name><surname>Atag&#xFC;nd&#xFC;z</surname><given-names>I.</given-names></name><name><surname>Kayhan</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment</article-title>. <source>Clin. Rheumatol.</source>
<volume>39</volume>, <fpage>2085</fpage>&#x2013;<lpage>2094</lpage>. <pub-id pub-id-type="doi">10.1007/s10067-020-05190-5</pub-id>
<pub-id pub-id-type="pmid">32474885</pub-id></mixed-citation>
      </ref>
      <ref id="B117">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stebbing</surname><given-names>J.</given-names></name><name><surname>Phelan</surname><given-names>A.</given-names></name><name><surname>Griffin</surname><given-names>I.</given-names></name><name><surname>Tucker</surname><given-names>C.</given-names></name><name><surname>Oechsle</surname><given-names>O.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title>. <source>Lancet Infect. Dis.</source>
<volume>20</volume>, <fpage>400</fpage>&#x2013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30132-8</pub-id>
<pub-id pub-id-type="pmid">32113509</pub-id></mixed-citation>
      </ref>
      <ref id="B118">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stevens</surname><given-names>J. P.</given-names></name><name><surname>Law</surname><given-names>A.</given-names></name><name><surname>Giannakoulis</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Acute respiratory distress syndrome</article-title>. <source>JAMA</source>
<volume>319</volume>, <fpage>732</fpage>. <pub-id pub-id-type="doi">10.1001/jama.2018.0483</pub-id>
<pub-id pub-id-type="pmid">29466593</pub-id></mixed-citation>
      </ref>
      <ref id="B119">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stockley</surname><given-names>R.</given-names></name><name><surname>De Soyza</surname><given-names>A.</given-names></name><name><surname>Gunawardena</surname><given-names>K.</given-names></name><name><surname>Perrett</surname><given-names>J.</given-names></name><name><surname>Forsman-Semb</surname><given-names>K.</given-names></name><name><surname>Entwistle</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis</article-title>. <source>Respir. Med.</source>
<volume>107</volume>, <fpage>524</fpage>&#x2013;<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2012.12.009</pub-id>
<pub-id pub-id-type="pmid">23433769</pub-id></mixed-citation>
      </ref>
      <ref id="B120">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Strausbaugh</surname><given-names>H. J.</given-names></name><name><surname>Rosen</surname><given-names>S. D.</given-names></name></person-group> (<year>2001</year>). <article-title>A potential role for annexin 1 as a physiologic mediator of glucocorticoid-induced L-selectin shedding from myeloid cells</article-title>. <source>J. Immunol.</source>
<volume>166</volume>, <fpage>6294</fpage>&#x2013;<lpage>6300</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.166.10.6294</pub-id>
<pub-id pub-id-type="pmid">11342653</pub-id></mixed-citation>
      </ref>
      <ref id="B121">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhao De</surname><given-names>W.</given-names></name></person-group> (<year>2016</year>). <article-title>Efficacy of N-acetylcysteine in idiopathic pulmonary fibrosis: a systematic review and meta-analysis</article-title>. <source>Med. (Baltimore)</source>
<volume>95</volume>, <elocation-id>e3629</elocation-id>. <pub-id pub-id-type="doi">10.1097/MD.0000000000003629</pub-id>
</mixed-citation>
      </ref>
      <ref id="B122">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>R. M.</given-names></name><name><surname>Mcauley</surname><given-names>D. F.</given-names></name></person-group> (<year>2016</year>). <article-title>Acute respiratory distress syndrome</article-title>. <source>Lancet</source>
<volume>388</volume>, <fpage>2416</fpage>&#x2013;<lpage>2430</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)00578-X</pub-id>
<pub-id pub-id-type="pmid">27133972</pub-id></mixed-citation>
      </ref>
      <ref id="B123">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tagami</surname><given-names>T.</given-names></name><name><surname>Tosa</surname><given-names>R.</given-names></name><name><surname>Omura</surname><given-names>M.</given-names></name><name><surname>Fukushima</surname><given-names>H.</given-names></name><name><surname>Kaneko</surname><given-names>T.</given-names></name><name><surname>Endo</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Effect of a selective neutrophil elastase inhibitor on mortality and ventilator-free days in patients with increased extravascular lung water: a post hoc analysis of the PiCCO Pulmonary Edema Study</article-title>. <source>J. Intensive Care</source>
<volume>2</volume>, <fpage>67</fpage>. <pub-id pub-id-type="doi">10.1186/s40560-014-0067-y</pub-id>
</mixed-citation>
      </ref>
      <ref id="B124">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talukdar</surname><given-names>S.</given-names></name><name><surname>Oh</surname><given-names>D. Y.</given-names></name><name><surname>Bandyopadhyay</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Mcnelis</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase</article-title>. <source>Nat. Med.</source>
<volume>18</volume>, <fpage>1407</fpage>&#x2013;<lpage>1412</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2885</pub-id>
<pub-id pub-id-type="pmid">22863787</pub-id></mixed-citation>
      </ref>
      <ref id="B125">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>M. K. X.</given-names></name><name><surname>Heng</surname><given-names>T. Y. J.</given-names></name><name><surname>Mak</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>The potential use of metformin, dipyridamole, N-acetylcysteine and statins as adjunctive therapy for systemic lupus erythematosus</article-title>. <source>Cells</source>
<volume>8</volume> (<issue>4</issue>), <fpage>323</fpage>. <pub-id pub-id-type="doi">10.3390/cells8040323</pub-id>
</mixed-citation>
      </ref>
      <ref id="B126">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thierry</surname><given-names>A. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Anti-protease treatments targeting plasmin(ogen) and neutrophil elastase may be beneficial in fighting COVID-19</article-title>. <source>Physiol. Rev.</source>
<volume>100</volume>, <fpage>1597</fpage>&#x2013;<lpage>1598</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00019.2020</pub-id>
<pub-id pub-id-type="pmid">32639219</pub-id></mixed-citation>
      </ref>
      <ref id="B127">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tisoncik</surname><given-names>J. R.</given-names></name><name><surname>Korth</surname><given-names>M. J.</given-names></name><name><surname>Simmons</surname><given-names>C. P.</given-names></name><name><surname>Farrar</surname><given-names>J.</given-names></name><name><surname>Martin</surname><given-names>T. R.</given-names></name><name><surname>Katze</surname><given-names>M. G.</given-names></name></person-group> (<year>2012</year>). <article-title>Into the eye of the cytokine storm</article-title>. <source>Microbiol. Mol. Biol. Rev.</source>
<volume>76</volume>, <fpage>16</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1128/MMBR.05015-11</pub-id>
<pub-id pub-id-type="pmid">22390970</pub-id></mixed-citation>
      </ref>
      <ref id="B128">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Todd</surname><given-names>C. M.</given-names></name><name><surname>Salter</surname><given-names>B. M.</given-names></name><name><surname>Murphy</surname><given-names>D. M.</given-names></name><name><surname>Watson</surname><given-names>R. M.</given-names></name><name><surname>Howie</surname><given-names>K. J.</given-names></name><name><surname>Milot</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects</article-title>. <source>Pulm. Pharmacol. Ther.</source>
<volume>41</volume>, <fpage>34</fpage>&#x2013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.pupt.2016.09.005</pub-id>
<pub-id pub-id-type="pmid">27640067</pub-id></mixed-citation>
      </ref>
      <ref id="B129">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tomar</surname><given-names>B.</given-names></name><name><surname>Anders</surname><given-names>H. J.</given-names></name><name><surname>Desai</surname><given-names>J.</given-names></name><name><surname>Mulay</surname><given-names>S. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19</article-title>. <source>Cells</source>
<volume>9</volume> (<issue>6</issue>), <fpage>1383</fpage>. <pub-id pub-id-type="doi">10.3390/cells9061383</pub-id>
</mixed-citation>
      </ref>
      <ref id="B130">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ton</surname><given-names>A. T.</given-names></name><name><surname>Gentile</surname><given-names>F.</given-names></name><name><surname>Hsing</surname><given-names>M.</given-names></name><name><surname>Ban</surname><given-names>F.</given-names></name><name><surname>Cherkasov</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds</article-title>. <source>Mol. Inform.</source>
<volume>39</volume> (<issue>8</issue>), <elocation-id>e2000028</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1002/minf.202000028</pub-id>
<pub-id pub-id-type="pmid">32162456</pub-id></mixed-citation>
      </ref>
      <ref id="B131">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaira</surname><given-names>L. A.</given-names></name><name><surname>Salzano</surname><given-names>G.</given-names></name><name><surname>Deiana</surname><given-names>G.</given-names></name><name><surname>De Riu</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Anosmia and ageusia: common findings in COVID-19 patients</article-title>. <source>Laryngoscope</source>
<volume>130</volume>, <fpage>1787</fpage>. <pub-id pub-id-type="doi">10.1002/lary.28692</pub-id>
<pub-id pub-id-type="pmid">32237238</pub-id></mixed-citation>
      </ref>
      <ref id="B132">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van De Veerdonk</surname><given-names>F. L.</given-names></name><name><surname>Netea</surname><given-names>M. G.</given-names></name></person-group> (<year>2020</year>). <article-title>Blocking IL-1 to prevent respiratory failure in COVID-19</article-title>. <source>Crit. Care</source>
<volume>24</volume>, <fpage>445</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-020-03166-0</pub-id>
<pub-id pub-id-type="pmid">32682440</pub-id></mixed-citation>
      </ref>
      <ref id="B133">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veras</surname><given-names>F. P.</given-names></name><name><surname>Pontelli</surname><given-names>M. C</given-names></name><name><surname>Silva</surname><given-names>C. M.</given-names></name><name><surname>Toller-Kawahisa</surname><given-names>J. E.</given-names></name><name><surname>De Lima</surname><given-names>M.</given-names></name><name><surname>Nascimento</surname><given-names>D. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology</article-title>. <source>J. Exp. Med.</source>
<volume>217</volume> (<issue>12</issue>), <fpage>e20201129</fpage>. <fpage>10.1084/jem.20201129</fpage>
<pub-id pub-id-type="pmid">32926098</pub-id></mixed-citation>
      </ref>
      <ref id="B134">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Von Nussbaum</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>V. M.</given-names></name><name><surname>Allerheiligen</surname><given-names>S.</given-names></name><name><surname>Anlauf</surname><given-names>S.</given-names></name><name><surname>B&#xE4;rfacker</surname><given-names>L.</given-names></name><name><surname>Bechem</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases</article-title>. <source>ChemMedChem</source>
<volume>10</volume>, <fpage>1163</fpage>&#x2013;<lpage>1173</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.201500131</pub-id>
<pub-id pub-id-type="pmid">26083237</pub-id></mixed-citation>
      </ref>
      <ref id="B135">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title>. <source>JAMA</source>
<volume>323</volume> (<issue>11</issue>), <fpage>1061</fpage>&#x2013;<lpage>1069</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id>
<pub-id pub-id-type="pmid">32031570</pub-id></mixed-citation>
      </ref>
      <ref id="B136">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watz</surname><given-names>H.</given-names></name><name><surname>Nagelschmitz</surname><given-names>J.</given-names></name><name><surname>Kirsten</surname><given-names>A.</given-names></name><name><surname>Pedersen</surname><given-names>F.</given-names></name><name><surname>Van Der Mey</surname><given-names>D.</given-names></name><name><surname>Schwers</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: a randomized controlled trial</article-title>. <source>Pulm. Pharmacol. Ther.</source>
<volume>56</volume>, <fpage>86</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.pupt.2019.03.009</pub-id>
<pub-id pub-id-type="pmid">30917927</pub-id></mixed-citation>
      </ref>
      <ref id="B137">
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Weber</surname><given-names>A. G.</given-names></name><name><surname>Chau</surname><given-names>A. S.</given-names></name><name><surname>Egeblad</surname><given-names>M.</given-names></name><name><surname>Barnes</surname><given-names>B. J.</given-names></name><name><surname>Janowitz</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series</article-title>. <source>medRxiv</source>
<elocation-id>2020.05.13.20087734</elocation-id>. <pub-id pub-id-type="doi">10.1101/2020.05.13.20087734</pub-id>
</mixed-citation>
      </ref>
      <ref id="B138">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>S. L.</given-names></name><name><surname>Wagner</surname><given-names>D. D.</given-names></name></person-group> (<year>2018</year>). <article-title>Peptidylarginine deiminase 4: a nuclear button triggering neutrophil extracellular traps in inflammatory diseases and aging</article-title>. <source>FASEB J.</source>
<volume>32</volume> (<issue>12</issue>), <fpage>6358 </fpage>&#x2013;<lpage>6370</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201800691R</pub-id>
</mixed-citation>
      </ref>
      <ref id="B139">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woodberry</surname><given-names>T.</given-names></name><name><surname>Bouffler</surname><given-names>S. E.</given-names></name><name><surname>Wilson</surname><given-names>A. S.</given-names></name><name><surname>Buckland</surname><given-names>R. L.</given-names></name><name><surname>Br&#xFC;stle</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>The emerging role of neutrophil granulocytes in multiple sclerosis</article-title>. <source>J. Clin. Med.</source>
<volume>7</volume> (<issue>12</issue>):<fpage>511</fpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/jcm7120511</pub-id>
</mixed-citation>
      </ref>
      <ref id="B140">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Fu</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effective treatment of severe COVID-19 patients with tocilizumab</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>117</volume>, <fpage>10970</fpage>&#x2013;<lpage>10975</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2005615117</pub-id>
<pub-id pub-id-type="pmid">32350134</pub-id></mixed-citation>
      </ref>
      <ref id="B141">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>S. C.</given-names></name><name><surname>Hwang</surname><given-names>T. L.</given-names></name></person-group> (<year>2016</year>). <article-title>The potential impacts of formyl peptide receptor 1 in inflammatory diseases</article-title>. <source>Front. Biosci. (Elite Ed.)</source>
<volume>8</volume>, <fpage>436</fpage>&#x2013;<lpage>449</lpage>.
<pub-id pub-id-type="pmid">27100350</pub-id></mixed-citation>
      </ref>
      <ref id="B142">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>I. A.</given-names></name><name><surname>Clarke</surname><given-names>M. S.</given-names></name><name><surname>Sim</surname><given-names>E. H.</given-names></name><name><surname>Fong</surname><given-names>K. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Inhaled corticosteroids for stable chronic obstructive pulmonary disease</article-title>. <source>Cochrane Database Syst. Rev.</source> (<issue>7</issue>), <elocation-id>Cd002991</elocation-id>. <pub-id pub-id-type="doi">10.1002/14651858.CD002991.pub3</pub-id>
<pub-id pub-id-type="pmid">22786484</pub-id></mixed-citation>
      </ref>
      <ref id="B143">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>S. C.</given-names></name><name><surname>Chung</surname><given-names>P. J.</given-names></name><name><surname>Ho</surname><given-names>C. M.</given-names></name><name><surname>Kuo</surname><given-names>C. Y.</given-names></name><name><surname>Hung</surname><given-names>M. F.</given-names></name><name><surname>Huang</surname><given-names>Y. T.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Propofol inhibits superoxide production, elastase release, and chemotaxis in formyl peptide-activated human neutrophils by blocking formyl peptide receptor 1</article-title>. <source>J. Immunol.</source>
<volume>190</volume>, <fpage>6511</fpage>&#x2013;<lpage>6519</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1202215</pub-id>
<pub-id pub-id-type="pmid">23670191</pub-id></mixed-citation>
      </ref>
      <ref id="B144">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>S. C.</given-names></name><name><surname>Chang</surname><given-names>S. H.</given-names></name><name><surname>Hsieh</surname><given-names>P. W.</given-names></name><name><surname>Huang</surname><given-names>Y. T.</given-names></name><name><surname>Ho</surname><given-names>C. M.</given-names></name><name><surname>Tsai</surname><given-names>Y. F.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Dipeptide HCH6-1 inhibits neutrophil activation and protects against acute lung injury by blocking FPR1</article-title>. <source>Free Radic. Biol. Med.</source>
<volume>106</volume>, <fpage>254</fpage>&#x2013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2017.02.038</pub-id>
<pub-id pub-id-type="pmid">28232203</pub-id></mixed-citation>
      </ref>
      <ref id="B145">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Shu</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title>. <source>Lancet Respir. Med.</source>
<volume>8</volume>, <fpage>475</fpage>&#x2013;<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id>
<pub-id pub-id-type="pmid">32105632</pub-id></mixed-citation>
      </ref>
      <ref id="B146">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yaqinuddin</surname><given-names>A.</given-names></name><name><surname>Kashir</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: targeting a potential IL-1beta/neutrophil extracellular traps feedback loop</article-title>. <source>Med. Hypotheses</source>
<volume>143</volume>, <elocation-id>109906</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.mehy.2020.109906</pub-id>
<pub-id pub-id-type="pmid">32505910</pub-id></mixed-citation>
      </ref>
      <ref id="B147">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yubero</surname><given-names>S.</given-names></name><name><surname>Ramudo</surname><given-names>L.</given-names></name><name><surname>Manso</surname><given-names>M. A.</given-names></name><name><surname>Coll&#xED;a</surname><given-names>F.</given-names></name><name><surname>De Dios</surname><given-names>I.</given-names></name></person-group> (<year>2012</year>). <article-title>Evaluation of N-acetylcysteine treatment in acute pancreatitis-induced lung injury</article-title>. <source>Inflamm. Res.</source>
<volume>61</volume>, <fpage>699</fpage>&#x2013;<lpage>705</lpage>. <pub-id pub-id-type="doi">10.1007/s00011-012-0462-6</pub-id>
<pub-id pub-id-type="pmid">22453841</pub-id></mixed-citation>
      </ref>
      <ref id="B148">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zawrotniak</surname><given-names>M.</given-names></name><name><surname>Rapala-Kozik</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Neutrophil extracellular traps (NETs) - formation and implications</article-title>. <source>Acta Biochim. Pol.</source>
<volume>60</volume>, <fpage>277</fpage>&#x2013;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.18388/abp.2013_1983</pub-id>
<pub-id pub-id-type="pmid">23819131</pub-id></mixed-citation>
      </ref>
      <ref id="B149">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zemans</surname><given-names>R. L.</given-names></name><name><surname>Matthay</surname><given-names>M. A.</given-names></name></person-group> (<year>2017</year>). <article-title>What drives neutrophils to the alveoli in ARDS</article-title>? <source>Thorax</source>
<volume>72</volume>, <fpage>1</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2016-209170</pub-id>
<pub-id pub-id-type="pmid">27974631</pub-id></mixed-citation>
      </ref>
      <ref id="B150">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group> (<year>2017</year>). <article-title>Effects of N-acetylcysteine treatment in acute respiratory distress syndrome: A meta-analysis</article-title>. <source>Exp. Ther. Med.</source>
<volume>14</volume>, <fpage>2863</fpage>&#x2013;<lpage>2868</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2017.4891</pub-id>
<pub-id pub-id-type="pmid">28928799</pub-id></mixed-citation>
      </ref>
      <ref id="B151">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Qiu</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis</article-title>. <source>Respir. Res.</source>
<volume>21</volume>, <fpage>74</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-020-01338-8</pub-id>
<pub-id pub-id-type="pmid">32216803</pub-id></mixed-citation>
      </ref>
      <ref id="B152">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Dai</surname><given-names>S. M.</given-names></name><name><surname>Tong</surname><given-names>Q.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression</article-title>. <source>J. Antimicrob. Chemother.</source>
<volume>75</volume>, <fpage>1667</fpage>&#x2013;<lpage>1670</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkaa114</pub-id>
<pub-id pub-id-type="pmid">32196083</pub-id></mixed-citation>
      </ref>
      <ref id="B153">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X. L.</given-names></name><name><surname>Wang</surname><given-names>X. G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source>
<volume>579</volume>, <fpage>270</fpage>&#x2013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>
<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation>
      </ref>
      <ref id="B154">
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Pang</surname><given-names>Z.</given-names></name></person-group> (<year>2020</year>). <article-title>Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development</article-title>. <source>Asian J. Pharm. Sci.</source> &#xA0;<pub-id pub-id-type="doi">10.1016/j.ajps.2020.06.001</pub-id>
</mixed-citation>
      </ref>
      <ref id="B155">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuo</surname><given-names>Y.</given-names></name><name><surname>Yalavarthi</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Gockman</surname><given-names>K.</given-names></name><name><surname>Zuo</surname><given-names>M.</given-names></name><name><surname>Madison</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Neutrophil extracellular traps in COVID-19</article-title>. <source>JCI Insight</source>
<volume>5</volume> (<issue>11</issue>), <elocation-id>e138999</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1172/jci.insight.138999</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="chapter-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems</journal-id>
      <journal-title-group>
        <journal-title>Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems</journal-title>
      </journal-title-group>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">7499344</article-id>
      <article-id pub-id-type="pii">B978-0-12-820658-4.00004-2</article-id>
      <article-id pub-id-type="doi">10.1016/B978-0-12-820658-4.00004-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Novel drug delivery systems and significance in respiratory diseases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="au0010">
          <name>
            <surname>Mishra</surname>
            <given-names>Brahmeshwar</given-names>
          </name>
          <xref rid="af0010" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author" id="au0015">
          <name>
            <surname>Singh</surname>
            <given-names>Juhi</given-names>
          </name>
          <xref rid="af0015" ref-type="aff">b</xref>
        </contrib>
        <aff id="af0010"><label>a</label>Department of Pharmaceutical Engineering &amp; Technology, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, India</aff>
        <aff id="af0015"><label>b</label>NTU Institute for Health Technologies, Nanyang Technological University, Singapore, Singapore</aff>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Dua</surname>
            <given-names>Kamal</given-names>
          </name>
        </contrib>
        <aff id="ed_af0010">Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia</aff>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Hansbro</surname>
            <given-names>Philip M.</given-names>
          </name>
        </contrib>
        <aff id="ed_af0015">Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, Sydney, NSW, Australia</aff>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Wadhwa</surname>
            <given-names>Ridhima</given-names>
          </name>
        </contrib>
        <aff id="ed_af0020">Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia</aff>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Haghi</surname>
            <given-names>Mehra</given-names>
          </name>
        </contrib>
        <aff id="ed_af0025">Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia</aff>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Pont</surname>
            <given-names>Lisa G.</given-names>
          </name>
        </contrib>
        <aff id="ed_af0030">Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia</aff>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Williams</surname>
            <given-names>Kylie A.</given-names>
          </name>
        </contrib>
        <aff id="ed_af0035">Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia</aff>
      </contrib-group>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <fpage>57</fpage>
      <lpage>95</lpage>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 Elsevier Inc. All rights reserved.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Elsevier Inc.</copyright-holder>
        <license>
          <license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
        </license>
      </permissions>
      <abstract id="ab0010">
        <p>Pulmonary drug delivery offers targeted therapy for the treatment of respiratory diseases such as asthma, lung cancer, and chronic obstructive pulmonary diseases. However, this route poses challenges like deposition mechanism, drug instability, and rapid clearance mechanism. Other factors like the type of inhaler device, patient compatibility, consistent delivery by device, and inhaler technique also affect the performance of pulmonary delivery systems. Thus, to overcome these issues, pulmonary delivery systems utilizing particle-based approaches (nano/microparticles) have emerged in the last two decades. This chapter provides insight into various mechanisms of pulmonary drug administration, the ideal requirements of a pulmonary system, and the general devices used for pulmonary delivery. An overview of new pulmonary delivery systems and their relevance in the treatment of respiratory diseases is provided. In the end, novel pulmonary technologies that have been patented and cleared clinical trials have been highlighted along with the advances in the inhaler device.</p>
      </abstract>
      <kwd-group id="ks0010">
        <title>Keywords</title>
        <kwd>Pulmonary drug delivery</kwd>
        <kwd>Nanoparticles</kwd>
        <kwd>Respiratory diseases</kwd>
        <kwd>Targeted delivery</kwd>
        <kwd>Administration mechanisms</kwd>
        <kwd>Asthma</kwd>
        <kwd>COPD</kwd>
        <kwd>Inhaler devices</kwd>
        <kwd>Aerosols</kwd>
        <kwd>Dendrimers</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s0010">
      <label>1</label>
      <title>Introduction</title>
      <p id="p0010">Chronic respiratory disorders (CRDs) comprise the group of diseases that affect the lungs, airways, and other associated structures. The World Health Organization (WHO) has categorized CRDs among the leading causes of global death and disability burden affecting people of all socioeconomic classes. The five most common diseases responsible for respiratory impairment and illness are asthma, chronic obstructive pulmonary disorder (COPD), tuberculosis (TB), lung cancer, and acute respiratory tract infections <xref rid="bb0010" ref-type="bibr">[1]</xref>. According to the WHO estimate, about 235 million people around the world currently have asthma, and more than 3 million people die every year from COPDs. This global disease burden has given rise to the clinical need for developments of delivery systems and tools aimed at the efficient prevention and treatment of these respiratory diseases.</p>
      <p id="p0015">The most common and ancient method of drug delivery to the lungs and airways has been through inhalation. The drugs delivered by inhalation have either of the three main purposes: prophylaxis, topical or systemic disease treatment, and therapy management. Inhaler devices like nebulizers, metered-dose inhalers, dry powder inhalers, and other aerosol-based device technologies are used for delivering drugs. Delivery to lungs through inhalation provides targeted delivery, which requires low drug doses to be delivered as compared with systemic delivery. The targeted approach reduces the systemic side effects caused due to delivery approaches like oral dosage and injections and enhances the therapeutic index by local delivery to the diseased site. The inhalation delivery method is also used for alveoli-based systemic administration owing to the large surface area of the human lungs. It has been found that drugs are more rapidly absorbed through lungs as compared with other noninvasive delivery methods. But rapid diffusion to blood through epithelia is often accompanied by rapid clearance of small molecule drugs and metabolic degradation of peptide therapeutics, thereby reducing the therapeutic efficiency of the inhaled drugs <xref rid="bb0015" ref-type="bibr">[2]</xref>.</p>
      <p id="p0020">Pulmonary drug delivery refers to the systems aimed at targeting the delivery of aerosols directly to epithelial cells and respiratory epithelium by means of inhalation. Based on the desired drug release characteristics, the design of the aerosol formulation is varied to provide prolonged retention or rapid absorption. This pulmonary delivery system can be categorized into immediate-release, controlled-release, and sustained-release systems. These systems vary in their polymeric composition and the excipients. The controlled- and sustained-release pulmonary systems are designed to have advantages like a reduced drug dose, improved therapeutic efficiency, enhanced patient compatibility, quick onset of action, bypassing the hepatic metabolism, localized delivery, reduced systemic side effects, prolonged action, and cost-effective treatment <xref rid="bb0020" ref-type="bibr">[3]</xref>. These delivery systems consist of particle-based technologies like microparticles, nanoparticles, micelles liposomes, and protein nanoparticles, which would be briefly introduced in this chapter.</p>
      <p id="p0025">Despite the discussed advantages of pulmonary delivery systems, the delivery to lungs through these devices pose some serious challenges that need to be addressed by the pharmaceutical industry and research community. Firstly the highly evolved defense mechanism of respiratory passage to fight against foreign particles treats the delivered drug carriers as foreign, thereby trying to prevent their deposition to lungs, remove them, or inactivate them if deposited <xref rid="bb0025" ref-type="bibr">[4]</xref>. Secondly the patients&#x2019; inability to adhere to the prescribed dosage regimen by making proper use of inhaler devices is another challenge that requires attention <xref rid="bb0030" ref-type="bibr">[5]</xref>.</p>
      <p id="p0030">This chapter would focus on the mechanisms of drug disposition and absorption through lungs and ideal characteristics of particle-based pulmonary delivery systems, thereby giving a broad idea about such systems. Later on the novel systems that have been developed for controlled and targeted delivery to respiratory disease sites would be discussed in brief. In the end the currently marketed systems and novel patented systems would be summarized, thereby giving an insight into the required delivery systems and the future research prospects.</p>
    </sec>
    <sec id="s0015">
      <label>2</label>
      <title>Novel pulmonary drug delivery systems&#x2014;An overview</title>
      <sec id="s0020">
        <label>2.1</label>
        <title>Mechanisms for pulmonary drug administration</title>
        <p id="p0035">The drugs can be primarily delivered by pulmonary delivery systems using two approaches:<list list-type="simple" id="l0010"><list-item id="o0010"><label>(a)</label><p id="p0040">Intranasal delivery</p></list-item><list-item id="o0015"><label>(b)</label><p id="p0045">Oral inhalative delivery<list list-type="simple" id="l0015"><list-item id="u0010"><label>&#x2022;</label><p id="p0050">intratracheal inhalation</p></list-item><list-item id="u0015"><label>&#x2022;</label><p id="p0055">intratracheal instillation</p></list-item></list>
</p></list-item></list>
</p>
        <p id="p0060">Intranasal delivery refers to the administration of drugs to lungs through the nasal passage, that is, nose-to-lungs aerosol delivery. The intranasal delivery can prove to be advantageous in cases where frequent dosing is required. The method being noninvasive can be used by the patients without external assistance while not interfering with the daily routine of the patients. Intranasal delivery has often observed to be employed for gas delivery with techniques like nasal high flow therapy, and low flow therapy <xref rid="bb0035" ref-type="bibr">[6]</xref>. Despite the advantages offered by intranasal delivery, the behavior of the nose as an effective particle filter hampers the efficient delivery of conventional aerosols with size ranging from 3 to 7&#xA0;&#x3BC;m. The nasal route has been shown to exhibit concentration loss as high as 85% while delivering small particles <xref rid="bb0040" ref-type="bibr">[7]</xref>, <xref rid="bb0045" ref-type="bibr">[8]</xref>.</p>
        <p id="p0065">Oral inhalative delivery is found to be far more effective when compared with intranasal administration in the delivery of small-sized particles with concentration loss as less as 20% <xref rid="bb0050" ref-type="bibr">[9]</xref>. Intratracheal instillation is the method of pulmonary delivery most commonly employed in laboratories for evaluating the pulmonary and systemic effectiveness of delivery systems in preclinical animal studies. In this method, drug solution or dispersion is delivered by means of a syringe, making the method simple, inexpensive, and fast while delivering quantifiable drug amounts. Despite the advantages, intratracheal instillation cannot be practically used in humans physiologically, hence limiting its application to animal studies only <xref rid="bb0055" ref-type="bibr">[10]</xref>. Contrary to this, intratracheal inhalation uses aerosol technology to deliver drug-carrying particles to the lungs with better penetration and uniform drug distribution. The deposition of the drug into lungs and airways using aerosol inhalation techniques generally occurs by three common mechanisms known as inertial impaction, sedimentation, and Brownian diffusion, as described in <xref rid="f0010" ref-type="fig">Fig. 1</xref>
. Reference source not found <xref rid="bb0060" ref-type="bibr">[11]</xref>. The deposition of drug particles in different regions of the respiratory tract is a complex phenomenon and depends on factors like particle size, the flow of air, and the respiratory region <xref rid="bb0065" ref-type="bibr">[12]</xref>. The mechanisms are briefly discussed here:<list list-type="simple" id="l0020"><list-item id="u0020"><label>&#x2022;</label><p id="p0070">
<bold>Inertial impaction</bold>: As the name suggests, this phenomenon occurs when the inertia of particles prevents them from changing their course of movement when the direction of bulk airflow changes. This change in the direction of airflow occurs whenever a bifurcation in the airways is reached. The particles are not able to change their flow direction owing to their momentum and therefore strike against the wall and get deposited. At each bifurcation the particles tend to change their paths from the original air streamline direction, ultimately colliding against the airway walls and getting deposited. Inertial impaction is the major deposition mechanism observed in the upper respiratory tract regions especially near the bronchial area, thus accounting for major deposition in these areas. Impaction-based deposition is generally observed in particles with large aerodynamic diameters. Particles with a diameter larger than 3&#xA0;&#x3BC;m and traveling near the airway walls are most prone to inertial impaction. The main factors affecting impaction are air velocity, particle mass, particle size, hyperventilation, and frequency of respiration. The chances of impaction increase with the increase in particle momentum, which is basically increase in the particle mass and flow velocity. This mechanism leads to the filtration of particles greater than 5&#xA0;&#x3BC;m in the upper respiratory tract regions like trachea and bronchi. The particles smaller than 3&#xA0;&#x3BC;m do not undergo inertial impaction <xref rid="bb0070" ref-type="bibr">[13]</xref>.</p></list-item><list-item id="u0025"><label>&#x2022;</label><p id="p0075">
<bold>Gravitational sedimentation</bold>: This phenomenon includes settling down of small particles under the influence of gravity on the walls. Particles with aerodynamic diameter ranging from 1 to 8&#xA0;&#x3BC;m deposit through this mechanism. This type of deposition is observed in small airways and alveolar regions of the lungs wherein the distance between the particles and the walls is very less. Breath-holding plays an important role in this type of deposition mechanism. Breath-holding allows the particles that have penetrated deep into the lungs enough time to settle down due to gravity and thus get deposited. The event of gravitational sedimentation occurs when the gravitational force acting on the particles exceeds the air resistance, thereby causing the particles to sediment. The rate at which sedimentation occurs, therefore, depends on the terminal settling velocity of the particles. Particles with higher aerodynamic diameters are more prone to sedimentation. Hygroscopic materials that tend to absorb moisture on their way tend to increase their aerodynamic diameter size, thereby undergoing sedimentation-based deposition. The probability of sedimentation increases with the increase in the particle diameter and residence time of the particle in the airways, whereas it decreases with the increase in breathing rate <xref rid="bb0065" ref-type="bibr">[12]</xref>.</p></list-item><list-item id="u0030"><label>&#x2022;</label><p id="p0080">
<bold>Brownian diffusion</bold>: In the case of small particles, deposition occurs through the diffusion mechanism, which is based on the Brownian motion principle. Particles with a diameter less than 0.5&#xA0;&#x3BC;m undergo this kind of deposition. This phenomenon is controlled by particle geometry rather than the aerodynamic diameter, as in the case of impaction and sedimentation. Diffusion can be defined as the movement of particle from high concentration area to low concentration area by means of Brownian movements. Moreover, the Brownian movement of small particles can be defined as the random motion of particles, which results due to collision with gas molecules applying nonuniform pressures on the particles&#x2019; surface. Deposition by diffusion generally occurs in the nasopharynx region and in the small airways of alveolar regions, bronchioles in the lungs where the airflow is less as compared with other regions. The diffusion-based deposition decreases with the increase in the aerodynamic particle diameter in contrary to that of impaction and sedimentation. The diffusion coefficients of the particles also play a major role in deposition through this mechanism <xref rid="bb0065" ref-type="bibr">[12]</xref>.</p></list-item></list>
<fig id="f0010"><label>Fig. 1</label><caption><p>Schematic representation of the lungs and deposition mechanism of aerosol particles.</p></caption><alt-text id="al0010">Fig. 1</alt-text><graphic xlink:href="f04-01-9780128206584"/></fig></p>
        <p id="p0085">Apart from these major mechanisms, some other phenomena like interception, turbulent mixing, and electrostatic precipitation also control the deposition of inhaled drugs into the lungs. Deposition through interception takes place when the particles come in contact with airways owing to their shape or size and then get deposited. This deposition is not like impaction where particles deviate from the main airstream and strike. This phenomenon occurs mostly for fibers in small airways wherein they easily come in contact with airways due to their shape. Another mechanism that dictates deposition is electrostatic precipitation, which causes deposition based on electrical charges. Charged particles present near the airway surfaces create a charged atmosphere that attracts the oppositely charged particles near the airways and leads to deposition due to electrostatic attraction. Another mechanism known as turbulent mixing dictates the particle deposition in upper respiratory regions with large airways. Turbulent mixing is referred to as the irregular fluctuations experienced by the particles of fluid in turbulent motion <xref rid="bb0075" ref-type="bibr">[14]</xref>. These fluctuations lead to the constant change in the flow velocity and flow direction of the particles, thereby leading them to strike against the airway wall and get deposited.</p>
      </sec>
      <sec id="s0025">
        <label>2.2</label>
        <title>Strategic criteria for particle-based pulmonary delivery systems</title>
        <p id="p0090">The discussion about the drug deposition mechanisms in the previous sections imply that the drug delivery systems should follow certain criteria to deliver the drug to the desired location in the respiratory tract while maintaining the therapeutic efficiency and desired release rate. As discussed earlier the inhalation is based on aerosolization techniques wherein aerosols consist of uniform-sized particles, further incorporating drug carriers/vehicles. To begin with the physicochemical properties of the particles play a pivotal role in determining the deposition, flow behavior, absorbance, and clearance rate of the system when administered through inhalation. Moreover, the properties of the aerosol formulation also affect efficient delivery. Some of the most important characteristics that should be taken care of in case of the pulmonary delivery system are discussed as follows:<list list-type="simple" id="l0025"><list-item id="u0035"><label>&#x2022;</label><p id="p0095">
<bold>Size of the particles in aerosols</bold>: Attempts have been made by pharmaceutical industries to form homogenous aerosol formulations with monodispersed particles. Despite the efforts the aerosols generally exhibit a wide range of particle size distribution while also affecting the shape of the particles. As mentioned earlier the difference in particle size and shape may lead to deposition of these particles in several undesired regions of the respiratory tract. Thus it is very important to obtain a monodisperse aerosol. An ideal aerosol system with monodispersed particles is considered to have a geometric standard deviation (GSD) of 1. But due to difficulties in the formulation of ideal aerosols, in practice, aerosols with GSD less than 1.22 are considered to be acceptably monodisperse, and any system with greater GSD is either polydispersed or heterodispersed. Thus the target of the manufacturer and researchers should be to obtain a monodisperse aerosol system with GSD less than 1.22 <xref rid="bb0080" ref-type="bibr">[15]</xref>.</p></list-item><list-item id="u0040"><label>&#x2022;</label><p id="p0100">
<bold>Physical stability</bold>: One of the vital factors that require attention is the physical stability of aerosol suspensions. The aerosols generally consist of very high concentrations of particles in a small volume, which leads to several interparticle interactions like repulsion and aggregation. These interactions might lead to suspension instability and particle aggregation during different storage conditions, thereby performing the product performance when inhaled <xref rid="bb0085" ref-type="bibr">[16]</xref>. This factor is particularly important for particles generated by systems like dry powder inhalers, wherein spray drying is used as the common method. Many of the compounds that are spray-dried are amorphous in nature, and these, when stored in high humidity conditions, tend to gain moisture and exhibit an increase in aerodynamic diameter <xref rid="bb0090" ref-type="bibr">[17]</xref>. This moisture gain leads to degradation of the aerosolization owing to enhanced capillary forces among the particles. Thus, to avoid this kind of instabilities, excipients such as mannitol, trehalose, and lactose are added to the aerosol formulations to maintain long-term physical stability and improve the aerosolization performance <xref rid="bb0095" ref-type="bibr">[18]</xref>.</p></list-item><list-item id="u0045"><label>&#x2022;</label><p id="p0105">
<bold>Particle density and shape</bold>: The density and shape of the particle also play an important role in determining the aerosolization and deposition mechanisms. As stated earlier the deposition mechanism followed by the particles depend on the aerodynamic diameter of the particles. The calculation of aerodynamic particles takes into consideration the density and the shape factor of the respective particles, thereby rendering these factors as significant. Particles of different shapes generate different drag forces and terminal settling velocities, thereby affecting the aerodynamic diameter that is again related to deposition mechanism. An increase in the surface roughness on account of shape change of particles has been found to decrease the aerodynamic diameter, which enables the particles to reach in deeper areas of lungs when compared with that of spherical particles <xref rid="bb0100" ref-type="bibr">[19]</xref>. It has also been observed that elongated particles exhibit a tendency to be suspended in the air for a longer period, which therefore can travel to deeper areas. Contrary to this, highly elongated particles also experience interception-based deposition <xref rid="bb0105" ref-type="bibr">[20]</xref>. Another phenomenon affected by particle shape is the interparticulate interactions. These interactions are based on van der Waals force, and thus the particle shape that allows minimum exposure area will lead to minimum interparticle interactions, thereby preventing particle aggregation and improving aerosolization performance <xref rid="bb0110" ref-type="bibr">[21]</xref>. Elongated particles exhibited higher attraction forces thereby not suitable for aerosolization <xref rid="bb0115" ref-type="bibr">[22]</xref>.</p></list-item><list-item id="u0050"><label>&#x2022;</label><p id="p0110">
<bold>pH and osmolarity</bold>: One of the challenges often faced during the formulation of aerosols is the maintenance of optimum pH and tonicity. Aerosol formulations with acidic pH and nonisotonic nature have been shown to induce bronchoconstriction, which is one of the major concerns while delivering aerosols to asthma patients. Lungs have been observed to exhibit limited buffering capacity, unlike the gastrointestinal tract. Thus one of the considerations while formulating should be pH and osmolarity management. Several salts like sodium chloride can be added to the formulations to maintain the osmolarity of the aerosols to around 300&#xA0;mosmol/L. In addition, HCl, citric acid, phosphate, and NaOH are used to adjust the pH of the aerosol solutions to neutrality <xref rid="bb0120" ref-type="bibr">[23]</xref>.</p></list-item><list-item id="u0055"><label>&#x2022;</label><p id="p0115">
<bold>Viscosity</bold>: Another factor that affects the output of aerosol formulations is viscosity. The droplet size is directly affected by the viscosity of the solution. It has been found that the increase in the viscosity of the solution leads to increased droplet size, thereby decreasing the output of the nebulizers. The decrease in temperature leads to an increase in the solution viscosity, which in turn affects the particle size, also modifying the deposition mechanism <xref rid="bb0125" ref-type="bibr">[24]</xref>.</p></list-item></list>
</p>
      </sec>
      <sec id="s0030">
        <label>2.3</label>
        <title>General types of pulmonary drug delivery devices</title>
        <p id="p0120">The delivery device plays a major role in the successful pulmonary administration. There has been remarkable research and development in the field of advanced systems for pulmonary administration. The selection of the delivery device is a very significant parameter in formulation design and is based on the desired site of administration in the respiratory tract. The device selected must have suitable characteristics enabling it to generate particles of appropriate aerodynamic diameter so as to deliver them to the desired locations in the lungs. The three most commonly used delivery devices for pulmonary administration are as follows:<list list-type="simple" id="l0030"><list-item id="u0060"><label>&#x2022;</label><p id="p0125">Pressurized metered-dose inhalers.</p></list-item><list-item id="u0065"><label>&#x2022;</label><p id="p0130">Dry powdered inhalers.</p></list-item><list-item id="u0070"><label>&#x2022;</label><p id="p0135">Nebulizers.</p></list-item></list>
</p>
        <p id="p0140">Pressurized metered-dose inhalers (pMDIs) are the most common delivery device employed for the treatment of respiratory tract diseases like chronic obstructive pulmonary disorder and asthma. All the inhalable drug classes are available for administration in the form of pMDIs either as a single formulation or combination of two or more drugs. In spite of the pMDIs being most commonly prescribed for obstructive respiratory diseases, it is not easy for patients to use this device correctly <xref rid="bb0130" ref-type="bibr">[25]</xref>. Conventionally the pMDIs consist of structural components like metal canister, metered valve, actuator, and mouthpiece <xref rid="bb0135" ref-type="bibr">[26]</xref>. The metering valve allows the delivery of precise amounts of aerosol after every actuation. The formulation for the pMDIs consists of either suspension or solution in the combination of suspending agents, surfactants, cosolvents, excipients, and propellants. When the drug particles reach the air, the difference between the boiling temperature of the formulation and the room temperature leads to the formation of aerosolized droplets due to evaporation. The aerosolized particle size varies from product to product <xref rid="bb0140" ref-type="bibr">[27]</xref>.</p>
        <p id="p0145">Dry powdered inhalers (DPIs) are another class of devices used for pulmonary delivery that require minimum coordination between the process of actuation and breathing for delivery of powdered drugs to respiratory tracts <xref rid="bb0145" ref-type="bibr">[28]</xref>. DPIs have greater chemical stability as they consist of a dried form of the medications as compared with that of suspensions or solutions in the case of pMDIs. However, the formulation and manufacturing of dried powder particles with appropriate characteristics to enable aerosolization and pulmonary delivery is complex <xref rid="bb0150" ref-type="bibr">[29]</xref>. Conventionally the dry powder consists of micronized drug particles in association with the large-sized excipients like lactose, sucrose, and glucose. Different varieties of DPIs are available like single-unit dose, multiunit dose, and multiple reservoirs. The energy required by the DPIs for drug delivery is derived from the inspiratory efforts of the patients. The structural components of DPIs include mesh, cyclone, manifold, and a spiral chamber. These components must be able to deaggregate the drug-excipient aggregates by utilizing the inhalation force. The inspiratory force required varies from product to product, but a minimum effort of 30&#x2013;60&#xA0;L/min is recommended <xref rid="bb0155" ref-type="bibr">[30]</xref>.</p>
        <p id="p0150">Nebulizers are the devices used to generate aerosol droplets ranging from 1 to 5&#xA0;&#x3BC;m aimed at inhalation-based pulmonary delivery. Two different kinds of nebulizers are generally used: jet and ultrasonic nebulizers. These two types of nebulizers differ in the type of force that they utilize to generate aerosols from liquid suspension/solution. Nebulizers do not require coordination between inspiration and actuation and thus can be used for a variety of patients who are unable to use pMDIs and DPIs. Moreover, nebulizers have the ability to administer large doses <xref rid="bb0160" ref-type="bibr">[31]</xref>. Jet nebulizers use the pressure-based mechanism to generate small aerosol particles, whereas ultrasonic nebulizers use sound waves to break large droplets to small aerosol droplets. Some factors that require to be optimized in the case of nebulizers for optimum delivery are the volume and viscosity of the drug solution loaded, air pressure, and the mouthpiece used. The formulation of solutions used for nebulizers is easy and cheap as compared with that required for pMDIs and DPIs. One of the major disadvantages associated with the use of nebulizers is that they require to be assembled and loaded before each use and disassembled and cleaned again after every use by the patient, which might be difficult for an untrained patient <xref rid="bb0130" ref-type="bibr">[25]</xref>.</p>
      </sec>
    </sec>
    <sec id="s0035">
      <label>3</label>
      <title>Novel delivery systems targeting respiratory diseases</title>
      <p id="p0155">The potential of pulmonary delivery for the treatment of respiratory diseases has been acknowledged and utilized for more than 3500&#xA0;years in the form of different technologies. The other routes that are used for lung diseases include oral and parenteral delivery. The concept of repurposing the established drugs for the treatment of respiratory diseases by developing novel pulmonary drug delivery systems has attracted the interest of the biomedical scientific community and the pharmaceutical companies owing to the drug absorption capacity of lungs. Different drug absorption mechanisms in the case of pulmonary delivery have been discussed in <xref rid="f0015" ref-type="fig">Fig. 2</xref>
. Several advantages of the pulmonary delivery systems that have intrigued the attention of researchers toward the development of novel pulmonary systems are as follows:<list list-type="simple" id="l0035"><list-item id="u0075"><label>&#x2022;</label><p id="p0160">Lungs have been found to have a high absorptive surface area of about 70&#x2013;140&#xA0;m<sup>2</sup> for an adult human covered with a thin layer of mucosa, which allows easy absorption.</p></list-item><list-item id="u0080"><label>&#x2022;</label><p id="p0165">Lungs also exhibit high permeability.</p></list-item><list-item id="u0085"><label>&#x2022;</label><p id="p0170">Peroral and systemic delivery leads to drug delivery throughout the body, thereby a small fraction of drugs reaching the lungs. Targeted delivery using the pulmonary route would enable the delivery of the required amount of drug locally to respiratory tract regions.</p></list-item><list-item id="u0090"><label>&#x2022;</label><p id="p0175">The unwanted systemic side effects caused due to the drug reaching every part of the body can be avoided or reduced.</p></list-item><list-item id="u0095"><label>&#x2022;</label><p id="p0180">Direct delivery to the diseased site would require delivering a lesser drug dose while also providing faster onset of action.</p></list-item><list-item id="u0100"><label>&#x2022;</label><p id="p0185">Several proteins, peptides, or other drugs sensitive to hepatic metabolism or enzymatic degradation can be delivered by pulmonary route in their active state while bypassing drug degradation.</p></list-item><list-item id="u0105"><label>&#x2022;</label><p id="p0190">The reduction in systemic side effects and drug dose can reduce the cost of the treatment in the long run.</p></list-item><list-item id="u0110"><label>&#x2022;</label><p id="p0195">When compared with parenteral administration, pulmonary administration avoids the use of injections, thereby making the treatment more patient compliant.</p></list-item><list-item id="u0115"><label>&#x2022;</label><p id="p0200">Enhanced therapeutic efficiency.</p></list-item></list>
<fig id="f0015"><label>Fig. 2</label><caption><p>Drug absorption mechanisms through pulmonary route includes (I) transcellular diffusion, (II) paracellular diffusion, (III) vesicle-based transport, and (IV) carrier-mediated transport.</p></caption><alt-text id="al0015">Fig. 2</alt-text><graphic xlink:href="f04-02-9780128206584"/></fig></p>
      <p id="p0205">The development of controlled drug delivery systems for pulmonary delivery has been an area of interest for researchers for long. Many systems have been developed for targeting specific respiratory diseases. The structure of different particle-based pulmonary systems and the factors influencing pulmonary delivery are demonstrated in <xref rid="f0020" ref-type="fig">Fig. 3</xref>
. However, in spite of increased investigations in this area, not many systems have translated to the market. Some of the most popularly developed systems and their significance for various respiratory diseases would be discussed in this section.<fig id="f0020"><label>Fig. 3</label><caption><p>Types of particle-based pulmonary systems and the factors influencing pulmonary drug delivery: (A) polymeric nanoparticles, (B) dendrimers, (C) micelles, (D) functionalized nanoparticles, (E) solid lipid nanoparticles, and (F) liposomes.</p></caption><alt-text id="al0020">Fig. 3</alt-text><graphic xlink:href="f04-03-9780128206584"/></fig></p>
      <sec id="s0040">
        <label>3.1</label>
        <title>Nanoparticles</title>
        <sec id="s0045">
          <label>3.1.1</label>
          <title>Polymeric nanoparticles</title>
          <p id="p0210">Polymeric nanoparticles can be described as colloidal carriers with diameters ranging from 10 to 1000&#xA0;nm. The opportunities available for copolymerization, surface modifications, and conjugation of polymers present forward the ability to develop targeted delivery systems, controlled and sustained delivery, and encapsulation of active ingredients. Commonly used polymers for formulation of nanoparticles include both synthetic and natural polymers like chitosan, alginate, albumin, gelatin, polylactic-<italic>co</italic>-glycolic acid (PLGA), poloxamer, poly(ethylene glycol), and poly(lactic) acid. Polymer-based nanoparticles can be broadly categorized into two types based on the drug encapsulation characteristics. The first type consists of nanocapsules wherein the drug is encapsulated within the polymeric nanocapsules, while the other category is nanospheres, wherein the drug is distributed all over the polymeric matrix. Pulmonary drug delivery through polymeric nanoparticles offers advantages like targeted delivery, escaping the pulmonary clearance, prevention of enzymatic drug degradation, sustained release, enhanced efficacy, and reduced side effects.</p>
          <p id="p0215">Various systems based on polymeric nanoparticles have been evaluated for its applications in the treatment of tuberculosis, infectious pulmonary diseases, fungal diseases, cystic fibrosis, and others. Deacon et al. described the preparation and characterization of tobramycin-loaded alginate/chitosan-based polymeric nanoparticles for treatment and prevention of <italic>Pseudomonas aeruginosa</italic> in cystic fibrosis. The study showed that drug-loaded nanoparticles (NPs) exhibited equivalent antimicrobial activity to that of pure drug. The NPs were further functionalized with dornase alfa, which led to improved penetration of tobramycin-loaded functionalized NPs into cystic fibrosis sputum. The study concluded that antibiotic-loaded functionalized NP therapy can be a good strategy to overcome the mucus barrier in the case of infectious diseases <xref rid="bb0165" ref-type="bibr">[32]</xref>.</p>
          <p id="p0220">Another study performed by Derbali et al. also reported the preparation and characterization of antibiotic levofloxacin-loaded polymeric nanoparticles based on poly(lactic acid)-grafted-poly(ethylene glycol) against bacterial infections in cystic fibrosis patients <xref rid="bb0170" ref-type="bibr">[33]</xref>. But these drug-loaded NPs were not further evaluated owing to quick drug release characteristics.</p>
          <p id="p0225">Tuberculosis is another pulmonary infectious disease causing the death of people worldwide. There has been ongoing research to improve the therapeutic efficiency of anti-TB drugs by incorporating them into nanoparticles. Costa-Gouveia et al. reported one such study wherein ethionamide, a second-line anti-TB drug, was loaded in combination with its booster into biodegradable &#x3B2;-cyclodextrin nanoparticles with an aim to improve the efficacy of the drug for the treatment of tuberculosis. The NPs were intended to overcome the issues presented by drug-like crystallization tendency and poor aqueous solubility of the booster. The in vivo study performed on mice wherein in cyclodextrin NPs were administered to mice lungs exhibited a 3-log decrease of pulmonary mycobacterial load <xref rid="bb0175" ref-type="bibr">[34]</xref>. This has been the first study wherein the coencapsulation of drugs has been reported for pulmonary administration targeting tuberculosis treatment. This technology can further be improvised, modified, and evaluated for pulmonary applications.</p>
          <p id="p0230">Despite the advantages offered by polymeric NPs for pulmonary delivery, there are some major limitations associated with these systems that need to be addressed to promote the translation of these systems to the market further. NPs based on natural polymers often tend to degrade quickly, leading to immediate drug release during in vivo administration. To overcome this, NPs based on biodegradable synthetic polymers are being looked at for sustained/prolonged-release inhalation purposes. Another concern associated with polymeric NPs is the accumulation of these drug carriers onto the airways upon repeated administration. Therefore the toxicity and degradable potential of the polymers used for NPs synthesis must be examined in depth. The stability of the aqueous NP formulations also poses challenges that must be addressed during formulation development.</p>
        </sec>
        <sec id="s0050">
          <label>3.1.2</label>
          <title>Solid lipid nanoparticles</title>
          <p id="p0235">Solid lipid nanoparticles (SLNs) can be defined as colloidal drug carriers with diameter size ranging from 50&#xA0;nm to 1&#xA0;&#x3BC;m. They are made up of solid lipids or mixture of different liquid and solid lipids stabilized with the aid of an emulsifier. The lipids generally used for the preparation of SLNs consist of physiological lipids like waxes, fatty acids, triglycerides, and steroids, which are biocompatible and thus can be well tolerated by the body. SLNs exhibit advantages over liposomes like improved stability of drug-loaded nanoparticles due to emulsion-based stabilization. SLNs offer other properties like the controlled release, incorporation of hydrophilic and lipophilic drug, target-based release, easy manufacturing, controllable particle size, easy scale-up, and reduced toxicity. These beneficial properties of SLNs have attracted researchers to evaluate its potential for targeted drug delivery. SLNs exhibit the potential of active targeting by means of surface modification with ligands and passive targeting by enhanced permeation and retention effect owing to their small size. However, for efficient incorporation of hydrophilic molecules, some amphiphilic substances need to be incorporated. SLNs have also found to provide protection to the incorporated drug molecules from physical, chemical, and enzymatic degradations. SLNs also have been found to exhibit enhanced bioavailability, improved pharmacokinetic profiles, and localized drug delivery to diseased sites in the lungs, thereby enhancing therapeutic efficiency and reducing side effects.</p>
          <p id="p0240">The potential of paclitaxel-loaded solid lipid nanoparticles for improved delivery to lung tumors was evaluated by Rosi&#xE8;re et al. <xref rid="bb0180" ref-type="bibr">[35]</xref>. It was reported that in vivo pulmonary delivery of coated SLNs exhibited prolonged exposure of paclitaxel in the lungs and reduced systemic delivery, thereby demonstrating that this strategy might enhance the antitumor activity. Another study performed by Ji et al. <xref rid="bb0185" ref-type="bibr">[36]</xref> presented the encapsulation of hydrophobic drug naringenin into solid lipid nanoparticles using emulsification and low-temperature solidification method. The pharmacokinetic study reported that pulmonary instillation of drug-loaded SLNs exhibited significant improvement in the drug bioavailability as compared with that of the pure drug suspension, thereby conforming that SLNs can be used for delivery and enhancing the bioavailability of poorly water-soluble drugs.</p>
          <p id="p0245">Makled et al. <xref rid="bb0190" ref-type="bibr">[37]</xref> evaluated the potential of sildenafil citrate-loaded SLNs for the treatment of pulmonary hypertension by means of targeted delivery via inhalation instead of conventional oral delivery. The drug-loaded SLNs exhibited high encapsulation efficiency, colloidal stability, and sustained-release profile for a period of over 24&#xA0;h and also remained stable upon nebulization using the jet nebulizer. Thus this SLN-based formulation can further be evaluated for its potential for targeted delivery, reduced dose, and dose frequency along with reduced side effects. SLNs loaded with rifabutin were encapsulated in microspheres using spray-drying method to enhance their stability and suitability for pulmonary administration in the form of dry powder inhaler in the study performed by Gaspar et al. <xref rid="bb0195" ref-type="bibr">[38]</xref>. In vivo studies performed in mice presented that DPI-based delivery of antibiotic-loaded SLNs to the lungs was efficient, although a relevant amount of drug was recovered from the spleen and liver. A significant decrease in the growth index of <italic>Mycobacterium tuberculosis</italic> was observed in the lungs of mice treated with SLN-loaded microspheres as compared with control, thereby concluding that pulmonary administration of antibiotic-loaded SLNs has promising potential in the treatment of tuberculosis.</p>
          <p id="p0250">Although a large number of research and review papers describing the potential of SLNs for pulmonary delivery are available, very few of these research formulations have actually been translated to the market for availability to patients. Some of the reasons for this gap between research and translation include reduced stability of formulations in a solution state or upon aerosolization/nebulization, off-target delivery, lack of in vivo evaluation supporting data, lack of efficacy evaluation in studies, and safety and compatibility issues. Thus attempts should be made to modify further and evaluate SLN-based systems for their therapeutic potential. Moreover the modifications should be performed, taking into consideration the reason for the failure of previous SLN-based systems in clinical trials.</p>
        </sec>
        <sec id="s0055">
          <label>3.1.3</label>
          <title>Inorganic nanoparticles</title>
          <p id="p0255">As the name suggests, this category includes nanoparticles made up of inorganic materials like gold, silver, platinum, and silica, among others. These nanoparticles have been widely investigated for their applications in disease detection, diagnosis, and treatment. The materials used for the preparation of such nanoparticles have been already explored for their application in therapeutics, for example, platinum-based therapeutics used for cancer treatment like cisplatin and carboplatin.</p>
          <p id="p0260">Gold nanoparticles have achieved significant attention of researchers for their applications in biomedical imaging, drug delivery, photothermal therapy, cancer diagnosis and treatment, and others. Gold nanoparticles alone or in combination with therapeutic moieties have also been evaluated widely for their potential in lung cancer therapy. A recent study performed by Ramalingam et al. <xref rid="bb0200" ref-type="bibr">[39]</xref> evaluated the potential of polyvinylpyrrolidone-silver nanoparticles (PVP-AuNPs) conjugated with doxorubicin against human lung cancer cells. The doxorubicin (Dox)-conjugated nanoparticles exhibited pH-responsive drug release wherein lowering the pH led to enhanced detachment of Dox from gold nanoparticle conjugate. Excellent cytotoxic activity exhibited by Dox-conjugated PVP-AuNPs as compared with free drug and pristine nanoparticles implied that conjugation of drug to PVP-AuNPs led to increased concentration of drug in A549 cells, thereby enhancing the cytotoxic effects. Furthermore, Dox-conjugated PVP-AuNPs led to increased production of ROS levels enhancing apoptosis in lung cancer cells while also increasing the expression of tumor suppressor genes. These characteristics exhibited by drug-conjugated PVP-AuNPs could further be evaluated for confirming its potential as a drug delivery system for targeting lung cancer cells.</p>
          <p id="p0265">Aerosol-based delivery of inflammation blocking antibodies to the lungs has been challenged by limitations like active clearance in lungs, reduced residence time, and tissue penetration. To address these shortcomings, various inorganic metal nanoparticles have been evaluated for direct delivery to the lungs in cases of inflammatory diseases. One such study performed by Halwani et al. <xref rid="bb0205" ref-type="bibr">[40]</xref> evaluated the potential of superparamagnetic iron oxide nanoparticles conjugated to anti-IL4R&#x3B1; blocking antibodies (SPION- anti-IL4R&#x3B1; NPs) for suppression of inflammation in case of asthma. The optimized SPION- anti-IL4R&#x3B1; NPs when used for the intrapulmonary treatment of OVA-sensitized mice were found to decrease the levels of proinflammatory cytokines in lung tissues significantly. The NPs also led to decreased proliferation of lung inflammatory cells along with a reduction in the frequency of such proliferation. The SPION- anti-IL4R&#x3B1; NPs provided better and prolonged control of lung inflammatory cytokines and cells until 7&#xA0;days&#x2019; postadministration, thereby efficiently reducing lung inflammation as compared with free anti-IL4R&#x3B1;. Such systems can further be worked on to modulate them according to clinical needs. Several SPION-based systems have already been approved, and some have reached clinical trials for their diagnostic, imaging, and treatment abilities.</p>
          <p id="p0270">Another inorganic material, calcium phosphate, has been examined as potential delivery system for codelivery of synergistic agents owing to its stable physicochemical properties and biocompatibility. One such study performed by Wu et al. <xref rid="bb0210" ref-type="bibr">[41]</xref> reported the formulation of hollow calcium phosphate nanoparticles coated with phospholipids and its evaluation for codelivery of synergistic drugs paclitaxel and doxorubicin against the lung cancer cells A549. The nanoparticles exhibited a sustained-release profile of the loaded antitumor drugs. Drug-loaded calcium phosphate nanoparticles exhibited high cell inhibition rate, suppressed the tumor proliferation, and promoted the apoptosis of A549 tumor cells. The nanoparticles also exhibited a decrease in tumor volume posttreatment. Based on these in vitro and in vivo results, it was implied that calcium phosphate nanoparticles show promising potential for drug delivery to the lungs, but there exists a need for an extensive evaluation of such systems for translation to clinical use.</p>
          <p id="p0275">Although there has been research going on for the development of inorganic nanoparticle-based delivery systems, not many of them have reached the market, and very few of them have undergone clinical trials. Some of the inorganic nanoparticle products that have been approved by FDA include NanoTherm for glioblastoma; Feraheme, Venofer, INFeD, and Dexferrum for iron deficiency; and Feridex and GastroMARK for imaging. Similar systems modulated according to pulmonary diseases and inhalation route should be focused on in the upcoming research.</p>
        </sec>
      </sec>
      <sec id="s0060">
        <label>3.2</label>
        <title>Liposomes</title>
        <p id="p0280">Liposomes can be defined as vesicles consisting of lipid bilayer membrane enclosing an aqueous core. The phospholipids that compose liposomes are amphiphilic lipid molecules wherein the unfavorable interaction of lipophilic parts of lipids with water leads to self-assembly to form spherical bilayer liposomes. Thus the liposomes have a hydrophilic core and hydrophobic lipid layer membrane, which makes it suitable for encapsulating drugs with various physical properties and drug combinations.</p>
        <p id="p0285">One of the major reasons for the utilization of liposomes for pulmonary delivery is the similarity of liposome composition to that of the lung surfactants comprising 80% of phospholipids and about 8% of neutral lipids. This chemical similarity of liposomes, along with its biocompatible and biodegradable nature, makes it more suitable for pulmonary delivery as the chances of local lung irritation are reduced. Liposomes offer the opportunity for sustained release of drug to a localized area while acting like the drug reservoir. Moreover the phospholipid nature of liposomes allows them to facilitate intracellular delivery to alveolar macrophages. Modifications of the surface of liposomes allow for targeted delivery by means of ligand or antibody binding.</p>
        <p id="p0290">Liposomes have been investigated for local delivery of drugs to the lung for the treatment of diseases like pulmonary infections, cystic fibrosis, asthma, and lung cancer. Treatment of these diseases has posed a challenge since long because most of the therapeutic moieties used for the treatment are hydrophobic in nature, thereby presenting issues in formulation development and delivery. Moreover the deposit of insoluble drugs in the lungs causes drug toxicity even if the drug is delivered locally to the lungs. Liposomes have been investigated for targeted treatment of such pulmonary infectious diseases. Recently a new drug, namely, Arikayce, which is amikacin-loaded liposomal suspension to be delivered by inhalation, has been approved by FDA for treatment of infectious lung diseases caused by a group of bacteria, namely, <italic>Mycobacterium avium</italic> complex. The controlled trials for this formulation exhibited that about 29% of patients administered with Arikayce exhibited no growth of mycobacteria in their sputum cultures for 3&#xA0;months. The formulation has also been found to be effective against <italic>Mycobacterium abscessus</italic> in patients with cystic fibrosis when administered once a day <xref rid="bb0070" ref-type="bibr">[13]</xref>. This therapeutic ability of inhalable liposomal amikacin formulation is because of its properties like enhanced drug delivery and retention in cystic fibrosis airways, the ability of liposomes to penetrate biofilms, and mucosal layers <xref rid="bb0215" ref-type="bibr">[42]</xref>. Similarly, another inhaled liposomal formulation of ciprofloxacin aimed for the treatment of noncystic fibrosis bronchiectasis (nontuberculosis mycobacterial infections) has cleared phase 2 and phase 3 clinical trials <xref rid="bb0220" ref-type="bibr">[43]</xref>, <xref rid="bb0225" ref-type="bibr">[44]</xref>. This formulation, namely, Pulmaquin, has been designated as a Qualified Infectious Disease Product (QIPD) by the FDA recently.</p>
        <p id="p0295">Another respiratory disease wherein the potential of liposomes for delivery and treatment is being evaluated is lung cancer. Generally, late diagnosis of the disease combined with poor treatment options leaves the option of surgical procedures in the end, which is not desirable. Systemic delivery of chemotherapeutics has not been successful owing to the serious associated side effects that are difficult to minimize. Many liposomal formulations consisting of chemotherapeutic drugs like cisplatin and doxorubicin have been developed in research labs, but they have been rejected in clinical trials either owing to toxicity or because they did not exhibit effects better than the already available formulations. For example, several liposomal formulations of cisplatin like lipoplatin, Li-PlaCls, and L-NDDP have reached clinical trials and exhibit lower toxicity as compared with free cisplatin, but they failed to exhibit enhanced efficacy <xref rid="bb0230" ref-type="bibr">[45]</xref>. Phase I study of aerosolized liposomal cisplatin proved to be safe, but further studies are yet to be performed for applications in lung carcinoma <xref rid="bb0235" ref-type="bibr">[46]</xref>. Similarly, attempts have been made to evaluate liposomal formulations of 9-nitrocamptothecin to overcome its limitations like poor bioavailability owing to poor solubility. Phase 2 clinical trials of liposomal 9-nitrocamptothecin administered by nebulizer indicated that the formulation was safe and feasible for administration to patients with pulmonary malignancies <xref rid="bb0240" ref-type="bibr">[47]</xref>.</p>
        <p id="p0300">Liposomal aerosolized formulations have been shown to improve the localized concentration of drugs at the target site, reduced side effects and cytotoxicity, and improved bioavailability in several clinical trials. For these formulations to be translated to market, enhanced drug efficacy profiles compared with the original drugs are required. The successful development of aerosolized liposomal formulation depends on the ability of the liposome formulation and aerosol delivery device to deliver the drug to the target area in the respiratory tracts in required doses while minimizing the side effects.</p>
      </sec>
      <sec id="s0065">
        <label>3.3</label>
        <title>Micellar systems</title>
        <p id="p0305">Polymeric micelles can be defined as nanosized colloidal carriers with a core-shell structure. Micelles are generated when amphiphilic polymers are dispersed in aqueous solutions above a threshold concentration known as critical micelle concentration (CMC) and a solution temperature known as critical micelle temperature. The amphiphilic polymers commonly used are composed of block polymers (bi- and tri-), polymer-lipid conjugates, and phospholipids. Self-assembly of amphiphilic polymers in aqueous solutions is guided by the decrease of free energy of the system. At concentrations higher than CMC, the hydrophobic segments of the polymer chain start to associate together, thereby reducing contact with water molecules and forming a core-shell structure with a hydrophobic core. The water molecules then get the opportunity to form hydrogen bonds with the hydrophilic segments of polymer chains, while the contact of hydrophobic molecules with the aqueous region is reduced. Both of these instances lead to a reduction of free energy of the system, thereby leading to the formation of micelles. Repulsions among the hydrophilic regions of micelles prevent the excessive formation of micellar structures. Micelles have been proposed to be used for their ability to encapsulate and deliver poorly water-soluble drugs. Micelles offer advantages like greater physical stability in vitro and in vivo, need-based modification of size, encapsulation efficiency, encapsulation of hydrophilic drugs into the micelle shell, and hydrophobic drugs on micelle core region.</p>
        <p id="p0310">Several micellar systems are being evaluated for their potential in pulmonary drug delivery. The study by Kim et al. <xref rid="bb0245" ref-type="bibr">[48]</xref> presented the formulation and characterization of coencapsulated antiinflammatory drug resveratrol and gene into cholesterol-conjugated polyamidoamine (Chol-PAM)-based polymeric micelles. Resveratrol-loaded Chol-PAM micelles exhibited antiinflammatory effects in the in vitro evaluations. Furthermore, an in vivo study revealed that the delivery of resveratrol and heme oxygenase-1 gene combination by Chol-PAM micelles through inhalation exhibited the highest antiinflammatory activity for acute lung infections model. Thus the study reported the efficiency of micelles as the carrier for drug and also the suitability of formulation for inhalation-based delivery.</p>
        <p id="p0315">Another study performed by Hu et al. evaluated the pharmacokinetic profile and biodistribution of curcumin acetate and Nile red-loaded PEG-PLGA micelles after intratracheal administration to rats <xref rid="bb0250" ref-type="bibr">[49]</xref>. The in vivo study demonstrated that the intratracheal administration of micelles prolonged the pulmonary retention time as compared with intravenous administration. Moreover the micelles exhibited localized sustained release for up to 24&#xA0;h. The micelles were also reported to have facilitated the uptake to pulmonary vascular endothelium, thereby paving the way for such systems targeting pulmonary arterial hypertension. The micelles were also found to penetrate the alveolar-blood barrier and reach other organs while maintaining its structure. This property of micelles can be utilized for noninvasive systemic delivery, but this might act as a disadvantage in cases where localized delivery to the lungs is desired.</p>
        <p id="p0320">In another study by Wang et al. <xref rid="bb0255" ref-type="bibr">[50]</xref>, paclitaxel-loaded polymeric micelles were developed and evaluated for the treatment of lung tumors by the administration through inhalation. Peptide conjugate Pluronic, in combination with succinylated gelatin, were used for micelle formulation. The unique property of this micellar system was that the release of paclitaxel was triggered by the presence of matrix metalloproteinase 2/9 (MMP 2/9), with the amount of drug released dependent on the concentration of MMP 2/9. The micellar system was found to be stable upon nebulization. The biodistribution study exhibited that the administration of drug-loaded micelles was able to reach similar drug concentrations in the lungs as that by intravenous administration of the system, although the systemic concentrations of drug in case of pulmonary administration was sevenfold less in comparison with that in the case of intravenous administration. Moreover the percentage of drug deposited into rat lungs via inhalation was less than that previously reported for human lungs. The paclitaxel-loaded micelles enhanced the sensitivity of tumor cells to delivered chemotherapeutics while also reducing the toxicity to healthy lung cells. These kinds of environment responsive systems could further be explored while aiming for targeted delivery and reduced side effects, especially in cases of lung cancers.</p>
        <p id="p0325">Despite the advantages offered by polymeric micelle-based systems like environment responsive delivery, reduced side effects, and encapsulation of hydrophobic drugs, several concerns need to be resolved for easier translation and regulatory approval of such systems into the market. The major issue of concern is the dependency of micellar stability on CMC, thereby increasing the chances for the burst release of drugs in case of instability. Moreover the polymers required for micelle preparation are very limited, thereby limiting the use of such systems. Furthermore, the methods for the preparation of micelle systems are difficult to scale up for large-scale production. Keeping in mind the opportunities and the limitations that these polymeric systems offer, attempts should be made to improvise the systems further to fit the clinical need.</p>
      </sec>
      <sec id="s0070">
        <label>3.4</label>
        <title>Microparticles</title>
        <p id="p0330">Microparticles are the particles with size ranging from 1 to 1000&#xA0;&#x3BC;m and made up of either natural or synthetic polymers. Generally the particles with a size range of 1&#x2013;3&#xA0;&#x3BC;m are used for inhalation delivery using dry powder inhalers. These particles have a density of around 1&#xA0;g/cm<sup>3</sup>, which leads to aggregation and rapid clearance by the macrophages. Thus, to prevent the particles from aggregation and macrophage clearance and assure deposition in the desired area, microparticles with larger size and low density, which are easy to disperse, are proposed. These particles with large size and high porosity exhibit small aerodynamic diameter, which allows them to avoid impaction in the upper tracts and thus the ability to get deposited in deeper regions of the lungs. These microparticles with high porosity are expected to easily escape the clearance by alveolar macrophages, thereby remaining at the site for longer duration and delivering drugs for sustained/prolonged periods.</p>
        <p id="p0335">Several polymers like gelatin, dextran, chitosan, PLGA, and PCL have been evaluated for the formulation and evaluation of microparticles aimed at pulmonary delivery. Among these polymers, PLGA has been the most explored polymer for this kind of application. One of the recent studies conducted by Ubale et al. described the use of PLGA microparticles loaded with antisense oligonucleotide (ASO) against NF-&#x3BA;B for treatment and prevention of lung inflammation <xref rid="bb0260" ref-type="bibr">[51]</xref>. The produced ASO-loaded PLGA microparticles were 2&#x2013;5&#xA0;&#x3BC;m in size and exhibited sustained release in vitro over a period of 72&#xA0;h. The particles were found to be uniformly distributed into the lungs and retained for about 48&#xA0;h after pulmonary administration in rats. These microparticles were found to control the lung inflammation significantly as compared with the control group by the mechanism of reducing the levels of proinflammatory cytokines like TNF-&#x3B1; and IL-1&#x3B2;. The successful retention of such microparticles in lungs sustained delivery, and reduced inflammation suggests the potential of the use of such systems for targeting inflammatory diseases of lungs. However, there are differences in the inhalation pattern that takes place in rats and humans, which suggests the further need for evaluation of such systems for human use.</p>
        <p id="p0340">Recently, in 2014, Acusphere Inc. received US patent for the development of porous microparticles loaded with the hydrophobic drug for pulmonary administration. Acusphere also has one of its products based on porous microparticles for targeting asthma treatment AI-850 under clinical trials. Porous microparticles have also been proposed for efficient delivery of paclitaxel, an anticancer drug, and also as a contrast agent for ultrasound <xref rid="bb0265" ref-type="bibr">[52]</xref>.</p>
        <p id="p0345">Another study performed by Parikh et al. reported the development and evaluation of isoniazid-loaded PCL microparticles and its evaluation for antitubercular activity <xref rid="bb0270" ref-type="bibr">[53]</xref>. The study reported that significantly high levels of isoniazid-loaded microparticles were found in alveolar macrophages when studied in vivo and in vitro owing to phagocytosis of the microparticles. The delivered microparticles lead to an increased level of NO production, which helps improve the efficacy of antitubercular agents without compromising cell viability. Thus it was concluded that such systems could be used to reduce the treatment time of tuberculosis by enhancing the efficacy of antibiotics delivered.</p>
        <p id="p0350">Despite the potential of enhanced efficacy and targeted delivery offered by microparticles, several limitations of these systems hamper their translation into the market and need to be addressed. PLGA-based microparticles, which are the most widely evaluated ones, exhibit limitations like initial burst release of the drug, low drug loading capacity of microparticles, risk of accumulation of PLGA into lungs, and drugs in the core that might be exposed to environmental factors leading to degradation. Porous microparticles expose more area in contact with the surrounding environment, thereby leading to burst release and drug degradation in some cases. The drug loading capacity of the polymeric system is conventionally around 10%. Furthermore the amount of inhalable mass load at a single time ranges from around 25 to 50&#xA0;mg depending upon the type of inhaler. These factors thus limit the use of polymeric microparticle-based systems for drugs that require low doses to be administered. PLGA degrades into acids, thereby creating an acidic environment that might cause local irritation and also degrade the active ingredients in some cases. Surface modifications to increase drug loading or conjugation could be one of the approaches that can be explored to prevent the burst release. Moreover the modifications require to be specific based on the required delivery rate. Taking into consideration the potential benefits and limitations offered by polymeric microparticles, these systems should be further explored.</p>
      </sec>
      <sec id="s0075">
        <label>3.5</label>
        <title>Dendrimers</title>
        <p id="p0355">Dendrimers, also known as dendritic polymers, are branched polymers with well-defined microstructures and polyfunctionality. These polymers differ from the random coil polymers owing to their peculiar structural characteristics. Dendrimers consist of three different components: (a) a core, (b) internal repeating unit layer, and (c) outer functional units. Some of the commonly used dendritic polymers are polyamidoamine (PAMAM), polyester, polyamide, poly (<sc>l</sc>-lysine), and polyether, among others. Dendrimers exhibit several properties that have attracted the attention of researchers for its application in pulmonary delivery. One of the beneficial characteristics is the ability to choose the suitable size of dendrimers by varying the dendrimer generation; therefore the dendrimer size can be selected based on the desired deposition region in the lungs. Dendrimers provide the opportunity for multifunctionalization owing to the presence of a large number of surface functional groups. Dendrimers have also shown to exhibit improved bioavailability and therapeutic efficiency for loaded drug molecules. Moreover, dendrimers have also shown to improve the physicochemical properties of the loaded therapeutic moieties.</p>
        <p id="p0360">Several dendrimer systems have been assessed for their pulmonary delivery abilities targeting diseases like cystic fibrosis, lung cancer, metastases, chronic asthma, and COPD. Zhong et al. reported the development of PAMAM-conjugated doxorubicin (DOX) nanocarrier systems and evaluated its potential for pulmonary administration and efficiency in the lung metastases model. DOX was conjugated to carboxylated terminals of PAMAM dendrimers by means of the intracellular trigged linker, which would release the drug in a pH-responsive manner (at intracellular pH&#xA0;4.5). The conjugated drug-PAMAM nanocarrier exhibited a significant decrease in the tumor burden and significant in the animal survival rate when compared with that of free DOX administered through intravenous and pulmonary route. Moreover, biodistribution studies revealed an enhanced localization of drug in the lungs and reduced distribution to heart as compared with the free drug <xref rid="bb0275" ref-type="bibr">[54]</xref>.</p>
        <p id="p0365">Another study performed by the same group evaluated the effects of surface modification of dendrimers with PEG on the biodistribution and pharmacokinetic profile of dendrimers after systemic and pulmonary administration <xref rid="bb0280" ref-type="bibr">[55]</xref>. In this study, amine-terminated PAMAM dendrimers were conjugated with PEG on the surface and evaluated further. It was found from the pharmacokinetic profiles that both PEGylated and non-PEGylated dendrimers reached their peak concentration within a few hours of administration via the pharyngeal aspiration route, thereby negating the effect of chemistry on peak plasma concentration. Therefore it was found through the study that a high density of surface modifications with PEG and the administration route affects the biodistribution and the pharmacokinetic profiles. Pulmonary delivery of unmodified PAMAM dendrimers led to the concentration of about 83% of delivered dendrimers in the lungs, while only 2% of dendrimers reached lungs after intravenous delivery. The PEGylated dendrimers also were reported to be readily internalized by lung endothelial cells (20%) as compared with that of unmodified ones. Contrary to this, about 35% of unmodified dendrimers were taken up by lung epithelial cells, whereas only 24% of PEGylated dendrimers were uptaken. This study therefore suggests that suitable surface modification of dendrimers can be performed to manipulate the biodistribution, pharmacokinetic profiles, and targeted delivery to desired organs. Moreover the chemistry of dendrimers also affects the cell uptake, thereby suggesting suitable modifications in cases where specific cells require to be targeted.</p>
        <p id="p0370">One of the novel strategies being worked upon to treat inflammatory lung diseases like asthma, COPD, barotrauma, inflammation, and reduced function caused after lung transplantation has been targeted delivery of RNA to lung endothelial cells. One such study performed by Khan et al. described the use of a combination of PAMAM and poly(propylene imine) (PPE) dendrimers with lipid substitution for encapsulation and delivery of siRNA <xref rid="bb0285" ref-type="bibr">[56]</xref>. The study showed that siRNA encapsulated in chemically modified dendrimers exhibited higher avidity toward lung endothelial cells. Among all different combinations evaluated, PAMAM-conjugated with C<sub>15</sub> lipid tails, PPE dendrimers with C<sub>15</sub>, and C<sub>14</sub> lipid chains were found to exhibit high potency dependent on diameter for optimal delivery to endothelial cells. Moreover, factors like the chemistry of modified dendrimers and p<italic>K</italic>
<sub>a</sub> values of nanoparticles were suggested to have an impact on the targeting window of dendrimers. Such systems can further be explored for targeted delivery of therapeutics like mRNA, DNA, and microRNA.</p>
        <p id="p0375">The aforementioned studies therefore lead to the conclusion that the dendrimer chemistry plays an important role in determining the behavior of dendrimers upon in vivo delivery. Therefore the chemistry of dendrimers, along with drug conjugation or encapsulation, can be exploited to achieve desired delivery characteristics. Moreover the route of administration also has a pivotal role to play. Despite the many advantages offered by dendrimer-based pulmonary delivery, toxicity caused by these positively charged dendrimers still remains a challenge. The positively charged dendrimer systems are known to react with negatively charged biological membranes, thereby causing potential cytotoxicity and hemolytic toxicity. Attempts have been made to reduce this toxic potential of dendrimers by masking the cationic charge by means of conjugation with hydrophilic polymers and PEG. Moreover the production of such dendrimer-based delivery systems at a large scale with required clinical standards still poses challenges required to be addressed.</p>
      </sec>
      <sec id="s0080">
        <label>3.6</label>
        <title>Gene therapy</title>
        <p id="p0380">Gene therapy, by means of viral and nonviral vectors, has also been evaluated for aerosolized administration targeting diseases like cystic fibrosis, lung cancer, alpha-1 antitrypsin deficiency, and asthma. Viral vectors have been found to be highly efficient in gene transfection, but they incite the formation of antibodies. Thus the nonviral vectors were developed and evaluated, which mainly consists of cationic polymers. These nonviral vectors are more efficient in binding to airway epithelium but less efficient in gene transfection as compared with that of viral vectors. Aerosolized gene therapy has been evaluated for tumor suppressing agents, epidermal growth factor suppressing agents, immunosuppressing agents and others. Various cationic polymers like polyethyleneimine (PEI), PEI/PEG complex, and amphiphilic block polymers have been explored to form nanocomplexes for gene delivery <xref rid="bb0290" ref-type="bibr">[57]</xref>.</p>
        <p id="p0385">Therapeutic proteins and peptides, which are often classified as biopharmaceuticals, have proved their potential for the treatment of various autoimmune diseases, diabetes, cancer, and others. Peptides and protein therapeutics exhibit high selectivity and efficacy as compared with small molecule drugs, which have led to increased demand for development of delivery methods for such therapeutics. The physicochemical properties of such therapeutics like high molecular weight and hydrophilic nature limit their applications for disease treatment. Protein/peptide therapeutics face difficulty in crossing the biological membranes due to their physicochemical nature, thereby resulting in low bioavailability. One of the ways to overcome such limitations has been the evaluation of pulmonary delivery of proteins and peptides for local and systemic applications.</p>
        <p id="p0390">A recent study published by Patel et al. reported the formulation of inhalable in vitro transcribed mRNA nanoformulation for protein production in the lungs. Herein cationic polymer poly(beta-amino esters) (PBAE) was used owing to its ionizable and biodegradable nature for the delivery of mRNA through nebulization. The strategy of hyperbranching was utilized to modulate the properties of the polymer in accordance with the requirements for inhalable systems while maintaining its chemical backbone preserved, which could be identified for efficient gene delivery. In vivo, pulmonary administration in rats exhibited a uniform distribution of luciferase mRNA throughout the lungs and the production of luciferase protein. It was also found that a single nebulized dose of hyperbranched PBAE polyplexes with mRNA transfects about 24.6% of lung epithelial cell population. Thus repeated dosing of this inhalable formulation was found to produce proteins consistently without causing local or systemic toxicity. This system can be used to deliver mRNAs to the lungs for the treatment of diseases like cystic fibrosis and others <xref rid="bb0295" ref-type="bibr">[58]</xref>. It can be observed here that the polymer was chosen based on its ability to degrade at the site and the chemical backbone required for gene delivery, further modified to make it suitable for pulmonary delivery. This kind of approach can be further evaluated with different polymers to develop suitable systems required to meet the clinical need.</p>
        <p id="p0395">Many systems have been evaluated for gene therapy, but very few of them have cleared the clinical trials and reached the market. One of the reasons behind the low translation of such systems into the market despite good results in animal studies has been safety and effectiveness in human disease models. Further investigations regarding the same needs to be performed to meet clinical needs.</p>
      </sec>
      <sec id="s0085">
        <label>3.7</label>
        <title>Immune therapy/vaccines</title>
        <p id="p0400">Chemotherapeutic agents like antibiotic and antiviral agents are the standard treatment modes for respiratory tract infections like cystic fibrosis, pneumonia, rhinosinusitis, chronic obstructive pulmonary disorder. However, there has been a decline in the effectiveness of these agents for the management of respiratory tract infections owing to pathogen resistance. Therefore many alternate treatment strategies are being worked upon with immunotherapeutics being one of the widely studied. Immune therapy consists of therapeutic antibodies and proteins that are delivered in the form of prophylactic for disease prevention and therapeutics for disease management through parenteral routes. However, preclinical studies have revealed that the parenteral route might not be the best route to administer the high-molecular weight immunotherapeutics due to their incapability to reach lungs efficiently <xref rid="bb0300" ref-type="bibr">[59]</xref>. Thus investigation of inhalation-based systems through oral and intranasal routes are being studied so as to overcome the barriers put forward by the parenteral routes. Immunotherapeutic delivery by pulmonary route has been studied for targeting local diseases in the lungs and for systemic delivery owing to high absorption property through the alveolar surface area <xref rid="bb0305" ref-type="bibr">[60]</xref>.</p>
        <p id="p0405">Aerosolized dornase alfa, which is a recombinant human deoxyribonuclease, is one of the earliest aerosolized therapy directed for cystic fibrosis treatment. Pulmozyme is the marketed formulation of therapeutic protein dornase alfa, which has been found to reduce the sputum viscoelasticity when administered in case of cystic fibrosis <xref rid="bb0310" ref-type="bibr">[61]</xref>. But this has been the only aerosolized nucleotide-based formulation to date.</p>
        <p id="p0410">FluMist Quadrivalent is a marketed nasal inhalation-based vaccine containing live attenuated influenza virus, which is sprayed into the nose to protect against influenza <xref rid="bb0315" ref-type="bibr">[62]</xref>. Another live attenuated vaccine Nasovac (Serum Institute of India Ltd.) is an intranasal vaccine against influenza A (H1N1) virus <xref rid="bb0320" ref-type="bibr">[63]</xref>.</p>
        <p id="p0415">Most of the intranasal vaccines introduced or studied are liquid in nature, thus making the incorporated immunotherapeutics susceptible to thermal degradation, formulation instability, and chemical instability, thus leading to degradation of the active therapeutic agent and loss of efficacy and potency. To overcome this challenge the formulation of vaccines in the form of dry powder inhalers could be the approach for further research. Many studies have evaluated the stability of dry powder vaccines at varying temperatures and humidity and found them to be stable and as efficacious as liquid vaccines when reconstituted. However, dry powder vaccines would be required to have protection against humidity <xref rid="bb0325" ref-type="bibr">[64]</xref>.</p>
      </sec>
    </sec>
    <sec id="s0090">
      <label>4</label>
      <title>Marketed pulmonary drug delivery systems</title>
      <sec id="s0095">
        <label>4.1</label>
        <title>Marketed devices for respiratory diseases</title>
        <p id="p0420">There are several nanoparticle/microparticle-based pulmonary inhalation systems that have been approved by the FDA and entered the market for their applications in imaging, diagnostics, and treatment of respiratory diseases. Despite a large number of pulmonary systems that have been researched on, very few of them make their way to clinical trials, and even fewer manage to pass through the trial and reach the market. The reasons for this are the complex preparation procedures for the nanoparticle-based systems, stability issues for the formulation, safety concerns associated with the biodegradability and biocompatibility of developed systems, chemical instability of encapsulated active ingredient, large-scale production, and economical nonfeasibility of the systems. <xref rid="t0010" ref-type="table">Table 1</xref>
enlists the pulmonary delivery systems that have reached the market for the treatment of respiratory diseases and for systemic delivery. It can be observed that most of the systems that have been translated into the market are liposome-based pulmonary inhalation systems.<table-wrap position="float" id="t0010"><label>Table 1</label><caption><p>List of pulmonary delivery systems launched in the market.</p></caption><alt-text id="al0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Sr. no</th><th>Device/formulation name</th><th>Company</th><th>Indication</th><th>Description</th><th>Drug</th></tr></thead><tbody><tr><td>1.</td><td>ARIKAYCE</td><td>Insmed</td><td><italic>Mycobacterium avium</italic> complex (MAC) lung disease</td><td>Liposomal suspension for inhalation administered using Lamira nebulizer system</td><td>Amikacin</td></tr><tr><td>2.</td><td>TOBI PODHALER</td><td>Novartis</td><td>Cystic fibrosis with <italic>Pseudomonas aeruginosa</italic></td><td>Dry powder formulation consisting of tobramycin enclosed in hypromellose capsule</td><td>Tobramycin</td></tr><tr><td>3.</td><td>Curosurf</td><td>Chiesi USA</td><td>Respiratory distress syndrome in premature infants</td><td>Liposomal nanoparticles intended for enhanced delivery and reduced side effects upon intratracheal instillation</td><td>Poractant alfa</td></tr><tr><td>4.</td><td>Apulmiq</td><td>Aradigm</td><td>Noncystic fibrosis bronchiectasis</td><td>Inhalable formulation consisting of free ciprofloxacin and ciprofloxacin loaded liposomes (cleared phase 3 trials)</td><td>Ciprofloxacin</td></tr><tr><td>5.</td><td>Afrezza</td><td>MannKind Corporation</td><td>Diabetes mellitus</td><td>Inhalable recombinant insulin with excipients that self-assembles to form microspheres in the acidic environment</td><td>Insulin</td></tr><tr><td>6.</td><td>Alveofact</td><td>Boehringer Ingelheim Pharma</td><td>Respiratory distress syndrome in premature infants</td><td>Liposomal suspension consisting of surfactant</td><td>Fat extracted from lung lavage fluid</td></tr><tr><td>7.</td><td>Survanta</td><td>Abbott</td><td>Respiratory distress syndrome in premature infants</td><td>Liposomal formulation consisting of surfactant</td><td>Beractant</td></tr><tr><td>8.</td><td>Paclitaxel-based DPI</td><td>InhaTarget</td><td>Lung cancer</td><td>Drug-loaded nanocarriers (micelles and SLNs) for targeted delivery to lungs, enhanced residence time (under development)</td><td>Paclitaxel</td></tr><tr><td>9.</td><td>Cisplatin-based DPI</td><td>InhaTarget</td><td>Lung cancer</td><td>Cisplatin dry powder for inhalation, noninvasive delivery (preclinical stage)</td><td>Cisplatin</td></tr><tr><td>10.</td><td>Pulmosphere</td><td>Novartis</td><td>Respiratory diseases</td><td>Phospholipid containing formulation with drug suspension, solution or drug-loaded porous microparticles</td><td>N/A</td></tr></tbody></table></table-wrap></p>
        <p id="p0425">Despite the plethora of research in nanoparticle-based delivery in the last five decades, very few of them have translated clinically. One of the major challenges arises when the functionality of nanoparticle systems is complexed to develop systems for targeted delivery, stimuli sensitive, or multifunctional. Multiple chemical synthesis steps are required to integrate multiple functionalities into the nanocarrier-based systems, which again becomes challenging for production at large scale wherein good manufacturing practices are required to be followed at each step. This results in increased production cost and increased evaluation criteria for the formulation of quality control <xref rid="bb0330" ref-type="bibr">[65]</xref>. Another factor that plays a role is the intellectual property (IP) rights associated with the developed systems. Many factors like targeted or nontargeted delivery, types of drugs that can be loaded, and intended application for the system affect the IP strategies, and thus any of these factors might contribute to weakening the IP, thereby adversely affecting the research and development of such products <xref rid="bb0335" ref-type="bibr">[66]</xref>. Moreover the clinical trials for nanomedicines are more complex as compared with that of conventional delivery systems owing to a large number of control groups required to assess the effects of various nanoparticle components on the cells and tissues.</p>
        <p id="p0430">Different types of inhaler devices are available in the market to assist the aerosol delivery to lungs for the treatment of respiratory diseases. <xref rid="t0015" ref-type="table">Table 2</xref>
enlists some of the aerosol delivery technologies that are clinically utilized. The systems generally comprise dry powder inhalers, pressured metered-dose inhalers, different types of nebulizers, and the advancements in these systems. The most commonly used type of inhaler devices used for pulmonary delivery is the pMDIs. They have been widely used for decades by patients suffering from diseases like COPD and asthma in the form of a single drug or combination of drugs. One of the major challenges associated with the use of pMDIs is the correct use of the device by the patients. To address this issue the new pMDIs have been developed with breath-actuated technology, wherein the drug is emitted from the device after it senses the patient&#x2019;s breath, thus solving the coordination problems with actuation and breathing. Another major development in the pMDI technology has been the shift from the use of chlorofluorocarbon (CFC)-based propellers to hydrofluoroalkane-based propellers for pMDIs <xref rid="bb0395" ref-type="bibr">[78]</xref>. Newer technologies like Respimat Soft Mist have been introduced, which is a combination of properties of pMDI and nebulizers that do not require a power supply and aerosolizes the drug solution in the form of soft mists. This combined technology was found to exhibit a significant reduction in the oropharyngeal deposition of the aerosol <xref rid="bb0400" ref-type="bibr">[79]</xref>.<table-wrap position="float" id="t0015"><label>Table 2</label><caption><p>Inhaler delivery systems available in the market.</p></caption><alt-text id="al0030">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Sr. no</th><th>Name</th><th>Type</th><th>Company</th><th>Description</th><th>Drug</th><th>References</th></tr></thead><tbody><tr><td>1.</td><td>ELLIPTA</td><td>DPI</td><td>GlaxoSmithKline</td><td>Single- or two-strip, single-step activation, multidose inhaler, can be used unassisted by patients above 7&#xA0;years of age; requires low inspiratory rate</td><td>Fluticasone furoate</td><td><xref rid="bb0340" ref-type="bibr">[67]</xref></td></tr><tr><td>2.</td><td>Pulmicort Flexhaler</td><td>DPI</td><td>AstraZeneca</td><td>Multiple-dose inhaler, driven by inspiratory flow, used for treatment of asthma in patients above 6&#xA0;years of age</td><td>Budesonide</td><td><xref rid="bb0345" ref-type="bibr">[68]</xref></td></tr><tr><td>3.</td><td>PROAIR RESPICLICK</td><td>DPI</td><td>Teva Pharmaceuticals</td><td>Multidose breath-actuated inhaler used for acute asthma symptoms, bronchospasm</td><td>Albuterol sulfate</td><td><xref rid="bb0350" ref-type="bibr">[69]</xref></td></tr><tr><td>4.</td><td>Diskus/Accuhaler</td><td>DPI</td><td>GlaxoSmithKline</td><td>Multidose inhaler with consistent dosing across varying flow rates. It consists of defined doses in laminated strips</td><td>Salbutamol/salmeterol/fluticasone propionate/salmeterol&#xA0;&#x2009;+&#xA0;&#x2009;fluticasone propionate</td><td><xref rid="bb0355" ref-type="bibr">[70]</xref></td></tr><tr><td>5.</td><td>AKITA Jet</td><td>Jet nebulizer</td><td>Vectura</td><td>Smart jet or mesh nebulizer. Individualized delivery of drug dose based on the patient&#x2019;s lung function information. Indicated for severe uncontrolled asthma (leading phase 3 trials)</td><td>Budesonide</td><td><xref rid="bb0360" ref-type="bibr">[71]</xref></td></tr><tr><td>6.</td><td>ProAir HFA</td><td>pMDI</td><td>Teva Pharmaceutical Industries</td><td>pMDI inhaler with inbuilt dose counter used for prevention or treatment of bronchospasm in asthma or COPD for patients aged 4&#xA0;years or older</td><td>Albuterol sulfate</td><td><xref rid="bb0365" ref-type="bibr">[72]</xref></td></tr><tr><td>7.</td><td>Ventolin HFA</td><td>pMDI</td><td>GlaxoSmithKline</td><td>pMDI inhaler with inbuilt dose counter used for prevention or treatment of bronchospasm in asthma or COPD for patients aged 4&#xA0;years or older</td><td>Salbutamol</td><td><xref rid="bb0365" ref-type="bibr">[72]</xref></td></tr><tr><td>8.</td><td>I-Neb</td><td>Mesh nebulizer</td><td>Philips</td><td>Battery powered mesh nebulizer comprising of adaptive aerosol delivery system. Optimal drug delivery, reduced nebulization time</td><td>N/A</td><td><xref rid="bb0370" ref-type="bibr">[73]</xref></td></tr><tr><td>9.</td><td>Respimat Soft Mist</td><td>Liquid inhaler</td><td>Boehringer Ingelheim Limited</td><td>Multidose inhaler that produces soft mist, propellant-free, handheld liquid inhaler. Indicated for patients with COPD and obstructive respiratory diseases</td><td>Tiotropium bromide monohydrate</td><td><xref rid="bb0375" ref-type="bibr">[74]</xref></td></tr><tr><td>10.</td><td>Staccato</td><td>Breath-actuated inhaler</td><td>Alexza Pharmaceuticals Inc.</td><td>Single breath activation system wherein rapid vaporization of drug occurs to form aerosol particles for inhalation delivery</td><td>N/A</td><td><xref rid="bb0380" ref-type="bibr">[75]</xref></td></tr><tr><td>11.</td><td>PARI eFlow</td><td>Rapid nebulizer</td><td>PARI International</td><td>Vibrating mesh nebulizer with easier handling and reduced time of nebulization</td><td>Tobramycin</td><td><xref rid="bb0385" ref-type="bibr">[76]</xref></td></tr><tr><td>12.</td><td>Conix</td><td>DPI</td><td>3&#xA0;M Drug Delivery Systems</td><td>Passive DPI that utilizes the high energy and shear forces of vortex to deagglomerate the particles. Unique feature is that only fine API particles are inhaled while large lactose particles are retained in the chamber</td><td>Fluticasone propionate<break/>Salmeterol xinafoate</td><td><xref rid="bb0390" ref-type="bibr">[77]</xref></td></tr></tbody></table></table-wrap></p>
        <p id="p0435">DPIs are another commonly marketed and clinically used inhaler devices that do not have coordination issues regarding patient breathing and device actuation. The DPIs are more stable chemically as compared with aerosolized suspension or solution because of low reactivity in powder form. Different types of DPIs are available, which can be classified as single-unit dose disposable, single-unit dose reusable, multiunit dose, and multidose reservoir. They can also be classified into passive and active DPIs. The main issue with passive DPIs is the variability in the inspiratory forces among patients of different ages and health conditions, thereby affecting dose uniformity. Active DPIs have internal energy sources added to them so that the dose uniformity is not dependent on the patient&#x2019;s inspiratory flow rate <xref rid="bb0405" ref-type="bibr">[80]</xref>.</p>
        <p id="p0440">Staccato is another breath-actuated inhaler device that vaporizes the drug film using heat, which is later condensed into the form of small droplets into the lungs and is intended for systemic application <xref rid="bb0410" ref-type="bibr">[81]</xref>.</p>
        <p id="p0445">Nebulizers are another type of inhaler device available in different varieties and have recently gained attention due to the higher costs of hydrofluoroalkane (HFA as propellant)-based inhaler devices. The nebulizers with advanced technologies include the breath-actuated, breath-enhanced, mesh, and vibrating nebulizers. Breath-actuated nebulizers release aerosolized formulation only when it senses that the patient is breathing. This coordinated release avoids wastage of drug during exhalation and avoids environmental exposure to toxic drugs. On the other hand a breath-enhanced nebulizer is designed such that it entertains the airflow during inspiration and vents out the expired air outside the device, thereby increasing the output rate and decreasing the administration time. Vibrating mesh nebulizers have a mesh plate attached to them, which vibrates upon the action of the piezoelectric element and breaks the aerosol droplets into fine particles before delivery, thereby increasing the aerosol deposition in the alveoli <xref rid="bb0415" ref-type="bibr">[82]</xref>. There have been newer technologies that sense the breathing pattern of patients and releases drug only when appropriate breathing is detected, for example, AKITA <xref rid="bb0420" ref-type="bibr">[83]</xref>.</p>
      </sec>
      <sec id="s0100">
        <label>4.2</label>
        <title>Patented novel pulmonary systems</title>
        <p id="p0450">As discussed in the previous sections, there have been many technological advancements in the field of pulmonary delivery devices and technologies like nebulizers, pMDIs, DPIs, and others to make the delivery more efficient and patient compliant. Despite numerous efforts, there still exist many unmet clinical needs in the area of pulmonary delivery that needs to be addressed and has been widely being worked upon by the researchers. <xref rid="t0020" ref-type="table">Table 3</xref>
enlists the recently patented novel pulmonary delivery systems utilizing the concept of nano/micro-based drug delivery.<table-wrap position="float" id="t0020"><label>Table 3</label><caption><p>Recently patented delivery systems intended at pulmonary delivery</p></caption><alt-text id="al0035">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Patent number</th><th>Year</th><th>Description of the invention</th><th>Disease targeted</th><th>Remarks</th><th>References</th></tr></thead><tbody><tr><td>US20190169224</td><td>2019</td><td>Intranasal composition consisting of nanocrystals of hydrophobic agents such as triamcinolone or fluticasone</td><td>Asthma, COPD</td><td>Proposed for treating or alleviating a respiratory disease</td><td><xref rid="bb0425" ref-type="bibr">[84]</xref></td></tr><tr><td>US10034837</td><td>2018</td><td>Polymeric nanoparticles or polymeric nanoparticles encapsulated within cross-linked polymeric microparticles of chitosan or chitosan-derived polymers</td><td>Chronic obstructive pulmonary disease (COPD), bronchial asthma, cystic fibrosis (CF), chlorine inhalation, influenza myocardial infarction (MI)</td><td>Nitric oxide- and nitrite donor-loaded polymeric nanoparticles are proposed to be delivered through DPI</td><td><xref rid="bb0430" ref-type="bibr">[85]</xref></td></tr><tr><td>WO2018031771A1</td><td>2018</td><td>Therapeutic drug-loaded polymeric nanoparticles with a coating of mucoadhesive polymer (PLGA nanoparticles with chitosan coating)</td><td>Allergic asthma, COPD</td><td>Increased therapeutic effects, prolonged residence time of NPs at site, targeted delivery</td><td><xref rid="bb0435" ref-type="bibr">[86]</xref></td></tr><tr><td>US10004764</td><td>2018</td><td>Red blood cell membrane-derived microparticles (RBC MPs) expressing phosphatidylserine on their surface delivered to lungs via inhalation</td><td>COPD, asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis</td><td>Enhanced production of immunoregulatory cytokines, reduced inflammation, reduced injury</td><td><xref rid="bb0440" ref-type="bibr">[87]</xref></td></tr><tr><td>US2018005580</td><td>2018</td><td>Aerodynamically light drug particles (levodopa) in combination with sugar or salt</td><td>Parkinson&#x2019;s disease</td><td>On-demand rapid delivery of drug</td><td><xref rid="bb0445" ref-type="bibr">[88]</xref></td></tr><tr><td>US20180161404</td><td>2018</td><td>Polymeric nanoparticle (PLGA) for controlled delivery of surfactant protein D to lungs</td><td>COPD, bronchitis, lung infections, hypoplasia, CF, influenza</td><td>Controlled delivery of protein</td><td><xref rid="bb0450" ref-type="bibr">[89]</xref></td></tr><tr><td>US9545401</td><td>2017</td><td>Aerosol formulation consisting of ciprofloxacin encapsulated in liposomes</td><td>Respiratory tract infections, cystic fibrosis</td><td/><td><xref rid="bb0455" ref-type="bibr">[90]</xref></td></tr><tr><td>US20170042818</td><td>2017</td><td>Gel microparticles wherein each microparticle consists of multiple drug-loaded nanoparticles</td><td>Nonsmall cell lung cancer</td><td>Fine-tuning of drug-loaded nanoparticles from microparticle matrix, active targeting, enhanced efficacy</td><td><xref rid="bb0460" ref-type="bibr">[91]</xref></td></tr><tr><td>US9421166</td><td>2016</td><td>Dispersible powder consisting of aminoglycoside with phospholipids as the carrier</td><td>Bronchiectasis, cystic fibrosis, localized respiratory infections</td><td>Reduced side effects due to localized delivery of antibiotics, reduced potential of antibiotic resistance</td><td><xref rid="bb0465" ref-type="bibr">[92]</xref></td></tr><tr><td>US20160113995</td><td>2016</td><td>Lipid nanoparticle of polymyxin</td><td>Respiratory tract infections (<italic>P. aeruginosa</italic>)</td><td>Polymyxin-loaded lipid nanoparticles (fatty acids and mono-, bi-, and triglycerides)</td><td><xref rid="bb0470" ref-type="bibr">[93]</xref></td></tr><tr><td>US9072664</td><td>2015</td><td>Surface-modified inorganic nanoparticles suspended in dryable liquid carriers</td><td>For drug delivery in case of respiratory diseases</td><td>Improved flowability of particles for DPIs</td><td><xref rid="bb0475" ref-type="bibr">[94]</xref></td></tr><tr><td>US20150224062</td><td>2015</td><td>Nanostructured aggregates consisting of immunosuppressive drugs (tacrolimus and cyclosporine) for delivery through pulmonary route</td><td>Pulmonary fibrosis, bronchiolar asthma, graft rejection</td><td>Rapid dissolution of nanoparticles in lungs, avoidance of hepatic first-pass metabolism, increased the local concentration</td><td><xref rid="bb0480" ref-type="bibr">[95]</xref></td></tr><tr><td>US20140294939</td><td>2014</td><td>Liposomes loaded with mRNA encoding the desired protein administered via the pulmonary route</td><td>Treatment of deficiencies of proteins and enzymes</td><td>Enhanced stability, the systemic release of proteins</td><td><xref rid="bb0485" ref-type="bibr">[96]</xref></td></tr><tr><td>US20130136688</td><td>2013</td><td>Aerosol consisting of polymeric nanoparticle with noncovalently anchored linker on one side and one coupling group (maleimide) on another portion</td><td>Treatment and diagnosis of lung cancer or bronchial dysplasia.</td><td>Potential for targeted delivery to desired tissue/cells by varying the linker and coupling group</td><td><xref rid="bb0490" ref-type="bibr">[97]</xref></td></tr><tr><td>US8574623</td><td>2013</td><td>Liposome carrier for delivery of therapeutic agent (siRNA)</td><td>Pulmonary fibrosis</td><td>Specific delivery to extracellular matrix producing cells in the lungs</td><td><xref rid="bb0495" ref-type="bibr">[98]</xref></td></tr><tr><td>US8574623</td><td>2013</td><td>Liposome carrier for delivery of therapeutic agent (siRNA)</td><td>Pulmonary fibrosis</td><td>Specific delivery to extracellular matrix producing cells in the lungs</td><td><xref rid="bb0495" ref-type="bibr">[98]</xref></td></tr><tr><td>US20100260853</td><td>2010</td><td>Compositions consisting of polypeptide/antibody domain with droplet size less than 5&#xA0;&#x3BC;m</td><td>COPD, asthma</td><td>Proposed for diagnostic, prophylactic or therapeutic purposes</td><td><xref rid="bb0500" ref-type="bibr">[99]</xref></td></tr><tr><td>US20080213373</td><td>2008</td><td>Dry powder consisting of drug-loaded nanoparticle aggregates or microparticles (capreomycin and leucine)</td><td>Tuberculosis, severe acute respiratory syndrome, Respiratory syncytial virus</td><td>Improved delivery, needleless delivery</td><td><xref rid="bb0505" ref-type="bibr">[100]</xref></td></tr><tr><td>US7182961</td><td>2007</td><td>Drug-loaded particulate composition with a particle tap density of less than 0.4&#xA0;g/cm<sup>3</sup> and a geometric diameter greater than 5&#xA0;&#x3BC;m</td><td>Airway diseases</td><td>Aerodynamically light particles, highly dispersible particles, optimal particles for aerosols</td><td><xref rid="bb0510" ref-type="bibr">[101]</xref></td></tr><tr><td>US6706892</td><td>2004</td><td>Particulate formulations consisting of active ingredients with the ability to form covalent bonds with blood/pulmonary proteins</td><td>Treating inflammation, bronchodilation</td><td>Enhancing the drug stability and blood absorption of the agents</td><td><xref rid="bb0515" ref-type="bibr">[102]</xref></td></tr></tbody></table></table-wrap></p>
        <p id="p0455">Some of the issues that need attention from the researchers have been discussed here. One of the most important factors is the consistency and reproducibility of the generated aerosols for pulmonary drug delivery. We need technologies that could assure the generation of consistent aerosols, thereby delivering an accurate amount of drug each time to every patient. Delivering large doses is also a crucial factor that poses challenges in the case of pulmonary delivery. A small fraction of the drug is deposited into the lungs when delivered through most of the inhaler systems, which might not be enough dose for treatment of some diseases, thereby creating the requirement for repeated delivery, thus reducing patient compatibility and causing discomfort. Moreover the choice of the inhaler, the comfort level of the patient to use the inhaler, inhaler technique, and adherence to inhaler regimen are some of the other concerns that require to be focused on while developing newer inhalation technologies.</p>
        <p id="p0460">The newly patented technologies consist of nanoparticle-based technologies for targeting respiratory diseases via pulmonary delivery. The patents include a wide range of polymeric nanoparticles, lipid nanoparticles, liposomes, micelles, dendrimers, and others. These novel systems are intended to have advantages like enhanced efficiency of delivery, enhanced therapeutic efficiency, controlled delivery, targeted delivery, an alternative to invasive delivery, and reduced side effects, as can be analyzed from the recent patents described in <xref rid="t0020" ref-type="table">Table 3</xref>. Despite the high number of advanced patented technologies, very few of them are actually translated to market because the developed systems turn out to be unsafe, causing side effects, not significantly more efficient than the already existing systems, along with issues in large-scale production and translation. There is a need to boost this translation of newer technologies from lab to land.</p>
      </sec>
    </sec>
    <sec id="s0105">
      <label>5</label>
      <title>Future prospects and conclusions</title>
      <p id="p0465">The pulmonary route has been found to be promising for the delivery of drugs locally to lungs and rapid systemic delivery for several diseases. The pulmonary delivery offers advantages like the rapid onset of delivery, self-administrable noninvasive delivery, enhanced efficiency, localized action, and reduced side effects. The inherent properties offered by lungs such as high surface area and low enzymatic environment further make pulmonary delivery even more desirable. However, there are several challenges that are required to be tackled for successful pulmonary delivery, which includes rapid drug degradation, clearance mechanism by the alveolar macrophages, limited control over the particle deposition, and site of deposition of inhaled formulations.</p>
      <p id="p0470">Several particle-based systems (nanoparticle/microparticle) have been found to be promising for optimized pulmonary delivery to lungs for targeting respiratory diseases that utilize the advantages offered by lungs while addressing the limitations offered by physiological barriers at the same time. Several such systems like polymeric nanoparticles, solid lipid nanoparticles, liposomes, micelles, and dendrimers that have been developed for pulmonary delivery have been discussed in brief. Particle properties of the different systems like particle size, surface properties, composition, shape, and others affect the delivery characteristics of the system. These properties of the nanoparticle-based systems are modified to achieve characteristics like the desired release rate, site of deposition, targeted release, and protection of the active ingredient. Various patents and marketed nanotechnology-based pulmonary systems have been discussed while indicating the novel feature that has introduced into the systems from an improvement perspective.</p>
      <p id="p0475">Despite great advancements in the development of nanoparticle-based pulmonary delivery systems, the clinical translation of such systems for targeting respiratory diseases remains a challenge. The physical properties and behavior of the inhaled particles are quite different than that characterized in vitro. These differences exhibited in the in vitro and in vivo behavior is often the reason that many nanoparticle-based delivery systems fail to perform significantly more efficient than the existing systems in the clinical trials. Therefore this factor should be taken into account while developing newer nanomedicines. Moreover, complexity of formulation procedure, formulation stability, batch-to-batch variability, economic burden, efficiency, and safety are some of the factors that require to be taken care of at the laboratory stage itself while developing newer systems. The systems further require to be specialized with respect to the specific requirements of the respiratory disease required to be targeted. After the development of a stable delivery system targeting lung diseases, another concern is its delivery in the form of aerosols through the inhaler devices. Delivery of the drug-loaded particles to the desired site of action through inhalation requires the use of appropriate inhaler that does not affect the formulation stability negatively while generating reproducible aerosols. Patient compliance and ease of use of the inhaler device correctly also play a crucial role. Modifications and advancements in the design of inhaler devices have been one of the strategies to enhance the drug bioavailability at site and residence time of the drug in the lungs.</p>
      <p id="p0480">The computational fluid dynamics modeling approach has provided new opportunities for the researchers to understand the dynamics of aerosol transport, dispersion, and deposition in the alveoli throughout the lungs. These kinds of studies can help to modulate the formulation parameters of inhalation-based pulmonary delivery systems <xref rid="bb0520" ref-type="bibr">[103]</xref>, <xref rid="bb0525" ref-type="bibr">[104]</xref>. Moreover, modeling strategies like in vitro, ex vivo, and in silico modeling have been introduced to study the transport and deposition of particles from inhaler-based systems to different regions of the respiratory tract and the significant factors affecting them. These systems can further be used for studying the mucociliary clearance of particle-based systems and penetration kinetics. Moreover the effect of factors like particle size, shape, charge, surface chemistry, functionalization, and others can be further evaluated to aid the design and development of newer, more efficient pulmonary delivery systems. These models also could be used for personalizing the delivery strategy and device design as per the patient&#x2019;s disease condition.</p>
      <p id="p0485">As discussed previously in the chapter, for the treatment of any respiratory tract infections, the pulmonary delivery system is required to deposit a minimum therapeutic dose to the diseased site to achieve the desired therapeutic effect with minimum side effects. Thus, along with the understanding of the deposition mechanism and the factors affecting it, studies are also required to understand the correlation between drug deposition and its pharmacokinetic behavior postdelivery. To achieve this, physiologically based pharmacokinetic modeling has been introduced to study the local concentration after deposition, predicted response, and toxicological assessment. This kind of modeling approach to understand and analyze the system better would help in the successful development of new pulmonary delivery systems and new therapeutics.</p>
      <p id="p0490">Novel pulmonary delivery technologies have made significant contributions to improve the efficiency of delivery and targeted delivery to lungs for respiratory diseases. An increase in the number of FDA-approved nanoparticulate delivery systems for various diagnostic and therapeutic purposes has led to an increase in the research and development of such systems. An adequate understanding of the lungs&#x2019; physiology and clearance mechanism can further aid in the development of novel and more efficient nanoparticulate pulmonary delivery systems with higher levels of safety and efficacy. Thus extensive research is still required to eliminate the gaps between laboratory and industrial production of formulations to ensure the translation of more advanced PDDS into the market to fight against the prevailing respiratory diseases.</p>
    </sec>
  </body>
  <back>
    <ref-list id="bi0010">
      <title>References</title>
      <ref id="bb0010">
        <label>1</label>
        <element-citation publication-type="book" id="rf0010">
          <person-group person-group-type="author">
            <name>
              <surname>F.o.I.R. Societies</surname>
            </name>
          </person-group>
          <chapter-title>The global impact of respiratory disease</chapter-title>
          <edition>2nd ed.</edition>
          <year>2017</year>
          <publisher-name>European Respiratory Society</publisher-name>
          <publisher-loc>Sheffield</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0015">
        <label>2</label>
        <element-citation publication-type="journal" id="rf0015">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>Q.T.</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>S.S.Y.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>J.G.Y.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>H.-K.</given-names>
            </name>
          </person-group>
          <article-title>Emerging inhalation aerosol devices and strategies: where are we headed?</article-title>
          <source>Adv Drug Deliv Rev</source>
          <volume>75</volume>
          <year>2014</year>
          <fpage>3</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="pmid">24732364</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0020">
        <label>3</label>
        <element-citation publication-type="journal" id="rf0020">
          <person-group person-group-type="author">
            <name>
              <surname>Todoroff</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Vanbever</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Fate of nanomedicines in the lungs</article-title>
          <source>Curr Opin Colloid Interface Sci</source>
          <volume>16</volume>
          <issue>3</issue>
          <year>2011</year>
          <fpage>246</fpage>
          <lpage>254</lpage>
        </element-citation>
      </ref>
      <ref id="bb0025">
        <label>4</label>
        <element-citation publication-type="journal" id="rf0025">
          <person-group person-group-type="author">
            <name>
              <surname>Labiris</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Dolovich</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications</article-title>
          <source>Br J Clin Pharmacol</source>
          <volume>56</volume>
          <issue>6</issue>
          <year>2003</year>
          <fpage>588</fpage>
          <lpage>599</lpage>
          <pub-id pub-id-type="pmid">14616418</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0030">
        <label>5</label>
        <element-citation publication-type="journal" id="rf0030">
          <person-group person-group-type="author">
            <name>
              <surname>Newman</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery</article-title>
          <source>Expert Opin Drug Deliv</source>
          <volume>11</volume>
          <issue>3</issue>
          <year>2014</year>
          <fpage>365</fpage>
          <lpage>378</lpage>
          <pub-id pub-id-type="pmid">24386924</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0035">
        <label>6</label>
        <element-citation publication-type="journal" id="rf0035">
          <person-group person-group-type="author">
            <name>
              <surname>Hess</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>The mask for noninvasive ventilation: principles of design and effects on aerosol delivery</article-title>
          <source>J Aerosol Med</source>
          <volume>20</volume>
          <issue>s1</issue>
          <year>2007</year>
          <fpage>S85</fpage>
          <lpage>S99</lpage>
          <pub-id pub-id-type="pmid">17411410</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0040">
        <label>7</label>
        <element-citation publication-type="journal" id="rf0040">
          <person-group person-group-type="author">
            <name>
              <surname>Ghadiri</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Traini</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Strategies to enhance drug absorption via nasal and pulmonary routes</article-title>
          <source>Pharmaceutics</source>
          <volume>11</volume>
          <issue>3</issue>
          <year>2019</year>
          <fpage>113</fpage>
        </element-citation>
      </ref>
      <ref id="bb0045">
        <label>8</label>
        <element-citation publication-type="journal" id="rf0045">
          <person-group person-group-type="author">
            <name>
              <surname>Kelly</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Asgharian</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Kimbell</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>B.A.</given-names>
            </name>
          </person-group>
          <article-title>Particle deposition in human nasal airway replicas manufactured by different methods. Part I: inertial regime particles</article-title>
          <source>Aerosol Sci Technol</source>
          <volume>38</volume>
          <issue>11</issue>
          <year>2004</year>
          <fpage>1063</fpage>
          <lpage>1071</lpage>
        </element-citation>
      </ref>
      <ref id="bb0050">
        <label>9</label>
        <element-citation publication-type="journal" id="rf0050">
          <person-group person-group-type="author">
            <name>
              <surname>Lippmann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yeates</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Albert</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Deposition, retention, and clearance of inhaled particles</article-title>
          <source>Occup Environ Med</source>
          <volume>37</volume>
          <issue>4</issue>
          <year>1980</year>
          <fpage>337</fpage>
          <lpage>362</lpage>
        </element-citation>
      </ref>
      <ref id="bb0055">
        <label>10</label>
        <element-citation publication-type="journal" id="rf0055">
          <person-group person-group-type="author">
            <name>
              <surname>Lizio</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Klenner</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Borchard</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Romeis</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Sarlikiotis</surname>
              <given-names>A.W.</given-names>
            </name>
            <name>
              <surname>Reissmann</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lehr</surname>
              <given-names>C.-M.</given-names>
            </name>
          </person-group>
          <article-title>Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats</article-title>
          <source>Eur J Pharm Sci</source>
          <volume>9</volume>
          <issue>3</issue>
          <year>2000</year>
          <fpage>253</fpage>
          <lpage>258</lpage>
          <pub-id pub-id-type="pmid">10594381</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0060">
        <label>11</label>
        <element-citation publication-type="journal" id="rf0060">
          <person-group person-group-type="author">
            <name>
              <surname>Groneberg</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Witt</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Fundamentals of pulmonary drug delivery</article-title>
          <source>Respir Med</source>
          <volume>97</volume>
          <issue>4</issue>
          <year>2003</year>
          <fpage>382</fpage>
          <lpage>387</lpage>
          <pub-id pub-id-type="pmid">12693798</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0065">
        <label>12</label>
        <element-citation publication-type="journal" id="rf0065">
          <person-group person-group-type="author">
            <name>
              <surname>Martonen</surname>
              <given-names>T.B.</given-names>
            </name>
            <name>
              <surname>Katz</surname>
              <given-names>I.M.</given-names>
            </name>
          </person-group>
          <article-title>Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters</article-title>
          <source>Pharm Res</source>
          <volume>10</volume>
          <issue>6</issue>
          <year>1993</year>
          <fpage>871</fpage>
          <lpage>878</lpage>
          <pub-id pub-id-type="pmid">8321856</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0070">
        <label>13</label>
        <element-citation publication-type="journal" id="rf0070">
          <person-group person-group-type="author">
            <name>
              <surname>Caimmi</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Martocq</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Trioleyre</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Guinet</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Godreuil</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Daniel</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Chiron</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Positive effect of liposomal amikacin for inhalation on Mycobacterium abcessus in cystic fibrosis patients</article-title>
          <source>Open Forum Infect Dis</source>
          <volume>5</volume>
          <issue>3</issue>
          <year>2018</year>
          <comment>ofy034</comment>
        </element-citation>
      </ref>
      <ref id="bb0075">
        <label>14</label>
        <element-citation publication-type="journal" id="rf0075">
          <person-group person-group-type="author">
            <name>
              <surname>Darquenne</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Aerosol deposition in health and disease</article-title>
          <source>J Aerosol Med Pulm Drug Deliv</source>
          <volume>25</volume>
          <issue>3</issue>
          <year>2012</year>
          <fpage>140</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="pmid">22686623</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0080">
        <label>15</label>
        <element-citation publication-type="book" id="rf0080">
          <person-group person-group-type="author">
            <name>
              <surname>Bisgaard</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>O&#x2019;Callaghan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Smaldone</surname>
              <given-names>G.C.</given-names>
            </name>
          </person-group>
          <chapter-title>Drug delivery to the lung</chapter-title>
          <year>2001</year>
          <publisher-name>CRC Press</publisher-name>
          <publisher-loc>New York, NY</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0085">
        <label>16</label>
        <element-citation publication-type="journal" id="rf0085">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Riordan</surname>
              <given-names>T.G.</given-names>
            </name>
          </person-group>
          <article-title>Formulations and nebulizer performance</article-title>
          <source>Respir Care</source>
          <volume>47</volume>
          <issue>11</issue>
          <year>2002</year>
          <fpage>1305</fpage>
          <lpage>1312</lpage>
          <comment>[discussion 1312-3]</comment>
          <pub-id pub-id-type="pmid">12425745</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0090">
        <label>17</label>
        <element-citation publication-type="journal" id="rf0090">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Okuda</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>X.-Y.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>H.-K.</given-names>
            </name>
          </person-group>
          <article-title>Amorphous powders for inhalation drug delivery</article-title>
          <source>Adv Drug Deliv Rev</source>
          <volume>100</volume>
          <year>2016</year>
          <fpage>102</fpage>
          <lpage>115</lpage>
          <pub-id pub-id-type="pmid">26780404</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0095">
        <label>18</label>
        <element-citation publication-type="journal" id="rf0095">
          <person-group person-group-type="author">
            <name>
              <surname>Shetty</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Zemlyanov</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Mangal</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bhujbal</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Q.T.</given-names>
            </name>
          </person-group>
          <article-title>Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation</article-title>
          <source>Int J Pharm</source>
          <volume>544</volume>
          <issue>1</issue>
          <year>2018</year>
          <fpage>222</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="pmid">29678544</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0100">
        <label>19</label>
        <element-citation publication-type="journal" id="rf0100">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>H.-K.</given-names>
            </name>
            <name>
              <surname>Raper</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Prediction of aerodynamic diameter of particles with rough surfaces</article-title>
          <source>Powder Technol</source>
          <volume>147</volume>
          <issue>1&#x2013;3</issue>
          <year>2004</year>
          <fpage>64</fpage>
          <lpage>78</lpage>
        </element-citation>
      </ref>
      <ref id="bb0105">
        <label>20</label>
        <element-citation publication-type="journal" id="rf0105">
          <person-group person-group-type="author">
            <name>
              <surname>Larhrib</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>G.P.</given-names>
            </name>
            <name>
              <surname>Prime</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Marriott</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers</article-title>
          <source>Eur J Pharm Sci</source>
          <volume>19</volume>
          <issue>4</issue>
          <year>2003</year>
          <fpage>211</fpage>
          <lpage>221</lpage>
          <pub-id pub-id-type="pmid">12885385</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0110">
        <label>21</label>
        <element-citation publication-type="journal" id="rf0110">
          <person-group person-group-type="author">
            <name>
              <surname>Zeng</surname>
              <given-names>X.M.</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>G.P.</given-names>
            </name>
            <name>
              <surname>Marriott</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Pritchard</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>The influence of carrier morphology on drug delivery by dry powder inhalers</article-title>
          <source>Int J Pharm</source>
          <volume>200</volume>
          <issue>1</issue>
          <year>2000</year>
          <fpage>93</fpage>
          <lpage>106</lpage>
          <pub-id pub-id-type="pmid">10845690</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0115">
        <label>22</label>
        <element-citation publication-type="journal" id="rf0115">
          <person-group person-group-type="author">
            <name>
              <surname>Visser</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Van der Waals and other cohesive forces affecting powder fluidization</article-title>
          <source>Powder Technol</source>
          <volume>58</volume>
          <issue>1</issue>
          <year>1989</year>
          <fpage>1</fpage>
          <lpage>10</lpage>
        </element-citation>
      </ref>
      <ref id="bb0120">
        <label>23</label>
        <element-citation publication-type="journal" id="rf0120">
          <person-group person-group-type="author">
            <name>
              <surname>Pilcer</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Amighi</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Formulation strategy and use of excipients in pulmonary drug delivery</article-title>
          <source>Int J Pharm</source>
          <volume>392</volume>
          <issue>1</issue>
          <year>2010</year>
          <fpage>1</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="pmid">20223286</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0125">
        <label>24</label>
        <element-citation publication-type="journal" id="rf0125">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Finlay</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Nebulizers for drug delivery to the lungs</article-title>
          <source>Expert Opin Drug Deliv</source>
          <volume>12</volume>
          <issue>6</issue>
          <year>2015</year>
          <fpage>889</fpage>
          <lpage>900</lpage>
          <pub-id pub-id-type="pmid">25534396</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0130">
        <label>25</label>
        <element-citation publication-type="journal" id="rf0130">
          <person-group person-group-type="author">
            <name>
              <surname>Hess</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Aerosol delivery devices in the treatment of asthma</article-title>
          <source>Respir Care</source>
          <volume>53</volume>
          <issue>6</issue>
          <year>2008</year>
          <fpage>699</fpage>
          <lpage>725</lpage>
          <pub-id pub-id-type="pmid">18501026</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0135">
        <label>26</label>
        <element-citation publication-type="journal" id="rf0135">
          <person-group person-group-type="author">
            <name>
              <surname>Smyth</surname>
              <given-names>H.D.</given-names>
            </name>
          </person-group>
          <article-title>The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers</article-title>
          <source>Adv Drug Deliv Rev</source>
          <volume>55</volume>
          <issue>7</issue>
          <year>2003</year>
          <fpage>807</fpage>
          <lpage>828</lpage>
          <pub-id pub-id-type="pmid">12842602</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0140">
        <label>27</label>
        <element-citation publication-type="journal" id="rf0140">
          <person-group person-group-type="author">
            <name>
              <surname>Pleasants</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Aerosol delivery devices for obstructive lung diseases</article-title>
          <source>Respir Care</source>
          <volume>63</volume>
          <issue>6</issue>
          <year>2018</year>
          <fpage>708</fpage>
          <pub-id pub-id-type="pmid">29794206</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0145">
        <label>28</label>
        <element-citation publication-type="journal" id="rf0145">
          <person-group person-group-type="author">
            <name>
              <surname>Dal Negro</surname>
              <given-names>R.W.</given-names>
            </name>
          </person-group>
          <article-title>Dry powder inhalers and the right things to remember: a concept review</article-title>
          <source>Multidiscip Respir Med</source>
          <volume>10</volume>
          <issue>1</issue>
          <year>2015</year>
          <fpage>13</fpage>
          <pub-id pub-id-type="pmid">25878791</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0150">
        <label>29</label>
        <element-citation publication-type="journal" id="rf0150">
          <person-group person-group-type="author">
            <name>
              <surname>Sanchis</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Corrigan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Viejo</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Inhaler devices&#x2014;from theory to practice</article-title>
          <source>Respir Med</source>
          <volume>107</volume>
          <issue>4</issue>
          <year>2013</year>
          <fpage>495</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="pmid">23290591</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0155">
        <label>30</label>
        <element-citation publication-type="journal" id="rf0155">
          <person-group person-group-type="author">
            <name>
              <surname>Mahler</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease</article-title>
          <source>Ann Am Thorac Soc</source>
          <volume>14</volume>
          <issue>7</issue>
          <year>2017</year>
          <fpage>1103</fpage>
          <lpage>1107</lpage>
          <pub-id pub-id-type="pmid">28481631</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0160">
        <label>31</label>
        <element-citation publication-type="journal" id="rf0160">
          <person-group person-group-type="author">
            <name>
              <surname>D.R.H.P.R. FAARC</surname>
            </name>
          </person-group>
          <article-title>Nebulizers: principles and performance</article-title>
          <source>Respir Care</source>
          <volume>45</volume>
          <issue>6</issue>
          <year>2000</year>
          <fpage>609</fpage>
          <pub-id pub-id-type="pmid">10894454</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0165">
        <label>32</label>
        <element-citation publication-type="journal" id="rf0165">
          <person-group person-group-type="author">
            <name>
              <surname>Deacon</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Abdelghany</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Schmid</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Megaw</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Donnelly</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Kissenpfennig</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Elborn</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Gilmore</surname>
              <given-names>B.F.</given-names>
            </name>
            <name>
              <surname>Taggart</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>C.J.</given-names>
            </name>
          </person-group>
          <article-title>Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase)</article-title>
          <source>J Control Release</source>
          <volume>198</volume>
          <year>2015</year>
          <fpage>55</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">25481442</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0170">
        <label>33</label>
        <element-citation publication-type="journal" id="rf0170">
          <person-group person-group-type="author">
            <name>
              <surname>Derbali</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Aoun</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Moussa</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Frei</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Tehrani</surname>
              <given-names>S.F.</given-names>
            </name>
            <name>
              <surname>Del&#x2019;Orto</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Hildgen</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Roullin</surname>
              <given-names>V.G.</given-names>
            </name>
            <name>
              <surname>Chain</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Tailored nanocarriers for the pulmonary delivery of levofloxacin against Pseudomonas aeruginosa: a comparative study</article-title>
          <source>Mol Pharm</source>
          <volume>16</volume>
          <issue>5</issue>
          <year>2019</year>
          <fpage>1906</fpage>
          <lpage>1916</lpage>
          <pub-id pub-id-type="pmid">30900903</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0175">
        <label>34</label>
        <element-citation publication-type="journal" id="rf0175">
          <person-group person-group-type="author">
            <name>
              <surname>Costa-Gouveia</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Pancani</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Jouny</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Machelart</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Delorme</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Salzano</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Iantomasi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Piveteau</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Queval</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>O.-R.</given-names>
            </name>
            <name>
              <surname>Flipo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Deprez</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Saint-Andr&#xE9;</surname>
              <given-names>J.-P.</given-names>
            </name>
            <name>
              <surname>Hureaux</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Majlessi</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Willand</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Baulard</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Brodin</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gref</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles</article-title>
          <source>Sci Rep</source>
          <volume>7</volume>
          <issue>1</issue>
          <year>2017</year>
          <fpage>5390</fpage>
          <pub-id pub-id-type="pmid">28710351</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0180">
        <label>35</label>
        <element-citation publication-type="journal" id="rf0180">
          <person-group person-group-type="author">
            <name>
              <surname>Rosi&#xE8;re</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Van Woensel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gelbcke</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mathieu</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Hecq</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Mathivet</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Vermeersch</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Van Antwerpen</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Amighi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wauthoz</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>New folate-grafted chitosan derivative to improve delivery of paclitaxel-loaded solid lipid nanoparticles for lung tumor therapy by inhalation</article-title>
          <source>Mol Pharm</source>
          <volume>15</volume>
          <issue>3</issue>
          <year>2018</year>
          <fpage>899</fpage>
          <lpage>910</lpage>
          <pub-id pub-id-type="pmid">29341619</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0185">
        <label>36</label>
        <element-citation publication-type="journal" id="rf0185">
          <person-group person-group-type="author">
            <name>
              <surname>Ji</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics</article-title>
          <source>Drug Des Devel Ther</source>
          <volume>10</volume>
          <year>2016</year>
          <fpage>911</fpage>
        </element-citation>
      </ref>
      <ref id="bb0190">
        <label>37</label>
        <element-citation publication-type="journal" id="rf0190">
          <person-group person-group-type="author">
            <name>
              <surname>Makled</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nafee</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Boraie</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor</article-title>
          <source>Int J Pharm</source>
          <volume>517</volume>
          <issue>1</issue>
          <year>2017</year>
          <fpage>312</fpage>
          <lpage>321</lpage>
          <pub-id pub-id-type="pmid">27979766</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0195">
        <label>38</label>
        <element-citation publication-type="journal" id="rf0195">
          <person-group person-group-type="author">
            <name>
              <surname>Gaspar</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Gaspar</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Eleut&#xE9;rio</surname>
              <given-names>C.V.</given-names>
            </name>
            <name>
              <surname>Grenha</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Blanco</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gon&#xE7;alves</surname>
              <given-names>L.M.D.</given-names>
            </name>
            <name>
              <surname>Taboada</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Remu&#xF1;&#xE1;n-L&#xF3;pez</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Microencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery</article-title>
          <source>Mol Pharm</source>
          <volume>14</volume>
          <issue>9</issue>
          <year>2017</year>
          <fpage>2977</fpage>
          <lpage>2990</lpage>
          <pub-id pub-id-type="pmid">28809501</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0200">
        <label>39</label>
        <element-citation publication-type="journal" id="rf0200">
          <person-group person-group-type="author">
            <name>
              <surname>Ramalingam</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Varunkumar</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ravikumar</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Rajaram</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Target delivery of doxorubicin tethered with PVP stabilized gold nanoparticles for effective treatment of lung cancer</article-title>
          <source>Sci Rep</source>
          <volume>8</volume>
          <issue>1</issue>
          <year>2018</year>
          <fpage>3815</fpage>
          <pub-id pub-id-type="pmid">29491463</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0205">
        <label>40</label>
        <element-citation publication-type="journal" id="rf0205">
          <person-group person-group-type="author">
            <name>
              <surname>Halwani</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Sultana Shaik</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ratemi</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Afzal</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kenana</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Al-Muhsen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Al Faraj</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>A novel anti-IL4R&#x3B1; nanoparticle efficiently controls lung inflammation during asthma</article-title>
          <source>Exp Mol Med</source>
          <volume>48</volume>
          <issue>10</issue>
          <year>2016</year>
          <fpage>e262</fpage>
          <pub-id pub-id-type="pmid">27713399</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0210">
        <label>41</label>
        <element-citation publication-type="journal" id="rf0210">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Application of a lipid-coated hollow calcium phosphate nanoparticle in synergistic co-delivery of doxorubicin and paclitaxel for the treatment of human lung cancer A549 cells</article-title>
          <source>Int J Nanomedicine</source>
          <volume>12</volume>
          <year>2017</year>
          <fpage>7979</fpage>
          <pub-id pub-id-type="pmid">29184399</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0215">
        <label>42</label>
        <element-citation publication-type="journal" id="rf0215">
          <person-group person-group-type="author">
            <name>
              <surname>Ehsan</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Clancy</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin</article-title>
          <source>Future Microbiol</source>
          <volume>10</volume>
          <issue>12</issue>
          <year>2015</year>
          <fpage>1901</fpage>
          <lpage>1912</lpage>
          <pub-id pub-id-type="pmid">26573178</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0220">
        <label>43</label>
        <element-citation publication-type="journal" id="rf0220">
          <person-group person-group-type="author">
            <name>
              <surname>Serisier</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Bilton</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>De Soyza</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Kolbe</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Greville</surname>
              <given-names>H.W.</given-names>
            </name>
            <name>
              <surname>Cipolla</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bruinenberg</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gonda</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>ORBIT-2 Investigators</surname>
            </name>
          </person-group>
          <article-title>Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial</article-title>
          <source>Thorax</source>
          <volume>68</volume>
          <issue>9</issue>
          <year>2013</year>
          <fpage>812</fpage>
          <lpage>817</lpage>
          <pub-id pub-id-type="pmid">23681906</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0225">
        <label>44</label>
        <element-citation publication-type="journal" id="rf0225">
          <person-group person-group-type="author">
            <name>
              <surname>Haworth</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Bilton</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Chalmers</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Froehlich</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gonda</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Wanner</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>O&#x2019;Donnell</surname>
              <given-names>A.E.</given-names>
            </name>
          </person-group>
          <article-title>Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials</article-title>
          <source>Lancet Respir Med</source>
          <volume>7</volume>
          <issue>3</issue>
          <year>2019</year>
          <fpage>213</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="pmid">30658914</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0230">
        <label>45</label>
        <element-citation publication-type="journal" id="rf0230">
          <person-group person-group-type="author">
            <name>
              <surname>Ventola</surname>
              <given-names>C.L.</given-names>
            </name>
          </person-group>
          <article-title>Progress in nanomedicine: approved and investigational nanodrugs</article-title>
          <source>P T</source>
          <volume>42</volume>
          <issue>12</issue>
          <year>2017</year>
          <fpage>742</fpage>
          <lpage>755</lpage>
          <pub-id pub-id-type="pmid">29234213</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0235">
        <label>46</label>
        <element-citation publication-type="journal" id="rf0235">
          <person-group person-group-type="author">
            <name>
              <surname>Wittgen</surname>
              <given-names>B.P.</given-names>
            </name>
            <name>
              <surname>Kunst</surname>
              <given-names>P.W.</given-names>
            </name>
            <name>
              <surname>van der Born</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>van Wijk</surname>
              <given-names>A.W.</given-names>
            </name>
            <name>
              <surname>Perkins</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Pilkiewicz</surname>
              <given-names>F.G.</given-names>
            </name>
            <name>
              <surname>Perez-Soler</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Postmus</surname>
              <given-names>P.E.</given-names>
            </name>
          </person-group>
          <article-title>Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung</article-title>
          <source>Clin Cancer Res</source>
          <volume>13</volume>
          <issue>8</issue>
          <year>2007</year>
          <fpage>2414</fpage>
          <lpage>2421</lpage>
          <pub-id pub-id-type="pmid">17438100</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0240">
        <label>47</label>
        <element-citation publication-type="journal" id="rf0240">
          <person-group person-group-type="author">
            <name>
              <surname>Verschraegen</surname>
              <given-names>C.F.</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>B.E.</given-names>
            </name>
            <name>
              <surname>Loyer</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Huaringa</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Newman</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Knight</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20 (s)-camptothecin in patients with advanced pulmonary malignancies</article-title>
          <source>Clin Cancer Res</source>
          <volume>10</volume>
          <issue>7</issue>
          <year>2004</year>
          <fpage>2319</fpage>
          <lpage>2326</lpage>
          <pub-id pub-id-type="pmid">15073107</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0245">
        <label>48</label>
        <element-citation publication-type="journal" id="rf0245">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Piao</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Self-assembled polymeric micelles for combined delivery of anti-inflammatory gene and drug to the lungs by inhalation</article-title>
          <source>Nanoscale</source>
          <volume>10</volume>
          <issue>18</issue>
          <year>2018</year>
          <fpage>8503</fpage>
          <lpage>8514</lpage>
          <pub-id pub-id-type="pmid">29693671</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0250">
        <label>49</label>
        <element-citation publication-type="journal" id="rf0250">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>F.-F.</given-names>
            </name>
            <name>
              <surname>Quan</surname>
              <given-names>L.-H.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>C.-Y.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X.-M.</given-names>
            </name>
            <name>
              <surname>Ehrhardt</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>Y.-H.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary delivered polymeric micelles&#x2014;pharmacokinetic evaluation and biodistribution studies</article-title>
          <source>Eur J Pharm Biopharm</source>
          <volume>88</volume>
          <issue>3</issue>
          <year>2014</year>
          <fpage>1064</fpage>
          <lpage>1075</lpage>
          <pub-id pub-id-type="pmid">25460153</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0255">
        <label>50</label>
        <element-citation publication-type="journal" id="rf0255">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Ren</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sha</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <article-title>Matrix metalloproteinase 2/9-triggered-release micelles for inhaled drug delivery to treat lung cancer: preparation and in vitro/in vivo studies</article-title>
          <source>Int J Nanomedicine</source>
          <volume>13</volume>
          <year>2018</year>
          <fpage>4641</fpage>
          <lpage>4659</lpage>
          <pub-id pub-id-type="pmid">30147314</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0260">
        <label>51</label>
        <element-citation publication-type="journal" id="rf0260">
          <person-group person-group-type="author">
            <name>
              <surname>Ubale</surname>
              <given-names>R.V.</given-names>
            </name>
            <name>
              <surname>Shastri</surname>
              <given-names>P.N.</given-names>
            </name>
            <name>
              <surname>Oettinger</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>D&#x2019;Souza</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary administration of microparticulate antisense oligonucleotide (ASO) for the treatment of lung inflammation</article-title>
          <source>AAPS PharmSciTech</source>
          <volume>19</volume>
          <issue>4</issue>
          <year>2018</year>
          <fpage>1908</fpage>
          <lpage>1919</lpage>
          <pub-id pub-id-type="pmid">29663290</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0265">
        <label>52</label>
        <element-citation publication-type="book" id="rf0265">
          <person-group person-group-type="author">
            <name>
              <surname>Bernstein</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Brito</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chickering</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Straub</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <chapter-title>Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration</chapter-title>
          <comment>Google Patents</comment>
          <year>2007</year>
        </element-citation>
      </ref>
      <ref id="bb0270">
        <label>53</label>
        <element-citation publication-type="journal" id="rf0270">
          <person-group person-group-type="author">
            <name>
              <surname>Parikh</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Dalwadi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Aboti</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis</article-title>
          <source>J Antibiot</source>
          <volume>67</volume>
          <issue>5</issue>
          <year>2014</year>
          <fpage>387</fpage>
        </element-citation>
      </ref>
      <ref id="bb0275">
        <label>54</label>
        <element-citation publication-type="journal" id="rf0275">
          <person-group person-group-type="author">
            <name>
              <surname>Zhong</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Bielski</surname>
              <given-names>E.R.</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Reineke</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>da Rocha</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Conjugation to poly(amidoamine) dendrimers and pulmonary delivery reduce cardiac accumulation and enhance antitumor activity of doxorubicin in lung metastasis</article-title>
          <source>Mol Pharm</source>
          <volume>13</volume>
          <issue>7</issue>
          <year>2016</year>
          <fpage>2363</fpage>
          <lpage>2375</lpage>
          <pub-id pub-id-type="pmid">27253493</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0280">
        <label>55</label>
        <element-citation publication-type="journal" id="rf0280">
          <person-group person-group-type="author">
            <name>
              <surname>Zhong</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Merkel</surname>
              <given-names>O.M.</given-names>
            </name>
            <name>
              <surname>Reineke</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>da Rocha</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Effect of the route of administration and PEGylation of poly(amidoamine) dendrimers on their systemic and lung cellular biodistribution</article-title>
          <source>Mol Pharm</source>
          <volume>13</volume>
          <issue>6</issue>
          <year>2016</year>
          <fpage>1866</fpage>
          <lpage>1878</lpage>
          <pub-id pub-id-type="pmid">27148629</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0285">
        <label>56</label>
        <element-citation publication-type="journal" id="rf0285">
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>O.F.</given-names>
            </name>
            <name>
              <surname>Zaia</surname>
              <given-names>E.W.</given-names>
            </name>
            <name>
              <surname>Jhunjhunwala</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Yun</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Dahlman</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Pelet</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Webber</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Tsosie</surname>
              <given-names>J.K.</given-names>
            </name>
            <name>
              <surname>Jacks</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Langer</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>D.G.</given-names>
            </name>
          </person-group>
          <article-title>Dendrimer-inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature</article-title>
          <source>Nano Lett</source>
          <volume>15</volume>
          <issue>5</issue>
          <year>2015</year>
          <fpage>3008</fpage>
          <lpage>3016</lpage>
          <pub-id pub-id-type="pmid">25789998</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0290">
        <label>57</label>
        <element-citation publication-type="journal" id="rf0290">
          <person-group person-group-type="author">
            <name>
              <surname>Zarogouldis</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Karamanos</surname>
              <given-names>N.K.</given-names>
            </name>
            <name>
              <surname>Porpodis</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Domvri</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hohenforst-Schimdt</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Zarogoulidis</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology</article-title>
          <source>Int J Mol Sci</source>
          <volume>13</volume>
          <issue>9</issue>
          <year>2012</year>
          <fpage>10828</fpage>
          <lpage>10862</lpage>
          <pub-id pub-id-type="pmid">23109824</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0295">
        <label>58</label>
        <element-citation publication-type="journal" id="rf0295">
          <person-group person-group-type="author">
            <name>
              <surname>Patel</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Kaczmarek</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Bose</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kauffman</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Mir</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Heartlein</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>DeRosa</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Langer</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>D.G.</given-names>
            </name>
          </person-group>
          <article-title>Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium</article-title>
          <source>Adv Mater</source>
          <volume>31</volume>
          <issue>8</issue>
          <year>2019</year>
          <fpage>e1805116</fpage>
          <pub-id pub-id-type="pmid">30609147</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0300">
        <label>59</label>
        <element-citation publication-type="journal" id="rf0300">
          <person-group person-group-type="author">
            <name>
              <surname>Dall&#x2019;Acqua</surname>
              <given-names>W.F.</given-names>
            </name>
            <name>
              <surname>Kiener</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)</article-title>
          <source>J Biol Chem</source>
          <volume>281</volume>
          <issue>33</issue>
          <year>2006</year>
          <fpage>23514</fpage>
          <lpage>23524</lpage>
          <pub-id pub-id-type="pmid">16793771</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0305">
        <label>60</label>
        <element-citation publication-type="journal" id="rf0305">
          <person-group person-group-type="author">
            <name>
              <surname>S&#xE9;cher</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Mayor</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Heuz&#xE9;-Vourc&#x2019;h</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Inhalation of immuno-therapeutics/-prophylactics to fight respiratory tract infections: an appropriate drug at the right place!</article-title>
          <source>Front Immunol</source>
          <volume>10</volume>
          <year>2019</year>
          <fpage>2760</fpage>
          <pub-id pub-id-type="pmid">31849954</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0310">
        <label>61</label>
        <element-citation publication-type="book" id="rf0310">
          <person-group person-group-type="author">
            <name>
              <surname>Molina</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>W.R.</given-names>
            </name>
          </person-group>
          <chapter-title>Chapter 12&#x2014;Cystic fibrosis: an overview of the past, present, and the future</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Sidhaye</surname>
              <given-names>V.K.</given-names>
            </name>
            <name>
              <surname>Koval</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <source>Lung epithelial biology in the pathogenesis of pulmonary disease</source>
          <year>2017</year>
          <publisher-name>Academic Press</publisher-name>
          <publisher-loc>Boston</publisher-loc>
          <fpage>219</fpage>
          <lpage>249</lpage>
        </element-citation>
      </ref>
      <ref id="bb0315">
        <label>62</label>
        <element-citation publication-type="journal" id="rf0315">
          <person-group person-group-type="author">
            <name>
              <surname>Billich</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Technology evaluation: FluMist, University of Michigan</article-title>
          <source>Curr Opin Mol Ther</source>
          <volume>2</volume>
          <issue>3</issue>
          <year>2000</year>
          <fpage>340</fpage>
          <lpage>344</lpage>
          <pub-id pub-id-type="pmid">11249630</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0320">
        <label>63</label>
        <element-citation publication-type="journal" id="rf0320">
          <person-group person-group-type="author">
            <name>
              <surname>Kulkarni</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Raut</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Dhere</surname>
              <given-names>R.M.</given-names>
            </name>
          </person-group>
          <article-title>A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac&#xAE;) in India</article-title>
          <source>Hum Vaccin Immunother</source>
          <volume>9</volume>
          <issue>1</issue>
          <year>2013</year>
          <fpage>122</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">23442586</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0325">
        <label>64</label>
        <element-citation publication-type="journal" id="rf0325">
          <person-group person-group-type="author">
            <name>
              <surname>Bahamondez-Canas</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Intranasal immunization with dry powder vaccines</article-title>
          <source>Eur J Pharm Biopharm</source>
          <volume>122</volume>
          <year>2018</year>
          <fpage>167</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="pmid">29122735</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0330">
        <label>65</label>
        <element-citation publication-type="journal" id="rf0330">
          <person-group person-group-type="author">
            <name>
              <surname>Tinkle</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>McNeil</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Muhlebach</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bawa</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Borchard</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Barenholz</surname>
              <given-names>Y.C.</given-names>
            </name>
            <name>
              <surname>Tamarkin</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Nanomedicines: addressing the scientific and regulatory gap</article-title>
          <source>Ann NY Acad Sci</source>
          <volume>1313</volume>
          <year>2014</year>
          <fpage>35</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">24673240</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0335">
        <label>66</label>
        <element-citation publication-type="journal" id="rf0335">
          <person-group person-group-type="author">
            <name>
              <surname>Murday</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Siegel</surname>
              <given-names>R.W.</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>J.F.</given-names>
            </name>
          </person-group>
          <article-title>Translational nanomedicine: status assessment and opportunities</article-title>
          <source>Nanomedicine</source>
          <volume>5</volume>
          <issue>3</issue>
          <year>2009</year>
          <fpage>251</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="pmid">19540359</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0340">
        <label>67</label>
        <element-citation publication-type="journal" id="rf0340">
          <person-group person-group-type="author">
            <name>
              <surname>Grant</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Garrill</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>The ELLIPTA&#xAE; dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers</article-title>
          <source>J Aerosol Med Pulm Drug Deliv</source>
          <volume>28</volume>
          <issue>6</issue>
          <year>2015</year>
          <fpage>474</fpage>
          <lpage>485</lpage>
          <pub-id pub-id-type="pmid">26372466</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0345">
        <label>68</label>
        <element-citation publication-type="journal" id="rf0345">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xF6;&#xF6;f</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Elfman</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Str&#xF6;m</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>T&#xF6;rngren</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Borgstr&#xF6;m</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Sustained mechanical and clinical functionality of the Flexhaler &#x2122; dry powder inhaler</article-title>
          <source>J Aerosol Med Pulm Drug Deliv</source>
          <volume>21</volume>
          <year>2008</year>
          <fpage>381</fpage>
          <lpage>388</lpage>
          <pub-id pub-id-type="pmid">18823260</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0350">
        <label>69</label>
        <mixed-citation publication-type="other" id="or0010">L.A. Raedler, ProAir RespiClick (Albuterol Sulfate): first breath-actuated inhaler approved for the treatment or prevention of bronchospasm, <italic>Inside Drug Update,</italic> November 2015, 3 (11).</mixed-citation>
      </ref>
      <ref id="bb0355">
        <label>70</label>
        <element-citation publication-type="journal" id="rf0350">
          <person-group person-group-type="author">
            <name>
              <surname>Chrystyn</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The Diskus: a review of its position among dry powder inhaler devices</article-title>
          <source>Int J Clin Pract</source>
          <volume>61</volume>
          <issue>6</issue>
          <year>2007</year>
          <fpage>1022</fpage>
          <lpage>1036</lpage>
          <pub-id pub-id-type="pmid">17504364</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0360">
        <label>71</label>
        <element-citation publication-type="book" id="rf0355">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kanbar-Agha</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Sharafkhaneh</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <chapter-title>Novel aerosol delivery devices</chapter-title>
          <conf-name>Seminars in respiratory and critical care medicine</conf-name>
          <year>2015</year>
          <publisher-name>Thieme Medical Publishers</publisher-name>
          <publisher-loc>New York, NY</publisher-loc>
          <fpage>543</fpage>
          <lpage>551</lpage>
        </element-citation>
      </ref>
      <ref id="bb0365">
        <label>72</label>
        <element-citation publication-type="journal" id="rf0360">
          <person-group person-group-type="author">
            <name>
              <surname>Conner</surname>
              <given-names>J.B.</given-names>
            </name>
            <name>
              <surname>Buck</surname>
              <given-names>P.O.</given-names>
            </name>
          </person-group>
          <article-title>Improving asthma management: the case for mandatory inclusion of dose counters on all rescue bronchodilators</article-title>
          <source>J Asthma</source>
          <volume>50</volume>
          <issue>6</issue>
          <year>2013</year>
          <fpage>658</fpage>
          <lpage>663</lpage>
          <pub-id pub-id-type="pmid">23544966</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0370">
        <label>73</label>
        <element-citation publication-type="journal" id="rf0365">
          <person-group person-group-type="author">
            <name>
              <surname>Denyer</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Nikander</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>The I-neb adaptive aerosol delivery (AAD) system</article-title>
          <source>MedicaMundi</source>
          <volume>54</volume>
          <issue>3</issue>
          <year>2010</year>
          <fpage>55</fpage>
        </element-citation>
      </ref>
      <ref id="bb0375">
        <label>74</label>
        <element-citation publication-type="journal" id="rf0370">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Use of Respimat soft mist inhaler in COPD patients</article-title>
          <source>Int J Chron Obstruct Pulmon Dis</source>
          <volume>1</volume>
          <issue>3</issue>
          <year>2006</year>
          <fpage>251</fpage>
          <lpage>259</lpage>
          <pub-id pub-id-type="pmid">18046862</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0380">
        <label>75</label>
        <element-citation publication-type="journal" id="rf0375">
          <person-group person-group-type="author">
            <name>
              <surname>Dinh</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Glazer</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shmidt</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Devereaux</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Simis</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Noymer</surname>
              <given-names>P.D.</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Choosakul</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Q.</given-names>
            </name>
          </person-group>
          <article-title>In vitro aerosol characterization of staccato&#xAE; Loxapine</article-title>
          <source>Int J Pharm</source>
          <volume>403</volume>
          <issue>1&#x2013;2</issue>
          <year>2011</year>
          <fpage>101</fpage>
          <lpage>108</lpage>
          <pub-id pub-id-type="pmid">20971174</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0385">
        <label>76</label>
        <element-citation publication-type="journal" id="rf0380">
          <person-group person-group-type="author">
            <name>
              <surname>Rottier</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>van Erp</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Sluyter</surname>
              <given-names>T.S.</given-names>
            </name>
            <name>
              <surname>Heijerman</surname>
              <given-names>H.G.</given-names>
            </name>
            <name>
              <surname>Frijlink</surname>
              <given-names>H.W.</given-names>
            </name>
            <name>
              <surname>Boer</surname>
              <given-names>A.H.</given-names>
            </name>
          </person-group>
          <article-title>Changes in performance of the Pari eFlow rapid and Pari LC plus during 6 months use by CF patients</article-title>
          <source>J Aerosol Med Pulm Drug Deliv</source>
          <volume>22</volume>
          <issue>3</issue>
          <year>2009</year>
          <fpage>263</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="pmid">19466906</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0390">
        <label>77</label>
        <element-citation publication-type="journal" id="rf0385">
          <person-group person-group-type="author">
            <name>
              <surname>Harrison</surname>
              <given-names>L.I.</given-names>
            </name>
            <name>
              <surname>Novak</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Needham</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Ratner</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma</article-title>
          <source>J Aerosol Med Pulm Drug Deliv</source>
          <volume>24</volume>
          <issue>5</issue>
          <year>2011</year>
          <fpage>245</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="pmid">21671752</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0395">
        <label>78</label>
        <element-citation publication-type="journal" id="rf0390">
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>S.W.</given-names>
            </name>
            <name>
              <surname>Thiel</surname>
              <given-names>C.G.</given-names>
            </name>
          </person-group>
          <article-title>The history of therapeutic aerosols: a chronological review</article-title>
          <source>J Aerosol Med Pulm Drug Deliv</source>
          <volume>30</volume>
          <issue>1</issue>
          <year>2017</year>
          <fpage>20</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">27748638</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0400">
        <label>79</label>
        <element-citation publication-type="journal" id="rf0395">
          <person-group person-group-type="author">
            <name>
              <surname>Kunkel</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Magnussen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bergmann</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Juergens</surname>
              <given-names>U.R.</given-names>
            </name>
            <name>
              <surname>de Mey</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Freund</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hinzmann</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Beckers</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Respimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients</article-title>
          <source>Respiration</source>
          <volume>67</volume>
          <issue>3</issue>
          <year>2000</year>
          <fpage>306</fpage>
          <lpage>314</lpage>
          <pub-id pub-id-type="pmid">10867600</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0405">
        <label>80</label>
        <element-citation publication-type="journal" id="rf0400">
          <person-group person-group-type="author">
            <name>
              <surname>Telko</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Hickey</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Dry powder inhaler formulation</article-title>
          <source>Respir Care</source>
          <volume>50</volume>
          <issue>9</issue>
          <year>2005</year>
          <fpage>1209</fpage>
          <lpage>1227</lpage>
          <pub-id pub-id-type="pmid">16122404</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0410">
        <label>81</label>
        <element-citation publication-type="journal" id="rf0405">
          <person-group person-group-type="author">
            <name>
              <surname>Ibrahim</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Garcia-Contreras</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Inhalation drug delivery devices: technology update</article-title>
          <source>Med Devices</source>
          <volume>8</volume>
          <year>2015</year>
          <fpage>131</fpage>
        </element-citation>
      </ref>
      <ref id="bb0415">
        <label>82</label>
        <element-citation publication-type="book" id="rf0410">
          <person-group person-group-type="author">
            <name>
              <surname>Javadzadeh</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Yaqoubi</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <chapter-title>Chapter 20&#x2014;Therapeutic nanostructures for pulmonary drug delivery</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Andronescu</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Grumezescu</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <source>Nanostructures for drug delivery</source>
          <year>2017</year>
          <publisher-name>Elsevier</publisher-name>
          <fpage>619</fpage>
          <lpage>638</lpage>
        </element-citation>
      </ref>
      <ref id="bb0420">
        <label>83</label>
        <element-citation publication-type="journal" id="rf0415">
          <person-group person-group-type="author">
            <name>
              <surname>Muellinger</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Kolb</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gessler</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Impact of real time feedback from inhalation devices on patient satisfaction and adherence</article-title>
          <source>J Aerosol Med Pulm Drug Deliv</source>
          <volume>32</volume>
          <year>2019</year>
          <fpage>A24</fpage>
        </element-citation>
      </ref>
      <ref id="bb0425">
        <label>84</label>
        <element-citation publication-type="book" id="rf0420">
          <person-group person-group-type="author">
            <name>
              <surname>Cavanagh</surname>
              <given-names>T.N.C.</given-names>
            </name>
            <name>
              <surname>Barman</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Hao</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Leland</surname>
              <given-names>T.B.</given-names>
            </name>
            <name>
              <surname>Thekkedath</surname>
              <given-names>R.V.</given-names>
            </name>
          </person-group>
          <chapter-title>Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof</chapter-title>
          <year>2019</year>
          <publisher-name>Nicox Ophthalmics</publisher-name>
          <publisher-loc>Fort Worth, TX</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0430">
        <label>85</label>
        <element-citation publication-type="book" id="rf0425">
          <person-group person-group-type="author">
            <name>
              <surname>Yacoub</surname>
              <given-names>M.H.L.</given-names>
            </name>
            <name>
              <surname>El-sherbiny</surname>
              <given-names>I.M.</given-names>
            </name>
          </person-group>
          <chapter-title>Nanoparticle drug delivery</chapter-title>
          <year>2018</year>
          <publisher-name>Heart Biotech Pharma Limited</publisher-name>
          <publisher-loc>London, GB</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0435">
        <label>86</label>
        <mixed-citation publication-type="other" id="or0015">A.S. Morris, S.C. Sebag, J.D. Paschke, A. Wongrakpanich, K. Ebeid, M.E. Anderson, Grumbach, I.M., Salem, A.K., Cationic CaMKII inhibiting nanoparticles prevent allergic asthma. Mol. Pharm. 14(6), 2017, 2166&#x2013;2175.</mixed-citation>
      </ref>
      <ref id="bb0440">
        <label>87</label>
        <element-citation publication-type="book" id="rf0430">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>J.S.P.</given-names>
            </name>
            <name>
              <surname>Corcoran</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Kagan</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <chapter-title>Red blood cell membrane-derived microparticles and their use for the treatment of lung disease</chapter-title>
          <year>2018</year>
          <publisher-name>University of Pittsburgh of the Commonwealth System of Higher Education</publisher-name>
          <publisher-loc>Pittsburgh, PA</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0445">
        <label>88</label>
        <element-citation publication-type="book" id="rf0435">
          <person-group person-group-type="author">
            <name>
              <surname>Jackson</surname>
              <given-names>B.C.S.G.</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Bartus</surname>
              <given-names>R.T.</given-names>
            </name>
            <name>
              <surname>Emerich</surname>
              <given-names>D.F.</given-names>
            </name>
          </person-group>
          <chapter-title>Pulmonary delivery for levodopa</chapter-title>
          <year>2018</year>
          <publisher-name>Civitas Therapeutics</publisher-name>
          <publisher-loc>Chelsea, MA</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0450">
        <label>89</label>
        <element-citation publication-type="book" id="rf0440">
          <person-group person-group-type="author">
            <name>
              <surname>Kost</surname>
              <given-names>J.O.</given-names>
            </name>
          </person-group>
          <chapter-title>Controlled release system for pulmonary delivery of surfactant protein D</chapter-title>
          <year>2018</year>
          <publisher-name>B.G. Negev Technologies and Applications Ltd</publisher-name>
          <publisher-loc>Beer Sheva, IL</publisher-loc>
          <comment>Cincinnati, OH: Children&#x2019;s Hospital Medical Center</comment>
        </element-citation>
      </ref>
      <ref id="bb0455">
        <label>90</label>
        <element-citation publication-type="book" id="rf0445">
          <person-group person-group-type="author">
            <name>
              <surname>Cipolla</surname>
              <given-names>D.C.S.R.</given-names>
            </name>
            <name>
              <surname>Blanchard</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <chapter-title>Concentrated, inhalable ciprofloxacin formulation</chapter-title>
          <year>2017</year>
          <publisher-name>Aradigm Corporation</publisher-name>
          <publisher-loc>Hayward, CA</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0460">
        <label>91</label>
        <element-citation publication-type="book" id="rf0450">
          <person-group person-group-type="author">
            <name>
              <surname>Prud&#x2019;homme</surname>
              <given-names>R.K.L.</given-names>
            </name>
          </person-group>
          <chapter-title>Lung targeting dual drug delivery system</chapter-title>
          <year>2017</year>
          <publisher-name>The Trustees of Princeton University</publisher-name>
          <publisher-loc>Princeton, NJ</publisher-loc>
          <comment>New Brunswick, NJ: Rutgers, The State University of New Jersey</comment>
        </element-citation>
      </ref>
      <ref id="bb0465">
        <label>92</label>
        <element-citation publication-type="book" id="rf0455">
          <person-group person-group-type="author">
            <name>
              <surname>Tarara</surname>
              <given-names>T.E.B.</given-names>
            </name>
            <name>
              <surname>Weers</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Venthoye</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <chapter-title>Pulmonary delivery of aminoglycoside</chapter-title>
          <year>2016</year>
          <publisher-name>Novartis AG</publisher-name>
          <publisher-loc>Basel, CH</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0470">
        <label>93</label>
        <element-citation publication-type="book" id="rf0460">
          <person-group person-group-type="author">
            <name>
              <surname>Gainza Lafuente</surname>
              <given-names>E.A.</given-names>
            </name>
          </person-group>
          <chapter-title>Lipid nanoparticle of polymyxin</chapter-title>
          <year>2016</year>
          <publisher-name>Biopraxis Research AIE</publisher-name>
          <publisher-loc>Alava, ES</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0475">
        <label>94</label>
        <element-citation publication-type="book" id="rf0465">
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>S.W.L.L.</given-names>
            </name>
            <name>
              <surname>Mueting</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Dunbar</surname>
              <given-names>T.D.</given-names>
            </name>
          </person-group>
          <chapter-title>Process for manufacturing flowable powder drug compositions</chapter-title>
          <year>2015</year>
          <publisher-name>3M Innovative Properties Company</publisher-name>
          <publisher-loc>St. Paul, MN</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0480">
        <label>95</label>
        <element-citation publication-type="book" id="rf0470">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>R.O.A.</given-names>
              <suffix>III</suffix>
            </name>
          </person-group>
          <chapter-title>Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery</chapter-title>
          <year>2015</year>
          <publisher-name>Board of Regents, The University of Texas System</publisher-name>
          <publisher-loc>United States</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0485">
        <label>96</label>
        <element-citation publication-type="book" id="rf0475">
          <person-group person-group-type="author">
            <name>
              <surname>Guild</surname>
              <given-names>B.C.C.</given-names>
            </name>
            <name>
              <surname>Derosa</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Heartlein</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <chapter-title>Pulmonary delivery of mRNA</chapter-title>
          <year>2014</year>
          <publisher-name>Shire Human Genetic Therapies</publisher-name>
          <publisher-loc>United States</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0490">
        <label>97</label>
        <element-citation publication-type="book" id="rf0480">
          <person-group person-group-type="author">
            <name>
              <surname>Borlak</surname>
              <given-names>J.L.O.I.</given-names>
            </name>
            <name>
              <surname>Benita</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Debotton</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Karra</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Harush-Frenkel</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <chapter-title>Nanoparticles for targeted delivery of active agents to the lung</chapter-title>
          <comment>United States</comment>
          <year>2013</year>
        </element-citation>
      </ref>
      <ref id="bb0495">
        <label>98</label>
        <element-citation publication-type="book" id="rf0485">
          <person-group person-group-type="author">
            <name>
              <surname>Niitsu</surname>
              <given-names>Y.S.</given-names>
            </name>
            <name>
              <surname>Takimoto</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Minomi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Miyazaki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kajiwara</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <chapter-title>Therapeutic agent for pulmonary fibrosis</chapter-title>
          <year>2013</year>
          <publisher-name>Nitto Denko Corporation</publisher-name>
          <publisher-loc>Ibaraki-Shi, Osaka, JP</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0500">
        <label>99</label>
        <element-citation publication-type="book" id="rf0490">
          <person-group person-group-type="author">
            <name>
              <surname>Basran</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Brewis</surname>
              <given-names>N.D.</given-names>
            </name>
            <name>
              <surname>Sparks</surname>
              <given-names>C.A.</given-names>
            </name>
          </person-group>
          <chapter-title>Compositions for pulmonary delivery</chapter-title>
          <comment>United States</comment>
          <year>2010</year>
        </element-citation>
      </ref>
      <ref id="bb0505">
        <label>100</label>
        <element-citation publication-type="book" id="rf0495">
          <person-group person-group-type="author">
            <name>
              <surname>Edwards</surname>
              <given-names>D.A.B.</given-names>
            </name>
            <name>
              <surname>Fiegel</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sung</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <chapter-title>Particles for treatment of pulmonary infection</chapter-title>
          <year>2008</year>
          <publisher-name>President and Fellows of Harvard College</publisher-name>
          <publisher-loc>Cambridge, MA</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0510">
        <label>101</label>
        <element-citation publication-type="book" id="rf0500">
          <person-group person-group-type="author">
            <name>
              <surname>Batycky</surname>
              <given-names>R.P.N.</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Lipp</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <chapter-title>Particulate compositions for pulmonary delivery</chapter-title>
          <year>2007</year>
          <publisher-name>Advanced Inhalation Research</publisher-name>
          <publisher-loc>Cambridge, MA</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0515">
        <label>102</label>
        <element-citation publication-type="book" id="rf0505">
          <person-group person-group-type="author">
            <name>
              <surname>Ezrin</surname>
              <given-names>A.M.M.</given-names>
            </name>
            <name>
              <surname>Fleser</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Robitaille</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Milner</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Bridon</surname>
              <given-names>D.P.</given-names>
            </name>
          </person-group>
          <chapter-title>Pulmonary delivery for bioconjugation</chapter-title>
          <year>2004</year>
          <publisher-name>Conjuchem</publisher-name>
          <publisher-loc>Montreal, CA</publisher-loc>
        </element-citation>
      </ref>
      <ref id="bb0520">
        <label>103</label>
        <element-citation publication-type="journal" id="rf0510">
          <person-group person-group-type="author">
            <name>
              <surname>Talaat</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Xi</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Computational modeling of aerosol transport, dispersion, and deposition in rhythmically expanding and contracting terminal alveoli</article-title>
          <source>J Aerosol Sci</source>
          <volume>112</volume>
          <year>2017</year>
          <fpage>19</fpage>
          <lpage>33</lpage>
        </element-citation>
      </ref>
      <ref id="bb0525">
        <label>104</label>
        <element-citation publication-type="journal" id="rf0515">
          <person-group person-group-type="author">
            <name>
              <surname>Asgharian</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>O.T.</given-names>
            </name>
            <name>
              <surname>Oldham</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L.-C.</given-names>
            </name>
            <name>
              <surname>Saunders</surname>
              <given-names>E.L.</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Mikheev</surname>
              <given-names>V.B.</given-names>
            </name>
            <name>
              <surname>Minard</surname>
              <given-names>K.R.</given-names>
            </name>
            <name>
              <surname>Teeguarden</surname>
              <given-names>J.G.</given-names>
            </name>
          </person-group>
          <article-title>Computational modeling of nanoscale and microscale particle deposition, retention and dosimetry in the mouse respiratory tract</article-title>
          <source>Inhal Toxicol</source>
          <volume>26</volume>
          <issue>14</issue>
          <year>2014</year>
          <fpage>829</fpage>
          <lpage>842</lpage>
          <pub-id pub-id-type="pmid">25373829</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Clin Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id>
      <journal-id journal-id-type="publisher-id">jcm</journal-id>
      <journal-title-group>
        <journal-title>Journal of Clinical Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2077-0383</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33374882</article-id>
      <article-id pub-id-type="pmc">7795777</article-id>
      <article-id pub-id-type="doi">10.3390/jcm10010023</article-id>
      <article-id pub-id-type="publisher-id">jcm-10-00023</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4128-0614</contrib-id>
          <name>
            <surname>Dagenais</surname>
            <given-names>Ren&#xE9;e V. E.</given-names>
          </name>
          <xref ref-type="aff" rid="af1-jcm-10-00023">1</xref>
          <xref ref-type="aff" rid="af2-jcm-10-00023">2</xref>
          <xref rid="c1-jcm-10-00023" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Su</surname>
            <given-names>Victoria C.</given-names>
          </name>
          <xref ref-type="aff" rid="af1-jcm-10-00023">1</xref>
          <xref ref-type="aff" rid="af2-jcm-10-00023">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Quon</surname>
            <given-names>Bradley S.</given-names>
          </name>
          <xref ref-type="aff" rid="af1-jcm-10-00023">1</xref>
          <xref ref-type="aff" rid="af3-jcm-10-00023">3</xref>
          <xref ref-type="aff" rid="af4-jcm-10-00023">4</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-jcm-10-00023"><label>1</label>Adult Cystic Fibrosis Program, St. Paul&#x2019;s Hospital, Vancouver, BC V6Z 1Y6, Canada; <email>VSu@providencehealth.bc.ca</email> (V.C.S.); <email>bradley.quon@hli.ubc.ca</email> (B.S.Q.)</aff>
      <aff id="af2-jcm-10-00023"><label>2</label>Department of Pharmacy, St. Paul&#x2019;s Hospital, Vancouver, BC V6Z 1Y6, Canada</aff>
      <aff id="af3-jcm-10-00023"><label>3</label>Department of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada</aff>
      <aff id="af4-jcm-10-00023"><label>4</label>Centre for Heart Lung Innovation, St. Paul&#x2019;s Hospital, Vancouver, BC V6Z 1Y6, Canada</aff>
      <author-notes>
        <corresp id="c1-jcm-10-00023"><label>*</label>Correspondence: <email>rdagenais1@providencehealth.bc.ca</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>12</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>1</month>
        <year>2021</year>
      </pub-date>
      <volume>10</volume>
      <issue>1</issue>
      <elocation-id>23</elocation-id>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>12</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>12</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2020 by the authors.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license license-type="open-access">
          <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies target the underlying cause of cystic fibrosis (CF), and are generally well-tolerated; however, real-world studies indicate the frequency of discontinuation and adverse events (AEs) may be higher than what was observed in clinical trials. The objectives of this systematic review were to summarize real-world AEs reported for market-available CFTR modulators (i.e., ivacaftor (IVA), lumacaftor/ivacaftor (LUM/IVA), tezacaftor/ivacaftor (TEZ/IVA), and elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA)), and to identify ways in which the pharmacist on CF healthcare teams may contribute to mitigating and managing these AEs. The MEDLINE, EMBASE, CINAHL, and Web of Science Core Collection online databases were searched from 2012 to 1 Aug 2020. Full manuscripts or conference abstracts of observational studies, case series, and case reports were eligible for inclusion. The included full manuscripts and conference abstracts comprised of 54 observational studies, 5 case series, and 9 case reports. The types of AEs reported generally aligned with what have been observed in clinical trials. LUM/IVA was associated with a higher frequency of respiratory-related AE and discontinuation in real-world studies. A signal for mental health and neurocognitive AEs was identified with all 4 CFTR modulators. A systematic approach to monitoring for AEs in people with CF on CFTR modulators in the real-world setting is necessary to help better understand potential AEs, as well as patient characteristics that may be associated with higher risk of certain AEs. Pharmacists play a key role in the safe initiation and monitoring of people with CF on CFTR modulator therapies.</p>
      </abstract>
      <kwd-group>
        <kwd>CFTR modulator</kwd>
        <kwd>ivacaftor</kwd>
        <kwd>lumacaftor</kwd>
        <kwd>tezacaftor</kwd>
        <kwd>elexacaftor</kwd>
        <kwd>real-world</kwd>
        <kwd>adverse events</kwd>
        <kwd>safety</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-jcm-10-00023">
      <title>1. Introduction</title>
      <p>Cystic fibrosis (CF) is an autosomal recessive disorder affecting the <italic>CF transmembrane conductance regulator (CFTR)</italic> gene, resulting in alteration of CFTR protein synthesis, processing, or function. The CFTR protein is a channel that transports chloride and bicarbonate across cell membranes, regulating fluid and electrolyte balance in several organs throughout the body; dysfunctional CFTR protein results in viscous mucus and secretions [<xref rid="B1-jcm-10-00023" ref-type="bibr">1</xref>]. In the lungs, this viscous mucus causes impaired mucociliary clearance as well as chronic infection and inflammation, which, over time, leads to irreversible airway damage and progressive lung function decline [<xref rid="B1-jcm-10-00023" ref-type="bibr">1</xref>]. The pancreas, gastrointestinal tract, and biliary ducts are among the extrapulmonary organs impacted by CF, resulting in complications such as nutrient malabsorption, bowel obstruction and hepatobiliary disease, respectively [<xref rid="B1-jcm-10-00023" ref-type="bibr">1</xref>]. Optimal management of CF requires a complex, multimodal medication regimen that may take upwards of 2 h to administer on a daily basis [<xref rid="B2-jcm-10-00023" ref-type="bibr">2</xref>]. Pharmacists have therefore been identified as integral members of multidisciplinary teams providing care to people with CF, with essential roles such as: optimizing the effectiveness of medication regimens and tailoring to each individuals&#x2019; needs; providing medication education and counselling; promoting adherence to therapies; as well as monitoring and managing drug-related adverse events (AE) and interactions [<xref rid="B3-jcm-10-00023" ref-type="bibr">3</xref>,<xref rid="B4-jcm-10-00023" ref-type="bibr">4</xref>,<xref rid="B5-jcm-10-00023" ref-type="bibr">5</xref>,<xref rid="B6-jcm-10-00023" ref-type="bibr">6</xref>].</p>
      <p>Prior to the development of CFTR modulator therapies, available treatments for CF only targeted symptom management, whereas CFTR modulators target the underlying cause [<xref rid="B1-jcm-10-00023" ref-type="bibr">1</xref>,<xref rid="B7-jcm-10-00023" ref-type="bibr">7</xref>]. CFTR modulators are small molecule therapies, with four single or combination therapies currently available on the market: ivacaftor (IVA; Kalydeco<sup>&#xAE;</sup>), lumacaftor/ivacaftor (LUM/IVA; Orkambi<sup>&#xAE;</sup>), tezacaftor/ivacaftor (TEZ/IVA; Symdeko<sup>&#xAE;</sup> or Symkevi<sup>&#xAE;</sup>), and elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA; Trikafta<sup>&#xAE;</sup> or Kaftrio<sup>&#xAE;</sup>) [<xref rid="B8-jcm-10-00023" ref-type="bibr">8</xref>,<xref rid="B9-jcm-10-00023" ref-type="bibr">9</xref>,<xref rid="B10-jcm-10-00023" ref-type="bibr">10</xref>,<xref rid="B11-jcm-10-00023" ref-type="bibr">11</xref>,<xref rid="B12-jcm-10-00023" ref-type="bibr">12</xref>,<xref rid="B13-jcm-10-00023" ref-type="bibr">13</xref>]. IVA was the first CFTR modulator brought to market, approved by the Food and Drug Administration (FDA) in 2012; it is a CFTR &#x201C;potentiator&#x201D; that increases the amount of time the CFTR protein channel remains open, targeting <italic>CFTR</italic> mutations that impact channel gating and conductance (e.g., <italic>G551D, R117H)</italic> [<xref rid="B8-jcm-10-00023" ref-type="bibr">8</xref>]. The remaining three CFTR modulator therapies combine IVA with one or two CFTR &#x201C;correctors&#x201D;. &#x201C;Correctors&#x201D; primarily target the most common <italic>CFTR</italic> mutation, <italic>F508del</italic>, improving CFTR protein conformation and subsequent processing and trafficking to the cell surface [<xref rid="B9-jcm-10-00023" ref-type="bibr">9</xref>,<xref rid="B10-jcm-10-00023" ref-type="bibr">10</xref>,<xref rid="B11-jcm-10-00023" ref-type="bibr">11</xref>,<xref rid="B12-jcm-10-00023" ref-type="bibr">12</xref>,<xref rid="B13-jcm-10-00023" ref-type="bibr">13</xref>]. Results from randomized, placebo-controlled clinical trials support the efficacy of CFTR modulator therapies in the treatment of people with CF: IVA in patients with at least one <italic>G551D</italic> or <italic>R117H</italic> mutation<italic>,</italic> non-<italic>G551D</italic> gating mutation, or residual function mutation [<xref rid="B14-jcm-10-00023" ref-type="bibr">14</xref>,<xref rid="B15-jcm-10-00023" ref-type="bibr">15</xref>,<xref rid="B16-jcm-10-00023" ref-type="bibr">16</xref>,<xref rid="B17-jcm-10-00023" ref-type="bibr">17</xref>,<xref rid="B18-jcm-10-00023" ref-type="bibr">18</xref>]; LUM/IVA in patients who are <italic>F508del</italic> homozygous [<xref rid="B19-jcm-10-00023" ref-type="bibr">19</xref>,<xref rid="B20-jcm-10-00023" ref-type="bibr">20</xref>]; TEZ/IVA in patients who are <italic>F508del</italic> homozygous or heterozygous with a residual function mutation [<xref rid="B18-jcm-10-00023" ref-type="bibr">18</xref>,<xref rid="B21-jcm-10-00023" ref-type="bibr">21</xref>]; and ELX/TEZ/IVA in patients who are <italic>F508del</italic> homozygous or heterozygous with a minimal function mutation [<xref rid="B22-jcm-10-00023" ref-type="bibr">22</xref>,<xref rid="B23-jcm-10-00023" ref-type="bibr">23</xref>].</p>
      <p>In the aforementioned clinical trials, CFTR modulators were generally well-tolerated, with the exception of LUM/IVA having higher rates of respiratory-related AE [<xref rid="B7-jcm-10-00023" ref-type="bibr">7</xref>,<xref rid="B19-jcm-10-00023" ref-type="bibr">19</xref>,<xref rid="B20-jcm-10-00023" ref-type="bibr">20</xref>]. However, observational studies with real-world CFTR modulator safety data have raised flags for higher rates of discontinuation as well as AE that were rarely observed or not described in the clinical trial setting. The objective of this systematic review was to summarize real-world AEs reported for CFTR modulator therapies, as well as to identify ways in which the pharmacist on CF healthcare teams may contribute to mitigating and managing these AEs.</p>
    </sec>
    <sec sec-type="methods" id="sec2-jcm-10-00023">
      <title>2. Methods</title>
      <sec id="sec2dot1-jcm-10-00023">
        <title>2.1. Search Strategy</title>
        <p>The MEDLINE, EMBASE, CINAHL, and Web of Science Core Collection online databases were systematically searched from 2012 to 1 August 2020 to identify literature related to the primary research question. The search terms and Boolean operators utilized in MEDLINE and EMBASE are outlined in <xref ref-type="app" rid="app1-jcm-10-00023">Appendix A</xref> as an example. References of relevant literature were searched manually to identify additional studies not identified in the electronic search, and grey literature was explored via conference abstracts identified in the search. The systematic review protocol was prospectively registered with PROSPERO (CRD42020188189).</p>
      </sec>
      <sec id="sec2dot2-jcm-10-00023">
        <title>2.2. Selection of Studies</title>
        <p>Observational studies, case series, and case reports were eligible for inclusion in the review if study participants had a diagnosis of CF, received at least one dose of a market-available CFTR modulator (i.e., IVA (Kalydeco<sup>&#xAE;</sup>), LUM/IVA (Orkambi<sup>&#xAE;</sup>), TEZ/IVA (Symdeko<sup>&#xAE;</sup> or Symkevi<sup>&#xAE;</sup>), or ELX/TEZ/IVA (Trikafta<sup>&#xAE;</sup> or Kaftrio<sup>&#xAE;</sup>) [<xref rid="B8-jcm-10-00023" ref-type="bibr">8</xref>,<xref rid="B9-jcm-10-00023" ref-type="bibr">9</xref>,<xref rid="B10-jcm-10-00023" ref-type="bibr">10</xref>,<xref rid="B11-jcm-10-00023" ref-type="bibr">11</xref>,<xref rid="B12-jcm-10-00023" ref-type="bibr">12</xref>,<xref rid="B13-jcm-10-00023" ref-type="bibr">13</xref>]) in the real-world setting, and reported AEs that occurred while participants were receiving the CFTR modulator. Conference abstracts that met the above criteria were also included. Studies were excluded if it was a clinical trial or study utilizing clinical trial data, was not available in the English language, if none of the AE were specified, or if it was reported that no AEs occurred in the study participants. Two authors (R.D. and V.S.) independently conducted a search and reviewed potentially relevant citations to determine whether the pre-defined criteria for inclusion were satisfied; any inconsistencies in studies selected for inclusion were resolved by discussion and consensus.</p>
      </sec>
      <sec id="sec2dot3-jcm-10-00023">
        <title>2.3. Data Extraction and Management</title>
        <p>Data from each included study were extracted and tabulated. Data extracted from full manuscripts included: first author; year of publication; study design; study location; study population age group, <italic>CFTR</italic> genotype, and baseline percent predicted of the forced expiratory volume in the first second (ppFEV<sub>1</sub>); CFTR modulator(s) received by study participants; follow-up time of study participants; type and frequency of AEs; CFTR modulator interruption, discontinuation, and/or dose modification secondary to AEs; and strategies to address or mitigate reported AEs (if described). Data extracted from conference abstracts was the same as for full manuscripts, with the exception of study location and follow-up time, as these were infrequently specified. Data were first extracted by the primary reviewer (R.D.) and checked by the secondary reviewer (V.S.); disagreements or inconsistencies regarding extracted data were resolved by discussion and consensus.</p>
      </sec>
      <sec id="sec2dot4-jcm-10-00023">
        <title>2.4. Quality Assessment</title>
        <p>All full manuscripts included in the review were independently assessed for quality by the primary and secondary reviewer (R.D. and V.S.) using a National Institutes of Health, National Heart, Lung, and Blood Institute Quality Assessment Tool appropriate for the study design [<xref rid="B24-jcm-10-00023" ref-type="bibr">24</xref>]. The quality of the manuscripts was assessed from the perspective of addressing safety events (i.e., a study may have been methodologically sound for assessment of effectiveness or other outcomes unrelated to safety but may have received a lower rating for this systematic review due to seemingly not having a robust approach to assessing safety outcomes). An overall rating of &#x2018;Good&#x2019;, &#x2018;Fair&#x2019;, or &#x2018;Poor&#x2019; was assigned to each manuscript after discussion and consensus based on the assessment tool criteria and study-specific factors that may affect the quality and internal validity. Case reports were not systematically assessed for quality due to absence of a standardized quality assessment tool, and conference abstracts were not formally assessed due to inherent lack of detail necessary to appropriately assess the quality of study methodology.</p>
      </sec>
      <sec id="sec2dot5-jcm-10-00023">
        <title>2.5. Data Analysis</title>
        <p>Descriptive analyses were performed on data extracted from the included studies.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3-jcm-10-00023">
      <title>3. Results</title>
      <sec id="sec3dot1-jcm-10-00023">
        <title>3.1. Description of Studies</title>
        <p>Of the 2333 articles identified in the search or through other sources, 278 were screened for eligibility. Of the 278 screened, 31 studies with full manuscripts and 37 conference abstracts met the inclusion criteria, and 210 articles were excluded (<xref ref-type="fig" rid="jcm-10-00023-f001">Figure 1</xref>). Of the 31 full manuscripts, 20 were observational studies, 5 were case series, and 6 were case reports. Of the 37 conference abstracts, 34 were observational studies and 3 were case reports. Characteristics of the full manuscripts and conference abstracts describing observational cohort studies are summarized in <xref rid="jcm-10-00023-t001" ref-type="table">Table 1</xref> and <xref rid="jcm-10-00023-t002" ref-type="table">Table 2</xref>, respectively. Two observational cohort studies included control subjects as comparison for non-safety outcomes related to LUM/IVA therapy [<xref rid="B25-jcm-10-00023" ref-type="bibr">25</xref>,<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>], but only data regarding the participants on LUM/IVA was extracted and included in the descriptive analysis of this review. One case series was based on survey results presented in aggregate [<xref rid="B27-jcm-10-00023" ref-type="bibr">27</xref>]; therefore, it was included in <xref rid="jcm-10-00023-t001" ref-type="table">Table 1</xref>. Characteristics of case series and case reports are otherwise summarized in <xref rid="jcm-10-00023-t003" ref-type="table">Table 3</xref>.</p>
        <p>The majority of the included studies and case series/reports regarded LUM/IVA, totaling 47 (69%) of the 68 included. IVA, TEZ/IVA, and ELX/TEZ/IVA were the subject of 11 (16%), 7 (10%), and 4 (6%) of the included manuscripts and abstracts, respectively (one study discussed both LUM/IVA and TEZ/IVA, so was included in the totals for both modulators [<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>]). Eleven (16%) of the included studies and case series/reports included only pediatrics (age &lt; 18 years old), 33 (49%) included only adults, 16 (24%) included both adult and pediatric patients, and the age groups included was not specified in 8 (12%). In the observational studies, the number of subjects included ranged from 4 to 845 (median: 28). Fourteen (26%) of the observational studies focused on patients with severe airflow obstruction, defined as ppFEV<sub>1</sub> &lt; 40%; in 11 of these studies, patients accessed the CFTR modulator via a compassionate access program (also referred to as a &#x201C;managed access&#x201D;, &#x201C;early access&#x2019;, &#x201C;expanded access&#x201D;, or &#x201C;named patient&#x201D; program) through the manufacturer [<xref rid="B25-jcm-10-00023" ref-type="bibr">25</xref>,<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>,<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>,<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>,<xref rid="B31-jcm-10-00023" ref-type="bibr">31</xref>,<xref rid="B32-jcm-10-00023" ref-type="bibr">32</xref>,<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>,<xref rid="B34-jcm-10-00023" ref-type="bibr">34</xref>,<xref rid="B35-jcm-10-00023" ref-type="bibr">35</xref>,<xref rid="B36-jcm-10-00023" ref-type="bibr">36</xref>,<xref rid="B37-jcm-10-00023" ref-type="bibr">37</xref>,<xref rid="B38-jcm-10-00023" ref-type="bibr">38</xref>,<xref rid="B39-jcm-10-00023" ref-type="bibr">39</xref>,<xref rid="B40-jcm-10-00023" ref-type="bibr">40</xref>]. Twenty (65%) of the full manuscripts were deemed to have safety as a primary focus or outcome [<xref rid="B27-jcm-10-00023" ref-type="bibr">27</xref>,<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>,<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>,<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>,<xref rid="B32-jcm-10-00023" ref-type="bibr">32</xref>,<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>,<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>,<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>,<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>,<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>,<xref rid="B46-jcm-10-00023" ref-type="bibr">46</xref>,<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>,<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>,<xref rid="B49-jcm-10-00023" ref-type="bibr">49</xref>,<xref rid="B50-jcm-10-00023" ref-type="bibr">50</xref>,<xref rid="B51-jcm-10-00023" ref-type="bibr">51</xref>,<xref rid="B52-jcm-10-00023" ref-type="bibr">52</xref>,<xref rid="B53-jcm-10-00023" ref-type="bibr">53</xref>,<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>].</p>
      </sec>
      <sec id="sec3dot2-jcm-10-00023">
        <title>3.2. Quality Assessment</title>
        <p>The 20 observational studies and 5 case series with full manuscripts were assessed for quality from the standpoint of AE follow-up and assessment. Ten of the observational studies were rated as &#x2018;Good&#x2019; quality, eight were rated as &#x2018;Fair&#x2019;, and two were rated as &#x2018;Poor&#x2019; (<xref ref-type="app" rid="app2-jcm-10-00023">Appendix B</xref>). Only one of the case series was rated as &#x2018;Good&#x2019; quality, while one was rated as &#x2018;Fair&#x2019; and three were rated as &#x2018;Poor&#x2019; (<xref ref-type="app" rid="app3-jcm-10-00023">Appendix C</xref>). The two leading factors contributing to lower quality ratings were unclear and/or inconsistent methods for follow-up and assessment of AEs, and lack of a reliable, validated tool or method to accurately assess and confirm a given AE.</p>
      </sec>
      <sec id="sec3dot3-jcm-10-00023">
        <title>3.3. AE-Related Outcomes</title>
        <p>The AE reported for IVA, LUM/IVA, TEZ/IVA, and ELX/TEZ/IVA are summarized in <xref rid="jcm-10-00023-t001" ref-type="table">Table 1</xref>, <xref rid="jcm-10-00023-t002" ref-type="table">Table 2</xref> and <xref rid="jcm-10-00023-t003" ref-type="table">Table 3</xref>.</p>
        <sec id="sec3dot3dot1-jcm-10-00023">
          <title>3.3.1. Ivacaftor (IVA)</title>
          <p>In the studies evaluating IVA, a large proportion of the reported AEs were respiratory-related. In two observational studies that reported serious respiratory-related AEs such as pulmonary exacerbation or respiratory infection, hemoptysis, and acute respiratory failure, these respiratory AEs did not prompt discontinuation and were attributable to patients&#x2019; underlying disease [<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>,<xref rid="B55-jcm-10-00023" ref-type="bibr">55</xref>]. Another study reported increased bronchial and nasal secretions after initiating IVA in a patient with low lung function (baseline ppFEV<sub>1</sub> 13.9%) prompting a severe pulmonary exacerbation, and IVA ultimately had to be discontinued due to difficulty clearing &#x201C;liquefied&#x201D; secretions despite decreases in dose [<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>]. Otherwise, respiratory AE reportedly resolved over time without changes to IVA therapy [<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>,<xref rid="B46-jcm-10-00023" ref-type="bibr">46</xref>].</p>
          <p>Relatively common were transaminitis and other hepatic AEs [<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>,<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>,<xref rid="B55-jcm-10-00023" ref-type="bibr">55</xref>,<xref rid="B56-jcm-10-00023" ref-type="bibr">56</xref>,<xref rid="B58-jcm-10-00023" ref-type="bibr">58</xref>,<xref rid="B64-jcm-10-00023" ref-type="bibr">64</xref>]. In one observational study, transaminitis and a diagnosis of liver cirrhosis resulted in IVA discontinuation in one individual each, and hepatitis warranted interruption of therapy [<xref rid="B58-jcm-10-00023" ref-type="bibr">58</xref>]. One case report indicated a decrease in IVA dose was necessary for normalization of transaminases [<xref rid="B46-jcm-10-00023" ref-type="bibr">46</xref>]. Hepatic AEs were not otherwise reported to require changes in IVA therapy.</p>
          <p>Abdominal pain was reported in a number of studies, though the overall frequency was often not specified [<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>,<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>,<xref rid="B58-jcm-10-00023" ref-type="bibr">58</xref>]. In some cases, abdominal pain was severe enough to warrant interruption or discontinuation of therapy [<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>,<xref rid="B58-jcm-10-00023" ref-type="bibr">58</xref>]. Nausea or vomiting, intestinal dysmotility, and gastroenteritis were other gastrointestinal-related AEs reported, of which vomiting was the only one to prompt interruption of therapy [<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>,<xref rid="B58-jcm-10-00023" ref-type="bibr">58</xref>].</p>
          <p>Headache and rash were also common, but only prompted IVA interruption in one study [<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>,<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>,<xref rid="B55-jcm-10-00023" ref-type="bibr">55</xref>,<xref rid="B57-jcm-10-00023" ref-type="bibr">57</xref>,<xref rid="B58-jcm-10-00023" ref-type="bibr">58</xref>,<xref rid="B62-jcm-10-00023" ref-type="bibr">62</xref>,<xref rid="B63-jcm-10-00023" ref-type="bibr">63</xref>,<xref rid="B65-jcm-10-00023" ref-type="bibr">65</xref>]. Less common but notable AEs included cataracts, depression, dizziness, and tinnitus; the latter two prompted discontinuation of IVA in one patient, while depression warranted interruption of therapy [<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>,<xref rid="B55-jcm-10-00023" ref-type="bibr">55</xref>,<xref rid="B57-jcm-10-00023" ref-type="bibr">57</xref>,<xref rid="B58-jcm-10-00023" ref-type="bibr">58</xref>,<xref rid="B65-jcm-10-00023" ref-type="bibr">65</xref>]. IVA was also implicated in causing recurrent morbilliform drug eruption (Type IV drug hypersensitivity) to trials of LUM/IVA and TEZ/IVA, with successful IVA desensitization thereafter [<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>].</p>
        </sec>
        <sec id="sec3dot3dot2-jcm-10-00023">
          <title>3.3.2. Lumacaftor/Ivacaftor (LUM/IVA)</title>
          <p>The majority of AEs reported with LUM/IVA were respiratory-related. Chest tightness, dyspnea, increased sputum, and declines in ppFEV<sub>1</sub> were among the most common respiratory AEs and tended to occur within the first few days after initiation, even as quickly as 3&#x2013;4 h after the first dose [<xref rid="B25-jcm-10-00023" ref-type="bibr">25</xref>,<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>,<xref rid="B27-jcm-10-00023" ref-type="bibr">27</xref>,<xref rid="B31-jcm-10-00023" ref-type="bibr">31</xref>,<xref rid="B32-jcm-10-00023" ref-type="bibr">32</xref>,<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>,<xref rid="B34-jcm-10-00023" ref-type="bibr">34</xref>,<xref rid="B35-jcm-10-00023" ref-type="bibr">35</xref>,<xref rid="B37-jcm-10-00023" ref-type="bibr">37</xref>,<xref rid="B38-jcm-10-00023" ref-type="bibr">38</xref>,<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>,<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>,<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>,<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>,<xref rid="B60-jcm-10-00023" ref-type="bibr">60</xref>,<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>,<xref rid="B66-jcm-10-00023" ref-type="bibr">66</xref>,<xref rid="B67-jcm-10-00023" ref-type="bibr">67</xref>,<xref rid="B68-jcm-10-00023" ref-type="bibr">68</xref>,<xref rid="B69-jcm-10-00023" ref-type="bibr">69</xref>,<xref rid="B70-jcm-10-00023" ref-type="bibr">70</xref>,<xref rid="B71-jcm-10-00023" ref-type="bibr">71</xref>,<xref rid="B72-jcm-10-00023" ref-type="bibr">72</xref>,<xref rid="B73-jcm-10-00023" ref-type="bibr">73</xref>,<xref rid="B74-jcm-10-00023" ref-type="bibr">74</xref>,<xref rid="B75-jcm-10-00023" ref-type="bibr">75</xref>,<xref rid="B76-jcm-10-00023" ref-type="bibr">76</xref>,<xref rid="B77-jcm-10-00023" ref-type="bibr">77</xref>,<xref rid="B78-jcm-10-00023" ref-type="bibr">78</xref>,<xref rid="B83-jcm-10-00023" ref-type="bibr">83</xref>,<xref rid="B84-jcm-10-00023" ref-type="bibr">84</xref>,<xref rid="B85-jcm-10-00023" ref-type="bibr">85</xref>,<xref rid="B90-jcm-10-00023" ref-type="bibr">90</xref>]. Bronchodilators were beneficial in mitigating symptoms of chest tightness, wheeze, and increased work of breathing in some individuals [<xref rid="B31-jcm-10-00023" ref-type="bibr">31</xref>,<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>,<xref rid="B66-jcm-10-00023" ref-type="bibr">66</xref>,<xref rid="B67-jcm-10-00023" ref-type="bibr">67</xref>,<xref rid="B75-jcm-10-00023" ref-type="bibr">75</xref>]. Improvement in or resolution of respiratory AEs generally occurred over the 1&#x2013;4 weeks following initiation, but symptoms and/or ppFEV<sub>1</sub> below baseline could persist beyond this time [<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>,<xref rid="B31-jcm-10-00023" ref-type="bibr">31</xref>,<xref rid="B32-jcm-10-00023" ref-type="bibr">32</xref>,<xref rid="B34-jcm-10-00023" ref-type="bibr">34</xref>,<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>,<xref rid="B73-jcm-10-00023" ref-type="bibr">73</xref>]. In studies assessing ppFEV<sub>1</sub> changes post-initial dose of LUM/IVA, a mean absolute decline in ppFEV<sub>1</sub> around 10% within 4 h was common [<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>,<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>,<xref rid="B67-jcm-10-00023" ref-type="bibr">67</xref>], with declines of up to 20% at 4 and 24 h reported even when bronchodilators were administered pre-dose [<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>]. One study reported a ppFEV<sub>1</sub> drop 39% below baseline in an individual; the timing of repeat spirometry after LUM/IVA initiation was not specified [<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>]. Declines in ppFEV<sub>1</sub> were not always accompanied by respiratory symptoms, and bronchodilators did not consistently improve acute drops in ppFEV<sub>1</sub> [<xref rid="B32-jcm-10-00023" ref-type="bibr">32</xref>,<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>,<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>,<xref rid="B66-jcm-10-00023" ref-type="bibr">66</xref>,<xref rid="B67-jcm-10-00023" ref-type="bibr">67</xref>,<xref rid="B84-jcm-10-00023" ref-type="bibr">84</xref>]. ppFEV<sub>1</sub> could take upwards of three months after initiation to recover to baseline values [<xref rid="B34-jcm-10-00023" ref-type="bibr">34</xref>,<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>]. Increased cough was common, sometimes resulting in discontinuation [<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>,<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>,<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>,<xref rid="B69-jcm-10-00023" ref-type="bibr">69</xref>,<xref rid="B73-jcm-10-00023" ref-type="bibr">73</xref>,<xref rid="B76-jcm-10-00023" ref-type="bibr">76</xref>,<xref rid="B85-jcm-10-00023" ref-type="bibr">85</xref>], while chest pain was infrequently reported [<xref rid="B37-jcm-10-00023" ref-type="bibr">37</xref>,<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>,<xref rid="B72-jcm-10-00023" ref-type="bibr">72</xref>,<xref rid="B85-jcm-10-00023" ref-type="bibr">85</xref>]. Two cases of hemoptysis and one case of pneumothorax reportedly caused discontinuation of LUM/IVA in one study; whether the hemoptysis and pneumothorax were attributable to underlying disease was not specified [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>].</p>
          <p>Intolerable respiratory AE could be overcome in some patients by reducing the dose of LUM/IVA [<xref rid="B66-jcm-10-00023" ref-type="bibr">66</xref>,<xref rid="B70-jcm-10-00023" ref-type="bibr">70</xref>]; however, discontinuation due to respiratory AEs remained common. Chest tightness and/or dyspnea were the most common respiratory AEs to prompt discontinuation, with reported frequencies between from 5 to 31%. In one case report, halving the LUM/IVA dose mitigated severe chest tightness, dyspnea, and exertional hypoxemia that onset after initiation, but therapy was ultimately discontinued with rapid recovery of symptoms and ppFEV<sub>1</sub> thereafter [<xref rid="B90-jcm-10-00023" ref-type="bibr">90</xref>]. A cohort study also reported resolution of respiratory AE upon LUM/IVA discontinuation [<xref rid="B35-jcm-10-00023" ref-type="bibr">35</xref>]. In observational studies that described retrials after LUM/IVA was discontinued, there were mixed outcomes among patients. In one study, 32 of the 90 patients who discontinued LUM/IVA at least once due to respiratory AE were retrialed&#x2014;16 were able to successfully restart therapy, and 16 had to discontinue indefinitely [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>]. Three studies also described LUM/IVA retrial following discontinuation due AE: in the first, of 25 patients who discontinued, 9 were retrialed, and 6 had recurrence of the same AE [<xref rid="B72-jcm-10-00023" ref-type="bibr">72</xref>]; in the second, 4 of 8 patients who discontinued were retrialed at full- or half-dose and experienced AE recurrence [<xref rid="B76-jcm-10-00023" ref-type="bibr">76</xref>]; and in the third, 6 of 8 patients who discontinued were retrialed and able to restart therapy, but 4 required half-dose in order to do so [<xref rid="B78-jcm-10-00023" ref-type="bibr">78</xref>]. The three studies were reported in abstracts and did not specify whether it was only patients with respiratory AE that were retrialed, but respiratory AE accounted for a large proportion of the AEs prompting discontinuation.</p>
          <p>A number of factors and patient characteristics were explored as potential risk factors for respiratory AE and/or discontinuation due to AE with LUM/IVA. Having a lower baseline ppFEV<sub>1</sub> was generally associated with greater risk of respiratory AE or discontinuation [<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>,<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B73-jcm-10-00023" ref-type="bibr">73</xref>,<xref rid="B75-jcm-10-00023" ref-type="bibr">75</xref>,<xref rid="B77-jcm-10-00023" ref-type="bibr">77</xref>], but differences were not always statistically significant [<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>,<xref rid="B35-jcm-10-00023" ref-type="bibr">35</xref>,<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>,<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>], and one study found the contrary [<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>]. One study, using multivariable logistic regression, found for every 10% decrease in baseline ppFEV<sub>1</sub>, there was a greater likelihood of LUM/IVA discontinuation overall and due to respiratory AE&#x2014;odds ratio (OR) 1.13 (95%CI, 1.02&#x2013;1.25; <italic>p</italic> = 0.02) and OR 1.32 (95%CI, 1.14&#x2013;1.51; <italic>p</italic> = 0.0001), respectively [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>]. Older age and greater use of IV antibiotics in the past year had conflicting results for whether they were significant risk factors for LUM/IVA discontinuation [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>,<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>]. The association with reactive airway disease and/or atopy was discussed in three studies. Reversible airway obstruction &#x2265;12%, but not personal or familial history of atopy, was significantly associated with a greater drop in ppFEV<sub>1</sub> when evaluated in one study [<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>], and higher frequency of discontinuation or drop in ppFEV<sub>1</sub> was found in patients with asthma or asthma/atopy, respectively [<xref rid="B67-jcm-10-00023" ref-type="bibr">67</xref>,<xref rid="B77-jcm-10-00023" ref-type="bibr">77</xref>]; whether statistical significance was reached in the latter two studies was not specified. Interestingly, higher rates of discontinuation overall were associated with female sex in one study (adjusted OR 3.12 (95%CI, 1.04&#x2013;9.38; <italic>p</italic> = 0.04) [<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>]), but this was not observed in another evaluating this relationship [<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>]. Discontinuation due to respiratory AE was associated with diabetes (OR 1.71 (95%CI, 1.03&#x2013;2.85; <italic>p</italic> = 0.04)) and low body mass index (BMI) (OR 1.11 (95%CI, 1.00&#x2013;1.23; <italic>p</italic> = 0.03) per 1 kg/m<sup>2</sup> decrease) [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>].</p>
          <p>Similar to IVA, hepatic AE were relatively common with LUM/IVA. Transaminitis and other liver function test (LFT) elevations were seemingly mild and/or transient without need for intervention for the most part, but sometimes warranted discontinuation [<xref rid="B34-jcm-10-00023" ref-type="bibr">34</xref>,<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>,<xref rid="B59-jcm-10-00023" ref-type="bibr">59</xref>,<xref rid="B60-jcm-10-00023" ref-type="bibr">60</xref>,<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>,<xref rid="B72-jcm-10-00023" ref-type="bibr">72</xref>,<xref rid="B76-jcm-10-00023" ref-type="bibr">76</xref>,<xref rid="B78-jcm-10-00023" ref-type="bibr">78</xref>,<xref rid="B81-jcm-10-00023" ref-type="bibr">81</xref>]. One study specified that transaminases were over 6 times the upper limit of normal when discontinued [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>]. A case of isolated alkaline phosphatase elevation was also reported, taking several months for the alkaline phosphatase to normalize after discontinuation of LUM/IVA [<xref rid="B91-jcm-10-00023" ref-type="bibr">91</xref>].</p>
          <p>Similarly common with LUM/IVA were gastrointestinal AEs, of which abdominal pain, nausea and/or vomiting, and diarrhea were the most frequently reported and resulted in discontinuation in two studies each [<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>,<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>,<xref rid="B34-jcm-10-00023" ref-type="bibr">34</xref>,<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>,<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>,<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>,<xref rid="B69-jcm-10-00023" ref-type="bibr">69</xref>,<xref rid="B71-jcm-10-00023" ref-type="bibr">71</xref>,<xref rid="B73-jcm-10-00023" ref-type="bibr">73</xref>,<xref rid="B78-jcm-10-00023" ref-type="bibr">78</xref>,<xref rid="B79-jcm-10-00023" ref-type="bibr">79</xref>,<xref rid="B85-jcm-10-00023" ref-type="bibr">85</xref>]. Uncommon gastrointestinal AEs were dysphagia and decreased appetite; the one case of dysphagia resulted in discontinuation [<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>,<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>].</p>
          <p>Rash and hypersensitivity reactions were notable with LUM/IVA. In several observational studies reporting rash, LUM/IVA was seemingly continued without intervention, but prompted discontinuation in a small number of patients [<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>,<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>,<xref rid="B35-jcm-10-00023" ref-type="bibr">35</xref>,<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>,<xref rid="B73-jcm-10-00023" ref-type="bibr">73</xref>,<xref rid="B76-jcm-10-00023" ref-type="bibr">76</xref>,<xref rid="B78-jcm-10-00023" ref-type="bibr">78</xref>]. More serious reactions in the observational studies were rash with facial swelling, allergic reaction with chest tightness, and suspected Stevens&#x2013;Johnson syndrome (SJS), reported in one individual each [<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>,<xref rid="B75-jcm-10-00023" ref-type="bibr">75</xref>]. The LUM component of LUM/IVA was implicated via in vitro testing to have triggered a T-cell-mediated reaction that caused a progressive severe, pruritic rash and facial swelling in one case report [<xref rid="B50-jcm-10-00023" ref-type="bibr">50</xref>]. Another case report described morbilliform drug eruption recurring on three separate trials of LUM/IVA, but IVA was deemed the likely culprit in the reactions [<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>]. In both case reports, the hypersensitivity reactions resolved quickly following discontinuation [<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>,<xref rid="B50-jcm-10-00023" ref-type="bibr">50</xref>].</p>
          <p>An important signal was noted for the impact of LUM/IVA on mental health. One large prospective cohort study reported four individuals (0.5% of the study cohort) discontinued LUM/IVA due to depression [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>], and one individual in each of two smaller retrospective cohorts reported anxiety as the cause of discontinuation (4 and 5% of the respective cohorts) [<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>,<xref rid="B75-jcm-10-00023" ref-type="bibr">75</xref>]. One case series described five adolescent females, comprising 24% of the adolescent females who initiated LUM/IVA at the reporting center, with new or worsening depression as early as two weeks following LUM/IVA initiation [<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>]. Two of the patients had suicidal ideation (one each with baseline and new-onset depression), while three of the patients had an attempted suicide requiring hospitalization (one with baseline and two with new-onset depression) [<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>]. In all but one patient, mood improved after discontinuing LUM/IVA [<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>]. One of the patients with new-onset depression and suicidal ideation also had worsening of baseline anxiety, which, along with menstrual irregularity, was the ultimate cause of LUM/IVA discontinuation [<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>]. A second case series described four individuals with worsening of their baseline psychiatric diagnoses, including depression, anxiety, bipolar disorder, and/or substance use disorder, as early as one month following LUM/IVA initiation [<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>]. In three individuals, worsening mental health triggered a clinical decline and pulmonary exacerbation, likely attributable to medication non-adherence [<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>]. One patient discontinued LUM/IVA due to worsening depression and anxiety, and required adjustment of psychotropic therapy to return to baseline [<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>]. The other two patients remained on LUM/IVA; for one patient, the mood returned to baseline only after adjustment of psychotropic medications and the other patient did not return to baseline levels of anxiety despite appropriate treatment interventions [<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>]. The final patient discontinued LUM/IVA due to non-adherence [<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>].</p>
          <p>Two uncommon but consequential AEs were elevations in blood pressure and creatine kinase (CK). In 1 cohort of 22 patients, 5 (23%) had elevations in blood pressure, of whom 4 discontinued [<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>]. Two of the patients had symptomatic hypertension: one presented with headache and required two antihypertensives to manage her blood pressure before LUM/IVA was stopped, and the second had a hypertensive emergency that onset within 12 h of his first LUM/IVA dose (notably, he was initiated at one-quarter dose due to a drug&#x2013;drug interaction with posaconazole) [<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>]. One of the patients with asymptomatic hypertension remained above his baseline blood pressure even after LUM/IVA discontinuation [<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>]. In a cohort of 30 patients admitted to hospital for LUM/IVA initiation, 1 (3%) discontinued due to hypertension; the onset of the hypertension was seemingly quick, as it occurred before the patient was discharged from hospital [<xref rid="B37-jcm-10-00023" ref-type="bibr">37</xref>]. An elevation in CK was reported in a large cohort study wherein 20 (2%) patients had a CK greater than five times the upper limit of normal, and five (0.6%) had to discontinue LUM/IVA due to a CK greater than 10 times the upper limit of normal accompanied by myalgia [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>]. One case report also describes an adult male who experienced rhabdomyolysis with a CK upwards of 17,000 U/L, attributed to a drug&#x2013;drug interaction between LUM/IVA and acyclovir; despite normalization of the CK following discontinuation of both LUM/IVA and acyclovir, lower limb myalgia persisted [<xref rid="B92-jcm-10-00023" ref-type="bibr">92</xref>].</p>
          <p>Headache and fatigue were reported relatively often overall but were not a common cause of LUM/IVA discontinuation [<xref rid="B25-jcm-10-00023" ref-type="bibr">25</xref>,<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>,<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>,<xref rid="B34-jcm-10-00023" ref-type="bibr">34</xref>,<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>,<xref rid="B69-jcm-10-00023" ref-type="bibr">69</xref>,<xref rid="B73-jcm-10-00023" ref-type="bibr">73</xref>,<xref rid="B76-jcm-10-00023" ref-type="bibr">76</xref>]. Menstrual irregularities and menorrhagia were reported infrequently but did result in discontinuation of LUM/IVA&#x2014;the former in one patient who also discontinued due to worsening anxiety [<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>], and the latter in three individuals (0.4%) in a large cohort [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>]. Uncommon AEs of note were cataracts, which prompted discontinuation in one individual [<xref rid="B60-jcm-10-00023" ref-type="bibr">60</xref>]; one case each of bradycardia and tachycardia, the latter of which prompted discontinuation [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>,<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>]; and a case of acute myelocytic leukemia (AML) post-partum [<xref rid="B27-jcm-10-00023" ref-type="bibr">27</xref>]. The authors of the case series reporting AML deemed it likely an unfortunate coincidence, unrelated to LUM/IVA [<xref rid="B27-jcm-10-00023" ref-type="bibr">27</xref>].</p>
        </sec>
        <sec id="sec3dot3dot3-jcm-10-00023">
          <title>3.3.3. Tezacaftor/Ivacaftor (TEZ/IVA)</title>
          <p>Limited data were available regarding real-world AEs with TEZ/IVA. Notable were neuropsychiatric AEs. In a cohort of 44 adults, 5 (11%) experienced neuropsychiatric AEs: out of body experience and visual hallucination; depersonalization and &#x201C;brain fog&#x201D;; severe migraine; and sleep pattern disturbance, which occurred in 2 individuals [<xref rid="B88-jcm-10-00023" ref-type="bibr">88</xref>]. The two individuals with sleep pattern disturbance remained on TEZ/IVA, but the remaining three individuals changed back to LUM/IVA and had resolution of symptoms thereafter [<xref rid="B88-jcm-10-00023" ref-type="bibr">88</xref>]. Another cohort study reported discontinuation due to unspecified mental health changes; the frequency was not reported [<xref rid="B86-jcm-10-00023" ref-type="bibr">86</xref>].</p>
          <p>A case study described morbilliform drug eruption that recurred on retrial of TEZ/IVA and resolved upon discontinuation; however, IVA was deemed the likely cause of the reaction, and after a stepwise desensitization to IVA the patient was able to resume TEZ/IVA [<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>]. One other cohort reported rash in two (9%) individuals that did not require discontinuation [<xref rid="B39-jcm-10-00023" ref-type="bibr">39</xref>]. Liver enzyme abnormalities or elevations resulted in TEZ/IVA discontinuation in two cohort studies [<xref rid="B86-jcm-10-00023" ref-type="bibr">86</xref>,<xref rid="B87-jcm-10-00023" ref-type="bibr">87</xref>], while hair loss and fatigue, and blurred vision were the cause of TEZ/IVA discontinuation in one individual each [<xref rid="B39-jcm-10-00023" ref-type="bibr">39</xref>,<xref rid="B89-jcm-10-00023" ref-type="bibr">89</xref>]. Acholic stools, persistent nausea and vomiting, changes in blood glucose, and new-onset hemoptysis were also reported to require discontinuation of TEZ/IVA, but the frequency was not specified [<xref rid="B86-jcm-10-00023" ref-type="bibr">86</xref>].</p>
          <p>One case report describes a delayed suspected drug&#x2013;drug interaction between TEZ/IVA and azithromycin [<xref rid="B51-jcm-10-00023" ref-type="bibr">51</xref>]. In an adult female with no history of cardiac arrhythmia and who had been on long-term therapy with azithromycin prior to TEZ/IVA initiation, an electrocardiogram (ECG) at 36 weeks of concomitant therapy revealed first-degree heart block (PR interval of 334 ms); ECGs at baseline and 4, 12, and 24 weeks after initiating TEZ/IVA were normal [<xref rid="B51-jcm-10-00023" ref-type="bibr">51</xref>]. The first-degree heart block resolved by four weeks after discontinuation of TEZ/IVA, and therapy was retrialed eight months later. Baseline and follow-up ECGs at 4, 8, 12, and 24 weeks were normal, but an ECG at 39 weeks revealed recurrence of the first-degree heart block (PR interval of 215 ms) [<xref rid="B51-jcm-10-00023" ref-type="bibr">51</xref>]. Azithromycin was discontinued and the PR interval normalized by four weeks thereafter [<xref rid="B51-jcm-10-00023" ref-type="bibr">51</xref>].</p>
        </sec>
        <sec id="sec3dot3dot4-jcm-10-00023">
          <title>3.3.4. Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)</title>
          <p>Given the relatively recent market approval in some countries, limited data were available regarding real-world AEs with ELX/TEZ/IVA. One case series reported on seven adults who experienced biliary colic following initiation of ELX/TEZ/IVA; all but one patient received a cholecystectomy [<xref rid="B53-jcm-10-00023" ref-type="bibr">53</xref>]. Only one of the seven patients was CFTR modulator na&#xEF;ve prior to ELX/TEZ/IVA, and five of the patients had chronic cholecystitis and cholelithiasis [<xref rid="B53-jcm-10-00023" ref-type="bibr">53</xref>]. In those receiving a cholecystectomy, ELX/TEZ/IVA remained unchanged in four patients and was briefly held perioperatively in two patients due to severe symptoms or postoperative complications; symptoms resolved in all six [<xref rid="B53-jcm-10-00023" ref-type="bibr">53</xref>]. ELX/TEZ/IVA was held two weeks before and four weeks after the cholecystectomy in the fourth patient, and based on personal communication with the corresponding author, although symptoms of biliary colic resolved, ELX/TEZ/IVA was subsequently held due to transaminitis [<xref rid="B53-jcm-10-00023" ref-type="bibr">53</xref>].</p>
          <p>A second case series described testicular pain that onset shortly after ELX/TEZ/IVA initiation in seven males [<xref rid="B52-jcm-10-00023" ref-type="bibr">52</xref>]. For five patients, ELX/TEZ/IVA continued uninterrupted&#x2014;three had no interventions and two required over-the-counter analgesics to manage pain [<xref rid="B52-jcm-10-00023" ref-type="bibr">52</xref>]. One patient required a brief interruption in therapy and restarted at full-dose, while the final patient required a dose reduction and titration back to full-dose in addition to over-the-counter analgesics and antibiotics for epididymoorchitis and scrotal wall cellulitis [<xref rid="B52-jcm-10-00023" ref-type="bibr">52</xref>]. All patients had resolution of the testicular symptoms, and at least three patients also experienced abdominal bloating or constipation [<xref rid="B52-jcm-10-00023" ref-type="bibr">52</xref>]. Transaminitis was reported in four (36%) patients in a cohort study, but intervention was not required [<xref rid="B40-jcm-10-00023" ref-type="bibr">40</xref>].</p>
          <p>ELX/TEZ/IVA was also associated with mental health-related AE, as described in a case report of a 19-year-old female [<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>]. In the described case, the patient experienced worsening of baseline depression and sleep paralysis with hypnopompic hallucinations, and new passive suicidal ideation following initiation of ELX/TEZ/IVA [<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>]. The latter resolved upon discontinuation, but initiation of an antidepressant was necessary to improve mood [<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>]. Over the course of several months, the ELX/TEZ/IVA dose was titrated, and dosage times changed in response to worsening mood, suicidality, anxiety, and sleep paralysis. Although interpersonal conflicts may have affected symptoms, the reported symptoms were seemingly worst at the full-dose of ELX/TEZ/IVA and improved with dose reductions [<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>]. The dose eventually settled on two ELX/TEZ/IVA tabs once daily in the morning, with depression and anxiety symptoms above baseline and recurrent episodes of sleep paralysis with hypnopompic hallucinations [<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>].</p>
        </sec>
        <sec id="sec3dot3dot5-jcm-10-00023">
          <title>3.3.5. Described Strategies to Address or Mitigate Reported Adverse Events</title>
          <p>Protocols and strategies utilized in studies and/or suggestions that arose as a result of observed study outcomes are summarized in <xref rid="jcm-10-00023-t004" ref-type="table">Table 4</xref>. To minimize respiratory-related AE and risk of discontinuation with LUM/IVA, two studies implemented an initiation protocol [<xref rid="B31-jcm-10-00023" ref-type="bibr">31</xref>,<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>], while another study informally made efforts to optimize inhaled therapies in patients with ppFEV<sub>1</sub> &#x2264; 40% [<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>]. A fourth study established a desensitization protocol for IVA and transition to TEZ/IVA following recurrent morbilliform drug eruption [<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>]. The majority of suggestions that resulted from study observations pertained to LUM/IVA, primarily in relation to respiratory AE [<xref rid="B25-jcm-10-00023" ref-type="bibr">25</xref>,<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>,<xref rid="B32-jcm-10-00023" ref-type="bibr">32</xref>,<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>,<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>,<xref rid="B49-jcm-10-00023" ref-type="bibr">49</xref>,<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>,<xref rid="B75-jcm-10-00023" ref-type="bibr">75</xref>], as well as new or worsening depression and anxiety [<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>,<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>], hypertension [<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>], and the potential drug&#x2013;drug interaction with PPIs [<xref rid="B79-jcm-10-00023" ref-type="bibr">79</xref>]. Three studies provided suggestions for ELX/TEZ/IVA based on direct observations&#x2014;one each for testicular pain, biliary colic, and worsening mental health&#x2014;and a fourth based indirectly on observed delayed-onset first-degree heart block with concomitant TEZ/IVA and azithromycin [<xref rid="B51-jcm-10-00023" ref-type="bibr">51</xref>,<xref rid="B52-jcm-10-00023" ref-type="bibr">52</xref>,<xref rid="B53-jcm-10-00023" ref-type="bibr">53</xref>,<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>]. In addition to the latter study, suggestions for TEZ/IVA were provided based on observed neurocognitive AEs [<xref rid="B88-jcm-10-00023" ref-type="bibr">88</xref>]. Suggestions for IVA regarded initiation in patients with severe lung disease and monitoring of pediatric patients for cataract formation [<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>,<xref rid="B57-jcm-10-00023" ref-type="bibr">57</xref>].</p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec4-jcm-10-00023">
      <title>4. Discussion</title>
      <sec id="sec4dot1-jcm-10-00023">
        <title>4.1. Putting Real-World Adverse Events into Context</title>
        <p>The primary objective of this systematic review was to evaluate the real-world AE profile of currently-marketed CFTR modulator therapies in the treatment of people with CF, with a secondary objective of evaluating reported strategies to address or mitigate reported AEs.</p>
        <p>When interpreting the real-world AE findings in the context of clinical trial data, it is prudent to keep in mind that study populations in clinical trials are fundamentally different from real-world populations due to reasons such as strict inclusion/exclusion criteria and participants being inherently more motivated to continue with the assigned therapy [<xref rid="B93-jcm-10-00023" ref-type="bibr">93</xref>]. In clinical trials evaluating CFTR modulators, study participants were clinically stable and those with severe or minimal lung disease (i.e., ppFEV<sub>1</sub> &lt; 40% and &gt; 90%, respectively) were typically excluded or grossly underrepresented [<xref rid="B94-jcm-10-00023" ref-type="bibr">94</xref>,<xref rid="B95-jcm-10-00023" ref-type="bibr">95</xref>]. Another important consideration is the differences between observational studies and clinical trials in AE evaluation and reporting. Clinical trials have more rigorous monitoring for AEs, increasing the likelihood of identifying AEs, and AEs are reported even if not attributed to the intervention; this is demonstrated in 3 clinical trials evaluating CFTR modulators, wherein an absolute difference in the frequency of AE overall and AE deemed related to trial drug ranged from 12 to 53% within the treatment arms [<xref rid="B18-jcm-10-00023" ref-type="bibr">18</xref>,<xref rid="B22-jcm-10-00023" ref-type="bibr">22</xref>,<xref rid="B96-jcm-10-00023" ref-type="bibr">96</xref>]. That said, patients and study investigators may also be less inclined to report AEs or attribute an AE to study drug to avoid the patient being removed from the trial, especially if the patient has experienced a dramatic clinical benefit. Any relative comparisons made hereinafter are general and should be interpreted with the aforementioned considerations in mind.</p>
        <p>For IVA and LUM/IVA, the majority of reported AE were reflective of what may be expected based on the findings in clinical trials; the same comparison could not be made for TEZ/IVA and ELX/TEZ/IVA due to the limited published real-world data available. Of the four CFTR modulators, LUM/IVA was seemingly associated with a higher frequency of AE, respiratory-related AE in particular. While this observation may be due to real-world studies predominantly reporting on experience with LUM/IVA, it reflects what has also been observed in the clinical trial setting [<xref rid="B7-jcm-10-00023" ref-type="bibr">7</xref>,<xref rid="B94-jcm-10-00023" ref-type="bibr">94</xref>,<xref rid="B95-jcm-10-00023" ref-type="bibr">95</xref>]. Dyspnea and chest tightness with LUM/IVA appear to have occurred more often in real-world studies, with higher frequencies overall and of discontinuation than reported in clinical trials. This is likely due to the larger proportion of patients with severe lung disease in real-world studies. In fact, when Burgel et al. re-examined the data from their prospective cohort study [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>], they found that in patients who discontinued LUM/IVA, respiratory AE were the cause in 74% of patients with a baseline ppFEV<sub>1</sub> &lt; 40%, compared to 42% and 29% in patients with a baseline ppFEV<sub>1</sub> of 40&#x2013;90% and &#x2265; 90%, respectively [<xref rid="B97-jcm-10-00023" ref-type="bibr">97</xref>]. However, even patients with a baseline ppFEV<sub>1</sub> &#x2265; 40% had overall LUM/IVA discontinuation rates upwards of threefold higher than in the clinical trial setting [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>]. Moreover, in the TRAFFIC/TRANSPORT trials, while the frequency of dyspnea was higher in the pooled LUM/IVA group compared to placebo overall, the frequency in study participants with a baseline ppFEV<sub>1</sub> &lt; 40% was approximately twice that of those with a baseline ppFEV<sub>1</sub> &#x2265; 40% [<xref rid="B98-jcm-10-00023" ref-type="bibr">98</xref>]. It should be noted that although there is greater reporting of respiratory-related AEs in patients with more advanced lung disease on LUM/IVA, asymptomatic acute drops in ppFEV<sub>1</sub> were also common in pediatric patients with milder lung disease [<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>,<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>].</p>
        <p>The mechanism behind the respiratory-related AE reported for LUM/IVA has not been fully elucidated but is unlikely explained by CFTR modulation alone as it has not been described with other more effective CFTR modulators. Furthermore, this effect is likely specific to LUM as it was not described with IVA monotherapy. Bronchoconstriction is a likely contributor, with the mitigation of respiratory AE observed with bronchodilators in real-world studies; this was also demonstrated in an open-label study in healthy subjects, wherein administration of a short-acting bronchodilator reversed the drop in ppFEV<sub>1</sub> observed at 4 h post-LUM/IVA dose, and long-acting bronchodilator administered 12 h pre-dose diminished the drop in ppFEV<sub>1</sub> [<xref rid="B99-jcm-10-00023" ref-type="bibr">99</xref>]. The incidence of respiratory-related AE with LUM/IVA is seemingly highest around initiation of therapy, justifying suggestions to initiate at lower doses, especially in those with lower lung function. Despite efforts to optimize inhaled therapy and initiate LUM/IVA at lower doses for at least a week in patients with ppFEV<sub>1</sub> &#x2264; 40%, Jennings et al. [<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>] still observed higher frequencies of respiratory-related AE in this subgroup; however, it is possible the frequency would have been higher without these precautions, which was the case in an open-label study of LUM/IVA by Taylor-Cousar et al. [<xref rid="B100-jcm-10-00023" ref-type="bibr">100</xref>]. In this study involving patients with advanced CF lung disease, treating physicians were permitted to initiate patients at half-dose for up to 15 days and titrate thereafter to full-dose; those initiated at half-dose had a lower incidence and duration of respiratory-related AE, and unlike those initiated at full-dose, respiratory-related AE did not necessitate discontinuation or dose modification of LUM/IVA in those initiated at half-dose [<xref rid="B100-jcm-10-00023" ref-type="bibr">100</xref>]. Moreover, Murer et al. [<xref rid="B31-jcm-10-00023" ref-type="bibr">31</xref>] attributed the relatively low frequency of discontinuation due to respiratory-related AE in their single-center study of patients with severe CF-related lung disease to their step-wise LUM/IVA initiation protocol. Burgel et al. [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>] reported higher discontinuation rates in those who initiated LUM/IVA at a reduced dose instead of full dose (25% vs. 17.3%, respectively), but this difference was not statistically significant and the majority of patients initiating at lower doses were due to potential drug interactions, not necessarily precautions due to low lung function. Further, in the case that lower initiation doses were utilized in patients deemed higher risk for respiratory-related AE, the higher discontinuation rate could be a reflection of confounding by indication.</p>
        <p>When considering the factors found to be associated with increased risk for AE or discontinuation of LUM/IVA, increased risk of respiratory AE and discontinuation due to AE in patients with lower lung function is expected from what has been observed in the literature. Accordingly, so is more frequent need for IV antibiotics, which may be a reflection of more advanced lung disease, as well as CF-related diabetes and low BMI, as both are correlated and associated with worse pulmonary function [<xref rid="B101-jcm-10-00023" ref-type="bibr">101</xref>,<xref rid="B102-jcm-10-00023" ref-type="bibr">102</xref>]. Older age as a risk factor may also be a reflection of lower lung function by nature of CF being a progressive disease over time, but the basis of female sex as a risk factor is unclear, and the authors too could not rationalize why this was observed [<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>]. With bronchoconstriction as a likely contributing mechanism in LUM/IVA respiratory-related AE, reversible airway obstruction &#x2265;12% as a risk factor is also justifiable, and although the studies evaluating asthma with or without atopy did not report on statistical significance, the sample sizes were likely too small to detect one [<xref rid="B67-jcm-10-00023" ref-type="bibr">67</xref>,<xref rid="B77-jcm-10-00023" ref-type="bibr">77</xref>].</p>
        <p>Rash was not uncommon, reported in real-world studies for each of IVA, LUM/IVA, and TEZ/IVA, with few individuals requiring interruption or discontinuation of therapy for rash or allergic reactions. Similar was seen in clinical trials, with cases of rash being reported for all four CFTR modulators, and serious rash or discontinuation due to rash being reported for ELX/TEZ/IVA [<xref rid="B22-jcm-10-00023" ref-type="bibr">22</xref>,<xref rid="B23-jcm-10-00023" ref-type="bibr">23</xref>,<xref rid="B103-jcm-10-00023" ref-type="bibr">103</xref>] and LUM/IVA [<xref rid="B19-jcm-10-00023" ref-type="bibr">19</xref>,<xref rid="B104-jcm-10-00023" ref-type="bibr">104</xref>]. Anecdotally at our site, one case of suspected anaphylaxis occurred following the first dose of TEZ/IVA; no CFTR modulators have ever been retrialed in this patient. Given no additional information regarding the suspected case of SJS was provided [<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>], it is not possible to evaluate whether it was potentially attributable to LUM/IVA; however, with the report of the severe delayed CD4+ lymphocyte-mediated reaction to LUM/IVA [<xref rid="B50-jcm-10-00023" ref-type="bibr">50</xref>], the possibility for SJS and other severe Type-IV (i.e., delayed) hypersensitivity reactions to CFTR modulators is not inconceivable. Unlike the described morbilliform drug reaction with successful desensitization to IVA [<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>], it would be inappropriate to attempt desensitization to these more serious delayed hypersensitivity reactions [<xref rid="B105-jcm-10-00023" ref-type="bibr">105</xref>]. In a phase 3 clinical trial of ELX/TEZ/IVA, the incidence of rash was highest in females, particularly those on hormonal contraceptives [<xref rid="B23-jcm-10-00023" ref-type="bibr">23</xref>]; the basis of the increased incidence of rash in either of these subgroups is unclear.</p>
        <p>An important signal of AE identified in the real-world studies that were uncommon or not reported in the clinical trials was related to mental health and neurocognitive or neuropsychiatric events. Though evidence-based interventions were also implemented in several cases, discontinuation or dose adjustment of the CFTR modulator seemingly resulted in symptom improvement for some individuals [<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>,<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>,<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>]. In PERSIST, the open-label extension study of the STRIVE and ENVISION trials, one study participant discontinued IVA due to depression and one suicide occurred; the latter was deemed unlikely related to IVA [<xref rid="B106-jcm-10-00023" ref-type="bibr">106</xref>]. Serious AE reported in one individual each were affective disorder, depression, major depression, suicidal ideation, and suicidal depression, but whether or not these were attributable to IVA was not stated [<xref rid="B106-jcm-10-00023" ref-type="bibr">106</xref>]. Though not published in the original manuscripts, McKinzie et al. [<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>] reported that a number of cases of depression, depressed mood, or anxiety were reported in the TRAFFIC/TRANSPORT trials and PROGRESS extension study for LUM/IVA; for two participants in the TRAFFIC/TRANSPORT trials the symptoms were reportedly considered related to study drug, but this was not specified for the PROGRESS study. Though causation cannot be attributed to CFTR modulators it is prudent to consider the potential for these medications to affect mental health outcomes, as depression has been associated with accelerated lung function decline in adolescents and adults with CF [<xref rid="B107-jcm-10-00023" ref-type="bibr">107</xref>] as well as increased five-year mortality in adults with CF, particularly in those with severe depression [<xref rid="B108-jcm-10-00023" ref-type="bibr">108</xref>]. Indeed, in three of the reported cases there was significant lung function decline following worsening mental health with LUM/IVA, potentially due to the negative impact of mood on adherence to maintenance therapies [<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>]. The mechanism by which CFTR modulators may impact mental health is not well-understood; induction of cytochrome P450 (CYP) enzymes by LUM and resultant decreased exposure to substrate psychotropic medications is one potential contributor [<xref rid="B9-jcm-10-00023" ref-type="bibr">9</xref>,<xref rid="B109-jcm-10-00023" ref-type="bibr">109</xref>], but this does not account for the other CFTR modulators which do not share this drug&#x2013;drug interaction or individuals who do not have a known history of mental health concerns and/or who are not on a psychotropic medication.</p>
        <p>A potential mechanism by which ELX/TEV/IVA (or other CFTR modulators) may trigger biliary colic was hypothesized by Safirstein et al. [<xref rid="B53-jcm-10-00023" ref-type="bibr">53</xref>]; restoring CFTR function in the biliary epithelium will cause changes in the fluidity and acidity of bile fluids, which may result in mobilization of existing gallstones and precipitation of biliary colic. This hypothesis has merit, given the underlying pathophysiology of CF-related hepatobiliary disease [<xref rid="B110-jcm-10-00023" ref-type="bibr">110</xref>]. That restoration of CFTR function may also dislodge mucus blockages from the testes and/or vas deferens was posed by Rotolo et al. [<xref rid="B52-jcm-10-00023" ref-type="bibr">52</xref>] as a potential the mechanism behind testicular pain in males following initiation of ELX/TEZ/IVA. One serious AE that was not mentioned in the included real-world studies but warrants discussion is distal intestinal obstruction syndrome (DIOS). DIOS has been reported in clinical trials for all four CFTR modulators, albeit at a low frequency [<xref rid="B15-jcm-10-00023" ref-type="bibr">15</xref>,<xref rid="B18-jcm-10-00023" ref-type="bibr">18</xref>,<xref rid="B19-jcm-10-00023" ref-type="bibr">19</xref>,<xref rid="B96-jcm-10-00023" ref-type="bibr">96</xref>,<xref rid="B103-jcm-10-00023" ref-type="bibr">103</xref>,<xref rid="B106-jcm-10-00023" ref-type="bibr">106</xref>,<xref rid="B111-jcm-10-00023" ref-type="bibr">111</xref>,<xref rid="B112-jcm-10-00023" ref-type="bibr">112</xref>,<xref rid="B113-jcm-10-00023" ref-type="bibr">113</xref>,<xref rid="B114-jcm-10-00023" ref-type="bibr">114</xref>]. Although DIOS may be secondary to the underlying CF itself, there is a plausible mechanism for how DIOS may be of concern with the CFTR modulators, particularly at the time of initiation. Chronic constipation is not uncommon in CF, with viscous intestinal mucus and gastrointestinal dysmotility resulting in undigested food adhering to the intestinal walls [<xref rid="B115-jcm-10-00023" ref-type="bibr">115</xref>]. Theoretically then, with initiation of a highly effective CFTR modulator and resultant hydration of viscous intestinal mucus, fecal matter may detach from the luminal wall and begin to move along the bowels simultaneously, increasing the potential for DIOS. Abdominal pain is a symptom of DIOS and can be for constipation as well [<xref rid="B115-jcm-10-00023" ref-type="bibr">115</xref>]; therefore, abdominal pain reported in real-world studies, particularly cases that were severe and/or warranted interruption or discontinuation of therapy, may have been in relation to sudden increased fecal transit. More information, such as timing of onset, location and quality of abdominal pain, findings on physical assessment and imaging, would be necessary to evaluate this possibility.</p>
        <p>Although CFTR is expressed in cervical epithelium and plays a role in hydration of cervical mucus throughout the menstrual cycle [<xref rid="B116-jcm-10-00023" ref-type="bibr">116</xref>], this does not explain the menstrual abnormalities reported with LUM/IVA in real-world studies. In the phase 3 clinical trial setting, menstrual abnormalities reportedly occurred more frequently in female participants treated with LUM/IVA compared to placebo, with an even higher frequency in the subgroup of participants taking hormonal contraceptives [<xref rid="B9-jcm-10-00023" ref-type="bibr">9</xref>]. This observation is very likely due to the induction of CYP3A and UDP-glucuronosyltransferase (UGT) enzymes by LUM, increasing the metabolism of and decreasing exposure to particular hormones in some hormonal contraceptive formulations [<xref rid="B9-jcm-10-00023" ref-type="bibr">9</xref>]; this induction is not observed with other CFTR modulators, nor is the increased frequency of menstrual abnormalities. It was not specified whether the females in the real-world studies who experienced menstrual abnormalities were taking hormonal contraceptives, but this drug&#x2013;drug interaction is a possible explanation.</p>
        <p>Elevations in blood pressure were reported in the phase 3 clinical trials for LUM/IVA. At the end of the 96-week open-label extension of the TRAFFIC/TRANSPORT trials, study participants who continued on LUM/IVA 400 mg/250 mg every 12 h after or who rolled over to this regimen from placebo had mean absolute increases from baseline systolic blood pressure (SBP) of 5.9 mmHg and 5.1 mmHg, respectively, and mean absolute increases from baseline diastolic blood pressure (DBP) of 4.4 mmHg and 4.1 mmHg, respectively [<xref rid="B113-jcm-10-00023" ref-type="bibr">113</xref>]. Moreover, one serious AE related to hypertension was reported in each of the TRAFFIC/TRANSPORT and PROGRESS trials [<xref rid="B113-jcm-10-00023" ref-type="bibr">113</xref>]. A recent case report describes a six-year-old boy with CF whose intermittently-elevated blood pressure became persistently elevated (&gt; 99th percentile for his age) after just two doses of LUM/IVA [<xref rid="B117-jcm-10-00023" ref-type="bibr">117</xref>]. Upon further investigation, posaconazole, initiated about two weeks prior to the first documented incidence of hypertension, was deemed the likely culprit through inhibition of 11&#x3B2;-hydroxylase and resultant accumulation of mineralocorticoid precursors [<xref rid="B117-jcm-10-00023" ref-type="bibr">117</xref>]. Interestingly, the individual in the real-world study who experienced a hypertensive emergency 12 h after his first LUM/IVA dose had been on posaconazole for five months prior, and, subjectively, his baseline blood pressure before LUM/IVA was relatively high (157/85 mmHg) [<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>]. Therefore, posaconazole and LUM independently may contribute to elevations in blood pressure, with more rapid elevations when used in combination. Elevations in blood pressure were also observed in the phase 3 study of ELX/TEZ/IVA, with mean absolute changes from baseline SBP of 3.1 mmHg and &#x2212;0.1 mmHg in the ELX/TEZ/IVA and placebo groups at 24 weeks, respectively, and mean absolute changes from baseline DBP of 1.9 mmHg and 0.3 mmHg, respectively [<xref rid="B23-jcm-10-00023" ref-type="bibr">23</xref>]. It has been hypothesized that people with CF have lower blood pressure when compared to age- and sex-matched controls due to salt wasting [<xref rid="B118-jcm-10-00023" ref-type="bibr">118</xref>]; with increased CFTR function and diminished salt wasting, it may then be expected for elevations in blood pressure to occur with these agents. That said, the elevations in blood pressure are not seemingly a class effect and a greater increase in blood pressure was not observed with highly-effective CFTR modulators, as would have been expected. Single cases each of tachycardia and bradycardia were reported, but only the latter is reflective of other available information. Statistically significant decreases in heart rate were reportedly observed with LUM/IVA over placebo in the clinical trial setting, with a greater proportion of patients in the LUM/IVA group having heart rates &lt; 50 beats per minute (bpm) [<xref rid="B9-jcm-10-00023" ref-type="bibr">9</xref>]. Whether these changes were clinically significant cannot be determined from the information available, but the single case of bradycardia reported was asymptomatic [<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>]. In one study, people with CF were found to have a higher baseline heart rate when compared to healthy controls [<xref rid="B119-jcm-10-00023" ref-type="bibr">119</xref>]; therefore, correction of CFTR function may theoretically reduce heart rate. However, again, this heart rate-lowering effect is seemingly unique to LUM/IVA.</p>
        <p>CK elevations have been reported in clinical trials for all four CFTR modulators, with some cases being serious enough to warrant interruption or discontinuation [<xref rid="B18-jcm-10-00023" ref-type="bibr">18</xref>,<xref rid="B19-jcm-10-00023" ref-type="bibr">19</xref>,<xref rid="B21-jcm-10-00023" ref-type="bibr">21</xref>,<xref rid="B103-jcm-10-00023" ref-type="bibr">103</xref>,<xref rid="B114-jcm-10-00023" ref-type="bibr">114</xref>]. The clinical significance of the CK elevations observed in both the clinical trials and real-world studies is unclear. In a large population-based study, 5.3% of individuals were found to have CK levels above the upper limit of normal established by age and sex; of those who obtained a &#x201C;control&#x201D; CK after three days of refraining from specific activities that may elevate CK (e.g., alcohol use, physical activity, and muscle training), 70% had normalization of CK values [<xref rid="B120-jcm-10-00023" ref-type="bibr">120</xref>]. In four cases where the initial CK measures ranged from 5660 U/L to 15,941 U/L, the individuals had participated in significant physical activity and all had normalization of CK in their subsequent &#x201C;control&#x201D; test [<xref rid="B120-jcm-10-00023" ref-type="bibr">120</xref>]. One clinical trial specified the CK elevations observed in both the placebo and ELX/TEZ/IVA groups were associated with exercise [<xref rid="B23-jcm-10-00023" ref-type="bibr">23</xref>]; the frequency of CK elevations were 10% and 5% in the ELX/TEZ/IVA and placebo groups, respectively, perhaps reflecting that those receiving active therapy had greater capacity to be physically active. CFTR protein is expressed in peripheral muscular tissue and has been studied as a potential contributor to CF-related muscle abnormalities such as atrophy and weakness [<xref rid="B121-jcm-10-00023" ref-type="bibr">121</xref>]; whether this too may explain some of the observed CK elevations with CFTR modulators is unclear.</p>
        <p>An important consideration to keep in mind is the potential for erroneous attribution of AEs to medication; assignment of causality is subjective, and it is not uncommon for clinicians to inadvertently ascribe an AE to a medication in error, as is readily observed in placebo-controlled trials [<xref rid="B122-jcm-10-00023" ref-type="bibr">122</xref>]. Moreover, while rare and unexpected AE may occur, a number of the AE reported in one or few individuals receiving CFTR modulators in the real-world studies did not have a clear pharmacokinetic or pharmacodynamic basis. Examples include dysphagia, pericarditis, worsening restless leg syndrome, swollen ear, tinnitus, secondary adrenal cortical insufficiency, and AML. Similar can be said for the single case of delayed onset first-degree heart block observed with concomitant TEZ/IVA and azithromycin reported [<xref rid="B51-jcm-10-00023" ref-type="bibr">51</xref>]. Phase 3 clinical trials were significantly shorter than the upwards of eight months that it took for this drug interaction to be observed; however, available preliminary data for the open-label phase 3 rollover study for TEZ/IVA indicate this drug&#x2013;drug interaction was not detected within the 100 weeks of total follow-up time [<xref rid="B114-jcm-10-00023" ref-type="bibr">114</xref>]. Additionally important is the potential for reported AE to be secondary to CF itself, such as pulmonary exacerbation, hemoptysis, pneumothorax, and respiratory failure, especially in patients with lower levels of lung function.</p>
      </sec>
      <sec id="sec4dot2-jcm-10-00023">
        <title>4.2. Role of the CF Pharmacist in the Safe Prescribing of CFTR Modulators</title>
        <p>As described, there are a number of potential AEs to be aware of with CFTR modulators. Although the safe initiation and monitoring of patients on CFTR modulators is a shared responsibility within a multidisciplinary CF team, pharmacists play an integral role. The following are highlights of pharmacists&#x2019; role in this, with additional suggestions and insights from the findings of this review.</p>
        <sec id="sec4dot2dot1-jcm-10-00023">
          <title>4.2.1. Selection of a CFTR Modulator</title>
          <p>Depending on an individual&#x2019;s <italic>CFTR</italic> genotype, there may be more than one CFTR modulator that he or she is eligible for. Efficacy outcomes aside, pharmacists can provide guidance into how the AE and drug&#x2013;drug interaction profile of each CFTR modulator differs and may impact selection based on patient-specific factors. For example, LUM/IVA is not a favorable alternative in general for individuals who are homozygous for the <italic>F508del</italic> mutation with severe lung disease (i.e., ppFEV<sub>1</sub> &lt; 40%) and/or reactive airway disease due to the high frequency of respiratory-related AE and associated discontinuation. Moreover, due to the induction of CYP and UGT enzymes, LUM is prone to a myriad of drug&#x2013;drug interactions [<xref rid="B9-jcm-10-00023" ref-type="bibr">9</xref>,<xref rid="B109-jcm-10-00023" ref-type="bibr">109</xref>]; pharmacists can help navigate which drug&#x2013;drug interactions are clinically significant and warrant avoidance in favor of an alternative CFTR modulator when possible. Selection may be limited, however, when CFTR modulators are not accessible (e.g., due to lack of regulatory approval, or exclusion from formularies of eligible public or private healthcare benefits).</p>
        </sec>
        <sec id="sec4dot2dot2-jcm-10-00023">
          <title>4.2.2. Patient Counseling and Education</title>
          <p>Before patients are initiated on CFTR modulators, pharmacists can provide the necessary counseling and education. Patients who are informed about potential AEs in advance may be more willing to trial a new medication [<xref rid="B123-jcm-10-00023" ref-type="bibr">123</xref>,<xref rid="B124-jcm-10-00023" ref-type="bibr">124</xref>], especially if strategies to address potential AEs are provided [<xref rid="B123-jcm-10-00023" ref-type="bibr">123</xref>]. Anecdotally, this has been true at our site: some patients have expressed hesitancy and concern about potential AEs secondary to CFTR modulators, but once monitoring and strategies to address potential AE were discussed, they were more open to a trial. Similarly, some patients at our site were reluctant to obtain baseline and follow-up assessments, such as blood work or imaging, but were amenable once educated about the rationale (i.e., to ensure appropriate monitoring of both the safety and effectiveness of the medication).</p>
          <p>It goes without saying that patients should be advised to inform their CF healthcare providers if new or changing symptoms arise, even if presenting as an expected AE, as it can be difficult to distinguish between something minor or self-limiting and something requiring timely attention. An example of this is increased respiratory secretions in the short-term following CFTR modulator initiation, often referred to as &#x201C;the purge&#x201D;. Though expected, increased respiratory secretions may also be manifest of a pulmonary exacerbation; the differentiation may be even more difficult with LUM/IVA due to additional respiratory AEs such as dyspnea, chest tightness, and declines in lung function.</p>
          <p>Further salient is education regarding the potential for withdrawal syndrome upon discontinuation of CFTR modulators. There are several reports of patients experiencing clinical decline and/or pulmonary exacerbations upon discontinuation of a CFTR modulator, even requiring IV antibiotics in the community or hospital setting in some cases [<xref rid="B27-jcm-10-00023" ref-type="bibr">27</xref>,<xref rid="B125-jcm-10-00023" ref-type="bibr">125</xref>,<xref rid="B126-jcm-10-00023" ref-type="bibr">126</xref>,<xref rid="B127-jcm-10-00023" ref-type="bibr">127</xref>,<xref rid="B128-jcm-10-00023" ref-type="bibr">128</xref>,<xref rid="B129-jcm-10-00023" ref-type="bibr">129</xref>,<xref rid="B130-jcm-10-00023" ref-type="bibr">130</xref>,<xref rid="B131-jcm-10-00023" ref-type="bibr">131</xref>]. Therefore, patients should be informed to notify the CF healthcare providers if considering discontinuation of a CFTR modulator so that a plan to do so safely and with close monitoring can be established, and also to ensure refills are requested in advance to avoid lapses in therapy.</p>
        </sec>
        <sec id="sec4dot2dot3-jcm-10-00023">
          <title>4.2.3. Initiation and Monitoring Plan</title>
          <p>Establishing patients&#x2019; baseline for parameters such as spirometry, blood work, vital signs, weight, and BMI, as well as clinical status for CF-related comorbidities is essential in monitoring for a number of the described AE following initiation of CFTR modulators. Pharmacists can also contribute to safe initiation and follow-up of CFTR modulators beyond these routine parameters.</p>
          <p>Respiratory AE: The respiratory AE with LUM/IVA are well-established, but in cases where better-tolerated alternatives are not accessible, pharmacists can help establish an initiation plan to mitigate these AE. Insight and recommendations gleaned from the real-world studies are summarized in <xref rid="jcm-10-00023-t004" ref-type="table">Table 4</xref>; although the majority of suggestions pertain to patients with severe lung disease, they may still benefit patients with higher lung function. Prior to LUM/IVA initiation, pharmacists can optimize patients&#x2019; pre-existing inhaled corticosteroid and bronchodilator therapies as well as establish a titration schedule. The titration schedule utilized by Murer et al. [<xref rid="B31-jcm-10-00023" ref-type="bibr">31</xref>] was the most conservative, starting with just one tablet (one-quarter dose) and increasing to the target dose of two tablets twice daily over several days to weeks, depending on whether patients experienced AEs. Given that CFTR modulator therapy is intended to be long-term and LUM/IVA-related respiratory AE were predominantly reported in the initial weeks of therapy, a &#x201C;start low, go slow&#x201D; approach is reasonable. Further advisable is having patients in a closely-monitored clinic or inpatient setting at least for their first dose, with bronchodilators readily available. At our site, pre-treatment with a course of oral or IV antibiotics has also been a strategy to optimize lung health and minimize the potential for confounding in the assessment of a patient who does experience significant respiratory AE upon initiation of LUM/IVA. Walayat et al. [<xref rid="B49-jcm-10-00023" ref-type="bibr">49</xref>] suggest patients may benefit from discontinuing hypertonic saline and continuing dornase alfa while on LUM/IVA to avoid patients &#x201C;drowning&#x201D; in liquefied secretions; although, a justifiable suggestion based on their case report, this may not be the experience of all individuals started on LUM/IVA or alternative CFTR modulators, and the risks versus benefits of discontinuing hypertonic saline (or dornase alfa) must be weighed against demonstrated benefit in pulmonary outcomes [<xref rid="B132-jcm-10-00023" ref-type="bibr">132</xref>,<xref rid="B133-jcm-10-00023" ref-type="bibr">133</xref>,<xref rid="B134-jcm-10-00023" ref-type="bibr">134</xref>]. Whether it is safe to stop hypertonic saline or dornase alfa in patients on ELX/TEZ/IVA is currently under investigation [<xref rid="B135-jcm-10-00023" ref-type="bibr">135</xref>], but unlike LUM/IVA, ELX/TEZ/IVA is considered a highly effective CFTR modulator and the study results would not be generalizable. Given that respiratory AEs have not been a notable concern with IVA, TEZ/IVA, and ELX/TEZ/IVA, there may be more comfort with initiating therapy at full-dose and in the community setting. That said, based on experience at our site and as described by Hebestreit et al. [<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>], when initiating patients with severe lung disease on highly effective CFTR modulators (i.e., IVA or ELX/TEZ/IVA) it is reasonable to consider an antibiotic &#x201C;tune-up&#x201D; and/or admission for close monitoring during the initial &#x201C;purge&#x201D;. We also recommend initiating ELX/TEZ/IVA at one orange tablet in the morning and one blue tablet in the evening for the first week in patients with severe lung disease to minimize the intensity of &#x201C;the purge&#x201D;, even if transitioning from LUM/IVA or TEZ/IVA.</p>
          <p>DIOS Risk: Another potential reason our site would recommend a reduced dose of ELX/TEZ/IVA for the first week is the aforementioned concern for potential DIOS and other gastrointestinal-related AE, with the goal again being to reduce the intensity of effects at initiation. For the same reason, our site has included a bowel preparation (or abdominal X-ray to rule-out fecal loading) in the initiation protocol for ELX/TEZ/IVA; though not guided by published literature, it was felt the benefit of this intervention outweighed the risk. The pharmacist now educates patients regarding these gastrointestinal precautions and ensures completion of the preparation.</p>
          <p>Drug&#x2013;Drug Interactions with LUM: As previously mentioned, LUM is prone to drug&#x2013;drug interactions due to induction of CYP and UGT enzymes; examples of medications impacted by this include azole antifungals, select psychotropic and antiepileptic medications (e.g., citalopram, sertraline, carbamazepine, and phenytoin), hormonal contraceptives, select immunosuppressants (e.g., tacrolimus and cyclosporine), and proton pump inhibitors [<xref rid="B9-jcm-10-00023" ref-type="bibr">9</xref>,<xref rid="B109-jcm-10-00023" ref-type="bibr">109</xref>]. How and whether to address a given interaction is not always straightforward. For individuals established on interacting medications prior to LUM/IVA initiation, depending on the medication and indication, close monitoring and adjusting the dose if necessary to maintain clinical stability may be a reasonable approach in some cases, whereas therapeutic drug monitoring (TDM) and close monitoring of drug levels before and after LUM/IVA initiation may be imperative in others. Although the pharmacist on the CF healthcare team may not be involved in the management of the medication(s) potentially impacted by LUM/IVA, he or she can liaise with the healthcare provider(s) responsible so that a plan may be implemented proactively.</p>
          <p>Rash and Hypersensitivity: If a patient experiences a rash or other hypersensitivity reaction secondary to a CFTR modulator, pharmacists can work with the healthcare team to appropriately manage based on the severity and confirmed or suspected diagnosis. Anecdotally there are a myriad of approaches to managing patients who experience rash or hypersensitivity reactions, such as holding therapy until resolved then rechallenging (if appropriate), use of one or more medications (e.g., first- or second-generation antihistamines, topical corticosteroids, and systemic corticosteroids) until resolution, or, as described by Patterson et al. [<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>], developing and implementing a desensitization protocol. In females taking both ELX/TEZ/IVA and hormonal contraceptives, there are recommendations to consider interruption of both therapies should rash occur, and to consider stepwise resumption as tolerated following rash resolution [<xref rid="B12-jcm-10-00023" ref-type="bibr">12</xref>]. Though these recommendations are founded on a clinical trial observation [<xref rid="B23-jcm-10-00023" ref-type="bibr">23</xref>], the basis of the association is not clear or confirmed. Pharmacists may help evaluate the risks versus benefits of interrupting or discontinuing hormonal contraceptives in females who experience rash while on ELX/TEZ/IVA, and to identify suitable contraceptive alternatives, as necessary.</p>
        </sec>
      </sec>
      <sec id="sec4dot3-jcm-10-00023">
        <title>4.3. Limitations</title>
        <p>The results of this review must be interpreted in the context of its limitations. Foremost, none of the studies had a comparator; however, even if there were a placebo or active comparator, it is possible, and not uncommon, for AEs to be misattributed to medications inadvertently [<xref rid="B122-jcm-10-00023" ref-type="bibr">122</xref>]. It is possible that reported AEs were secondary to concomitant medications, comorbid conditions, the underlying CF itself, or other unrelated causes. Furthermore, validated methods to evaluate AEs were not consistently utilized. For example, in the case reports and case series describing changes in mental health and neuropsychiatric AEs following CFTR modulator initiation, in only one of the described cases was use of a validated tool (the GAD-7) reported [<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>,<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>,<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>]. This has the potential to overestimate AEs by misclassifying subjectively-reported symptoms, or underestimate AEs, as patients who do not self-report symptoms and are otherwise not evaluated regarding specific symptoms may go undetected. Similarly, safety was not a primary outcome for over one third of the studies available as full manuscripts; without systematic evaluation, it is possible AEs went undetected.</p>
        <p>In addition to differences in the methodology for AE assessment, there was significant heterogeneity in both the size and characteristics of the patient populations across the included studies. As observed in this review and in the clinical trial setting, certain patient characteristics may be associated with a higher risk of particular AEs, and with smaller sample sizes, each individual AE results in a larger incremental change in the reported overall AE frequency. Therefore, the reported frequencies are not generalizable and must be interpreted in the context of the individual studies.</p>
        <p>Although a robust search strategy was utilized in this systematic review, it is possible that relevant literature was missed. The majority of included studies were in the form of conference abstracts, which inherently do not include sufficient detail to assess the study quality or methodology for evaluating AEs. However, it was felt that exclusion of conference abstracts would risk missing potential signals for AEs that were not otherwise reported in the literature. Finally, a number of studies did not specify or clearly describe all of the AEs reported and/or did not specify the frequency of each AE within the study population, limiting the ability to more accurately characterize the CFTR modulator AE profiles.</p>
      </sec>
    </sec>
    <sec sec-type="conclusions" id="sec5-jcm-10-00023">
      <title>5. Conclusions</title>
      <p>As a growing number of people with CF gain access to CFTR modulators, it is prudent for healthcare providers to be aware of potential AEs as well as approaches for prevention and/or management to optimize patient safety. While the studies included in this review add value to the growing collective knowledge of potential AEs associated with CFTR modulators, this review also highlights the need for a systematic, comprehensive approach to monitoring for AEs in patients on these medications. It is also imperative that CF centers continue to share and publish their real-world experiences with patients on CFTR modulators to help better understand the potential short- and long-term AEs with these medications as well as patient characteristics that may be associated with higher risk of certain AEs. With this knowledge and their unique expertise within the CF healthcare team, pharmacists can play a key role in the safe initiation of people with CF on CFTR modulator therapy, as well as monitoring for and managing AEs that may arise thereafter.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Publisher&#x2019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <notes>
      <title>Author Contributions</title>
      <p>Conceptualization, R.V.E.D., V.C.S., and B.S.Q.; methodology, R.V.E.D., V.C.S., and B.S.Q.; writing&#x2014;original draft preparation, R.V.E.D.; writing&#x2014;review and editing, R.V.E.D., V.C.S., and B.S.Q.; supervision, B.S.Q. All authors have read and agreed to the published version of the manuscript.</p>
    </notes>
    <notes>
      <title>Funding</title>
      <p>This research received no external funding</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest</p>
    </notes>
    <app-group>
      <app id="app1-jcm-10-00023">
        <title>Appendix A. Search Terms and Boolean Operators Used in Medline and Embase Electronic Databases</title>
        <p>MEDLINE:<list list-type="order"><list-item><p>exp Cystic Fibrosis Transmembrane Conductance Regulator/or CFTR modulator*.mp.</p></list-item><list-item><p>ivacaftor.mp.</p></list-item><list-item><p>lumacaftor.mp.</p></list-item><list-item><p>tezacaftor.mp.</p></list-item><list-item><p>elexacaftor.mp.</p></list-item><list-item><p>kalydeco.mp.</p></list-item><list-item><p>orkambi.mp.</p></list-item><list-item><p>symdeko.mp.</p></list-item><list-item><p>trikafta.mp.</p></list-item><list-item><p>VX-770.mp.</p></list-item><list-item><p>VX-445.mp.</p></list-item><list-item><p>VX-809.mp.</p></list-item><list-item><p>VX-661.mp.</p></list-item><list-item><p>adverse event*.mp.</p></list-item><list-item><p>side effect*.mp. or exp Treatment Outcome/</p></list-item><list-item><p>phase IV.mp.</p></list-item><list-item><p>phase 4.mp.</p></list-item><list-item><p>adverse reaction*.mp.</p></list-item><list-item><p>toxicity.mp.</p></list-item><list-item><p>toxicities.mp.</p></list-item><list-item><p>exp Product Surveillance, Postmarketing/or pharmacovigilance.mp. or exp Pharmacovigilance/or exp &#x201C;Drug-Related Side Effects and Adverse Reactions&#x201D;/or exp Adverse Drug Reaction Reporting Systems/</p></list-item><list-item><p>post-marketing.mp.</p></list-item><list-item><p>tolerability.mp.</p></list-item><list-item><p>exp Drug Tolerance/or tolerance.mp.</p></list-item><list-item><p>harm*.mp</p></list-item><list-item><p>complication*.mp.</p></list-item><list-item><p>drug safety.mp.</p></list-item><list-item><p>drug hypersensitivity.mp. or exp Drug Hypersensitivity/</p></list-item><list-item><p>14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28</p></list-item><list-item><p>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13</p></list-item><list-item><p>29 and 30</p></list-item></list></p>
        <p>EMBASE:<list list-type="order"><list-item><p>exp cystic fibrosis transmembrane conductance regulator/or CFTR modulator *.mp.</p></list-item><list-item><p>exp ivacaftor plus tezacaftor/or exp ivacaftor/or exp ivacaftor plus lumacaftor/or exp elexacaftor plus ivacaftor plus tezacaftor/or ivacaftor.mp.</p></list-item><list-item><p>tezacaftor.mp. or exp tezacaftor/</p></list-item><list-item><p>exp lumacaftor/or lumacaftor.mp.</p></list-item><list-item><p>exp elexacaftor/or elexacaftor.mp.</p></list-item><list-item><p>kalydeco.mp.</p></list-item><list-item><p>orkambi.mp.</p></list-item><list-item><p>symdeko.mp.</p></list-item><list-item><p>symkevi.mp.</p></list-item><list-item><p>trikafta.mp.</p></list-item><list-item><p>VX-770.mp.</p></list-item><list-item><p>VX-445.mp.</p></list-item><list-item><p>VX-809.mp.</p></list-item><list-item><p>VX-661.mp.</p></list-item><list-item><p>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14</p></list-item><list-item><p>exp adverse event/or adverse event*.mp. or exp adverse drug reaction/</p></list-item><list-item><p>exp side effect/or side effect*.mp.</p></list-item><list-item><p>adverse reaction*.mp. or exp drug hypersensitivity/</p></list-item><list-item><p>toxicity/or toxicity.mp. or exp drug toxicity/</p></list-item><list-item><p>toxicities.mp.</p></list-item><list-item><p>post-marketing.mp. or exp drug surveillance program/or exp postmarketing surveillance/</p></list-item><list-item><p>exp drug safety/or exp pharmacovigilance/or pharmacovigilance.mp.</p></list-item><list-item><p>phase 4.mp.</p></list-item><list-item><p>exp phase 4 clinical trial/or phase IV.mp.</p></list-item><list-item><p>drug tolerance.mp. or exp drug tolerance/</p></list-item><list-item><p>drug hypersensitivity.mp.</p></list-item><list-item><p>complication*.mp.</p></list-item><list-item><p>exp patient harm/or harm*.mp.</p></list-item><list-item><p>16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28</p></list-item><list-item><p>15 and 29</p></list-item></list></p>
      </app>
      <app id="app2-jcm-10-00023">
        <title>Appendix B</title>
        <table-wrap id="jcm-10-00023-t0A1" orientation="portrait" position="anchor">
          <object-id pub-id-type="pii">jcm-10-00023-t0A1_Table A1</object-id>
          <label>Table A1</label>
          <caption>
            <p>Summary of methodological ratings of included observational studies <sup>a,b</sup>.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <tbody>
              <tr>
                <td valign="middle" style="border-top:solid thin;border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<bold>Criteria</bold>
</td>
                <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>Burgel et al.</bold><bold>2020</bold> [<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>]</td>
                <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>Diab-C&#xE1;ceres et al. 2018</bold> [<xref rid="B34-jcm-10-00023" ref-type="bibr">34</xref>]</td>
                <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>Dryden et al. 2018</bold> [<xref rid="B57-jcm-10-00023" ref-type="bibr">57</xref>]</td>
                <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>Finnegan et al. 2020</bold> [<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>]</td>
                <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>Gomez-Pastrana et al. 2019</bold> [<xref rid="B56-jcm-10-00023" ref-type="bibr">56</xref>]</td>
                <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>Hebestreit et al. 2013</bold> [<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>]</td>
                <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><bold>Hubert et al.</bold><bold>2017</bold> [<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>]</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">1. Study objective clearly stated</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">2. Study population clearly defined</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">3. Participation &#x2265; 50% of eligible persons</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">4. Study subjects from same or similar population, inclusion/exclusion criteria pre-specified and uniformly applied</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">5. Sample size justification, power description, or variance and effect estimates provided</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">6. Exposure of interest measured prior to outcome assessed</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">7. Timeframe sufficient to observe association between exposure/outcome </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">8. Study examined different levels of exposure as related to outcome</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">9. Exposure measures clearly defined, valid, reliable, implemented consistently </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">10. Exposure assessed more than once</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">11. Outcome measures clearly defined, valid, reliable, implemented consistently</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">12. Outcome assessors blinded to exposure status of study subjects</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">13. Loss to follow-up &#x2264; 20%</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">14. Key potential confounders measured and adjusted statistically for impact on relationship between exposure/outcome </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<bold>Final rating</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GOOD</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GOOD</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>FAIR</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GOOD</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>FAIR</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>FAIR</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GOOD</bold>
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<bold>Criteria</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Hubert et al.</bold>
<bold>2018 [<xref rid="B58-jcm-10-00023" ref-type="bibr">58</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Jennings et al. 2017 [<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Kopp et al.</bold>
<bold>2018 [<xref rid="B59-jcm-10-00023" ref-type="bibr">59</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Labaste et al. 2017 [<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Loukou et al. 2020 [<xref rid="B60-jcm-10-00023" ref-type="bibr">60</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Murer et al.</bold>
<bold>2018 [<xref rid="B31-jcm-10-00023" ref-type="bibr">31</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Pohl et al.</bold>
<bold>2018 [<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>]</bold>
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">1. Study objective clearly stated</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">2. Study population clearly defined</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">3. Participation &#x2265; 50% of eligible persons</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">4. Study subjects from same or similar population, inclusion/exclusion criteria pre-specified and uniformly applied</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">5. Sample size justification, power description, or variance and effect estimates provided</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">6. Exposure of interest measured prior to outcome assessed</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">7. Timeframe sufficient to observe association between exposure/outcome </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">8. Study examined different levels of exposure as related to outcome</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">9. Exposure measures clearly defined, valid, reliable, implemented consistently </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">10. Exposure assessed more than once</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">11. Outcome measures clearly defined, valid, reliable, implemented consistently</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">12. Outcome assessors blinded to exposure status of study subjects</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">13. Loss to follow-up &#x2264; 20%</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">14. Key potential confounders measured and adjusted statistically for impact on relationship between exposure/outcome </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<bold>Final rating</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>FAIR</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GOOD</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>POOR</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GOOD</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>FAIR</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GOOD</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GOOD</bold>
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<bold>Criteria</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Popowicz et al. 2017 [<xref rid="B32-jcm-10-00023" ref-type="bibr">32</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sergeev et al. 2019 [<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Stalling et al. 2018 [<xref rid="B55-jcm-10-00023" ref-type="bibr">55</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Taylor-Cousar et al. 2016 [<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Tong et al. 2019 [<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Wark et al. 2019 [<xref rid="B25-jcm-10-00023" ref-type="bibr">25</xref>]</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">1. Study objective clearly stated</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">2. Study population clearly defined</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">3. Participation &#x2265; 50% of eligible persons</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">4. Study subjects from same or similar population, inclusion/exclusion criteria pre-specified and uniformly applied</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">5. Sample size justification, power description, or variance and effect estimates provided</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">6. Exposure of interest measured prior to outcome assessed</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">7. Timeframe sufficient to observe association between exposure/outcome </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">8. Study examined different levels of exposure as related to outcome</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">9. Exposure measures clearly defined, valid, reliable, implemented consistently </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">10. Exposure assessed more than once</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">11. Outcome measures clearly defined, valid, reliable, implemented consistently</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">12. Outcome assessors blinded to exposure status of study subjects</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">13. Loss to follow-up &#x2264; 20%</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">14. Key potential confounders measured and adjusted statistically for impact on relationship between exposure/outcome </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<bold>Final rating</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GOOD</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>FAIR</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>POOR</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>FAIR</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>GOOD</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>FAIR</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p><sup>a</sup> Studies were rated against the 14 criteria of the Quality Assessment for Observational Cohort and Cross-Sectional Studies from the National Institutes of Health, National Heart, Lung, and Blood Institute [<xref rid="B24-jcm-10-00023" ref-type="bibr">24</xref>] from the standpoint of AE assessment. <sup>b</sup> Only observational studies with a full manuscript were assessed for quality. <bold>AE</bold>, adverse event; <bold>CD</bold>, cannot determine; <bold>N</bold>, no; <bold>N/A</bold>, not applicable; <bold>Y</bold>, yes.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </app>
      <app id="app3-jcm-10-00023">
        <title>Appendix C</title>
        <table-wrap id="jcm-10-00023-t0A2" orientation="portrait" position="anchor">
          <object-id pub-id-type="pii">jcm-10-00023-t0A2_Table A2</object-id>
          <label>Table A2</label>
          <caption>
            <p>Summary of methodological ratings of included case series <sup>a,b</sup>.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Criteria</th>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">McKinzie et al., 2017 [<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>]</th>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nash et al., 2020 [<xref rid="B27-jcm-10-00023" ref-type="bibr">27</xref>]</th>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rotolo et al., 2020 [<xref rid="B53-jcm-10-00023" ref-type="bibr">53</xref>]</th>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Safirstein et al., 2020 [<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>]</th>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Talkwalker et al., 2017 [<xref rid="B49-jcm-10-00023" ref-type="bibr">49</xref>]</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">1. Study objective clearly stated</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">2. Study population clearly defined, using case definition</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">3. Cases consecutive</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">4. Subjects comparable</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">5. Intervention clearly described</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">6. Outcome measures clearly defined, valid, reliable, implemented consistently</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">7. Adequate length of follow-up </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">8. Statistical methods well-described</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">9. Results well-described </td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y</td>
              </tr>
              <tr>
                <td valign="middle" style="border-bottom:solid thin" align="left" rowspan="1" colspan="1">
<bold>Final rating</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Poor</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Poor</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Fair</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Good</bold>
</td>
                <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Poor</bold>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p><sup>a</sup> Studies were rated against the 9 criteria of the Quality Assessment for Case Series Studies from the National Institutes of Health, National Heart, Lung, and Blood Institute [<xref rid="B24-jcm-10-00023" ref-type="bibr">24</xref>] from the standpoint of AE assessment; <sup>b</sup> Only case series with a full manuscript were assessed for quality. <bold>AE</bold>, adverse event; <bold>CD</bold>, cannot determine; <bold>N</bold>, no; <bold>N/A</bold>, not applicable; <bold>NR</bold>, not reported; <bold>Y</bold>, yes.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </app>
    </app-group>
    <ref-list>
      <title>References</title>
      <ref id="B1-jcm-10-00023">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elborn</surname>
              <given-names>J.S.</given-names>
            </name>
          </person-group>
          <article-title>Cystic Fibrosis</article-title>
          <source>Lancet</source>
          <year>2016</year>
          <volume>388</volume>
          <fpage>2519</fpage>
          <lpage>2531</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(16)00576-6</pub-id>
          <pub-id pub-id-type="pmid">27140670</pub-id>
        </element-citation>
      </ref>
      <ref id="B2-jcm-10-00023">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sawicki</surname>
              <given-names>G.S.</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>W.M.</given-names>
            </name>
          </person-group>
          <article-title>High treatment burden in adults with cystic fibrosis: Challenges to disease self-management</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2009</year>
          <volume>8</volume>
          <fpage>91</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2008.09.007</pub-id>
          <pub-id pub-id-type="pmid">18952504</pub-id>
        </element-citation>
      </ref>
      <ref id="B3-jcm-10-00023">
        <label>3.</label>
        <element-citation publication-type="web">
          <person-group person-group-type="author">
            <collab>Cystic Fibrosis Foundation</collab>
          </person-group>
          <article-title>Your CF Care Team</article-title>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.cff.org/Care/Your-CF-Care-Team/">https://www.cff.org/Care/Your-CF-Care-Team/</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-10-12">(accessed on 12 October 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B4-jcm-10-00023">
        <label>4.</label>
        <element-citation publication-type="web">
          <person-group person-group-type="author">
            <name>
              <surname>McIntosh</surname>
              <given-names>I.D.</given-names>
            </name>
          </person-group>
          <article-title>Health Human Resources Guidelines: Minimum Staffing Standards for CF Healthcare Teams. Cystic Fibrosis Canada</article-title>
          <year>2014</year>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.cysticfibrosis.ca/uploads/cf%20care/Health-Human-Resources-Guidelines.pdf">https://www.cysticfibrosis.ca/uploads/cf%20care/Health-Human-Resources-Guidelines.pdf</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-10-12">(accessed on 12 October 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B5-jcm-10-00023">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conway</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Balfour-Lynn</surname>
              <given-names>I.M.</given-names>
            </name>
            <name>
              <surname>De Rijcke</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Drevinek</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Foweraker</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Havermans</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Heijerman</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lannefors</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Lindblad</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Macek</surname>
              <given-names>M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>European Cystic Fibrosis Society standards of care: Framework for the cystic fibrosis centre</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2014</year>
          <volume>13</volume>
          <fpage>S3</fpage>
          <lpage>S22</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2014.03.009</pub-id>
          <pub-id pub-id-type="pmid">24856776</pub-id>
        </element-citation>
      </ref>
      <ref id="B6-jcm-10-00023">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Redfern</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>A.K.</given-names>
            </name>
          </person-group>
          <article-title>Benefits of a dedicated cystic fibrosis pharmacist</article-title>
          <source>J. R. Soc. Med.</source>
          <year>2004</year>
          <volume>97</volume>
          <fpage>2</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">15239289</pub-id>
        </element-citation>
      </ref>
      <ref id="B7-jcm-10-00023">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Habib</surname>
              <given-names>A.-R.R.</given-names>
            </name>
            <name>
              <surname>Kajbafzadeh</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Skolnik</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Quon</surname>
              <given-names>B.S.</given-names>
            </name>
          </person-group>
          <article-title>A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis</article-title>
          <source>Sci. Rep.</source>
          <year>2019</year>
          <volume>9</volume>
          <fpage>7234:1</fpage>
          <lpage>7234:9</lpage>
          <pub-id pub-id-type="doi">10.1038/s41598-019-43652-2</pub-id>
          <pub-id pub-id-type="pmid">31076617</pub-id>
        </element-citation>
      </ref>
      <ref id="B8-jcm-10-00023">
        <label>8.</label>
        <element-citation publication-type="web">
          <person-group person-group-type="author">
            <collab>Vertex</collab>
          </person-group>
          <article-title>Kalydeco<sup>&#xAE;</sup> Product Monograph</article-title>
          <year>2019</year>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://pi.vrtx.com/files/Canadapm_kalydeco_en.pdf">https://pi.vrtx.com/files/Canadapm_kalydeco_en.pdf</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-09-21">(accessed on 21 September 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B9-jcm-10-00023">
        <label>9.</label>
        <element-citation publication-type="web">
          <person-group person-group-type="author">
            <collab>Vertex</collab>
          </person-group>
          <article-title>Orkambi<sup>&#xAE;</sup> Product Monograph</article-title>
          <year>2019</year>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://pi.vrtx.com/files/Canadapm_orkambi_en.pdf">https://pi.vrtx.com/files/Canadapm_orkambi_en.pdf</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-09-21">(accessed on 21 September 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B10-jcm-10-00023">
        <label>10.</label>
        <element-citation publication-type="web">
          <person-group person-group-type="author">
            <collab>Vertex</collab>
          </person-group>
          <article-title>Symdeko<sup>&#xAE;</sup> Product Monograph</article-title>
          <year>2020</year>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://pi.vrtx.com/files/Canadapm_symdeko_en.pdf">https://pi.vrtx.com/files/Canadapm_symdeko_en.pdf</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-09-21">(accessed on 21 September 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B11-jcm-10-00023">
        <label>11.</label>
        <element-citation publication-type="gov">
          <person-group person-group-type="author">
            <collab>European Medicines Agency</collab>
          </person-group>
          <article-title>Symkevi</article-title>
          <year>2020</year>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/Symkevi">https://www.ema.europa.eu/en/medicines/human/EPAR/Symkevi</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-09-21">(accessed on 21 September 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B12-jcm-10-00023">
        <label>12.</label>
        <element-citation publication-type="web">
          <person-group person-group-type="author">
            <collab>Vertex</collab>
          </person-group>
          <article-title>Trikafta<sup>&#xAE;</sup> Prescribing Information</article-title>
          <year>2020</year>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://pi.vrtx.com/files/uspi_elexacaftor_tezacaftor_ivacaftor.pdf">https://pi.vrtx.com/files/uspi_elexacaftor_tezacaftor_ivacaftor.pdf</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-09-21">(accessed on 21 September 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B13-jcm-10-00023">
        <label>13.</label>
        <element-citation publication-type="gov">
          <person-group person-group-type="author">
            <collab>European Medicines Agency</collab>
          </person-group>
          <article-title>Kaftrio</article-title>
          <year>2020</year>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/Kaftrio">https://www.ema.europa.eu/en/medicines/human/EPAR/Kaftrio</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-11-07">(accessed on 7 November 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B14-jcm-10-00023">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Wainwright</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Canny</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Chilvers</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Howenstine</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Munck</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mainz</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yen</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a <italic>G551D</italic> mutation</article-title>
          <source>Am. J. Respir. Crit. Care Med.</source>
          <year>2013</year>
          <volume>187</volume>
          <fpage>1219</fpage>
          <lpage>1225</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.201301-0153OC</pub-id>
          <pub-id pub-id-type="pmid">23590265</pub-id>
        </element-citation>
      </ref>
      <ref id="B15-jcm-10-00023">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Boeck</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Munck</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Faro</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hiatt</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gilmartin</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-<italic>G551D</italic> gating mutation</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2014</year>
          <volume>13</volume>
          <fpage>674</fpage>
          <lpage>680</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2014.09.005</pub-id>
          <pub-id pub-id-type="pmid">25266159</pub-id>
        </element-citation>
      </ref>
      <ref id="B16-jcm-10-00023">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramsey</surname>
              <given-names>B.W.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>McElvaney</surname>
              <given-names>N.G.</given-names>
            </name>
            <name>
              <surname>Tullis</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Drevinek</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Griese</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>McKone</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Wainwright</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Konstan</surname>
              <given-names>M.W.</given-names>
            </name>
          </person-group>
          <article-title>A CFTR potentiator in patients with cystic fibrosis and the <italic>G551D</italic> mutation</article-title>
          <source>N. Eng. J. Med.</source>
          <year>2011</year>
          <volume>365</volume>
          <fpage>1663</fpage>
          <lpage>1672</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1105185</pub-id>
          <pub-id pub-id-type="pmid">22047557</pub-id>
        </element-citation>
      </ref>
      <ref id="B17-jcm-10-00023">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moss</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Flume</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Elborn</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Cooke</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>McColley</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Rubenstein</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of ivacaftor treatment: Randomized trial in subjects with cystic fibrosis who have an <italic>R117H-CFTR</italic> mutation</article-title>
          <source>Lancet Respir. Med.</source>
          <year>2015</year>
          <volume>3</volume>
          <fpage>524</fpage>
          <lpage>533</lpage>
          <pub-id pub-id-type="doi">10.1016/S2213-2600(15)00201-5</pub-id>
          <pub-id pub-id-type="pmid">26070913</pub-id>
        </element-citation>
      </ref>
      <ref id="B18-jcm-10-00023">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rowe</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Daines</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ringshausen</surname>
              <given-names>F.C.</given-names>
            </name>
            <name>
              <surname>Kerem</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tullis</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Nair</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Simard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Ingenito</surname>
              <given-names>E.P.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis</article-title>
          <source>N. Eng. J. Med.</source>
          <year>2017</year>
          <volume>377</volume>
          <fpage>2024</fpage>
          <lpage>2035</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1709847</pub-id>
        </element-citation>
      </ref>
      <ref id="B19-jcm-10-00023">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wainwright</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Elborn</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>B.W.</given-names>
            </name>
            <name>
              <surname>Marigowda</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Cipolli</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Colombo</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>De Boeck</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Flume</surname>
              <given-names>P.A.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del <italic>CFTR</italic></article-title>
          <source>N. Eng. J. Med.</source>
          <year>2015</year>
          <volume>373</volume>
          <fpage>220</fpage>
          <lpage>231</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1409547</pub-id>
          <pub-id pub-id-type="pmid">25981758</pub-id>
        </element-citation>
      </ref>
      <ref id="B20-jcm-10-00023">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ratjen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Hug</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Marigowda</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Stanojevic</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Milla</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>P.D.</given-names>
            </name>
            <name>
              <surname>Waltz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of lumacaftor and ivacaftor in patients aged 6&#x2013;11 years with cystic fibrosis homozygous for <italic>F508del-CFTR</italic>: A randomized, placebo-controlled, phase 3 trial</article-title>
          <source>Lancet Respir. Med.</source>
          <year>2017</year>
          <volume>5</volume>
          <fpage>557</fpage>
          <lpage>567</lpage>
          <pub-id pub-id-type="doi">10.1016/S2213-2600(17)30215-1</pub-id>
          <pub-id pub-id-type="pmid">28606620</pub-id>
        </element-citation>
      </ref>
      <ref id="B21-jcm-10-00023">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor-Cousar</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Munck</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>McKone</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Van der Ent</surname>
              <given-names>C.K.</given-names>
            </name>
            <name>
              <surname>Moeller</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Simard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L.T.</given-names>
            </name>
            <name>
              <surname>Ingenito</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>McKee</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>Y.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del</article-title>
          <source>N. Eng. J. Med.</source>
          <year>2017</year>
          <volume>377</volume>
          <fpage>2013</fpage>
          <lpage>2023</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1709846</pub-id>
          <pub-id pub-id-type="pmid">29099344</pub-id>
        </element-citation>
      </ref>
      <ref id="B22-jcm-10-00023">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heijerman</surname>
              <given-names>H.G.</given-names>
            </name>
            <name>
              <surname>McKone</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Downey</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Van Braeckel</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Tullis</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Mall</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Welter</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>B.W.</given-names>
            </name>
            <name>
              <surname>McKee</surname>
              <given-names>C.M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the <italic>F508del</italic> mutation: A double-blind, randomised, phase 3 trial</article-title>
          <source>Lancet</source>
          <year>2019</year>
          <volume>394</volume>
          <fpage>1940</fpage>
          <lpage>1948</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(19)32597-8</pub-id>
          <pub-id pub-id-type="pmid">31679946</pub-id>
        </element-citation>
      </ref>
      <ref id="B23-jcm-10-00023">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Middleton</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Mall</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Drevinek</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lands</surname>
              <given-names>L.C.</given-names>
            </name>
            <name>
              <surname>McKone</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Polineni</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>B.W.</given-names>
            </name>
            <name>
              <surname>Taylour-Cousar</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Tullis</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Vermeulen</surname>
              <given-names>F.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele</article-title>
          <source>N. Eng. J. Med.</source>
          <year>2019</year>
          <volume>381</volume>
          <fpage>1809</fpage>
          <lpage>1819</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1908639</pub-id>
          <pub-id pub-id-type="pmid">31697873</pub-id>
        </element-citation>
      </ref>
      <ref id="B24-jcm-10-00023">
        <label>24.</label>
        <element-citation publication-type="gov">
          <person-group person-group-type="author">
            <collab>NIH National Heart, Lung, and Blood Institute</collab>
          </person-group>
          <article-title>Study Quality Assessment Tools</article-title>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools">https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-07-15">(accessed on 15 July 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B25-jcm-10-00023">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wark</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Cookson</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Thiruchelvam</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Brannan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Dorahy</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <article-title>Lumacaftor/ivacaftor improves exercise tolerance in patients with cystic fibrosis and severe airflow obstruction</article-title>
          <source>BMC Pulm. Med.</source>
          <year>2019</year>
          <volume>19</volume>
          <fpage>106:1</fpage>
          <lpage>106:8</lpage>
          <pub-id pub-id-type="doi">10.1186/s12890-019-0866-y</pub-id>
          <pub-id pub-id-type="pmid">31208380</pub-id>
        </element-citation>
      </ref>
      <ref id="B26-jcm-10-00023">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tong</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>France</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Burr</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Greville</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Visser</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Middleton</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Wainwright</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Dorahy</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Wark</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2020</year>
          <volume>19</volume>
          <fpage>415</fpage>
          <lpage>420</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2019.12.006</pub-id>
          <pub-id pub-id-type="pmid">31848044</pub-id>
        </element-citation>
      </ref>
      <ref id="B27-jcm-10-00023">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nash</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Middleton</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Taylor-Cousar</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators&#x2014;An international survey</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2020</year>
          <volume>19</volume>
          <fpage>521</fpage>
          <lpage>526</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2020.02.018</pub-id>
          <pub-id pub-id-type="pmid">32151568</pub-id>
        </element-citation>
      </ref>
      <ref id="B28-jcm-10-00023">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patterson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Autry</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Murth</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Ivacaftor drug desensitization</article-title>
          <source>Pediatr. Pulmonol.</source>
          <year>2019</year>
          <volume>54</volume>
          <fpage>672</fpage>
          <lpage>674</lpage>
          <pub-id pub-id-type="doi">10.1002/ppul.24319</pub-id>
          <pub-id pub-id-type="pmid">30912311</pub-id>
        </element-citation>
      </ref>
      <ref id="B29-jcm-10-00023">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor-Cousar</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Niknian</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gilmartin</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pilewski</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2016</year>
          <volume>15</volume>
          <fpage>116</fpage>
          <lpage>122</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2015.01.008</pub-id>
          <pub-id pub-id-type="pmid">25682022</pub-id>
        </element-citation>
      </ref>
      <ref id="B30-jcm-10-00023">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hebestreit</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sauer-Heilborn</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kading</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mainz</surname>
              <given-names>J.G.</given-names>
            </name>
          </person-group>
          <article-title>Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2013</year>
          <volume>12</volume>
          <fpage>599</fpage>
          <lpage>603</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2013.05.006</pub-id>
          <pub-id pub-id-type="pmid">23757359</pub-id>
        </element-citation>
      </ref>
      <ref id="B31-jcm-10-00023">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murer</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>L.C.</given-names>
            </name>
            <name>
              <surname>Kurowski</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hirt</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>B&#x252;rgi</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Benden</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial&#x2014;Preliminary results</article-title>
          <source>Swiss Med. Wkly.</source>
          <year>2018</year>
          <volume>148</volume>
          <fpage>w14593:1</fpage>
          <lpage>w14593:5</lpage>
          <pub-id pub-id-type="doi">10.4414/smw.2018.14593</pub-id>
          <pub-id pub-id-type="pmid">29451946</pub-id>
        </element-citation>
      </ref>
      <ref id="B32-jcm-10-00023">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Popowicz</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tai</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Morey</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mulrennan</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2017</year>
          <volume>16</volume>
          <fpage>392</fpage>
          <lpage>394</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2017.02.009</pub-id>
          <pub-id pub-id-type="pmid">28314539</pub-id>
        </element-citation>
      </ref>
      <ref id="B33-jcm-10-00023">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hubert</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Chiron</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Camara</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Grenet</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Pr&#xE9;votat</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bassinet</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Dominique</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rault</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Macey</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Honor&#xE9;</surname>
              <given-names>I.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2017</year>
          <volume>16</volume>
          <fpage>388</fpage>
          <lpage>391</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2017.03.003</pub-id>
          <pub-id pub-id-type="pmid">28325531</pub-id>
        </element-citation>
      </ref>
      <ref id="B34-jcm-10-00023">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diab-C&#xE1;ceres</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Gir&#xF3;n-Moreno</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Pastor-Sanz</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Quintana-Gallego</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Delgado-Pecell&#xED;n</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Blanco-Aparicio</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Maiz</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a-Clemente</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Luna-Paredes</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mond&#xE9;jar-Lopez</surname>
              <given-names>P.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Compassionate use of lumacaftor/ivacaftor in cystic fibrosis: Spanish experience</article-title>
          <source>Arch. Bronconeumol.</source>
          <year>2018</year>
          <volume>54</volume>
          <fpage>614</fpage>
          <lpage>618</lpage>
          <pub-id pub-id-type="doi">10.1016/j.arbres.2018.05.004</pub-id>
          <pub-id pub-id-type="pmid">30518496</pub-id>
        </element-citation>
      </ref>
      <ref id="B35-jcm-10-00023">
        <label>35.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Etherington</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Spoletini</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Whitaker</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Clifton</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Peckham</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Early experience of the Orkambi &#x201C;managed Access Programme&#x201D; in a regional adult UK CF centre</article-title>
          <source>Proceedings of the 40th European Cystic Fibrosis Conference</source>
          <conf-loc>Seville, Spain</conf-loc>
          <conf-date>7&#x2013;10 June 2017</conf-date>
          <fpage>56</fpage>
        </element-citation>
      </ref>
      <ref id="B36-jcm-10-00023">
        <label>36.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Wareham</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Brennan</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Bright-Thomas</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Horsley</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Barry</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>Lumacaftor/ivacaftor is associated with high discontinuation rates in patients with baseline severe lung function but also benefits in those who tolerate therapy</article-title>
          <source>Proceedings of the British Thoracic Society Winter Meeting</source>
          <conf-loc>London, UK</conf-loc>
          <conf-date>6&#x2013;8 December 2017</conf-date>
          <fpage>247</fpage>
        </element-citation>
      </ref>
      <ref id="B37-jcm-10-00023">
        <label>37.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Wadsworth</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Riley</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Barry</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Physiotherapeutic objective and subjective evaluation of lumacaftor/ivacaftor initiation in patients with severe lung disease in a large adult CF centre</article-title>
          <source>Proceedings of the 33rd Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Nashville, TN, USA</conf-loc>
          <conf-date>31 October&#x2013;2 November 2019</conf-date>
          <fpage>468</fpage>
        </element-citation>
      </ref>
      <ref id="B38-jcm-10-00023">
        <label>38.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Carter</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Kearns</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Grogan</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hisert</surname>
              <given-names>K.B.</given-names>
            </name>
            <name>
              <surname>Cooke</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>P.K.</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>C.G.</given-names>
            </name>
            <name>
              <surname>McKone</surname>
              <given-names>E.F.</given-names>
            </name>
          </person-group>
          <article-title>Effects of lumacaftor/ivacaftor in patients homozygous for F508del mutation with very advanced lung disease</article-title>
          <source>Proceedings of the 40th European Cystic Fibrosis Conference</source>
          <conf-loc>Seville, Spain</conf-loc>
          <conf-date>7&#x2013;10 June 2017</conf-date>
          <fpage>47</fpage>
        </element-citation>
      </ref>
      <ref id="B39-jcm-10-00023">
        <label>39.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>FitzMaurice</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dawood</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nazareth</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Walshaw</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Symkevi: Real-world experience in an ill cohort at an adult cystic fibrosis centre</article-title>
          <source>Proceedings of the 43rd European Cystic Fibrosis Conference</source>
          <conf-loc>Lyon, France</conf-loc>
          <conf-date>3&#x2013;6 June 2020</conf-date>
          <fpage>219</fpage>
        </element-citation>
      </ref>
      <ref id="B40-jcm-10-00023">
        <label>40.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Bowen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Alemayehu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Battle</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>A.W.</given-names>
            </name>
          </person-group>
          <article-title>Promising results with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis patients with advanced lung disease: Beyond the clinical trial inclusion criteria</article-title>
          <source>Proceedings of the American Thoracic Society 2020 International Conference</source>
          <conf-loc>Philadelphia, PA, USA</conf-loc>
          <conf-date>15&#x2013;20 May 2020</conf-date>
          <year>1164</year>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.atsjournals.org/doi/book/10.1164/ajrccm-conference.2020.D12">https://www.atsjournals.org/doi/book/10.1164/ajrccm-conference.2020.D12</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-08-01">(accessed on 1 August 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B41-jcm-10-00023">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Labaste</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ohlmann</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mainguy</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jubin</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Perceval</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Coutier</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Reix</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Real-life acute lung function changes after lumacaftor/ivacaftor first administration in pediatric patients with cystic fibrosis</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2017</year>
          <volume>16</volume>
          <fpage>709</fpage>
          <lpage>712</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2017.05.002</pub-id>
          <pub-id pub-id-type="pmid">28529073</pub-id>
        </element-citation>
      </ref>
      <ref id="B42-jcm-10-00023">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burgel</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Munck</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Durieu</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Chiron</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Mely</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Prevotat</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Murris-Espin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Porzio</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Abely</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Reix</surname>
              <given-names>P.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis</article-title>
          <source>Am. J. Respir. Crit. Care Med.</source>
          <year>2020</year>
          <volume>201</volume>
          <fpage>188</fpage>
          <lpage>197</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.201906-1227OC</pub-id>
          <pub-id pub-id-type="pmid">31601120</pub-id>
        </element-citation>
      </ref>
      <ref id="B43-jcm-10-00023">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Finnegan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>O&#x2019;Grady</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Smyth</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Williamson</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Evidence of small airways disease and the immediate effects of lumacaftor/ivacaftor in children with cystic fibrosis</article-title>
          <source>Ir. Med. J.</source>
          <year>2020</year>
          <volume>113</volume>
          <fpage>70:1</fpage>
          <lpage>70:7</lpage>
          <pub-id pub-id-type="pmid">32603566</pub-id>
        </element-citation>
      </ref>
      <ref id="B44-jcm-10-00023">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jennings</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Dezube</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Paranjape</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>N.E.</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Grant</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Merlo</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Lechtzin</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>An observational study of outcomes and tolerances in patients with cystic fibrosis initiated on lumacaftor/ivacaftor</article-title>
          <source>Ann. Am. Thorac. Soc.</source>
          <year>2017</year>
          <volume>14</volume>
          <fpage>1662</fpage>
          <lpage>1666</lpage>
          <pub-id pub-id-type="doi">10.1513/AnnalsATS.201701-058OC</pub-id>
          <pub-id pub-id-type="pmid">28406713</pub-id>
        </element-citation>
      </ref>
      <ref id="B45-jcm-10-00023">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sergeev</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Flores</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Kerr</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Wilcox</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Quon</surname>
              <given-names>B.S.</given-names>
            </name>
          </person-group>
          <article-title>Safety and effectiveness of lumacaftor-ivacaftor in adults with cystic fibrosis: A single-centre Canadian experience</article-title>
          <source>Can. J. Respir. Crit. Care Sleep Med.</source>
          <year>2019</year>
          <volume>4</volume>
          <fpage>174</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="doi">10.1080/24745332.2019.1649608</pub-id>
        </element-citation>
      </ref>
      <ref id="B46-jcm-10-00023">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Welsner</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Strasburg</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Taube</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Sivagurunathan</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T: A case report</article-title>
          <source>BMC Pulm. Med.</source>
          <year>2019</year>
          <volume>19</volume>
          <fpage>76:1</fpage>
          <lpage>76:6</lpage>
          <pub-id pub-id-type="doi">10.1186/s12890-019-0840-8</pub-id>
          <pub-id pub-id-type="pmid">30975115</pub-id>
        </element-citation>
      </ref>
      <ref id="B47-jcm-10-00023">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKinzie</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Goralski</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Noah</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Retsch-Bogart</surname>
              <given-names>G.Z.</given-names>
            </name>
            <name>
              <surname>Prieur</surname>
              <given-names>M.B.</given-names>
            </name>
          </person-group>
          <article-title>Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2017</year>
          <volume>16</volume>
          <fpage>525</fpage>
          <lpage>527</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2017.05.008</pub-id>
          <pub-id pub-id-type="pmid">28602538</pub-id>
        </element-citation>
      </ref>
      <ref id="B48-jcm-10-00023">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Talwalkar</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Koff</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>H.B.</given-names>
            </name>
            <name>
              <surname>Britto</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Mulenos</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Georgiopoulos</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Cystic fibrosis transmembrane regulator modulators: Implications for the management of depression and anxiety in cystic fibrosis</article-title>
          <source>Psychosomatics</source>
          <year>2017</year>
          <volume>58</volume>
          <fpage>343</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="doi">10.1016/j.psym.2017.04.001</pub-id>
          <pub-id pub-id-type="pmid">28576305</pub-id>
        </element-citation>
      </ref>
      <ref id="B49-jcm-10-00023">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walayat</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hussain</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hussain</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Dhillon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Aulakh</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Chittivelu</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced dyspnea versus cystic fibrosis exacerbation: A diagnostic dilemma</article-title>
          <source>Int. Med. Case Rep. J.</source>
          <year>2017</year>
          <volume>10</volume>
          <fpage>243</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="doi">10.2147/IMCRJ.S139022</pub-id>
          <pub-id pub-id-type="pmid">28769592</pub-id>
        </element-citation>
      </ref>
      <ref id="B50-jcm-10-00023">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roehmel</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Ogese</surname>
              <given-names>M.O.</given-names>
            </name>
            <name>
              <surname>Rohrbach</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mall</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Naisbitt</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <article-title>Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4+ T lymphocytes</article-title>
          <source>J. Allergy Clin. Immunol.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2020.05.041</pub-id>
        </element-citation>
      </ref>
      <ref id="B51-jcm-10-00023">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Palacios</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Thiagalingam</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Middleton</surname>
              <given-names>P.G.</given-names>
            </name>
          </person-group>
          <article-title>Azithromycin and tezacaftor/ivacaftor is associated with first-degree heart block in an adult with cystic fibrosis</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2020.07.016</pub-id>
          <pub-id pub-id-type="pmid">32768310</pub-id>
        </element-citation>
      </ref>
      <ref id="B52-jcm-10-00023">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rotolo</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Duehlmeyer</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Slack</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>H.R.</given-names>
            </name>
            <name>
              <surname>Heckman</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2020</year>
          <volume>19</volume>
          <fpage>e39</fpage>
          <lpage>e41</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2020.04.017</pub-id>
          <pub-id pub-id-type="pmid">32471772</pub-id>
        </element-citation>
      </ref>
      <ref id="B53-jcm-10-00023">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Safirstein</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Grant</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Clausen</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Savant</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Dezube</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2020.07.014</pub-id>
          <pub-id pub-id-type="pmid">32736949</pub-id>
        </element-citation>
      </ref>
      <ref id="B54-jcm-10-00023">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tindell</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Oros</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Rayapati</surname>
              <given-names>A.O.</given-names>
            </name>
            <name>
              <surname>Rakesh</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Trikafta and psychopathology in cystic fibrosis: A case report</article-title>
          <source>Psychosomatics</source>
          <year>2020</year>
          <volume>61</volume>
          <fpage>735</fpage>
          <lpage>738</lpage>
          <pub-id pub-id-type="doi">10.1016/j.psym.2020.06.021</pub-id>
          <pub-id pub-id-type="pmid">32763020</pub-id>
        </element-citation>
      </ref>
      <ref id="B55-jcm-10-00023">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stalling</surname>
              <given-names>V.A.</given-names>
            </name>
            <name>
              <surname>Sainath</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Oberle</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bertolaso</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Schall</surname>
              <given-names>J.I.</given-names>
            </name>
          </person-group>
          <article-title>Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations</article-title>
          <source>J. Pediatr.</source>
          <year>2018</year>
          <volume>201</volume>
          <fpage>229</fpage>
          <lpage>237</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpeds.2018.05.018</pub-id>
          <pub-id pub-id-type="pmid">30029855</pub-id>
        </element-citation>
      </ref>
      <ref id="B56-jcm-10-00023">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gomez-Pastrana</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Nwokoro</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>McLean</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Pao</surname>
              <given-names>C.S.</given-names>
            </name>
          </person-group>
          <article-title>Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation</article-title>
          <source>An. Pediatr. (Barc.)</source>
          <year>2019</year>
          <volume>90</volume>
          <fpage>148</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1016/j.anpedi.2018.05.022</pub-id>
          <pub-id pub-id-type="pmid">30093322</pub-id>
        </element-citation>
      </ref>
      <ref id="B57-jcm-10-00023">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dryden</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Brooker</surname>
              <given-names>J.R.</given-names>
            </name>
          </person-group>
          <article-title>The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G115D mutation: A review</article-title>
          <source>Arch. Dis. Child.</source>
          <year>2018</year>
          <volume>103</volume>
          <fpage>68</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1136/archdischild-2015-310420</pub-id>
          <pub-id pub-id-type="pmid">27288428</pub-id>
        </element-citation>
      </ref>
      <ref id="B58-jcm-10-00023">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hubert</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Dehillotte</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Munck</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Baek</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Mely</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Dominique</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ramel</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Danner-Boucher</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Lefeuvre</surname>
              <given-names>S.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2018</year>
          <volume>17</volume>
          <fpage>89</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2017.07.001</pub-id>
          <pub-id pub-id-type="pmid">28711222</pub-id>
        </element-citation>
      </ref>
      <ref id="B59-jcm-10-00023">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kopp</surname>
              <given-names>B.T.</given-names>
            </name>
            <name>
              <surname>McCulloch</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shrestha</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Sarzynski</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Woodley</surname>
              <given-names>F.W.</given-names>
            </name>
            <name>
              <surname>Hayes</surname>
              <given-names>D.</given-names>
              <suffix>Jr.</suffix>
            </name>
          </person-group>
          <article-title>Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis</article-title>
          <source>Pediatr. Pulmonol.</source>
          <year>2018</year>
          <volume>53</volume>
          <fpage>583</fpage>
          <lpage>591</lpage>
          <pub-id pub-id-type="doi">10.1002/ppul.23972</pub-id>
          <pub-id pub-id-type="pmid">29461009</pub-id>
        </element-citation>
      </ref>
      <ref id="B60-jcm-10-00023">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loukou</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Moustaki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Plyta</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Douros</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Longitudinal changes in lung function following initiation of lumacaftor/ivacaftor combination</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2020</year>
          <volume>19</volume>
          <fpage>534</fpage>
          <lpage>539</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2019.09.009</pub-id>
          <pub-id pub-id-type="pmid">31676345</pub-id>
        </element-citation>
      </ref>
      <ref id="B61-jcm-10-00023">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pohl</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Taylor-Cousar</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Saavedra</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Strand</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Nick</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Bratcher</surname>
              <given-names>P.E.</given-names>
            </name>
          </person-group>
          <article-title>Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation</article-title>
          <source>PLoS ONE</source>
          <year>2018</year>
          <volume>13</volume>
          <fpage>e0209026:1</fpage>
          <lpage>e0209026:19</lpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0209026</pub-id>
          <pub-id pub-id-type="pmid">30540818</pub-id>
        </element-citation>
      </ref>
      <ref id="B62-jcm-10-00023">
        <label>62.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>De Gregorio</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Tosco</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Casale</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sepe</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cimbalo</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Catzola</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Castaldo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Slavadori</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Raia</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of Kalydeco oral granules: The experience of our centre</article-title>
          <source>Proceedings of the 23rd Italian Congress of Cystic Fibrosis and the 13th National Congress of Cystic Fibrosis Italian Society</source>
          <conf-loc>Naples, Italy</conf-loc>
          <conf-date>22&#x2013;25 November 2017</conf-date>
          <fpage>29</fpage>
        </element-citation>
      </ref>
      <ref id="B63-jcm-10-00023">
        <label>63.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Robson</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Feltbower</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Real world ivacaftor efficacy in children: Five years on&#x2026;</article-title>
          <source>Proceedings of the 42nd European Cystic Fibrosis Conference</source>
          <conf-loc>Liverpool, UK</conf-loc>
          <conf-date>5&#x2013;8 June 2019</conf-date>
          <fpage>252</fpage>
        </element-citation>
      </ref>
      <ref id="B64-jcm-10-00023">
        <label>64.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Rashdi</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Al-Busaidi</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>The effect of ivacaftor on adult cystic fibrosis patients at the Royal Hospital in Oman</article-title>
          <source>Proceedings of the 42nd European Cystic Fibrosis Conference</source>
          <conf-loc>Liverpool, UK</conf-loc>
          <conf-date>5&#x2013;8 June 2019</conf-date>
          <fpage>256</fpage>
        </element-citation>
      </ref>
      <ref id="B65-jcm-10-00023">
        <label>65.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Spencer-Clegg</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Sapina-Vivo</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Cullen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Walshaw</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Ivacaftor in the real world-early experience in a large adult CF centre</article-title>
          <source>Proceedings of the 27th Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Salt Lake City, UT, USA</conf-loc>
          <conf-date>17&#x2013;19 October 2013</conf-date>
          <fpage>228</fpage>
        </element-citation>
      </ref>
      <ref id="B66-jcm-10-00023">
        <label>66.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Flanagan</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Donovan</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Keating</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Jennings</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Shanahan</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Crowley</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cronin</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Mullane</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Ni Chroinin</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Orkambi: The Cork pediatric experience Cork University Hospital</article-title>
          <source>Proceedings of the Irish Thoracic Society Annual Scientific Meeting</source>
          <conf-loc>Limerick, Ireland</conf-loc>
          <conf-date>10&#x2013;11 November 2017</conf-date>
        </element-citation>
      </ref>
      <ref id="B67-jcm-10-00023">
        <label>67.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>McKinney</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Noizelier</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tellier</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Marcottee</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Berube</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tse</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Change in FEV1 and bronchodilator response after first dose of lumacaftor/ivacaftor</article-title>
          <source>Proceedings of the 31st Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Indianapolis, IN, USA</conf-loc>
          <conf-date>2&#x2013;4 November 2017</conf-date>
          <fpage>314</fpage>
        </element-citation>
      </ref>
      <ref id="B68-jcm-10-00023">
        <label>68.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Chiron</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hubert</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Reix</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Collas-Aubert</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kiefer</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kinnman</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Lumacaftor/ivacaftor (LUM/IVA) treatment in patients (pts) with cystic fibrosis (CF) aged &#x2265;12 years homozygous for F508del-CFTR: Description of a French Temporary Authorization for Use (ATU) cohort</article-title>
          <source>Proceedings of the 40th European Cystic Fibrosis Conference</source>
          <conf-loc>Seville, Spain</conf-loc>
          <conf-date>7&#x2013;10 June 2017</conf-date>
          <fpage>49</fpage>
        </element-citation>
      </ref>
      <ref id="B69-jcm-10-00023">
        <label>69.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Brokaar</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Van Leeuwen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Leegwater</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ploeger</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Van der Meer</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Adverse drug reactions and discontinuation rate during the first year on Orkambi&#x2014;The earliest results of the STORM study</article-title>
          <source>Proceedings of the 42nd European Cystic Fibrosis Conference</source>
          <conf-loc>Liverpool, UK</conf-loc>
          <conf-date>5&#x2013;8 June 2019</conf-date>
          <fpage>260</fpage>
        </element-citation>
      </ref>
      <ref id="B70-jcm-10-00023">
        <label>70.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Anstead</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tupayachi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Autry</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Bulkley</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Lumacaftor/ivacaftor: Real world experience in a CF center</article-title>
          <source>Proceedings of the 30th Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Orlando, FL, USA</conf-loc>
          <conf-date>27&#x2013;29 October 2016</conf-date>
          <fpage>290</fpage>
        </element-citation>
      </ref>
      <ref id="B71-jcm-10-00023">
        <label>71.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Tolle</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Lumacaftor-ivacaftor tolerance in cystic fibrosis patients homozygous for Phe508del CFTR: A single-center observational study</article-title>
          <source>Proceedings of the 30th Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Orlando, FL, USA</conf-loc>
          <conf-date>27&#x2013;29 October 2016</conf-date>
          <fpage>264</fpage>
        </element-citation>
      </ref>
      <ref id="B72-jcm-10-00023">
        <label>72.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmad</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Zanni</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Marmolegos</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Allwein</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Kitch</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Brosius</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Isenberg</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mills</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Stephen</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Side effect profile of lumacaftor/ivacaftor</article-title>
          <source>Proceedings of the 31st Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Indianapolis, IN, USA</conf-loc>
          <conf-date>2&#x2013;4 November 2017</conf-date>
          <fpage>310</fpage>
        </element-citation>
      </ref>
      <ref id="B73-jcm-10-00023">
        <label>73.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Hubert</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kanaan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Honor&#xE9;</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Burgel</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Reasons for not starting or discontinuing lumacaftor/ivacaftor: A single center observational study</article-title>
          <source>Proceedings of the 31st Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Indianapolis, IN, USA</conf-loc>
          <conf-date>2&#x2013;4 November 2017</conf-date>
          <fpage>224</fpage>
        </element-citation>
      </ref>
      <ref id="B74-jcm-10-00023">
        <label>74.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Walker</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Henry</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Sueblinvong</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>W.R.</given-names>
            </name>
          </person-group>
          <article-title>Experience of a large academic CF center with lumcaftor/ivacaftor</article-title>
          <source>Proceedings of the 30th Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Orlando, FL, USA</conf-loc>
          <conf-date>27&#x2013;29 October 2016</conf-date>
          <fpage>291</fpage>
        </element-citation>
      </ref>
      <ref id="B75-jcm-10-00023">
        <label>75.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lester</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Benitez</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Beringer</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Use of in-clinic challenge dosing to assess safety and tolerability of lumcaftor/ivacaftor (L/I)</article-title>
          <source>Proceedings of the 30th Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Orlando, FL, USA</conf-loc>
          <conf-date>27&#x2013;29 October 2016</conf-date>
          <fpage>448</fpage>
        </element-citation>
      </ref>
      <ref id="B76-jcm-10-00023">
        <label>76.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Indihar</surname>
              <given-names>M.V.</given-names>
            </name>
            <name>
              <surname>Trapnell</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Burns</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Major</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Montag</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Early experience initiating Orkambi therapy in adult cystic fibrosis patients</article-title>
          <source>Proceedings of the 30th Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Orlando, FL, USA</conf-loc>
          <conf-date>27&#x2013;29 October 2016</conf-date>
          <fpage>286</fpage>
        </element-citation>
      </ref>
      <ref id="B77-jcm-10-00023">
        <label>77.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Albon</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Cagnina</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Patient factors contributing to Orkambi discontinuation in adult cystic fibrosis, single center experience</article-title>
          <source>Proceedings of the 31st Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Indianapolis, IN, USA</conf-loc>
          <conf-date>2&#x2013;4 November 2017</conf-date>
          <fpage>305</fpage>
        </element-citation>
      </ref>
      <ref id="B78-jcm-10-00023">
        <label>78.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmad</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mills</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Stephen</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Real world experience of lumacaftor-ivacaftor at an urban cystic fibrosis center</article-title>
          <source>Proceedings of the 30th Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Orlando, FL, USA</conf-loc>
          <conf-date>27&#x2013;29 October 2016</conf-date>
          <fpage>32</fpage>
        </element-citation>
      </ref>
      <ref id="B79-jcm-10-00023">
        <label>79.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Roth</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Novak</surname>
              <given-names>K.J.</given-names>
            </name>
          </person-group>
          <article-title>Retrospective review of proton pump inhibitor use in cystic fibrosis patients initiating lumacaftor-ivacaftor (Orkambi) treatment</article-title>
          <source>Proceedings of the 31st Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Indianapolis, IN, USA</conf-loc>
          <conf-date>2&#x2013;4 November 2017</conf-date>
          <fpage>624</fpage>
        </element-citation>
      </ref>
      <ref id="B80-jcm-10-00023">
        <label>80.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Beringer</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of lumacaftor/ivacaftor in patients with mild lung disease</article-title>
          <source>Proceedings of the 31st Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Indianapolis, IN, USA</conf-loc>
          <conf-date>2&#x2013;4 November 2017</conf-date>
          <fpage>40</fpage>
        </element-citation>
      </ref>
      <ref id="B81-jcm-10-00023">
        <label>81.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Paluck</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Linnane</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Liver tests in F508del homozygous cystic fibrosis patients on Orkambi</article-title>
          <source>Proceedings of the 9th Eruopaediatrics Congress of Royal College of Paediatrics and Child Health</source>
          <conf-loc>Dublin, Ireland</conf-loc>
          <conf-date>13&#x2013;15 June 2019</conf-date>
          <fpage>274</fpage>
        </element-citation>
      </ref>
      <ref id="B82-jcm-10-00023">
        <label>82.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Melotti</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Tridello</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pintani</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Meneghelli</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Volpi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Spinelli</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>D&#x2019;Orazio</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Effects of ivacaftor/lumacaftor in cystic fibrosis patients homozygous for F508del CFTR mutation</article-title>
          <source>Proceedings of the 24th Congress of the Italian Society of Cystic Fibrosis and the 14th National Congress of Cystic Fibrosis Italian Society</source>
          <conf-loc>Salerno, Italy</conf-loc>
          <conf-date>8&#x2013;10 November 2018</conf-date>
          <fpage>251</fpage>
        </element-citation>
      </ref>
      <ref id="B83-jcm-10-00023">
        <label>83.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Bourgani</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Stagaki</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gioka</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nakou</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Antonogiannaki</surname>
              <given-names>E.-M.</given-names>
            </name>
            <name>
              <surname>Padapopoulos</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Diamantea</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Two years&#x2019; experience of lumacaftor/ivacaftor treatment at an adult cystic fibrosis centre in Athens, Greece</article-title>
          <source>Proceedings of the 42nd European Cystic Fibrosis Conference</source>
          <conf-loc>Liverpool, UK</conf-loc>
          <conf-date>5&#x2013;8 June 2019</conf-date>
          <fpage>267</fpage>
        </element-citation>
      </ref>
      <ref id="B84-jcm-10-00023">
        <label>84.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Bonizzoni</surname>
              <given-names>G.D.M.</given-names>
            </name>
            <name>
              <surname>Bellocchia</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bena</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Clivati</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Biglia</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Demichelis</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bandelli</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Grande</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Traversa</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Albera</surname>
              <given-names>C.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Real life experience of lumacaftor/ivacaftor in adult Phe508del homozygous cystic fibrosis patients</article-title>
          <source>Proceedings of the European Respiratory Society International Congress</source>
          <conf-loc>Paris, France</conf-loc>
          <conf-date>15&#x2013;19 September 2018</conf-date>
          <fpage>1322</fpage>
        </element-citation>
      </ref>
      <ref id="B85-jcm-10-00023">
        <label>85.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Ong</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Cassidy</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>McNamara</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lion</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Standardized clinical assessment of CFTR modulator use and safety monitoring: A descriptive quality improvement project</article-title>
          <source>Proceedings of the 30th Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Orlando, FL, USA</conf-loc>
          <conf-date>27&#x2013;29 October 2016</conf-date>
          <fpage>554</fpage>
        </element-citation>
      </ref>
      <ref id="B86-jcm-10-00023">
        <label>86.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Pan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Autry</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>McKinzie</surname>
              <given-names>C.J.</given-names>
            </name>
          </person-group>
          <article-title>Real world multicenter experience of pediatric cystic fibrosis patients started on tezacaftor/ivacaftor + ivacaftor</article-title>
          <source>Proceedings of the 33rd Annual North American Cystic Fibrosis Conference</source>
          <conf-loc>Nashville, TN, USA</conf-loc>
          <conf-date>31 October&#x2013;2 November 2019</conf-date>
          <fpage>477</fpage>
        </element-citation>
      </ref>
      <ref id="B87-jcm-10-00023">
        <label>87.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Robinson</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>McMullan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Berwick</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>McIntosh</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>McCabe</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hardisty</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>R.D.</given-names>
            </name>
          </person-group>
          <article-title>CFTR modulators in the real world: An observational study of patient response to tezacaftor/ivacaftor therapy</article-title>
          <source>Proceedings of the 43rd European Cystic Fibrosis Conference</source>
          <conf-loc>Lyon, France</conf-loc>
          <conf-date>3&#x2013;6 June 2020</conf-date>
          <fpage>218</fpage>
        </element-citation>
      </ref>
      <ref id="B88-jcm-10-00023">
        <label>88.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Perez</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Jue</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Dawson</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kleinhenz</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Neurocognitive side effects thwart transition to tezacaftor/ivacaftor CFTR modulator therapy in patients with F508del homozygous cystic fibrosis</article-title>
          <source>Proceedings of the American Thoracic Society International Conference</source>
          <conf-loc>Dallas, TX, USA</conf-loc>
          <conf-date>17&#x2013;22 May 2019</conf-date>
        </element-citation>
      </ref>
      <ref id="B89-jcm-10-00023">
        <label>89.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Ridge</surname>
              <given-names>P.C.</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>O&#x2019;Mahony</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Real-world outcomes of adult patients transitioning from Orkambi to Symkevi</article-title>
          <source>Proceedings of the 43rd European Cystic Fibrosis Conference</source>
          <conf-loc>Lyon, France</conf-loc>
          <conf-date>3&#x2013;6 June 2020</conf-date>
          <fpage>217</fpage>
        </element-citation>
      </ref>
      <ref id="B90-jcm-10-00023">
        <label>90.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Richards</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Sicilian</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Neuringer</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Decline and recovery of lung function with the initiation and cessation of lumacaftor-ivacaftor</article-title>
          <source>Proceedings of the American Thoracic Society 2017 International Conference</source>
          <conf-loc>Washington, DC, USA</conf-loc>
          <conf-date>19&#x2013;24 May 2017</conf-date>
        </element-citation>
      </ref>
      <ref id="B91-jcm-10-00023">
        <label>91.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Howsare</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>El-Kersh</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Isolated extreme elevation of alkaline phosphatase associated with lumacaftor-ivacaftor therapy: First report</article-title>
          <source>Proceedings of the American Thoracic Society 2017 International Conference</source>
          <conf-loc>Washington, DC, USA</conf-loc>
          <conf-date>19&#x2013;24 May 2017</conf-date>
        </element-citation>
      </ref>
      <ref id="B92-jcm-10-00023">
        <label>92.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Joyau</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Veyrac</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Haloun</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Jolliet</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Severe rhabdomyolysis in a patient treated with lumacaftor/ivacaftor association and aciclovir</article-title>
          <source>Proceedings of the Annual Meeting of French Society of Pharmacology and Therapeutics, and INSERM Clinical Research Centers, CIC Meeting</source>
          <conf-loc>Rouen, France</conf-loc>
          <conf-date>19&#x2013;21 April 2017</conf-date>
        </element-citation>
      </ref>
      <ref id="B93-jcm-10-00023">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>S&#xD8;rensen</surname>
              <given-names>H.T.</given-names>
            </name>
            <name>
              <surname>Lash</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Rothman</surname>
              <given-names>K.J.</given-names>
            </name>
          </person-group>
          <article-title>Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studies</article-title>
          <source>Hepatology</source>
          <year>2006</year>
          <volume>44</volume>
          <fpage>1075</fpage>
          <lpage>1082</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.21404</pub-id>
          <pub-id pub-id-type="pmid">17058242</pub-id>
        </element-citation>
      </ref>
      <ref id="B94-jcm-10-00023">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shteinberg</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Taylor-Cousar</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease</article-title>
          <source>Eur. Respir. Rev.</source>
          <year>2020</year>
          <volume>29</volume>
          <fpage>190112:1</fpage>
          <lpage>190112:8</lpage>
          <pub-id pub-id-type="doi">10.1183/16000617.0112-2019</pub-id>
          <pub-id pub-id-type="pmid">32198216</pub-id>
        </element-citation>
      </ref>
      <ref id="B95-jcm-10-00023">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gramegna</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Contarini</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Aliberti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Casciaro</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Blasi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Castellani</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>From ivacaftor to triple combination: A systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis</article-title>
          <source>Int. J. Mol. Sci.</source>
          <year>2020</year>
          <volume>21</volume>
          <elocation-id>5882</elocation-id>
          <pub-id pub-id-type="doi">10.3390/ijms21165882</pub-id>
        </element-citation>
      </ref>
      <ref id="B96-jcm-10-00023">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwarz</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Sivagurunathan</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Epaud</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Klingsberg</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Audhya</surname>
              <given-names>P.K.</given-names>
            </name>
            <name>
              <surname>Ahluwalia</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>You</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Ferro</surname>
              <given-names>T.J.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2020.06.001</pub-id>
        </element-citation>
      </ref>
      <ref id="B97-jcm-10-00023">
        <label>97.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burgel</surname>
              <given-names>P.-R.</given-names>
            </name>
            <name>
              <surname>Durieu</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Chiron</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Mely</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Prevotat</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Murris-Espin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Porzio</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Abely</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Reix</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Marguet</surname>
              <given-names>C.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2020.06.012</pub-id>
          <pub-id pub-id-type="pmid">32591294</pub-id>
        </element-citation>
      </ref>
      <ref id="B98-jcm-10-00023">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elborn</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>B.W.</given-names>
            </name>
            <name>
              <surname>Boyle</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Konstan</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Marigowda</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Waltz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Wainwright</surname>
              <given-names>C.E.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del <italic>CFTR</italic> by pulmonary function subgroup: A pooled analysis</article-title>
          <source>Lancet Respir. Med.</source>
          <year>2016</year>
          <volume>4</volume>
          <fpage>617</fpage>
          <lpage>626</lpage>
          <pub-id pub-id-type="doi">10.1016/S2213-2600(16)30121-7</pub-id>
          <pub-id pub-id-type="pmid">27298017</pub-id>
        </element-citation>
      </ref>
      <ref id="B99-jcm-10-00023">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marigowda</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Waltz</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2017</year>
          <volume>16</volume>
          <fpage>246</fpage>
          <lpage>249</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2016.11.001</pub-id>
          <pub-id pub-id-type="pmid">27894875</pub-id>
        </element-citation>
      </ref>
      <ref id="B100-jcm-10-00023">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor-Cousar</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Barto</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Haddad</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Atkinson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Marigowda</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Waltz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Pilewski</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for <italic>F508del-CFTR</italic></article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2018</year>
          <volume>17</volume>
          <fpage>228</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2017.09.012</pub-id>
          <pub-id pub-id-type="pmid">29126871</pub-id>
        </element-citation>
      </ref>
      <ref id="B101-jcm-10-00023">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Granados</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Ode</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Moheet</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Moran</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Holl</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2019</year>
          <volume>18</volume>
          <fpage>S3</fpage>
          <lpage>S9</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2019.08.016</pub-id>
          <pub-id pub-id-type="pmid">31679726</pub-id>
        </element-citation>
      </ref>
      <ref id="B102-jcm-10-00023">
        <label>102.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Culhane</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Pearo</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Spoede</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Malnutrition in cystic fibrosis: A review</article-title>
          <source>Nutr. Clin. Pract.</source>
          <year>2013</year>
          <volume>28</volume>
          <fpage>676</fpage>
          <lpage>683</lpage>
          <pub-id pub-id-type="doi">10.1177/0884533613507086</pub-id>
          <pub-id pub-id-type="pmid">24170579</pub-id>
        </element-citation>
      </ref>
      <ref id="B103-jcm-10-00023">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keating</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Marigowda</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Burr</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Daines</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mall</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>McKone</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>B.W.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Sass</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Tullis</surname>
              <given-names>E.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles</article-title>
          <source>N. Eng. J. Med.</source>
          <year>2018</year>
          <volume>379</volume>
          <fpage>1612</fpage>
          <lpage>1620</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1807120</pub-id>
        </element-citation>
      </ref>
      <ref id="B104-jcm-10-00023">
        <label>104.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milla</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Ratjen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Marigowda</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Waltz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Rosenfeld</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Lumacaftor/ivacaftor in patients aged 6&#x2013;11 years with cystic fibrosis and homozygous for <italic>F508del-CFTR</italic></article-title>
          <source>Am. J. Respir. Crit. Care Med.</source>
          <year>2017</year>
          <volume>195</volume>
          <fpage>912</fpage>
          <lpage>920</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.201608-1754OC</pub-id>
          <pub-id pub-id-type="pmid">27805836</pub-id>
        </element-citation>
      </ref>
      <ref id="B105-jcm-10-00023">
        <label>105.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scherer</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Brockow</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Aberer</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Gooi</surname>
              <given-names>J.H.C.</given-names>
            </name>
            <name>
              <surname>Demoly</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schnyder</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Whitaker</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cernadas</surname>
              <given-names>J.S.R.</given-names>
            </name>
            <name>
              <surname>Bircher</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Desensitization in delayed drug hypersensitivity reactions&#x2014;An EAACI position paper of the Drug Allergy Interest Group</article-title>
          <source>Allergy</source>
          <year>2013</year>
          <volume>68</volume>
          <fpage>844</fpage>
          <lpage>852</lpage>
          <pub-id pub-id-type="doi">10.1111/all.12161</pub-id>
          <pub-id pub-id-type="pmid">23745779</pub-id>
        </element-citation>
      </ref>
      <ref id="B106-jcm-10-00023">
        <label>106.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKone</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Borowitz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Drevinek</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Griese</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Konstan</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Wainwright</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ratjen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Sermet-Gaudelus</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Plant</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Munck</surname>
              <given-names>A.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-<italic>CFTR</italic> mutation: A phase 3, open-label extension study (PERSIST)</article-title>
          <source>Lancet Respir. Med.</source>
          <year>2014</year>
          <volume>2</volume>
          <fpage>902</fpage>
          <lpage>910</lpage>
          <pub-id pub-id-type="doi">10.1016/S2213-2600(14)70218-8</pub-id>
          <pub-id pub-id-type="pmid">25311995</pub-id>
        </element-citation>
      </ref>
      <ref id="B107-jcm-10-00023">
        <label>107.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fidika</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Herle</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Goldbeck</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Symptoms of depression impact the course of lung function in adolescents and adults with cystic fibrosis</article-title>
          <source>BMC Pulm. Med.</source>
          <year>2014</year>
          <volume>14</volume>
          <fpage>205:1</fpage>
          <lpage>205:6</lpage>
          <pub-id pub-id-type="doi">10.1186/1471-2466-14-205</pub-id>
          <pub-id pub-id-type="pmid">25515072</pub-id>
        </element-citation>
      </ref>
      <ref id="B108-jcm-10-00023">
        <label>108.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schechter</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Ostrenga</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Fink</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Sawicki</surname>
              <given-names>G.S.</given-names>
            </name>
            <name>
              <surname>Quittner</surname>
              <given-names>A.L.</given-names>
            </name>
          </person-group>
          <article-title>Decreased survival in cystic fibrosis patients with a positive screen for depression</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2020.07.020</pub-id>
          <pub-id pub-id-type="pmid">32800486</pub-id>
        </element-citation>
      </ref>
      <ref id="B109-jcm-10-00023">
        <label>109.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jordan</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Noah</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Henry</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis</article-title>
          <source>Pediatr. Pulmonol.</source>
          <year>2016</year>
          <volume>51</volume>
          <fpage>S61</fpage>
          <lpage>S70</lpage>
          <pub-id pub-id-type="doi">10.1002/ppul.23505</pub-id>
          <pub-id pub-id-type="pmid">27662106</pub-id>
        </element-citation>
      </ref>
      <ref id="B110-jcm-10-00023">
        <label>110.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Assis</surname>
              <given-names>D.N.</given-names>
            </name>
            <name>
              <surname>Debray</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Gallbladder and bile duct disease in cystic fibrosis</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2017</year>
          <volume>16</volume>
          <fpage>S62</fpage>
          <lpage>S69</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2017.07.006</pub-id>
          <pub-id pub-id-type="pmid">28986023</pub-id>
        </element-citation>
      </ref>
      <ref id="B111-jcm-10-00023">
        <label>111.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sheridan</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Cunningham</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Elborn</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Milla</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Starner</surname>
              <given-names>T.D.</given-names>
            </name>
            <name>
              <surname>Weiner</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>P.-S.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a <italic>G551D-CFTR</italic> mutation and preserved spirometry: A randomized controlled trial</article-title>
          <source>Lancet Respir. Med.</source>
          <year>2013</year>
          <volume>1</volume>
          <fpage>630</fpage>
          <lpage>638</lpage>
          <pub-id pub-id-type="doi">10.1016/S2213-2600(13)70182-6</pub-id>
          <pub-id pub-id-type="pmid">24461666</pub-id>
        </element-citation>
      </ref>
      <ref id="B112-jcm-10-00023">
        <label>112.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Griese</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Linnemann</surname>
              <given-names>R.W.</given-names>
            </name>
            <name>
              <surname>Mall</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>McKone</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Polineni</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Quon</surname>
              <given-names>B.S.</given-names>
            </name>
            <name>
              <surname>Ringshausen</surname>
              <given-names>F.C.</given-names>
            </name>
            <name>
              <surname>Taylor-Cousar</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Withers</surname>
              <given-names>N.J.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for &#x2265;24 weeks in people with CF and &#x2265;1 F508del allele: Interim results of an open-label phase three clinical trial</article-title>
          <source>Am. J. Respir. Crit. Care Med.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1164/rccm.202008-3176LE</pub-id>
          <pub-id pub-id-type="pmid">32969708</pub-id>
        </element-citation>
      </ref>
      <ref id="B113-jcm-10-00023">
        <label>113.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Konstan</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>McKone</surname>
              <given-names>E.F.</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Marigowda</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Waltz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Lubarsky</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Millar</surname>
              <given-names>S.J.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the <italic>F508del-CFTR</italic> mutation (PROGRESS): A phase 3, extension study</article-title>
          <source>Lancet Respir. Med.</source>
          <year>2017</year>
          <volume>5</volume>
          <fpage>107</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="doi">10.1016/S2213-2600(16)30427-1</pub-id>
          <pub-id pub-id-type="pmid">28011037</pub-id>
        </element-citation>
      </ref>
      <ref id="B114-jcm-10-00023">
        <label>114.</label>
        <element-citation publication-type="gov">
          <person-group person-group-type="author">
            <collab>U.S. National Library of Medicine</collab>
          </person-group>
          <article-title>A study to Evaluate the Safety and Efficacy of Long Term Treatment with VX-661 in Combination with Ivacaftor in Subjects with Cystic Fibrosis Who Have an F508del-CFTR Mutation. Identifier NCT02565914</article-title>
          <month>10</month>
          <year>2015</year>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/results/NCT02565914?view=results">https://clinicaltrials.gov/ct2/show/results/NCT02565914?view=results</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-10-12">(accessed on 12 October 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B115-jcm-10-00023">
        <label>115.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Assis</surname>
              <given-names>D.N.</given-names>
            </name>
            <name>
              <surname>Freedman</surname>
              <given-names>S.D.</given-names>
            </name>
          </person-group>
          <article-title>Gastrointestinal disorders in cystic fibrosis</article-title>
          <source>Clin. Chest Med.</source>
          <year>2016</year>
          <volume>37</volume>
          <fpage>109</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccm.2015.11.004</pub-id>
          <pub-id pub-id-type="pmid">26857772</pub-id>
        </element-citation>
      </ref>
      <ref id="B116-jcm-10-00023">
        <label>116.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edenborough</surname>
              <given-names>F.P.</given-names>
            </name>
          </person-group>
          <article-title>Women with cystic fibrosis and their potential for reproduction</article-title>
          <source>Thorax</source>
          <year>2001</year>
          <volume>56</volume>
          <fpage>649</fpage>
          <lpage>655</lpage>
          <pub-id pub-id-type="doi">10.1136/thorax.56.8.649</pub-id>
          <pub-id pub-id-type="pmid">11462069</pub-id>
        </element-citation>
      </ref>
      <ref id="B117-jcm-10-00023">
        <label>117.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Apperley</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>N.F.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Ghataore</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Rumsby</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Treslove</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Holt</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Thursfield</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Senniappan</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Posaconazole-induced hypertension masquerading as congenital adrenal hyperplasia in a child with cystic fibrosis</article-title>
          <source>Case Rep. Med.</source>
          <year>2020</year>
          <fpage>8153012:1</fpage>
          <lpage>8153012:5</lpage>
          <pub-id pub-id-type="doi">10.1155/2020/8153012</pub-id>
          <pub-id pub-id-type="pmid">32908540</pub-id>
        </element-citation>
      </ref>
      <ref id="B118-jcm-10-00023">
        <label>118.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lieberman</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rodbard</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Low blood pressure in young adults with cystic fibrosis: An effect of chronic salt loss in sweat?</article-title>
          <source>Ann. Int. Med.</source>
          <year>1975</year>
          <volume>82</volume>
          <fpage>806</fpage>
          <lpage>808</lpage>
          <pub-id pub-id-type="doi">10.7326/0003-4819-82-6-806</pub-id>
          <pub-id pub-id-type="pmid">1138590</pub-id>
        </element-citation>
      </ref>
      <ref id="B119-jcm-10-00023">
        <label>119.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bisch</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Wheatley</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Peitzman</surname>
              <given-names>E.R.</given-names>
            </name>
            <name>
              <surname>Van Iterson</surname>
              <given-names>E.H.</given-names>
            </name>
            <name>
              <surname>Laguna</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>W.J.</given-names>
            </name>
            <name>
              <surname>Snyder</surname>
              <given-names>E.M.</given-names>
            </name>
          </person-group>
          <article-title>Cystic fibrosis transmembrane conductance regulator genotype, not circulating catecholamines, influences cardiovascular function in patients with cystic fibrosis</article-title>
          <source>Clin. Med. Insights Circ. Respir. Pulm. Med.</source>
          <year>2019</year>
          <volume>13</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1177/1179548419835788</pub-id>
          <pub-id pub-id-type="pmid">30956528</pub-id>
        </element-citation>
      </ref>
      <ref id="B120-jcm-10-00023">
        <label>120.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lilleng</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Abeler</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Johnsen</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Stensland</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>L&#xD8;seth</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Jorde</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Figenschau</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Lindal</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wilsgaard</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Bekkelund</surname>
              <given-names>S.I.</given-names>
            </name>
          </person-group>
          <article-title>Variation of serum creatinine kinase (CK) levels and prevalence of persistent hyperCKemia in a Norwegian normal population. The Troms&#xD8; Study</article-title>
          <source>Neuromuscul. Disord.</source>
          <year>2011</year>
          <volume>21</volume>
          <fpage>494</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="doi">10.1016/j.nmd.2011.04.007</pub-id>
          <pub-id pub-id-type="pmid">21592795</pub-id>
        </element-citation>
      </ref>
      <ref id="B121-jcm-10-00023">
        <label>121.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gruet</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Troosters</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Verges</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Peripheral muscle abnormalities in cystic fibrosis: Etiology, clinical implications and response to therapeutic interventions</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2017</year>
          <volume>16</volume>
          <fpage>538</fpage>
          <lpage>552</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2017.02.007</pub-id>
          <pub-id pub-id-type="pmid">28262570</pub-id>
        </element-citation>
      </ref>
      <ref id="B122-jcm-10-00023">
        <label>122.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Le-Rademacher</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hillman</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Loprinzi</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Limburg</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Mandrekar</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: Analyses of data from randomized double-blind placebo-controlled clinical trials</article-title>
          <source>Ann. Oncol.</source>
          <year>2017</year>
          <volume>28</volume>
          <fpage>1183</fpage>
          <lpage>1190</lpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdx043</pub-id>
          <pub-id pub-id-type="pmid">28184420</pub-id>
        </element-citation>
      </ref>
      <ref id="B123-jcm-10-00023">
        <label>123.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bitonti</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Dickinson</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Knapp</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Blalock</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>The effect of counseling on willingness to use a hypothetical medication and perceptions of medication safety</article-title>
          <source>Res. Soc. Adm. Pharm.</source>
          <year>2018</year>
          <volume>14</volume>
          <fpage>295</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="doi">10.1016/j.sapharm.2017.03.058</pub-id>
          <pub-id pub-id-type="pmid">28412153</pub-id>
        </element-citation>
      </ref>
      <ref id="B124-jcm-10-00023">
        <label>124.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agyapong</surname>
              <given-names>V.I.O.</given-names>
            </name>
            <name>
              <surname>Nwankwo</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Bangaru</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kirrane</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Sources of patients&#x2019; knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services</article-title>
          <source>J. Clin. Psychopharmacol.</source>
          <year>2009</year>
          <volume>29</volume>
          <fpage>565</fpage>
          <lpage>570</lpage>
          <pub-id pub-id-type="doi">10.1097/JCP.0b013e3181befa3e</pub-id>
          <pub-id pub-id-type="pmid">19910722</pub-id>
        </element-citation>
      </ref>
      <ref id="B125-jcm-10-00023">
        <label>125.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Keating</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Kotsimbos</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Ivacaftor withdrawal syndrome during a randomised placebo-controlled cross-over study</article-title>
          <source>Proceedings of the 42nd European Cystic Fibrosis Conference</source>
          <conf-loc>Liverpool, UK</conf-loc>
          <conf-date>5&#x2013;8 June 2019</conf-date>
          <fpage>259</fpage>
        </element-citation>
      </ref>
      <ref id="B126-jcm-10-00023">
        <label>126.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>McKone</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Connolly</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Impact of ivacaftor treatment disruption on clinical outcomes: A single centre study</article-title>
          <source>Proceedings of the 42nd European Cystic Fibrosis Conference</source>
          <conf-loc>Liverpool, UK</conf-loc>
          <conf-date>5&#x2013;8 June 2019</conf-date>
          <fpage>208</fpage>
        </element-citation>
      </ref>
      <ref id="B127-jcm-10-00023">
        <label>127.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trimble</surname>
              <given-names>A.T.</given-names>
            </name>
            <name>
              <surname>Donaldson</surname>
              <given-names>S.H.</given-names>
            </name>
          </person-group>
          <article-title>Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2018</year>
          <volume>17</volume>
          <fpage>e13</fpage>
          <lpage>e16</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2017.09.006</pub-id>
          <pub-id pub-id-type="pmid">29079142</pub-id>
        </element-citation>
      </ref>
      <ref id="B128-jcm-10-00023">
        <label>128.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vekaria</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Popowicz</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>S.W.</given-names>
            </name>
            <name>
              <surname>Mulrennan</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>To be or not to be on CFTR modulators during pregnancy: Risks to be considered</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2020</year>
          <volume>19</volume>
          <fpage>e7</fpage>
          <lpage>e8</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2019.12.004</pub-id>
          <pub-id pub-id-type="pmid">31882306</pub-id>
        </element-citation>
      </ref>
      <ref id="B129-jcm-10-00023">
        <label>129.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mainz</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Michl</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Beiersdorf</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Lorenz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Groten</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Jaudszus</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Successful pregnancy of a patient with cystic fibrosis genotype F508del/F508del and progressed pulmonary destruction on lumacaftor/ivacaftor</article-title>
          <source>Klin. Padiatr.</source>
          <year>2019</year>
          <volume>231</volume>
          <fpage>271</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="doi">10.1055/a-0973-8565</pub-id>
          <pub-id pub-id-type="pmid">31408905</pub-id>
        </element-citation>
      </ref>
      <ref id="B130-jcm-10-00023">
        <label>130.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trimble</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>McKinzie</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Terrell</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Stringer</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Esther</surname>
              <given-names>C.R.</given-names>
            </name>
          </person-group>
          <article-title>Measured fetal and neonatal exposure to lumacaftor and ivacaftor during pregnancy and while breastfeeding</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2018</year>
          <volume>17</volume>
          <fpage>779</fpage>
          <lpage>782</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2018.05.009</pub-id>
          <pub-id pub-id-type="pmid">29866531</pub-id>
        </element-citation>
      </ref>
      <ref id="B131-jcm-10-00023">
        <label>131.</label>
        <element-citation publication-type="confproc">
          <person-group person-group-type="author">
            <name>
              <surname>Carpino</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Fowler</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Uluer</surname>
              <given-names>A.Z.</given-names>
            </name>
            <name>
              <surname>Sawicki</surname>
              <given-names>G.S.</given-names>
            </name>
          </person-group>
          <article-title>Acute clinical outcomes following participation in short-term CFTR modulator trials in adults with cystic fibrosis: A retrospective chart review</article-title>
          <source>Proceedings of the 32nd North American Cystic Fibrosis Conference</source>
          <conf-loc>Denver, CO, USA</conf-loc>
          <conf-date>18&#x2013;20 October 2018</conf-date>
          <fpage>300</fpage>
        </element-citation>
      </ref>
      <ref id="B132-jcm-10-00023">
        <label>132.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wark</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>V.M.</given-names>
            </name>
          </person-group>
          <article-title>Nebulized hypertonic saline for cystic fibrosis</article-title>
          <source>Cochrane Database Syst. Rev.</source>
          <year>2018</year>
          <volume>9</volume>
          <fpage>CD001506:1</fpage>
          <lpage>CD001506:123</lpage>
          <pub-id pub-id-type="doi">10.1002/14651858.CD001506.pub4</pub-id>
          <pub-id pub-id-type="pmid">30260472</pub-id>
        </element-citation>
      </ref>
      <ref id="B133-jcm-10-00023">
        <label>133.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Dornase alfa for cystic fibrosis</article-title>
          <source>Cochrane Database Syst. Rev.</source>
          <year>2018</year>
          <volume>9</volume>
          <fpage>CD001127:1</fpage>
          <lpage>CD001127:115</lpage>
          <pub-id pub-id-type="doi">10.1002/14651858.CD001127.pub4</pub-id>
          <pub-id pub-id-type="pmid">30187450</pub-id>
        </element-citation>
      </ref>
      <ref id="B134-jcm-10-00023">
        <label>134.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mogayzel</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Naureckas</surname>
              <given-names>E.T.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Mueller</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hadjiliadis</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hoag</surname>
              <given-names>J.B.</given-names>
            </name>
            <name>
              <surname>Lubsch</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Hazle</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Sabadosa</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health</article-title>
          <source>Am. J. Respir. Crit. Care Med.</source>
          <year>2013</year>
          <volume>187</volume>
          <fpage>680</fpage>
          <lpage>689</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.201207-1160OE</pub-id>
          <pub-id pub-id-type="pmid">23540878</pub-id>
        </element-citation>
      </ref>
      <ref id="B135-jcm-10-00023">
        <label>135.</label>
        <element-citation publication-type="gov">
          <person-group person-group-type="author">
            <name>
              <surname>Nichols</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Mayer-Hamblett</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Gifford</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Impact of Discontinuing Chronic Therapies in People with Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY). Identifier NCT04378153</article-title>
          <day>7</day>
          <month>5</month>
          <year>2020</year>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04378153">https://clinicaltrials.gov/ct2/show/NCT04378153</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-10-12">(accessed on 12 October 2020)</date-in-citation>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="jcm-10-00023-f001" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>PRISMA flow diagram of study selection <sup>1</sup>. <sup>1</sup> From: Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; The PRISMA Group. <italic>P</italic>referred <italic>R</italic>eporting <italic>I</italic>tems for <italic>S</italic>ystematic Reviews and <italic>M</italic>eta-<italic>A</italic>nalyses: The PRISMA Statement. <italic>PLoS Med</italic>. <bold>2009</bold>, <italic>6</italic>, e1000097, doi:10.1371/journal.pmed1000097.</p>
      </caption>
      <graphic xlink:href="jcm-10-00023-g001"/>
    </fig>
    <table-wrap id="jcm-10-00023-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">jcm-10-00023-t001_Table 1</object-id>
      <label>Table 1</label>
      <caption>
        <p>Summary of characteristics and results of cohort or survey studies with full manuscript.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design &amp; Location</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Population <sup>a</sup></th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>n</italic>
</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Recruitment Period &amp; Follow-up Duration</th>
            <th colspan="3" align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Overall Adverse Events (AE) <sup>b,c</sup></th>
            <th colspan="3" align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Dose Modification, Interruption, or Discontinuation Due to AE <sup>b,c</sup></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="11" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Ivacaftor</bold>
</td>
          </tr>
          <tr>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B29-jcm-10-00023" ref-type="bibr">29</xref>]</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Prospective Cohort <sup>d</sup><break/>&#x2003;<break/>United States</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Mean: 33 yr<break/>- Range: 10&#x2013;61 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2265; 1 copy G551D<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 30%</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">44</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>Prior to commercial availability<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>NS</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><bold><underline>AE in <italic toggle="yes">n</italic> = 38 </underline></bold><underline>(<bold>86%</bold>)</underline>:</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Discontinuation</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">- Pulmonary exacerbation<break/>- Hemoptysis<break/>- Increased sputum<break/>- Increased cough<break/>- URTI<break/>- Dyspnea<break/>- Abnormal respiration <break/>- Respiratory tract congestion<break/>- Headache<break/>- Rash</td>
            <td align="left" valign="top" rowspan="1" colspan="1">20<break/>7<break/>7<break/>6<break/>6<break/>3<break/>3<break/>3<break/>5<break/>4</td>
            <td align="left" valign="top" rowspan="1" colspan="1">45<break/>16<break/>16<break/>14<break/>14<break/>7<break/>7<break/>7<break/>11<break/>9</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1">- Severe abdominal pain<break/>- Dizziness/tinnitus</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1">1<break/>1</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1">2<break/>2</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">&#x2003;<break/><bold><underline>SAE in <italic toggle="yes">n</italic> = 14 </underline></bold><underline>(<bold>32%</bold>)</underline><bold>:</bold></td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Pulmonary exacerbation<break/>- Hemoptysis<break/>- Pneumothorax<break/>- Acute respiratory failure<break/>- URTI<break/>- Abdominal pain<break/>- Gastroenteritis<break/>- Abnormal LFTs<break/>- Syncope<break/>- Secondary adrenocortical insufficiency</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-</td>
          </tr>
          <tr>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B55-jcm-10-00023" ref-type="bibr">55</xref>]</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Prospective Cohort<break/>&#x2003;<break/>United States<break/>Canada<break/>Italy</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Mean: 17 yr<break/>- Range: 5&#x2013;61 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2265;1 gating mutation<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 86%</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">23</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>Mar 2014 to Aug 2015<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>3 mo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>49 AE in <italic toggle="yes">n</italic> = 21 </underline></bold>
<underline>(<bold>91%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">- Respiratory, unspecified<break/>- Gastrointestinal, unspecified<break/>- Infection, unspecified<break/>- Headache<break/>- Weakness<break/>- Dizziness<break/>- Fatigue</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-</td>
            <td rowspan="3" colspan="3" align="left" valign="top" style="border-bottom:solid thin">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>5 SAE in <italic toggle="yes">n</italic> = 3 </underline></bold>
<underline>(<bold>13%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Respiratory infection<break/>- Acute changes in metabolic and liver status</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">4<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">17<break/>4</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-jcm-10-00023" ref-type="bibr">56</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort<break/>&#x2003;<break/>United Kingdom<break/>(1 center)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric <break/>- Mean: 9 yr<break/>- Range: 6&#x2013;14 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>1 copy G551D<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 68% <sup>e</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Recruitment Period</bold><break/>Jan 2013 to Jun 2015<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>Mean: 24 mo</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Transaminitis (&lt;3 x ULN)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>25</td>
            <td colspan="3" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">None reported</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-jcm-10-00023" ref-type="bibr">57</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort<break/>&#x2003;<break/>Scotland<break/>(11 centers)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric <break/>- Median: 9 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2265;1 copy G551D<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 85%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Recruitment Period</bold><break/>NS (Jan 2013 to Mar 2013 for 85%)<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>Mean: 17 mo</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Headache <break/>- Swollen ear <break/>- Cataracts</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1<break/>1<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>4<break/>4<break/>17 <sup>f</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B58-jcm-10-00023" ref-type="bibr">58</xref>]</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Retrospective Cohort<break/>&#x2003;<break/>France<break/>(25 centers)</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Median: 18 yr<break/>- Range: 6&#x2013;52 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2265;1 copy G551D<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 72%</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">57</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>Pre-1 Jun 2013 up to 30 Sep 2014 <break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>Up to 2 yr</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>34 AE in <italic toggle="yes">n</italic> = 21 </underline></bold>
<underline>(<bold>37%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Interruption in <italic toggle="yes">n</italic> = 7 </underline></bold>
<underline>(<bold>12%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1">- Transaminitis<break/>- Rhinopharyngitis<break/>- Asthma<break/>- Fever<break/>- Chest pain<break/>- Abdominal pain<break/>- Nausea or vomiting<break/>- Intestinal dysmotility<break/>- Headache<break/>- Fatigue<break/>- Rash or eczema<break/>- Depression<break/>- Myalgia<break/>- Arthritis<break/>- Breast hypertrophy<break/>- Orchitis<break/>- Atrial fibrillation</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1">3<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1">5<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-</td>
            <td align="left" valign="top" rowspan="1" colspan="1">- Hepatitis<break/>- Rhinopharyngitis<break/>- Abdominal pain<break/>- Vomiting<break/>- Headache<break/>- Rash<break/>- Severe depression</td>
            <td align="left" valign="top" rowspan="1" colspan="1">NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS</td>
            <td align="left" valign="top" rowspan="1" colspan="1">-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold>:</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Transaminitis<break/>- Liver cirrhosis diagnosis</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2<break/>2</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort <sup>d</sup><break/>&#x2003;<break/>Germany<break/>(multicenter)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean: 34 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2265;1 copy G551D<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 25%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Recruitment Period</bold><break/>Sep 2012 to Apr 2013<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>Mean: 235 days</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Increased bronchial<break/> and nasal secretions <break/>- Headache<break/>- Worsening RLS<break/>- Abdominal pain<break/>- Hyperbilirubinemia (mild)<break/>- Transaminitis (&lt;3 to 4x ULN)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>3<break/>&#x2003;<break/>1<break/>1<break/>1<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>21<break/>&#x2003;<break/>7<break/>7<break/>7<break/>7<break/>7</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold>:<break/>- Increased bronchial and nasal <break/> secretions *<break/>&#x2003;<break/>* Trial of reduced dose before discontinuation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>7</td>
          </tr>
          <tr>
            <td colspan="11" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Lumacaftor/Ivacaftor</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort<break/>&#x2003;<break/>France <break/>(1 center)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric<break/>- Mean: 16 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 87%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Recruitment Period</bold><break/>Mar 2016 to Dec 2016<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>4 h post-first dose</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Acute drop in ppFEV<sub>1</sub><break/>- Wheeze</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>32<break/>3</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>100<break/>9</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B42-jcm-10-00023" ref-type="bibr">42</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Prospective Cohort <break/>&#x2003;<break/>France<break/>(47 centers)</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Mean: 22 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 65%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">845</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>1 Jan 2016 to 31 Dec 2016<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>12 mo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>AE in <italic toggle="yes">n</italic> = 494 </underline></bold>
<underline>(<bold>59%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Interruption</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Respiratory<break/>- Digestive<break/>- Menstrual abnormality<break/>- Fatigue<break/>- Headache<break/>- CK &gt; 5xULN <break/>- Transaminitis (&gt; 3xULN)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">316<break/>181<break/>53<break/>37<break/>19<break/>20<break/>5</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">37<break/>21<break/>6<break/>4<break/>2<break/>2<break/>0.6</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Respiratory<break/>- &#x2018;Non-respiratory&#x2019;<break/>&#x2003;<break/><bold><underline>Discontinuation</underline></bold>:<break/><underline>Respiratory</underline>
<break/>- Chest tightness/dyspnea<break/>- Bronchospasm<break/>- Increased cough/sputum<break/>- Hemoptysis<break/>- Pneumothorax<break/>&#x2003;<break/><underline>Non-respiratory</underline><break/>- Diarrhea, abdominal pain<break/>- CK &gt;10xULN + myalgia <break/>- Fatigue<break/>- Headache<break/>- Depression<break/>- Metrorrhagia<break/>- Transaminitis (&gt;6xULN) <break/>- Cutaneous rash<break/>- Tachycardia</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">16<break/>8<break/>&#x2003;<break/><italic><underline>n</underline></italic><break/>&#x2003;<break/>38<break/>24<break/>9<break/>2<break/>1<break/>&#x2003;<break/>&#x2003;<break/>18<break/>5<break/>5<break/>4<break/>4<break/>3<break/>2<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2<break/>1<break/>&#x2003;<break/><underline>%</underline><break/>&#x2003;<break/>5<break/>3<break/>1<break/>0.2<break/>0.1<break/>&#x2003;<break/>&#x2003;<break/>2<break/>0.6<break/>0.6<break/>0.5<break/>0.5<break/>0.4<break/>0.2<break/>0.1<break/>0.1</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-jcm-10-00023" ref-type="bibr">59</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort<break/>&#x2003;<break/>United States<break/>(1 center)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Mean: 23 yr<break/>- Range: 12&#x2013;48 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 70%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Recruitment Period</bold><break/>NS<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>6 mo</td>
            <td colspan="3" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline>:</bold><break/>- Transaminitis<break/>- Unspecified AE</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1<break/>4</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>4<break/>15</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B34-jcm-10-00023" ref-type="bibr">34</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Prospective Cohort <sup>d</sup><break/>&#x2003;<break/>Switzerland<break/>(1 center)</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Mean NR<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Median: 30%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">20</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>Jan 2016 to Jan 2017<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>1 mo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><bold><underline>Reduced dose</underline></bold>:</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Dyspnea<break/> &#x2003;- 3 h<break/> &#x2003;- 24 h<break/> &#x2003;- 1 mo<break/>- Chest tightness<break/> &#x2003;- 3 h<break/> &#x2003;- 24 h<break/> &#x2003;- 1 mo<break/>- Increased sputum <break/> &#x2003;- 3 h<break/> &#x2003;- 24 h<break/> &#x2003;- 1 mo<break/>- Pulmonary exacerbation<break/> &#x2003;- 1 mo</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>0<break/>1<break/>1<break/>&#x2003;<break/>1<break/>10<break/>1<break/>&#x2003;<break/>1<break/>8<break/>3<break/>&#x2003;<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>-<break/>5<break/>5<break/>&#x2003;<break/>5<break/>50<break/>5<break/>&#x2003;<break/>5<break/>40<break/>15<break/>&#x2003;<break/>10</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Respiratory intolerance<break/>&#x2003;<break/><bold><underline>Discontinuation</underline>:</bold><break/>- Chest tightness (at 24 h)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">3<break/>&#x2003;<break/>&#x2003;<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">15<break/>&#x2003;<break/>&#x2003;<break/>5</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B32-jcm-10-00023" ref-type="bibr">32</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Prospective Cohort<break/>&#x2003;<break/>Australia<break/>(1 center) </td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Mean: 27 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Median: 36%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">12</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>Jan 2016 to Oct 2016<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>1 mo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Discontinuation</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Acute drop in ppFEV<sub>1</sub><break/>- Respiratory AE overall<break/> &#x2003;- 4 h<break/> &#x2003;- 24 h<break/> &#x2003;- 1 mo<break/>- Dyspnea<break/> &#x2003;- 4 h<break/> &#x2003;- 24 h<break/> &#x2003;- 1 mo<break/>- Chest tightness<break/> &#x2003;- 4 h<break/> &#x2003;- 24 h<break/> &#x2003;- 1 mo<break/>- Increased sputum<break/> &#x2003;- 4 h<break/> &#x2003;- 24 h<break/> &#x2003;- 1 mo<break/>- Pulmonary exacerbation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">12<break/>&#x2003;<break/>5<break/>10<break/>8<break/>&#x2003;<break/>2<break/>6<break/>7<break/>&#x2003;<break/>4<break/>8<break/>5<break/>&#x2003;<break/>0<break/>2<break/>1<break/>6</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">100<break/>&#x2003;<break/>42<break/>83<break/>67<break/>&#x2003;<break/>17<break/>50<break/>58<break/>&#x2003;<break/>33<break/>67<break/>42<break/>&#x2003;<break/>-<break/>17<break/>8<break/>50</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Chest tightness/dyspnea *<break/>&#x2003;<break/>* <italic>n</italic> = 2 discontinued after 1mo follow-up (5 wk and 9 wk)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Prospective Cohort<break/>&#x2003;<break/>France<break/>(11 centers)</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Mean: 31 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 32%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">53</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>Jan 2016 to Jun 2016 <break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>3 mo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>AE in <italic toggle="yes">n</italic> = 34 </underline></bold>
<underline>(<bold>63%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Discontinuation</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Abnormal respiration<break/>- Dyspnea<break/>- Increased cough<break/>- Abdominal pain, nausea, diarrhea, or vomiting<break/>- Fatigue<break/>- Rash<break/>- Pruritus<break/>- Breast tension</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">13<break/>11<break/>3<break/>9<break/>&#x2003;<break/>2<break/>1<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">25<break/>21<break/>6<break/>17<break/>&#x2003;<break/>4<break/>2<break/>2<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Respiratory intolerance<break/>- Vomiting<break/>- Fatigue</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">13<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">25<break/>2<break/>2</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-jcm-10-00023" ref-type="bibr">25</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort <sup>d,g</sup><break/>&#x2003;<break/>Australia<break/>(1 center)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Mean: 27 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 36% </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Recruitment Period</bold><break/>NS<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>52 wk</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>AE in <italic toggle="yes">n</italic> = 6 </underline></bold><underline>(<bold>60%</bold>)</underline><bold>:</bold><break/>- Chest tightness/dyspnea<break/>- Headache</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>6<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>60<break/>20</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort<break/>&#x2003;<break/>Ireland<break/>(1 center)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric<break/>- Mean: 14 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 77% </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Recruitment Period</bold><break/>Sep 2016 to Aug 2017<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Acute drop in ppFEV<sub>1</sub><break/>- Chest tightness<break/>- Increased sputum</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>14<break/>2<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>93<break/>13<break/>13</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Retrospective Cohort <break/>&#x2003;<break/>United States<break/>(1 center)</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Mean: 25 yr<break/>- Range: 12&#x2013;59 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 67%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">116</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>NS<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>Up to 11 mo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>AE in <italic toggle="yes">n</italic> = 46 </underline></bold>
<underline>(<bold>40%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Reduced dose</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Chest tightness<break/>- Dyspnea<break/>- Increased cough<break/>- Diarrhea<break/>- Nausea<break/>- Decreased appetite<break/>- Rash</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">23<break/>12<break/>10<break/>5<break/>3<break/>2<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">20<break/>10<break/>9<break/>4<break/>3<break/>2<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- AE not specified<break/>&#x2003;<break/><bold><underline>Discontinuation</underline></bold>:<break/>- Reasons not specified <sup>h</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">10<break/>&#x2003;<break/>&#x2003;<break/>20</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">9<break/>&#x2003;<break/>&#x2003;<break/>17</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-jcm-10-00023" ref-type="bibr">60</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort<break/>&#x2003;<break/>Greece<break/>(1 center)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Mean: 16 yr <sup>i</sup><break/>- Range: 12&#x2013;23 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean 92% <sup>i</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">62</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Recruitment Period</bold><break/>Mar 2016 to Aug 2017<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>12 mo</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Chest tightness</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>3</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline>:</bold><break/>- Transaminitis<break/>- Cataract</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>2<break/>2</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B34-jcm-10-00023" ref-type="bibr">34</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Retrospective Cohort <sup>d</sup><break/>&#x2003;<break/>Spain<break/>(multicenter)</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Mean: 27 yr<break/>- Range: 10&#x2013;45 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 32%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">20</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>2016<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>6 mo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>AE in <italic toggle="yes">n</italic> = 15 </underline></bold>
<underline>(<bold>75%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Discontinuation</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Chest tightness<break/>- Dyspnea<break/>- Headache<break/>- Weight loss<break/>- &#x2018;Sickness&#x2019; (not defined)<break/>- Asthenia<break/>- Abdominal pain<break/>- Transaminitis</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">9<break/>8<break/>5<break/>5<break/>3<break/>3<break/>2<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">45<break/>40<break/>25<break/>25<break/>15<break/>15<break/>10<break/>10</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Decreased ppFEV<sub>1</sub><break/>- AE not specified</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1<break/>6</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">5<break/>30</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Retrospective Cohort<break/>&#x2003;<break/>Canada<break/>(1 center)</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Median: 32 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Median: 40%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">22</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>Apr 2016 to Jun 2018<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>Median: 10 mo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>AE in <italic toggle="yes">n</italic> = 19 </underline></bold>
<underline>(<bold>86%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Discontinuation</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Chest tightness<break/>- Wheeze<break/>- Dyspnea<break/>- Increased sputum<break/>- Increased cough<break/>- Flu-like symptoms<break/>- Elevated blood pressure<break/>- Headache<break/>- Nausea<break/>- Elevated AST<break/>- Anxiety<break/>- Bradycardia <break/>- Pleuritic chest pain</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">14<break/>4<break/>3<break/>3<break/>2<break/>1<break/>5<break/>4<break/>2<break/>1<break/>1<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">64<break/>18<break/>14<break/>14<break/>9<break/>5<break/>23<break/>18<break/>9<break/>5<break/>5<break/>5<break/>5</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Respiratory symptoms<break/>- Asymptomatic hypertension<break/>- Symptomatic hypertension<break/> &#x2003;- Headache<break/> &#x2003;- Hypertensive emergency<break/>- Anxiety</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">3<break/>2<break/>&#x2003;<break/>1<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">14<break/>9<break/>&#x2003;<break/>5<break/>5<break/>5</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort<break/>&#x2003;<break/>United States<break/>(1 center)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Mean NR<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">82</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Recruitment Period</bold><break/>Jul 2015 to Jun 2016<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>12 mo</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold>:<break/>Total overall:<break/>- Chest tightness * <break/>- Diarrhea **<break/>- Abdominal pain<break/>- Nausea **<break/>- Dysphagia<break/>- Elevated LFTs<break/>- Pericarditis<break/>- Allergic reaction **<break/>- Suspected Stevens&#x2013;Johnson syndrome<break/>&#x2003;<break/>* <italic>n</italic> = 3 also had significant drop in ppFEV<sub>1</sub><break/>** <italic>n</italic> = 1 also discontinued due to chest tightness</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>17<break/>11<break/>2<break/>1<break/>1<break/>1<break/>1<break/>1<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>21<break/>13<break/>2<break/>1<break/>1<break/>1<break/>1<break/>1<break/>1<break/>1</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Retrospective Cohort <sup>d,g</sup><break/>&#x2003;<break/>Australia<break/>(7 centers)</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Mean: 31 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 37%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">72</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Recruitment Period</bold><break/>Nov 2015 to Mar 2017<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>12 mo</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Discontinuation</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Chest tightness/dyspnea<break/>- Increased sputum<break/>- Decrease in ppFEV<sub>1</sub><break/>- Headache<break/>- Fatigue<break/>- Nausea<break/>- Rash</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">40<break/>4<break/>2<break/>2<break/>5<break/>1<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">56<break/>6<break/>3<break/>3<break/>7<break/>1<break/>3</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Chest tightness/dyspnea</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">31</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-jcm-10-00023" ref-type="bibr">27</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Case Series (Survey) <sup>j</sup><break/>&#x2003;<break/>International (31 centers)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean: 30 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 59%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Recruitment Period</bold><break/>Questionnaire sent in 2018&#x2013;2019<break/>&#x2003;<break/><bold>Follow-up Duration</bold><break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Pulmonary exacerbation<break/>- Post-partum acute myelocytic leukemia</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>4<break/>4</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline>:</bold><break/>- Chest tightness</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>8</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p><sup>a</sup> When adult and pediatric patients both included, age range reported when possible; <sup>b</sup> Rates not reported for all AE, as indicated by &#x2018;NS&#x2019;; <sup>c</sup> To avoid redundancy, if AE only reported in context of dose modification, interruption, and/or discontinuation of therapy, it was not listed in overall AE; <sup>d</sup> Study population part of a compassionate, &#x2018;expanded access&#x2019;, &#x2018;managed access&#x2019;, or &#x2018;named patient&#x2019; program; <sup>e</sup> Mean calculated from <italic>n</italic> = 3 (75%) of study subjects, as baseline not reported for <italic>n</italic> = 1 (25%); <sup>f</sup> Frequency of 17% based on <italic>n</italic> = 12 screened; 8% frequency for overall cohort of <italic>n</italic> = 26; <sup>g</sup> Study was case-control, but only LUM/IVA-treated participants included in systematic review; therefore, assessed as cohort study; <sup>h</sup> Reason for discontinuation was not consistently assessed, and may include reasons unrelated to AE; <sup>i</sup> Mean baseline age and ppFEV<sub>1</sub> based on <italic>n</italic> = 52 in final analysis of outcomes assessing effectiveness; <italic>n</italic> = 10 excluded from this analysis; <sup>j</sup> This case series is included in <xref rid="jcm-10-00023-t001" ref-type="table">Table 1</xref> due to results being presented in aggregate. <bold>AST</bold>, aspartate aminotransferase; <bold>CFTR</bold>, cystic fibrosis transmembrane conductance regulator; <bold>CK</bold>, creatine kinase; <bold>h</bold>, hour(s); <bold>LFT</bold>, liver function test; <bold>mo</bold>, month(s); <bold>NR</bold>, not reported; <bold>NS</bold>, not specified; <bold>ppFEV<sub>1</sub></bold>, percent predicted Forced Expiratory Volume in 1 sec; <bold>RLS</bold>, restless leg syndrome; <bold>SAE</bold>, serious adverse events; <bold>ULN</bold>, upper limit of normal; <bold>URTI</bold>, upper respiratory tract infection; <bold>wk</bold>, week(s); <bold>yr,</bold> year(s).</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="jcm-10-00023-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">jcm-10-00023-t002_Table 2</object-id>
      <label>Table 2</label>
      <caption>
        <p>Summary of characteristics and results of cohort or survey studies in abstract form.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Population</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>n</italic>
</th>
            <th colspan="3" align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Overall Adverse Events (AE) <sup>a,b</sup></th>
            <th colspan="3" align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Dose Modification, Interruption, or Discontinuation Due to AE <sup>a,b</sup></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="10" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Ivacaftor</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-jcm-10-00023" ref-type="bibr">62</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric<break/>- Mean: 5 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2265;1 gating mutation<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>AE in <italic toggle="yes">n</italic> = 2 </underline></bold><underline>(<bold>50%</bold>)</underline><bold>:</bold><break/>- URTI<break/>- Nasal congestion<break/>- Headache</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>NS<break/>NS<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>-<break/>-<break/>-</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-jcm-10-00023" ref-type="bibr">63</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric <break/>- Mean: 6 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2265;1 gating mutation<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Median: 87%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Transient rash<break/>- Increased obesity</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>2<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>20<break/>10</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-jcm-10-00023" ref-type="bibr">64</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Mean NR<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2265;1 copy S549R<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 54%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Liver enzyme derangement </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>13</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-jcm-10-00023" ref-type="bibr">65</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional Survey</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Mean: 26 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2265;1G551D<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 62%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">11 <sup>d</sup>
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>AE in <italic toggle="yes">n</italic> = 8 </underline></bold><underline>(<bold>73%</bold>) <bold><sup>d</sup></bold></underline><bold>:</bold><break/>- Transient rash<break/>- Dizziness<break/>- Unspecified AE</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>NS<break/>NS<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>-<break/>-<break/>-</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td colspan="10" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Lumacaftor/Ivacaftor</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-jcm-10-00023" ref-type="bibr">66</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric <break/>- Mean: 13 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 91%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Acute drop in ppFEV<sub>1</sub>
<break/> (asymptomatic)<break/>- Chest tightness, tachypnea <break/> (requiring oxygen)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1<break/>&#x2003;<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>7<break/>&#x2003;<break/>7</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Reduced dose </underline></bold>*:<break/>- Chest tightness, tachypnea<break/>&#x2003;<break/>* Eventual titration to full dose</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>7</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-jcm-10-00023" ref-type="bibr">67</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric <break/>- Mean: 14 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 87%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Drop in ppFEV<sub>1</sub> requiring salbutamol</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>7</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>54</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B68-jcm-10-00023" ref-type="bibr">68</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Prospective Cohort</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Mean: 23 yr <sup>e</sup><break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean 61% <sup>e</sup></td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">369</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold>:</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Bronchospasm<break/>- Dyspnea<break/>- Abnormal respiration <break/>- Unspecified respiratory AE<break/>- Unspecified AE </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">15<break/>12<break/>7<break/>4<break/>120</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">4<break/>3<break/>2<break/>1<break/>33</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Unspecified AE</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-jcm-10-00023" ref-type="bibr">69</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult<break/>- Mean: 25 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">311</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>379 AE in <italic toggle="yes">n</italic> = 213 </underline></bold><underline>(<bold>68%</bold>)</underline><bold>:</bold><break/>- Dyspnea<break/>- Cough<break/>- GI discomfort (e.g., diarrhea, <break/> nausea, abdominal pain)<break/>- Headache<break/>- Fatigue<break/>- Unspecified</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>n <sup>f</sup></underline><break/>NS<break/>NS<break/>NS<break/>&#x2003;<break/>NS<break/>NS<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>31<break/>6<break/>31<break/>&#x2003;<break/>6<break/>5<break/>NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Interruption </underline></bold><underline>(<bold>stop/restart</bold>)</underline><bold>:</bold><break/>- Unspecified AE and other reasons <sup>g</sup><break/>&#x2003;<break/><bold><underline>Discontinuation</underline></bold>:<break/>- Unspecified AE and other reasons <sup>g</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>12<break/>&#x2003;<break/>&#x2003;<break/>42</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>4<break/>&#x2003;<break/>&#x2003;<break/>14</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-jcm-10-00023" ref-type="bibr">35</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort <sup>c</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Median: 31 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Median: 28%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Chest tightness, breathless<break/>- Rash</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>7<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>50<break/>7</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold>:<break/>- Respiratory AE and/or rash</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>4</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>29</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-jcm-10-00023" ref-type="bibr">70</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean NR<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Chest tightness *<break/>&#x2003;<break/>* <italic>n</italic> = 4 cases severe, requiring hospitalization for IV steroids and antibiotics</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>13</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>45</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Reduced dose</underline>:</bold><break/>- Chest tightness <break/>&#x2003;<break/><bold><underline>Discontinuation</underline></bold>:<break/>- Chest tightness</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>2<break/>&#x2003;<break/>&#x2003;<break/>5</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>7<break/>&#x2003;<break/>&#x2003;<break/>17</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B36-jcm-10-00023" ref-type="bibr">36</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Prospective Cohort <sup>c</sup></td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Mean NR <sup>h</sup><break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">32</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>AE in 88%</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>n <sup>f</sup></underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Interruption </underline></bold>
<underline>(<bold>stop/restart</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Respiratory AE<break/>- Drop in ppFEV<sub>1</sub></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NS<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">87<break/>-</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Unspecified AEA<break/>&#x2003;<break/><bold><underline>Discontinuation</underline></bold>:<break/>- Unspecified AE</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1<break/>&#x2003;<break/>&#x2003;<break/>8</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">3<break/>&#x2003;<break/>&#x2003;<break/>25</td>
          </tr>
          <tr>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B71-jcm-10-00023" ref-type="bibr">71</xref>]</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Retrospective Cohort</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult <break/>- Mean NR <break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1">34</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><bold><underline>AE in <italic toggle="yes">n</italic> = 29 </underline></bold><underline>(<bold>85%</bold>)</underline><bold>:</bold><break/>- Pulmonary exacerbation<break/>- Chest tightness<break/>- Dyspnea<break/>- Diarrhea<break/>- Abdominal pain</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>16<break/>9<break/>3<break/>3<break/>3</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><underline>%</underline><break/>47<break/>26<break/>9<break/>9<break/>9</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold><underline>Discontinuation</underline>:</bold><break/>- Unspecified AE</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><italic><underline>n</underline></italic><break/>10</td>
            <td rowspan="3" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><underline>%</underline><break/>29</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Serious AE in <italic toggle="yes">n</italic> = 8 </underline></bold>
<underline>(<bold>24%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Respiratory failure <sup>i</sup><break/>- Unspecified AE</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1<break/>7</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">3<break/>21</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-jcm-10-00023" ref-type="bibr">72</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult <break/>- Mean: 26 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 68%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">103</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Interruption/discontinuation </underline><sup>j</sup></bold>:<break/>- Chest tightness and/or pain<break/>- Elevated LFTs</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>17<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>17<break/>-</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B73-jcm-10-00023" ref-type="bibr">73</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Retrospective Cohort</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean: 31 yr <break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 50%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">71</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>AE in <italic toggle="yes">n</italic> = 41 </underline></bold>
<underline>(<bold>58%</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Discontinuation</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Chest tightness<break/>- Dyspnea<break/>- Increased cough<break/>- GI (pain, constipation, or <break/> diarrhea)<break/>- Rash<break/>- Pruritus<break/>- Irregular menses or metrorrhagia<break/>- Breast tension<break/>- Headache<break/>- Myalgia</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">22<break/>8<break/>4<break/>6<break/>&#x2003;<break/>4<break/>1<break/>3<break/>2<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">31<break/>11<break/>6<break/>9<break/>&#x2003;<break/>6<break/>1<break/>4<break/>3<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Dyspnea<break/>- Chest tightness<break/>- Increased cough<break/>- Fatigue</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">7<break/>6<break/>3<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">10<break/>9<break/>4<break/>1</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-jcm-10-00023" ref-type="bibr">74</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Mean NR <sup>h</sup><break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">54</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold>:<break/>- Chest tightness, dyspnea, and/or drop in ppFEV<sub>1</sub></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>8</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>15</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-jcm-10-00023" ref-type="bibr">75</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean: 31 yr <break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Increased work of breathing or <break/> chest tightness<break/>- Drop in ppFEV<sub>1</sub></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>12<break/>&#x2003;<break/>5</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>43<break/>&#x2003;<break/>18</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold><break/>- Respiratory intolerance vs. pulmonary <break/> exacerbation<break/>- Persistent respiratory intolerance/chest <break/> tightness<break/>- Rash and swelling of face<break/>- Increased anxiety</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1<break/>&#x2003;<break/>3<break/>&#x2003;<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>4<break/>&#x2003;<break/>11<break/>&#x2003;<break/>4<break/>4</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B76-jcm-10-00023" ref-type="bibr">76</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Retrospective Cohort</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean NR<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">46</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Discontinuation</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Drop in ppFEV<sub>1</sub>
<break/>- Transaminitis</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">21<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">46<break/>4</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Dyspnea, cough, CFPEx, and/or chest <break/> tightness<break/>- Transaminitis<break/>- Headache<break/>- Muscle ache<break/>- Fatigue<break/>- Rash</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">4<break/>&#x2003;<break/>1<break/>NS<break/>NS<break/>NS<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">9<break/>&#x2003;<break/>2<break/>-<break/>-<break/>-<break/>-</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-jcm-10-00023" ref-type="bibr">77</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean NR<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline>:</bold><break/>- SOB and/or drop in ppFEV<sub>1</sub></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>15</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>54</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B78-jcm-10-00023" ref-type="bibr">78</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Retrospective Cohort</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Mean: 32 yr <sup>h</sup><break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 62%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">20</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Overall AE</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Interruption </underline></bold>
<underline>(<bold>stop/restart</bold>)</underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Chest tightness<break/>- Elevated LFTs<break/>- Upset stomach<break/>- Increased stool output<break/>- Rash<break/>- Elevated thyroid function test<break/>- RA exacerbation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">-<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Unspecified AE<break/> &#x2003;- full-dose restart<break/> &#x2003;- half-dose restart<break/>&#x2003;<break/><bold><underline>Discontinuation</underline></bold>:<break/>- Unspecified AE</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>2<break/>4<break/>&#x2003;<break/>&#x2003;<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>10<break/>20<break/>&#x2003;<break/>&#x2003;<break/>10</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-jcm-10-00023" ref-type="bibr">79</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Mean NR <sup>h</sup><break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Heartburn/reflux<break/>- Abdominal pain<break/>- Loose/oily stools</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>20<break/>19<break/>17</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>33<break/>32<break/>28</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td colspan="2" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-jcm-10-00023" ref-type="bibr">80</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Mean: 29 yr <sup>h,k</sup><break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 80% <sup>k</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold>:<break/>Overall total:<break/>&#x2003;- Respiratory AE (70%) <sup>f</sup><break/>&#x2003;- Unspecified reasons <sup>g</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>11<break/>NS<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>32<break/>-<break/>-</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-jcm-10-00023" ref-type="bibr">81</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort <sup>l</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric<break/>- Mean NR<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- AST &gt;3x ULN</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>5</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-jcm-10-00023" ref-type="bibr">82</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort <sup>l</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric and Adult <break/>- Range: 13&#x2013;48 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">47</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline>:</bold><break/>- Thoracic oppression and unspecified AE</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>4</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>9</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-jcm-10-00023" ref-type="bibr">83</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort <sup>l</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean: 28 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 61%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">46</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline>:</bold><break/>- Dyspnea, increased sputum, and unspecified AE</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>6</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>13</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-jcm-10-00023" ref-type="bibr">37</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort <sup>c,l</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean: 31 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 28%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Drop in ppFEV<sub>1</sub><break/>- Dyspnea, chest tightness, or chest <break/> pain<break/>- Increased sputum<break/>&#x2003;<break/>* Based on 31 trials of LUM/IVA in 30 patients</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>30 *<break/>25 *<break/>&#x2003;<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>97<break/>81<break/>&#x2003;<break/>-</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline>:</bold><break/>- Respiratory AE, unspecified<break/>- Hypertension</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>3<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>10<break/>3</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-jcm-10-00023" ref-type="bibr">84</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort <sup>l</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean: 31yr <break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 40%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Interruption</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Interruption in <italic toggle="yes">n</italic> = 1 </underline></bold><underline>(<bold>13%</bold>)</underline>:<break/>- Drop in ppFEV<sub>1</sub><break/>- Eczema</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>13<break/>13</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-jcm-10-00023" ref-type="bibr">38</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort <sup>c,l</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Mean NR <sup>h</sup><break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold>:<break/>- Chest tightness and dyspnea</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>4</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>21</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B85-jcm-10-00023" ref-type="bibr">85</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Cross-sectional <break/>questionnaire</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Mean NR <sup>h</sup><break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">11</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold><underline>AE in <italic toggle="yes">n</italic> = 5 </underline></bold><underline>(<bold>46%</bold>)</underline><bold>:</bold><break/>- Increased cough<break/>- Chest pain<break/>- Trouble breathing<break/>- Chest tightness<break/>- Stomach pain</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Discontinuation</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">4<break/>2<break/>2<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">36<break/>18<break/>18<break/>9<break/>9</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Increased cough</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
          </tr>
          <tr>
            <td colspan="10" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Tezacaftor/Ivacaftor</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-jcm-10-00023" ref-type="bibr">86</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Pediatric<break/>- Mean: 16 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508 homozygous or heterozygous<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 82%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">72</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold>:<break/>Overall total:<break/>- New-onset hemoptysis<break/>- Persistent nausea/vomiting<break/>- Elevated LFTs<break/>- Mental health changes<break/>- Alterations in blood glucose<break/>- Acholic stools</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>8<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS<break/>NS</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>11<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-jcm-10-00023" ref-type="bibr">87</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Mean NR <sup>h</sup><break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>NR<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">50</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- AE not specified</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>5</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>10</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline>:</bold><break/>- Liver function abnormalities</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>2</td>
          </tr>
          <tr>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B88-jcm-10-00023" ref-type="bibr">88</xref>]</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">Prospective Cohort</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Mean: 34 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 51%</td>
            <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">5 <sup>m</sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>AE in <italic toggle="yes">n</italic> = 5 </underline></bold>
<underline>(<bold>11%</bold>) <bold><sup>m</sup></bold></underline>
<bold>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
<sup>m</sup>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<bold><underline>Discontinuation</underline>:</bold>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<italic><underline>n</underline></italic>
</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<underline>%</underline>
<sup>m</sup>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Sleep pattern disturbance<break/>- Out of body experience<break/>- Visual hallucination<break/>- Depersonalization<break/>- &#x201C;Brain fog&#x201D;<break/>- Severe migraine</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2<break/>1<break/>1<break/>1<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">5<break/>2<break/>2<break/>2<break/>2<break/>2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">- Out of body experience, visual hallucination<break/>- Depersonalization, &#x201C;brain fog&#x201D;<break/>- Severe migraine</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2<break/>2<break/>2</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-jcm-10-00023" ref-type="bibr">89</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Mean NR<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2206;F508/&#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean NR</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">See <bold>Discontinuation</bold></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinuation</underline></bold>:<break/>- Hair loss and fatigue</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">%<break/>6</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-jcm-10-00023" ref-type="bibr">39</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort <sup>c,l</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult <break/>- Mean NR<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>NR <break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 34%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>AE in <italic toggle="yes">n</italic> = 3 </underline></bold><underline>(<bold>14%</bold>)</underline><bold>:</bold><break/>- Rash<break/>- Blurred vision<break/>- Viral symptoms</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>2<break/>1<break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>9<break/>5<break/>5</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Discontinued</underline>:</bold><break/>- Blurred vision</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>5</td>
          </tr>
          <tr>
            <td colspan="10" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Elexacaftor/Tezacaftor/Ivacaftor</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-jcm-10-00023" ref-type="bibr">40</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective Cohort</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Baseline Age</bold><break/>Adult<break/>- Mean: 36 yr<break/>&#x2003;<break/><bold>CFTR Genotype</bold><break/>&#x2265;1 copy &#x2206;F508<break/>&#x2003;<break/><bold>Baseline ppFEV<sub>1</sub></bold><break/>Mean: 31%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2003;<break/>- Transaminitis</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic><underline>n</underline></italic><break/>4</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>%</underline><break/>36</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">None reported</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p><sup>a</sup> Rates not reported for all AE, as indicated by &#x2018;NS&#x2019;; <sup>b</sup> To avoid redundancy, if AE only reported in context of dose modification, interruption, and/or discontinuation of therapy, it was not listed in overall AE; <sup>c</sup> Study population part of a compassionate, &#x2018;early access&#x2019;, &#x2018;expanded access&#x2019;, &#x2018;managed access&#x2019;, or &#x2018;named patient&#x2019; program; <sup>d</sup> Total study cohort of <italic>n</italic> = 11, but only <italic>n</italic> = 9 patients completed symptom questionnaire; AE frequency calculated based on total <italic>n</italic> = 11, <sup>e</sup> Mean baseline age and ppFEV<sub>1</sub> based on <italic>n</italic> = 135 in final analysis of outcomes assessing effectiveness; <italic>n</italic> = 234 excluded from this analysis; <sup>f</sup> As reported, unable to accurately determine the absolute number of patients who experienced AE ; <sup>g</sup> Frequency of specific reasons for interruption or discontinuation not clear and include reasons unrelated to AE; <sup>h</sup> Included age groups (i.e., pediatric and/or adult) not specified; <sup>i</sup> Respiratory failure occurred in 1 individual on two occasions, both within 24 h of initiating and reinitiating LUM/IVA; <sup>j</sup> Of the <italic>n</italic> = 25 who stopped, 9 restarted and 6 of experienced the same AE; unclear which AE the 3 who restarted experienced and whether the 6 who experienced the same AE then discontinued permanently; <sup>k</sup> Mean baseline age and ppFEV<sub>1</sub> based on <italic>n</italic> = 23 in final analysis of outcomes assessing effectiveness; <italic>n</italic> = 11 excluded from this analysis; <sup>l</sup> Unable to discern if prospective versus retrospective based on reported information; <sup>m</sup> Total study cohort of <italic>n</italic> = 44, but focused on neurocognitive AE in <italic>n</italic> = 5; AE frequencies calculated based on total <italic>n</italic> = 44. <bold>AST</bold>, aspartate aminotransferase; <bold>CFTR</bold>, cystic fibrosis transmembrane conductance regulator; <bold>CFPEx</bold>, cystic fibrosis pulmonary exacerbation; <bold>GI</bold>, gastrointestinal; <bold>LFT</bold>, liver function test; <bold>LUM/IVA</bold>, lumacaftor/ivacaftor; <bold>NR</bold>, not reported; <bold>NS</bold>, not specified; <bold>ppFEV<sub>1</sub>,</bold> percent predicted forced expiratory volume in 1 sec; <bold>RA</bold>, rheumatoid arthritis; <bold>SOB</bold>, shortness of breath; <bold>ULN</bold>, upper limit of normal; <bold>URTI</bold>, upper respiratory tract infection; <bold>yr,</bold> year(s).</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="jcm-10-00023-t003" orientation="portrait" position="float">
      <object-id pub-id-type="pii">jcm-10-00023-t003_Table 3</object-id>
      <label>Table 3</label>
      <caption>
        <p>Summary of characteristics and results of case series and case reports.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Location</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>n</italic>
</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient Information</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description of Adverse Events (AE) <sup>a</sup></th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose Modification, Interruption or Discontinuation of Therapy, or Other Intervention(s) Due to AE</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="6" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Ivacaftor</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-jcm-10-00023" ref-type="bibr">46</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Germany</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 1</underline></bold>: 55F<break/><bold><underline>Case 2</underline>:</bold> 55F</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Bronchial tightness<break/>&#x2013; AST and ALT 2-3x ULN</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; No interventions reported &#x2013; resolved by approximately 14 days<break/>&#x2013; <bold>IVA decreased to half-dose</bold>; transaminase subsequently normalized</td>
          </tr>
          <tr>
            <td colspan="6" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Lumacaftor/Ivacaftor</bold>
</td>
          </tr>
          <tr>
            <td rowspan="5" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>]</td>
            <td rowspan="5" align="left" valign="top" style="border-bottom:solid thin" colspan="1">United States</td>
            <td rowspan="5" align="left" valign="top" style="border-bottom:solid thin" colspan="1">5</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 1</underline></bold>: 15F</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 2 wk: new depression and SI<break/>&#x2013; Within 7 mo: increased anxiety attack</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Initiation of CBT and sertraline<break/>&#x2013; <bold>LUM/IVA discontinued at 11 mo</bold> (anxiety, menstrual irregularity); mood improved within 10 days of discontinuation </td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 2</underline></bold>: 17F</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Within 2 mo: new worsening baseline depression, new SI</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Initiation of CBT, increased fluoxetine dose<break/>&#x2013; <bold>LUM/IVA discontinued at 9 mo</bold> (GI intolerance); mood improved following discontinuation</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 3</underline></bold>: 14F</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Within 9 mo: new depression and SI<break/>&#x2013; Suicide attempt (ibuprofen overdose)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Initiation of CBT and fluoxetine; psychiatric hospitalization<break/>&#x2013; <bold>LUM/IVA discontinued at 12 mo</bold> (depression, SI); mood improved following discontinuation</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 4</underline>:</bold> 12F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 2 mo: new depression and SI<break/>&#x2013; Suicide attempt (cutting)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Initiation of CBT; psychiatric hospitalization; <underline>After LUM/IVA</underline>
<underline>discontinuation</underline>: initiation of sertraline<break/>&#x2013; <bold>LUM/IVA discontinued at 3 mo</bold> (depression, SI); mood improved within 3 wk of discontinuation</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 5</underline>:</bold> 17F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 7 mo: worsening baseline depression<break/>&#x2013; <underline>After LUM/IVA discontinuation</underline>: suicide attempt (escitalopram overdose)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Initiation of escitalopram; <underline>After LUM/IVA discontinuation</underline>: trials of mirtazapine and fluoxetine; psychiatric hospitalization<break/>&#x2013; <bold>LUM/IVA discontinued at 7 mo</bold> (depression)<break/>&#x2013; Continued worsening depression; <bold>LUM/IVA restarted months later</bold>
</td>
          </tr>
          <tr>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>]</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">United States</td>
            <td rowspan="4" align="left" valign="top" style="border-bottom:solid thin" colspan="1">4</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 1</underline></bold>: 44F</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Within 1 mo: worsening baseline depression and anxiety, limiting adherence to CF therapies<break/>&#x2013; Increased cough and sputum, ppFEV<sub>1</sub> decline from 74% to 49%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Increased citalopram dose; citalopram replaced by alternative psychotropic medications; hospitalizations for CFPEx management<break/>&#x2013; <bold>LUM/IVA discontinued at 4 mo</bold> (depression, anxiety); mood and anxiety improved, but not to baseline until prior citalopram resumed</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 2</underline></bold>: 26M</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Within 3 mo: worsened depression (baseline bipolar disorder and recent bereavement)<break/>&#x2013; ppFEV<sub>1</sub> decline from 69% to 44%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Change in psychotropic medications; CFPEx management<break/>&#x2013; <bold>LUM/IVA continued unchanged</bold><break/>&#x2013; Mood and ppFEV<sub>1</sub> back to baseline several months after interventions</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 3</underline></bold>: 36M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Worsening baseline anxiety and opioid use disorder; subsequent worsening baseline depression, limiting medication adherence<break/>&#x2013; ppFEV<sub>1</sub> decline from 38% to 28%</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Change in psychotropic medications; hospitalization for psychiatric evaluation and CFPEx management; intensive outpatient mental health program<break/>&#x2013; <bold>LUM/IVA discontinued</bold> (non-adherence)</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 4</underline></bold>: 13M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 9 mo: worsening baseline anxiety (supported by increased GAD-7 score) with clinical impairment</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Re-initiation of CBT; increased citalopram dose <break/>&#x2013; <bold>LUM/IVA continued unchanged</bold>; ongoing residual anxiety</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-jcm-10-00023" ref-type="bibr">49</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">United States</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case</underline></bold>: 31F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Within 6 wk: increased fatigue, &#x201C;more winded&#x201D;, dyspnea, &#x201C;drowning&#x201D; in sputum and sinus secretions<break/>&#x2013; ppFEV<sub>1</sub> decline from 58% to 34% </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Hospitalization for CFPEx management and aggressive pulmonary rehab<break/>&#x2013; <bold>LUM/IVA continued unchanged</bold>; respiratory symptoms &#x2018;near&#x2019; baseline and ppFEV<sub>1</sub> improved to 42% (below baseline) after 2-wk hospitalization</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-jcm-10-00023" ref-type="bibr">90</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">United States</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case</underline></bold>: 36M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Immediate severe dyspnea, chest tightness<break/>&#x2013; ppFEV<sub>1</sub> drop from 31% to 23%; SpO<sub>2</sub> drop from 95% at rest to 87% on exertion </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; <bold>LUM/IVA decreased to half-dose</bold> (respiratory AE)<break/>&#x2013; <bold>LUM/IVA discontinued at 6 mo</bold> (ongoing respiratory AE despite dose reduction); immediate improvement in respiratory AE, resolution of hypoxia on exertion, 1 mo ppFEV<sub>1</sub> returned to baseline</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-jcm-10-00023" ref-type="bibr">50</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Germany</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case</underline></bold>: 20F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 2 wk: malaise, severe progressive rash, pruritus, and facial swelling <break/>&#x2013; Skin prick test negative for acute or delayed reaction to IVA, LUM/IVA, and TEZ/IVA <break/>&#x2013; In vitro T-cell-mediated reaction to LUM</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Hospitalization for high-dose corticosteroids<break/>&#x2013; <bold>LUM/IVA discontinued</bold>; rapid resolution of symptoms following discontinuation</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">United States</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case</underline></bold>: 18F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 7 days: non-confluent, red, bumpy, pruritic rash on shins and forearms; persisted 1 mo<break/>&#x2013; Symptom recurrence upon rechallenging (within 3 and 7 days of first and second rechallenge, respectively)</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; <bold>LUM/IVA discontinued;</bold> resolution of rash<break/>&#x2013; <bold>Retrialed at full- and half-dose</bold> (retrials both 1 wk after discontinuation)<break/>&#x2013; <bold>LUM/IVA discontinued indefinitely</bold> (recurrent rash); resolution of rash following discontinuation</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-jcm-10-00023" ref-type="bibr">91</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">United States</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case</underline></bold>: 27M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 4 wk: abdominal pain, diarrhea, N/V<break/>&#x2013; AlkP 8477 U/L (other LFTs WNL) </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Hospitalization for supportive care, rule-out other cause<break/>&#x2013; <bold>LUM/IVA discontinued</bold>; AlkP declined to WNL by 6 mo later</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-jcm-10-00023" ref-type="bibr">92</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">France</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case</underline></bold>: 26M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; New myalgia following acyclovir initiation<break/>&#x2013; Weeks later: rhabdomyolysis with worsening myalgia, muscle edema, dark urine, CK 17,582 U/L, AST 10x ULN, and ALT 4x ULN</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Hospitalization for supportive care<break/>&#x2013; <bold>LUM/IVA discontinued</bold> (along with acyclovir); CK returned to normal, but residual lower limb myalgia</td>
          </tr>
          <tr>
            <td colspan="6" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Tezacaftor/Ivacaftor</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">United States</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case</underline></bold>: 18F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 3 days: non-confluent, red, bumpy, pruritic rash on shins and forearms <break/>&#x2013; Symptom recurrence within 7 days upon rechallenging </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; <bold>TEZ/IVA discontinued</bold>; resolution of rash<break/>&#x2013; <bold>Retrialed 2 mo later</bold>, <bold>then discontinued</bold> (recurrent rash)<break/>&#x2013; IVA desensitization protocol, titrating to full-dose IVA over 10 days; <bold>TEZ/IVA restarted successfully thereafter</bold></td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-jcm-10-00023" ref-type="bibr">51</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Australia</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case</underline></bold>: 21F</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Long-term azithromycin therapy and no past cardiac arrhythmia before initiation<break/>&#x2013; 36 wk: PR interval of 334 ms (WNL at baseline then 4, 12, and 24 wk). QT and QTc normal<break/>&#x2013; <underline>After TEZ/IVA held</underline>, PR interval WNL at 4 wk<break/>&#x2013; <underline>After TEZ/IVA retrialed</underline>: 39 wk, PR interval 25&#x2013;30 ms longer than at 4, 8, 12, and 24 wk</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Rule-out other causes (e.g., echocardiogram, blood work, viral testing) <break/>&#x2013; <bold>TEZ/IVA held</bold> (PR prolonged on repeat ECG at 37 and 38 wk)<break/>&#x2013; <bold>TEZ/IVA retrialed ~8 mo later</bold><break/>&#x2013; Azithromycin discontinued at 39 wk (PR interval lengthening on ECG); PR interval back to baseline 4 wk later and remained normal thereafter<break/>&#x2013; <bold>TEZ/IVA continued</bold></td>
          </tr>
          <tr>
            <td colspan="6" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Elexacaftor/Tezacaftor/Ivacaftor</bold>
</td>
          </tr>
          <tr>
            <td rowspan="7" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B52-jcm-10-00023" ref-type="bibr">52</xref>]</td>
            <td rowspan="7" align="left" valign="top" style="border-bottom:solid thin" colspan="1">United States</td>
            <td rowspan="7" align="left" valign="top" style="border-bottom:solid thin" colspan="1">7</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 1</underline></bold>: 23M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 12 days: new right testicular discomfort, intermittent sharp pain, sensitivity to touch and pressure </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; OTC analgesics<break/>&#x2013; <bold>ELX/TEZ/IVA unchanged</bold>; symptoms resolved in 12 days</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 2</underline></bold>: 23M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 3 days: new right testicular soreness</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; OTC analgesics<break/>&#x2013; <bold>ELX/TEZ/IVA unchanged</bold>; symptoms resolved in 7 days</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 3</underline></bold>: 17M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 2 days: new left testicular pain, difficulty urinating, lower abdominal pain</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; No interventions reported<break/>&#x2013; <bold>ELX/TEZ/IVA unchanged</bold>; symptoms resoled in 1 day</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 4</underline></bold>: 22M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 7 days: new sharp, twisting, cramping testicular pain</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; <bold>ELX/TEZ/IVA interrupted for 2 days, restarted at full dose</bold>; symptoms resolved in 7 days, no recurrence reported</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 5</underline></bold>: 30M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 3&#x2013;4 days: new right testicular pain and discomfort, increased ejaculate volume<break/>&#x2013; Constipation identified on abdominal CT</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; No interventions reported<break/>&#x2013; <bold>ELX/TEZ/IVA unchanged</bold>; symptoms resolved in 21 days</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 6</underline></bold>: 37M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 2&#x2013;3 days: new testicular pain and discomfort when driving &#x201C;bumpy roads&#x201D;</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; No interventions reported<break/>&#x2013; <bold>ELX/TEZ/IVA unchanged</bold>; symptoms resolved in 2&#x2013;3 days</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 7</underline></bold>: 39M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 3 days: new left testicular pain <break/>&#x2013; PE and ultrasound findings of bilateral epididymoorchitis and scrotal wall cellulitis</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; OTC analgesics; antibiotic for epididymoorchitis<break/>&#x2013; <bold>ELX/TEZ/IVA dose reduced to 1 tab daily</bold>, <bold>titrated to full dose</bold>; symptoms resolved in 1&#x2013;2 days, no recurrence reported</td>
          </tr>
          <tr>
            <td rowspan="7" align="left" valign="top" style="border-bottom:solid thin" colspan="1">[<xref rid="B53-jcm-10-00023" ref-type="bibr">53</xref>]</td>
            <td rowspan="7" align="left" valign="top" style="border-bottom:solid thin" colspan="1">United States</td>
            <td rowspan="7" align="left" valign="top" style="border-bottom:solid thin" colspan="1">7</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 1</underline></bold>: 38F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Within 1 mo: RUQ pain <break/>&#x2013; Peak LFTs: AST 79 U/L, ALT 59 U/L, AlkP 103 U/L, total bili 12 umol/L</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Laparoscopic cholecystectomy (chronic cholecystitis with cholelithiasis; serosal fibrous adhesions) <sup>b</sup><break/>&#x2013; <bold>ELX/TEZ/IVA unchanged</bold> (except morning dose held pre-op) </td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 2</underline></bold>: 33F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Day 1: RUQ pain, nausea<break/>&#x2013; Peak LFTs: AST 69 U/L, ALT 106 U/L, AlkP 138 U/L, total bili 55 umol/L</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Laparoscopic cholecystectomy (acute cholecystitis with cholelithiasis, mucosal necrosis) <sup>b</sup>; common biliary duct stent for persistent bile leak<break/>&#x2013; <bold>ELX/TEZ/IVA held Day 3&#x2013;7</bold> (biliary colic), restarted post-op; <bold>held 1.5 days peri-op for stent placement</bold> (post-op complications) <sup>c</sup><break/>&#x2013; <bold>Resumed full dose post-stent placement</bold>; symptoms resolved</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 3</underline></bold>: 28M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Day 3: epigastric radiating to RUQ; N/V<break/>&#x2013; Peak LFTs: AST 34 U/L, ALT 37 U/L, AlkP 259 U/L, total bili 9 umol/L</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Laparoscopic cholecystectomy (chronic cholecystitis with cholelithiasis, extensive mucosal erosion, serositis, wall fibrosis) <sup>b</sup><break/>&#x2013; <bold>ELX/TEZ/IVA unchanged</bold> (except morning dose held pre-op)</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 4</underline></bold>: 28M </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Within 1 day: RUQ pain, nausea <sup>c</sup><break/>&#x2013; Peak LFTs: AST 42 U/L, ALT 65 U/L, AlkP 121 U/L, total bili 22 umol/L</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Laparoscopic cholecystectomy (chronic cholecystitis with cholelithiasis) <sup>b</sup><break/>&#x2013; <bold>ELX/TEZ/IVA held 2 wk pre-op, resumed 4 wk post-op</bold>, symptoms resolved <break/>&#x2013; <bold>ELX/TEZ/IVA subsequently held</bold> (transaminitis), plans to retrial reduced dose upon transaminase normalization <sup>c</sup></td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 5</underline></bold>: 40F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Day 1: lower abdominal and epigastric pain<break/>&#x2013; Day 7: severe RUQ pain <break/>&#x2013; Peak LFTs: AST 49 U/L, ALT 56 U/L, AlkP 335 U/L, total bili 10 umol/L</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; No surgical intervention<break/>&#x2013; <bold>ELX/TEZ/IVA unchanged</bold></td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 6</underline></bold>: 26F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; 2 wk: progressive abdominal pain; N/V<break/>&#x2013; Peak LFTs: AST 516 U/L, ALT 283 U/L, AlkP 134 U/L, total bili 26 umol/L</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Laparoscopic cholecystectomy (chronic cholecystitis with cholelithiasis) <sup>b</sup><break/>&#x2013; <bold>ELX/TEZ/IVA unchanged</bold> (except morning dose held pre-op)</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case 7</underline></bold>: 27F </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Day 1: central abdominal pain, anorexia, N/V <break/>&#x2013; Peak LFTs of AST 103 U/L, ALT 36 U/L, AlkP 253 U/L, total bili 10 umol/L</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Hospitalization for symptom management; elective laparoscopic cholecystectomy at later date (chronic cholecystitis with cholelithiasis) <sup>b</sup><break/>&#x2013; <bold>ELX/TEZ/IVA held Day 5</bold> (biliary colic), restarted Day 6 <sup>c</sup><break/>&#x2013; <bold>ELX/TEZ/IVA held Day 7</bold> (symptom recurrence), restarted Day 8 <sup>c</sup>
<break/>&#x2013; Symptoms resolved (only held morning dose pre-op thereafter) <sup>c</sup></td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">United States</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><underline>Case</underline></bold>: 19F</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; Within 2 wk: worsening baseline depression with new SI. At 3 wk, sleep paralysis with vivid hypnopompic hallucinations on 3 consecutive nights (history of 3 episodes of sleep paralysis previously)<break/>&#x2013; <underline>After ELX/TEZ/IVA restarted</underline>: worsening depression and anxiety; subsequent improved depression and anxiety, resolved SI and sleep paralysis/hallucinations<break/>&#x2013; <underline>1&#x2013;2 mo after full-dose ELX/TEZ/IVA</underline>: oscillating anxiety and depression, intermittent SI and sleep paralysis<break/>&#x2013; <underline>After ELX/TEZ/IVA and IVA dose times switched</underline>: worsening depression and anxiety<break/>&#x2013; <underline>After decrease to ELX/TEZ/IVA 2 tabs in AM</underline>: some improvement in depression; recurrence of sleep paralysis with hypnopompic hallucination</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2013; <bold>ELX/TEZA/IVA discontinued at ~3 wk</bold> (worsening mood, sleep paralysis); resolution of sleep paralysis and hypnopompic hallucinations within 2 days<break/>&#x2013; Sertraline initiated for ongoing depression. Subsequently, sertraline and baseline quetiapine doses increased, clonazepam initiated<break/>&#x2013; <bold>ELX/TEZA/IVA restarted ~1 mo after discontinuation</bold> (respiratory status worsened); <bold>titrated to 1.5 ELX/TEZA/IVA tabs + 1.5 IVA tabs in AM</bold><break/>&#x2013; Sertraline and clonazepam doses increased, quetiapine dose decreased, bupropion initiated adjunctively (bupropion later stopped due to intolerance) <break/>&#x2013; <bold>ELX/TEZA/IVA titrated to full-dose</bold> over ~1 mo; <bold>ELX/TEZ/IVA tabs moved to PM, IVA tab to AM</bold> 1&#x2013;2 mo later (worsening psychiatric symptoms)<break/>&#x2013; <bold>ELX/TEZA/IVA dose decreased to 2 ELX/TEZ/IVA tabs in AM</bold> ~2 mo later (worsening depression and anxiety); improvement in depressive symptoms and cognition, sertraline, quetiapine, and clonazepam doses increased<break/>&#x2013; <bold>Continued 2 ELX/TEZ/IVA tabs in AM</bold>; symptoms of depression, anxiety, and sleep paralysis remained above baseline</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p><sup>a</sup> Time indicates onset from start of CFTR modulator; <sup>b</sup> Per the cholecystectomy pathology report; <sup>c</sup> Per personal communication with corresponding author <bold>AlkP</bold>, alkaline phosphatase; <bold>ALT</bold>, alanine aminotransferase; <bold>AM</bold>, ante meridiem (i.e., morning); <bold>AST</bold>, aspartate aminotransferase; <bold>bili</bold>, bilirubin; <bold>CBT</bold>, cognitive behavioral therapy; <bold>CF</bold>, cystic fibrosis; <bold>CFPEx</bold>, CF pulmonary exacerbation; <bold>CFTR</bold>, cystic fibrosis transmembrane conductance regulator; <bold>CK</bold>, creatine kinase; <bold>CT</bold>, computerized tomography; <bold>ECG</bold>, electrocardiogram; <bold>ELX/TEZ/IVA</bold>, elexacaftor/tezacaftor/ivacaftor; <bold>IVA</bold>, ivacaftor; <bold>GAD-7</bold>, Generalized Anxiety Disorder 7-item scale; <bold>GI</bold>, gastrointestinal; <bold>LUM/IVA</bold>, lumacaftor/ivacaftor; <bold>mo</bold>, month(s); <bold>N/V</bold>, nausea and vomiting; <bold>OTC</bold>, over-the-counter; <bold>ppFEV<sub>1</sub></bold>, percent predicted Forced Expiratory Volume in 1 sec; <bold>peri-op</bold>, perioperatively; <bold>PM</bold>, post meridiem (i.e., evening); <bold>pre-op</bold>, pre-operatively; <bold>RUQ</bold>, right upper quadrant; <bold>SI</bold> suicidal ideation; <bold>SpO<sub>2</sub></bold>, oxygen saturation; <bold>TEZ/IVA</bold>, tezacaftor/ivacaftor; <bold>ULN</bold>, upper limit of normal; <bold>wk</bold>, week(s); <bold>WNL</bold>, within normal limits.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="jcm-10-00023-t004" orientation="portrait" position="float">
      <object-id pub-id-type="pii">jcm-10-00023-t004_Table 4</object-id>
      <label>Table 4</label>
      <caption>
        <p>Study protocols, strategies, or suggested management and monitoring for reported adverse events.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CFTR Modulator</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adverse Event (AE)</th>
            <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Protocol/Strategy or Suggested Management/Monitoring for AE</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="4" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Protocols/Strategies utilized in study</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-jcm-10-00023" ref-type="bibr">43</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE and acute drop in ppFEV<sub>1</sub></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Initiation protocol:</bold>
<list list-type="order"><list-item><p>Nebulized salbutamol 15 min prior to first dose</p></list-item><list-item><p>Initiate half-dose (LUM 200 mg/IVA 125 mg twice daily), unless using granule formulation for pediatrics, which cannot be halved</p></list-item><list-item><p>At 1 week, increase to full-dose (LUM 400 mg/IVA 250 mg twice daily) as tolerated</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-jcm-10-00023" ref-type="bibr">31</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE resulting in discontinuation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Initiation protocol:</bold>
<list list-type="order"><list-item><p>First dose (1 tablet; LUM 200 mg/IVA 125 mg) in outpatient clinic with 3-h monitoring post-dose</p></list-item><list-item><p>Clinic to follow-up with patient every third day to reassess:
<list list-type="simple"><list-item><p>- increase dose by 1 tablet if tolerated</p></list-item><list-item><p>- decrease dose by 1 tablet if AE</p></list-item></list></p></list-item><list-item><p>If dose decreased due to AE:<list list-type="simple"><list-item><p>- once AE resolved and stable 2 weeks, increase dose by 1 tablet</p></list-item><list-item><p>- if AE symptoms persist, decrease dose further by 1 tablet</p></list-item></list></p></list-item><list-item><p>Goal to increase step-wise to full-dose (LUM 400 mg/IVA 250 mg q12 h)</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-jcm-10-00023" ref-type="bibr">44</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE resulting in discontinuation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Initiation strategy:</bold><break/>For patients with ppFEV<sub>1</sub> &#x2264; 40%, make effort to ensure use of combination inhaled beta<sub>2</sub>-agonist and corticosteroid, and lower initial dose for &#x2265;7 days before increasing to recommended full dose.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TEZ/IVA and IVA <sup>a</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-jcm-10-00023" ref-type="bibr">28</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Morbilliform drug eruption (Type IV drug allergy), recurrent upon rechallenge</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Desensitization protocol:</bold>
<list list-type="order"><list-item><p>Prepare IVA dilutions as directed and follow 10-day desensitization protocol, with IVA doses escalating from 5 mcg to 150 mg</p></list-item><list-item><p>Once IVA dose of 150 mg tolerated, continue 150 mg q12 h</p></list-item><list-item><p>If plan to start TEZ/IVA, continue IVA 150 mg q12 h for 3 days before transition to TEZ/IVA</p></list-item><list-item><p>If tolerated, counsel patient that ongoing adherence is prudent to avoid potential symptom recurrence and need for repeat desensitization</p></list-item></list>
</td>
          </tr>
          <tr>
            <td colspan="4" align="left" valign="top" style="border-bottom:solid thin" rowspan="1">
<bold>Suggested Strategy, Management, and/or Monitoring as a Result of Observations</bold>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-jcm-10-00023" ref-type="bibr">30</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Difficulty clearing liquefied airway secretions</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">For patients with severe lung disease, consider hospitalization for IV antibiotics and intense physiotherapy prior to initiation and for the first week of therapy.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IVA <sup>b</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-jcm-10-00023" ref-type="bibr">57</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cataract formation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">In pediatric patients, baseline and follow-up ophthalmological examinations should be performed to assess for cataract formation.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-jcm-10-00023" ref-type="bibr">41</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE and acute drop in ppFEV<sub>1</sub>
</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Closely monitor patients in clinic in the hours following the first dose, especially if low baseline ppFEV<sub>1</sub> and/or known reversible airway obstruction &#x2265; 12%.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-jcm-10-00023" ref-type="bibr">32</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE and acute drop in ppFEV<sub>1</sub></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">For patients with ppFEV<sub>1</sub> &lt; 40%, consider lower initiation dose and monitor closely following initiation for lung function decline and respiratory AE.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-jcm-10-00023" ref-type="bibr">25</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE resulting in discontinuation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">In patients with ppFEV<sub>1</sub> &lt; 40%, use caution with administration in case of poor tolerance.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-jcm-10-00023" ref-type="bibr">33</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE resulting in discontinuation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-treat with long-acting bronchodilator therapy before initiation, as a strategy to mitigate respiratory AEs and potential subsequent discontinuation.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-jcm-10-00023" ref-type="bibr">61</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE resulting in discontinuation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Consider slow titration of dose during treatment initiation to mitigate AE.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-jcm-10-00023" ref-type="bibr">75</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE resulting in discontinuation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Consider slower titration of dose or increased use of bronchodilators to mitigate AE on initiation, especially in patients with ppFEV<sub>1</sub> &#x2264; 40%.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-jcm-10-00023" ref-type="bibr">26</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE resulting in discontinuation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Suggested consideration for patients homozygous for <italic>F508del</italic> mutation:</bold><break/>Preference for TEZ/IVA over LUM/IVA may be considered in patients with ppFEV<sub>1</sub> &lt; 40%, as TEZ/IVA does not share the same respiratory AE profile of chest tightness and dyspnea causing high rates of discontinuation. </td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-jcm-10-00023" ref-type="bibr">49</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory AE upon initiation, presenting as pulmonary exacerbation </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Educate patients regarding potential for symptoms such as dyspnea, increased cough and sputum production, and malaise, as well as the importance of continuing pulmonary rehab and airway clearance</p></list-item><list-item><p>Consider avoiding combination of both dornase alfa and hypertonic saline upon LUM/IVA initiation to minimize excess watery secretions and feeling of &#x201C;drowning&#x201D; in secretions</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-jcm-10-00023" ref-type="bibr">45</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypertension</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Monitor blood pressure routinely both short- and long-term, and manage accordingly. </td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-jcm-10-00023" ref-type="bibr">47</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">New or worsening depression and anxiety</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Monitor all patients routinely for new or worsening depression and anxiety</p></list-item><list-item><p>In patients already on psychotropic medications, evaluate drug&#x2013;drug interactions prior to LUM/IVA initiation and consider increased monitoring and potential need to adjust psychotropic medications&#x2019; dose to maintain clinical effect after initiation</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-jcm-10-00023" ref-type="bibr">48</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Worsening depression and anxiety</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Suggested initiation monitoring and management in patients already on citalopram, escitalopram, or sertraline:</bold>
<list list-type="order"><list-item><p>Close monitoring of mental health, only changing treatment plan if needed</p></list-item><list-item><p>Counsel patients regarding potential for changes in mood and anxiety</p></list-item><list-item><p>Complete PHQ-9 and GAD-7 scales before and after LUM/IVA initiation</p></list-item><list-item><p>If available, consider drawing drug levels before and after LUM/IVA initiation, bearing in mind that changes in SSRI levels may not be clinically significant and the SSRI should be dosed to response and tolerability</p></list-item><list-item><p>Any decisions to adjust psychotropic therapy and/or to decrease or stop LUM/IVA should be a shared decision with the patient and should consider potential for medical and/or psychiatric decline</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">LUM/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-jcm-10-00023" ref-type="bibr">79</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Breakthrough heartburn or GERD due to increased PPI metabolism</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Suggested initiation monitoring and management for patients already on a PPI</bold>:<break/>Maintain patients on the lowest effective dose, increasing PPI dose only if patients present with breakthrough symptoms of heartburn/GERD. </td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TEZ/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-jcm-10-00023" ref-type="bibr">88</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurocognitive side effects</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Counsel patients regarding the possibility of neurocognitive AE (e.g., sleep pattern disturbances, visual hallucinations, out-of-body experiences) when initiating. </td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TEZ/IVA and ELX/TEZ/IVA <sup>c</sup></td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-jcm-10-00023" ref-type="bibr">51</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">First-degree heart block in combination with azithromycin </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Suggested monitoring for patients already on azithromycin</bold> (<bold>or initiating azithromycin in patients already on TEZ/IVA or ELX/TEZ/IVA <sup>b</sup></bold>):<break/>Obtain ECG at baseline and 3, 6, 9, and 12 months after combination to monitor for PR interval prolongation (onset may be delayed &gt;8 months).</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">ELX/TEZ/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-jcm-10-00023" ref-type="bibr">52</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Testicular pain following initiation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Until more is known about its impact on the reproductive system and fertility, may consider advising male patients to use contraception if having intercourse with females of child-bearing age, or refer to appropriate family planning resources if interested in pursuing pregnancy.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">ELX/TEZ/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-jcm-10-00023" ref-type="bibr">53</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Biliary colic following initiation</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior to initiation, assess for history of postprandial RUQ pain and/or biliary colic. Following initiation, closely monitor LFTs and symptoms of biliary colic.</td>
          </tr>
          <tr>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">ELX/TEZ/IVA</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B54-jcm-10-00023" ref-type="bibr">54</xref>]</td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">New or worsening depression, SI, anxiety, and/or sleep paralysis with hypnopompic hallucinations </td>
            <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Suggested initiation monitoring</bold>:<break/>Following initiation, screen and closely monitor for new and/or worsening symptoms of depression, SI, and anxiety hallucinations.</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p><sup>a</sup> In the case reported, the patient had the morbilliform drug eruption while taking both LUM/IVA and TEZ/IVA; however, the described desensitization protocol was specific to IVA, with transition to TEZ/IVA; <sup>b</sup> In the observational study, patients were receiving IVA. However, the product monographs of LUM/IVA, TEZ/IVA, and ELX/TEZ/IVA also recommend baseline and follow-up ophthalmological examinations in pediatric patients initiating therapy; <sup>c</sup> In the case reported, the patient had PR interval prolongation with the combination of azithromycin and TEZ/IVA; therefore, it is suggested that the same may occur with azithromycin in combination with ELX/TEZ/IVA. <bold>CFTR</bold>, cystic fibrosis transmembrane conductance regulator; <bold>ECG</bold>, electrocardiogram; <bold>ELX/TEZ/IVA</bold>, elexacaftor/tezacaftor/ivacaftor; <bold>GAD-7</bold>, general anxiety disorder-7; <bold>GERD</bold>, gastroesophageal reflux disease; <bold>h</bold>, hour(s); <bold>IVA</bold>, ivacaftor; <bold>LFTs</bold>, liver function tests; <bold>LUM/IVA</bold>, lumacaftor/ivacaftor; <bold>PHQ-9</bold>, patient health questionnaire-9; <bold>ppFEV<sub>1</sub></bold>, percent predicted Forced Expiratory Volume in 1 sec; <bold>PPI</bold>, proton pump inhibitor; <bold>q12 h</bold>, every 12 h; <bold>RUQ</bold>, right upper quadrant; <bold>SI</bold>, suicidal ideation; <bold>SSRI</bold>, selective serotonin reuptake inhibitor; <bold>TEZ/IVA</bold>, tezacaftor/ivacaftor.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Best Pract Res Clin Rheumatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Best Pract Res Clin Rheumatol</journal-id>
      <journal-title-group>
        <journal-title>Best Practice &amp; Research. Clinical Rheumatology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1521-6942</issn>
      <issn pub-type="epub">1532-1770</issn>
      <publisher>
        <publisher-name>Elsevier Ltd.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">7831864</article-id>
      <article-id pub-id-type="pii">S1521-6942(21)00003-6</article-id>
      <article-id pub-id-type="doi">10.1016/j.berh.2021.101661</article-id>
      <article-id pub-id-type="publisher-id">101661</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The interplay between neutrophils, complement, and microthrombi in COVID-19</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="au1">
          <name>
            <surname>Zuo</surname>
            <given-names>Yu</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author" id="au2">
          <name>
            <surname>Kanthi</surname>
            <given-names>Yogendra</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author" id="au3">
          <name>
            <surname>Knight</surname>
            <given-names>Jason S.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author" id="au4">
          <name>
            <surname>Kim</surname>
            <given-names>Alfred H.J.</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
          <xref rid="cor1" ref-type="corresp">&#x2217;</xref>
        </contrib>
        <aff id="aff1"><label>a</label>Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA</aff>
        <aff id="aff2"><label>b</label>Division of Intramural Research National Heart, Lung and Blood Institute Bethesda, Maryland, USA</aff>
        <aff id="aff3"><label>c</label>Division of Rheumatology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>&#x2217;</label>Corresponding author. 660 S. Euclid Ave. Campus Box 8045 St. Louis, MO, USA 63110.</corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>13</day>
        <month>1</month>
        <year>2021</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
        <day>13</day>
        <month>1</month>
        <year>2021</year>
      </pub-date>
      <elocation-id>101661</elocation-id>
      <permissions>
        <copyright-statement>&#xA9; 2021 Elsevier Ltd. All rights reserved.</copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
        </license>
      </permissions>
      <abstract id="abs0010">
        <p>As of the end of 2020, coronavirus disease 2019 (<bold>COVID-19</bold>) remains a global healthcare challenge with alarming death tolls. In the absence of targeted therapies, supportive care continues to be the mainstay of treatment. The hallmark of severe COVID-19 is a thromboinflammatory storm driven by innate immune responses. This manifests clinically as acute respiratory distress syndrome, and in some patients, widespread thrombotic microangiopathy. Neutrophils and complement are key players in the innate immune system, and their role in perpetuating fatal severe COVID-19 continues to receive increasing attention. Here, we review the interplay between neutrophils, neutrophil extracellular traps, and complement in COVID-19 immunopathology, and highlight potential therapeutic strategies to combat these pathways.</p>
      </abstract>
      <kwd-group id="kwrds0010">
        <title>Keywords</title>
        <kwd>COVID-19</kwd>
        <kwd>SARS-CoV-2</kwd>
        <kwd>Neutrophil extracellular traps</kwd>
        <kwd>NETs</kwd>
        <kwd>Complement</kwd>
        <kwd>Innate immunity</kwd>
        <kwd>Thrombotic microangiopathy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>Introduction</title>
      <p id="p0010">The coronavirus disease 2019 (<bold>COVID-19</bold>) is caused by the novel severe acute respiratory syndrome coronavirus 2 (<bold>SARS-CoV-2</bold>) [<xref rid="bib1" ref-type="bibr">1</xref>]. SARS-CoV-2 can present as asymptomatic infection or it may cause a wide spectrum of disease, ranging from mild upper respiratory tract infection to life-threatening sepsis with multiorgan failure [<xref rid="bib2" ref-type="bibr">2</xref>]. Given its rapid spread, high contagiousness, and lack of specific effective treatment, this pandemic remains a global healthcare challenge [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib4" ref-type="bibr">4</xref>].</p>
      <p id="p0015">SARS-CoV-2 displays a complex relationship with the human immune system [<xref rid="bib5" ref-type="bibr">5</xref>]. It has a unique ability during early infection to inhibit host type I interferon and natural killer cell responses, thereby compromising the body's antiviral defenses and leading to high viral loads in some patients [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>]. As a result of initial immune evasion, the body then mounts a compensatory hyperinflammatory response to aid in viral clearance. This is characterized by persistent hyperactivation of innate immunity with the overproduction of proinflammatory cytokines; hyperinfiltration of neutrophils, monocytes, and macrophages in lung parenchyma; and extensive epithelial and endothelial damage [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib8" ref-type="bibr">8</xref>]. This fulminant inflammatory storm can lead to acute respiratory distress syndrome, and, in some patients, provoke thrombotic widespread microangiopathy, which results in multiorgan failure and death. Neutrophils and complement are key players in our innate immune system, and their roles to potentiate severe COVID-19 continues to receive much attention. Here, we will review potential roles of neutrophils and complement in COVID-19 immunopathology and highlight some potential therapeutic strategies that may target these pathways.</p>
    </sec>
    <sec id="sec2">
      <title>Neutrophil extracellular traps and COVID-19</title>
      <p id="p0020">Neutrophils are the most abundant immune cells in circulation. They act as the first responder against various infections. For decades it was assumed that phagocytosis was the primary mechanism by which neutrophils neutralized pathogens. However, in 2004, Brinkmann and colleagues described another distinct activity of neutrophils, in which neutrophils release sticky extracellular &#x201C;spider webs&#x201D; composed of neutrophil-derived chromatin, microbicidal proteins, and mitochondrial remnants [<xref rid="bib9" ref-type="bibr">9</xref>]. They named this process neutrophil extracellular trap (<bold>NET</bold>) release or NETosis. NETs act to prevent the spread of infections and also use their antimicrobial peptides to kill pathogens [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>]. By exposing potential autoantigens, such as nucleic acids and modified proteins, NETs may also contribute to autoimmune responses in susceptible individuals [<xref rid="bib10" ref-type="bibr">10</xref>]. In recent years, it has also been revealed that NETs are prothrombotic [<xref rid="bib11" ref-type="bibr">11</xref>]. NETs activate platelets and the clotting cascade, and ultimately form an integral part of arterial and venous thrombi [<xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>].</p>
      <sec id="sec2.1">
        <title>Prior knowledge regarding NETs in viral infection</title>
        <p id="p0025">Many viruses can directly trigger NET release [<xref rid="bib16" ref-type="bibr">16</xref>]. HIV and respiratory syncytial virus (<bold>RSV</bold>) induce NETosis through toll-like receptor-mediated signaling [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib18" ref-type="bibr">18</xref>]. Viruses can also promote NETosis indirectly through triggers such as IL-8, type I interferon, and activated platelets [<xref rid="bib16" ref-type="bibr">16</xref>]. NETs contribute to antiviral immunity by immobilizing viral particles and inactivating them through the release of antimicrobial molecules such as myeloperoxidase, &#x3B1;-defensin, and cathelicidins [<xref rid="bib16" ref-type="bibr">16</xref>]. While NETs help contain viral spread, they may also cause damage to the host. For example, NETs promote alveolar-capillary injury in RSV and influenza models [<xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>, <xref rid="bib21" ref-type="bibr">[21]</xref>]. High levels of NETs are observed in patients with pneumonia-associated acute respiratory distress syndrome (<bold>ARDS</bold>) [<xref rid="bib16" ref-type="bibr">16</xref>], where isolated neutrophils have a lower threshold for spontaneous NET release.</p>
      </sec>
      <sec id="sec2.2">
        <title>NETs in COVID-19</title>
        <p id="p0030">It was recognized early in the pandemic that many patients hospitalized with COVID-19 demonstrate neutrophilia, which predicts critical illness and in-hospital mortality [<xref rid="bib22" ref-type="bibr">[22]</xref>, <xref rid="bib23" ref-type="bibr">[23]</xref>, <xref rid="bib24" ref-type="bibr">[24]</xref>]. Furthermore, autopsy reports of COVID-19 lung tissues revealed intra-alveolar and capillary neutrophil hyperinfiltration, acute capillaritis with fibrin deposition, and neutrophilic mucositis [<xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>, <xref rid="bib27" ref-type="bibr">[27]</xref>]. In April 2020, high levels of NETs in the blood of patients with severe COVID were first reported [<xref rid="bib28" ref-type="bibr">28</xref>]. This study assessed three markers of NETs [cell-free DNA, myeloperoxidase (<bold>MPO</bold>)-DNA complexes, and citrullinated histone H3 (<bold>Cit-H3</bold>)] in sera of 50 patients hospitalized with COVID-19 as compared to 30 healthy controls [<xref rid="bib28" ref-type="bibr">28</xref>]. All three markers were significantly elevated in COVID-19 sera, while high levels of NETs were associated with the severest disease [<xref rid="bib28" ref-type="bibr">28</xref>]. Notably, COVID-19 sera robustly triggers NET release from healthy donor neutrophils [<xref rid="bib28" ref-type="bibr">28</xref>]. These findings were soon confirmed by independent groups. In a prospective cohort of 33 patients hospitalized with COVID-19, high levels of MPO-DNA complexes were associated with severe respiratory status and worse clinical outcomes [<xref rid="bib29" ref-type="bibr">29</xref>]. Upon convalescence, levels of MPO-DNA complexes decreased [<xref rid="bib29" ref-type="bibr">29</xref>]. Others have also confirmed high circulating NETs among COVID-19 patients and their tendency to tracking with disease severity [<xref rid="bib30" ref-type="bibr">30</xref>,<xref rid="bib31" ref-type="bibr">31</xref>].</p>
        <p id="p0035">The first microscopic confirmation of NETs was reported in an autopsy series from New Orleans where degenerative neutrophils with strands of extracellular material that stained weakly positive for DNA were present in COVID-19 lungs [<xref rid="bib32" ref-type="bibr">32</xref>]. Histological detection of NETs has since been made not only in the pulmonary vasculature, but also in the microvasculature of the kidney and heart [<xref rid="bib30" ref-type="bibr">30</xref>,<xref rid="bib31" ref-type="bibr">31</xref>,<xref rid="bib33" ref-type="bibr">33</xref>]. Notably, the transcriptomic analysis of four COVID-19 patients&#x2019; lung tissue and bronchial alveolar lavage fluid revealed marked enrichment of NET-associated genes [<xref rid="bib34" ref-type="bibr">34</xref>]. In summary, several lines of data have supported the presence of NETs in the severest forms of COVID-19 (<xref rid="tbl1" ref-type="table">Table 1</xref>
).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Studies investigating NETs in COVID-19.</p></caption><alt-text id="alttext0010">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Reference</th><th>Publication Date</th><th>Study Design</th><th>Study Population</th><th>Main Findings</th></tr></thead><tbody><tr><td>Zuo [<xref rid="bib28" ref-type="bibr">28</xref>]</td><td>April 24, 2020</td><td>Cohort</td><td>N&#xA0;=&#xA0;50</td><td>Markedly elevated NETs (cell-free DNA, MPO-DNA, and Cit-H3) were detected in the sera of patients hospitalized with COVID-19. Markers of NETs associated with severe respiratory status. Sera from individuals with COVID-19 triggered NET release from control neutrophils <italic>in&#xA0;vitro.</italic></td></tr><tr><td>Fox [<xref rid="bib35" ref-type="bibr">35</xref>]</td><td>May 27, 2020</td><td>Autopsy series</td><td>N&#xA0;=&#xA0;10</td><td>First microscopic confirmation of NETs in alveoli.</td></tr><tr><td>Middleton [<xref rid="bib29" ref-type="bibr">29</xref>]</td><td>June 29, 2020</td><td>Prospective Cohort</td><td>N&#xA0;=&#xA0;33</td><td>High level of NETs (MPO-DNA) were detected in COVID-19 blood, where they were associated with worse respiratory status and clinical outcomes. Platelet-derived factors known to trigger NETosis were also elevated. COVID-19 plasma potentiated NET release <italic>in&#xA0;vitro</italic>, which could be attenuated by neonatal NET-inhibitory factor. Autopsies revealed colocalization of PF4 and NETs in pulmonary vessels.</td></tr><tr><td>Nicolai [<xref rid="bib33" ref-type="bibr">33</xref>]</td><td>July 22, 2020</td><td>Cohort</td><td>N&#xA0;=&#xA0;38</td><td>Immunothrombi enriched with neutrophils were seen in COVID-19 lungs. Distinct neutrophil signatures were appreciated in COVID-19, which range from a hypoactive phenotype in patients with intermediate COVID-19 to excessive neutrophil activation in severe COVID-19. Platelets isolated from patients with severe COVID-19 were bound to neutrophils and potentiated NETosis <italic>in&#xA0;vitro.</italic></td></tr><tr><td>Leppkes [<xref rid="bib30" ref-type="bibr">30</xref>]</td><td>July 31, 2020</td><td>Cohort</td><td>N&#xA0;=&#xA0;71</td><td>High level of NETs (cell-free DNA, MPO-DNA, Cit-H3, and neutrophil elastase-DNA complexes) were appreciated in COVID-19 blood, where they were associated with severe disease. Significantly increased low-density neutrophils that have high propensity for spontaneous NETosis were observed in COVID-19 patients. Autopsy of COVID-19 patients demonstrated the occlusion of pulmonary vessels by aggregated NETs.</td></tr><tr><td>Wang [<xref rid="bib34" ref-type="bibr">34</xref>]</td><td>Aug 18, 2020</td><td>Cohort</td><td>N&#xA0;=&#xA0;4</td><td>Transcriptomic analysis of COVID-19 lung tissue and BAL fluid revealed marked enrichment of NET-associated genes.</td></tr><tr><td>Veras [<xref rid="bib31" ref-type="bibr">31</xref>]</td><td>Sep 14, 2020</td><td>Cohort</td><td>N&#xA0;=&#xA0;32</td><td>High levels of NETs (MPO-DNA) were detected in the blood of COVID-19 patients. SARS-CoV-2 directly induced NETosis through a mechanism that was dependent upon PAD4, effective viral replication, and host cell ACE2.</td></tr></tbody></table><table-wrap-foot><fn><p>MPO&#xA0;=&#xA0;myeloperoxidase; Cit-H3&#xA0;=&#xA0;citrullinated histone H3; PF4&#xA0;=&#xA0;platelet factor 4; NETs&#xA0;=&#xA0;neutrophil extracellular traps; PAD4&#xA0;=&#xA0;protein arginine deiminase 4; and BAL&#xA0;=&#xA0;bronchial alveolar lavage.</p></fn></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="sec2.3">
        <title>NET induction in COVID-19</title>
        <p id="p0040">In COVID-19, NETs are likely produced in both direct and indirect fashion. NETs can be induced by incubating SARS-CoV-2 with healthy neutrophils [<xref rid="bib31" ref-type="bibr">31</xref>]; in this context, the inhibition of either PAD4 or RNA polymerase abrogates NETosis. SARS-CoV-2 utilizes ACE2 receptor and serine protease TMPRSS2 to enter host cells [<xref rid="bib36" ref-type="bibr">36</xref>], and the blockade of either ACE2 or serine protease activity antagonizes SARS-CoV-2-triggered NETosis [<xref rid="bib31" ref-type="bibr">31</xref>]. Other studies have suggested that NETs are produced indirectly in COVID-19 through activated platelets. Platelets from patients with severe COVID-19 demonstrate increased adhesion to neutrophils <italic>in&#xA0;vivo</italic>, while triggering NETosis from healthy neutrophils <italic>in&#xA0;vitro</italic> [<xref rid="bib33" ref-type="bibr">33</xref>]. Furthermore, platelet-derived molecules such as platelet factor 4 (<bold>PF4</bold>) and RANTES, which are known to trigger NETosis, are markedly elevated in COVID-19 patients [<xref rid="bib37" ref-type="bibr">37</xref>]. Autopsy specimens have revealed the colocalization of PF4 and NETs in the pulmonary vasculature [<xref rid="bib37" ref-type="bibr">37</xref>]. Considering that severe COVID-19 is also associated with high levels of myriad cytokines and chemokines, their role as pro-NET factors should also be considered.</p>
      </sec>
      <sec id="sec2.4">
        <title>NETs and SARS-CoV-2 pathology</title>
        <p id="p0045">NETs have direct cytotoxic effects against epithelial and endothelial cells. Indeed, one study demonstrated that SARS-CoV-2-associated NETs induce pulmonary epithelial cell death, which results in alveolar damage and fibrosis [<xref rid="bib31" ref-type="bibr">31</xref>]. NETs likely also potentiate microvascular thrombosis in COVID-19, as multiple autopsy studies have revealed NET-containing microthrombi and neutrophil-platelet infiltration in the microvasculature of the lung, kidney, and heart [<xref rid="bib31" ref-type="bibr">31</xref>,<xref rid="bib37" ref-type="bibr">[37]</xref>, <xref rid="bib38" ref-type="bibr">[38]</xref>, <xref rid="bib39" ref-type="bibr">[39]</xref>]. While not well investigated, disproportionate NET formation may also lead to pathogenic autoantibody production that likely contributes to further local or systemic damage. In summary, clinical, pathological, and molecular evidence support the presence of NETs in COVID-19. SARS-CoV-2 can directly and indirectly induce NET formation, which contributes to COVID-19 pathology.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>Complement: helpful early in COVID-19, detrimental late</title>
      <p id="p0050">Data from clinical, pathological, and molecular studies suggest an important role for complement activation in the development of severe COVID-19 manifestations. Yet, it is also clear that complement is critical for protective responses early in COVID-19.</p>
      <sec id="sec3.1">
        <title>Complement in immunity and disease</title>
        <p id="p0055">The complement system is composed of over 40 serine proteases, inhibitors, and receptors initiated by three pathways (classical, lectin, and alternative). Each pathway is uniquely triggered to drive a proteolytic cascade, which generates a potent, highly regulated, innate immune response [<xref rid="bib40" ref-type="bibr">40</xref>]. Its activation induces: 1) membrane perturbation mediated by C4b- and C3b-facilitated opsonization and phagocytosis as well as a lytic process through the membrane attack complex (<bold>MAC and C5b-9</bold>), and 2) the generation of a proinflammatory milieu largely mediated through the anaphylatoxins, C3a and C5a. Using these two phenomena, the complement system also assists in the clearance of apoptotic material and cellular debris. Additionally, intracellular complement activation enables cells to modulate metabolic pathways and thereby regulate immune responsiveness [<xref rid="bib41" ref-type="bibr">41</xref>].</p>
        <p id="p0060">These same pathways though are utilized in several complement-mediated diseases. In systemic lupus erythematosus and related autoimmune diseases, immune complexes generated by autoantibodies drive type II and III hypersensitivity reactions, driving classical pathway activation to initiate destructive inflammatory responses. In age-related macular degeneration (<bold>AMD</bold>) and atypical hemolytic uremic syndrome (<bold>aHUS</bold>), loss-of-function (commonly haploinsufficiency) of complement regulatory proteins or gain-of-function in complement-activating components promote excessive alternative pathway engagement, leading to retinal damage in AMD and microthrombi featuring endothelial injury in aHUS [<xref rid="bib42" ref-type="bibr">42</xref>,<xref rid="bib43" ref-type="bibr">43</xref>].</p>
      </sec>
      <sec id="sec3.2">
        <title>Complement activation is likely required for controlling early COVID-19</title>
        <p id="p0065">Complement has a well-established role in immunity against viruses. Initiated by natural and cross-reacting antibodies and lectins, viruses trigger complement action to drive the opsonization of viruses and virus-infected cells, generation of an antiviral inflammatory state, and boost virus-specific immune responses [<xref rid="bib44" ref-type="bibr">44</xref>].</p>
        <p id="p0070">Indeed, several lines of data support that SARS-CoV-2 can directly activate complement. <italic>In&#xA0;vitro</italic>, SARS-CoV-2 spike proteins 1 and 2 expressed on the human cell line PIGAnull TF1 primarily drives the activation of the alternative pathway through heparan sulfate [<xref rid="bib45" ref-type="bibr">45</xref>], and in a preprint, the N protein activated the mannan-binding lectin-associated serine protease (<bold>MASP-2</bold>) [<xref rid="bib46" ref-type="bibr">46</xref>]. Furthermore, virus infection appears to drive the early activation of complement <italic>in&#xA0;vivo</italic>, as in a murine model of SARS-CoV, infected mice generate C3 activation products (C3a, C3b, iC3b, C3c, and C3d) in the lung within 24&#xA0;h [<xref rid="bib47" ref-type="bibr">47</xref>]. While numerous reports have observed elevated complement activation product levels in severe COVID-19 patients (as discussed later), only one report assessed complement component levels in early COVID-19 infection. Here, low complement C3 was found in 57% of day 1 samples in COVID-19 patients who eventually developed nonserious pneumonia [<xref rid="bib48" ref-type="bibr">48</xref>]. This may be an underestimation of complement activation though, as C3 is an acute phase reactant [<xref rid="bib49" ref-type="bibr">49</xref>]. Thus, normal C3 levels may also represent elevated complement activation status due to the elevated production of C3 in inflammatory states.</p>
        <p id="p0075">To counteract complement activation, viruses have developed evasion tactics. While these have yet to be observed for coronaviruses, other viruses have well-described mechanisms (reviewed in Ref.&#xA0;[<xref rid="bib50" ref-type="bibr">50</xref>]). For example, poxviruses express a protein with similar structure and function to complement regulatory proteins, while flaviviruses neutralize complement regulators by binding to them.</p>
        <p id="p0080">While our understanding of the role of complement in early COVID-19 remains in its infancy, we do speculate that complement, along with other immune pathways such as interferons and neutrophil activation, serve to drive important antivirus responses. If compromised, this can lead to inadequate control of SARS-CoV-2, which leads to severe manifestations of COVID-19.</p>
      </sec>
      <sec id="sec3.3">
        <title>Complement contributes to immunopathology observed in severe COVID-19</title>
        <p id="p0085">Initial data that support a prominent role of complement in severe COVID-19 came from clinicopathological studies. Jeffrey Laurence's group identified complement deposition (specifically C5b-9, C4d, and MASP-2), in the skin of deceased COVID-19 patients with retiform and purpuric lesions and the lung of those with septal capillary injury [<xref rid="bib25" ref-type="bibr">25</xref>]. Notably, they also found the C4d and C5b-9 colocalized with SARS-CoV-2 S protein in these organs [<xref rid="bib25" ref-type="bibr">25</xref>]. Similarly, mannose-binding lectins (<bold>MBL</bold>), C4, C3, and C3b-9 were observed in alveolar epithelial cells and alveolar exudate in deceased patients [<xref rid="bib46" ref-type="bibr">46</xref>]. Furthermore, C5b-9 deposition was also observed in the apical brush border of tubular epithelial cells in the kidney [<xref rid="bib51" ref-type="bibr">51</xref>].</p>
        <p id="p0090">Additional histopathological features with similarities to other complement-mediated diseases indicate that complement activation is a central player in severe COVID-19. Endothelial cell abnormalities, such as cellular swelling with foamy degeneration in the setting of a thrombotic microangiopathy (<bold>TMA</bold>), have been observed in numerous organs [<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib52" ref-type="bibr">[52]</xref>, <xref rid="bib53" ref-type="bibr">[53]</xref>, <xref rid="bib54" ref-type="bibr">[54]</xref>, <xref rid="bib55" ref-type="bibr">[55]</xref>, <xref rid="bib56" ref-type="bibr">[56]</xref>], consistent with C5b-9 mediated injury and a hypercoagulable state [<xref rid="bib57" ref-type="bibr">57</xref>]. In the lungs of those with COVID-19-associated ARDS, septal microangiopathy was observed characterized by endothelial cell injury, mural fibrin deposition, and variable intraluminal thrombus formation [<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib58" ref-type="bibr">58</xref>,<xref rid="bib59" ref-type="bibr">59</xref>]. Consistent with these pathological observations, C3-deficient mice infected with SARS-CoV demonstrated less lung inflammation and injury and weight loss despite having similar viral loads as compared to wild-type mice [<xref rid="bib47" ref-type="bibr">47</xref>].</p>
        <p id="p0095">Both proteomic [<xref rid="bib46" ref-type="bibr">46</xref>,<xref rid="bib60" ref-type="bibr">[60]</xref>, <xref rid="bib61" ref-type="bibr">[61]</xref>, <xref rid="bib62" ref-type="bibr">[62]</xref>, <xref rid="bib63" ref-type="bibr">[63]</xref>, <xref rid="bib64" ref-type="bibr">[64]</xref>] and transcriptomic [<xref rid="bib62" ref-type="bibr">62</xref>,<xref rid="bib65" ref-type="bibr">65</xref>] studies of blood and lung samples from severe COVID-19 confirm the notion that complement activation is an immune signature characteristic of severe disease. The earliest data were observed in Chinese COVID-19 patients, as elevated serum C5a was uniquely noted in those with severe respiratory distress or hypoxia on room air as compared to those with mild symptoms or healthy controls [<xref rid="bib46" ref-type="bibr">46</xref>]. C5a was confirmed as a potential biomarker of severe disease in a longitudinal analysis of a French cohort, and both anti-C5aR1-treated or C5aR1-knockout mice had attenuated lung injury following C5a instillation into the lungs [<xref rid="bib66" ref-type="bibr">66</xref>]. MBL was associated with plasma D-dimer concentration in a Swedish cohort of critically ill COVID-19 patients [<xref rid="bib67" ref-type="bibr">67</xref>]. Using the Albany Medical Center (New York) cohort, plasma target metabolomics identified complement activation and its regulation as two of the top six GO (gene ontogeny) pathways unique to hospitalized COVID-19 patients who require ICU admission as compared to those on the medical floor [<xref rid="bib64" ref-type="bibr">64</xref>]. Data from the Columbia University Irving Medical Center/New York-Presbyterian Hospital cohort confirmed these observations as hospitalized patients with COVID-19 exhibited elevated serum levels of factor H and I along with C5, as assessed by mass spectroscopy, as compared to healthy controls [<xref rid="bib60" ref-type="bibr">60</xref>]. Using immunoassays in the Norwegian cohort, elevated plasma sC5b-9, C5a, C3b/iC3b/C3c, alternative pathway C3 convertase (C3bBbP), and C4d were observed in majority of COVID-19 patients in respiratory failure and were higher as compared to those that were not [<xref rid="bib61" ref-type="bibr">61</xref>]. Similar observations were made in the lungs at the transcriptomic level, as lung biopsy samples from COVID-19 patients showed a pronounced complement signature (including C3 transcripts) following GO pathway analysis as compared to healthy controls [<xref rid="bib65" ref-type="bibr">65</xref>]. They confirmed this observation using <italic>in&#xA0;vitro</italic> SARS-CoV-2-infected primary bronchial epithelial cells or a type II human pneumocyte cell line (A549) with or without ACE2 overexpression, which demonstrates a similar complement signature, which was not observed in influenza A- or respiratory syncytial virus-infected cells [<xref rid="bib65" ref-type="bibr">65</xref>].</p>
        <p id="p0100">Collectively, these data provide substantial evidence that complement activation occurs in COVID-19, with emerging data that this positively correlates with disease severity.</p>
      </sec>
    </sec>
    <sec id="sec4">
      <title>Interplay between NETs and complement</title>
      <p id="p0105">As discussed above, NETs are webs of extracellular chromatin decorated with factors derived from neutrophil cytoplasm, granules, and mitochondria. NETs restrain invading microbes through both immobilization and killing, but when released intravascularly they are an important nidus for thromboinflammation. For example, NETs activate platelets [<xref rid="bib68" ref-type="bibr">68</xref>], capture red blood cells [<xref rid="bib68" ref-type="bibr">68</xref>], and potentiate both intrinsic [<xref rid="bib13" ref-type="bibr">13</xref>] and extrinsic pathways [<xref rid="bib69" ref-type="bibr">69</xref>] of coagulation.</p>
      <sec id="sec4.1">
        <title>Prior knowledge regarding the interplay between NETs and complement</title>
        <p id="p0110">The communication between NETs and complement is bidirectional and, if not tightly regulated, has potential to form a self-amplifying loop. C5a recruits and then primes neutrophils for NETosis through the upregulation of various immune receptors, including TLRs and complement receptors such as CR1 and CR3 [<xref rid="bib70" ref-type="bibr">70</xref>,<xref rid="bib71" ref-type="bibr">71</xref>]. Pathogens opsonized with C3b and iC3b may then trigger NETosis through the engagement of neutrophils CR1 and CR3, respectively [<xref rid="bib72" ref-type="bibr">72</xref>]. Furthermore, once NETs have been released into the extracellular space, complement components&#x2014;and perhaps particularly C1q&#x2014;stabilize their structure and prevent clearance by DNase I [<xref rid="bib73" ref-type="bibr">73</xref>].</p>
        <p id="p0115">Emphasizing the bidirectional nature of the relationship, neutrophils express Factor B, C3, and properdin, the combination of which allows for the production and stabilization of the C3-convertase on the neutrophil surface [<xref rid="bib74" ref-type="bibr">74</xref>] and also on NETs themselves [<xref rid="bib75" ref-type="bibr">75</xref>]. At the same time, myeloperoxidase and serine proteases such as cathepsin G and proteinase 3 bind to and activate properdin with the potential to further potentiate complement activation on NETs [<xref rid="bib76" ref-type="bibr">76</xref>]. The end result is NETs as a fertile platform for the generation of anaphylatoxins C3a and C5a [<xref rid="bib73" ref-type="bibr">73</xref>], which can lead to further immune system activation.</p>
      </sec>
      <sec id="sec4.2">
        <title>NETs, complement, and thrombotic microangiopathy</title>
        <p id="p0120">Prior to COVID-19, circulating NET remnants were already known to track closely with the activity of various <bold>TMAs,</bold> including thrombotic thrombocytopenic purpura [<xref rid="bib77" ref-type="bibr">77</xref>,<xref rid="bib78" ref-type="bibr">78</xref>], hemolytic uremic syndrome [<xref rid="bib79" ref-type="bibr">79</xref>,<xref rid="bib80" ref-type="bibr">80</xref>], transplant-associated TMA [<xref rid="bib78" ref-type="bibr">78</xref>,<xref rid="bib81" ref-type="bibr">81</xref>], and likely catastrophic antiphospholipid syndrome [<xref rid="bib82" ref-type="bibr">82</xref>]. At the same time, these TMAs are also clearly complementopathies as evidenced by the utility of inhibitors of C5 cleavage as effective therapies [<xref rid="bib83" ref-type="bibr">83</xref>]. One interesting study contrasted transplant-associated TMA with another complication of stem-cell transplant, graft versus host disease (<bold>GVHD</bold>) [<xref rid="bib84" ref-type="bibr">84</xref>]. While markers of endothelial damage/activation such as thrombomodulin were elevated in both situations, only transplant-associated TMA was associated with elevations in soluble C5b-9, NET remnants, including myeloperoxidase-DNA complexes and markers of coagulation pathways such as thrombin-antithrombin complexes [<xref rid="bib84" ref-type="bibr">84</xref>].</p>
        <p id="p0125">The potential for cross talk between complement and NETs has recently been evaluated in COVID-19. Specifically, Skendros and colleagues found that C3 inhibitor compstatin Cp40 disrupted tissue factor expression by COVID-19 neutrophils, while C5a receptor blockade attenuated NETosis triggered by COVID-19 platelet-rich plasma [<xref rid="bib85" ref-type="bibr">85</xref>]. The group also found that COVID-19 NETs are decorated with particularly high levels of tissue factor and through this and likely other pathways are potent activators of cultured endothelial cells [<xref rid="bib85" ref-type="bibr">85</xref>]. Taken together, it is not difficult to see how these pathways could conspire to occlude the COVID-19 microvasculature <italic>in&#xA0;vivo</italic>.</p>
      </sec>
    </sec>
    <sec id="sec5">
      <title>Potential approaches to treatment</title>
      <p id="p0130">As we await what will hopefully be definitive antiviral solutions to the current pandemic, anti-neutrophil and anti-complement therapies have potential to help mitigate the severest manifestations of COVID-19.</p>
      <sec id="sec5.1">
        <title>Medications already used in the treatment of COVID-19</title>
        <p id="p0135">Patients with COVID-19 are increasingly being treated with the combination of heparin-based anticoagulation and dexamethasone. The former may modulate NETs by the neutralization of cytotoxic histones [<xref rid="bib86" ref-type="bibr">86</xref>] and by the potentiation of NET clearance through DNase I [<xref rid="bib30" ref-type="bibr">30</xref>]. At the same time, corticosteroids such as dexamethasone can also reduce NET formation <italic>in&#xA0;vivo</italic> [<xref rid="bib87" ref-type="bibr">87</xref>], most likely through the modulation of the inflammatory mediators that activate neutrophils. Other agents being trialed in COVID-19 such as JAK-STAT inhibitors, anakinra (IL-1 receptor antagonist), and colchicine also have potential to reduce NET release [<xref rid="bib88" ref-type="bibr">[88]</xref>, <xref rid="bib89" ref-type="bibr">[89]</xref>, <xref rid="bib90" ref-type="bibr">[90]</xref>].</p>
      </sec>
      <sec id="sec5.2">
        <title>DNases</title>
        <p id="p0140">Recombinant DNase I cleaves the DNA scaffold of NETs and thereby has the potential to relieve intravascular thrombosis and airway obstruction [<xref rid="bib30" ref-type="bibr">30</xref>]. Applying this logic, a small single-center case series has suggested that nebulized endotracheal dornase alfa (a biosynthetic form of human DNase I) reduced oxygen requirements in all treated patients [<xref rid="bib91" ref-type="bibr">91</xref>]. Going forward, COVIDornase (NCT04355364) and COVASE (NCT04359654) are two studies evaluating nebulized dornase alfa in prospective randomized controlled trials. While there are not (to our knowledge) any active studies for intravenous administration, one wonders if some of the products might find their way into circulation through the damaged airways of COVID-19 [<xref rid="bib92" ref-type="bibr">92</xref>].</p>
      </sec>
      <sec id="sec5.3">
        <title>Treatment by modulation of purinergic signaling with dipyridamole</title>
        <p id="p0145">The activation of surface adenosine receptors suppresses NETosis through cyclic AMP-dependent signaling [<xref rid="bib93" ref-type="bibr">93</xref>]. Dipyridamole is an inexpensive, FDA-approved drug with a favorable safety profile. Dipyridamole potentiates adenosine receptor signaling by both the inhibition of ectonucleoside reuptake and stabilization of intracellular cyclic AMP. Dipyridamole tempers NET release <italic>in&#xA0;vitro</italic>, which prevents NET-dependent thrombosis in mice [<xref rid="bib93" ref-type="bibr">93</xref>]. In a small study, dipyridamole suppressed D-dimer levels in patients with COVID-19 [<xref rid="bib94" ref-type="bibr">94</xref>]. Larger studies are now underway to evaluate clinical outcomes (NCT04391179, NCT04424901) [<xref rid="bib95" ref-type="bibr">95</xref>].</p>
      </sec>
      <sec id="sec5.4">
        <title>Treatment with complement inhibitors</title>
        <p id="p0150">C5 has been an early experimental target for severe COVID-19 given that eculizumab is already FDA-approved for several complementopathies. Severe COVID-19 patients treated with C5 cleavage inhibitors (i.e., eculizumab, ravulizumab, and LFG316) have resulted in success in several small case series and reports [<xref rid="bib96" ref-type="bibr">[96]</xref>, <xref rid="bib97" ref-type="bibr">[97]</xref>, <xref rid="bib98" ref-type="bibr">[98]</xref>, <xref rid="bib99" ref-type="bibr">[99]</xref>, <xref rid="bib100" ref-type="bibr">[100]</xref>, <xref rid="bib101" ref-type="bibr">[101]</xref>], and a small number of patients already on a C5 cleavage inhibitor for PNH or TMA-associated lupus nephritis failed to progress to severe COVID-19 [<xref rid="bib102" ref-type="bibr">[102]</xref>, <xref rid="bib103" ref-type="bibr">[103]</xref>, <xref rid="bib104" ref-type="bibr">[104]</xref>]. A C5a inhibitor, vilobelimab (IFX-1), failed to meet the primary endpoint of improved lung function in this small (n&#xA0;=&#xA0;30) exploratory study, although two secondary outcome measures, pulmonary embolism and renal impairment, were improved in the IFX-1 treatment group [<xref rid="bib105" ref-type="bibr">105</xref>]. It remains too early to tell whether inhibiting C5a, C5b-9, or both is required to suppress severe manifestations of COVID-19, but several clinical trials inhibiting C5 cleavage (eculizumab: NCT04346797, NCT04355494, ravulizumab: NCT04369469, NCT04390464, and zilucoplan: NCT04382755) and the C5a receptor (avdoralimab: NCT0431367 and IFX-1: NCT04333420) are currently ongoing.</p>
        <p id="p0155">Given its central position, another attractive inhibitory target of complement activation is C3. AMY-101 is a compstatin-based C3 inhibitor that prevents the conformational change of C3 required for subsequent cleavage to C3 and C3b [<xref rid="bib106" ref-type="bibr">106</xref>], which was described earlier to attenuate neutrophil tissue factor expression [<xref rid="bib85" ref-type="bibr">85</xref>]. A phase II study is now active examining the utility of AMY-101 (NCT04395456), and a total of four patients with severe COVID-19 have been successfully treated with AMY-101 [<xref rid="bib101" ref-type="bibr">101</xref>,<xref rid="bib107" ref-type="bibr">107</xref>]. There may be a theoretical advantage to inhibiting C3 rather than C5, as greater inhibition of NET formation, neutrophil and lymphocyte recovery, and more rapid LDH decline [<xref rid="bib101" ref-type="bibr">101</xref>].</p>
        <p id="p0160">Additional targets, including the C1 esterase inhibitor (conestat alfa, NCT04414631 and rocunest, NCT04530136) [<xref rid="bib108" ref-type="bibr">108</xref>] and MASP-2 [<xref rid="bib109" ref-type="bibr">109</xref>] have also been tried in pilot populations with success.</p>
      </sec>
    </sec>
    <sec id="sec6">
      <title>Summary</title>
      <p id="p0165">In summary, NET-releasing neutrophils and complement appear to play central roles in the immunopathogenesis of COVID-19. This review has presented various points of cross talk between NETs and complement in SARS-CoV-2 infection. These intermingled pathways conspire to promote a thromboinflammatory storm in some individuals with severe COVID-19. Therefore, the development of novel therapeutic strategies that target NET formation and complement activation may help reduce COVID-19 morbidity and mortality.<boxed-text id="dtbox1"><caption><title>Practice points</title></caption><p id="p0170">
<list list-type="simple" id="olist0010"><list-item id="u0010"><label>&#x2022;</label><p id="p0175">SARS-CoV-2 displays a complex relationship with the human immune system. The interplay between neutrophils, neutrophil extracellular traps, and complement&#x2014;important players in innate immunity&#x2014;contribute to the thromboinflammatory milieu of COVID-19.</p></list-item><list-item id="u0015"><label>&#x2022;</label><p id="p0180">SARS-CoV-2 can directly and indirectly induce NET formation, which contributes to COVID-19 pathology.</p></list-item><list-item id="u0020"><label>&#x2022;</label><p id="p0185">NETs contribute to COVID-19 pathology by:<list list-type="simple" id="ulist0010"><list-item id="u0025"><label>&#x25CB;</label><p id="p0190">direct cytotoxic effects against epithelial and endothelial cells</p></list-item><list-item id="u0030"><label>&#x25CB;</label><p id="p0195">microthrombi formation and microvascular damage in multiple organs</p></list-item><list-item id="u0035"><label>&#x25CB;</label><p id="p0200">perpetuating pathogenic autoantibody production</p></list-item></list>
</p></list-item><list-item id="u0040"><label>&#x2022;</label><p id="p0205">While providing early viral containment, complement activation heightens immunopathology and contributes to COVID-19 severity.</p></list-item><list-item id="u0045"><label>&#x2022;</label><p id="p0210">The cross-talk between NETs and complement are key drivers of COVID-19 thrombotic microangiopathy.</p></list-item><list-item id="u0050"><label>&#x2022;</label><p id="p0215">Anti-neutrophil and anti-complement therapies have potential to mitigate the severest manifestations of COVID-19.</p></list-item></list>
</p></boxed-text>
<boxed-text id="dtbox2"><caption><title>Research agenda</title></caption><p id="p0220">
<list list-type="simple" id="ulist0015"><list-item id="u0055"><label>&#x2022;</label><p id="p0225">Deep dive into the mechanisms that govern the tripartite immunopathogenesis of COVID-19 and their downstream and long-term sequela.</p></list-item><list-item id="u0060"><label>&#x2022;</label><p id="p0230">Identify clinically actionable biomarkers for NETs and complement pathway activation thus enables precision management.</p></list-item><list-item id="u0065"><label>&#x2022;</label><p id="p0235">Evaluate therapeutics to target NETs and complement in COVID-19.</p></list-item></list>
</p></boxed-text>
</p>
    </sec>
    <sec id="sec7">
      <title>Funding</title>
      <p id="p0240">The authors have no relevant financial conflicts to report.</p>
    </sec>
    <sec sec-type="COI-statement">
      <title>Declaration of competing interest</title>
      <p id="p0245">The authors have no relevant conflicts to report.</p>
    </sec>
  </body>
  <back>
    <ref-list id="cebib0010">
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal" id="sref1">
          <person-group person-group-type="author">
            <name>
              <surname>Zhu</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>A&#xA0;novel coronavirus from patients with pneumonia in China, 2019</article-title>
          <source>N&#xA0;Engl J Med</source>
          <volume>382</volume>
          <year>2020</year>
          <fpage>727</fpage>
          <lpage>733</lpage>
          <pub-id pub-id-type="pmid">31978945</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal" id="sref2">
          <person-group person-group-type="author">
            <name>
              <surname>Wiersinga</surname>
              <given-names>W.J.</given-names>
            </name>
            <name>
              <surname>Rhodes</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>A.C.</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review</article-title>
          <source>J&#xA0;Am Med Assoc</source>
          <volume>324</volume>
          <year>2020</year>
          <fpage>782</fpage>
          <lpage>793</lpage>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal" id="sref3">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>X.L.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X.G.</given-names>
            </name>
          </person-group>
          <article-title>A&#xA0;pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
          <source>Nature</source>
          <volume>579</volume>
          <year>2020</year>
          <fpage>270</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="pmid">32015507</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal" id="sref4">
          <person-group person-group-type="author">
            <name>
              <surname>Ruan</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</article-title>
          <source>Intensive Care Med</source>
          <volume>46</volume>
          <year>2020</year>
          <fpage>846</fpage>
          <lpage>848</lpage>
          <pub-id pub-id-type="pmid">32125452</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal" id="sref5">
          <person-group person-group-type="author">
            <name>
              <surname>Maggi</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Canonica</surname>
              <given-names>G.W.</given-names>
            </name>
            <name>
              <surname>Moretta</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>COVID-19: unanswered questions on immune response and pathogenesis</article-title>
          <source>J&#xA0;Allergy Clin Immunol</source>
          <volume>146</volume>
          <year>2020</year>
          <fpage>18</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="pmid">32389590</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal" id="sref6">
          <person-group person-group-type="author">
            <name>
              <surname>Ye</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Mao</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>The pathogenesis and treatment of the `Cytokine Storm' in COVID-19</article-title>
          <source>J&#xA0;Infect</source>
          <volume>80</volume>
          <year>2020</year>
          <fpage>607</fpage>
          <lpage>613</lpage>
          <pub-id pub-id-type="pmid">32283152</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal" id="sref7">
          <person-group person-group-type="author">
            <name>
              <surname>Lo</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Kemper</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Woodruff</surname>
              <given-names>T.M.</given-names>
            </name>
          </person-group>
          <article-title>COVID-19: complement, coagulation, and collateral damage</article-title>
          <source>J&#xA0;Immunol</source>
          <volume>205</volume>
          <year>2020</year>
          <fpage>1488</fpage>
          <lpage>1495</lpage>
          <pub-id pub-id-type="pmid">32699160</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal" id="sref8">
          <person-group person-group-type="author">
            <name>
              <surname>Menter</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Haslbauer</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Nienhold</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction</article-title>
          <source>Histopathology</source>
          <volume>77</volume>
          <issue>2</issue>
          <year>2020 Aug</year>
          <fpage>198</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="pmid">32364264</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal" id="sref9">
          <person-group person-group-type="author">
            <name>
              <surname>Brinkmann</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Reichard</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Goosmann</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps kill bacteria</article-title>
          <source>Science</source>
          <volume>303</volume>
          <year>2004</year>
          <fpage>1532</fpage>
          <lpage>1535</lpage>
          <pub-id pub-id-type="pmid">15001782</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal" id="sref10">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>K.H.</given-names>
            </name>
            <name>
              <surname>Kronbichler</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>D.D.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review</article-title>
          <source>Autoimmun Rev</source>
          <volume>16</volume>
          <year>2017</year>
          <fpage>1160</fpage>
          <lpage>1173</lpage>
          <pub-id pub-id-type="pmid">28899799</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="journal" id="sref11">
          <person-group person-group-type="author">
            <name>
              <surname>Thalin</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hisada</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Lundstrom</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <volume>39</volume>
          <year>2019</year>
          <fpage>1724</fpage>
          <lpage>1738</lpage>
          <pub-id pub-id-type="pmid">31315434</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <element-citation publication-type="journal" id="sref12">
          <person-group person-group-type="author">
            <name>
              <surname>Massberg</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Grahl</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>von Bruehl</surname>
              <given-names>M.L.</given-names>
            </name>
          </person-group>
          <article-title>Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases</article-title>
          <source>Nat Med</source>
          <volume>16</volume>
          <year>2010</year>
          <fpage>887</fpage>
          <lpage>896</lpage>
          <pub-id pub-id-type="pmid">20676107</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <element-citation publication-type="journal" id="sref13">
          <person-group person-group-type="author">
            <name>
              <surname>von Bruhl</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Steinhart</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in&#xA0;vivo</article-title>
          <source>J&#xA0;Exp Med</source>
          <volume>209</volume>
          <year>2012</year>
          <fpage>819</fpage>
          <lpage>835</lpage>
          <pub-id pub-id-type="pmid">22451716</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <element-citation publication-type="journal" id="sref14">
          <person-group person-group-type="author">
            <name>
              <surname>Knight</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>O'Dell</surname>
              <given-names>A.A.</given-names>
            </name>
          </person-group>
          <article-title>Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis</article-title>
          <source>Circ Res</source>
          <volume>114</volume>
          <year>2014</year>
          <fpage>947</fpage>
          <lpage>956</lpage>
          <pub-id pub-id-type="pmid">24425713</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <element-citation publication-type="journal" id="sref15">
          <person-group person-group-type="author">
            <name>
              <surname>Borissoff</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Joosen</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Versteylen</surname>
              <given-names>M.O.</given-names>
            </name>
          </person-group>
          <article-title>Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <volume>33</volume>
          <year>2013</year>
          <fpage>2032</fpage>
          <lpage>2040</lpage>
          <pub-id pub-id-type="pmid">23818485</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <label>16</label>
        <element-citation publication-type="journal" id="sref16">
          <person-group person-group-type="author">
            <name>
              <surname>Schonrich</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Raftery</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps go viral</article-title>
          <source>Front Immunol</source>
          <volume>7</volume>
          <year>2016</year>
          <fpage>366</fpage>
          <pub-id pub-id-type="pmid">27698656</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <element-citation publication-type="journal" id="sref17">
          <person-group person-group-type="author">
            <name>
              <surname>Funchal</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Jaeger</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Czepielewski</surname>
              <given-names>R.S.</given-names>
            </name>
          </person-group>
          <article-title>Respiratory syncytial virus fusion protein promotes TLR-4-dependent neutrophil extracellular trap formation by human neutrophils</article-title>
          <source>PloS One</source>
          <volume>10</volume>
          <year>2015</year>
          <comment>e0124082</comment>
        </element-citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <element-citation publication-type="journal" id="sref18">
          <person-group person-group-type="author">
            <name>
              <surname>Saitoh</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Komano</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Saitoh</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1</article-title>
          <source>Cell Host Microbe</source>
          <volume>12</volume>
          <year>2012</year>
          <fpage>109</fpage>
          <lpage>116</lpage>
          <pub-id pub-id-type="pmid">22817992</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <element-citation publication-type="journal" id="sref19">
          <person-group person-group-type="author">
            <name>
              <surname>Gupta</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Joshi</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Philippova</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death</article-title>
          <source>FEBS Lett</source>
          <volume>584</volume>
          <year>2010</year>
          <fpage>3193</fpage>
          <lpage>3197</lpage>
          <pub-id pub-id-type="pmid">20541553</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <element-citation publication-type="journal" id="sref20">
          <person-group person-group-type="author">
            <name>
              <surname>Saffarzadeh</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Juenemann</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Queisser</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones</article-title>
          <source>PloS One</source>
          <volume>7</volume>
          <year>2012</year>
          <object-id pub-id-type="publisher-id">e32366</object-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <label>21</label>
        <element-citation publication-type="journal" id="sref21">
          <person-group person-group-type="author">
            <name>
              <surname>Cortjens</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>de Boer</surname>
              <given-names>O.J.</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease</article-title>
          <source>J&#xA0;Pathol</source>
          <volume>238</volume>
          <year>2016</year>
          <fpage>401</fpage>
          <lpage>411</lpage>
          <pub-id pub-id-type="pmid">26468056</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <element-citation publication-type="journal" id="sref22">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Xiang</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage</article-title>
          <source>J&#xA0;Transl Med</source>
          <volume>18</volume>
          <year>2020</year>
          <fpage>206</fpage>
          <pub-id pub-id-type="pmid">32434518</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <label>23</label>
        <element-citation publication-type="journal" id="sref23">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps are indirectly triggered by lipopolysaccharide and contribute to acute lung injury</article-title>
          <source>Sci Rep</source>
          <volume>6</volume>
          <year>2016</year>
          <fpage>37252</fpage>
          <pub-id pub-id-type="pmid">27849031</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <label>24</label>
        <element-citation publication-type="journal" id="sref24">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19</article-title>
          <source>J&#xA0;Infect</source>
          <volume>81</volume>
          <year>2020</year>
          <fpage>e6</fpage>
          <lpage>e12</lpage>
        </element-citation>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <element-citation publication-type="journal" id="sref25">
          <person-group person-group-type="author">
            <name>
              <surname>Magro</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mulvey</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Berlin</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases</article-title>
          <source>Transl Res</source>
          <volume>220</volume>
          <year>2020</year>
          <fpage>1</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">32299776</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <element-citation publication-type="journal" id="sref26">
          <person-group person-group-type="author">
            <name>
              <surname>Fox</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Akmatbekov</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Harbert</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans</article-title>
          <source>Lancet Respir Med</source>
          <volume>8</volume>
          <issue>7</issue>
          <year>2020 Jul</year>
          <fpage>681</fpage>
          <lpage>686</lpage>
          <pub-id pub-id-type="pmid">32473124</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <element-citation publication-type="journal" id="sref27">
          <person-group person-group-type="author">
            <name>
              <surname>Barnes</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Adrover</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Baxter-Stoltzfus</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Targeting potential drivers of COVID-19: neutrophil extracellular traps</article-title>
          <source>J&#xA0;Exp Med</source>
          <year>2020</year>
          <fpage>217</fpage>
        </element-citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <element-citation publication-type="journal" id="sref28">
          <person-group person-group-type="author">
            <name>
              <surname>Zuo</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Yalavarthi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps in COVID-19</article-title>
          <source>JCI Insight</source>
          <year>2020</year>
        </element-citation>
      </ref>
      <ref id="bib29">
        <label>29</label>
        <element-citation publication-type="journal" id="sref29">
          <person-group person-group-type="author">
            <name>
              <surname>Middleton</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>X.Y.</given-names>
            </name>
            <name>
              <surname>Denorme</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome</article-title>
          <source>Blood</source>
          <volume>136</volume>
          <year>2020</year>
          <fpage>1169</fpage>
          <lpage>1179</lpage>
          <pub-id pub-id-type="pmid">32597954</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <element-citation publication-type="journal" id="sref30">
          <person-group person-group-type="author">
            <name>
              <surname>Leppkes</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Knopf</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Naschberger</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Vascular occlusion by neutrophil extracellular traps in COVID-19</article-title>
          <source>EBioMedicine</source>
          <volume>58</volume>
          <year>2020</year>
          <fpage>102925</fpage>
          <pub-id pub-id-type="pmid">32745993</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <element-citation publication-type="journal" id="sref31">
          <person-group person-group-type="author">
            <name>
              <surname>Veras</surname>
              <given-names>F.P.</given-names>
            </name>
            <name>
              <surname>Pontelli</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>C.M.</given-names>
            </name>
          </person-group>
          <article-title>SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology</article-title>
          <source>J&#xA0;Exp Med</source>
          <year>2020</year>
          <fpage>217</fpage>
        </element-citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <element-citation publication-type="journal" id="sref32">
          <person-group person-group-type="author">
            <name>
              <surname>Fox</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Akmatbekov</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Harbert</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans</article-title>
          <source>Lancet Respir Med</source>
          <volume>8</volume>
          <year>2020</year>
          <fpage>681</fpage>
          <lpage>686</lpage>
          <pub-id pub-id-type="pmid">32473124</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <element-citation publication-type="journal" id="sref33">
          <person-group person-group-type="author">
            <name>
              <surname>Nicolai</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Leunig</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Brambs</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy</article-title>
          <source>Circulation</source>
          <volume>142</volume>
          <year>2020</year>
          <fpage>1176</fpage>
          <lpage>1189</lpage>
          <pub-id pub-id-type="pmid">32755393</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <element-citation publication-type="journal" id="sref34">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Excessive neutrophils and neutrophil extracellular traps in COVID-19</article-title>
          <source>Front Immunol</source>
          <volume>11</volume>
          <year>2020</year>
          <fpage>2063</fpage>
          <pub-id pub-id-type="pmid">33013872</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <element-citation publication-type="journal" id="sref35">
          <person-group person-group-type="author">
            <name>
              <surname>Darnell</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products</article-title>
          <source>Transfusion</source>
          <volume>46</volume>
          <year>2006</year>
          <fpage>1770</fpage>
          <lpage>1777</lpage>
          <pub-id pub-id-type="pmid">17002634</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <element-citation publication-type="journal" id="sref36">
          <person-group person-group-type="author">
            <name>
              <surname>Hoffmann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kleine-Weber</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Schroeder</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>
          <source>Cell</source>
          <volume>181</volume>
          <year>2020</year>
          <fpage>271</fpage>
          <lpage>280 e8</lpage>
          <pub-id pub-id-type="pmid">32142651</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <label>37</label>
        <element-citation publication-type="journal" id="sref37">
          <person-group person-group-type="author">
            <name>
              <surname>Middleton</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>X.Y.</given-names>
            </name>
            <name>
              <surname>Denorme</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps (NETs) contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome</article-title>
          <source>Blood</source>
          <volume>181</volume>
          <issue>2</issue>
          <year>2020 Apr 16</year>
          <fpage>271</fpage>
          <lpage>280.e8</lpage>
        </element-citation>
      </ref>
      <ref id="bib38">
        <label>38</label>
        <element-citation publication-type="journal" id="sref38">
          <person-group person-group-type="author">
            <name>
              <surname>Tian</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Niu</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer</article-title>
          <source>J&#xA0;Thorac Oncol</source>
          <volume>15</volume>
          <issue>5</issue>
          <year>2020 May</year>
          <fpage>700</fpage>
          <lpage>704</lpage>
          <pub-id pub-id-type="pmid">32114094</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <label>39</label>
        <element-citation publication-type="journal" id="sref39">
          <person-group person-group-type="author">
            <name>
              <surname>Bosmuller</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Traxler</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bitzer</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation</article-title>
          <source>Virchows Arch</source>
          <volume>477</volume>
          <year>2020</year>
          <fpage>349</fpage>
          <lpage>357</lpage>
          <pub-id pub-id-type="pmid">32607684</pub-id>
        </element-citation>
      </ref>
      <ref id="bib40">
        <label>40</label>
        <element-citation publication-type="journal" id="sref40">
          <person-group person-group-type="author">
            <name>
              <surname>Holers</surname>
              <given-names>V.M.</given-names>
            </name>
          </person-group>
          <article-title>Complement and its receptors: new insights into human disease</article-title>
          <source>Annu Rev Immunol</source>
          <volume>32</volume>
          <year>2014</year>
          <fpage>433</fpage>
          <lpage>459</lpage>
          <pub-id pub-id-type="pmid">24499275</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <label>41</label>
        <element-citation publication-type="journal" id="sref41">
          <person-group person-group-type="author">
            <name>
              <surname>Liszewski</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Elvington</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kulkarni</surname>
              <given-names>H.S.</given-names>
            </name>
            <name>
              <surname>Atkinson</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>Complement's hidden arsenal: new insights and novel functions inside the cell</article-title>
          <source>Mol Immunol</source>
          <volume>84</volume>
          <year>2017</year>
          <fpage>2</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">28196665</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <label>42</label>
        <element-citation publication-type="journal" id="sref42">
          <person-group person-group-type="author">
            <name>
              <surname>Java</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Apicelli</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Liszewski</surname>
              <given-names>M.K.</given-names>
            </name>
          </person-group>
          <article-title>The complement system in COVID-19: friend and foe?</article-title>
          <source>JCI Insight</source>
          <volume>5</volume>
          <year>2020</year>
        </element-citation>
      </ref>
      <ref id="bib43">
        <label>43</label>
        <element-citation publication-type="journal" id="sref43">
          <person-group person-group-type="author">
            <name>
              <surname>Liszewski</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Java</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schramm</surname>
              <given-names>E.C.</given-names>
            </name>
            <name>
              <surname>Atkinson</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>Complement dysregulation and disease: insights from contemporary genetics</article-title>
          <source>Annu Rev Pathol</source>
          <volume>12</volume>
          <year>2017</year>
          <fpage>25</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">27959629</pub-id>
        </element-citation>
      </ref>
      <ref id="bib44">
        <label>44</label>
        <element-citation publication-type="journal" id="sref44">
          <person-group person-group-type="author">
            <name>
              <surname>Agrawal</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Nawadkar</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ojha</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sahu</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Complement evasion strategies of viruses: an overview</article-title>
          <source>Front Microbiol</source>
          <volume>8</volume>
          <year>2017</year>
          <fpage>1117</fpage>
          <pub-id pub-id-type="pmid">28670306</pub-id>
        </element-citation>
      </ref>
      <ref id="bib45">
        <label>45</label>
        <element-citation publication-type="journal" id="sref45">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition</article-title>
          <source>Blood</source>
          <volume>136</volume>
          <issue>18</issue>
          <year>2020 Oct 29</year>
          <fpage>2080</fpage>
          <lpage>2089</lpage>
          <pub-id pub-id-type="pmid">32877502</pub-id>
        </element-citation>
      </ref>
      <ref id="bib46">
        <label>46</label>
        <element-citation publication-type="book" id="sref46">
          <person-group person-group-type="author">
            <name>
              <surname>Gao</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <chapter-title>Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation</chapter-title>
          <year>2020</year>
          <fpage>20041962</fpage>
          <comment>2020.03.29</comment>
        </element-citation>
      </ref>
      <ref id="bib47">
        <label>47</label>
        <element-citation publication-type="journal" id="sref47">
          <person-group person-group-type="author">
            <name>
              <surname>Gralinski</surname>
              <given-names>L.E.</given-names>
            </name>
            <name>
              <surname>Sheahan</surname>
              <given-names>T.P.</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis</article-title>
          <source>mBio</source>
          <volume>9</volume>
          <year>2018</year>
        </element-citation>
      </ref>
      <ref id="bib48">
        <label>48</label>
        <element-citation publication-type="journal" id="sref48">
          <person-group person-group-type="author">
            <name>
              <surname>Wei</surname>
              <given-names>X.S.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X.R.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2</article-title>
          <source>J&#xA0;Microbiol Immunol Infect</source>
          <year>2020 Apr 27</year>
          <comment>S1684-1182(20)30107-9</comment>
        </element-citation>
      </ref>
      <ref id="bib49">
        <label>49</label>
        <element-citation publication-type="journal" id="sref49">
          <person-group person-group-type="author">
            <name>
              <surname>Gabay</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Kushner</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Acute-phase proteins and other systemic responses to inflammation</article-title>
          <source>N&#xA0;Engl J Med</source>
          <volume>340</volume>
          <year>1999</year>
          <fpage>448</fpage>
          <lpage>454</lpage>
          <pub-id pub-id-type="pmid">9971870</pub-id>
        </element-citation>
      </ref>
      <ref id="bib50">
        <label>50</label>
        <element-citation publication-type="journal" id="sref50">
          <person-group person-group-type="author">
            <name>
              <surname>Stoermer</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Complement and viral pathogenesis</article-title>
          <source>Virology</source>
          <volume>411</volume>
          <year>2011</year>
          <fpage>362</fpage>
          <lpage>373</lpage>
          <pub-id pub-id-type="pmid">21292294</pub-id>
        </element-citation>
      </ref>
      <ref id="bib51">
        <label>51</label>
        <element-citation publication-type="book" id="sref51">
          <person-group person-group-type="author">
            <name>
              <surname>Diao</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <chapter-title>Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection</chapter-title>
          <year>2020</year>
          <fpage>20031120</fpage>
          <comment>2020.03.04</comment>
        </element-citation>
      </ref>
      <ref id="bib52">
        <label>52</label>
        <element-citation publication-type="journal" id="sref52">
          <person-group person-group-type="author">
            <name>
              <surname>Varga</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Flammer</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Steiger</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Endothelial cell infection and endotheliitis in COVID-19</article-title>
          <source>Lancet</source>
          <volume>395</volume>
          <year>2020</year>
          <fpage>1417</fpage>
          <lpage>1418</lpage>
          <pub-id pub-id-type="pmid">32325026</pub-id>
        </element-citation>
      </ref>
      <ref id="bib53">
        <label>53</label>
        <element-citation publication-type="journal" id="sref53">
          <person-group person-group-type="author">
            <name>
              <surname>Su</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China</article-title>
          <source>Kidney Int</source>
          <volume>98</volume>
          <year>2020</year>
          <fpage>219</fpage>
          <lpage>227</lpage>
          <pub-id pub-id-type="pmid">32327202</pub-id>
        </element-citation>
      </ref>
      <ref id="bib54">
        <label>54</label>
        <element-citation publication-type="journal" id="sref54">
          <person-group person-group-type="author">
            <name>
              <surname>Jhaveri</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Meir</surname>
              <given-names>L.R.</given-names>
            </name>
            <name>
              <surname>Flores Chang</surname>
              <given-names>B.S.</given-names>
            </name>
          </person-group>
          <article-title>Thrombotic microangiopathy in a patient with COVID-19</article-title>
          <source>Kidney Int</source>
          <volume>98</volume>
          <year>2020</year>
          <fpage>509</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="pmid">32525010</pub-id>
        </element-citation>
      </ref>
      <ref id="bib55">
        <label>55</label>
        <element-citation publication-type="journal" id="sref55">
          <person-group person-group-type="author">
            <name>
              <surname>Korkeala</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Makela</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of lactic acid bacteria isolated from vacuum-packed cooked ring sausages</article-title>
          <source>Int J Food Microbiol</source>
          <volume>9</volume>
          <year>1989</year>
          <fpage>33</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">2641274</pub-id>
        </element-citation>
      </ref>
      <ref id="bib56">
        <label>56</label>
        <element-citation publication-type="book" id="sref56">
          <person-group person-group-type="author">
            <name>
              <surname>Bryce</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Grimes</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Pujadas</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <chapter-title>Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response</chapter-title>
          <source>The Mount Sinai COVID-19 autopsy experience</source>
          <year>2020</year>
          <fpage>20099960</fpage>
          <comment>2020.05.18</comment>
        </element-citation>
      </ref>
      <ref id="bib57">
        <label>57</label>
        <element-citation publication-type="journal" id="sref57">
          <person-group person-group-type="author">
            <name>
              <surname>Timmermans</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Abdul-Hamid</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Potjewijd</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension</article-title>
          <source>J&#xA0;Am Soc Nephrol</source>
          <volume>29</volume>
          <year>2018</year>
          <fpage>2234</fpage>
          <lpage>2243</lpage>
          <pub-id pub-id-type="pmid">29858281</pub-id>
        </element-citation>
      </ref>
      <ref id="bib58">
        <label>58</label>
        <element-citation publication-type="journal" id="sref58">
          <person-group person-group-type="author">
            <name>
              <surname>Ackermann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Verleden</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Kuehnel</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19</article-title>
          <source>N&#xA0;Engl J Med</source>
          <volume>383</volume>
          <year>2020</year>
          <fpage>120</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="pmid">32437596</pub-id>
        </element-citation>
      </ref>
      <ref id="bib59">
        <label>59</label>
        <element-citation publication-type="journal" id="sref59">
          <person-group person-group-type="author">
            <name>
              <surname>Schaller</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hirschbuhl</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Burkhardt</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Postmortem examination of patients with COVID-19</article-title>
          <source>J&#xA0;Am Med Assoc</source>
          <volume>323</volume>
          <year>2020</year>
          <fpage>2518</fpage>
          <lpage>2520</lpage>
        </element-citation>
      </ref>
      <ref id="bib60">
        <label>60</label>
        <element-citation publication-type="journal" id="sref60">
          <person-group person-group-type="author">
            <name>
              <surname>D&#x2019;Alessandro</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Dzieciatkowska</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Serum proteomics in COVID-19 patients: altered coagulation and complement status as a function of IL-6 level</article-title>
          <source>J&#xA0;Proteome Res</source>
          <volume>19</volume>
          <issue>11</issue>
          <year>2020 Nov 6</year>
          <fpage>4417</fpage>
          <lpage>4427</lpage>
          <pub-id pub-id-type="pmid">32786691</pub-id>
        </element-citation>
      </ref>
      <ref id="bib61">
        <label>61</label>
        <element-citation publication-type="journal" id="sref61">
          <person-group person-group-type="author">
            <name>
              <surname>Holter</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Pischke</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>de Boer</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>117</volume>
          <issue>40</issue>
          <year>2020 Oct 6</year>
          <fpage>25018</fpage>
          <lpage>25025</lpage>
          <pub-id pub-id-type="pmid">32943538</pub-id>
        </element-citation>
      </ref>
      <ref id="bib62">
        <label>62</label>
        <element-citation publication-type="journal" id="sref62">
          <person-group person-group-type="author">
            <name>
              <surname>Overmyer</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Shishkova</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>I.J.</given-names>
            </name>
          </person-group>
          <article-title>Large-scale multi-omic analysis of COVID-19 severity</article-title>
          <source>medRxiv</source>
          <year>2020</year>
        </element-citation>
      </ref>
      <ref id="bib63">
        <label>63</label>
        <element-citation publication-type="journal" id="sref63">
          <person-group person-group-type="author">
            <name>
              <surname>Cugno</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Meroni</surname>
              <given-names>P.L.</given-names>
            </name>
            <name>
              <surname>Gualtierotti</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Complement activation in patients with COVID-19: a novel therapeutic target</article-title>
          <source>J&#xA0;Allergy Clin Immunol</source>
          <volume>146</volume>
          <year>2020</year>
          <fpage>215</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="pmid">32417135</pub-id>
        </element-citation>
      </ref>
      <ref id="bib64">
        <label>64</label>
        <element-citation publication-type="book" id="sref64">
          <person-group person-group-type="author">
            <name>
              <surname>Lam</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Kuri-Cervantes</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <chapter-title>Erythrocytes reveal complement activation in patients with COVID-19</chapter-title>
          <year>2020</year>
          <fpage>20104398</fpage>
          <comment>2020.05.20</comment>
        </element-citation>
      </ref>
      <ref id="bib65">
        <label>65</label>
        <element-citation publication-type="journal" id="sref65">
          <person-group person-group-type="author">
            <name>
              <surname>Yan</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Freiwald</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Chauss</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>SARS-CoV2 drives JAK1/2-dependent local and systemic complement hyper-activation</article-title>
          <source>Res Sq</source>
          <year>2020 Jun 9</year>
          <comment>rs.3.rs-33390</comment>
        </element-citation>
      </ref>
      <ref id="bib66">
        <label>66</label>
        <element-citation publication-type="journal" id="sref66">
          <person-group person-group-type="author">
            <name>
              <surname>Carvelli</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Demaria</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Vely</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis</article-title>
          <source>Nature</source>
          <volume>588</volume>
          <issue>7836</issue>
          <year>2020 Dec</year>
          <fpage>146</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="pmid">32726800</pub-id>
        </element-citation>
      </ref>
      <ref id="bib67">
        <label>67</label>
        <element-citation publication-type="journal" id="sref67">
          <person-group person-group-type="author">
            <name>
              <surname>Eriksson</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Hultstrom</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Persson</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Mannose-binding lectin is associated with thrombosis and coagulopathy in critically ill COVID-19 patients</article-title>
          <source>Thromb Haemostasis</source>
          <volume>120</volume>
          <issue>12</issue>
          <year>2020 Dec</year>
          <fpage>1720</fpage>
          <lpage>1724</lpage>
          <pub-id pub-id-type="pmid">32871607</pub-id>
        </element-citation>
      </ref>
      <ref id="bib68">
        <label>68</label>
        <element-citation publication-type="journal" id="sref68">
          <person-group person-group-type="author">
            <name>
              <surname>Fuchs</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Brill</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Duerschmied</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Extracellular DNA traps promote thrombosis</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <volume>107</volume>
          <year>2010</year>
          <fpage>15880</fpage>
          <lpage>15885</lpage>
          <pub-id pub-id-type="pmid">20798043</pub-id>
        </element-citation>
      </ref>
      <ref id="bib69">
        <label>69</label>
        <element-citation publication-type="journal" id="sref69">
          <person-group person-group-type="author">
            <name>
              <surname>Kambas</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Mitroulis</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Apostolidou</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis</article-title>
          <source>PloS One</source>
          <volume>7</volume>
          <year>2012</year>
          <object-id pub-id-type="publisher-id">e45427</object-id>
        </element-citation>
      </ref>
      <ref id="bib70">
        <label>70</label>
        <element-citation publication-type="journal" id="sref70">
          <person-group person-group-type="author">
            <name>
              <surname>Martinelli</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Urosevic</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Daryadel</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation</article-title>
          <source>J&#xA0;Biol Chem</source>
          <volume>279</volume>
          <year>2004</year>
          <fpage>44123</fpage>
          <lpage>44132</lpage>
          <pub-id pub-id-type="pmid">15302890</pub-id>
        </element-citation>
      </ref>
      <ref id="bib71">
        <label>71</label>
        <element-citation publication-type="journal" id="sref71">
          <person-group person-group-type="author">
            <name>
              <surname>Behnen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Leschczyk</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Moller</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via FcgammaRIIIB and Mac-1</article-title>
          <source>J&#xA0;Immunol</source>
          <volume>193</volume>
          <year>2014</year>
          <fpage>1954</fpage>
          <lpage>1965</lpage>
          <pub-id pub-id-type="pmid">25024378</pub-id>
        </element-citation>
      </ref>
      <ref id="bib72">
        <label>72</label>
        <element-citation publication-type="journal" id="sref72">
          <person-group person-group-type="author">
            <name>
              <surname>Palmer</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Damgaard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Holmstrup</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>C.H.</given-names>
            </name>
          </person-group>
          <article-title>Influence of complement on neutrophil extracellular trap release induced by bacteria</article-title>
          <source>J&#xA0;Periodontal Res</source>
          <volume>51</volume>
          <year>2016</year>
          <fpage>70</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="pmid">25900429</pub-id>
        </element-citation>
      </ref>
      <ref id="bib73">
        <label>73</label>
        <element-citation publication-type="journal" id="sref73">
          <person-group person-group-type="author">
            <name>
              <surname>Leffler</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gullstrand</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease</article-title>
          <source>J&#xA0;Immunol</source>
          <volume>188</volume>
          <year>2012</year>
          <fpage>3522</fpage>
          <lpage>3531</lpage>
          <pub-id pub-id-type="pmid">22345666</pub-id>
        </element-citation>
      </ref>
      <ref id="bib74">
        <label>74</label>
        <element-citation publication-type="journal" id="sref74">
          <person-group person-group-type="author">
            <name>
              <surname>Camous</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Roumenina</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Bigot</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Complement alternative pathway acts as a positive feedback amplification of neutrophil activation</article-title>
          <source>Blood</source>
          <volume>117</volume>
          <year>2011</year>
          <fpage>1340</fpage>
          <lpage>1349</lpage>
          <pub-id pub-id-type="pmid">21063021</pub-id>
        </element-citation>
      </ref>
      <ref id="bib75">
        <label>75</label>
        <element-citation publication-type="journal" id="sref75">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps can activate alternative complement pathways</article-title>
          <source>Clin Exp Immunol</source>
          <volume>181</volume>
          <year>2015</year>
          <fpage>518</fpage>
          <lpage>527</lpage>
          <pub-id pub-id-type="pmid">25963026</pub-id>
        </element-citation>
      </ref>
      <ref id="bib76">
        <label>76</label>
        <element-citation publication-type="journal" id="sref76">
          <person-group person-group-type="author">
            <name>
              <surname>O'Flynn</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Dixon</surname>
              <given-names>K.O.</given-names>
            </name>
            <name>
              <surname>Krol</surname>
              <given-names>M.C.F.</given-names>
            </name>
          </person-group>
          <article-title>Myeloperoxidase directs properdin-mediated complement activation</article-title>
          <source>Journal of Innate Immunity</source>
          <volume>6</volume>
          <year>2014</year>
          <fpage>417</fpage>
          <lpage>425</lpage>
          <pub-id pub-id-type="pmid">24355864</pub-id>
        </element-citation>
      </ref>
      <ref id="bib77">
        <label>77</label>
        <element-citation publication-type="journal" id="sref77">
          <person-group person-group-type="author">
            <name>
              <surname>Jimenez-Alcazar</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Napirei</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Panda</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies</article-title>
          <source>J&#xA0;Thromb Haemostasis</source>
          <volume>13</volume>
          <year>2015</year>
          <fpage>732</fpage>
          <lpage>742</lpage>
          <pub-id pub-id-type="pmid">25418346</pub-id>
        </element-citation>
      </ref>
      <ref id="bib78">
        <label>78</label>
        <element-citation publication-type="journal" id="sref78">
          <person-group person-group-type="author">
            <name>
              <surname>Arai</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Yamashita</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Mizugishi</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation</article-title>
          <source>Biol Blood Marrow Transplant</source>
          <volume>19</volume>
          <year>2013</year>
          <fpage>1683</fpage>
          <lpage>1689</lpage>
          <pub-id pub-id-type="pmid">24055655</pub-id>
        </element-citation>
      </ref>
      <ref id="bib79">
        <label>79</label>
        <element-citation publication-type="journal" id="sref79">
          <person-group person-group-type="author">
            <name>
              <surname>Leffler</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Prohaszka</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Mikes</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Decreased neutrophil extracellular trap degradation in shiga toxin-associated haemolytic uraemic syndrome</article-title>
          <source>J&#xA0;Innate Immun</source>
          <volume>9</volume>
          <year>2017</year>
          <fpage>12</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">27784011</pub-id>
        </element-citation>
      </ref>
      <ref id="bib80">
        <label>80</label>
        <element-citation publication-type="journal" id="sref80">
          <person-group person-group-type="author">
            <name>
              <surname>Ramos</surname>
              <given-names>M.V.</given-names>
            </name>
            <name>
              <surname>Mejias</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Sabbione</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Induction of neutrophil extracellular traps in shiga toxin-associated hemolytic uremic syndrome</article-title>
          <source>J&#xA0;Innate Immun</source>
          <volume>8</volume>
          <year>2016</year>
          <fpage>400</fpage>
          <lpage>411</lpage>
          <pub-id pub-id-type="pmid">27230920</pub-id>
        </element-citation>
      </ref>
      <ref id="bib81">
        <label>81</label>
        <element-citation publication-type="journal" id="sref81">
          <person-group person-group-type="author">
            <name>
              <surname>Gloude</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>Khandelwal</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Luebbering</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD</article-title>
          <source>Blood</source>
          <volume>130</volume>
          <year>2017</year>
          <fpage>1259</fpage>
          <lpage>1266</lpage>
          <pub-id pub-id-type="pmid">28705839</pub-id>
        </element-citation>
      </ref>
      <ref id="bib82">
        <label>82</label>
        <element-citation publication-type="journal" id="sref82">
          <person-group person-group-type="author">
            <name>
              <surname>Sule</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kelley</surname>
              <given-names>W.J.</given-names>
            </name>
            <name>
              <surname>Gockman</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Increased adhesive potential of antiphospholipid syndrome neutrophils mediated by beta 2 integrin mac-1</article-title>
          <source>Arthritis Rheum</source>
          <volume>72</volume>
          <year>2020</year>
          <fpage>114</fpage>
          <lpage>124</lpage>
        </element-citation>
      </ref>
      <ref id="bib83">
        <label>83</label>
        <element-citation publication-type="journal" id="sref83">
          <person-group person-group-type="author">
            <name>
              <surname>Legendre</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Licht</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Muus</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome</article-title>
          <source>N&#xA0;Engl J Med</source>
          <volume>368</volume>
          <year>2013</year>
          <fpage>2169</fpage>
          <lpage>2181</lpage>
          <pub-id pub-id-type="pmid">23738544</pub-id>
        </element-citation>
      </ref>
      <ref id="bib84">
        <label>84</label>
        <element-citation publication-type="journal" id="sref84">
          <person-group person-group-type="author">
            <name>
              <surname>Gavriilaki</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Chrysanthopoulou</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sakellari</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy</article-title>
          <source>Thromb Haemostasis</source>
          <volume>119</volume>
          <year>2019</year>
          <fpage>1433</fpage>
          <lpage>1440</lpage>
          <pub-id pub-id-type="pmid">31266080</pub-id>
        </element-citation>
      </ref>
      <ref id="bib85">
        <label>85</label>
        <element-citation publication-type="journal" id="sref85">
          <person-group person-group-type="author">
            <name>
              <surname>Skendros</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mitsios</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Chrysanthopoulou</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis</article-title>
          <source>J&#xA0;Clin Invest</source>
          <volume>130</volume>
          <issue>11</issue>
          <year>2020 Nov 2</year>
          <fpage>6151</fpage>
          <lpage>6157</lpage>
          <pub-id pub-id-type="pmid">32759504</pub-id>
        </element-citation>
      </ref>
      <ref id="bib86">
        <label>86</label>
        <element-citation publication-type="journal" id="sref86">
          <person-group person-group-type="author">
            <name>
              <surname>Buijsers</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Yanginlar</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Maciej-Hulme</surname>
              <given-names>M.L.</given-names>
            </name>
          </person-group>
          <article-title>Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients</article-title>
          <source>EBioMedicine</source>
          <volume>59</volume>
          <year>2020</year>
          <fpage>102969</fpage>
          <pub-id pub-id-type="pmid">32853989</pub-id>
        </element-citation>
      </ref>
      <ref id="bib87">
        <label>87</label>
        <element-citation publication-type="journal" id="sref87">
          <person-group person-group-type="author">
            <name>
              <surname>Vargas</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Boivin</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Cano</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma</article-title>
          <source>Respir Res</source>
          <volume>18</volume>
          <year>2017</year>
          <fpage>207</fpage>
          <pub-id pub-id-type="pmid">29233147</pub-id>
        </element-citation>
      </ref>
      <ref id="bib88">
        <label>88</label>
        <element-citation publication-type="journal" id="sref88">
          <person-group person-group-type="author">
            <name>
              <surname>Furumoto</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>C.K.</given-names>
            </name>
            <name>
              <surname>Blanco</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Tofacitinib ameliorates murine lupus and its associated vascular dysfunction</article-title>
          <source>Arthritis Rheum</source>
          <volume>69</volume>
          <year>2017</year>
          <fpage>148</fpage>
          <lpage>160</lpage>
        </element-citation>
      </ref>
      <ref id="bib89">
        <label>89</label>
        <element-citation publication-type="journal" id="sref89">
          <person-group person-group-type="author">
            <name>
              <surname>Yadav</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1beta-driven venous thrombosis</article-title>
          <source>J&#xA0;Clin Invest</source>
          <volume>129</volume>
          <year>2019</year>
          <fpage>2872</fpage>
          <lpage>2877</lpage>
          <pub-id pub-id-type="pmid">30990798</pub-id>
        </element-citation>
      </ref>
      <ref id="bib90">
        <label>90</label>
        <element-citation publication-type="journal" id="sref90">
          <person-group person-group-type="author">
            <name>
              <surname>Apostolidou</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Skendros</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kambas</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps regulate IL-1beta-mediated inflammation in familial Mediterranean fever</article-title>
          <source>Ann Rheum Dis</source>
          <volume>75</volume>
          <year>2016</year>
          <fpage>269</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="pmid">25261578</pub-id>
        </element-citation>
      </ref>
      <ref id="bib91">
        <label>91</label>
        <element-citation publication-type="journal" id="sref91">
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Chau</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Egeblad</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series</article-title>
          <source>Mol Med</source>
          <volume>26</volume>
          <year>2020</year>
          <fpage>91</fpage>
          <pub-id pub-id-type="pmid">32993479</pub-id>
        </element-citation>
      </ref>
      <ref id="bib92">
        <label>92</label>
        <element-citation publication-type="journal" id="sref92">
          <person-group person-group-type="author">
            <name>
              <surname>Aitken</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study</article-title>
          <source>J&#xA0;Am Med Assoc</source>
          <volume>267</volume>
          <year>1992</year>
          <fpage>1947</fpage>
          <lpage>1951</lpage>
        </element-citation>
      </ref>
      <ref id="bib93">
        <label>93</label>
        <element-citation publication-type="journal" id="sref93">
          <person-group person-group-type="author">
            <name>
              <surname>Ali</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Gandhi</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome</article-title>
          <source>Nat Commun</source>
          <volume>10</volume>
          <year>2019</year>
          <fpage>1916</fpage>
          <pub-id pub-id-type="pmid">31015489</pub-id>
        </element-citation>
      </ref>
      <ref id="bib94">
        <label>94</label>
        <element-citation publication-type="journal" id="sref94">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19</article-title>
          <source>Acta Pharm Sin B</source>
          <volume>10</volume>
          <year>2020</year>
          <fpage>1205</fpage>
          <lpage>1215</lpage>
          <pub-id pub-id-type="pmid">32318327</pub-id>
        </element-citation>
      </ref>
      <ref id="bib95">
        <label>95</label>
        <element-citation publication-type="journal" id="sref95">
          <person-group person-group-type="author">
            <name>
              <surname>Kanthi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Knight</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Zuo</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Pinsky</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <article-title>New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm</article-title>
          <source>JCI Insight</source>
          <volume>5</volume>
          <year>2020</year>
        </element-citation>
      </ref>
      <ref id="bib96">
        <label>96</label>
        <element-citation publication-type="journal" id="sref96">
          <person-group person-group-type="author">
            <name>
              <surname>Diurno</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Numis</surname>
              <given-names>F.G.</given-names>
            </name>
            <name>
              <surname>Porta</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience</article-title>
          <source>Eur Rev Med Pharmacol Sci</source>
          <volume>24</volume>
          <year>2020</year>
          <fpage>4040</fpage>
          <lpage>4047</lpage>
          <pub-id pub-id-type="pmid">32329881</pub-id>
        </element-citation>
      </ref>
      <ref id="bib97">
        <label>97</label>
        <element-citation publication-type="journal" id="sref97">
          <person-group person-group-type="author">
            <name>
              <surname>Mahajan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lipton</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Broglie</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Eculizumab treatment for renal failure in a pediatric patient with COVID-19</article-title>
          <source>J&#xA0;Nephrol</source>
          <volume>33</volume>
          <issue>6</issue>
          <year>2020 Dec</year>
          <fpage>1373</fpage>
          <lpage>1376</lpage>
          <pub-id pub-id-type="pmid">32981025</pub-id>
        </element-citation>
      </ref>
      <ref id="bib98">
        <label>98</label>
        <element-citation publication-type="journal" id="sref98">
          <person-group person-group-type="author">
            <name>
              <surname>Laurence</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Mulvey</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Seshadri</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19</article-title>
          <source>Clin Immunol</source>
          <volume>219</volume>
          <year>2020</year>
          <fpage>108555</fpage>
          <pub-id pub-id-type="pmid">32771488</pub-id>
        </element-citation>
      </ref>
      <ref id="bib99">
        <label>99</label>
        <element-citation publication-type="journal" id="sref99">
          <person-group person-group-type="author">
            <name>
              <surname>Zelek</surname>
              <given-names>W.M.</given-names>
            </name>
            <name>
              <surname>Cole</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ponsford</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Complement inhibition with the C5 blocker LFG316 in severe COVID-19</article-title>
          <source>Am J Respir Crit Care Med</source>
          <volume>202</volume>
          <issue>9</issue>
          <year>2020 Nov 1</year>
          <fpage>1304</fpage>
          <lpage>1308</lpage>
          <pub-id pub-id-type="pmid">32897730</pub-id>
        </element-citation>
      </ref>
      <ref id="bib100">
        <label>100</label>
        <element-citation publication-type="journal" id="sref100">
          <person-group person-group-type="author">
            <name>
              <surname>Peffault de Latour</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bergeron</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lengline</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Complement C5 inhibition in patients with COVID-19 - a promising target?</article-title>
          <source>Haematologica</source>
          <volume>105</volume>
          <issue>12</issue>
          <year>2020 Dec 1</year>
          <fpage>2847</fpage>
          <lpage>2850</lpage>
          <pub-id pub-id-type="pmid">33256385</pub-id>
        </element-citation>
      </ref>
      <ref id="bib101">
        <label>101</label>
        <element-citation publication-type="journal" id="sref101">
          <person-group person-group-type="author">
            <name>
              <surname>Mastellos</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Pires da</surname>
              <given-names>Silva BGP.</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>B.A.L.</given-names>
            </name>
          </person-group>
          <article-title>Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy</article-title>
          <source>Clin Immunol</source>
          <volume>220</volume>
          <year>2020</year>
          <fpage>108598</fpage>
          <pub-id pub-id-type="pmid">32961333</pub-id>
        </element-citation>
      </ref>
      <ref id="bib102">
        <label>102</label>
        <element-citation publication-type="journal" id="sref102">
          <person-group person-group-type="author">
            <name>
              <surname>Araten</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Belmont</surname>
              <given-names>H.M.</given-names>
            </name>
            <name>
              <surname>Schaefer-Cutillo</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Mild clinical course of COVID-19 in 3 patients receiving therapeutic monoclonal antibodies targeting C5 complement for hematologic disorders</article-title>
          <source>Am J Case Rep</source>
          <volume>21</volume>
          <year>2020</year>
          <comment>e927418</comment>
        </element-citation>
      </ref>
      <ref id="bib103">
        <label>103</label>
        <element-citation publication-type="journal" id="sref103">
          <person-group person-group-type="author">
            <name>
              <surname>Kulasekararaj</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Lazana</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Large</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Terminal complement inhibition dampens the inflammation during COVID-19</article-title>
          <source>Br J Haematol</source>
          <volume>190</volume>
          <year>2020</year>
          <fpage>e141</fpage>
          <lpage>e143</lpage>
          <pub-id pub-id-type="pmid">32495372</pub-id>
        </element-citation>
      </ref>
      <ref id="bib104">
        <label>104</label>
        <element-citation publication-type="journal" id="sref104">
          <person-group person-group-type="author">
            <name>
              <surname>Pike</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Muus</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Munir</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>COVID-19 infection in patients on anti-complement therapy: the Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience</article-title>
          <source>Br J Haematol</source>
          <volume>191</volume>
          <issue>1</issue>
          <year>2020 Oct</year>
          <fpage>e1</fpage>
          <lpage>e4</lpage>
          <pub-id pub-id-type="pmid">32945525</pub-id>
        </element-citation>
      </ref>
      <ref id="bib105">
        <label>105</label>
        <element-citation publication-type="journal" id="sref105">
          <person-group person-group-type="author">
            <name>
              <surname>Vlaar</surname>
              <given-names>A.P.J.</given-names>
            </name>
            <name>
              <surname>de Bruin</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Busch</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial</article-title>
          <source>Lancet Rheumatol</source>
          <volume>2</volume>
          <issue>12</issue>
          <year>2020 Dec</year>
          <fpage>e764</fpage>
          <lpage>e773</lpage>
          <pub-id pub-id-type="pmid">33015643</pub-id>
        </element-citation>
      </ref>
      <ref id="bib106">
        <label>106</label>
        <element-citation publication-type="journal" id="sref106">
          <person-group person-group-type="author">
            <name>
              <surname>Mastellos</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Yancopoulou</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kokkinos</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention</article-title>
          <source>Eur J Clin Invest</source>
          <volume>45</volume>
          <year>2015</year>
          <fpage>423</fpage>
          <lpage>440</lpage>
          <pub-id pub-id-type="pmid">25678219</pub-id>
        </element-citation>
      </ref>
      <ref id="bib107">
        <label>107</label>
        <element-citation publication-type="journal" id="sref107">
          <person-group person-group-type="author">
            <name>
              <surname>Mastaglio</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ruggeri</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Risitano</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>The first case of COVID-19 treated with the complement C3 inhibitor AMY-101</article-title>
          <source>Clin Immunol</source>
          <volume>215</volume>
          <year>2020</year>
          <fpage>108450</fpage>
          <pub-id pub-id-type="pmid">32360516</pub-id>
        </element-citation>
      </ref>
      <ref id="bib108">
        <label>108</label>
        <element-citation publication-type="journal" id="sref108">
          <person-group person-group-type="author">
            <name>
              <surname>Urwyler</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Moser</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Charitos</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Treatment of COVID-19 with conestat alfa, a regulator of the complement, contact activation and kallikrein-kinin system</article-title>
          <source>Front Immunol</source>
          <volume>11</volume>
          <year>2020</year>
          <fpage>2072</fpage>
          <pub-id pub-id-type="pmid">32922409</pub-id>
        </element-citation>
      </ref>
      <ref id="bib109">
        <label>109</label>
        <element-citation publication-type="journal" id="sref109">
          <person-group person-group-type="author">
            <name>
              <surname>Rambaldi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gritti</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Mico</surname>
              <given-names>M.C.</given-names>
            </name>
          </person-group>
          <article-title>Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab</article-title>
          <source>Immunobiology</source>
          <year>2020</year>
          <fpage>152001</fpage>
          <pub-id pub-id-type="pmid">32943233</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1663-9812</issn>
      <publisher>
        <publisher-name>Frontiers Media S.A.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33013419</article-id>
      <article-id pub-id-type="pmc">7516261</article-id>
      <article-id pub-id-type="doi">10.3389/fphar.2020.576293</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Pharmacology</subject>
          <subj-group>
            <subject>Review</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Perrem</surname>
            <given-names>Lucy</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
          <xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/996165"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ratjen</surname>
            <given-names>Felix</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
<sup>1</sup>
<institution>Division of Respiratory Medicine, The Hospital for Sick Children</institution>, <addr-line>Toronto, ON</addr-line>, <country>Canada</country>
</aff>
      <aff id="aff2">
<sup>2</sup>
<institution>Department of Paediatrics, University of Toronto</institution>, <addr-line>Toronto, ON</addr-line>, <country>Canada</country>
</aff>
      <aff id="aff3">
<sup>3</sup>
<institution>Translational Medicine Program, SickKids Research Institute</institution>, <addr-line>Toronto, ON</addr-line>, <country>Canada</country>
</aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Noel Gerard McElvaney, Royal College of Surgeons in Ireland, Ireland</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Luigi Brunetti, University of Studies G. d&#x2019;Annunzio Chieti and Pescara, Italy; Giustino Orlando, University of Studies G. d&#x2019;Annunzio Chieti and Pescara, Italy</p>
        </fn>
        <corresp id="fn001">*Correspondence: Lucy Perrem, <email xlink:href="mailto:lucy.perrem@sickkids.ca" xlink:type="simple">lucy.perrem@sickkids.ca</email>
</corresp>
        <fn fn-type="other" id="fn002">
          <p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>576293</elocation-id>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>6</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>8</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 Perrem and Ratjen</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Perrem and Ratjen</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The inflammatory response in the CF airway begins early in the disease process and becomes persistent through life in most patients. Inflammation, which is predominantly neutrophilic, worsens airway obstruction and plays a critical role in the development of structural lung damage. While cystic fibrosis transmembrane regulator modulators will likely have a dramatic impact on the trajectory of CF lung disease over the coming years, addressing other important aspects of lung disease such as inflammation will nevertheless remain a priority. Considering the central role of neutrophils and their products in the inflammatory response, potential therapies should ultimately affect neutrophils and their products. The ideal anti-inflammatory therapy would exert a dual effect on the pro-inflammatory and pro-resolution arms of the inflammatory cascade, both of which contribute to dysregulated inflammation in CF. This review outlines the key factors to be considered in the design of clinical trials evaluating anti-inflammatory therapies in CF. Important lessons have been learned from previous clinical trials in this area and choosing the right efficacy endpoints is key to the success of any anti-inflammatory drug development program. Identifying and validating non-invasive biomarkers, novel imaging techniques and sensitive lung function tests capable of monitoring disease activity and therapeutic response are important areas of research and will be useful for the design of future anti-inflammatory drug trials.</p>
      </abstract>
      <kwd-group>
        <kwd>anti-inflammatories</kwd>
        <kwd>cystic fibrosis</kwd>
        <kwd>clinical trials</kwd>
        <kwd>lung</kwd>
        <kwd>airway inflammation</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="1"/>
        <equation-count count="0"/>
        <ref-count count="92"/>
        <page-count count="9"/>
        <word-count count="4424"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Airway inflammation plays a critical role in the development of bronchiectasis in cystic fibrosis (CF) and contributes to the progressive decline in lung function (<xref rid="B57" ref-type="bibr">Pillarisetti et&#xA0;al., 2011</xref>; <xref rid="B73" ref-type="bibr">Sagel et&#xA0;al., 2012</xref>; <xref rid="B79" ref-type="bibr">Sly et&#xA0;al., 2013</xref>; <xref rid="B51" ref-type="bibr">Nichols and Chmiel, 2015</xref>). Inflammation typically beings early in the disease process and becomes persistent in most patients (<xref rid="B57" ref-type="bibr">Pillarisetti et&#xA0;al., 2011</xref>; <xref rid="B73" ref-type="bibr">Sagel et&#xA0;al., 2012</xref>; <xref rid="B79" ref-type="bibr">Sly et&#xA0;al., 2013</xref>; <xref rid="B51" ref-type="bibr">Nichols and Chmiel, 2015</xref>).</p>
      <p>The inflammatory process in CF is predominantly driven by neutrophils (<xref rid="B14" ref-type="bibr">Cohen-Cymberknoh et&#xA0;al., 2013</xref>). Neutrophils are recruited into the airway in response to infection and then kill bacteria by releasing their contents including peroxidases and proteases (<xref rid="B89" ref-type="bibr">Watt et&#xA0;al., 2005</xref>). A key feature of inflammation in CF is that the response is excessive relative to the burden of infection due to a combination of increased influx and decreased clearance of pathogens and inflammatory cells (<xref rid="B51" ref-type="bibr">Nichols and Chmiel, 2015</xref>). Normally, once the intracellular contents are released, neutrophils undergo apoptosis by alveolar macrophages. However, in the CF airway, neutrophils undergo necrosis rather than apoptosis and this results in the release of damaging intracellular contents and chemoattractants and fuels further neutrophil influx (<xref rid="B89" ref-type="bibr">Watt et&#xA0;al., 2005</xref>; <xref rid="B15" ref-type="bibr">Cohen-Cymberknoh et&#xA0;al., 2016</xref>). The release of massive quantities of neutrophil elastase overwhelms the endogenous anti-proteases, such as anti-1 antitrypsin, needed to neutralize proteolytic activity, and this ultimately leads to the destruction of lung tissue (<xref rid="B6" ref-type="bibr">Birrer et&#xA0;al., 1994</xref>). The actions of neutrophil elastase also work to make the neutrophils in CF airways less effective at killing bacteria, partly due to cleavage of immunoglobulins and complement (<xref rid="B46" ref-type="bibr">McElvaney, 2016</xref>). This becomes a vicious cycle of neutrophilic inflammation, protease release, and oxidative stress which leads to tissue destruction and fibrosis of the lungs (<xref rid="B14" ref-type="bibr">Cohen-Cymberknoh et&#xA0;al., 2013</xref>).</p>
      <p>Cystic fibrosis transmembrane regulator (CFTR) modulators are a new class of therapy that targets the basic genetic defect and could dramatically change the landscape of CF care. These drugs are potentially efficacious for approximately 90% of the CF population (<xref rid="B5" ref-type="bibr">Bell et&#xA0;al., 2020</xref>). However, despite the impressive improvements in lung function observed with ivacaftor in CF patients with gating mutations (<xref rid="B90" ref-type="bibr">Whiting et&#xA0;al., 2014</xref>), there is limited evidence that CFTR modulators impact inflammation. In a multicenter prospective cohort study in the post-approval setting, Rowe and co-workers found that patients on ivacaftor experienced significant improvements in forced expiratory volume in 1 second (FEV<sub>1</sub>) and reductions in sweat chloride, but there were no significant changes in any sputum inflammatory markers (<xref rid="B70" ref-type="bibr">Rowe et&#xA0;al., 2014</xref>). In contrast, Hisert and co-workers evaluated the impact of ivacaftor on airway inflammation over a longer period of time and reported a significant reduction in sputum inflammatory markers including neutrophil elastase, IL-8 and IL-1b (<xref rid="B70" ref-type="bibr">Rowe et&#xA0;al., 2014</xref>). However, even in this study, most patients had ongoing chronic infection and inflammation, albeit at a lower level. A large observational study designed to evaluate the effects of the triple combination CFTR modulator (elexacaftor/tezacaftor/ivacaftor) may be able to more definitively establish how this class of drug impacts airway inflammation (<xref rid="B7" ref-type="bibr">Block et&#xA0;al., 2006</xref>).</p>
      <p>Considering that the clinical response to CFTR modulators is variable, they are not universally available and, if bronchiectasis is already established, chronic infection and inflammation persist and lung function continues to decline (<xref rid="B76" ref-type="bibr">Sawicki et&#xA0;al., 2015</xref>), developing new therapies that target other aspects of CF lung disease remains a priority (<xref rid="B56" ref-type="bibr">Perrem and Ratjen, 2019</xref>). The purpose of this review is to outline key aspects to be considered in the design of clinical trials evaluating the efficacy of anti-inflammatory therapies.</p>
    </sec>
    <sec id="s2">
      <title>What Is the Ideal Inflammatory Pathway to Target?</title>
      <p>The complexity of the inflammatory process in CF provides multiple potential targets for intervention. Due to the central role of neutrophils in the inflammatory process, effective anti-inflammatory therapies must target neutrophils or their products (<xref rid="B85" ref-type="bibr">Torphy et&#xA0;al., 2015</xref>).</p>
      <p>The CF airway contains a broad spectrum of pro-inflammatory mediators, such as TNF-alpha, IL-1beta, IL-6, IL-8, IL-17, IL-33. GM-CSF, G-CSF, and HMGB-1 (<xref rid="B51" ref-type="bibr">Nichols and Chmiel, 2015</xref>). The downregulation of inflammation is also defective, with many studies demonstrating a deficiency in counter-regulatory molecules such as IL-10 and lipoxin-A4 (LXA4). The multiplicity of inflammatory pathways and inherent redundancy in the process makes it challenging to target specific components, both the pro-inflammatory and pro-resolving pathways offer potential targets for therapeutic interventions.</p>
      <p>Longitudinal data from the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (<italic>AREST</italic> CF) surveillance program demonstrated that free neutrophil elastase activity in bronchoalveolar lavage (BAL) fluid at 3 months of age was associated with bronchiectasis on computed tomography (CT) scan at 1 and 3 years of age (<xref rid="B79" ref-type="bibr">Sly et&#xA0;al., 2013</xref>). While it is unclear whether targeting a specific mediator of inflammation will be successful, given the intense burden of neutrophil elastase in CF and the predictive value of this biomarker, neutrophil elastase is a key target for anti-inflammatory therapy. Studies investigating alpha-1 antitrypsin therapy as a way to restore the protease-antiprotease balance in the CF airway have shown an improvement in neutrophil function, a reduction in inflammation, and augmentation on bacterial clearance (<xref rid="B45" ref-type="bibr">McElvaney et&#xA0;al., 1991</xref>; <xref rid="B6" ref-type="bibr">Birrer et&#xA0;al., 1994</xref>; <xref rid="B26" ref-type="bibr">Griese et&#xA0;al., 2007</xref>; <xref rid="B46" ref-type="bibr">McElvaney, 2016</xref>). This provides proof of concept that this approach could be successful in future clinical trials.</p>
    </sec>
    <sec id="s3">
      <title>Lessons Learned From Previous Trials</title>
      <p>Previous studies investigating anti-inflammatory therapies have demonstrated the importance of choosing the right target and the right dose of active drug.</p>
      <p>The major concern in undertaking trials with anti-inflammatory agents in CF is the potential that suppressing the inflammatory response in a chronically infected airway will impair host defense and exacerbate infections (<xref rid="B85" ref-type="bibr">Torphy et&#xA0;al., 2015</xref>). We learned these lessons from a large phase II clinical trial of an LTB4 receptor antagonist (BIIL 284 BS). The CF inflammatory response is mediated in part by LTB4, a key modulator of inflammation that attracts and activates neutrophils in the airway. Preclinical studies suggested that LTB4-receptor inhibition could have positive clinical effects (<xref rid="B32" ref-type="bibr">Konstan et&#xA0;al., 1993</xref>) but the phase II BIL 284BS trial was terminated early because of increased pulmonary exacerbations in the adults treated with the study drug, combined with evidence of decreased pulmonary function and increased circulating neutrophils (<xref rid="B35" ref-type="bibr">Konstan et&#xA0;al., 2014</xref>). To understand the mechanisms underlying these negative results, subsequent studies in mice found that lower doses of the drug attenuated the inflammatory response without increasing infection, but high doses, like the dose used in the clinical trial, overly suppressed the inflammatory response and were associated with increased bacterial colony counts (<xref rid="B20" ref-type="bibr">D&#xF6;ring et&#xA0;al., 2014</xref>). Therefore, future trials evaluating anti-inflammatory drugs in the clinical trial setting should first have generated sufficient information about the possible harms of the drug. Preclinical studies or data available from studies investigating the same drug in other patient populations are essential to ensure a drug is safe for clinical trials in CF. <xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref> describes how the study design and outcome measure will vary with the development phase when investigating anti-inflammatory therapies in cystic fibrosis.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>The study design and outcome measure will vary with the development phase of an anti-inflammatory therapy.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">Phase of development</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Population</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Duration</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Outcome measures</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Example</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Preclinical study</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Animal models<break/>In vitro assays</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Days</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Safety</bold>
<break/>Lack of negative effect on airway infection</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CFTR-deficient mouse model to investigate infection susceptibilities associated with study drug<break/>(<xref rid="B8" ref-type="bibr">Bonfield, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Phase I</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Healthy volunteers or Non-CF patients</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2264;3 months</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Safety and pharmacokinetics</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase 1 study of acebilistat in CF patients and healthy volunteers<break/>(<xref rid="B22" ref-type="bibr">Elborn et&#xA0;al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Phase IIa</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CF adults</td>
              <td valign="top" align="left" rowspan="1" colspan="1">8&#x2013;12 weeks</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Biomarkers</bold>
<break/>
<bold>e.g. sputum NE, IL-6, IL-8</bold>
<break/>
<bold>serum CRP, calprotectin</bold>
<break/>Trends in a reduction in PEx<break/>
<italic>New imaging techniques e.g. MRI, PET-CT</italic>
<break/>
<italic>Functional tests e.g. MBW</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase II randomized placebo-controlled trial of acebilustat<break/>48-week study<break/>Primary endpoint: change in FEV1pp and safety outcomes<break/>Secondary outcomes: PEx rate, time to first PEx and biomarkers of inflammation<break/>(<xref rid="B23" ref-type="bibr">Elborn et&#xA0;al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Phase IIb/III</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CF adolescents and adults</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2265;6 months</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>PEx rate</bold>
<break/>FEV1 decline<break/>
<italic>Evolution of bronchiectasis on CT</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase IIb placebo-controlled trial of lenabasum in cystic fibrosis.<break/>28-week study<break/>Primary outcome: PEx rate<break/>Secondary outcomes: time to first PEx; PEx rate using secondary PEx definition; change in CFQ-R Respiratory domain score; Change in FEV1pp; Adverse events<break/>(<xref rid="B86" ref-type="bibr">Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis</xref>&#x2014;Full Text View&#x2014;ClinicalTrials.gov)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Alternative study design</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CF adolescents and adults</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Treatment during PEx</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>FEV1 change with treatment</bold>
<break/>
<bold>FEV1 recovery post treatment</bold>
<break/>Biomarkers</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Randomized placebo-controlled trial<break/>Of prednisone in cystic fibrosis PEx<break/>Primary outcome the proportion of subjects who achieve &gt;90% of baseline FEV1% predicted at day 14 of IV antibiotic treatment<break/>(<xref rid="B58" ref-type="bibr">Prednisone in Cystic Fibrosis Pulmonary Exacerbations</xref> - Full Text View - ClinicalTrials.gov)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>NE, neutrophil elastase; CRP, C-reactive protein; CFQ-R, Cystic Fibrosis Questionnaire- Revised; MRI, magnetic resonance imaging; PET-CT positron emission tomography &#x2013; computed tomography; PEx; pulmonary exacerbation; FEV1pp, FEV<sub>1</sub> percent predicted; MBW, multiple breath washout.</p>
          <p>Key outcome measures in bold, potential future outcome measures in italics.</p>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="s4">
      <title>Role of Biomarkers</title>
      <p>Given the important role of inflammation in CF lung disease, identifying biomarkers capable of monitoring disease activity or therapeutic response would be very useful (<xref rid="B83" ref-type="bibr">Tiddens et&#xA0;al., 2015</xref>). In clinical drug development, biomarkers can be used in early phase studies to demonstrate the biological safety and efficacy of new therapies, confirm the mechanism of action and inform dose selection (<xref rid="B50" ref-type="bibr">Muhlebach et&#xA0;al., 2016</xref>). Biomarkers can also be useful to compare results from preclinical and clinical studies (<xref rid="B85" ref-type="bibr">Torphy et&#xA0;al., 2015</xref>; <xref rid="B50" ref-type="bibr">Muhlebach et&#xA0;al., 2016</xref>). The relatively poor success rate in developing new anti-inflammatory therapies can, in part, be attributed to a lack of accurate, reproducible, noninvasive biomarkers that reflect the anti-inflammatory process (<xref rid="B43" ref-type="bibr">Martinez et&#xA0;al., 2011</xref>).</p>
      <sec id="s4_1">
        <title>Lung-Derived Inflammatory Biomarkers</title>
        <p>Bronchoalveolar lavage (BAL) is considered the gold standard for quantifying airway inflammation in the CF (<xref rid="B83" ref-type="bibr">Tiddens et&#xA0;al., 2015</xref>). However, the use of BAL longitudinally is limited by the invasiveness of the procedure. Sputum is an alternative way of obtaining material directly from the site of inflammation. For younger subjects or those with mild lung disease who cannot expectorate, sputum induction improves sample acquisition and biomarker measurements and are reasonably comparable with expectorated sputum (<xref rid="B71" ref-type="bibr">Sagel et&#xA0;al., 2001</xref>; <xref rid="B92" ref-type="bibr">Zemanick et&#xA0;al., 2015</xref>). However, both spontaneously expectorated and induced sputum are variable, making it difficult to track patients over time (<xref rid="B72" ref-type="bibr">Sagel et&#xA0;al., 2007</xref>; <xref rid="B12" ref-type="bibr">Chmiel et&#xA0;al., 2015</xref>).</p>
        <p>The utility of sputum biomarkers of inflammation in CF clinical trials has been previously reviewed in detail, with findings from multiple studies supporting the association between pro-inflammatory cytokines and disease status in CF subjects (<xref rid="B72" ref-type="bibr">Sagel et&#xA0;al., 2007</xref>; <xref rid="B83" ref-type="bibr">Tiddens et&#xA0;al., 2015</xref>; <xref rid="B50" ref-type="bibr">Muhlebach et&#xA0;al., 2016</xref>). A secondary analysis of data from four randomized controlled trials, which included a diverse CF population, demonstrated that free neutrophil elastase and IL-8 were negatively correlated with FEV1. Neutrophil elastase, a key mediator of lung damage, was the inflammatory marker with the strongest relationship with FEV<sub>1</sub> (<xref rid="B44" ref-type="bibr">Mayer-Hamblett et&#xA0;al., 2007</xref>), correlating with FEV<sub>1</sub> both cross-sectionally and longitudinally. As neutrophil elastase correlates with bronchiectasis (<xref rid="B18" ref-type="bibr">DeBoer et&#xA0;al., 2014</xref>), tracks with and is predictive of future lung function decline (<xref rid="B44" ref-type="bibr">Mayer-Hamblett et&#xA0;al., 2007</xref>; <xref rid="B73" ref-type="bibr">Sagel et&#xA0;al., 2012</xref>), relates to treatment response and predicts time to next exacerbation (<xref rid="B52" ref-type="bibr">Ordo&#xF1;ez et&#xA0;al., 2003</xref>; <xref rid="B88" ref-type="bibr">Waters et&#xA0;al., 2015</xref>), it is currently considered the most informative sputum biomarker to monitor CF lung disease.</p>
        <p>Another sputum biomarker with supportive longitudinal data is high-mobility group box-1 protein (HMGB-1); this inflammatory marker predicted subsequent pulmonary exacerbations and survival during 7 years of follow-up (<xref rid="B40" ref-type="bibr">Liou et&#xA0;al., 2001</xref>).</p>
        <p>Despite these strong observational data, it is still not clear what magnitude of biomarker change that could be considered clinically meaningful in the interventional setting. Furthermore, for biomarkers to convincingly reflect the treatment effect of an investigational drug, multiple biomarkers should improve rather than just a single one. Chmiel and colleagues designed a placebo-controlled randomized trial to investigate whether sputum biomarkers could be used to screen candidate anti-inflammatory therapies over a short period of time (<xref rid="B12" ref-type="bibr">Chmiel et&#xA0;al., 2015</xref>). Results from a screening study such as this could provide a go-no-go decision on whether to proceed with a phase 2 trial. Given than high-dose ibuprofen is the only anti-inflammatory drug recommended for use in CF (<xref rid="B47" ref-type="bibr">Mogayzel et&#xA0;al., 2013</xref>), it was chosen to test this hypothesis. Ibuprofen is a non-steroidal anti-inflammatory drug that affects the cyclo-oxygenase pathway and results in the inhibition of prostaglandin synthesis and, at high doses, is associated with a reduction in neutrophil migration into the lung (<xref rid="B33" ref-type="bibr">Konstan et&#xA0;al., 2003</xref>). However, in this proof of concept study, there was no significant change in key inflammatory markers, including neutrophil elastase, over a 28-day trial period. It is conceivable that a longer trial is required to see a decrease in inflammatory markers in a chronically infected airway; alternatively, ibuprofen may not have been the ideal drug to test the hypothesis.</p>
      </sec>
      <sec id="s4_2">
        <title>Blood-Based Inflammatory Markers</title>
        <p>Blood-based markers are relatively non-invasive, are easily standardized and can be obtained from subjects of any age and disease severity. Although the data linking blood-based inflammatory markers to clinical outcomes is less extensive than for sputum and BAL markers, systemic inflammatory biomarkers correlate with important clinical events including pulmonary exacerbations and lung function decline (<xref rid="B59" ref-type="bibr">Proesmans et&#xA0;al., 2011</xref>; <xref rid="B77" ref-type="bibr">Shoki et&#xA0;al., 2013</xref>; <xref rid="B69" ref-type="bibr">Reid et&#xA0;al., 2015</xref>; <xref rid="B60" ref-type="bibr">Quon et&#xA0;al., 2016</xref>).</p>
        <p>A clinical trial of school-age children with CF uninfected with <italic>Pseudomonas aeruginosa</italic> investigated the responsiveness of a panel of systemic inflammatory markers to treatment with azithromycin (<xref rid="B65" ref-type="bibr">Ratjen et&#xA0;al., 2012</xref>). Azithromycin, a macrolide antibiotic, is presumed to exert its proinflammatory effect in the CF airway by reducing proinflammatory cytokine production by cells such as neutrophils, monocytes, and bronchial epithelial cells; although its precise mechanism of action remains unclear (<xref rid="B55" ref-type="bibr">Parnham et&#xA0;al., 2005</xref>). The trial by Ratjen and co-workers demonstrated that circulating neutrophil counts, C-reactive protein, serum amyloid A, and calprotectin all significantly reduced within 28-days of treatment. Furthermore, reductions in these inflammatory markers were correlated with improvements in lung function and weight gain, providing indirect evidence that these changes were associated with clinically meaningful outcomes. A secondary analysis of this study data showed that early changes in serum calprotectin levels after the first 28 days of azithromycin treatment were predictive of pulmonary exacerbation risk by day 168 (<xref rid="B19" ref-type="bibr">Dong et&#xA0;al., 2019</xref>). This demonstrates that early changes in biomarkers have the potential to predict meaningful longer-term outcomes and could be useful outcome measures in interventional trials.</p>
      </sec>
    </sec>
    <sec id="s5">
      <title>Capturing the Effect on Lung Disease</title>
      <sec id="s5_1">
        <title>Spirometry</title>
        <p>Reduced FEV<sub>1</sub>, derived from spirometry, is strongly linked with increased morbidity and mortality and is, therefore, a key outcome measure in CF clinical studies (<xref rid="B30" ref-type="bibr">Kerem et&#xA0;al., 1992</xref>). Unlike drugs targeting other aspects of CF lung disease (e.g., CFTR modulators and mucoactive drugs) which have shown improvements in FEV<sub>1</sub> within 14 to 28 days (<xref rid="B25" ref-type="bibr">Fuchs et&#xA0;al., 1994</xref>; <xref rid="B62" ref-type="bibr">Ramsey et&#xA0;al., 2011</xref>), trials evaluating anti-inflammatory drugs have not reported immediate effects on lung function (<xref rid="B56" ref-type="bibr">Perrem and Ratjen, 2019</xref>). However, failure to show short-term improvements in expiratory flows airway resistance does not necessarily predict long-term benefits in lung function decline. This was demonstrated by trials investigating ibuprofen, a non-steroidal anti-inflammatory drug that reduces neutrophil influx into the lung a at higher dose (<xref rid="B47" ref-type="bibr">Mogayzel et&#xA0;al., 2013</xref>). High dose ibuprofen does not improve FEV<sub>1</sub>, but data from two prospective clinical trials that included 226 participants, showed that the use of ibuprofen twice daily slows the decline of FEV<sub>1</sub> (<xref rid="B34" ref-type="bibr">Konstan et&#xA0;al., 2007</xref>; <xref rid="B39" ref-type="bibr">Lands et&#xA0;al., 2007</xref>; <xref rid="B38" ref-type="bibr">Lands and Stanojevic, 2019</xref>). A recent observational study also demonstrated that this beneficial effect of high-dose ibuprofen translates to improved survival (<xref rid="B36" ref-type="bibr">Konstan et&#xA0;al., 2018</xref>). Ibuprofen, therefore, provides proof of concept that targeting inflammation might improve outcomes for patients with CF, but that short-term benefits in lung function may not be seen. However, this does not exclude the possibility that a more potent anti-inflammatory compound could potentially achieve this. Interventional studies using lung function decline as an endpoint would need to be conducted over multiple years with large sample sizes size and few drug development programs would be willing to take this route. This highlights the need to identify sensitive biomarkers that can more rapidly screen candidate drugs and be used as surrogate endpoints in phase II trials reducing the failure of drugs in phase III.</p>
        <p>A <italic>post hoc</italic> analysis of data from the ibuprofen trial from Konstan et&#xA0;al. showed a slower rate of annual decline in lung function in the ibuprofen group in younger children than in those 13 years and older (<xref rid="B36" ref-type="bibr">Konstan et&#xA0;al., 2018</xref>). The findings were consistent for all lung function outcomes (FEV<sub>1</sub>, FVC, and FEF 25%&#x2013;75%) and suggest that ibuprofen is more efficacious when used in individuals with mild CF lung disease. It is also possible that it is the trajectory of lung function and not just baseline FEV<sub>1</sub> that influences response to therapy. Future trials should consider stratifying patients not only based on the severity of lung disease but also on the trajectory of lung function over time.</p>
      </sec>
      <sec id="s5_2">
        <title>Multiple Breath Washout Test</title>
        <p>With more CF patients categorized as early lung disease with FEV<sub>1</sub> in the normal range, there is an urgent need for more sensitive outcome measures (<xref rid="B83" ref-type="bibr">Tiddens et&#xA0;al., 2015</xref>). The lung clearance index (LCI), derived from the multiple breath washout (MBW) test, reflects ventilation inhomogeneity with higher values indicating more severe lung disease. LCI is a reliable, valid, and responsive functional test and is now an established outcome measure in interventional trials (<xref rid="B29" ref-type="bibr">Kent et&#xA0;al., 2014</xref>). LCI also correlates with markers of systemic inflammation(<xref rid="B28" ref-type="bibr">Horsley et&#xA0;al., 2013</xref>; <xref rid="B53" ref-type="bibr">O&#x2019;Neill et&#xA0;al., 2018</xref>), including CRP and calprotectin, and with the extent of airway inflammation (<xref rid="B63" ref-type="bibr">Ramsey et&#xA0;al., 2017</xref>). The LCI has been shown to detect treatment effects to medications such as hypertonic saline in trials involving both preschool (<xref rid="B82" ref-type="bibr">Subbarao et&#xA0;al., 2013</xref>; <xref rid="B67" ref-type="bibr">Ratjen et&#xA0;al., 2019</xref>) and school-age CF subjects with preserved spirometry (<xref rid="B2" ref-type="bibr">Amin et&#xA0;al., 2010</xref>; <xref rid="B3" ref-type="bibr">Amin et&#xA0;al., 2011</xref>; <xref rid="B16" ref-type="bibr">Davies et&#xA0;al., 2013</xref>; <xref rid="B66" ref-type="bibr">Ratjen et&#xA0;al., 2017</xref>), where a change in FEV<sub>1</sub> with treatment was not detected. The published treatment effects for LCI range from less than 1 units (0.6 for hypertonic saline, 0.9 units for dornase alfa) (<xref rid="B3" ref-type="bibr">Amin et&#xA0;al., 2011</xref>; <xref rid="B80" ref-type="bibr">Stanojevic and Ratjen, 2016</xref>) up to 2.2 units for ivacaftor in patients with CFTR gating mutations (<xref rid="B16" ref-type="bibr">Davies et&#xA0;al., 2013</xref>). LCI has not yet been incorporated into the design of a clinical trial for an anti-inflammatory therapy but the enhanced sensitivity to detect treatment effects compared to FEV<sub>1</sub> may potentially facilitate anti-inflammatory trials in the future.</p>
      </sec>
      <sec id="s5_3">
        <title>Pulmonary Exacerbations</title>
        <p>Pulmonary exacerbations are important clinical events in the disease process and directly contribute to the progression of lung disease (<xref rid="B74" ref-type="bibr">Sanders et&#xA0;al., 2010</xref>; <xref rid="B27" ref-type="bibr">Heltshe et&#xA0;al., 2016</xref>; <xref rid="B81" ref-type="bibr">Stanojevic et&#xA0;al., 2017</xref>; <xref rid="B87" ref-type="bibr">van Horck et&#xA0;al., 2018</xref>). Therefore, pulmonary exacerbations also serve as meaningful clinical efficacy endpoints in interventional trials. Multiple clinical trials investigating different classes of CF medications, such as CFTR modulators (<xref rid="B16" ref-type="bibr">Davies et&#xA0;al., 2013</xref>; Ratjen et&#xA0;al., 2018) dornase alfa (<xref rid="B25" ref-type="bibr">Fuchs et&#xA0;al., 1994</xref>), hypertonic saline (<xref rid="B24" ref-type="bibr">Elkins and Dentice, 2020</xref>), and tobramycin (<xref rid="B61" ref-type="bibr">Ramsey et&#xA0;al., 1999</xref>) have shown a reduction in pulmonary exacerbations compared with placebo. Given the role of inflammation in pulmonary exacerbations, targeting the inflammatory process should logically result in a reduction in pulmonary exacerbations but this has not yet been proven in phase III trials. Furthermore, given the improved overall state of health in CF, powering a study to pulmonary exacerbation endpoints, particularly in patients with mild lung disease, require large numbers of subjects, and longer follow-up times to demonstrate a treatment effect. With respect to pulmonary exacerbations, it is unclear as to what is the best definition and surrogate outcome measure &#x2014; risk, frequency, or time to the next pulmonary exacerbation event. Studies using pulmonary exacerbations as an endpoint could reduce the number of patients required by limiting recruitment to individuals with a recent history of exacerbations as this has predictive value for future events (<xref rid="B7" ref-type="bibr">Block et&#xA0;al., 2006</xref>). This concept has been implemented in the design of a phase 2 study investigating lenabasum (<xref rid="B11" ref-type="bibr">Chmiel and Elborn</xref>); a drug that acts as a selective agonist of the cannabinoid receptor on type 2 immune cells and exerts anti-inflammatory and pro-resolution effects without suppressing the immune system (<xref rid="B49" ref-type="bibr">Motwani et&#xA0;al., 2018</xref>).</p>
        <p>The ideal timing to initiate anti-inflammatory therapies is unclear, whether they would be most efficacious if initiated when a patient is clinically stable or during a pulmonary exacerbation when the inflammatory process is at its peak. A pilot randomized controlled trial investigating the short-term use of oral prednisone in CF patients presenting with pulmonary exacerbations demonstrated a modest improvement in lung function (<xref rid="B21" ref-type="bibr">Dovey et&#xA0;al., 2007</xref>). The PIPE study is an ongoing multisite randomized placebo-controlled trial that is investigating the efficacy of oral prednisone as an adjunctive therapy during pulmonary exacerbations. If successful, this study design could provide a model for evaluating other anti-inflammatory therapies in the future (<xref rid="B58" ref-type="bibr">Prednisone in Cystic Fibrosis Pulmonary Exacerbations</xref> - Full Text View - ClinicalTrials.gov).</p>
      </sec>
      <sec id="s5_4">
        <title>Other Outcome Measures</title>
        <p>Various types of imaging techniques are now available to determine the presence and extent of lung disease in patients with CF, including CT and chest magnetic resonance imaging (MRI) (<xref rid="B83" ref-type="bibr">Tiddens et&#xA0;al., 2015</xref>). Studies have demonstrated that infection, inflammation, and abnormal chest CT findings are already present in a significant proportion of asymptomatic infants with CF at 3-months of age (<xref rid="B78" ref-type="bibr">Sly et&#xA0;al., 2009</xref>) and that these early structural changes are progressive (<xref rid="B48" ref-type="bibr">Mott et&#xA0;al., 2012</xref>). On the other end of the spectrum, in CF patients screened for lung transplantation, those with a higher volume of infection/inflammation-like changes were shown to have a higher risk of dying on the waiting list (<xref rid="B41" ref-type="bibr">Loeve et&#xA0;al., 2009</xref>). Furthermore, individuals with more extensive structural lung disease on CT experience more pulmonary exacerbations (<xref rid="B9" ref-type="bibr">Brody et&#xA0;al., 2005</xref>; <xref rid="B42" ref-type="bibr">Loeve et&#xA0;al., 2011</xref>).</p>
        <p>While chest CT scans are sensitive at detecting structural changes, the evolution of these changes over time is slow, with bronchiectasis deteriorating at about 1.5% per year on serial CT scans in CF patients(<xref rid="B17" ref-type="bibr">De Jong et&#xA0;al., 2006</xref>). Therefore, trials using the development of bronchiectasis on CT as the primary endpoint would take multiple years and/or large numbers of subjects (<xref rid="B17" ref-type="bibr">De Jong et&#xA0;al., 2006</xref>; <xref rid="B54" ref-type="bibr">Owens et&#xA0;al., 2011</xref>).</p>
        <p>Pulmonary MRI can now provide high&#x2010;resolution images that are sensitive to early disease and specific to inflammation in cystic fibrosis (CF) lung disease (<xref rid="B1" ref-type="bibr">Amin and Ratjen, 2008</xref>; <xref rid="B83" ref-type="bibr">Tiddens et&#xA0;al., 2015</xref>; <xref rid="B13" ref-type="bibr">Ciet et&#xA0;al., 2017</xref>; <xref rid="B91" ref-type="bibr">Woods et&#xA0;al., 2019</xref>). Unlike CT, MRI does not use ionizing radiation, and this is particularly advantageous in children and when scans need to be repeated within a relatively short time period (<xref rid="B1" ref-type="bibr">Amin and Ratjen, 2008</xref>; <xref rid="B83" ref-type="bibr">Tiddens et&#xA0;al., 2015</xref>). MRI techniques can track changes in lung function longitudinally and quantify treatment response (<xref rid="B68" ref-type="bibr">Rayment et&#xA0;al., 2018</xref>; <xref rid="B75" ref-type="bibr">Santyr et&#xA0;al., 2019</xref>; <xref rid="B91" ref-type="bibr">Woods et&#xA0;al., 2019</xref>). Proton density and T<sub>1</sub>/T<sub>2</sub> contrast images can be obtained within a single breath&#x2010;hold, providing a depiction of structural abnormalities and active inflammation. Hyperpolarized&#x2010;gas MRI, increasingly using&#xA0;<sup>129</sup>Xe, is now becoming more widespread and has been demonstrated to have high sensitivity to early airway obstruction in CF and could have utility as an endpoint in future clinical trials, particularly in the acute setting of pulmonary exacerbations.</p>
        <p>Another promising non-invasive imaging technique that provides information about the level of inflammation is positron emission tomography (PET) with [18]fluorodeoxyglucose ([18]FDG; FDG-PET). 18F-FDG is taken up by activated neutrophils, macrophages, and lymphocytes so in contrast to other imaging techniques, FDG-PET scans assess CF airway inflammation directly. Several observational studies have shown that 18F-FDG uptake can determine the location and intensity of pulmonary inflammation and, combined with CT, PET can be used to assess anatomy and structures. (<xref rid="B37" ref-type="bibr">Labiris et&#xA0;al., 2003</xref>; <xref rid="B10" ref-type="bibr">Chen et&#xA0;al., 2006</xref>; <xref rid="B31" ref-type="bibr">Klein et&#xA0;al., 2009</xref>; <xref rid="B4" ref-type="bibr">Amin et&#xA0;al., 2012</xref>). A study by Amin and co-workers, demonstrated that FDG PET/CT depicts changes in inflammation in the lung after intravenous antibiotics for a pulmonary exacerbation, with the PET signal correlating with the burden of sputum neutrophils (<xref rid="B4" ref-type="bibr">Amin et&#xA0;al., 2012</xref>). Data from this study support the utility of FDG PET/CT as an outcome measure in treatment studies, although it is not yet a validated outcome for use in interventional trials.</p>
      </sec>
    </sec>
    <sec id="s6">
      <title>CFTR Modulators and Anti-Inflammatory Therapies</title>
      <p>Time will tell how increasing CFTR modulator access will affect future anti-inflammatory therapeutic development. The positive effects of CFTR modulators on the progression of CF lung disease are undoubtedly positive but this will make the issues of endpoints for anti-inflammatory trials event more challenging.</p>
      <p>Acebilustat is an inhibitor of leukotriene A4 hydrolase (LTA4H), an enzyme that catalyzes the rate-limiting step in the formation of leukotriene B4 (LTB4), a potent chemoattractant and activator of inflammatory immune cells including neutrophils (<xref rid="B64" ref-type="bibr">Rao et&#xA0;al., 2010</xref>). This anti-inflammatory drug is also proposed to work by shunting substrates down the metabolic pathway to produce the pro-resolving mediator LXA4 (<xref rid="B84" ref-type="bibr">Tobin et&#xA0;al., 2010</xref>). In the Acebilustat phase IIb trial, the observed reduction in pulmonary exacerbations during the 48-week study period was also observed in the subgroup of patients taking CFTR modulators (<xref rid="B26" ref-type="bibr">Griese et&#xA0;al., 2007</xref>). This suggests that patients taking modulators may receive additional benefit from anti-inflammatory drugs. It would be important for future trials to take this into account and stratify groups based on whether subjects are taking CFTR modulators.</p>
    </sec>
    <sec id="s7">
      <title>Conclusion</title>
      <p>Designing trials of anti-inflammatory therapies in CF faces specific challenges different from other drug development programs. Demonstrating safety data from preclinical studies, choosing appropriate and realistic efficacy endpoints and integrating sensitive imaging and lung function outcomes into future trials are important considerations. These measures will increase the likelihood that potentially efficacious therapies are not abandoned prematurely and that efficacy can be conclusively demonstrated in studies that can be completed in reasonable time frames.</p>
    </sec>
    <sec id="s8">
      <title>Author Contributions</title>
      <p>Both authors conceptualized the content of the review. LP wrote the first draft and FR reviewed and edited the final manuscript.</p>
    </sec>
    <sec id="s9">
      <title>Conflict of Interest</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
  </body>
  <back>
    <sec id="s10">
      <title>Abbreviations</title>
      <p>CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane regulator; NE, neutrophil elastase; MRI, magnetic resonance imaging; CT, computed tomography; PET, positron emission tomography; MBW, multiple breath washout; FEV1, forced expiratory volume in 1 s.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amin</surname><given-names>R.</given-names></name><name><surname>Ratjen</surname><given-names>F.</given-names></name></person-group> (<year>2008</year>). <article-title>MRI: the next frontier for cystic fibrosis clinicians</article-title>? <source>Expert Rev. Respir. Med.</source>
<volume>2</volume>, <fpage>179</fpage>&#x2013;<lpage>182</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1586/17476348.2.2.179</pub-id>
<pub-id pub-id-type="pmid">20477247</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amin</surname><given-names>R.</given-names></name><name><surname>Subbarao</surname><given-names>P.</given-names></name><name><surname>Jabar</surname><given-names>A.</given-names></name><name><surname>Balkovec</surname><given-names>S.</given-names></name><name><surname>Jensen</surname><given-names>R.</given-names></name><name><surname>Kerrigan</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function</article-title>. <source>Thorax</source>
<volume>65</volume>, <fpage>379</fpage>&#x2013;<lpage>383</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thx.2009.125831</pub-id>
<pub-id pub-id-type="pmid">20435858</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amin</surname><given-names>R.</given-names></name><name><surname>Subbarao</surname><given-names>P.</given-names></name><name><surname>Lou</surname><given-names>W.</given-names></name><name><surname>Jabar</surname><given-names>A.</given-names></name><name><surname>Balkovec</surname><given-names>S.</given-names></name><name><surname>Jensen</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis</article-title>. <source>Eur. Respir. J.</source>
<volume>37</volume>, <fpage>806</fpage>&#x2013;<lpage>812</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1183/09031936.00072510</pub-id>
<pub-id pub-id-type="pmid">20693248</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amin</surname><given-names>R.</given-names></name><name><surname>Charron</surname><given-names>M.</given-names></name><name><surname>Grinblat</surname><given-names>L.</given-names></name><name><surname>Shammas</surname><given-names>A.</given-names></name><name><surname>Grasemann</surname><given-names>H.</given-names></name><name><surname>Graniel</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Cystic fibrosis: Detecting changes in airway inflammation with FDG PET/CT</article-title>. <source>Radiology</source>
<volume>264</volume>, <fpage>868</fpage>&#x2013;<lpage>875</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1148/radiol.12111873</pub-id>
<pub-id pub-id-type="pmid">22829680</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bell</surname><given-names>S. C.</given-names></name><name><surname>Mall</surname><given-names>M. A.</given-names></name><name><surname>Gutierrez</surname><given-names>H.</given-names></name><name><surname>Macek</surname><given-names>M.</given-names></name><name><surname>Madge</surname><given-names>S.</given-names></name><name><surname>Davies</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The future of cystic fibrosis care: a global perspective</article-title>. <source>Lancet Respir. Med.</source>
<volume>8</volume>, <fpage>65</fpage>&#x2013;<lpage>124</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/S2213-2600(19)30337-6</pub-id>
<pub-id pub-id-type="pmid">31570318</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Birrer</surname><given-names>P.</given-names></name><name><surname>McElvaney</surname><given-names>N. G.</given-names></name><name><surname>R&#xFC;deberg</surname><given-names>A.</given-names></name><name><surname>Sommer</surname><given-names>C. W.</given-names></name><name><surname>Liechti-Gallati</surname><given-names>S.</given-names></name><name><surname>Kraemer</surname><given-names>R.</given-names></name><etal/></person-group> (<year>1994</year>). <article-title>Protease-antiprotease imbalance in the lungs of children with cystic fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>150</volume>, <fpage>207</fpage>&#x2013;<lpage>213</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/ajrccm.150.1.7912987</pub-id>
<pub-id pub-id-type="pmid">7912987</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Block</surname><given-names>J. K.</given-names></name><name><surname>Vandemheen</surname><given-names>K. L.</given-names></name><name><surname>Tullis</surname><given-names>E.</given-names></name><name><surname>Fergusson</surname><given-names>D.</given-names></name><name><surname>Doucette</surname><given-names>S.</given-names></name><name><surname>Haase</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria</article-title>. <source>Thorax</source>
<volume>61</volume>, <fpage>969</fpage>&#x2013;<lpage>974</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thx.2006.061366</pub-id>
<pub-id pub-id-type="pmid">16844728</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bonfield</surname><given-names>T. L.</given-names></name></person-group> (<year>2020</year>). <article-title>Preclinical modeling for therapeutic development in cystic fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>201</volume>, <fpage>267</fpage>&#x2013;<lpage>268</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.201910-2056ED</pub-id>
<pub-id pub-id-type="pmid">31697560</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brody</surname><given-names>A. S.</given-names></name><name><surname>Sucharew</surname><given-names>H.</given-names></name><name><surname>Campbell</surname><given-names>J. D.</given-names></name><name><surname>Millard</surname><given-names>S. P.</given-names></name><name><surname>Molina</surname><given-names>P. L.</given-names></name><name><surname>Klein</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>172</volume>, <fpage>1128</fpage>&#x2013;<lpage>1132</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.200407-989OC</pub-id>
<pub-id pub-id-type="pmid">16100015</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>D. L.</given-names></name><name><surname>Ferkol</surname><given-names>T. W.</given-names></name><name><surname>Mintun</surname><given-names>M. A.</given-names></name><name><surname>Pittman</surname><given-names>J. E.</given-names></name><name><surname>Rosenbluth</surname><given-names>D. B.</given-names></name><name><surname>Schuster</surname><given-names>D. P.</given-names></name></person-group> (<year>2006</year>). <article-title>Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>173</volume>, <fpage>1363</fpage>&#x2013;<lpage>1369</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.200506-934OC</pub-id>
<pub-id pub-id-type="pmid">16543553</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Chmiel</surname><given-names>J.</given-names></name><name><surname>Elborn</surname><given-names>S.</given-names></name></person-group>
<source>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis</source>. Available at: <uri xlink:type="simple" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03451045">https://clinicaltrials.gov/ct2/show/NCT03451045</uri> (Accessed <date-in-citation>March 26, 2019</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chmiel</surname><given-names>J. F.</given-names></name><name><surname>Konstan</surname><given-names>M. W.</given-names></name><name><surname>Accurso</surname><given-names>F. J.</given-names></name><name><surname>Lymp</surname><given-names>J.</given-names></name><name><surname>Mayer-Hamblett</surname><given-names>N.</given-names></name><name><surname>VanDevanter</surname><given-names>D. R.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis</article-title>. <source>J. Cyst. Fibros.</source>
<volume>14</volume>, <fpage>720</fpage>&#x2013;<lpage>726</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jcf.2015.03.007</pub-id>
<pub-id pub-id-type="pmid">25869324</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ciet</surname><given-names>P.</given-names></name><name><surname>Bertolo</surname><given-names>S.</given-names></name><name><surname>Ros</surname><given-names>M.</given-names></name><name><surname>Andrinopoulou</surname><given-names>E. R.</given-names></name><name><surname>Tavano</surname><given-names>V.</given-names></name><name><surname>Lucca</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Detection and monitoring of lung inflammation in cystic fibrosis during respiratory tract exacerbation using diffusion-weighted magnetic resonance imaging</article-title>. <source>Eur. Respir. J.</source>
<volume>50</volume>, <fpage>1601437</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1183/13993003.01437-2016</pub-id>
<pub-id pub-id-type="pmid">28729470</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen-Cymberknoh</surname><given-names>M.</given-names></name><name><surname>Kerem</surname><given-names>E.</given-names></name><name><surname>Ferkol</surname><given-names>T.</given-names></name><name><surname>Elizur</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications</article-title>. <source>Thorax</source>
<volume>68</volume>, <fpage>1157</fpage>&#x2013;<lpage>1162</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thoraxjnl-2013-203204</pub-id>
<pub-id pub-id-type="pmid">23704228</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen-Cymberknoh</surname><given-names>M.</given-names></name><name><surname>Gilead</surname><given-names>N.</given-names></name><name><surname>Gartner</surname><given-names>S.</given-names></name><name><surname>Rovira</surname><given-names>S.</given-names></name><name><surname>Blau</surname><given-names>H.</given-names></name><name><surname>Mussaffi</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis</article-title>. <source>J. Cyst. Fibros.</source>
<volume>15</volume>, <fpage>776</fpage>&#x2013;<lpage>782</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jcf.2016.04.006</pub-id>
<pub-id pub-id-type="pmid">27143583</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davies</surname><given-names>J.</given-names></name><name><surname>Sheridan</surname><given-names>H.</given-names></name><name><surname>Bell</surname><given-names>N.</given-names></name><name><surname>Cunningham</surname><given-names>S.</given-names></name><name><surname>Davis</surname><given-names>S. D.</given-names></name><name><surname>Elborn</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: A randomised controlled trial</article-title>. <source>Lancet Respir. Med.</source>
<volume>1</volume>, <fpage>630</fpage>&#x2013;<lpage>638</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/S2213-2600(13)70182-6</pub-id>
<pub-id pub-id-type="pmid">24461666</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Jong</surname><given-names>P. A.</given-names></name><name><surname>Lindblad</surname><given-names>A.</given-names></name><name><surname>Rubin</surname><given-names>L.</given-names></name><name><surname>Hop</surname><given-names>W. C. J.</given-names></name><name><surname>De Jongste</surname><given-names>J. C.</given-names></name><name><surname>Brink</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis</article-title>. <source>Thorax</source>
<volume>61</volume>, <fpage>80</fpage>&#x2013;<lpage>85</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thx.2005.045146</pub-id>
<pub-id pub-id-type="pmid">16244089</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeBoer</surname><given-names>E. M.</given-names></name><name><surname>Swiercz</surname><given-names>W.</given-names></name><name><surname>Heltshe</surname><given-names>S. L.</given-names></name><name><surname>Anthony</surname><given-names>M. M.</given-names></name><name><surname>Szefler</surname><given-names>P.</given-names></name><name><surname>Klein</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Automated ct scan scores of bronchiectasis and air trapping in cystic fibrosis</article-title>. <source>Chest</source>
<volume>145</volume>, <fpage>593</fpage>&#x2013;<lpage>603</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1378/chest.13-0588</pub-id>
<pub-id pub-id-type="pmid">24114359</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Dong</surname><given-names>K.</given-names></name><name><surname>Singh</surname><given-names>A.</given-names></name><name><surname>Ng</surname><given-names>R. T.</given-names></name><name><surname>Sin</surname><given-names>D. D.</given-names></name><name><surname>Tebbutt</surname><given-names>S. J.</given-names></name><name><surname>Ratjen</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2019</year>). &#x201C;<article-title>Proteomic Profiling to Identify Blood Biomarkers Predictive of Response to Azithromycin in Children and Adolescents With Cystic Fibrosis</article-title>,&#x201D; in <source>Chest</source> (<publisher-name>Elsevier Inc</publisher-name>), <fpage>667</fpage>&#x2013;<lpage>673</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.chest.2019.05.017</pub-id>
</mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D&#xF6;ring</surname><given-names>G.</given-names></name><name><surname>Bragonzi</surname><given-names>A.</given-names></name><name><surname>Paroni</surname><given-names>M.</given-names></name><name><surname>Akt&#xFC;rk</surname><given-names>F.-F.</given-names></name><name><surname>Cigana</surname><given-names>C.</given-names></name><name><surname>Schmidt</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>BIIL 284 reduces neutrophils numbers but increases P. aeruginosa bacteraemia and inflammation in mouse lungs</article-title>. <source>J. Cyst. Fibros.</source>
<volume>13</volume>, <fpage>156</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/J.JCF.2013.10.007</pub-id>
<pub-id pub-id-type="pmid">24183915</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dovey</surname><given-names>M.</given-names></name><name><surname>Aitken</surname><given-names>M. L.</given-names></name><name><surname>Emerson</surname><given-names>J.</given-names></name><name><surname>McNamara</surname><given-names>S.</given-names></name><name><surname>Waltz</surname><given-names>D. A.</given-names></name><name><surname>Gibson</surname><given-names>R.&#xA0;L.</given-names></name></person-group> (<year>2007</year>). <article-title>Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: A pilot study</article-title>. <source>Chest</source>
<volume>132</volume>, <fpage>1212</fpage>&#x2013;<lpage>1218</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1378/chest.07-0843</pub-id>
<pub-id pub-id-type="pmid">17646219</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elborn</surname><given-names>J. S.</given-names></name><name><surname>Bhatt</surname><given-names>L.</given-names></name><name><surname>Grosswald</surname><given-names>R.</given-names></name><name><surname>Ahuja</surname><given-names>S.</given-names></name><name><surname>Springman</surname><given-names>E. B.</given-names></name></person-group> (<year>2017</year>). <article-title>Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction</article-title>. <source>Clin. Transl. Sci.</source>
<volume>10</volume>, <fpage>20</fpage>&#x2013;<lpage>27</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/cts.12426</pub-id>
<pub-id pub-id-type="pmid">27792868</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elborn</surname><given-names>J. S.</given-names></name><name><surname>Ahuja</surname><given-names>S.</given-names></name><name><surname>Springman</surname><given-names>E.</given-names></name><name><surname>Mershon</surname><given-names>J.</given-names></name><name><surname>Grosswald</surname><given-names>R.</given-names></name><name><surname>Rowe</surname><given-names>S. M.</given-names></name></person-group> (<year>2018</year>). <article-title>EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis &#x2013; Study design and patient demographics</article-title>. <source>Contemp. Clin. Trials</source>
<volume>72</volume>, <fpage>86</fpage>&#x2013;<lpage>94</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.cct.2018.07.014</pub-id>
<pub-id pub-id-type="pmid">30056216</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elkins</surname><given-names>M.</given-names></name><name><surname>Dentice</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Timing of hypertonic saline inhalation for cystic fibrosis</article-title>. <source>Cochrane Database Syst. Rev</source>. <volume>2020</volume>. &#xA0;<pub-id pub-id-type="doi">10.1002/14651858.CD008816.pub4</pub-id>
</mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>H. J.</given-names></name><name><surname>Borowitz</surname><given-names>D. S.</given-names></name><name><surname>Christiansen</surname><given-names>D. H.</given-names></name><name><surname>Morris</surname><given-names>E. M.</given-names></name><name><surname>Nash</surname><given-names>M. L.</given-names></name><name><surname>Ramsey</surname><given-names>B. W.</given-names></name><etal/></person-group> (<year>1994</year>). <article-title>Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis</article-title>. <source>N. Engl. J. Med.</source>
<volume>331</volume>, <fpage>637</fpage>&#x2013;<lpage>642</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1056/NEJM199409083311003</pub-id>
<pub-id pub-id-type="pmid">7503821</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griese</surname><given-names>M.</given-names></name><name><surname>Latzin</surname><given-names>P.</given-names></name><name><surname>Kappler</surname><given-names>M.</given-names></name><name><surname>Weckerle</surname><given-names>K.</given-names></name><name><surname>Heinzimaier</surname><given-names>T.</given-names></name><name><surname>Bernhardt</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>&#x3B1;1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients</article-title>. <source>Eur. Respir. J.</source>
<volume>29</volume>, <fpage>240</fpage>&#x2013;<lpage>250</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1183/09031936.00047306</pub-id>
<pub-id pub-id-type="pmid">17050563</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heltshe</surname><given-names>S. L.</given-names></name><name><surname>Goss</surname><given-names>C. H.</given-names></name><name><surname>Thompson</surname><given-names>V.</given-names></name><name><surname>Sagel</surname><given-names>S. D.</given-names></name><name><surname>Sanders</surname><given-names>D. B.</given-names></name><name><surname>Marshall</surname><given-names>B.&#xA0;C.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis</article-title>. <source>Thorax</source>
<volume>71</volume>, <fpage>223</fpage>&#x2013;<lpage>229</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thoraxjnl-2014-206750</pub-id>
<pub-id pub-id-type="pmid">25911223</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horsley</surname><given-names>A. A. R.</given-names></name><name><surname>Davies</surname><given-names>J. C. J.</given-names></name><name><surname>Gray</surname><given-names>R. R. D.</given-names></name><name><surname>Macleod</surname><given-names>K. A.</given-names></name><name><surname>Donovan</surname><given-names>J.</given-names></name><name><surname>Aziz</surname><given-names>Z. A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation</article-title>. <source>Thorax</source>
<volume>68</volume>, <fpage>532</fpage>&#x2013;<lpage>539</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thoraxjnl-2012-202538</pub-id>
<pub-id pub-id-type="pmid">23396354</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kent</surname><given-names>L.</given-names></name><name><surname>Reix</surname><given-names>P.</given-names></name><name><surname>Innes</surname><given-names>J. A.</given-names></name><name><surname>Zielen</surname><given-names>S.</given-names></name><name><surname>Le Bourgeois</surname><given-names>M.</given-names></name><name><surname>Braggion</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Lung clearance index: evidence for use in clinical trials in cystic fibrosis</article-title>. <source>J. Cyst. Fibros.</source>
<volume>13</volume>, <fpage>123</fpage>&#x2013;<lpage>138</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jcf.2013.09.005</pub-id>
<pub-id pub-id-type="pmid">24315208</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kerem</surname><given-names>E.</given-names></name><name><surname>Reisman</surname><given-names>J.</given-names></name><name><surname>Corey</surname><given-names>M.</given-names></name><name><surname>Canny</surname><given-names>G. J.</given-names></name><name><surname>Levison</surname><given-names>H.</given-names></name></person-group> (<year>1992</year>). <article-title>Prediction of mortality in patients with cystic fibrosis</article-title>. <source>N. Engl. J. Med.</source>
<volume>326</volume>, <fpage>1187</fpage>&#x2013;<lpage>1191</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1056/NEJM199204303261804</pub-id>
<pub-id pub-id-type="pmid">1285737</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klein</surname><given-names>M.</given-names></name><name><surname>Cohen-Cymberknoh</surname><given-names>M.</given-names></name><name><surname>Armoni</surname><given-names>S.</given-names></name><name><surname>Shoseyov</surname><given-names>D.</given-names></name><name><surname>Chisin</surname><given-names>R.</given-names></name><name><surname>Orevi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>18F-fluorodeoxyglucose-PET/CT imaging of lungs in patients with cystic fibrosis</article-title>. <source>Chest</source>
<volume>136</volume>, <fpage>1220</fpage>&#x2013;<lpage>1228</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1378/chest.09-0610</pub-id>
<pub-id pub-id-type="pmid">19696124</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konstan</surname><given-names>M. W.</given-names></name><name><surname>Walenga</surname><given-names>R. W.</given-names></name><name><surname>Hilliard</surname><given-names>K. A.</given-names></name><name><surname>Hilliard</surname><given-names>J. B.</given-names></name></person-group> (<year>1993</year>). <article-title>Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis</article-title>. <source>Am. Rev. Respir. Dis.</source>
<volume>148</volume>, <fpage>896</fpage>&#x2013;<lpage>901</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/ajrccm/148.4_Pt_1.896</pub-id>
<pub-id pub-id-type="pmid">8214945</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konstan</surname><given-names>M. W.</given-names></name><name><surname>Krenicky</surname><given-names>J. E.</given-names></name><name><surname>Finney</surname><given-names>M. R.</given-names></name><name><surname>Kirchner</surname><given-names>H. L.</given-names></name><name><surname>Hilliard</surname><given-names>K. A.</given-names></name><name><surname>Hilliard</surname><given-names>J. B.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>306</volume>, <fpage>1086</fpage>&#x2013;<lpage>1091</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1124/jpet.103.052449</pub-id>
<pub-id pub-id-type="pmid">12807998</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konstan</surname><given-names>M. W.</given-names></name><name><surname>Schluchter</surname><given-names>M. D.</given-names></name><name><surname>Xue</surname><given-names>W.</given-names></name><name><surname>Davis</surname><given-names>P. B.</given-names></name></person-group> (<year>2007</year>). <article-title>Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>176</volume>, <fpage>1084</fpage>&#x2013;<lpage>1089</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.200702-181OC</pub-id>
<pub-id pub-id-type="pmid">17872492</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konstan</surname><given-names>M. W.</given-names></name><name><surname>D&#xF6;ring</surname><given-names>G.</given-names></name><name><surname>Heltshe</surname><given-names>S. L.</given-names></name><name><surname>Lands</surname><given-names>L. C.</given-names></name><name><surname>Hilliard</surname><given-names>K. A.</given-names></name><name><surname>Koker</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis</article-title>. <source>J. Cyst. Fibros.</source>
<volume>13</volume>, <fpage>148</fpage>&#x2013;<lpage>155</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jcf.2013.12.009</pub-id>
<pub-id pub-id-type="pmid">24440167</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konstan</surname><given-names>M. W.</given-names></name><name><surname>VanDevanter</surname><given-names>D. R.</given-names></name><name><surname>Sawicki</surname><given-names>G. S.</given-names></name><name><surname>Pasta</surname><given-names>D. J.</given-names></name><name><surname>Foreman</surname><given-names>A. J.</given-names></name><name><surname>Neiman</surname><given-names>E. A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis</article-title>. <source>Ann. Am. Thorac. Soc</source>
<volume>15</volume>, <fpage>485</fpage>&#x2013;<lpage>493</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1513/AnnalsATS.201706-486OC</pub-id>
<pub-id pub-id-type="pmid">29313709</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Labiris</surname><given-names>N. R.</given-names></name><name><surname>Nahmias</surname><given-names>C.</given-names></name><name><surname>Freitag</surname><given-names>A. P.</given-names></name><name><surname>Thompson</surname><given-names>M. L.</given-names></name><name><surname>Dolovich</surname><given-names>M. B.</given-names></name></person-group> (<year>2003</year>). <article-title>Uptake of 18fluorodeoxyglucose in the cystic fibrosis lung: A measure of lung inflammation</article-title>? <source>Eur. Respir. J.</source>
<volume>21</volume>, <fpage>848</fpage>&#x2013;<lpage>854</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1183/09031936.03.00065102</pub-id>
<pub-id pub-id-type="pmid">12765432</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lands</surname><given-names>L. C.</given-names></name><name><surname>Stanojevic</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis</article-title>. <source>Cochrane Database Syst. Rev.</source>
<volume>2019</volume>. &#xA0;<pub-id pub-id-type="doi">10.1002/14651858.CD001505.pub5</pub-id>
</mixed-citation>
      </ref>
      <ref id="B39">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lands</surname><given-names>L. C.</given-names></name><name><surname>Milner</surname><given-names>R.</given-names></name><name><surname>Cantin</surname><given-names>A. M.</given-names></name><name><surname>Manson</surname><given-names>D.</given-names></name><name><surname>Corey</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial</article-title>. <source>J. Pediatr.</source>
<volume>151</volume>, <fpage>249</fpage>&#x2013;<lpage>254</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jpeds.2007.04.009</pub-id>
<pub-id pub-id-type="pmid">17719932</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liou</surname><given-names>T. G.</given-names></name><name><surname>Adler</surname><given-names>F. R.</given-names></name><name><surname>Fitzsimmons</surname><given-names>S. C.</given-names></name><name><surname>Cahill</surname><given-names>B. C.</given-names></name><name><surname>Hibbs</surname><given-names>J. R.</given-names></name><name><surname>Marshall</surname><given-names>B. C.</given-names></name></person-group> (<year>2001</year>). <article-title>Predictive 5-year survivorship model of cystic fibrosis</article-title>. <source>Am. J. Epidemiol.</source>
<volume>153</volume>, <fpage>345</fpage>&#x2013;<lpage>352</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1093/aje/153.4.345</pub-id>
<pub-id pub-id-type="pmid">11207152</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loeve</surname><given-names>M.</given-names></name><name><surname>van Hal</surname><given-names>P. T. W.</given-names></name><name><surname>Robinson</surname><given-names>P.</given-names></name><name><surname>de Jong</surname><given-names>P. A.</given-names></name><name><surname>Lequin</surname><given-names>M. H.</given-names></name><name><surname>Hop</surname><given-names>W. C.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>The spectrum of structural abnormalities on CT scans from patients with CF with severe advanced lung disease</article-title>. <source>Thorax</source>
<volume>64</volume>, <fpage>876</fpage>&#x2013;<lpage>882</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thx.2008.110908</pub-id>
<pub-id pub-id-type="pmid">19541686</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loeve</surname><given-names>M.</given-names></name><name><surname>Gerbrands</surname><given-names>K.</given-names></name><name><surname>Hop</surname><given-names>W. C.</given-names></name><name><surname>Rosenfeld</surname><given-names>M.</given-names></name><name><surname>Hartmann</surname><given-names>I. C.</given-names></name><name><surname>Tiddens</surname><given-names>H. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Bronchiectasis and pulmonary exacerbations in children and young adults with cystic fibrosis</article-title>. <source>Chest</source>
<volume>140</volume>, <fpage>178</fpage>&#x2013;<lpage>185</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1378/chest.10-1152</pub-id>
<pub-id pub-id-type="pmid">21148242</pub-id></mixed-citation>
      </ref>
      <ref id="B43">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez</surname><given-names>F. J.</given-names></name><name><surname>Donohue</surname><given-names>J. F.</given-names></name><name><surname>Rennard</surname><given-names>S.</given-names><suffix>II</suffix></name></person-group> (<year>2011</year>). <article-title>The future of chronic obstructive pulmonary disease treatment - Difficulties of and barriers to drug development</article-title>. <source>Lancet</source>
<volume>378</volume>, <fpage>1027</fpage>&#x2013;<lpage>1037</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/S0140-6736(11)61047-7</pub-id>
<pub-id pub-id-type="pmid">21907866</pub-id></mixed-citation>
      </ref>
      <ref id="B44">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mayer-Hamblett</surname><given-names>N.</given-names></name><name><surname>Aitken</surname><given-names>M. L.</given-names></name><name><surname>Accurso</surname><given-names>F. J.</given-names></name><name><surname>Kronmal</surname><given-names>R. A.</given-names></name><name><surname>Konstan</surname><given-names>M. W.</given-names></name><name><surname>Burns</surname><given-names>J. L.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Association between pulmonary function and sputum biomarkers in cystic fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>175</volume>, <fpage>822</fpage>&#x2013;<lpage>828</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.200609-1354OC</pub-id>
<pub-id pub-id-type="pmid">17234902</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McElvaney</surname><given-names>N. G.</given-names></name><name><surname>Hubbard</surname><given-names>R. C.</given-names></name><name><surname>Birrer</surname><given-names>P.</given-names></name><name><surname>Crystal</surname><given-names>R. G.</given-names></name><name><surname>Chernick</surname><given-names>M. S.</given-names></name><name><surname>Frank</surname><given-names>M. M.</given-names></name><etal/></person-group> (<year>1991</year>). <article-title>Aerosol &#x3B1;1 -antitrypsin treatment for cystic fibrosis</article-title>. <source>Lancet</source>
<volume>337</volume>, <fpage>392</fpage>&#x2013;<lpage>394</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/0140-6736(91)91167-S</pub-id>
<pub-id pub-id-type="pmid">1671425</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>McElvaney</surname><given-names>N. G.</given-names></name></person-group> (<year>2016</year>). &#x201C;<article-title>Alpha-1 antitrypsin therapy in cystic fibrosis and the lung disease associated with alpha-1 antitrypsin deficiency</article-title>,&#x201D; in <source>Annals of the American Thoracic Society</source> (<publisher-name>American Thoracic Society</publisher-name>), <fpage>S191</fpage>&#x2013;<lpage>S196</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1513/AnnalsATS.201504-245KV</pub-id>
</mixed-citation>
      </ref>
      <ref id="B47">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mogayzel</surname><given-names>P. J.</given-names></name><name><surname>Naureckas</surname><given-names>E. T.</given-names></name><name><surname>Robinson</surname><given-names>K. A.</given-names></name><name><surname>Mueller</surname><given-names>G.</given-names></name><name><surname>Hadjiliadis</surname><given-names>D.</given-names></name><name><surname>Hoag</surname><given-names>J. B.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>187</volume>, <fpage>680</fpage>&#x2013;<lpage>689</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.201207-1160OE</pub-id>
<pub-id pub-id-type="pmid">23540878</pub-id></mixed-citation>
      </ref>
      <ref id="B48">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mott</surname><given-names>L. S.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Murray</surname><given-names>C. P.</given-names></name><name><surname>Gangell</surname><given-names>C. L.</given-names></name><name><surname>De Klerk</surname><given-names>N. H.</given-names></name><name><surname>Robinson</surname><given-names>P. J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Progression of early structural lung disease in young children with cystic fibrosis assessed using CT</article-title>. <source>Thorax</source>
<volume>67</volume>, <fpage>509</fpage>&#x2013;<lpage>516</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thoraxjnl-2011-200912</pub-id>
<pub-id pub-id-type="pmid">22201161</pub-id></mixed-citation>
      </ref>
      <ref id="B49">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Motwani</surname><given-names>M. P.</given-names></name><name><surname>Bennett</surname><given-names>F.</given-names></name><name><surname>Norris</surname><given-names>P. C.</given-names></name><name><surname>Maini</surname><given-names>A. A.</given-names></name><name><surname>George</surname><given-names>M. J.</given-names></name><name><surname>Newson</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>104</volume>, <fpage>675</fpage>&#x2013;<lpage>686</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/cpt.980</pub-id>
<pub-id pub-id-type="pmid">29238967</pub-id></mixed-citation>
      </ref>
      <ref id="B50">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muhlebach</surname><given-names>M. S.</given-names></name><name><surname>Clancy</surname><given-names>J. P.</given-names></name><name><surname>Heltshe</surname><given-names>S. L.</given-names></name><name><surname>Ziady</surname><given-names>A.</given-names></name><name><surname>Kelley</surname><given-names>T.</given-names></name><name><surname>Accurso</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Biomarkers for cystic fibrosis drug development</article-title>. <source>J. Cyst. Fibros.</source>
<volume>15</volume>, <fpage>714</fpage>&#x2013;<lpage>723</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jcf.2016.10.009</pub-id>
<pub-id pub-id-type="pmid">28215711</pub-id></mixed-citation>
      </ref>
      <ref id="B51">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nichols</surname><given-names>D. P.</given-names></name><name><surname>Chmiel</surname><given-names>J. F.</given-names></name></person-group> (<year>2015</year>). <article-title>Inflammation and its genesis in cystic fibrosis</article-title>. <source>Pediatr. Pulmonol.</source>
<volume>50</volume>, <fpage>S39</fpage>&#x2013;<lpage>S56</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/ppul.23242</pub-id>
<pub-id pub-id-type="pmid">26335954</pub-id></mixed-citation>
      </ref>
      <ref id="B52">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ordo&#xF1;ez</surname><given-names>C. L.</given-names></name><name><surname>Henig</surname><given-names>N. R.</given-names></name><name><surname>Mayer-Hamblett</surname><given-names>N.</given-names></name><name><surname>Accurso</surname><given-names>F. J.</given-names></name><name><surname>Burns</surname><given-names>J. L.</given-names></name><name><surname>Chmiel</surname><given-names>J. F.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Inflammatory and Microbiologic Markers in Induced Sputum after Intravenous Antibiotics in Cystic Fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>168</volume>, <fpage>1471</fpage>&#x2013;<lpage>1475</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.200306-731OC</pub-id>
<pub-id pub-id-type="pmid">12969869</pub-id></mixed-citation>
      </ref>
      <ref id="B53">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x2019;Neill</surname><given-names>K.</given-names></name><name><surname>Bradley</surname><given-names>J. M.</given-names></name><name><surname>Reid</surname><given-names>A.</given-names></name><name><surname>Downey</surname><given-names>D. G.</given-names></name><name><surname>Rendall</surname><given-names>J.</given-names></name><name><surname>McCaughan</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Airway infection, systemic inflammation and lung clearance index in children and adults with cystic fibrosis</article-title>. <source>Eur. Respir. J.</source>
<volume>51</volume>, <fpage>1701704</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1183/13993003.01704-2017</pub-id>
<pub-id pub-id-type="pmid">29386349</pub-id></mixed-citation>
      </ref>
      <ref id="B54">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Owens</surname><given-names>C. M.</given-names></name><name><surname>Aurora</surname><given-names>P.</given-names></name><name><surname>Stanojevic</surname><given-names>S.</given-names></name><name><surname>Bush</surname><given-names>A.</given-names></name><name><surname>Wade</surname><given-names>A.</given-names></name><name><surname>Oliver</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Lung clearance index and HRCT are complementary markers of lung abnormalities in young children with CF</article-title>. <source>Thorax</source>
<volume>66</volume>, <fpage>481</fpage>&#x2013;<lpage>488</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thx.2010.150375</pub-id>
<pub-id pub-id-type="pmid">21422040</pub-id></mixed-citation>
      </ref>
      <ref id="B55">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parnham</surname><given-names>M. J.</given-names></name><name><surname>&#x10C;uli&#x107;</surname><given-names>O.</given-names></name><name><surname>Erakovi&#x107;</surname><given-names>V.</given-names></name><name><surname>Muni&#x107;</surname><given-names>V.</given-names></name><name><surname>Popovi&#x107;-Grle</surname><given-names>S.</given-names></name><name><surname>Bari&#x161;i&#x107;</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>517</volume>, <fpage>132</fpage>&#x2013;<lpage>143</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.ejphar.2005.05.023</pub-id>
<pub-id pub-id-type="pmid">15964564</pub-id></mixed-citation>
      </ref>
      <ref id="B56">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perrem</surname><given-names>L.</given-names></name><name><surname>Ratjen</surname><given-names>F.</given-names></name></person-group> (<year>2019</year>). <article-title>Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators</article-title>. <source>Pediatr. Pulmonol.</source>
<volume>54</volume> Suppl 3, <fpage>S46</fpage>&#x2013;<lpage>S55</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/ppul.24364</pub-id>
<pub-id pub-id-type="pmid">31715088</pub-id></mixed-citation>
      </ref>
      <ref id="B57">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pillarisetti</surname><given-names>N.</given-names></name><name><surname>Williamson</surname><given-names>E.</given-names></name><name><surname>Linnane</surname><given-names>B.</given-names></name><name><surname>Skoric</surname><given-names>B.</given-names></name><name><surname>Robertson</surname><given-names>C. F.</given-names></name><name><surname>Robinson</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Infection, Inflammation, and Lung Function Decline in Infants with Cystic Fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>184</volume>, <fpage>75</fpage>&#x2013;<lpage>81</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.201011-1892OC</pub-id>
<pub-id pub-id-type="pmid">21493738</pub-id></mixed-citation>
      </ref>
      <ref id="B58">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Prednisone in Cystic Fibrosis Pulmonary Exacerbations</collab></person-group>
<source>Full Text View - ClinicalTrials.gov</source>. Available at: <uri xlink:type="simple" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03070522">https://clinicaltrials.gov/ct2/show/NCT03070522</uri> (Accessed <date-in-citation>August 10, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B59">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Proesmans</surname><given-names>M.</given-names></name><name><surname>Els</surname><given-names>C.</given-names></name><name><surname>Vermeulen</surname><given-names>F.</given-names></name><name><surname>De Boeck</surname><given-names>K.</given-names></name></person-group> (<year>2011</year>). <article-title>Change in IgG and evolution of lung function in children with cystic fibrosis</article-title>. <source>J. Cyst. Fibros.</source>
<volume>10</volume>, <fpage>128</fpage>&#x2013;<lpage>131</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jcf.2010.12.004</pub-id>
<pub-id pub-id-type="pmid">21220215</pub-id></mixed-citation>
      </ref>
      <ref id="B60">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quon</surname><given-names>B. S.</given-names></name><name><surname>Dai</surname><given-names>D. L. Y.</given-names></name><name><surname>Hollander</surname><given-names>Z.</given-names></name><name><surname>Ng</surname><given-names>R. T.</given-names></name><name><surname>Tebbutt</surname><given-names>S. J.</given-names></name><name><surname>Man</surname><given-names>S. F. P.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry</article-title>. <source>Thorax</source>
<volume>71</volume>, <fpage>216</fpage>&#x2013;<lpage>222</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thoraxjnl-2014-206710</pub-id>
<pub-id pub-id-type="pmid">25777587</pub-id></mixed-citation>
      </ref>
      <ref id="B61">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>B. W.</given-names></name><name><surname>Pepe</surname><given-names>M. S.</given-names></name><name><surname>Quan</surname><given-names>J. M.</given-names></name><name><surname>Otto</surname><given-names>K. L.</given-names></name><name><surname>Montgomery</surname><given-names>A. B.</given-names></name><name><surname>Williams-Warren</surname><given-names>J.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis</article-title>. <source>N. Engl. J. Med.</source>
<volume>340</volume>, <fpage>23</fpage>&#x2013;<lpage>30</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1056/NEJM199901073400104</pub-id>
<pub-id pub-id-type="pmid">9878641</pub-id></mixed-citation>
      </ref>
      <ref id="B62">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>B. W.</given-names></name><name><surname>Davies</surname><given-names>J.</given-names></name><name><surname>McElvaney</surname><given-names>N. G.</given-names></name><name><surname>Tullis</surname><given-names>E.</given-names></name><name><surname>Bell</surname><given-names>S. C.</given-names></name><name><surname>D&#x159;ev&#xED;nek</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>A CFTR Potentiator in Patients with Cystic Fibrosis and the <italic>G551D</italic> Mutation</article-title>. <source>N. Engl. J. Med.</source>
<volume>365</volume>, <fpage>1663</fpage>&#x2013;<lpage>1672</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1056/NEJMoa1105185</pub-id>
<pub-id pub-id-type="pmid">22047557</pub-id></mixed-citation>
      </ref>
      <ref id="B63">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>K.</given-names></name><name><surname>Foong</surname><given-names>R.</given-names></name><name><surname>Grdosic</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Multiple breath washout outcomes are sensitive to inflammation and infection in children with cystic fibrosis</article-title>. <source>Ann. Am. Thorac. Soc.</source>
<volume>14</volume>, <fpage>1436</fpage>&#x2013;<lpage>1442</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.201611-935OC</pub-id>
<pub-id pub-id-type="pmid">28481640</pub-id></mixed-citation>
      </ref>
      <ref id="B64">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rao</surname><given-names>N. L.</given-names></name><name><surname>Riley</surname><given-names>J. P.</given-names></name><name><surname>Banie</surname><given-names>H.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>B.</given-names></name><name><surname>Crawford</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Leukotriene A<sub>4</sub> Hydrolase Inhibition Attenuates Allergic Airway Inflammation and Hyperresponsiveness</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>181</volume>, <fpage>899</fpage>&#x2013;<lpage>907</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.200807-1158OC</pub-id>
<pub-id pub-id-type="pmid">20110560</pub-id></mixed-citation>
      </ref>
      <ref id="B65">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ratjen</surname><given-names>F.</given-names></name><name><surname>Saiman</surname><given-names>L.</given-names></name><name><surname>Mayer-Hamblett</surname><given-names>N.</given-names></name><name><surname>Lands</surname><given-names>L. C.</given-names></name><name><surname>Kloster</surname><given-names>M.</given-names></name><name><surname>Thompson</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Effect of Azithromycin on Systemic Markers of Inflammation in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa</article-title>. <source>Chest</source>
<volume>142</volume>, <fpage>1259</fpage>&#x2013;<lpage>1266</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1378/chest.12-0628</pub-id>
<pub-id pub-id-type="pmid">22595153</pub-id></mixed-citation>
      </ref>
      <ref id="B66">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ratjen</surname><given-names>F.</given-names></name><name><surname>Hug</surname><given-names>C.</given-names></name><name><surname>Marigowda</surname><given-names>G.</given-names></name><name><surname>Tian</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Stanojevic</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Efficacy and safety of lumacaftor and ivacaftor in patients aged 6&#x2013;11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial</article-title>. <source>Lancet Respir. Med.</source>
<volume>5</volume>, <fpage>557</fpage>&#x2013;<lpage>567</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/S2213-2600(17)30215-1</pub-id>
<pub-id pub-id-type="pmid">28606620</pub-id></mixed-citation>
      </ref>
      <ref id="B67">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ratjen</surname><given-names>F.</given-names></name><name><surname>Davis</surname><given-names>S. D.</given-names></name><name><surname>Stanojevic</surname><given-names>S.</given-names></name><name><surname>Kronmal</surname><given-names>R. A.</given-names></name><name><surname>Hinckley Stukovsky</surname><given-names>K. D.</given-names></name><name><surname>Jorgensen</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet Respir. Med</source>. <volume>9</volume>, <fpage>802</fpage>&#x2013;<lpage>809</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/S2213-2600(19)30187-0</pub-id>
</mixed-citation>
      </ref>
      <ref id="B68">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rayment</surname><given-names>J. H.</given-names></name><name><surname>Stanojevic</surname><given-names>S.</given-names></name><name><surname>Davis</surname><given-names>S. D.</given-names></name><name><surname>Retsch-Bogart</surname><given-names>G.</given-names></name><name><surname>Ratjen</surname><given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title>Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis</article-title>. <source>Thorax</source>
<volume>73</volume>, <fpage>451</fpage>&#x2013;<lpage>458</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thoraxjnl-2017-210979</pub-id>
<pub-id pub-id-type="pmid">29449440</pub-id></mixed-citation>
      </ref>
      <ref id="B69">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reid</surname><given-names>P. A.</given-names></name><name><surname>McAllister</surname><given-names>D. A.</given-names></name><name><surname>Boyd</surname><given-names>A. C.</given-names></name><name><surname>Innes</surname><given-names>J. A.</given-names></name><name><surname>Porteous</surname><given-names>D.</given-names></name><name><surname>Greening</surname><given-names>A.&#xA0;P.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>191</volume>, <fpage>233</fpage>&#x2013;<lpage>236</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.201407-1365LE</pub-id>
<pub-id pub-id-type="pmid">25590159</pub-id></mixed-citation>
      </ref>
      <ref id="B70">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rowe</surname><given-names>S. M.</given-names></name><name><surname>Heltshe</surname><given-names>S. L.</given-names></name><name><surname>Gonska</surname><given-names>T.</given-names></name><name><surname>Donaldson</surname><given-names>S. H.</given-names></name><name><surname>Borowitz</surname><given-names>D.</given-names></name><name><surname>Gelfond</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>190</volume>, <fpage>175</fpage>&#x2013;<lpage>184</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.201404-0703OC</pub-id>
<pub-id pub-id-type="pmid">24927234</pub-id></mixed-citation>
      </ref>
      <ref id="B71">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sagel</surname><given-names>S. D.</given-names></name><name><surname>Kapsner</surname><given-names>R.</given-names></name><name><surname>Osberg</surname><given-names>I.</given-names></name><name><surname>Sontag</surname><given-names>M. K.</given-names></name><name><surname>Accurso</surname><given-names>F. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>164</volume>, <fpage>1425</fpage>&#x2013;<lpage>1431</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/ajrccm.164.8.2104075</pub-id>
<pub-id pub-id-type="pmid">11704590</pub-id></mixed-citation>
      </ref>
      <ref id="B72">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Sagel</surname><given-names>S. D.</given-names></name><name><surname>Chmiel</surname><given-names>J. F.</given-names></name><name><surname>Konstan</surname><given-names>M. W.</given-names></name></person-group> (<year>2007</year>). &#x201C;<article-title>Sputum biomarkers of inflammation in cystic fibrosis lung disease</article-title>,&#x201D; in <source>Proceedings of the American Thoracic Society</source> (<publisher-name>Proc Am Thorac Soc</publisher-name>), <fpage>406</fpage>&#x2013;<lpage>417</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1513/pats.200703-044BR</pub-id>
</mixed-citation>
      </ref>
      <ref id="B73">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sagel</surname><given-names>S. D.</given-names></name><name><surname>Wagner</surname><given-names>B. D.</given-names></name><name><surname>Anthony</surname><given-names>M. M.</given-names></name><name><surname>Emmett</surname><given-names>P.</given-names></name><name><surname>Zemanick</surname><given-names>E. T.</given-names></name></person-group> (<year>2012</year>). <article-title>Sputum Biomarkers of Inflammation and Lung Function Decline in Children with Cystic Fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>186</volume>, <fpage>857</fpage>&#x2013;<lpage>865</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.201203-0507OC</pub-id>
<pub-id pub-id-type="pmid">22904182</pub-id></mixed-citation>
      </ref>
      <ref id="B74">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanders</surname><given-names>D. B.</given-names></name><name><surname>Bittner</surname><given-names>R. C. L.</given-names></name><name><surname>Rosenfeld</surname><given-names>M.</given-names></name><name><surname>Hoffman</surname><given-names>L. R.</given-names></name><name><surname>Redding</surname><given-names>G. J.</given-names></name><name><surname>Goss</surname><given-names>C. H.</given-names></name></person-group> (<year>2010</year>). <article-title>Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>182</volume>, <fpage>627</fpage>&#x2013;<lpage>632</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.200909-1421OC</pub-id>
<pub-id pub-id-type="pmid">20463179</pub-id></mixed-citation>
      </ref>
      <ref id="B75">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Santyr</surname><given-names>G.</given-names></name><name><surname>Kanhere</surname><given-names>N.</given-names></name><name><surname>Morgado</surname><given-names>F.</given-names></name><name><surname>Rayment</surname><given-names>J. H.</given-names></name><name><surname>Ratjen</surname><given-names>F.</given-names></name><name><surname>Couch</surname><given-names>M. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Hyperpolarized Gas Magnetic Resonance Imaging of Pediatric Cystic Fibrosis Lung Disease</article-title>. <source>Acad. Radiol.</source>
<volume>26</volume>, <fpage>344</fpage>&#x2013;<lpage>354</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.acra.2018.04.024</pub-id>
<pub-id pub-id-type="pmid">30087066</pub-id></mixed-citation>
      </ref>
      <ref id="B76">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sawicki</surname><given-names>G. S.</given-names></name><name><surname>McKone</surname><given-names>E. F.</given-names></name><name><surname>Pasta</surname><given-names>D. J.</given-names></name><name><surname>Millar</surname><given-names>S. J.</given-names></name><name><surname>Wagener</surname><given-names>J. S.</given-names></name><name><surname>Johnson</surname><given-names>C. A.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>192</volume>, <fpage>836</fpage>&#x2013;<lpage>842</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.201503-0578OC</pub-id>
<pub-id pub-id-type="pmid">26132840</pub-id></mixed-citation>
      </ref>
      <ref id="B77">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shoki</surname><given-names>A. H.</given-names></name><name><surname>Mayer-Hamblett</surname><given-names>N.</given-names></name><name><surname>Wilcox</surname><given-names>P. G.</given-names></name><name><surname>Sin</surname><given-names>D. D.</given-names></name><name><surname>Quon</surname><given-names>B. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations</article-title>. <source>Chest</source>
<volume>144</volume>, <fpage>1659</fpage>&#x2013;<lpage>1670</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1378/chest.13-0693</pub-id>
<pub-id pub-id-type="pmid">23868694</pub-id></mixed-citation>
      </ref>
      <ref id="B78">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sly</surname><given-names>P. D.</given-names></name><name><surname>Brennan</surname><given-names>S.</given-names></name><name><surname>Gangell</surname><given-names>C.</given-names></name><name><surname>de Klerk</surname><given-names>N.</given-names></name><name><surname>Murray</surname><given-names>C.</given-names></name><name><surname>Mott</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Lung Disease at Diagnosis in Infants with Cystic Fibrosis Detected by Newborn Screening</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>180</volume>, <fpage>146</fpage>&#x2013;<lpage>152</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.200901-0069OC</pub-id>
<pub-id pub-id-type="pmid">19372250</pub-id></mixed-citation>
      </ref>
      <ref id="B79">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sly</surname><given-names>P. D.</given-names></name><name><surname>Gangell</surname><given-names>C. L.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Ware</surname><given-names>R. S.</given-names></name><name><surname>Ranganathan</surname><given-names>S.</given-names></name><name><surname>Mott</surname><given-names>L. S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Risk Factors for Bronchiectasis in Children with Cystic Fibrosis</article-title>. <source>NEJM. Org. N Engl. J. Med.</source>
<volume>21</volume>, <fpage>1963</fpage>&#x2013;<lpage>1970</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1056/NEJMoa1301725</pub-id>
</mixed-citation>
      </ref>
      <ref id="B80">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stanojevic</surname><given-names>S.</given-names></name><name><surname>Ratjen</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Physiologic endpoints for clinical studies for cystic fibrosis</article-title>. <source>J. Cyst. Fibros.</source>
<volume>15</volume>, <fpage>416</fpage>&#x2013;<lpage>423</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jcf.2016.05.014</pub-id>
<pub-id pub-id-type="pmid">27316663</pub-id></mixed-citation>
      </ref>
      <ref id="B81">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stanojevic</surname><given-names>S.</given-names></name><name><surname>McDonald</surname><given-names>A.</given-names></name><name><surname>Waters</surname><given-names>V.</given-names></name><name><surname>MacDonald</surname><given-names>S.</given-names></name><name><surname>Horton</surname><given-names>E.</given-names></name><name><surname>Tullis</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis</article-title>. <source>Thorax</source>
<volume>72</volume>, <fpage>327</fpage>&#x2013;<lpage>332</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thoraxjnl-2016-208450</pub-id>
<pub-id pub-id-type="pmid">27539619</pub-id></mixed-citation>
      </ref>
      <ref id="B82">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Subbarao</surname><given-names>P.</given-names></name><name><surname>Stanojevic</surname><given-names>S.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Jensen</surname><given-names>R.</given-names></name><name><surname>Rosenfeld</surname><given-names>M.</given-names></name><name><surname>Davis</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Lung Clearance Index as an Outcome Measure for Clinical Trials in Young Children with Cystic Fibrosis A Pilot Study Using Inhaled Hypertonic Saline</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>188</volume>, <fpage>456</fpage>&#x2013;<lpage>460</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1164/rccm.201302-0219OC</pub-id>
<pub-id pub-id-type="pmid">23742699</pub-id></mixed-citation>
      </ref>
      <ref id="B83">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tiddens</surname><given-names>H. A. W. M.</given-names></name><name><surname>Puderbach</surname><given-names>M.</given-names></name><name><surname>Venegas</surname><given-names>J. G.</given-names></name><name><surname>Ratjen</surname><given-names>F.</given-names></name><name><surname>Donaldson</surname><given-names>S. H.</given-names></name><name><surname>Davis</surname><given-names>S. D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Novel outcome measures for clinical trials in cystic fibrosis</article-title>. <source>Pediatr. Pulmonol.</source>
<volume>50</volume>, <fpage>302</fpage>&#x2013;<lpage>315</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/ppul.23146</pub-id>
<pub-id pub-id-type="pmid">25641878</pub-id></mixed-citation>
      </ref>
      <ref id="B84">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tobin</surname><given-names>D. M.</given-names></name><name><surname>Vary</surname><given-names>J. C.</given-names></name><name><surname>Ray</surname><given-names>J. P.</given-names></name><name><surname>Walsh</surname><given-names>G. S.</given-names></name><name><surname>Dunstan</surname><given-names>S. J.</given-names></name><name><surname>Bang</surname><given-names>N. D.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>The lta4h Locus Modulates Susceptibility to Mycobacterial Infection in Zebrafish and Humans</article-title>. <source>Cell</source>
<volume>140</volume>, <fpage>717</fpage>&#x2013;<lpage>730</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/J.CELL.2010.02.013</pub-id>
<pub-id pub-id-type="pmid">20211140</pub-id></mixed-citation>
      </ref>
      <ref id="B85">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Torphy</surname><given-names>T. J.</given-names></name><name><surname>Allen</surname><given-names>J.</given-names></name><name><surname>Cantin</surname><given-names>A. M.</given-names></name><name><surname>Konstan</surname><given-names>M. W.</given-names></name><name><surname>Accurso</surname><given-names>F. J.</given-names></name><name><surname>Joseloff</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2015</year>). &#x201C;<article-title>Considerations for the conduct of clinical trials with antiinflammatory agents in cystic fibrosis: A cystic fibrosis foundation workshop report</article-title>,&#x201D; in <source>Annals of the American Thoracic Society</source> (<publisher-name>American Thoracic Society</publisher-name>), <fpage>1398</fpage>&#x2013;<lpage>1406</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1513/AnnalsATS.201506-361OT</pub-id>
</mixed-citation>
      </ref>
      <ref id="B86">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis</collab></person-group>
<source>Full Text View - ClinicalTrials.gov</source>. Available at: <uri xlink:type="simple" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03451045">https://clinicaltrials.gov/ct2/show/NCT03451045</uri> (Accessed <date-in-citation>August 13, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B87">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Horck</surname><given-names>M.</given-names></name><name><surname>van de Kant</surname><given-names>K.</given-names></name><name><surname>Winkens</surname><given-names>B.</given-names></name><name><surname>Wesseling</surname><given-names>G.</given-names></name><name><surname>Gulmans</surname><given-names>V.</given-names></name><name><surname>Hendriks</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Risk factors for lung disease progression in children with cystic fibrosis</article-title>. <source>Eur. Respir. J.</source>
<volume>51</volume>, <fpage>1702509</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1183/13993003.02509-2017</pub-id>
<pub-id pub-id-type="pmid">29773689</pub-id></mixed-citation>
      </ref>
      <ref id="B88">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Waters</surname><given-names>V. J.</given-names></name><name><surname>Stanojevic</surname><given-names>S.</given-names></name><name><surname>Sonneveld</surname><given-names>N.</given-names></name><name><surname>Klingel</surname><given-names>M.</given-names></name><name><surname>Grasemann</surname><given-names>H.</given-names></name><name><surname>Yau</surname><given-names>Y. C.&#xA0;W.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients</article-title>. <source>J. Cyst. Fibros.</source>
<volume>14</volume>, <fpage>755</fpage>&#x2013;<lpage>762</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jcf.2015.01.007</pub-id>
<pub-id pub-id-type="pmid">25690407</pub-id></mixed-citation>
      </ref>
      <ref id="B89">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watt</surname><given-names>A. P.</given-names></name><name><surname>Courtney</surname><given-names>J.</given-names></name><name><surname>Moore</surname><given-names>J.</given-names></name><name><surname>Ennis</surname><given-names>M.</given-names></name><name><surname>Elborn</surname><given-names>J. S.</given-names></name></person-group> (<year>2005</year>). <article-title>Neutrophil cell death, activation and bacterial infection in cystic fibrosis</article-title>. <source>Thorax</source>
<volume>60</volume>, <fpage>659</fpage>&#x2013;<lpage>664</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1136/thx.2004.038240</pub-id>
<pub-id pub-id-type="pmid">16061707</pub-id></mixed-citation>
      </ref>
      <ref id="B90">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whiting</surname><given-names>P.</given-names></name><name><surname>Maiwenn</surname><given-names>Al</given-names></name><name><surname>Burgers</surname><given-names>L.</given-names></name><name><surname>Westwood</surname><given-names>M.</given-names></name><name><surname>Ryder</surname><given-names>S.</given-names></name><name><surname>Hoogendoorn</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: A systematic review and cost-effectiveness analysis</article-title>. <source>Health Technol. Assess. (Rockv).</source>
<volume>18</volume>, <fpage>1</fpage>&#x2013;<lpage>106</lpage>. &#xA0;<pub-id pub-id-type="doi">10.3310/hta18180</pub-id>
</mixed-citation>
      </ref>
      <ref id="B91">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woods</surname><given-names>J. C.</given-names></name><name><surname>Wild</surname><given-names>J. M.</given-names></name><name><surname>Wielp&#xFC;tz</surname><given-names>M. O.</given-names></name><name><surname>Clancy</surname><given-names>J. P.</given-names></name><name><surname>Hatabu</surname><given-names>H.</given-names></name><name><surname>Kauczor</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Current state of the art MRI for the longitudinal assessment of cystic fibrosis</article-title>. <source>J. Magn. Reson. Imaging</source>
<volume>10.1002</volume>, <fpage>jmri.27030</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/jmri.27030</pub-id>
</mixed-citation>
      </ref>
      <ref id="B92">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zemanick</surname><given-names>E. T.</given-names></name><name><surname>Wagner</surname><given-names>B. D.</given-names></name><name><surname>Robertson</surname><given-names>C. E.</given-names></name><name><surname>Stevens</surname><given-names>M. J.</given-names></name><name><surname>Szefler</surname><given-names>S. J.</given-names></name><name><surname>Accurso</surname><given-names>F. J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods</article-title>. <source>Ann. Am. Thorac. Soc</source>
<volume>12</volume>, <fpage>221</fpage>&#x2013;<lpage>229</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1513/AnnalsATS.201407-310OC</pub-id>
<pub-id pub-id-type="pmid">25474078</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id>
      <journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id>
      <journal-id journal-id-type="publisher-id">pharmaceutics</journal-id>
      <journal-title-group>
        <journal-title>Pharmaceutics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1999-4923</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32824123</article-id>
      <article-id pub-id-type="pmc">7466038</article-id>
      <article-id pub-id-type="doi">10.3390/pharmaceutics12080776</article-id>
      <article-id pub-id-type="publisher-id">pharmaceutics-12-00776</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Compatible Stability and Aerosol Characteristics of Atrovent<sup>&#xAE;</sup> (Ipratropium Bromide) Mixed with Salbutamol Sulfate, Terbutaline Sulfate, Budesonide, and Acetylcysteine</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Yiting</given-names>
          </name>
          <xref ref-type="aff" rid="af1-pharmaceutics-12-00776">1</xref>
          <xref ref-type="author-notes" rid="fn1-pharmaceutics-12-00776">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Du</surname>
            <given-names>Shilin</given-names>
          </name>
          <xref ref-type="aff" rid="af2-pharmaceutics-12-00776">2</xref>
          <xref ref-type="author-notes" rid="fn1-pharmaceutics-12-00776">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Zhirui</given-names>
          </name>
          <xref ref-type="aff" rid="af1-pharmaceutics-12-00776">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>He</surname>
            <given-names>Wenxiu</given-names>
          </name>
          <xref ref-type="aff" rid="af1-pharmaceutics-12-00776">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>Enhao</given-names>
          </name>
          <xref ref-type="aff" rid="af1-pharmaceutics-12-00776">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Rui</given-names>
          </name>
          <xref ref-type="aff" rid="af1-pharmaceutics-12-00776">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sha</surname>
            <given-names>Xianyi</given-names>
          </name>
          <xref ref-type="aff" rid="af1-pharmaceutics-12-00776">1</xref>
          <xref ref-type="aff" rid="af3-pharmaceutics-12-00776">3</xref>
          <xref rid="c1-pharmaceutics-12-00776" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>Yan</given-names>
          </name>
          <xref ref-type="aff" rid="af4-pharmaceutics-12-00776">4</xref>
          <xref rid="c1-pharmaceutics-12-00776" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-pharmaceutics-12-00776"><label>1</label>Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai 201203, China; <email>18211030015@fudan.edu.cn</email> (Y.C.); <email>16301030052@fudan.edu.cn</email> (Z.Z.); <email>18111030032@fudan.edu.cn</email> (W.H.); <email>19211030026@fudan.edu.cn</email> (E.L.); <email>19111030038@fudan.edu.cn</email> (R.W.)</aff>
      <aff id="af2-pharmaceutics-12-00776"><label>2</label>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China; <email>du.shilin@zs-hospital.sh.cn</email></aff>
      <aff id="af3-pharmaceutics-12-00776"><label>3</label>The Institutes of Integrative Medicine of Fudan University, Shanghai 200040, China</aff>
      <aff id="af4-pharmaceutics-12-00776"><label>4</label>Shanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, Shanghai 200030, China</aff>
      <author-notes>
        <corresp id="c1-pharmaceutics-12-00776"><label>*</label>Correspondence: <email>shaxy@fudan.edu.cn</email> (X.S.); <email>mayan@smhc.org.cn</email> (Y.M.); Tel.: +86-21-51980072 (X.S.)</corresp>
        <fn id="fn1-pharmaceutics-12-00776">
          <label>&#x2020;</label>
          <p>These authors contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>8</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>8</month>
        <year>2020</year>
      </pub-date>
      <volume>12</volume>
      <issue>8</issue>
      <elocation-id>776</elocation-id>
      <history>
        <date date-type="received">
          <day>02</day>
          <month>7</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>8</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2020 by the authors.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license license-type="open-access">
          <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>(1) Background: It is common practice in the treatment of respiratory diseases to mix different inhalation solutions for simultaneous inhalation. At present, a small number of studies have been published that evaluate the physicochemical compatibility and aerosol characteristics of different inhalation medications. However, none of them studied Atrovent<sup>&#xAE;</sup>. Our work aims to address the lack of studies on Atrovent<sup>&#xAE;</sup>. (2) Methods: Portions of admixtures were withdrawn at certain time intervals after mixing and were tested by pH determination, osmolarity measurement, and high-performance liquid chromatography (HPLC) assay of each active ingredient as measures of physicochemical compatibility. The geometrical and aerosol particle size distribution, active drug delivery rate, and total active drug delivered were measured to characterize aerosol behaviors. (3) Results: During the testing time, no significant variation was found in the pH value, the osmotic pressure, or the active components of admixtures. With the increase in nebulization volume after mixing, fine particle dose (FPD) and total active drug delivered showed statistically significant improvements, while the active drug delivery rate decreased compared to the single-drug preparations. (4) Conclusions: These results endorse the physicochemical compatibility of Atrovent<sup>&#xAE;</sup> over 1 h when mixed with other inhalation medications. Considering aerosol characteristics, simultaneous inhalation is more efficient.</p>
      </abstract>
      <kwd-group>
        <kwd>Atrovent<sup>&#xAE;</sup></kwd>
        <kwd>Ventolin<sup>&#xAE;</sup></kwd>
        <kwd>Bricanyl<sup>&#xAE;</sup></kwd>
        <kwd>Pulmicort<sup>&#xAE;</sup></kwd>
        <kwd>Fluimucil<sup>&#xAE;</sup></kwd>
        <kwd>ipratropium</kwd>
        <kwd>nebulization</kwd>
        <kwd>compatibility</kwd>
        <kwd>aerosol characteristics</kwd>
        <kwd>simultaneous inhalation</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-pharmaceutics-12-00776">
      <title>1. Introduction</title>
      <p>Aerosol therapy is defined as an inhalation treatment that utilizes inhaler devices to transform pharmaceutical agents into aerosol form [<xref rid="B1-pharmaceutics-12-00776" ref-type="bibr">1</xref>]. The specific features of the pulmonary route, such as large absorption area, thin alveolar-capillary wall, low enzyme activity, and avoidance of the first-pass effect make pulmonary drug delivery advantageous in terms of fast absorption and high bioavailability. Thus, aerosol therapy is widely used in the diagnosis and treatment of lung pathology, including, but not limited to, chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis (CF) [<xref rid="B2-pharmaceutics-12-00776" ref-type="bibr">2</xref>]. Furthermore, from the perspective of clinical medicine, aerosol therapy is quite suitable for children, aged patients, and patients with difficulties in swallowing. Frequently used inhaler devices are classified into three types: pressurized metered dose inhalers (pMDI), dry powder inhalers (DPI), and nebulizers. Among these, the use of nebulizers is well-established, seen extensively both in hospitals and domiciliary settings [<xref rid="B1-pharmaceutics-12-00776" ref-type="bibr">1</xref>]. Several classes of respiratory therapeutic medications, including short-acting beta<sub>2</sub> receptor agonists (SABA, e.g., salbutamol sulfate), long-acting beta<sub>2</sub> receptor agonists (LABA, e.g., formoterol fumarate), short-acting muscarinic antagonists (SAMA, e.g., ipratropium bromide), long-acting muscarinic antagonists (LAMA, e.g., tiotropium bromide), and inhaled corticosteroids (ICS, e.g., budesonide), have been formulated into inhalation solutions as mainstream medicines for COPD and asthma [<xref rid="B3-pharmaceutics-12-00776" ref-type="bibr">3</xref>].</p>
      <p>The pathogenesis of COPD and asthma is so complicated that the target sites are multiple and combination therapies are often necessary. According to the suggestions of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Initiative for Asthma (GINA), dual combination therapy of LAMA/LABA or ICS/LABA is optimal for patients who are suffering from poorly controlled symptoms or frequent exacerbation. If the symptoms persist or the patients are at a high risk of exacerbation after undergoing dual combination therapy, treatment should be escalated to trimodal therapy of ICS/LABA/LAMA [<xref rid="B4-pharmaceutics-12-00776" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-12-00776" ref-type="bibr">5</xref>].</p>
      <p>It is worth noting that patients prescribed concomitant nebulized medications prefer admixing multiple drugs for simultaneous inhalation in order to reduce administration time and increase patients&#x2019; compliance. Although most of the previous studies have proven the advantages of combination therapies in terms of addictive/synergistic pharmacological activities [<xref rid="B6-pharmaceutics-12-00776" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-12-00776" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-12-00776" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-12-00776" ref-type="bibr">9</xref>], the potential incompatibility between excipients and/or drugs in different commercial products may lead to adverse effects and toxicity, which should not be ignored. Nevertheless, little research has been carried out on the physicochemical compatibility of mixtures [<xref rid="B10-pharmaceutics-12-00776" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-12-00776" ref-type="bibr">11</xref>], especially on aerosol characteristics [<xref rid="B12-pharmaceutics-12-00776" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-12-00776" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-12-00776" ref-type="bibr">14</xref>], which may significantly impact drug absorption and subsequently inhalation efficacy. A study has shown that Pulmozymel<sup>&#xAE;</sup> (brand of dornase alfa) should not be used along with Atrovent<sup>&#xAE;</sup> (brand of ipratropium) or Sultanol<sup>&#xAE;</sup> (brand of albuterol) because benzalkonium chloride (BAC) and disodium edetate used as excipients in Atrovent<sup>&#xAE;</sup> or Sultanol<sup>&#xAE;</sup> may destroy the integrity of dornase alfa, thereby causing microbiological instability [<xref rid="B15-pharmaceutics-12-00776" ref-type="bibr">15</xref>]. Likewise, cloudiness that occurs when mixing colistin or cromolyn with Atrovent<sup>&#xAE;</sup> or Sultanol<sup>&#xAE;</sup> is attributed to BAC [<xref rid="B10-pharmaceutics-12-00776" ref-type="bibr">10</xref>]. It is necessary to monitor the changes in pH and osmolality while mixing, which influence the tolerability of inhalation solutions. The extreme pH value (&lt;2.6 or &gt;10.0) will cause tissue irritation. The best osmolality is between 150 and 1200 mOsm/kg to prevent coughing or bronchoconstriction [<xref rid="B16-pharmaceutics-12-00776" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-12-00776" ref-type="bibr">17</xref>]. Another crucial factor that affects drug delivery efficiency to the deep alveolar region of the lung is the aerosol particle size distribution, which is often measured with metrics such as fine particle dose (FPD), fine particle fraction (FPF), and mass medium aerodynamic diameter (MMAD). To obtain optimal aerosol delivery, the aerodynamic diameter should be 1&#x2013;5 &#xB5;m, for the reason that particles smaller than 0.5 &#xB5;m are more likely to be exhaled via the Brownian movement and larger particles (&gt;5 &#xB5;m) easily deposit in the upper respiratory tract [<xref rid="B18-pharmaceutics-12-00776" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-12-00776" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-12-00776" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-12-00776" ref-type="bibr">21</xref>]. The aerosol characteristics will be affected by the physical characteristics and compositions of formulations [<xref rid="B22-pharmaceutics-12-00776" ref-type="bibr">22</xref>]. Additionally, solutions and suspensions for nebulization behave differently with regard to heterogeneous distribution [<xref rid="B23-pharmaceutics-12-00776" ref-type="bibr">23</xref>]. Taken together, these findings suggest that simultaneous inhalations of different solutions/suspensions may influence the deposition of inhaled aerosols into the lung by altering aerosol particle size distribution and simultaneous inhalation [<xref rid="B24-pharmaceutics-12-00776" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-12-00776" ref-type="bibr">25</xref>].</p>
      <p>Atrovent<sup>&#xAE;</sup> (ipratropium bromide), the most commonly used SAMA, is a bronchodilator that works via blockade of muscarinic cholinergic receptors and is clinically used in combination with other inhalation solutions/suspensions for enhanced treatment efficacy [<xref rid="B26-pharmaceutics-12-00776" ref-type="bibr">26</xref>]. For example, concomitant therapy containing ipratropium bromide with albuterol or salbutamol can be taken as relief medication or used for maintenance therapy [<xref rid="B27-pharmaceutics-12-00776" ref-type="bibr">27</xref>]. It was reported that ipratropium bromide combined with salmeterol exhibited excellent improvements in post-bronchodilator forced expiratory volume in 1 s (FEV<sub>1</sub>) [<xref rid="B28-pharmaceutics-12-00776" ref-type="bibr">28</xref>]. However, until now, there has been no systematic study on the physicochemical compatibility and aerosol characteristics of Atrovent<sup>&#xAE;</sup> mixed with other inhalation solutions/suspensions. Therefore, in this work, we attempt to fill this research gap in order to create a useful reference for medical personnel.</p>
    </sec>
    <sec id="sec2-pharmaceutics-12-00776">
      <title>2. Materials and Methods</title>
      <sec id="sec2dot1-pharmaceutics-12-00776">
        <title>2.1. Materials</title>
        <p>Atrovent<sup>&#xAE;</sup> (ipratropium bromide solution for inhalation, 250 &#xB5;g/2 mL per vial; Boehringer Ingelheim, Ingelheim am Rhein, Germany), Ventolin<sup>&#xAE;</sup> (salbutamol sulfate inhalation solution, 5 mg/2.5 mL per vial; GlaxoSmithKline, Boronia Vic 3155, Australia), Bricanyl<sup>&#xAE;</sup> (terbutaline sulfate solution for nebulization, 5 mg/2 mL; AstraZeneca, Cambridge, UK), Pulmicort<sup>&#xAE;</sup> (budesonide suspension for inhalation, 1 mg/2 mL per vial; AstraZeneca, Cambridge, UK), and Fluimucil<sup>&#xAE;</sup> (<italic>N</italic>-acetylcysteine(NAC) solution for inhalation, 0.3 g/3 mL per ampule; Zambon, Bresso, Italy) were available commercially. Reference substances including ipratropium bromide, salbutamol sulfate, and terbutaline sulfate were purchased from Dalian Meilun Biotechnology Co., Ltd. (Dalian, China), while reference substances of budesonide and acetylcysteine were obtained from National Institutes for Food and Drug Control (Beijing, China). Sodium dihydrogen phosphate was purchased from Beijing Solarbio Science &amp; Technology Co., Ltd. (Beijing, China). Phosphoric acid was purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). Acetonitrile (HPLC grade) was purchased from Merck KGaA (Darmstadt, Germany). Deionized water was produced by a Milli-Q water purification system (Millipore, Bedford, MA, USA).</p>
      </sec>
      <sec id="sec2dot2-pharmaceutics-12-00776">
        <title>2.2. Preparation of Samples</title>
        <p>The binary admixtures were prepared by mixing a single dose of Atrovent<sup>&#xAE;</sup> with a single dose of Ventolin<sup>&#xAE;</sup>, Bricanyl<sup>&#xAE;</sup>, Pulmicort<sup>&#xAE;</sup>, and Fluimucil<sup>&#xAE;</sup> separately, while the ternary mixture contained one dose of Atrovent<sup>&#xAE;</sup>, Ventolin<sup>&#xAE;</sup>, and Pulmicort<sup>&#xAE;</sup>. All the admixtures were oscillated gently to ensure uniformity and homogeneity. The preparation and testing processes were conducted at ambient room temperature to simulate real-world usage. For physical compatibility assessments, a single dose of each drug served as the control group. For aerosol characteristics, two control groups were set: a single dose of each drug and each drug diluted with saline solution (0.9% NaCl). Unless otherwise stated, all admixtures were prepared in quadruplicate and all the experiments following were repeated five times.</p>
        <p>The nebulization of all samples was conducted by a PARI Turboboy N compressor/LC Plus nebulizer (PARI GmbH, Starnberg, Germany). To determine the nebulization time before formal experiments, the tested sample was placed in a dried nebulization cup connected with the PARI Turboboy N compressor/LC Plus nebulizer and continuously nebulized until no more aerosol formed. The whole process was timed with a stopwatch and recorded (any fraction of one minute was counted as one minute to ensure complete nebulization). The volume and nebulization times of all samples are summarized in <xref rid="pharmaceutics-12-00776-t001" ref-type="table">Table 1</xref>.</p>
      </sec>
      <sec id="sec2dot3-pharmaceutics-12-00776">
        <title>2.3. Physical Compatibility Assessments</title>
        <p>Portions of samples were withdrawn from each mixture at predetermined time intervals (0(T<sub>0</sub>), 0.25(T<sub>0.25</sub>), 0.5(T<sub>0.5</sub>), and 1(T<sub>1</sub>) hour after preparation). Then, the pH value was measured using a calibrated pH meter (FiveEasy Plus&#x2122; FE28-Meter, Mettler Toledo, Greifensee, Switzerland) and the osmolality was analyzed by the freezing point depression method (Osmomat 030, Gonotec, Berlin, Germany).</p>
      </sec>
      <sec id="sec2dot4-pharmaceutics-12-00776">
        <title>2.4. Chemical Stability Assessments</title>
        <p>To evaluate chemical stability, 100 &#xB5;L samples collected from each solution at 0(T<sub>0</sub>), 0.25(T<sub>0.25</sub>), 0.5(T<sub>0.5</sub>), and 1(T<sub>1</sub>) hour after mixing were diluted to certain proportions with mobile phase and were immediately quantitatively analyzed on an Agilent 1260 HPLC system equipped with a quaternary pump, a vacuum degasser, an autosampler, and a diode array detector (DAD) to calculate the concentration of each active component. For all analyses, the HPLC column used a DiKMA Spursil C18 column (5 &#x3BC;m, 250 &#xD7; 4.6 mm) with a flow rate of 1 mL/min and a column temperature of 35 &#xB0;C. Mobile phase A was sodium dihydrogen phosphate (NaH<sub>2</sub>PO<sub>4</sub>) buffer (3.17 g NaH<sub>2</sub>PO<sub>4</sub> and 0.23 g phosphoric acid were dissolved in 800 mL deionized water; then, the pH value of solutions was adjusted to 3.2 and deionized water was used to adjust the final volume to 1 L.). Acetonitrile was served as mobile phase B. The ratio of the mobile phase, injection volume, run time, and the detection wavelength are listed in <xref rid="pharmaceutics-12-00776-t002" ref-type="table">Table 2</xref>. The concentration of each active component was calculated by building standard curves.</p>
      </sec>
      <sec id="sec2dot5-pharmaceutics-12-00776">
        <title>2.5. Particle Size Distribution Characterization by Laser Diffraction</title>
        <p>The geometrical particle size of a single dose of each drug or the prepared mixtures was characterized by laser diffraction using the Sympatec HELOS/BF laser diffraction meter (Sympatec GmbH, Clausthal-Zellerfeld, Germany). Before the first experiment, the background was tested in the dark condition for calibration. For testing, the nebulization cup, containing a single dose of each drug or the prepared mixtures, was positioned so that the laser beam went through the center of the spray area and so as to keep a vertical distance between the nozzle of nebulization cup and the center of laser light source of 6 cm. The instrument parameters and detailed settings were as follows: lens: R1 (0.1/0.18&#x2013;0.35&#x3BC;m); start: 10 s after c.opt &#x2265; 3.0%; stop: 30 s after start or 0.0 s after c.opt &#x2265; 3.0%; time base: 5 ms. A series of experimental data, X10 (particle size which corresponds to 10% of cumulative volume distribution), X50 (particle size which corresponds to 50% of cumulative volume distribution), X90 (particle size which corresponds to 90% of cumulative volume distribution), volume median droplet diameter (VMD), was calculated by the data-processing software WINDOX (Sympatec, Clausthal-Zellerfeld, Germany).</p>
      </sec>
      <sec id="sec2dot6-pharmaceutics-12-00776">
        <title>2.6. Aerosol Particle Distribution Measurement by the Next-Generation Impactor</title>
        <p>The next-generation impactor (NGI, Copley Scientific, Nottingham, UK) with seven stages with progressively decreasing cut-off diameters and a Micro-Orifice Collector (MOC, Copley Scientific, Nottingham, UK) were used to determine the aerosol particle distribution. Before the inception of the experiment, a leak test was carried out and the flow rate was set to 15 L/min within &#xB1;5% by a flow meter (flow meter model DFM4, Copley Scientific, Nottingham, UK). All the NGI experiments were performed in an NGI cooler (Copley Scientific, Nottingham, UK) at a controlled temperature of 5 &#xB1; 1.5 &#xB0;C, with a pre-cooling time of at least 90 min. Following the manufacturers&#x2019; instructions, the NGI was attached with the induction port and connected with a vacuum pump (high capacity pump model HCP5, Copley Scientific, Nottingham, UK). The admixtures were prepared separately in the nebulization cup, connected with the induction port by a suitable mouthpiece adapter. After corresponding aerosol time, the nebulizer (PARI Turboboy N compressor/LC Plus nebulizer, PARI GmbH, Starnberg, Germany) and the pump were switched off in turn. The samples in the induction port and removable impaction cups were collected into suitable volumetric flasks with deionized water/acetonitrile (3:1) and were analyzed with HPLC. The results of the various tests, including FPD, FPF, and MMAD, were calculated by Copley inhaler testing data analysis software (CITDAS, Copley Scientific, Nottingham, UK).</p>
      </sec>
      <sec id="sec2dot7-pharmaceutics-12-00776">
        <title>2.7. Active Drug Delivery Rate and Total Active Drug Delivered</title>
        <p>The active drug delivery rate and total active drug delivered were tested by a delivered dose sampling apparatus consisting of a breathing simulator (breathing simulator model BRS 1100, Copley Scientific, Nottingham, UK), an angle adapter, an inhalation filter, and a filter holder. The nebulization cup containing a single dose of drug or admixtures prepared as above was inserted into a mouthpiece adapter to connect with the delivered dose sampling apparatus and was positioned upright. The breathing profile that is representative of an adult was set as follows: tidal volume was 500 mL; frequency was 15 cycles/min; waveform was sinusoidal; inhalation/exhalation (I/E) ratio was 1:1. Following the completion of the assembly and the set, the nebulizer and the breathing simulator were switched on at the same time and also were paused simultaneously after 60 s. The drug deposited on the filter and filter holder was collected with deionized water/acetonitrile (3:1); then, a new fresh filter was placed, and the test was maintained until the preset nebulization time ran out. In the same way, the drug was collected and analyzed with the HPLC method. Finally, we divided the drug content collected from the first filter and filter device by 1 min to obtain the active drug delivery rate. The total active drug delivered was defined as the sum of the drug content in all filters.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3-pharmaceutics-12-00776">
      <title>3. Results</title>
      <sec id="sec3dot1-pharmaceutics-12-00776">
        <title>3.1. Physicochemical Compatibility</title>
        <p>The changes in pH value and osmolarity value of test samples over time are presented in <xref ref-type="fig" rid="pharmaceutics-12-00776-f001">Figure 1</xref>. The pH and osmolarity of admixtures seem to be a compromise value between the value of each component. Furthermore, for all admixtures, these two values showed a small variation that can be ignored within the 1 h testing time.</p>
        <p>The contents of active components in test samples remained basically stable within the accepted range of HPLC error compared with those at the initial time after mixing (T<sub>0</sub>), with the exception that the content of NAC in Atrovent<sup>&#xAE;</sup>/ Pulmicort<sup>&#xAE;</sup> showed a slight decrease after 0.5 h (<xref ref-type="fig" rid="pharmaceutics-12-00776-f002">Figure 2</xref>). The representative chromatograms of admixtures and single-drug preparations are presented in <xref ref-type="fig" rid="pharmaceutics-12-00776-f003">Figure 3</xref> and <xref ref-type="fig" rid="pharmaceutics-12-00776-f004">Figure 4</xref>. It needs to be explained that the drifting baselines in some of the chromatograms were occasioned by the steep gradient elution. Taking <xref ref-type="fig" rid="pharmaceutics-12-00776-f004">Figure 4</xref>C as an example, the gradient elution of separating ipratropium bromide and budesonide (see <xref rid="pharmaceutics-12-00776-t002" ref-type="table">Table 2</xref>) resulted in the drifting baseline at a short wavelength (<xref ref-type="fig" rid="pharmaceutics-12-00776-f004">Figure 4</xref>Ca, 210 nm) but no substantial change at the longer wavelength (<xref ref-type="fig" rid="pharmaceutics-12-00776-f004">Figure 4</xref>Cb, 246 nm). However, the drift at 210 nm did not interfere with the determination of ipratropium bromide. Similarly, the drifts caused by gradient elution could also be observed in <xref ref-type="fig" rid="pharmaceutics-12-00776-f003">Figure 3</xref>Fa and <xref ref-type="fig" rid="pharmaceutics-12-00776-f004">Figure 4</xref>Db. Except that the double peaks were assigned to the two isomers of budesonide at about 23 min in <xref ref-type="fig" rid="pharmaceutics-12-00776-f003">Figure 3</xref>Fa,c and <xref ref-type="fig" rid="pharmaceutics-12-00776-f004">Figure 4</xref>Ca, the rest of the unidentified peaks were solvent peaks.</p>
      </sec>
      <sec id="sec3dot2-pharmaceutics-12-00776">
        <title>3.2. Geometrical Particle Size Distribution</title>
        <p><xref rid="pharmaceutics-12-00776-t003" ref-type="table">Table 3</xref> shows that the X10 values of all test samples, including the single dose of each drug and the mixed inhalation solutions, were less than 2 &#x3BC;m; the X50 and VMD values were in the scope of 3 to 5 &#x3BC;m, and the X90 values ranged from 6 to 9 &#x3BC;m.</p>
      </sec>
      <sec id="sec3dot3-pharmaceutics-12-00776">
        <title>3.3. Aerosol Particle Size Distribution</title>
        <p>The FPD values of each active component in the mixed inhalation solutions were consistent with the values of the saline control groups but showed a statistically significant increase (<italic>p</italic> &lt; 0.05) compared with the single-drug preparations (<xref rid="pharmaceutics-12-00776-t004" ref-type="table">Table 4</xref> and <xref ref-type="fig" rid="pharmaceutics-12-00776-f005">Figure 5</xref>). On the other hand, the FPF and MMAD of admixtures remained unaffected in comparison with the two control groups, with the exception that the MMAD of budesonide exhibited a slight increase after mixing.</p>
      </sec>
      <sec id="sec3dot4-pharmaceutics-12-00776">
        <title>3.4. Active Drug Delivery Rate and Total Active Drug Delivered</title>
        <p>Based on the data presented in <xref rid="pharmaceutics-12-00776-t005" ref-type="table">Table 5</xref> and <xref ref-type="fig" rid="pharmaceutics-12-00776-f006">Figure 6</xref> and <xref ref-type="fig" rid="pharmaceutics-12-00776-f007">Figure 7</xref>, a significantly lower delivery rate and a higher amount of total active drug delivered were observed in admixtures compared with single-drug preparations. Additionally, no significant difference was found between admixtures and saline control groups in drug delivery characteristics.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec4-pharmaceutics-12-00776">
      <title>4. Discussion</title>
      <p>The administration of combined inhalation solutions is frequently used in the treatment of pulmonary diseases. At present, only a few publications have focused on the impact generated by simultaneous inhalation [<xref rid="B10-pharmaceutics-12-00776" ref-type="bibr">10</xref>,<xref rid="B12-pharmaceutics-12-00776" ref-type="bibr">12</xref>,<xref rid="B14-pharmaceutics-12-00776" ref-type="bibr">14</xref>,<xref rid="B29-pharmaceutics-12-00776" ref-type="bibr">29</xref>]. To our knowledge, this study is the first systematic one addressing the physicochemical compatibility and aerosol characteristics of Atrovent<sup>&#xAE;</sup> mixed with Ventolin<sup>&#xAE;</sup>, Bricanyl<sup>&#xAE;</sup>, Pulmicort<sup>&#xAE;</sup>, and Fluimucil<sup>&#xAE;</sup>.</p>
      <p>In our study, variations in pH and osmolality were regarded as evaluation indicators of physical compatibility. The pH values of admixtures, which fell into the suitable range for inhalation, were laid between those of single-drug preparations. There was little meaningful change in the pH value of mixed inhalation solution within the short period of 1 h. Although the pH values of admixtures were stable during the testing time, the results might be quite different for longer timescales. Several studies suggest that, due to the susceptibility of the ester linkage in ipratropium bromide to hydrolysis, a high-pH environment (pH &gt; 4) promotes the progress of hydrolysis of ipratropium bromide to tropic acid and a tropine derivative, leading to a more than 10% loss of ipratropium after 2 h [<xref rid="B30-pharmaceutics-12-00776" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-12-00776" ref-type="bibr">31</xref>]. Given this situation and the existing data, the mixed inhalation solutions, especially Atrovent<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup>, Atrovent<sup>&#xAE;</sup>/Fluimucil<sup>&#xAE;</sup>, and Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup>, should be used as soon as possible after mixing. Likewise, considering the slight decrease in NAC content, Atrovent<sup>&#xAE;</sup>/Fluimucil<sup>&#xAE;</sup> should be used immediately to avoid efficacy reduction. Similar trends to those of pH values were seen regarding osmotic pressure. Mixing with Atrovent<sup>&#xAE;</sup> decreased the osmolarity of Fluimucil<sup>&#xAE;</sup> to a more appropriate level, reducing the occurrence of tissue irritation and coughing related to inhalation of hyperosmotic solutions [<xref rid="B29-pharmaceutics-12-00776" ref-type="bibr">29</xref>]. Together with the experimental data on chemical compatibility, our work indicates that Atrovent<sup>&#xAE;</sup> is physiochemically stable with Ventolin<sup>&#xAE;</sup>, Bricanyl<sup>&#xAE;</sup>, Pulmicort<sup>&#xAE;</sup>, and Fluimucil<sup>&#xAE;</sup>.</p>
      <p>While physicochemical properties remain stable, simultaneous inhalation may alter the aerosol characteristics including particle size distribution, active drug delivery rate, and total active drug delivered. No major change was observed in the geometrical particle size distribution determined by the laser diffraction method. A slight decrease in X90 was observed in all mixtures in comparison with single-drug preparations. The FPD values of mixed inhalation solutions escalated markedly (<italic>p</italic> &lt; 0.05) compared to single-drug preparations. The obvious changes occurred because the total mass output by nebulization increased with the rinsing volume of inhalation solutions on account of the constant dead volume of the nebulization cup. This also corroborates the significant increase in total active drug delivered and the roughly unchanged FPF after mixing [<xref rid="B13-pharmaceutics-12-00776" ref-type="bibr">13</xref>,<xref rid="B32-pharmaceutics-12-00776" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-12-00776" ref-type="bibr">33</xref>]. The lower concentration resulting from mixing and the limited nebulization volume in a fixed time were the two factors that were attributed to the substantial decrease in active drug delivery rate of admixtures compared to single-drug preparations. Besides the above, the similar results between admixtures and the saline control groups confirmed that it was the solution volume, rather than the drug by itself or excipients in formulations, that influenced the aerosol characteristics.</p>
      <p>The present study has certain limitations. Firstly, an additional set of experiments should be executed to validate the results and further strengthen our conclusions. For instance, groups controlling excipients at working concentrations should be added to eliminate the effects of excipients. Meanwhile, the determinant role of solution volume in changing aerosol behavior could be confirmed by groups that keep solution volume constant for all mixture compositions. If the results of this experiment show that there is no significant difference in aerosol characteristics between relevant groups, this will support our conjecture. Secondly, since we believe that the dead volume of the nebulization cup has a great impact; different models or brands of nebulization devices with different dead volumes or different properties may produce different results in terms of aerosol parameters. Several studies have demonstrated that different nebulizer cups affect the character of the produced aerosol significantly, not only because of the dead volume but also because of the design and construction [<xref rid="B34-pharmaceutics-12-00776" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-12-00776" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-12-00776" ref-type="bibr">36</xref>].</p>
      <p>In conclusion, Atrovent<sup>&#xAE;</sup> is physically and chemically compatible with Ventolin<sup>&#xAE;</sup>, Bricanyl<sup>&#xAE;</sup>, Pulmicort<sup>&#xAE;</sup>, and Fluimucil<sup>&#xAE;</sup> and simultaneous inhalation is more efficient since the FPD and total active drug delivered increase.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors thank Maudie Carey at New York University and Yuxin Qiu at the University of Padua for their help in language polishing.</p>
    </ack>
    <notes>
      <title>Author Contributions</title>
      <p>Conceptualization, X.S. and Y.M.; investigation, Y.C. and S.D.; writing&#x2014;original draft preparation, Y.C. and S.D.; writing&#x2014;review and editing, Y.M.; validation, Z.Z., W.H., E.L. and R.W. All authors have read and agreed to the published version of the manuscript.</p>
    </notes>
    <notes>
      <title>Funding</title>
      <p>This work was supported by grants from the National Natural Science Foundation of China (81773201), Development Project of Shanghai Peak Disciplines&#x2014;Integrative Medicine (20180101), and the Flexible Talent Program in Xinjiang province.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-pharmaceutics-12-00776">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Finlay</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Nebulizers for drug delivery to the lungs</article-title>
          <source>Expert Opin. Drug Deliv.</source>
          <year>2015</year>
          <volume>12</volume>
          <fpage>889</fpage>
          <lpage>900</lpage>
          <pub-id pub-id-type="doi">10.1517/17425247.2015.995087</pub-id>
          <pub-id pub-id-type="pmid">25534396</pub-id>
        </element-citation>
      </ref>
      <ref id="B2-pharmaceutics-12-00776">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patton</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Fishburn</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Weers</surname>
              <given-names>J.G.</given-names>
            </name>
          </person-group>
          <article-title>The lungs as a portal of entry for systemic drug delivery</article-title>
          <source>Proc. Am. Thorac. Soc.</source>
          <year>2004</year>
          <volume>1</volume>
          <fpage>338</fpage>
          <lpage>344</lpage>
          <pub-id pub-id-type="doi">10.1513/pats.200409-049TA</pub-id>
          <pub-id pub-id-type="pmid">16113455</pub-id>
        </element-citation>
      </ref>
      <ref id="B3-pharmaceutics-12-00776">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Currie</surname>
              <given-names>G.P.</given-names>
            </name>
            <name>
              <surname>Lipworth</surname>
              <given-names>B.J.</given-names>
            </name>
          </person-group>
          <article-title>Inhaled treatment for chronic obstructive pulmonary disease: What&#x2019;s new and how does it fit?</article-title>
          <source>QJM</source>
          <year>2016</year>
          <volume>109</volume>
          <fpage>505</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="doi">10.1093/qjmed/hcv212</pub-id>
          <pub-id pub-id-type="pmid">26559079</pub-id>
        </element-citation>
      </ref>
      <ref id="B4-pharmaceutics-12-00776">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mirza</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Clay</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Koslow</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Scanlon</surname>
              <given-names>P.D.</given-names>
            </name>
          </person-group>
          <article-title>COPD Guidelines: A Review of the 2018 GOLD Report</article-title>
          <source>Mayo Clin. Proc.</source>
          <year>2018</year>
          <volume>93</volume>
          <fpage>1488</fpage>
          <lpage>1502</lpage>
          <pub-id pub-id-type="doi">10.1016/j.mayocp.2018.05.026</pub-id>
          <pub-id pub-id-type="pmid">30286833</pub-id>
        </element-citation>
      </ref>
      <ref id="B5-pharmaceutics-12-00776">
        <label>5.</label>
        <element-citation publication-type="web">
          <article-title>GOLD: Global Initiative for Chronic Obstructive Lung Disease</article-title>
          <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://goldcopd.org/gold-reports/">https://goldcopd.org/gold-reports/</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2020-04-03">(accessed on 3 April 2020)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B6-pharmaceutics-12-00776">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aziz</surname>
              <given-names>M.I.A.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>L.E.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Chua</surname>
              <given-names>G.S.W.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>P.T.</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: A systematic review and network meta-analysis</article-title>
          <source>Int. J. Chronic Obstr. Pulm. Dis.</source>
          <year>2018</year>
          <volume>13</volume>
          <fpage>3203</fpage>
          <lpage>3231</lpage>
          <pub-id pub-id-type="doi">10.2147/COPD.S173472</pub-id>
          <pub-id pub-id-type="pmid">30349228</pub-id>
        </element-citation>
      </ref>
      <ref id="B7-pharmaceutics-12-00776">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sion</surname>
              <given-names>K.Y.J.</given-names>
            </name>
            <name>
              <surname>Huisman</surname>
              <given-names>E.L.</given-names>
            </name>
            <name>
              <surname>Punekar</surname>
              <given-names>Y.S.</given-names>
            </name>
            <name>
              <surname>Naya</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Ismaila</surname>
              <given-names>A.S.</given-names>
            </name>
          </person-group>
          <article-title>A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting beta2-Agonist (LABA) Combinations in COPD</article-title>
          <source>Pulm. Ther.</source>
          <year>2017</year>
          <volume>3</volume>
          <fpage>297</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="doi">10.1007/s41030-017-0048-0</pub-id>
          <pub-id pub-id-type="pmid">32026346</pub-id>
        </element-citation>
      </ref>
      <ref id="B8-pharmaceutics-12-00776">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cazzola</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Page</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Calzetta</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Matera</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>Pharmacology and therapeutics of bronchodilators</article-title>
          <source>Pharmacol. Rev.</source>
          <year>2012</year>
          <volume>64</volume>
          <fpage>450</fpage>
          <lpage>504</lpage>
          <pub-id pub-id-type="doi">10.1124/pr.111.004580</pub-id>
          <pub-id pub-id-type="pmid">22611179</pub-id>
        </element-citation>
      </ref>
      <ref id="B9-pharmaceutics-12-00776">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Calzetta</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Di Marco</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Blasi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Cazzola</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Centanni</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Micheletto</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rogliani</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis</article-title>
          <source>Pulm. Pharmacol. Ther.</source>
          <year>2019</year>
          <volume>59</volume>
          <fpage>101855</fpage>
          <pub-id pub-id-type="doi">10.1016/j.pupt.2019.101855</pub-id>
          <pub-id pub-id-type="pmid">31639476</pub-id>
        </element-citation>
      </ref>
      <ref id="B10-pharmaceutics-12-00776">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kamin</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Schwabe</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Inhalation solutions: Which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers</article-title>
          <source>J. Cyst. Fibros.</source>
          <year>2006</year>
          <volume>5</volume>
          <fpage>205</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcf.2006.03.007</pub-id>
          <pub-id pub-id-type="pmid">16678502</pub-id>
        </element-citation>
      </ref>
      <ref id="B11-pharmaceutics-12-00776">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burchett</surname>
              <given-names>D.K.</given-names>
            </name>
            <name>
              <surname>Darko</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Zahra</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Noviasky</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Probst</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Mixing and compatibility guide for commonly used aerosolized medications</article-title>
          <source>Am. J. Health Syst. Pharm.</source>
          <year>2010</year>
          <volume>67</volume>
          <fpage>227</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="doi">10.2146/ajhp080261</pub-id>
          <pub-id pub-id-type="pmid">20101066</pub-id>
        </element-citation>
      </ref>
      <ref id="B12-pharmaceutics-12-00776">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mohammed Abdul</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Beng</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Aerosol Characteristics and Physico-Chemical Compatibility of Combivent((R)) (Containing Salbutamol and Ipratropium Bromide) Mixed with Three Other Inhalants: Budesonide, Beclomethasone or N-Acetylcysteine</article-title>
          <source>Pharmaceutics</source>
          <year>2020</year>
          <volume>12</volume>
          <elocation-id>78</elocation-id>
          <pub-id pub-id-type="doi">10.3390/pharmaceutics12010078</pub-id>
          <pub-id pub-id-type="pmid">31963493</pub-id>
        </element-citation>
      </ref>
      <ref id="B13-pharmaceutics-12-00776">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akapo</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>McCrea</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Roach</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions</article-title>
          <source>Ann. Pharmacother.</source>
          <year>2008</year>
          <volume>42</volume>
          <fpage>1416</fpage>
          <lpage>1424</lpage>
          <pub-id pub-id-type="doi">10.1345/aph.1L273</pub-id>
          <pub-id pub-id-type="pmid">18780805</pub-id>
        </element-citation>
      </ref>
      <ref id="B14-pharmaceutics-12-00776">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Itazawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Adachi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Higuchi</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Mochizuki</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Shimojo</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol</article-title>
          <source>Allergol. Int.</source>
          <year>2013</year>
          <volume>62</volume>
          <fpage>131</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="doi">10.2332/allergolint.12-OA-0482</pub-id>
          <pub-id pub-id-type="pmid">23348859</pub-id>
        </element-citation>
      </ref>
      <ref id="B15-pharmaceutics-12-00776">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kramer</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Schwabe</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lichtinghagen</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kamin</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol</article-title>
          <source>Pharm. Sci.</source>
          <year>2007</year>
          <volume>62</volume>
          <fpage>760</fpage>
          <lpage>766</lpage>
        </element-citation>
      </ref>
      <ref id="B16-pharmaceutics-12-00776">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Desager</surname>
              <given-names>K.N.</given-names>
            </name>
            <name>
              <surname>Van Bever</surname>
              <given-names>H.P.</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>W.J.</given-names>
            </name>
          </person-group>
          <article-title>Osmolality and pH of anti-asthmatic drug solutions</article-title>
          <source>Agents Actions</source>
          <year>1990</year>
          <volume>31</volume>
          <fpage>225</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="doi">10.1007/BF01997612</pub-id>
          <pub-id pub-id-type="pmid">2150739</pub-id>
        </element-citation>
      </ref>
      <ref id="B17-pharmaceutics-12-00776">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lowry</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Higenbottam</surname>
              <given-names>T.W.</given-names>
            </name>
          </person-group>
          <article-title>Effects of pH and osmolarity on aerosol-induced cough in normal volunteers</article-title>
          <source>Clin. Sci. (Lond.)</source>
          <year>1988</year>
          <volume>74</volume>
          <fpage>373</fpage>
          <lpage>376</lpage>
          <pub-id pub-id-type="doi">10.1042/cs0740373</pub-id>
          <pub-id pub-id-type="pmid">3356109</pub-id>
        </element-citation>
      </ref>
      <ref id="B18-pharmaceutics-12-00776">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chrystyn</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Anatomy and physiology in delivery: Can we define our targets?</article-title>
          <source>Allergy</source>
          <year>1999</year>
          <volume>54</volume>
          <issue>Suppl. 49</issue>
          <fpage>82</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1398-9995.1999.tb04393.x</pub-id>
        </element-citation>
      </ref>
      <ref id="B19-pharmaceutics-12-00776">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Usmani</surname>
              <given-names>O.S.</given-names>
            </name>
            <name>
              <surname>Biddiscombe</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size</article-title>
          <source>Am. J. Respir. Crit. Care Med.</source>
          <year>2005</year>
          <volume>172</volume>
          <fpage>1497</fpage>
          <lpage>1504</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.200410-1414OC</pub-id>
          <pub-id pub-id-type="pmid">16192448</pub-id>
        </element-citation>
      </ref>
      <ref id="B20-pharmaceutics-12-00776">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nikander</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>von Hollen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Larhrib</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The size and behavior of the human upper airway during inhalation of aerosols</article-title>
          <source>Expert Opin. Drug Deliv.</source>
          <year>2017</year>
          <volume>14</volume>
          <fpage>621</fpage>
          <lpage>630</lpage>
          <pub-id pub-id-type="doi">10.1080/17425247.2016.1227780</pub-id>
          <pub-id pub-id-type="pmid">27547842</pub-id>
        </element-citation>
      </ref>
      <ref id="B21-pharmaceutics-12-00776">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>Y.S.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of pharmaceutical aerosol deposition in the respiratory tract</article-title>
          <source>AAPS PharmSciTech</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>630</fpage>
          <lpage>640</lpage>
          <pub-id pub-id-type="doi">10.1208/s12249-014-0092-0</pub-id>
          <pub-id pub-id-type="pmid">24563174</pub-id>
        </element-citation>
      </ref>
      <ref id="B22-pharmaceutics-12-00776">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lip Kwok</surname>
              <given-names>P.C.</given-names>
            </name>
          </person-group>
          <article-title>Electrostatics of Pharmaceutical Aerosols for Pulmonary Delivery</article-title>
          <source>Curr. Pharm. Des.</source>
          <year>2015</year>
          <volume>21</volume>
          <fpage>3945</fpage>
          <lpage>3954</lpage>
          <pub-id pub-id-type="doi">10.2174/1381612821666150820110407</pub-id>
          <pub-id pub-id-type="pmid">26290198</pub-id>
        </element-citation>
      </ref>
      <ref id="B23-pharmaceutics-12-00776">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berg</surname>
              <given-names>E.B.</given-names>
            </name>
            <name>
              <surname>Picard</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns</article-title>
          <source>Respir. Care</source>
          <year>2009</year>
          <volume>54</volume>
          <fpage>1671</fpage>
          <lpage>1678</lpage>
          <pub-id pub-id-type="pmid">19961633</pub-id>
        </element-citation>
      </ref>
      <ref id="B24-pharmaceutics-12-00776">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Boer</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Gjaltema</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hagedoorn</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Frijlink</surname>
              <given-names>H.W.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of inhalation aerosols: A critical evaluation of cascade impactor analysis and laser diffraction technique</article-title>
          <source>Int. J. Pharm.</source>
          <year>2002</year>
          <volume>249</volume>
          <fpage>219</fpage>
          <lpage>231</lpage>
          <pub-id pub-id-type="doi">10.1016/S0378-5173(02)00526-4</pub-id>
          <pub-id pub-id-type="pmid">12433450</pub-id>
        </element-citation>
      </ref>
      <ref id="B25-pharmaceutics-12-00776">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melani</surname>
              <given-names>A.S.</given-names>
            </name>
          </person-group>
          <article-title>Effects on aerosol performance of mixing of either budesonide or beclomethasone dipropionate with albuterol and ipratropium bromide</article-title>
          <source>Respir. Care</source>
          <year>2011</year>
          <volume>56</volume>
          <fpage>319</fpage>
          <lpage>326</lpage>
          <pub-id pub-id-type="doi">10.4187/respcare.00955</pub-id>
          <pub-id pub-id-type="pmid">21255509</pub-id>
        </element-citation>
      </ref>
      <ref id="B26-pharmaceutics-12-00776">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ejiofor</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Pharmacotherapies for COPD</article-title>
          <source>Clin. Med. Insights Circ. Respir. Pulm. Med.</source>
          <year>2013</year>
          <volume>7</volume>
          <fpage>17</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.4137/CCRPM.S7211</pub-id>
          <pub-id pub-id-type="pmid">23700381</pub-id>
        </element-citation>
      </ref>
      <ref id="B27-pharmaceutics-12-00776">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albertson</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Chenoweth</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Murin</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS)</article-title>
          <source>Expert Opin. Pharmacother.</source>
          <year>2020</year>
          <volume>21</volume>
          <fpage>213</fpage>
          <lpage>231</lpage>
          <pub-id pub-id-type="doi">10.1080/14656566.2019.1701656</pub-id>
          <pub-id pub-id-type="pmid">31955671</pub-id>
        </element-citation>
      </ref>
      <ref id="B28-pharmaceutics-12-00776">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Appleton</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Poole</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Pilotto</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lasserson</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Muhammad</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease</article-title>
          <source>Cochrane Database Syst. Rev.</source>
          <year>2006</year>
          <pub-id pub-id-type="doi">10.1002/14651858.CD006101</pub-id>
        </element-citation>
      </ref>
      <ref id="B29-pharmaceutics-12-00776">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonasia</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ong</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs</article-title>
          <source>Curr. Med. Res. Opin.</source>
          <year>2007</year>
          <volume>23</volume>
          <fpage>2477</fpage>
          <lpage>2483</lpage>
          <pub-id pub-id-type="doi">10.1185/030079907X233106</pub-id>
          <pub-id pub-id-type="pmid">17784997</pub-id>
        </element-citation>
      </ref>
      <ref id="B30-pharmaceutics-12-00776">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kasawar</surname>
              <given-names>G.B.</given-names>
            </name>
            <name>
              <surname>Farooqui</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Development and validation of a stability indicating RP-HPLC method for the simultaneous determination of related substances of albuterol sulfate and ipratropium bromide in nasal solution</article-title>
          <source>J. Pharm. Biomed. Anal.</source>
          <year>2010</year>
          <volume>52</volume>
          <fpage>19</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpba.2009.11.026</pub-id>
          <pub-id pub-id-type="pmid">20045275</pub-id>
        </element-citation>
      </ref>
      <ref id="B31-pharmaceutics-12-00776">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>T.Y.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C.N.</given-names>
            </name>
            <name>
              <surname>Chiang</surname>
              <given-names>Y.C.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H.Y.</given-names>
            </name>
          </person-group>
          <article-title>Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium</article-title>
          <source>Am. J. Health Syst. Pharm.</source>
          <year>2005</year>
          <volume>62</volume>
          <fpage>828</fpage>
          <lpage>833</lpage>
          <pub-id pub-id-type="doi">10.1093/ajhp/62.8.828</pub-id>
          <pub-id pub-id-type="pmid">15821276</pub-id>
        </element-citation>
      </ref>
      <ref id="B32-pharmaceutics-12-00776">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nikander</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Denyer</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Smaldone</surname>
              <given-names>G.C.</given-names>
            </name>
          </person-group>
          <article-title>Effects of equipment dead space and pediatric breathing patterns on inhaled mass of nebulized budesonide</article-title>
          <source>J. Aerosol Med.</source>
          <year>1999</year>
          <volume>12</volume>
          <fpage>67</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="doi">10.1089/jam.1999.12.67</pub-id>
          <pub-id pub-id-type="pmid">10539709</pub-id>
        </element-citation>
      </ref>
      <ref id="B33-pharmaceutics-12-00776">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hess</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Pooler</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kacmarek</surname>
              <given-names>R.M.</given-names>
            </name>
          </person-group>
          <article-title>Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand</article-title>
          <source>Chest</source>
          <year>1996</year>
          <volume>110</volume>
          <fpage>498</fpage>
          <lpage>505</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.110.2.498</pub-id>
          <pub-id pub-id-type="pmid">8697857</pub-id>
        </element-citation>
      </ref>
      <ref id="B34-pharmaceutics-12-00776">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Beng</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Ke</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Effects of flow pattern, device and formulation on particle size distribution of nebulized aerosol</article-title>
          <source>Int. J. Pharm.</source>
          <year>2019</year>
          <volume>560</volume>
          <fpage>35</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.01.025</pub-id>
          <pub-id pub-id-type="pmid">30664994</pub-id>
        </element-citation>
      </ref>
      <ref id="B35-pharmaceutics-12-00776">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walz-Jung</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Kamin</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Drug Output and Aerosol Characteristics of Different Jet Nebulisers for Adults While Simulating the Nebulisation of Salbutamol</article-title>
          <source>Pneumologie</source>
          <year>2018</year>
          <volume>72</volume>
          <fpage>820</fpage>
          <lpage>831</lpage>
          <pub-id pub-id-type="doi">10.1055/a-0749-5520</pub-id>
          <pub-id pub-id-type="pmid">30453377</pub-id>
        </element-citation>
      </ref>
      <ref id="B36-pharmaceutics-12-00776">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ochowiak</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Matuszak</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wlodarczak</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>The analysis of pneumatic atomization of Newtonian and non-Newtonian fluids for different medical nebulizers</article-title>
          <source>Drug Dev. Ind. Pharm.</source>
          <year>2017</year>
          <volume>43</volume>
          <fpage>1999</fpage>
          <lpage>2010</lpage>
          <pub-id pub-id-type="doi">10.1080/03639045.2017.1358274</pub-id>
          <pub-id pub-id-type="pmid">28737431</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="pharmaceutics-12-00776-f001" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>The pH value (<bold>A</bold>) and osmolarity value (<bold>B</bold>) of test samples over time. Experiments were replicated 5 times.</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00776-g001"/>
    </fig>
    <fig id="pharmaceutics-12-00776-f002" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p>The content of active components in single dose of each drug (<bold>A</bold>), binary admixtures (<bold>B</bold>), and ternary admixtures (<bold>C</bold>) over time (mean &#xB1; s.d. shown). <italic>n</italic> = 5 in each group. * <italic>p</italic> &lt; 0.05 with analysis of variance (ANOVA), ** <italic>p</italic> &lt; 0.01 with ANOVA. Abbreviations: Ipra&#x2014;ipratropium bromide; Sal&#x2014;salbutamol sulfate; Ter&#x2014;terbutaline sulfate; Bud&#x2014;budesonide; NAC&#x2014;N-acetylcysteine; A<sup>&#xAE;</sup>/V<sup>&#xAE;</sup>&#x2014;Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup>; A<sup>&#xAE;</sup>/B<sup>&#xAE;</sup>&#x2014;Atrovent<sup>&#xAE;</sup>/Bricanyl<sup>&#xAE;</sup>; A<sup>&#xAE;/</sup>P<sup>&#xAE;</sup>&#x2014;Atrovent<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup>; A<sup>&#xAE;</sup>/F<sup>&#xAE;</sup>&#x2014;Atrovent<sup>&#xAE;</sup>/ Fluimucil<sup>&#xAE;</sup>; A<sup>&#xAE;</sup>/V<sup>&#xAE;</sup>/P<sup>&#xAE;</sup>&#x2014;Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup>.</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00776-g002"/>
    </fig>
    <fig id="pharmaceutics-12-00776-f003" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <p>HPLC chromatograms of (<bold>A</bold>) Atrovent<sup>&#xAE;</sup> (210 nm), (<bold>B</bold>) Ventolin<sup>&#xAE;</sup> (276 nm), (<bold>C</bold>) Bricanyl<sup>&#xAE;</sup> (276 nm), (<bold>D</bold>) Pulmicort<sup>&#xAE;</sup> (246 nm), (<bold>E</bold>) Fluimucil<sup>&#xAE;</sup> (214 nm), and (<bold>F</bold>) Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup> ((<bold>a</bold>) 210 nm for ipratropium bromide, (<bold>b</bold>) 246 nm for budesonide, and (<bold>c</bold>) 276 nm for salbutamol sulfate)).</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00776-g003"/>
    </fig>
    <fig id="pharmaceutics-12-00776-f004" orientation="portrait" position="float">
      <label>Figure 4</label>
      <caption>
        <p>HPLC chromatograms of (<bold>A</bold>) Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup> ((<bold>a</bold>) 210 nm for ipratropium bromide, (<bold>b</bold>) 276 nm for salbutamol sulfate)), (<bold>B</bold>) Atrovent<sup>&#xAE;</sup>/ Bricanyl<sup>&#xAE;</sup> ((<bold>a</bold>) 210 nm for ipratropium bromide, (<bold>b</bold>) 276 nm for terbutaline sulfate)), (<bold>C</bold>) Atrovent<sup>&#xAE;</sup>/ Pulmicort<sup>&#xAE;</sup> ((<bold>a</bold>) 210 nm for ipratropium bromide, (<bold>b</bold>) 246 nm for budesonide)), and (<bold>D</bold>) Atrovent<sup>&#xAE;</sup>/ Fluimucil<sup>&#xAE;</sup> ((<bold>a</bold>) 210 nm for ipratropium bromide, (<bold>b</bold>) 214 nm for NAC)).</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00776-g004"/>
    </fig>
    <fig id="pharmaceutics-12-00776-f005" orientation="portrait" position="float">
      <label>Figure 5</label>
      <caption>
        <p>The FPD of ipratropium bromide (<bold>A</bold>), salbutamol sulfate (<bold>B</bold>), terbutaline sulfate (<bold>C</bold>), budesonide (<bold>D</bold>), and NAC (<bold>E</bold>) in admixtures or single-drug preparations. Results are shown as mean &#xB1; standard deviation (<italic>n</italic> = 5). Statistical calculations were performed using ANOVA multiple comparison. * and ** indicate <italic>p</italic> &lt; 0.05 and <italic>p</italic> &lt; 0.01.</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00776-g005"/>
    </fig>
    <fig id="pharmaceutics-12-00776-f006" orientation="portrait" position="float">
      <label>Figure 6</label>
      <caption>
        <p>Active drug delivery rate of ipratropium bromide (<bold>A</bold>), salbutamol sulfate (<bold>B</bold>), terbutaline sulfate (<bold>C</bold>), budesonide (<bold>D</bold>), and NAC (<bold>E</bold>) in admixtures or single-drug preparations. Results are shown as mean &#xB1; standard deviation (<italic>n</italic> = 5) analyzed via ANOVA. * and ** indicate <italic>p</italic> &lt; 0.05 and <italic>p</italic> &lt; 0.01.</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00776-g006"/>
    </fig>
    <fig id="pharmaceutics-12-00776-f007" orientation="portrait" position="float">
      <label>Figure 7</label>
      <caption>
        <p>Total active drug delivered of ipratropium bromide (<bold>A</bold>), salbutamol sulfate (<bold>B</bold>), terbutaline sulfate (<bold>C</bold>), budesonide (<bold>D</bold>), and NAC (<bold>E</bold>) in admixtures or single-drug preparations. Results are shown as mean &#xB1; standard deviation (<italic>n</italic> = 5). * and ** indicate <italic>p</italic> &lt; 0.05 and <italic>p</italic> &lt; 0.01 by ANOVA.</p>
      </caption>
      <graphic xlink:href="pharmaceutics-12-00776-g007"/>
    </fig>
    <table-wrap id="pharmaceutics-12-00776-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">pharmaceutics-12-00776-t001_Table 1</object-id>
      <label>Table 1</label>
      <caption>
        <p>Volume and nebulization times of all samples.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Samples</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Volume (mL)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nebulization Time (min)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Ventolin<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">9</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Bricanyl<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">8</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Fluimucil<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">10</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">13</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/Bricanyl<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">13</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">14</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/Fluimucil<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">14</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="pharmaceutics-12-00776-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">pharmaceutics-12-00776-t002_Table 2</object-id>
      <label>Table 2</label>
      <caption>
        <p>Chromatographic parameters.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Admixtures</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Components</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ratio of Mobile Phase (A/B) by Volume</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Injection Volume (&#x3BC;L)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Run Time (min)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Detection Wavelength<break/>(nm)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75/25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ventolin<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75/25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">276</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bricanyl<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">terbutaline sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75/25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">276</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62/38</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluimucil<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91/9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">214</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">75/25</td>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">80</td>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">7.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">276</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Bricanyl<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">75/25</td>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">80</td>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">7.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">terbutaline sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">276</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0 min 75/25<break/>8 min 75/25<break/>12 min 55/45<break/>16.5 min 55/45<break/>19.5 min 65/35</td>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">80</td>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Fluimucil<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75/25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 min 91/9<break/>5 min 91/9<break/>12 min 40/60</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">214</td>
          </tr>
          <tr>
            <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0 min 75/25<break/>8 min 75/25<break/>12 min 55/45<break/>16.5 min 55/45<break/>19.5 min 65/35</td>
            <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">80</td>
            <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">276</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">246</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Abbreviation: NAC, <italic>N</italic>-acetylcysteine.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="pharmaceutics-12-00776-t003" orientation="portrait" position="float">
      <object-id pub-id-type="pii">pharmaceutics-12-00776-t003_Table 3</object-id>
      <label>Table 3</label>
      <caption>
        <p>X10, X50, X90, and VMD of test samples.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Samples</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">X10<break/>(&#x3BC;m)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">X50<break/>(&#x3BC;m)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">X90<break/>(&#x3BC;m)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">VMD<break/>(&#x3BC;m)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.67 &#xB1; 0.20</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.19 &#xB1; 0.08</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.01 &#xB1; 0.17</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.26 &#xB1; 0.14</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Ventolin<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.68 &#xB1; 0.11</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.32 &#xB1; 0.13</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.75 &#xB1; 0.16</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.24 &#xB1; 0.05</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Bricanyl<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.66 &#xB1; 0.06</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.40 &#xB1; 0.05</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.64 &#xB1; 0.18</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.55 &#xB1; 0.08</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.87 &#xB1; 0.09</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.37 &#xB1; 0.02</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">7.19 &#xB1; 0.17</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.97 &#xB1; 0.07</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Fluimucil<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.54 &#xB1; 0.13</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.03 &#xB1; 0.09</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.69 &#xB1; 0.11</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.18 &#xB1; 0.11</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.69 &#xB1; 0.10</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.93 &#xB1; 0.04</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.25 &#xB1; 0.16</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.95 &#xB1; 0.16</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/Bricanyl<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.68 &#xB1; 0.11</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.10 &#xB1; 0.12</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.82 &#xB1; 0.09</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.20 &#xB1; 0.04</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.73 &#xB1; 0.07</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.02 &#xB1; 0.18</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.38 &#xB1; 0.04</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.03 &#xB1; 0.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/Fluimucil<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" rowspan="1" colspan="1">1.55 &#xB1; 0.15</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">3.95 &#xB1; 0.08</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">6.89 &#xB1; 0.17</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">4.10 &#xB1; 0.13</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.70 &#xB1; 0.11</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.09 &#xB1; 0.13</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.61 &#xB1; 0.09</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.13 &#xB1; 0.12</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Results are shown as mean &#xB1; standard deviation (<italic>n</italic> = 5). Abbreviation: VMD, volume median droplet diameter.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="pharmaceutics-12-00776-t004" orientation="portrait" position="float">
      <object-id pub-id-type="pii">pharmaceutics-12-00776-t004_Table 4</object-id>
      <label>Table 4</label>
      <caption>
        <p>FPD, FPF, and MMAD of test samples.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Samples</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Components</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FPD <sup>1</sup></th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FPF<break/>(%)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MMAD<break/>(&#x3BC;m)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.98 &#xB1; 0.28</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66.40 &#xB1; 1.01</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.07 &#xB1; 0.11</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ventolin<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">856.07 &#xB1; 16.23</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.90 &#xB1; 1.40</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.12 &#xB1; 0.13</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bricanyl<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">terbutaline sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1004.28 &#xB1; 9.35</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.33 &#xB1; 2.27</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.82 &#xB1; 0.20</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">193.14 &#xB1; 19.80</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.65 &#xB1; 1.77</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.06 &#xB1; 0.16</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluimucil<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.91 &#xB1; 11.04</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.38 &#xB1; 7.21</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.44 &#xB1; 0.58</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/2.5 mL saline</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.72 &#xB1; 6.37</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63.92 &#xB1; 2.49</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.39 &#xB1; 0.03</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ventolin<sup>&#xAE;</sup>/2 mL saline</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1934.29 &#xB1; 103.40</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63.02 &#xB1; 1.25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.42 &#xB1; 0.18</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bricanyl<sup>&#xAE;</sup>/2 mL saline</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">terbutaline sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1630.02 &#xB1; 180.39</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.32 &#xB1; 1.96</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.28 &#xB1; 0.28</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmicort<sup>&#xAE;</sup>/2 mL saline</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">282.29 &#xB1; 27.93</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46.20 &#xB1; 3.05</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.30 &#xB1; 0.84</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluimucil<sup>&#xAE;</sup>/2 mL saline</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120.83 &#xB1; 4.07</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.40 &#xB1; 2.04</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.38 &#xB1; 0.06</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.23 &#xB1; 6.37</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.54 &#xB1; 1.80</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.15 &#xB1; 0.06</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2112.95 &#xB1; 217.01</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.27 &#xB1; 0.98</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.18 &#xB1; 0.07</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Bricanyl<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.28 &#xB1; 0.17</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.71 &#xB1; 0.04</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.63 &#xB1; 0.02</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">terbutaline sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1491.85 &#xB1; 276.90</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.79 &#xB1; 2.80</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.46 &#xB1; 0.17</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.90 &#xB1; 25.08</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.50 &#xB1; 8.94</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.89 &#xB1; 0.77</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">274.23 &#xB1; 23.13</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.01 &#xB1; 4.91</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.45 &#xB1; 0.49</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Fluimucil<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.17 &#xB1; 5.81</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54.73 &#xB1; 1.30</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.48 &#xB1; 0.15</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111.61 &#xB1; 2.86</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.39 &#xB1; 1.64</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.55 &#xB1; 0.17</td>
          </tr>
          <tr>
            <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120.16 &#xB1; 4.18</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.97 &#xB1; 5.32</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.68 &#xB1; 0.43</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2359.09 &#xB1; 198.30</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.66 &#xB1; 4.23</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.68 &#xB1; 0.33</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">279.87 &#xB1; 10.79</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.78 &#xB1; 1.76</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.29 &#xB1; 0.27</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p><sup>1</sup> Concentrations of FPD are mg for Fluimucil<sup>&#xAE;</sup>, Fluimucil<sup>&#xAE;</sup>/2 mL saline, and Atrovent<sup>&#xAE;</sup>/Fluimucil<sup>&#xAE;</sup> and &#x3BC;g for all other groups. Results are shown as mean &#xB1; standard deviation (<italic>n</italic> = 5). Abbreviations: FPD, fine particle dose; FPF, fine particle fraction; MMAD, mass medium aerodynamic diameter.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="pharmaceutics-12-00776-t005" orientation="portrait" position="float">
      <object-id pub-id-type="pii">pharmaceutics-12-00776-t005_Table 5</object-id>
      <label>Table 5</label>
      <caption>
        <p>Active drug delivery rate and total active drug delivered of test samples.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Samples</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Components</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Drug Delivery Rate <sup>1</sup></th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total Active Drug Delivered <sup>2</sup></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.43 &#xB1; 3.30</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.34 &#xB1; 14.37</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ventolin<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">218 &#xB1; 38.50</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1201.00 &#xB1; 56.20</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bricanyl<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">terbutaline sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">237.96 &#xB1; 29.20</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1084.73 &#xB1; 95.26</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.27 &#xB1; 2.33</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">190.46 &#xB1; 14.13</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluimucil<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.39 &#xB1; 0.35</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.14 &#xB1; 1.91</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atrovent<sup>&#xAE;</sup>/2.5 mL saline</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.93 &#xB1; 0.92</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.39 &#xB1; 8.92</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ventolin<sup>&#xAE;</sup>/2 mL saline</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120.37 &#xB1; 3.24</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1830.47 &#xB1; 72.39</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bricanyl<sup>&#xAE;</sup>/2 mL saline</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">terbutaline sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109.49 &#xB1; 7.34</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1640.28 &#xB1; 50.76</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmicort<sup>&#xAE;</sup>/2 mL saline</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.57 &#xB1; 2.78</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">237.33 &#xB1; 27.07</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluimucil<sup>&#xAE;</sup>/2 mL saline</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.04 &#xB1; 0.53</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86.99 &#xB1; 9.67</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.05 &#xB1; 0.36</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.32 &#xB1; 13.57</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113.53 &#xB1; 10.27</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1936 &#xB1; 53.87</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Bricanyl<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.83 &#xB1; 0.80</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102.22 &#xB1; 11.48</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">terbutaline sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.41 &#xB1; 9.29</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1694.74 &#xB1; 29.66</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.58 &#xB1; 1.14</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104.27 &#xB1; 20.94</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.74 &#xB1; 0.44</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">237.87 &#xB1; 35.50</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Fluimucil<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.73 &#xB1; 0.29</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83.39 &#xB1; 16.60</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.93 &#xB1; 0.91</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.02 &#xB1; 16.09</td>
          </tr>
          <tr>
            <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Atrovent<sup>&#xAE;</sup>/Ventolin<sup>&#xAE;</sup>/Pulmicort<sup>&#xAE;</sup></td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ipratropium bromide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.55 &#xB1; 1.84</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.90 &#xB1; 15.32</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">salbutamol sulfate</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.01 &#xB1; 37.75</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1981.51 &#xB1; 283.01</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">budesonide</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.76 &#xB1; 4.77</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">277.82 &#xB1; 19.42</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p><sup>1</sup> Concentrations are mg/min for Fluimucil<sup>&#xAE;</sup>, Fluimucil<sup>&#xAE;</sup>/2 mL saline, and Atrovent<sup>&#xAE;</sup>/ Fluimucil<sup>&#xAE;</sup> and &#x3BC;g/min for all other groups. <sup>2</sup> Concentrations are mg for Fluimucil<sup>&#xAE;</sup>, Fluimucil<sup>&#xAE;</sup>/2 mL saline, and Atrovent<sup>&#xAE;</sup>/ Fluimucil<sup>&#xAE;</sup> and &#x3BC;g for all other groups. Results are shown as mean &#xB1; standard deviation (<italic>n</italic> = 5). </p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Dermatol Ther</journal-id>
      <journal-id journal-id-type="iso-abbrev">Dermatol Ther</journal-id>
      <journal-id journal-id-type="doi">10.1111/(ISSN)1529-8019</journal-id>
      <journal-id journal-id-type="publisher-id">DTH</journal-id>
      <journal-title-group>
        <journal-title>Dermatologic Therapy</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1396-0296</issn>
      <issn pub-type="epub">1529-8019</issn>
      <publisher>
        <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
        <publisher-loc>Hoboken, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32358890</article-id>
      <article-id pub-id-type="pmc">7262017</article-id>
      <article-id pub-id-type="doi">10.1111/dth.13476</article-id>
      <article-id pub-id-type="publisher-id">DTH13476</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Special Issue Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Special Issue Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cutaneous s&#x131;de&#x2010;effects of the potential <styled-content style="fixed-case" toggle="no">COVID&#x2010;19</styled-content> drugs</article-title>
        <alt-title alt-title-type="left-running-head">T&#xFC;rsen et al.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="dth13476-cr-0001" contrib-type="author" corresp="yes">
          <name>
            <surname>T&#xFC;rsen</surname>
            <given-names>&#xDC;mit</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5807-6759</contrib-id>
          <xref ref-type="aff" rid="dth13476-aff-0001">
<sup>1</sup>
</xref>
          <address>
            <email>utursen@gmail.com</email>
          </address>
        </contrib>
        <contrib id="dth13476-cr-0002" contrib-type="author">
          <name>
            <surname>T&#xFC;rsen</surname>
            <given-names>Belma</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4735-0705</contrib-id>
          <xref ref-type="aff" rid="dth13476-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="dth13476-cr-0003" contrib-type="author">
          <name>
            <surname>Lotti</surname>
            <given-names>Torello</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0840-1936</contrib-id>
          <xref ref-type="aff" rid="dth13476-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="dth13476-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<institution>School of Medicine, Mersin University</institution>
<city>Mersin</city>
<country country="TR">Turkey</country>
</aff>
      <aff id="dth13476-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Health Science</named-content>
<institution>Toros University</institution>
<city>Mersin</city>
<country country="TR">Turkey</country>
</aff>
      <aff id="dth13476-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<institution>School of Medicine, Marconi University</institution>
<city>Rome</city>
<country country="IT">Italy</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
&#xDC;mit T&#xFC;rsen, Department of Dermatology, School of Medicine, Mersin University, Mersin, Turkey.<break/>
Email: <email>utursen@gmail.com</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>5</month>
        <year>2020</year>
      </pub-date>
      <elocation-id>e13476</elocation-id>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>4</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>4</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 Wiley Periodicals, Inc. <copyright-statement>-->
        <copyright-statement content-type="article-copyright">&#xA9; 2020 Wiley Periodicals LLC.</copyright-statement>
        <license>
          <license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:DTH-9999-e13476.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>COVID&#x2010;19 disease is a highly contagious and particularly popular problem in all countries. A variety of repurposed drugs and investigational drugs such as remdesivir, chloroquine, hydroxychloroquine, ritonavir, lopinavir, interferon&#x2010;beta, and other potential drugs have been studied for COVID19 treatment. We reviewed the potential dermatological side&#x2010;effects of these drugs.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="dth13476-kwd-0001">COVID&#x2010;19</kwd>
        <kwd id="dth13476-kwd-0002">dermatology</kwd>
        <kwd id="dth13476-kwd-0003">side&#x2010;effects</kwd>
        <kwd id="dth13476-kwd-0004">skin</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="1"/>
        <page-count count="6"/>
        <word-count count="4159"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>edited-state</meta-name>
          <meta-value>corrected-proof</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:01.06.2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="dth13476-cit-9001">
<string-name>
<surname>T&#xFC;rsen</surname>
<given-names>&#xDC;</given-names>
</string-name>, <string-name>
<surname>T&#xFC;rsen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lotti</surname>
<given-names>T</given-names>
</string-name>. <article-title>Cutaneous s&#x131;de&#x2010;effects of the potential COVID&#x2010;19 drugs</article-title>. <source xml:lang="en">Dermatologic Therapy</source>. <year>2020</year>;<elocation-id>e13476</elocation-id>
<pub-id pub-id-type="doi">10.1111/dth.13476</pub-id>
<pub-id pub-id-type="pmid">32358890</pub-id></mixed-citation>
</p>
    </notes>
  </front>
  <body id="dth13476-body-0001">
    <sec id="dth13476-sec-0001">
      <label>1</label>
      <title>INTRODUCTION</title>
      <p>COVID&#x2010;19 infection has rapidly spread across the world since its identification at the end of 2019. There are still no available evidence&#x2010;based therapies for this infection.<xref rid="dth13476-bib-0001" ref-type="ref">
<sup>1</sup>
</xref> We present the information on potential cutaneous adverse events of anti&#x2010;COVID&#x2010;19 drugs on dermatology practice.</p>
    </sec>
    <sec id="dth13476-sec-0002">
      <label>2</label>
      <title>ANTIMALARIALS</title>
      <p>We use chloroquine and hydroxychloroquine for the treatment of discoid lupus erythematosus and understand its relative safety. Hydroxychloroquine and chloroquine have antiviral activity against COVID&#x2010;19 in vitro and small&#x2010;uncontrolled clinical studies with limited and inconclusive results. In COVID&#x2010;19, a small non&#x2010;randomized study from France indicated some benefits with serious methodological flaws, and a follow&#x2010;up study still lacked a control group. However, another very small, randomized study from China in patients with mild to moderate COVID&#x2010;19 and also a quasi&#x2010;randomized study from the United States found no difference in the recovery rates.<xref rid="dth13476-bib-0002" ref-type="ref">2</xref>, <xref rid="dth13476-bib-0003" ref-type="ref">3</xref> Cutaneous adverse events of antimalarials include cutaneous eruptions such as acute generalized exanthematous pustulosis, urticaria, pruritus, dry skin, rashes, flares of psoriasis and exfoliating lesions, Stevens&#x2010;Johnson&#x2010;like syndrome, mucocutaneous dyspigmentation, alopecia and bleaching of hair.<xref rid="dth13476-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> We also have to do the differential diagnosis of the skin manifestations of COVID&#x2010;19 infection such as erythematous rash, petechia, urticaria, and vesicles in patients with COVID&#x2010;19<xref rid="dth13476-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> who are using antimalarials.</p>
    </sec>
    <sec id="dth13476-sec-0003">
      <label>3</label>
      <title>AZITHROMYCIN</title>
      <p>Due to the remarkable pharmacokinetics and efficacy, azithromycin with immunomodulatory and anti&#x2010;inflammatory properties is well&#x2010;established as a potent treatment for some skin diseases such as rosacea, psoriasis, and synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome.<xref rid="dth13476-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> Combining hydroxychloroquine with the antibiotic azithromycin has also been associated with positive patient outcomes according to the low&#x2010;powered France study.<xref rid="dth13476-bib-0007" ref-type="ref">
<sup>7</sup>
</xref> Whether this results in better clinical outcomes is still being debated. Skin adverse events of azithromycin are cutaneous severe skin reaction associated fever, angioedema, burning in eyes, skin pain, generalized red or purple skin rashes, blistering, skin peeling, toxic pustuloderma, anaphylaxis, DRESS syndrome, cutaneous leukocytoclastic vasculitis, and fixed drug eruptions.<xref rid="dth13476-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> These eruptions occur in also COVID infections' findings.</p>
    </sec>
    <sec id="dth13476-sec-0004">
      <label>4</label>
      <title>COLCHICINE</title>
      <p>Colchicine has been used to treat various dermatologic diseases, some of which are quite seldom, which include Beh&#xE7;et's disease, epidermolysis bullosa acquisita, recurrent oral aphthosis, cutaneous vasculitis, chronic urticaria and Sweet syndrome for its anti&#x2010;neutrophilic immunomodulatory effect. In the last clinical trial called COLCORONA (Colchicine COVID&#x2010;19 Trial), colchicine is being used to reduce the inflammatory reaction caused by COVID&#x2010;19 that can lead to pulmonary involvement, organ failure, and death. It will be used for its anti&#x2010;inflammatory and anti&#x2010;cytokine storm effects when treating COVID&#x2010;19.<xref rid="dth13476-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> Skin side&#x2010;effects of colchicine include diffuse, blanchable, violaceous, morbilliform rash, lichenoid drug eruption, alopecia, toxic epidermal necrolysis&#x2010;like reaction, erythema&#x2010;bullous, and erythema&#x2010;nodosum&#x2010;like lesions.<xref rid="dth13476-bib-0010" ref-type="ref">10</xref>, <xref rid="dth13476-bib-0011" ref-type="ref">11</xref>
</p>
    </sec>
    <sec id="dth13476-sec-0005">
      <label>5</label>
      <title>REMDESIVIR</title>
      <p>Remdesivir shuts down viral replication by inhibiting a key viral enzyme, the RNA polymerase. The drug, which is given intravenously, has been used in hundreds of COVID&#x2010;19 patients in China, the United States, and Europe as clinical studies. One of the most common adverse events is skin rashes.<xref rid="dth13476-bib-0012" ref-type="ref">
<sup>12</sup>
</xref>
</p>
    </sec>
    <sec id="dth13476-sec-0006">
      <label>6</label>
      <title>OSELTAMIVIR/FAVIPIRAVIR/UMIFENOVIR</title>
      <p>These drugs have been approved for the treatment of pandemic influenza A and B treatments. Oseltamivir inhibits the viral neuraminidase and, blocks the release of viral particles from host cells, decreasing the spread in the pulmonary system. Oseltamivir is studied in lots of clinical trials with multiple combinations with chloroquine and favipiravir for COVID&#x2010;19. Favipiravir is a nucleoside analog that is well&#x2010;known as a broad&#x2010;spectrum antiviral drug with a lower side&#x2010;effects profile.<xref rid="dth13476-bib-0013" ref-type="ref">
<sup>13</sup>
</xref> Oseltamivir can cause Stevens&#x2010;Johnson syndrome/toxic epidermal necrolysis, angioedema allergic, or idiosyncratic cutaneous drug reactions.<xref rid="dth13476-bib-0014" ref-type="ref">14</xref>, <xref rid="dth13476-bib-0015" ref-type="ref">15</xref> Umifenovir inhibits membrane fusion of the viral envelope and S protein/ACE2 interaction. It is approved for influenza treatment in Russia and China and a randomized&#x2010;controlled trial of umifenovir is still going on the anti&#x2010;COVID&#x2010;19 agent. There are no reports on the skin reaction of umifenovir.<xref rid="dth13476-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>
</p>
    </sec>
    <sec id="dth13476-sec-0007">
      <label>7</label>
      <title>RIBAVIRIN/INTERFERONS</title>
      <p>It is a broad antiviral against respiratory viruses such as influenza A and B viruses and parainfluenza 1 virus. Ribavirin, telbivudine, vitamin B12, nicotinamide combinations are proposed for COVID&#x2010;19 treatment.<xref rid="dth13476-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> Dermatological side effects of ribavirin include acneiform eruptions, alopecia, localized scleroderma, maculopapular, and eczematous lesions, skin dryness, pruritus, and rash.<xref rid="dth13476-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> Interferon is a broad&#x2010;spectrum antiviral via interaction with the toll&#x2010;like receptors and it can inhibit the viral replication. There is an ongoing study to evaluate the efficacy and safety of interferon&#x2010;&#x3B1;&#x2009;+&#x2009;ribavirin combination.<xref rid="dth13476-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> Cutaneous side&#x2010;effects of interferons are injection site reactions, psoriasis, eczematous drug reactions, alopecia, sarcoidosis, lupus, cutaneous vasculitic lesions, psoriasis, and lichenoid drug reactions. These adverse events are estimated to occur as 13% to 23%.<xref rid="dth13476-bib-0018" ref-type="ref">18</xref>, <xref rid="dth13476-bib-0019" ref-type="ref">19</xref>
</p>
      <sec id="dth13476-sec-0008">
        <label>7.1</label>
        <title>Lopinavir/ritanavir and the other antiretrovirals</title>
        <p>We use these agents for HIV diseases and they also have anti&#x2010;coronavirus activity via inhibition of 3&#x2010;chymotrypsin&#x2010;like protease. There are mostly case reports and small retrospective non&#x2010;randomized cohort studies lopinavir and ritonavir as anti&#x2010;COVID&#x2010;19 drugs. Although additional randomized controlled trials of these agents are ongoing, the current findings suggest a limited effect for antiretrovirals in COVID&#x2010;19 treatment. In vitro studies indicated activities of darunavir, protease inhibitors, and integrase strand transfer inhibitors against COVID&#x2010;19.<xref rid="dth13476-bib-0020" ref-type="ref">20</xref>, <xref rid="dth13476-bib-0022" ref-type="ref">22</xref> Cutaneous adverse events of antiretroviral drugs include maculopapular drug eruptions, exfoliative erythroderma, Stevens&#x2010;Johnson syndrome or toxic epidermal necrolysis, severe cutaneous drug reactions, injection site reactions such as cysts, nodules, induration, or scleroderma&#x2010;like lesions, lichenoid drug eruption, lipodystrophy, annular erythema and photosensitivity, nail, oral mucosa, and skin hyperpigmentations, pruritus, alopecia, paronychia, urticaria, mosquito bite hypersensitivity.<xref rid="dth13476-bib-0021" ref-type="ref">21</xref>, <xref rid="dth13476-bib-0023" ref-type="ref">23</xref>, <xref rid="dth13476-bib-0024" ref-type="ref">24</xref>
</p>
      </sec>
      <sec id="dth13476-sec-0009">
        <label>7.2</label>
        <title>Nitazoxanide</title>
        <p>It has broad antiviral and antihelmintic activity with lesser side&#x2010;effect risks. In vitro studies suggest that nitazoxanide shows anti&#x2010;COVID19 and immunomodulatory activities.<xref rid="dth13476-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> Hair loss, pruritus, and allergic skin reactions such as urticaria, rash, redness are cutaneous skin side&#x2010;effects.<xref rid="dth13476-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>
</p>
      </sec>
      <sec id="dth13476-sec-0010">
        <label>7.3</label>
        <title>Camostat mesylate/dornase alfa</title>
        <p>Camostat mesylate can inhibit host serine protease as the anti&#x2010;COVID&#x2010;19 agent. It is an approved drug in Japan for pancreatitis. Rash, itch, yellow discoloration of the skin or conjunctiva, and purpura are the skin effects of this drug.<xref rid="dth13476-bib-0026" ref-type="ref">
<sup>26</sup>
</xref> Dornase alfa is a highly purified solution of recombinant human deoxyribonuclease and this drug can reduce mucus viscosity in the lungs and also improve the clearance of secretions. It has no serious side&#x2010;effects on the skin and phase studies also are still going on as anti&#x2010;COVID19 agent.<xref rid="dth13476-bib-0027" ref-type="ref">
<sup>27</sup>
</xref>
</p>
      </sec>
    </sec>
    <sec id="dth13476-sec-0011">
      <label>8</label>
      <title>ADJUNCTIVE TREATMENTS</title>
      <p>These therapies are steroids, anti&#x2010;cytokine or immunomodulatory agents, and immunoglobulin therapy.</p>
      <sec id="dth13476-sec-0012">
        <label>8.1</label>
        <title>Steroids</title>
        <p>Corticosteroids have anti&#x2010;inflammatory functions and they can suppress the inflammation during COVID&#x2010;19 associated acute respiratory distress syndrome. Short term (3&#x2010;5&#x2009;days) and very low doses (methylprednisolone 1&#x2010;2 mg/kg/day) are recommended.<xref rid="dth13476-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> Skin side&#x2010;effects of steroids include pruritus, burning, stinging, folliculitis, dryness, acneiform eruptions, skin atrophy, telangiectasia, erythema, edema, fissures, urticaria, disease exacerbation, acne, papulopustular lesions, hirsutism, and stria.<xref rid="dth13476-bib-0028" ref-type="ref">
<sup>28</sup>
</xref>
</p>
      </sec>
      <sec id="dth13476-sec-0013">
        <label>8.2</label>
        <title>Baricitinib and the other Janus kinase inhibitors</title>
        <p>Artificial intelligence predicts that Janus kinase (JAK) inhibitors like baricitinib may block viral entry into pneumocytes in COVID&#x2010;19 infection.<xref rid="dth13476-bib-0029" ref-type="ref">29</xref>, <xref rid="dth13476-bib-0030" ref-type="ref">30</xref> JAK inhibition also can affect inflammation.<xref rid="dth13476-bib-0037" ref-type="ref">
<sup>37</sup>
</xref> Palmoplantar pustulosis&#x2010;like eruption, allergic skin rashes, <italic>herpes</italic> simplex, and zona zoster infections, melanoma and nonmelanoma skin cancers, urticaria, rash, angioedema are cutaneous side effects of baricitinib and the other JAK inhibitors.<xref rid="dth13476-bib-0031" ref-type="ref">31</xref>, <xref rid="dth13476-bib-0038" ref-type="ref">38</xref>, <xref rid="dth13476-bib-0039" ref-type="ref">39</xref>
</p>
      </sec>
      <sec id="dth13476-sec-0014">
        <label>8.3</label>
        <title>Tocilizumab</title>
        <p>COVID&#x2010;19 can induce the uncontrolled cytokine and chemokine response known as a &#x201C;cytokine storm,&#x201D; and this condition leads to the over&#x2010;activation of effector T cells and production of pro&#x2010;inflammatory cytokines, which in turn lead to acute respiratory distress syndrome associated with increasing plasma leakage, vascular permeability, and disseminated intravascular coagulation. Tocilizumab, a humanized monoclonal antibody against IL&#x2010;6 receptors, can reverse the cytokine storm as anti&#x2010;COVID&#x2010;19 agent.<xref rid="dth13476-bib-0009" ref-type="ref">
<sup>9</sup>
</xref>
<italic>Skin infection</italic>, pruritus, skin hypersensitivity reactions, <italic>psoriasiform dermatitis</italic> are the cutaneous side&#x2010;effects of Tocilizumab.<xref rid="dth13476-bib-0032" ref-type="ref">32</xref>, <xref rid="dth13476-bib-0033" ref-type="ref">33</xref>
</p>
      </sec>
      <sec id="dth13476-sec-0015">
        <label>8.4</label>
        <title>
<styled-content style="fixed-case" toggle="no">Anti&#x2010;IL</styled-content>&#x2010;1 (Anakinra)</title>
        <p>In hyper inflammation during COVID&#x2010;19 infection, immunosuppression is likely to be beneficial. IL&#x2010;1 blockade with anakinra in sepsis, showed a significant survival benefit in patients with hyper inflammation, without increased adverse events according to phase 3 randomized controlled trial results.<xref rid="dth13476-bib-0034" ref-type="ref">
<sup>34</sup>
</xref> Cutaneous side&#x2010;effects of anakinra include rash, injection&#x2010;site reactions, and skin infections such as wound infection, cellulitis.<xref rid="dth13476-bib-0035" ref-type="ref">35</xref>, <xref rid="dth13476-bib-0036" ref-type="ref">36</xref>
</p>
      </sec>
      <sec id="dth13476-sec-0016">
        <label>8.5</label>
        <title>
<styled-content style="fixed-case" toggle="no">Anti&#x2010;TNF</styled-content>&#x2010;&#x3B1; biologics</title>
        <p>Higher TNF&#x2010;&#x3B1; levels have been found in patients with COVID&#x2010;19 and these correlate with disease severity. It has been suggested that anti&#x2010;TNF&#x2010;&#x3B1; treatment of COVID&#x2010;19 may be a potential option, and a randomized, controlled trial of adalimumab has been started.<xref rid="dth13476-bib-0040" ref-type="ref">
<sup>40</sup>
</xref> Cutaneous side&#x2010;effects of anti&#x2010;TNFs include infusion and injection site reactions, psoriasis and psoriasiform&#x2010;like lesions, lupus&#x2010;like syndromes, cutaneous vasculitis, cutaneous infections, eczematous reactions, lichenoid eruptions, granulomatous reactions, cutaneous lymphoma, epithelial skin cancers or melanoma.<xref rid="dth13476-bib-0039" ref-type="ref">
<sup>39</sup>
</xref>
</p>
      </sec>
      <sec id="dth13476-sec-0017">
        <label>8.6</label>
        <title>
<styled-content style="fixed-case" toggle="no">High&#x2010;dose</styled-content> intravenous immunoglobulin</title>
        <p>High&#x2010;dose intravenous immunoglobulin (IVIG) collected from recovered Coronavirus&#x2010;19 patients may protect against COVID&#x2010;19 and strengthen the immune system of new severe and treatment&#x2010;resistant patients.<xref rid="dth13476-bib-0041" ref-type="ref">41</xref>, <xref rid="dth13476-bib-0042" ref-type="ref">42</xref> Skin adverse events of IVIG treatments include anaphylactic reaction, facial vasculitic rash, urticaria, maculopapular rashes, petechiae, eczema, erythema multiforme, and alopecia.<xref rid="dth13476-bib-0043" ref-type="ref">43</xref>, <xref rid="dth13476-bib-0044" ref-type="ref">44</xref>
</p>
      </sec>
      <sec id="dth13476-sec-0018">
        <label>8.7</label>
        <title>Checkpoints inhibitors</title>
        <p>The inhibition of CD200&#x2010;CD200R1 and anti&#x2010;PD agents have positive effects on coronavirus infection, restoring IFN production, and increasing virus clearance. Studies on checkpoint inhibitors are ongoing in CoViD&#x2010;19 patients.<xref rid="dth13476-bib-0045" ref-type="ref">
<sup>45</sup>
</xref> Rash, pruritus, xerosis, alopecia, stomatitis, urticaria, photosensitivity reaction, hyperhidrosis, vitiligo, skin exfoliation, hair color changes, impaired skin wound healing, periungual pyogenic granuloma&#x2010;like lesions, sarcoidosis&#x2010;like reactions, granulomatous panniculitis, granuloma annulare, and granulomatous dermatitis are the cutaneous adverse events of checkpoints inhibitors.<xref rid="dth13476-bib-0046" ref-type="ref">
<sup>46</sup>
</xref>
</p>
      </sec>
    </sec>
    <sec id="dth13476-sec-0019">
      <label>9</label>
      <title>DISCUSSION</title>
      <p>Skin manifestations of COVID&#x2010;19 infections include erythematous rash, acute hemorrhagic edema, petechiae, morbilliform rash, chickenpox&#x2010;like vesicles, livedoid lesions, localized or widespread urticaria confluent erythematous&#x2010;yellowish papules and plaques may be the most common manifestations in acute severe COVID&#x2010;19 cases. However, it can be difficult to distinguish the underlying cause of whether viral infection or newly prescribed anti&#x2010;COVID&#x2010;medication (<xref rid="dth13476-bib-0047" ref-type="ref">
<sup>47</sup>
</xref>). Complete blood count analysis with atypical lymphocytosis, neutrophilia, eosinophilia, higher blood drug, histamine, tryptase and beta&#x2010;tryptase levels, cutaneous histopathologic examinations with the presence of eosinophils, edema, and inflammation may indicate cutaneous drug eruptions. A good and complete history taking is very vital and helpful for the differential diagnosis.<xref rid="dth13476-bib-0048" ref-type="ref">
<sup>48</sup>
</xref> We should obtain the history anti&#x2010;COVID&#x2010;19 and other drug exposures including dosage, date started, duration and interruptions in use, initiation of drug use and the onset of reaction, previous adverse cutaneous drug reactions, and type of adverse reaction and previous family or personal history of skin drug eruptions, hypersensitivity syndromes and atopy. Re&#x2010;exposure to a drug and exacerbation of skin reaction, the improvement after a decrease in drug dosage, or discontinuation of the drug (rechallenge test) are clues for the diagnosis of drug eruptions. In the management of the cutaneous anti&#x2010;COVID 19 drug eruptions, medium&#x2010;to&#x2010;high potency topical corticosteroids generally sufficed, although oral antihistamines and corticosteroids were occasionally needed. In severe cases, we can start at cyclosporin 5&#x2009;mg/kg/day and IVIG treatments.<xref rid="dth13476-bib-0048" ref-type="ref">
<sup>48</sup>
</xref> Early diagnosis of a cutaneous drug eruption allows the clinician the ability to narrow in on a culprit drug and determine whether the medication is safe to continue. A variety of drugs have been identified for COVID19 treatment. However, evaluation of the investigational agents requires adequately powered, randomized, controlled trials with realistic eligibility criteria and appropriate stratification of the patients. There are several clinical trials on potential anti&#x2010;COVID19 therapies such as ivermectin, recombinant human angiotensin&#x2010;converting enzyme 2 (APN01), natural killer cells, mesenchymal stem cells, SARS&#x2010;CoV&#x2010;2&#x2010;specific neutralizing antibodies, anti&#x2010;C5a monoclonal antibody, thalidomide, fingolimod (highly potent functional antagonist of S1P1 receptors in the lymph node T cells), Bevacizumab (recombinant humanized VEGF monoclonal antibody), vaccine, mRNA&#x2010;1273 (encodes the prefusion&#x2010;stabilized viral spike protein), INO&#x2010;4800, ChAdOx1 nCoV&#x2010;19, stabilized subunit vaccines, nanoparticle&#x2010;based vaccines, pathogen&#x2010;specific artificial antigen&#x2010;presenting cells taking place with potential new cutaneous side&#x2010;effects like others (Table <xref rid="dth13476-tbl-0001" ref-type="table">1</xref>).<xref rid="dth13476-bib-0040" ref-type="ref">
<sup>41</sup>
</xref> After examining all the treatments, although potentiality effective against COVID&#x2010;19, we may start them one by one required by the safest and the most effective appropriate drug to minimize the development of the cutaneous drug eruptions and for the easy diagnosis.</p>
      <table-wrap id="dth13476-tbl-0001" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
        <label>TABLE 1</label>
        <caption>
          <p>Cutaneous side&#x2010;effects of potential anti&#x2010;COVID19 drugs</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col align="left" span="1"/>
          <col align="left" span="1"/>
          <thead valign="bottom">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="bottom" rowspan="1" colspan="1">Drugs</th>
              <th align="left" valign="bottom" rowspan="1" colspan="1">Cutaneous side&#x2010;effects</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Chloroquine, hydroxychloroquine, and other antimalarials</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Acute generalized exanthematous pustulosis, urticaria, pruritus, dry skin, rashes, flares of psoriasis and exfoliating lesions, Stevens&#x2013;Johnson&#x2010;like syndrome, mucocutaneous dyspigmentation, alopecia, and bleaching of hair</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">
<p>Azithromycin</p>
</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Cutaneous severe skin reaction associated fever, angioedema, burning in eyes, skin pain, generalized red or purple skin rashes, blistering, skin peeling, toxic pustuloderma, anaphylaxis, DRESS syndrome, cutaneous leukocytoclastic vasculitis, and fixed drug eruptions</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Colchicine</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Diffuse, branchable, violaceous, morbilliform rash, lichenoid drug eruption, alopecia, toxic epidermal necrolysis&#x2010;like reaction, erythema&#x2010;bullous and erythema&#x2010;nodosum&#x2010;like lesions</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Remdesivir</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Skin rashes</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Oseltamivir/Favipiravir/Umifenovir</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Stevens&#x2013;Johnson syndrome/toxic epidermal necrolysis, angioedema allergic or an idiosyncratic cutaneous drug reactions</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Ribavirin</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Acneiform eruptions, alopecia, localized scleroderma, maculopapular and eczematous lesions, skin dryness, pruritus, and rash</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Interferons</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Injection site reactions, psoriasis, eczematous drug reactions, alopecia, sarcoidosis, lupus, cutaneous vasculitic lesions, psoriasis, and lichenoid drug reactions</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Lopinavir/Ritanavir and other Antiretrovirals</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Maculopapular drug eruptions, exfoliative erythroderma, Stevens&#x2010;Johnson syndrome or toxic epidermal necrolysis, severe cutaneous drug reactions, injection site reactions such as cysts, nodules, induration, or scleroderma&#x2010;like lesions, lichenoid drug eruption, lipodystrophy, annular erythema and photosensitivity, nail, oral mucosa, and skin hyperpigmentations, pruritus, alopecia, paronychia, urticaria, mosquito bite hypersensitivity</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Nitazoxanide</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Hair loss, pruritus, allergic skin reactions; urticaria, rash, redness</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Camostat mesylate</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Rash, itch, yellow discoloration of the skin or conjunctiva, purpura</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Corticosteroids</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Transient and mild to moderate pruritus, burning, stinging, folliculitis, dryness, acneiform eruptions, skin atrophy, telangiectasia, erythema, edema, fissures, urticaria, disease exacerbation, acne, papular and pustular lesions, hirsutism and stria</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Tocilizumab</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<italic>Skin infections</italic>, pruritus, skin hypersensitivity reactions, <italic>psoriasiform dermatitis</italic>
</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Anakinra</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Skin rashes, injection&#x2010;site reactions and skin infections such as wound infection, cellulitis</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Baricitinib and the other JAK inhibitors</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Palmoplantar pustulosis&#x2010;like eruption, herpes zoster, and herpes simplex activations, melanoma and nonmelanoma skin cancers, urticaria, rash, angioedema</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Anti&#x2010;TNF biologics</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Infusion and injection site reactions, psoriasis and psoriasiform&#x2010;like lesions, lupus&#x2010;like syndromes, cutaneous vasculitis, cutaneous infections, eczematous reactions, lichenoid eruptions, granulomatous reactions, cutaneous lymphoma, epithelial skin cancers or melanoma</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">IVIG treatments</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Anaphylactic reaction, facial vasculitic rash, urticaria, maculopapular rashes, petechiae, eczema, erythema multiforme, and alopecia</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Checkpoints inhibitors</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Rash, pruritus, xerosis, alopecia, stomatitis, urticaria, photosensitivity reaction, hyperhidrosis, vitiligo, skin exfoliation, hair color changes, impaired skin wound healing, periungual pyogenic granuloma&#x2010;like lesions, sarcoidosis&#x2010;like reactions, granulomatous panniculitis, granuloma annulare, and granulomatous dermatitis</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Vaccines</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Urticaria, scleroderma, maculapapular rashes injection site reactions<xref rid="dth13476-bib-0049" ref-type="ref">
<sup>49</sup>
</xref>
</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec sec-type="COI-statement" id="dth13476-sec-0020">
      <title>CONFLICT OF INTEREST</title>
      <p>The authors declare no conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ref-list id="dth13476-bibl-0001" content-type="cited-references">
      <title>REFERENCES</title>
      <ref id="dth13476-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0001">
<string-name>
<surname>Riou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Althaus</surname>
<given-names>CL</given-names>
</string-name>. <article-title>Pattern of early human&#x2010;to&#x2010;human transmission of Wuhan 2019 novel coronavirus (2019&#x2010;nCoV), December 2019 to January 2020</article-title>. <source xml:lang="en">Euro Surveill</source>. <year>2020</year>;<volume>25</volume>:<fpage>4</fpage>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0002">
<string-name>
<surname>Ying&#x2010;Hui</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>Z&#x2010;S</given-names>
</string-name>, et al. <article-title>A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019&#x2010;nCoV) infected pneumonia (standard version)</article-title>. <source xml:lang="en">Mil Med Res</source>. <year>2020</year>;<volume>7</volume>:<fpage>4</fpage>.<pub-id pub-id-type="pmid">32029004</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0003">
<string-name>
<surname>Joshua</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Daniel</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Freedman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Le</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>X</given-names>
</string-name>. <article-title>Clinical outcomes of hydroxichloroquine in hospitalized patients with COVID&#x2010;19: a quasi&#x2010;randomized comparative study</article-title>. <source xml:lang="en">N Eng J med</source>. <year>2020</year>;<volume>20</volume>:<fpage>882</fpage>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0004">
<string-name>
<surname>Salido</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Joven</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>D'Cruz</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Khamashta</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>
<given-names>GR</given-names>
</string-name>. <article-title>Increased cutaneous reactions to hydroxychloroquine (Plaquenil) possibly associated with formulation change: comment on the letter by Alarc&#xF3;n</article-title>. <source xml:lang="en">Arthritis Rheum</source>. <year>2002</year>;<volume>246</volume>(<issue>12</issue>):<fpage>3392</fpage>&#x2010;<lpage>3396</lpage>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0005">
<string-name>
<surname>Recalcati</surname>
<given-names>S</given-names>
</string-name>. <article-title>Cutaneous manifestations in COVID&#x2010;19: a first perspective</article-title>. <source xml:lang="en">J Eur Acad Dermatol Venereol</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1111/jdv.16387</pub-id>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0006">
<string-name>
<surname>Esther</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>van Zuuren</surname>
<given-names>ZF</given-names>
</string-name>, <string-name>
<surname>Carter</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>van der Linden</surname>
<given-names>MMD</given-names>
</string-name>, <string-name>
<surname>Charland</surname>
<given-names>L</given-names>
</string-name>. <article-title>Cochrane skin group interventions for rosacea</article-title>. <source xml:lang="en">Cochrane Database Syst Rev</source>. <year>2015</year>;<volume>4</volume>:<elocation-id>CD003262</elocation-id>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0007">
<string-name>
<surname>Gautret</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lagie</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Parola</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID&#x2010;19: results of an open&#x2010;label non&#x2010;randomized clinical trial</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;<volume>20</volume>:<elocation-id>105949</elocation-id>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0008">
<string-name>
<surname>Das</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sancheti</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Podder</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Das</surname>
<given-names>NK</given-names>
</string-name>. <article-title>Azithromycin induced bullous fixed drug eruption</article-title>. <source xml:lang="en">Indian J Pharmacol</source>. <year>2016</year>;<volume>48</volume>(<issue>1</issue>):<fpage>83</fpage>&#x2010;<lpage>85</lpage>.<pub-id pub-id-type="pmid">26997729</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0009">
<string-name>
<surname>Liu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Research and development on therapeutic agents and vaccines for COVID&#x2010;19 and related human coronavirus diseases</article-title>. <source xml:lang="en">ACS Cent Sci</source>. <year>2020</year>;<volume>6</volume>(<issue>3</issue>):<fpage>315</fpage>&#x2010;<lpage>331</lpage>.<pub-id pub-id-type="pmid">32226821</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0010">
<string-name>
<surname>Mason</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Smoller</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Wilkerson</surname>
<given-names>AE</given-names>
</string-name>. <article-title>Colchicine intoxication diagnosed in a skin biopsy: a case report</article-title>. <source xml:lang="en">J Cutan Pathol</source>. <year>2006</year>;<volume>33</volume>(<issue>4</issue>):<fpage>309</fpage>&#x2010;<lpage>311</lpage>.<pub-id pub-id-type="pmid">16630182</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0011">
<string-name>
<surname>An</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Demir</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Akdeniz</surname>
<given-names>S</given-names>
</string-name>. <article-title>Lichenoid drug eruption induced by colchicine: case report</article-title>. <source xml:lang="en">Cut Ocul Toxicol</source>. <year>2017</year>;<volume>36</volume>(<issue>2</issue>):<fpage>199</fpage>&#x2010;<lpage>200</lpage>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0012">
<string-name>
<surname>Grein</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ohmagari</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Diaz</surname>
<given-names>G</given-names>
</string-name>. <article-title>Compassionate use of Remdesivir for patients with severe Covid&#x2010;19</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1056/NEJMoa2007016</pub-id>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0013">
<string-name>
<surname>Russell</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Moss</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Associations between immune&#x2010;suppressive and stimulating drugs and novel COVID&#x2010;19&#x2014;a systematic review of current evidence</article-title>. <source xml:lang="en">E Cancer Med Sci</source>. <year>2020</year>;<volume>14</volume>:<fpage>1022</fpage>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0014">
<string-name>
<surname>Zuo</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wen</surname>
<given-names>LP</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mei</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>B</given-names>
</string-name>. <article-title>Oseltamivir induced Stevens&#x2010;Johnson syndrome/toxic epidermal necrolysis&#x2010;case report</article-title>. <source xml:lang="en">Medicine (Baltimore)</source>. <year>2019</year>;<volume>98</volume>(<issue>19</issue>):<elocation-id>e15553</elocation-id>.<pub-id pub-id-type="pmid">31083216</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0015">
<string-name>
<surname>Kalsi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Stevenson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wade</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kinirons</surname>
<given-names>M</given-names>
</string-name>. <article-title>Tongue swelling in association with oseltamivir (Tamiflu)</article-title>. <source xml:lang="en">BMJ Case Rep</source>. <year>2011</year>;<volume>4</volume>:<fpage>2011</fpage>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0016">
<string-name>
<surname>Chen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yin</surname>
<given-names>P</given-names>
</string-name>. <article-title>Favipiravir versus Arbidol for COVID&#x2010;19: a randomized clinical trial</article-title>. <source xml:lang="en">MedRXiv</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.03.17.20037432</pub-id>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0017">
<string-name>
<surname>Gupta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Aggarwal</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bhari</surname>
<given-names>N</given-names>
</string-name>. <article-title>Acneiform eruptions: An unusual dermatological side effect of ribavirin</article-title>. <source xml:lang="en">Dermatol Ther</source>. <year>2018</year>;<volume>31</volume>(<issue>5</issue>):<elocation-id>e12679</elocation-id>.<pub-id pub-id-type="pmid">30230152</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0018">
<string-name>
<surname>Lorcy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gaudy&#x2010;Marqueste</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Botta</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: a multicenter prospective cohort study</article-title>. <source xml:lang="en">Ann Dermatol Venereol</source>. <year>2016</year>;<volume>143</volume>(<issue>5</issue>):<fpage>336</fpage>&#x2010;<lpage>346</lpage>.<pub-id pub-id-type="pmid">27161648</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0019">
<string-name>
<surname>Bush</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Hymes</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Silapunt</surname>
<given-names>S</given-names>
</string-name>. <article-title>Lichenoid dermatitis from interferon alpha&#x2010;2a in a patient with metastatic renal cell carcinoma and seronegative HCV</article-title>. <source xml:lang="en">J Drugs Dermatol</source>. <year>2017</year>;<volume>16</volume>(<issue>7</issue>):<fpage>714</fpage>&#x2010;<lpage>716</lpage>.<pub-id pub-id-type="pmid">28697228</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0020">
<string-name>
<surname>Kandeel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Al&#x2010;Nazawi</surname>
<given-names>M</given-names>
</string-name>. <article-title>Virtual screening and repurposing of FDA approved drugs against COVID&#x2010;19 main protease</article-title>. <source xml:lang="en">Life Sci</source>. <year>2020</year>;<volume>251</volume>:<fpage>117627</fpage>.<pub-id pub-id-type="pmid">32251634</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0021">
<string-name>
<surname>Pistone</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pistone</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sorbello</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Viviano</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bongiorno</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Cutaneous adverse reactions to highly antiretroviral therapy in HIV&#x2010;positive patients</article-title>. <source xml:lang="en">Case Rep Dermatol</source>. <year>2014</year>;<volume>6</volume>(<issue>2</issue>):<fpage>145</fpage>&#x2010;<lpage>149</lpage>.<pub-id pub-id-type="pmid">24932169</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0022">
<string-name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kleine&#x2010;Weber</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>SARS&#x2010;CoV&#x2010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease Inhibitor</article-title>. <source xml:lang="en">Cell</source>. <year>2020</year>;<volume>181</volume>:<elocation-id>271&#x2010;280.e8</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>.<pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0023">
<string-name>
<surname>Introcaso</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Hines</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Kovarik</surname>
<given-names>CL</given-names>
</string-name>. <article-title>Cutaneous toxicities of antiretroviral therapy for HIV: part I. lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors</article-title>. <source xml:lang="en">J Am Acad Dermatol</source>. <year>2010</year>;<volume>63</volume>(<issue>4</issue>):<fpage>549</fpage>&#x2010;<lpage>561</lpage>.<pub-id pub-id-type="pmid">20846563</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0024">
<string-name>
<surname>Sharma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vora</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Modi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Marfatia</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Adverse effects of antiretroviral treatment</article-title>. <source xml:lang="en">Indian J Dermatol Venereol Leprol</source>. <year>2008</year>;<volume>74</volume>(<issue>3</issue>):<fpage>234</fpage>&#x2010;<lpage>237</lpage>.<pub-id pub-id-type="pmid">18583790</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0025">
<string-name>
<surname>Speich</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ame</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Ali</surname>
<given-names>SM</given-names>
</string-name>, et al. <article-title>Efficacy and safety of nitazoxanide, albendazole, and nitazoxanide&#x2010;albendazole against Trichuris trichiura infection: a randomized controlled trial</article-title>. <source xml:lang="en">PLoS Negl Trop Dis</source>. <year>2012</year>;<volume>6</volume>(<issue>6</issue>):<elocation-id>e1685</elocation-id>.<pub-id pub-id-type="pmid">22679525</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0026">
<string-name>
<surname>Reihill</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>RA</given-names>
</string-name>, et al. <article-title>Inhibition of Protease&#x2010;Epithelial Sodium Channel Signaling Improves Mucociliary Function in Cystic Fibrosis Airways</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2016</year>;<volume>194</volume>(<issue>6</issue>):<fpage>701</fpage>&#x2010;<lpage>710</lpage>.<pub-id pub-id-type="pmid">27014936</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0027">
<string-name>
<surname>Yang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Montgomery</surname>
<given-names>M</given-names>
</string-name>. <article-title>Dornase alfa for cystic fibrosis</article-title>. <source xml:lang="en">Cochrane Database Syst Rev</source>. <year>2018</year>;<volume>9</volume>:<elocation-id>CD001127</elocation-id>.<pub-id pub-id-type="pmid">30187450</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0028">
<string-name>
<surname>Spada</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Barnes</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Greive</surname>
<given-names>KA</given-names>
</string-name>. <article-title>Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids</article-title>. <source xml:lang="en">Australas J Dermatol</source>. <year>2018</year>;<volume>59</volume>(<issue>3</issue>):<fpage>e168</fpage>&#x2010;<lpage>e174</lpage>.<pub-id pub-id-type="pmid">29411351</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0029">
<string-name>
<surname>Richardson</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Tucker</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Baricitinib as potential treatment for 2019&#x2010;nCoV acute respiratory disease</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>e30</fpage>&#x2010;<lpage>e31</lpage>.<pub-id pub-id-type="pmid">32032529</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0030">
<string-name>
<surname>Praveen</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chowdary</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Aanandhi</surname>
<given-names>MV</given-names>
</string-name>. <article-title>
<sc>b</sc>aricitinib&#x2010; a januase kinase inhibitor&#x2010; not an ideal option for management of <sc>covid</sc> 19</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;<volume>4</volume>:<elocation-id>105967</elocation-id>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0031">
<string-name>
<surname>Koumaki</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Koumaki</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Lagoudaki</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bertsias</surname>
<given-names>G</given-names>
</string-name>. <article-title>Palmoplantar Pustulosis&#x2010;like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis</article-title>. <source xml:lang="en">Eur J Case Rep Intern Med</source>. <year>2019</year>;<volume>7</volume>(<issue>1</issue>):<elocation-id>001383</elocation-id>.<pub-id pub-id-type="pmid">32015973</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0032">
<string-name>
<surname>Markatseli</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Theodoridou</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zakalka</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Persistence and adherence during the first six months of tocilizumab treatment among rheumatoid arthritis patients in routine clinical practice in Greece. Results from the single arm REMISSION II study (NCT01649817)</article-title>. <source xml:lang="en">Mediterr J Rheumatol</source>. <year>2019</year>;<volume>30</volume>(<issue>3</issue>):<fpage>177</fpage>&#x2010;<lpage>185</lpage>.<pub-id pub-id-type="pmid">32185362</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0033">
<string-name>
<surname>Matsushima</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mizutani</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Psoriasiform dermatitis developing during treatment of juvenile idiopathic arthritis with tocilizumab</article-title>. <source xml:lang="en">Case Rep Dermatol</source>. <year>2019</year>;<volume>11</volume>(<issue>3</issue>):<fpage>317</fpage>&#x2010;<lpage>321</lpage>.<pub-id pub-id-type="pmid">31911769</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0034">
<string-name>
<surname>Shakoory</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Carcillo</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Chatham</surname>
<given-names>WW</given-names>
</string-name>, et al. <article-title>Interleukin&#x2010;1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iii trial</article-title>. <source xml:lang="en">Crit Care Med</source>. <year>2016</year>;<volume>44</volume>:<fpage>275</fpage>&#x2010;<lpage>281</lpage>.<pub-id pub-id-type="pmid">26584195</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0035">
<string-name>
<surname>Vastert</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Jamilloux</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Quartier</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Anakinra in children and adults with Still's disease</article-title>. <source xml:lang="en">Rheumatology (Oxford)</source>. <year>2019</year>;<volume>58</volume>(<issue>Suppl 6</issue>):<fpage>vi9</fpage>&#x2010;<lpage>vi22</lpage>.<pub-id pub-id-type="pmid">31769856</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0036">
<string-name>
<surname>Kullenberg</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>L&#xF6;fqvist</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Leinonen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Goldbach&#x2010;Mansky</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Olivecrona</surname>
<given-names>H</given-names>
</string-name>. <article-title>Long&#x2010;term safety profile of anakinra in patients with severe cryopyrin&#x2010;associated periodic syndromes</article-title>. <source xml:lang="en">Rheumatology (Oxford)</source>. <year>2016</year>;<volume>55</volume>(<issue>8</issue>):<fpage>1499</fpage>&#x2010;<lpage>1506</lpage>.<pub-id pub-id-type="pmid">27143789</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0037">
<string-name>
<surname>Peterson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Damsky</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>King</surname>
<given-names>B</given-names>
</string-name>. <article-title>The use of Janus kinase inhibitors in the time of SARS&#x2010;CoV&#x2010;2</article-title>. <source xml:lang="en">J Am Acad Dermatol</source>. <year>2020</year>;<volume>9</volume>: pii: S0190&#x2010;9622(20)30522&#x2013;3.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0038">
<string-name>
<surname>Sonthalia</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aggarwal</surname>
<given-names>P</given-names>
</string-name>. <article-title>Oral Tofacitinib: contemporary appraisal of its role in dermatology</article-title>. <source xml:lang="en">Indian Dermatol Online J</source>. <year>2019</year>;<volume>10</volume>(<issue>5</issue>):<fpage>503</fpage>&#x2010;<lpage>518</lpage>.<pub-id pub-id-type="pmid">31544068</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0039">
<string-name>
<surname>Sehgal</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Stratman</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Cutlan</surname>
<given-names>JE</given-names>
</string-name>. <article-title>Biologic agent&#x2010;associated cutaneous adverse events: a single center experience</article-title>. <source xml:lang="en">Clin Med Res</source>. <year>2018</year>;<volume>16</volume>(<issue>1&#x2013;2</issue>):<fpage>41</fpage>&#x2010;<lpage>46</lpage>.<pub-id pub-id-type="pmid">29610119</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0040">
        <label>40</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0040">
<string-name>
<surname>Tu</surname>
<given-names>YF</given-names>
</string-name>, <string-name>
<surname>Chien</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Yarmishyn</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>YY</given-names>
</string-name>, et al. <article-title>A review of SARS&#x2010;CoV&#x2010;2 and the ongoing clinical trials</article-title>. <source xml:lang="en">Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>7</issue>):<elocation-id>E2657</elocation-id>.<pub-id pub-id-type="pmid">32290293</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0041">
        <label>41</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0041">
<string-name>
<surname>Cao</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Bai</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>High&#x2010;dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019</article-title>. <source xml:lang="en">Open Forum Infect Dis</source>. <year>2020</year>;<volume>21</volume>(<issue>3</issue>):<fpage>7</fpage> ofaa102.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0042">
        <label>42</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0042">
<string-name>
<surname>Jawhara</surname>
<given-names>S</given-names>
</string-name>. <article-title>Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID&#x2010;19 and strengthen the immune system of new patients?</article-title>
<source xml:lang="en">Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>7</issue>):<fpage>2</fpage>&#x2010;<lpage>5</lpage>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0043">
        <label>43</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0043">
<string-name>
<surname>Verma</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dayal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jain</surname>
<given-names>VK</given-names>
</string-name>, <string-name>
<surname>Amrani</surname>
<given-names>A</given-names>
</string-name>. <article-title>Alopecia universalis as a side effect of pegylated interferon &#x3B1;&#x2010;r combination therapy for hepatitis C: a rare case report</article-title>. <source xml:lang="en">J Chemother</source>. <year>2017</year>;<volume>29</volume>(<issue>6</issue>):<fpage>380</fpage>&#x2010;<lpage>382</lpage>.<pub-id pub-id-type="pmid">27741937</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0044">
        <label>44</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0044">
<string-name>
<surname>Brannagan</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Nagle</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Lange</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Rowland</surname>
<given-names>LP</given-names>
</string-name>. <article-title>Complications of intravenous immune globulin treatment in neurologic disease</article-title>. <source xml:lang="en">Neurology</source>. <year>1996</year>;<volume>47</volume>:<fpage>674</fpage>&#x2010;<lpage>677</lpage>.<pub-id pub-id-type="pmid">8797463</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0045">
        <label>45</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0045">
<string-name>
<surname>Vaine</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Soberman</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>The CD200&#x2010;CD200R1 inhibitory signaling pathway: immune regulation and host&#x2010;pathogen interactions</article-title>. <source xml:lang="en">Adv Immunol</source>. <year>2014</year>;<volume>121</volume>:<fpage>191</fpage>&#x2010;<lpage>211</lpage>.<pub-id pub-id-type="pmid">24388216</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0046">
        <label>46</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0046">
<string-name>
<surname>Belum</surname>
<given-names>VR</given-names>
</string-name>, <string-name>
<surname>Benhuri</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Postow</surname>
<given-names>MA</given-names>
</string-name>, et al. <article-title>Characterisation and management of dermatologic adverse events to agents targeting the PD&#x2010;1 receptor</article-title>. <source xml:lang="en">Eur J Cancer</source>. <year>2016</year>;<volume>60</volume>:<fpage>12</fpage>&#x2010;<lpage>25</lpage>.<pub-id pub-id-type="pmid">27043866</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0047">
        <label>47</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0047">
<string-name>
<surname>Estebanez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>P&#xE9;rez&#x2010;Santiago</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Silva</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Guillen&#x2010;Climent</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Garc&#xED;a&#x2010;V&#xE1;zquez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ram&#xF3;n</surname>
<given-names>MD</given-names>
</string-name>. <article-title>Cutaneous manifestations in COVID&#x2010;19: a new contribution</article-title>. <source xml:lang="en">J Eur Acad Dermatol Venereol</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1111/jdv.16474</pub-id>.</mixed-citation>
      </ref>
      <ref id="dth13476-bib-0048">
        <label>48</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0048">
<string-name>
<surname>Perez</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Dyer</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Cutaneous Drug Eruptions in Pediatrics&#x2010;A Primer</article-title>. <source xml:lang="en">Pediatr Ann</source>. <year>2020</year>;<volume>49</volume>(<issue>3</issue>):<fpage>e132</fpage>&#x2010;<lpage>e139</lpage>.<pub-id pub-id-type="pmid">32155279</pub-id></mixed-citation>
      </ref>
      <ref id="dth13476-bib-0049">
        <label>49</label>
        <mixed-citation publication-type="journal" id="dth13476-cit-0049">
<string-name>
<surname>Holdiness</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Adverse cutaneous reactions to influenza vaccinations and chemotherapy</article-title>. <source xml:lang="en">Int J Dermatol</source>. <year>2001</year>;<volume>40</volume>(<issue>7</issue>):<fpage>427</fpage>&#x2010;<lpage>430</lpage>.<pub-id pub-id-type="pmid">11678994</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
